pyrroles has been researched along with su 11248 in 3082 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 662 (21.48) | 29.6817 |
| 2010's | 2383 (77.32) | 24.3611 |
| 2020's | 37 (1.20) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, TJ; Cherrington, JM; Heinrich, MC; Hong, W; Lee, LB; Louie, SG; Manning, WC; Murray, LJ; Ngai, TJ; O'Farrell, AM; Smolich, BD; Town, A; Wong, LM; Yee, KW; Yuen, HA | 1 |
| Abrams, TJ; Blake, RA; Carver, J; Chan, E; Cherrington, JM; Christensen, JG; Haznedar, JO; Laird, AD; Lee, LB; Li, G; Louie, SG; McMahon, G; Mendel, DB; Miller, T; Moss, KG; Murray, LJ; Ngai, TJ; Schreck, RE; Shirazian, S; Sukbuntherng, J; Sun, L; Tang, C; Xin, X | 1 |
| Chen, H; Chu, JY; Cui, J; Fukuda, JY; Liang, C; Luu, TC; Miller, T; Nematalla, A; Shirazian, S; Sistla, A; Sun, L; Tang, C; Tang, F; Wang, X; Wei, J; Zhou, Y | 1 |
| Abrams, TJ; Cherrington, JM; Lee, LB; Murray, LJ; Pryer, NK | 1 |
| Donnelly, E; Geng, L; Hallahan, DE; Himmelfarb, E; McMahon, G; Mendel, D; Schueneman, AJ; Tan, J | 1 |
| Cherrington, JM; Laird, AD; Mendel, DB; Moss, KG; Toner, GC | 1 |
| Blake, RA; Moshinsky, DJ; Ruslim, L; Tang, F | 1 |
| Abrams, TJ; Cherrington, JM; Colombo, T; Holway, VW; Lee, LB; Murray, LJ; Pesenti, E; Pryer, NK | 1 |
| von Mehren, M | 2 |
| Shiotsu, Y | 1 |
| Bello, C; Berdel, WE; Cherrington, JM; Cooper, MA; Fiedler, W; Foran, JM; Heinrich, MC; Jacobs, M; Kelsey, S; Kim, H; Louie, SG; Manning, WC; Nicholas, S; O'Farrell, AM; Paquette, RL; Scigalla, P; Serve, H; Yuen, HA | 1 |
| Abrams, TJ; Brassard, JA; Cherrington, JM; Hong, W; Keast, PK; Long, KR; Murray, LJ; Ngai, TJ; O'Farrell, AM; Olson, LM; Pryer, NK | 1 |
| Barattè, S; Frigerio, E; James, CA; Sarati, S; Ye, C; Zhang, Q | 1 |
| Cherrington, JM; Manning, WC; McArthur, G; Morimoto, AM; Smolich, BD; Tan, N; Toner, GC; West, K | 1 |
| Koparkar, A; Phung, K; Shenoy, N; Sistla, A; Sunga, A | 1 |
| Broxterman, HJ; Georgopapadakou, NH | 1 |
| Dellian, M; Eichhorn, ME; Strieth, S | 1 |
| Bainbridge, T; Cherrington, JM; Heinrich, MC; McGreevey, L; O'Farrell, AM; Schittenhelm, M; Town, AR; Yee, KW | 1 |
| Tuma, RS | 2 |
| Allred, R; Bello, CL; Berdel, WE; Brega, NM; Cherrington, JM; Döhner, H; Fiedler, W; Hong, W; Hossfeld, DK; Louie, SG; Manning, WC; Massimini, G; O'Farrell, AM; Ottmann, OG; Schwittay, M; Scigalla, P; Serve, H | 1 |
| Hanahan, D; Pietras, K | 1 |
| Fu, A; Geng, L; Hallahan, DE; Osusky, KL; Shyr, Y; Ye, F | 1 |
| Sakamoto, KM | 1 |
| Desai, AA; Stadler, WM | 1 |
| Donnelly, EF; Fleischer, AC; Geng, L; Hallahan, DE; Niermann, KJ; Schueneman, AJ | 1 |
| Branca, MA | 1 |
| Miller, KD; Sledge, GW; Wang, JQ; Zheng, QH | 1 |
| Motzer, RJ; Rini, BI; Sosman, JA | 1 |
| Atteridge, CE; Biggs, WH; Carter, TA; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Grotzfeld, RM; Herrgard, S; Insko, DE; Lockhart, DJ; Mehta, SA; Milanov, ZV; Pao, W; Patel, HK; Sawyers, CL; Shah, NP; Treiber, DK; Varmus, H; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Armand, JP; Escudier, B; Faivre, S; Raymond, E; Robert, C | 1 |
| Cooney, MM; Remick, SC; Vogelzang, NJ | 2 |
| Calderan, L; Crescimanno, C; Degrassi, A; Farace, P; Giusti, A; Marzola, P; Nicolato, E; Osculati, F; Pesenti, E; Sandri, M; Sbarbati, A; Terron, A | 1 |
| Schiller, JH; Wakelee, HA | 1 |
| Stadler, WM | 3 |
| Armand, JP; Bello, C; Brega, N; Delbaldo, C; Deprimo, S; Faivre, S; Lassau, N; Lozahic, S; Massimini, G; Raymond, E; Robert, C; Scigalla, P; Vera, K | 1 |
| Vogelzang, NJ | 2 |
| Baum, CM; Bello, CL; DePrimo, SE; Figlin, RA; George, DJ; Ginsberg, MS; Hudes, GR; Kim, ST; Li, JZ; Michaelson, MD; Motzer, RJ; Redman, BG; Rini, BI; Theuer, CP; Wilding, G | 1 |
| Fu, A; Hallahan, DE; Huamani, J; Kim, DW | 1 |
| Baldwin, SJ; Kotyk, JJ; Pagel, MD; Rader, RK | 1 |
| Rini, BI | 7 |
| Kiyoi, H | 1 |
| Chaganti, RS; Motzer, RJ; Patel, PH | 1 |
| Autenrieth, M; Blum, P; Gschwend, J; Herkommer, K; Hofer, M; Kuefer, R; Merseburger, A; Ringhoffer, M; Rinnab, L | 1 |
| Kanetake, H; Koga, S | 1 |
| Bello, CL; Klamerus, KJ; Mount, J; Sherman, L; Smeraglia, J; Verkh, L; Zhou, J | 1 |
| Susman, E | 1 |
| Ardizzoni, A; Franciosi, V; Tiseo, M | 1 |
| Atkins, M; Jones, CA; Kirkpatrick, P | 1 |
| Bello, CL; Christensen, JG; Hoosen, S; Motzer, RJ | 1 |
| Cools, J; Debiec-Rychter, M; Folens, C; Marynen, P; Mentens, N; Prenen, H; Schöffski, P; Sciot, R; Van Oosterom, A | 1 |
| Borner, MM | 1 |
| Bertagnolli, MM; Demetri, GD; Desai, J; Fletcher, CD; George, S; Morgan, JA; Posner, M; Raut, CP; Zahrieh, D | 1 |
| de Groot, JW; Links, TP; van der Graaf, WT | 1 |
| Barone, A; Cherrington, JM; Laird, AD; Li, G; Mendel, DB; Moss, KG; Nannini, MA; Potapova, O | 1 |
| Bacik, J; Baum, CM; Bukowski, RM; Curti, BD; George, DJ; Ginsberg, MS; Hudes, GR; Kim, ST; Margolin, KA; Merchan, JR; Michaelson, MD; Motzer, RJ; Redman, BG; Rini, BI; Wilding, G | 1 |
| Pasche, B | 1 |
| Saito, Y; Suzuki, Y; Tokuda, Y | 1 |
| Chew, K; Fong, K; Jaeger, E; Rini, BI; Sein, N; Simko, J; Small, EJ; Waldman, FM; Weinberg, V | 1 |
| Hampton, T | 1 |
| Cabebe, E; Wakelee, H | 2 |
| Chung, HK; Hwang, JH; Jo, KW; Jo, YS; Jung, HS; Kim, DW; Kweon, GR; Lee, SJ; Park, KC; Park, SH; Rha, SY; Shong, M; Song, JH | 1 |
| Eto, M; Naito, S | 1 |
| Reddy, K | 1 |
| Bukowski, RM; Rini, BI; Shaheen, PE | 1 |
| Mancuso, A; Sternberg, CN | 1 |
| Obata, R; Takahashi, H; Tamaki, Y | 1 |
| Bandobashi, K; Ikezoe, T; Koeffler, HP; Nakatani, H; Nishioka, C; Taguchi, H; Taguchi, T; Yang, Y | 1 |
| Biedrzycki, BA | 1 |
| King, CR | 1 |
| Bankhead, C | 1 |
| Ginsberg, MS; Kondagunta, GV; Motzer, RJ; Ronnen, EA; Russo, P | 1 |
| Stadler, W | 1 |
| Curtiss, FR | 1 |
| Bainbridge, T; Braziel, RM; Cherrington, JM; Griffith, DJ; Haley, AD; Heinrich, MC; McGreevey, L; O'Farrell, AM; Schittenhelm, MM; Town, A; Tyner, JW; Yee, KW | 1 |
| Desch, CE | 1 |
| Ikezoe, T; Koeffler, HP; Nishioka, C; Taguchi, H; Taguchi, T; Yang, Y; Zhu, WG | 1 |
| Haseke, N; Heinemann, G; Schöppler, G; Stadler, T; Staehler, M; Stief, CG | 1 |
| Blanke, CD; Schnadig, ID | 1 |
| Ikezoe, T; Koeffler, HP; Komatsu, N; Nishioka, C; Taguchi, H; Tasaka, T; Togitani, K; Yang, Y | 1 |
| Joensuu, H | 3 |
| Baum, CM; Bello, CL; Blackstein, ME; Casali, PG; Demetri, GD; Desai, J; Fletcher, CD; Garrett, CR; George, S; Heinrich, MC; Huang, X; Judson, IR; McArthur, G; Morgan, JA; Shah, MH; van Oosterom, AT; Verweij, J | 1 |
| Vollmer, H | 1 |
| Antonescu, CR; Dupont, J; Linkov, I; Maki, RG; Seandel, M; Shia, J | 1 |
| Gascón, P; Mellado, B | 1 |
| Bacik, J; Ishill, N; Kondagunta, GV; Motzer, RJ; Reuter, V; Ronnen, EA; Russo, P; Spodek, L | 1 |
| Alexander, EK; Chen, MH; Demetri, GD; Desai, J; Dychter, SS; Frates, MC; George, S; Larsen, PR; Marqusee, E; Morgan, JA; Yassa, L | 1 |
| Blanke, C | 2 |
| Cardinal, E; Gallina, A; Karakiewicz, PI; Perrotte, P; Saad, F; Trinh, QD | 1 |
| Wetherbee, SL | 1 |
| Buhaescu, I; Deray, G; Izzedine, H; Rixe, O | 1 |
| Deeks, ED; Keating, GM | 1 |
| Burstein, HJ; Rugo, HS; Sledge, GW | 1 |
| Bukowski, RM; Motzer, RJ | 1 |
| Chang, JW; Hong, HS; Kuo, TT; Tsai, KY; Yang, CH | 1 |
| Culine, S; Pouessel, D | 3 |
| Chadalavada, RS; Chaganti, RS; Motzer, RJ; Patel, PH | 1 |
| Bukowski, RM; Dreicer, R; Garcia, J; Reddy, S; Rini, BI; Salas, R; Shaheen, P; Tamaskar, I; Wood, L | 1 |
| Fletcher, JA; Rubin, BP | 1 |
| Baum, CM; Bukowski, RM; Bycott, PW; Chen, I; Figlin, RA; Hutson, TE; Kim, ST; Michaelson, MD; Motzer, RJ; Negrier, S; Oudard, S; Rixe, O; Szczylik, C; Tomczak, P | 1 |
| Drazen, JM; Zarin, DA | 1 |
| Brugarolas, J | 1 |
| Dagher, R; Goodman, V; Jiang, JX; Justice, R; Mahjoob, K; Morse, D; Pazdur, R; Rock, EP; Verbois, SL | 1 |
| Chen, I; Kim, ST; Rini, BI; Rosenberg, JE; Shaw, V | 1 |
| Dreicer, R | 1 |
| Creel, P; George, D; Speca, J; Yenser, S | 1 |
| Herbst, RS | 1 |
| George, DJ | 1 |
| Hussar, DA | 1 |
| Senior, K | 1 |
| Colantuoni, G; Comunale, D; De Vita, A; Del Gaizo, F; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Dudek, AZ; Keshtgarpour, M | 1 |
| Chow, LQ; Eckhardt, SG | 1 |
| Abraham, S; Booth, BP; Chidambaram, N; Dagher, R; Gobburu, JV; Goodman, VL; Jiang, JX; Justice, R; Liang, CY; Mahjoob, K; Morse, DE; Pazdur, R; Ramchandani, RP; Rock, EP; Tang, S; Verbois, SL | 1 |
| Figlin, RA | 3 |
| Alberti, L; Blay, JY; Cassier, PA; Dufresne, A; Fayette, J; Ranchere, D; Ray-Coquard, I | 1 |
| Roskoski, R | 1 |
| Michaelson, MD | 2 |
| Miroglu, C; Silay, MS | 1 |
| Heldin, CH; Ostman, A | 1 |
| Dumez, H; Schöffski, P; Wolter, P | 1 |
| Maki, RG | 1 |
| Kruck, S; Kuczyk, M; Merseburger, AS | 1 |
| Fletcher, CD; Hornick, JL | 1 |
| Linehan, WM; Novakovic, KR; Pinto, PA; Vira, MA | 1 |
| Ardizzoni, A; Tiseo, M | 1 |
| Force, T; Krause, DS; Van Etten, RA | 1 |
| Angele, MK; Bruns, CJ; Eichhorn, ME; Jauch, KW; Kleespies, A | 1 |
| De Mulder, PH; Mulder, SF; van Spronsen, DJ | 1 |
| de Lima Lopes, G; Rocha Lima, CM | 1 |
| Dinolfo, M; Hershman, JM; Mulay, M; Rosen, LS; Sugawara, M; Tomoda, C; Vanvugt, A; Wong, E | 1 |
| Senan, S; Smit, EF | 1 |
| Baum, C; Beaudry, P; Bello, C; Demetri, GD; DePrimo, SE; Desai, J; Folkman, J; Force, J; Heymach, JV; Maki, R; Manola, J; Norden-Zfoni, A; Shalinsky, DR | 1 |
| Blay, JY | 4 |
| Baum, C; Bello, CL; Britten, CD; Hecht, JR; Kabbinavar, F; Li, J; Slamon, D | 1 |
| Corless, CL; Heinrich, MC; Rubin, BP | 1 |
| Kamba, T; McDonald, DM | 1 |
| Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P | 1 |
| Cerny, T; Gillessen, S; Graf, L; Korte, W | 1 |
| Camci, C; Kalender, M; Sevinc, A; Sirikci, A; Tutar, E | 1 |
| Boven, E; van den Eertwegh, AJ; van der Veldt, AA | 1 |
| Davis, ID; Nicholaou, T; Wong, R | 1 |
| Davis, PJ; Garfield, DH; Hercbergs, A | 1 |
| Feldman, DR; Martorella, AJ; Motzer, RJ; Robbins, RJ | 1 |
| MacIntyre, J | 1 |
| Di Lorenzo, G | 1 |
| Baz, RC; Bukowski, RM; Choueiri, TK; Elson, P; Garcia, JA; Golshayan, AR; Khasawneh, M; Rini, BI; Usman, S; Wood, L | 1 |
| Billemont, B; Izzedine, H; Rixe, O | 2 |
| George, S | 1 |
| Cartenì, G; D'Attino, R; Grimaldi, AM; Guida, T; Masala, A; Otero, M; Perrotta, E | 1 |
| Etienne-Grimaldi, MC; Ferrero, JM; Fischel, JL; Formento, P; Guérin, O; Hofman, P; Lo Nigro, C; Merlano, M; Milano, G | 1 |
| Beck-Peccoz, P; Bertuelli, R; Carletto, M; Casali, PG; Coco, P; Fugazzola, L; Mannavola, D; Vannucchi, G | 1 |
| Seynaeve, C; Sleijfer, S; Verweij, J; Wiemer, E | 1 |
| Di Lorenzo, L | 1 |
| Baum, CM; Bello, CL; Deprimo, SE; Michaelson, MD; Motzer, RJ; Rini, BI; Smeraglia, J; Spinella, D | 1 |
| Flaherty, KT; Stein, MN | 1 |
| Atkins, MB | 1 |
| Siehl, J; Thiel, E | 1 |
| Rini, BI; Unnithan, J | 1 |
| Chouhan, JD; Grabinski, JL; Lai, PH; Oramasionwu, CU; Zamarripa, DE | 1 |
| Christensen, JG; de Boüard, S; Gauduchon, P; Guillamo, JS; Herlin, P; Lemoisson, E; Raymond, E | 1 |
| Benjamin, RS; Blanke, CD; Blay, JY; Casali, P; Choi, H; Corless, CL; Debiec-Rychter, M; DeMatteo, RP; Demetri, GD; Ettinger, DS; Fisher, GA; Fletcher, CD; Gronchi, A; Hohenberger, P; Hughes, M; Joensuu, H; Judson, I; Le Cesne, A; Maki, RG; Morse, M; Pappo, AS; Pisters, PW; Raut, CP; Reichardt, P; Tyler, DS; Van den Abbeele, AD; von Mehren, M; Wayne, JD; Zalcberg, J | 1 |
| Billemont, B; Izzedine, H; Rixe, O; Thibault, F | 1 |
| Billemont, B; Rixe, O; Thibault, F | 1 |
| Albers, P; Bergmann, L; Geschwend, JE; Jäger, E; Jakse, G; Marschner, N; Miller, K | 1 |
| Goldspiel, BR; Grandinetti, CA | 1 |
| Jewett, MA; Neill, MG; Wei, AC | 1 |
| Bodrogi, I | 1 |
| Kibble, A; Shumoogam, J | 1 |
| Belcaceres, JL; Cojocarasu, O; Halimi, P; Medioni, J; Oudard, S | 1 |
| Reid, TR; Saylor, PJ | 1 |
| Bellido, L; Cruz, JJ; Martín, G | 1 |
| Nishida, T | 1 |
| Demetri, G; Faivre, S; Raymond, E; Sargent, W | 1 |
| Chorianopoulos, E; Frey, N; Jäger, D; Katus, HA | 1 |
| Hayes, DF; Miller, K; Sledge, G | 1 |
| Bihan, H; Cohen, R; des Guetz, G; Krivitzky, A; Uzzan, B | 1 |
| Daniels, GH; Faris, JE; Moore, AF | 1 |
| Chu, CY; Huang, CL; Sheen, YS | 1 |
| Bulusu, R; Carroll, N; Hatcher, H; Jessop, F; Judson, I; Murray, M; Williams, D | 1 |
| George, D; Verweij, J | 1 |
| Bello, C; DePrimo, SE | 1 |
| Demetri, G; Judson, I | 1 |
| George, D; Medioni, J; Motzer, R; Oudard, S | 1 |
| Christensen, JG | 1 |
| Scagliotti, GV | 1 |
| Dettori, M; Fazio, N; Lorizzo, K | 1 |
| Adams, VR; Leggas, M | 1 |
| Shen, L | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Billemont, B; Izzedine, H; Méric, JB; Rixe, O; Sultan-Amar, V; Taillade, L | 1 |
| Robert, C | 1 |
| Bukowski, RM; Curti, BD; George, DJ; Hudes, GR; Margolin, KA; Michaelson, MD; Motzer, RJ; Redman, BG; Rosenberg, J; Wilding, G | 1 |
| Duyster, J; Grundler, R; Kancha, RK; Peschel, C | 1 |
| Brand, A; Gelderblom, H; Kapiteijn, E; Kroep, J | 1 |
| Barkhof, F; Boven, E; Hoekman, K; van den Eertwegh, AJ; van der Veldt, AA | 1 |
| Fiedler, W; Grünwald, V; Heinzer, H | 1 |
| Berets, O; Bladé, JS; Defuentes, G | 1 |
| Alba, E; Medina, MA; Quesada, AR | 1 |
| Arroyo, V; Carmeliet, P; Fernandez-Varo, G; Friedman, SL; Jiménez, W; Morales-Ruiz, M; Muñoz-Luque, J; Rodés, J; Ros, J; Tugues, S | 1 |
| Bjelogrlic, SK; Radulovic, S | 1 |
| Christensen, JG; Ebos, JM; Kerbel, RS; Lee, CR; Mutsaers, AJ | 1 |
| Polyzos, A | 1 |
| Gratama, JW; Kraan, J; Sleijfer, S; Strijbos, MH | 1 |
| Belt, RJ; Bergsland, EK; Chao, RC; Chow-Maneval, E; DePrimo, SE; Eckhardt, SG; Haller, DG; Huang, X; Hurwitz, HI; Lenz, HJ; Lockhart, AC; Marshall, JL; Rocha Lima, CM; Rosen, LS; Saltz, LB | 1 |
| Davis, P; Garfield, D; Hercbergs, A | 1 |
| Thomas, X | 1 |
| Irani, J | 1 |
| Ikezoe, T; Koeffler, HP; Komatsu, N; Nishioka, C; Takeshita, A; Taniguchi, A; Togitani, K; Yang, J; Yokoyama, A | 1 |
| Faivre, S; Le Tourneau, C; Raymond, E | 1 |
| Brozmanova, K; Mardiak, J; Mego, M; Obertova, J; Reckova, M; Sycova-Mila, Z | 1 |
| Bukowski, RM; Dreicer, R; Elson, P; Garcia, JA; Mekhail, T; Rini, BI; Tamaskar, I; Wood, L | 1 |
| Culine, S; Patard, JJ; Pouessel, D; Verhoest, G | 1 |
| Baccala, A; Fergany, A; Gilligan, T; Hedgepeth, R; Kaouk, J; Magi-Galluzzi, C | 1 |
| Corless, CL; Heinrich, MC | 1 |
| Zhu, AX | 1 |
| Audet, P; Ghosn, P; Jeldres, C; Karakiewicz, PI; Patard, JJ; Perrotte, P; Suardi, N | 1 |
| Bhojani, N; Hutterer, G; Jeldres, C; Karakiewicz, PI; Oudard, S; Patard, JJ; Patenaude, F; Perrotte, P; Suardi, N | 1 |
| Dova, L; Fountzilas, G; Georgiou, I; Golfinopoulos, V; Malamou-Mitsi, V; Ntemou, A; Pavlidis, N; Pentheroudakis, G; Vartholomatos, G | 1 |
| Hopkins, TG; Marples, M; Stark, D | 1 |
| Cassiola, F; Chen, JH; Chen, MH; Chu, TF; Dallabrida, SM; Demetri, GD; Desai, J; Force, T; George, S; Harris, DM; Ismail, NS; Kerkela, R; Morgan, JA; Nguyen, L; Pravda, E; Rupnick, MA; Schoen, FJ; Van den Abbeele, AD; Woulfe, K; Zurakowski, D | 1 |
| Basch, E; Motzer, RJ | 1 |
| Bukowski, RM; Choueiri, TK; Elson, P; Escudier, B; Negrier, S; Oudard, S; Plantade, A; Ravaud, A; Rini, BI; Zhou, M | 1 |
| Boven, E; Droogendijk, H; Haanen, JG; Helgason, HH; Mallo, HA; van den Eertwegh, AJ; van der Veldt, AA | 1 |
| Dham, A; Dudek, AZ; Truskinovsky, AM | 1 |
| Azizi, M; Chedid, A; Oudard, S | 1 |
| Alexander, HR; Blansfield, JA; Caragacianu, D; Libutti, SK; Lorang, D; Morita, SY; Muller, G; Royal, RE; Schafer, P; Stirling, D; Tangrea, MA | 1 |
| Khurana, A | 1 |
| Bonomi, L; Imarisio, I; Paglino, C; Porta, C | 1 |
| Hiles, JJ; Kolesar, JM | 1 |
| Astorino, M; Biasco, G; Brandi, G; Castellucci, P; Catena, F; Di Battista, M; Di Scioscio, V; Pantaleo, MA; Piazzi, G; Santini, D; Saponara, M | 1 |
| Margulis, V; Wood, CG | 2 |
| Luisa Del Valle, M; Sanz Rubiales, A | 1 |
| Berg, BC; Chow, S; Suwattee, P; Warshaw, EM | 1 |
| Bui, B; Italiano, A | 1 |
| Atkins, JN; Belani, CP; Brahmer, JR; Chao, RC; Gillenwater, HH; Govindan, R; Novello, S; Pallares, C; Rosell, R; Sanchez, JM; Scagliotti, GV; Selaru, P; Socinski, MA; Tye, L | 1 |
| Holen, KD; Loconte, NK; Mulherin, B | 1 |
| Cohen, AF; Dubois, EA; Osanto, S; van Bronswijk, H | 1 |
| Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Yoshida, J | 1 |
| Demetri, GD; George, S; Humphreys, BD; Maki, RG; Morgan, JA; Patel, TV; Quigley, M | 1 |
| Bukowski, RM; Garcia, J; Heng, DY; Rini, BI; Wood, L | 1 |
| Bradley, DA; Dreicer, R; Dunn, R; Hussain, M; Nanus, D; Rosenberg, J; Smith, DC; Stadler, W | 1 |
| Bletard, N; Bonbled, F; Duck, L; Jacquet, L; Machiels, JP; Pirenne, P | 1 |
| Kuzel, T; Lacouture, ME; Newman, MA; Rosenbaum, SE; West, DP; Wu, S | 1 |
| Dudek, AZ; Mulamalla, K; Truskinovsky, AM | 1 |
| Ehninger, G; Illmer, T | 1 |
| Motzer, RJ; O'Brien, MF; Russo, P | 1 |
| Banzo, I; Barragan, J; Carril, JM; Jimenez-Bonilla, J; Martinez-Rodriguez, I; Portilla-Quattrociocchi, H; Quirce, R; Sainz-Esteban, A | 1 |
| Giordano, S; Petrelli, A | 1 |
| Debiec-Rychter, M; Dziewirski, W; Grzesiakowska, U; Michej, W; Nowecki, Z; Ruka, W; Rutkowski, P; Siedlecki, JA; Szawłowski, A | 1 |
| Courtright, J; Houghton, PJ; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Tajbakhsh, M; Wu, J | 1 |
| Brauer, KM; Brossart, P; Hilf, N; Hipp, MM; Radsak, MP; Singh-Jasuja, H; Walter, S; Weinschenk, T; Werth, D | 1 |
| Gallo, JM; Guo, P; Zhou, Q | 1 |
| Brändle, M; Cerny, T; Gillessen, S; Templeton, A | 1 |
| Autier, J; Mateus, C; Robert, C; Spatz, A; Wechsler, J | 1 |
| Chevreau, C; Delord, JP; Deslandres, M; Sibaud, V | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
| Kataja, V; Kellokumpu-Lehtinen, PL; Martikainen, JA; Purmonen, T; Soini, EJ; Vuorinen, RL | 1 |
| Adams, BJ; Baum, CM; Bello, CL; Burstein, HJ; Cobleigh, MA; DePrimo, SE; Eisenberg, PD; Elias, AD; Lehman, M; Miller, KD; Rugo, HS; Wolff, AC | 1 |
| Arnaud, L; Bousquet, G; Kerob, D; Lebbe, C; Madelaine, I; Sarandi, F; Schartz, NE; Verola, O | 1 |
| Brown, JE; Hall, PS; Kancherla, K; Sastry, PS | 1 |
| Dudek, AZ; Franklin, M; Nguyen, S | 1 |
| Bellersen, L | 1 |
| Blackstein, ME; Chabot, I; LeLorier, J | 1 |
| Arsenault, DA; Flynn, E; Greene, AK; Heymach, JV; Kim, S; Le, H; Lee, S; Meisel, J; Novak, K; Puder, M | 1 |
| Kelleher, FC; McDermott, R | 1 |
| de Mulder, PH; Gietema, JA; Groenewegen, G; Haanen, JB; Jansen, RL; Kruit, WH; Mulders, PF; Osanto, S; Richel, DJ; Sleijfer, S; van den Eertwegh, AJ; Voest, EE | 1 |
| Kasper, KA; Kuzel, TM; Meeks, JJ; Smith, ND; Yang, X | 1 |
| Bickford, C; Champion, JC; Durand, JB; Halushka, M; Kassiotis, CM; Khakoo, AY; Lenihan, DJ; Plana, JC; Tannir, N; Trent, J | 1 |
| Apice, G; Bruni, GS; Caponigro, F; Iaffaioli, RV; Milano, A | 1 |
| Davis, ID; Desai, J; Grossmann, M; Premaratne, E | 1 |
| Pinthus, J | 1 |
| Athar, U; Gentile, TC | 1 |
| Hotte, S; Kavsak, PA | 1 |
| Hariharan, S; Lowry, S | 1 |
| Agulnik, M; Aranha, O; Stein, E | 1 |
| Avakian, R; Belldegrun, AS; Kabbinavar, FF; LaRochelle, JC; Pantuck, AJ; Patard, JJ; Riggs, SB; Shuch, B | 1 |
| Bex, A; Boven, E; de Gast, G; Haanen, JB; Meijerink, MR; van den Eertwegh, AJ; van der Veldt, AA | 1 |
| Conus, NM; Dawson, SJ; Hicks, RJ; McArthur, G; Raleigh, JM; Rischin, D; Toner, GC | 1 |
| Fisher, GA; Srinivas, S; Telli, ML; Witteles, RM | 1 |
| Lee, CB; Socinski, MA | 1 |
| Baker, SD; Dahl, GV; Hu, S; Inaba, H; Minkin, P; Niu, H; Orwick, S; Rubnitz, J; Shimada, A | 1 |
| Buhl, R; Fischer, B | 1 |
| Jonasch, E; Margulis, V; Matin, SF; Swanson, DA; Tamboli, P; Tannir, N; Wood, CG | 1 |
| Staehler, M | 1 |
| Doi, T | 1 |
| Bieber, T; Homey, B; ten Freyhaus, K; Wilsmann-Theis, D | 1 |
| Bitker, MO; Boostan, H; Comperat, E; Meric, JB; Mozer, P; Renard-Penna, R; Richard, F; Rixe, O; Thibault, F | 1 |
| Calvo, E; Prat, A; Serrano, C; Valverde, C | 1 |
| Contreras-Hernández, I; Dávila-Loaiza, G; Garduño-Espinosa, J; Granados-García, V; Mould-Quevedo, JF; Petersen, JA; Salinas-Escudero, G; Silva, A; Villasís-Keever, MA | 1 |
| Gettinger, S | 1 |
| Harisinghani, MG; Iliopoulos, O; McDermott, DF; McGovern, FJ; Michaelson, MD; Oliva, E | 1 |
| Hueman, MT; Schulick, RD | 1 |
| Chakravarthy, AB; Cuneo, KC; Fu, A; Geng, L; Hallahan, DE; Orton, D | 1 |
| Akamatsu, S; Kanamaru, S; Soeda, A; Takenawa, J | 1 |
| Socinski, MA | 1 |
| Rutkowski, P; Siedlecki, JA; Symonides, M; Zdzienicki, M | 1 |
| Nahleh, ZA | 1 |
| Gerami, P; Guitart, J; Lacouture, ME; Reilly, LM | 1 |
| Del Conte, G; Guibal, A; Rüegg, C; Sessa, C | 1 |
| Breaker, K; Flaig, TW; Kim, FJ; La Rosa, FG; Russ, PD; Schoen, J | 1 |
| Baker, S; Christensen, R; Furman, WL; Minkin, P; Navid, F; Stewart, CF | 1 |
| Fenton, MS; Hershman, JM; Marion, KM; Salem, AK | 1 |
| Cumashi, A; Iacobelli, S; Lattanzio, R; Natoli, C; Piantelli, M; Rossi, C; Tinari, N | 1 |
| Kuczyk, MA; Merseburger, AS | 1 |
| Figlin, R; Moldawer, NP | 1 |
| Bierer, S; Bolenz, C; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C | 1 |
| Berkhof, J; Boven, E; de Gast, G; Haanen, JB; Helgason, HH; Mallo, H; Tillier, CN; van den Eertwegh, AJ; van der Veldt, AA; van Wouwe, M | 1 |
| Hes, O; Mardiak, J; Mego, M; Obertova, J; Rajec, J; Rejlekova, K; Rychly, B; Sycova-Mila, Z | 1 |
| Baum, CM; Bergsland, E; Fuchs, CS; Huang, X; Kulke, MH; Lenz, HJ; Li, JZ; Meropol, NJ; Picus, J; Posey, J; Ryan, DP; Stuart, K; Tye, L | 1 |
| Strumberg, D | 1 |
| Gakis, G; Kramer, MW; Kruck, S; Kuczyk, MA; Merseburger, AS; Stenzl, A | 2 |
| Bukowski, RM; Choueiri, TK; Cotta, C; Dreicer, R; Elson, P; Garcia, J; Khasawneh, MK; Mekhail, T; Rini, BI; Unnithan, J; Wood, L | 1 |
| Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; Heinrich, MC; Kepten, I; Le, C; Liegl, B; Zhu, M | 1 |
| Feng, CC; Kao, WY; Lin, HF; Lu, CC; Yu, CY | 1 |
| Alexandrescu, DT; Dasanu, CA; Dawson, N; Farzanmehr, H; Popoveniuc, G; Wartofsky, L | 1 |
| Bhalla, IP; Bukowski, RM; Choueiri, TK; Elson, P; Ganapathi, R; Golshayan, AR; Jaeger, E; Rini, BI; Sein, N; Sercia, L; Simko, J; Small, EJ; Vaziri, SA; Waldman, FM; Weinberg, V; Wood, L; Zhou, M | 1 |
| Cao, R; Cao, Y; Hauptmann, G; Jensen, LD; Söll, I | 1 |
| Mueller, EW; Rashkin, MC; Rockey, ML | 1 |
| Dykens, JA; Hirakawa, B; Hynes, J; Jamieson, J; Jessen, BA; Marroquin, LD; Nadanaciva, S; Patyna, S; Will, Y | 1 |
| Bex, M; Carmeliet, P; Decallonne, B; Dumez, H; Schöffski, P; Stefan, C; Wolter, P | 1 |
| Bukowski, RM; Chen, I; DePrimo, SE; George, DJ; Harmon, CS; Hutson, TE; Kim, ST; Margolin, K; Michaelson, MD; Rini, BI; Rosenberg, JE; Sosman, JA; Stadler, WM | 1 |
| Bushmakin, A; Cappelleri, JC; Cella, D; Charbonneau, C; Chen, I; Kim, ST; Li, JZ; Motzer, RJ | 1 |
| Rini, BI; Vakkalanka, BK | 1 |
| Rübben, H | 1 |
| Culine, S; Patard, JJ; Pouessel, D | 2 |
| Chun, FK; Eichelberg, C; Heinzer, H; Heuer, R; Hinrichs, K; Huland, H; Zacharias, M | 1 |
| O'Dowd, A | 1 |
| Bierer, S; Hertle, L; Nitschmann, S | 1 |
| Bensalah, K; Cornu, JN; Oudard, S; Patard, JJ; Rouprêt, M | 1 |
| Humphreys, BD; Obhrai, JS; Patel, TV | 1 |
| Berneburg, M; Guenova, E; Hoetzenecker, W; Metzler, G; Mitev, V; Röcken, M; Voykov, B; Weber, HO | 1 |
| Charbonneau, C; Kim, ST; Motzer, RJ; Négrier, S; Remák, E | 1 |
| Alexandrescu, DT; Dasanu, CA; Farzanmehr, H; McClure, R | 1 |
| Bierer, S; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C | 1 |
| Bischoff, J; Costa, SD; Ignatov, A; Smith, B; Taran, A | 1 |
| Baum, CM; Bukowski, RM; Figlin, RA; Hutson, TE; Kattan, MW; Kim, ST; Michaelson, MD; Motzer, RJ | 1 |
| Clohisy, DR; Dudek, AZ; Ericson, ME; Gallus, NJ; Jasinski, P; Terai, K; Zwolak, P | 1 |
| Billemont, B; Boudou-Rouquette, P; Goldwasser, F; Loriot, Y; Ropert, S | 1 |
| Moch, H | 1 |
| Stergiopoulos, K; Wu, S; Zhu, X | 1 |
| Barete, S; Billemont, B; Rixe, O | 1 |
| Reichardt, P | 3 |
| Alexandrescu, DT; Anderson, RT; Atkins, MB; Dutcher, JP; Garbe, C; Guitart, J; Hauschild, A; Kong, HH; Lacouture, ME; Puzanov, I; Robert, C; Wood, L; Wu, S | 1 |
| Harshman, L; Srinivas, S | 1 |
| Casper, J; Freund, M; Hilgendorf, I; Kahl, C | 1 |
| Hershman, JM; Moatamed, F; Naeim, F; Sugawara, M; Tomoda, C | 1 |
| Boven, E; Broxterman, HJ; de Gruijl, TD; Giaccone, G; Haanen, JB; Hoekman, K; Oosterhoff, D; Scheper, RJ; van Cruijsen, H; van den Eertwegh, AJ; van der Veldt, AA; Vroling, L | 1 |
| Fujioka, T; Obara, W | 1 |
| Kakehi, Y | 1 |
| Aguilar-Ponce, JL; Buzaid, AC; de la Garza, J; Fernandes, Gdos S; Kann, AG; Maluf, FC | 1 |
| Etienne-Grimaldi, MC; Izzedine, H; Milano, G; Renée, N; Vignot, S | 1 |
| Bensalah, K; Culine, S; Laguerre, B; Patard, JJ; Raffi, A; Thuret, R | 1 |
| Bukowski, RM; Vakkalanka, BK | 1 |
| Hasinoff, BB; O'Hara, KA; Patel, D | 1 |
| Baker, SD; Chen, Z; Gelderblom, H; Minkin, P; Ouwerkerk, J; Zhao, M | 1 |
| Jain, R; Mathew, P; Tannir, NM; Wood, CG | 1 |
| Asmar, L; Berry, WR; Boehm, KA; Hutson, TE; Sonpavde, G | 1 |
| Davis, P; Garfield, DH; Hercbergs, A; Schöffski, P; Wolter, P | 1 |
| Haseke, N; Karl, A; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K | 1 |
| Maitland, ML | 1 |
| Chowdhury, S; Gore, ME; Larkin, JM | 1 |
| Ferrière, JM; Grenier, N; Kilkoski, F; Ravaud, A; Sire, M; Wallerand, H | 1 |
| Figlin, RA; Hutson, TE; Kuhn, JG; Motzer, RJ | 1 |
| Lenihan, DJ | 1 |
| Bojic, A; Bojic, M; Hejna, M; Ruhsam, M; Schmidinger, H; Schmidinger, M; Schukro, C; Vogl, UM; Zielinski, CC | 1 |
| Billemont, B; Helley, D; Medioni, J; Meric, JB; Oudard, S; Rixe, O; Taillade, L | 1 |
| Basso, U; Bedogni, A; Brunello, A; Saia, G; Scaglione, D | 1 |
| Daher, IN; Yeh, ET | 1 |
| Bukowski, R; Dreicer, R; Elson, P; Finke, JH; Garcia, J; Golshayan, A; Ireland, J; Rayman, P; Richmond, A; Rini, B; Wood, L | 1 |
| Hutson, TE | 2 |
| Hur, H; Jee, SB; Jeon, HM; Jung, SE; Kim, W; Park, AR | 1 |
| Bórquez Ma, P; Neveu C, R | 1 |
| Bamias, A | 1 |
| Bex, A; Cosentino, M; Ficarra, V; Flörcken, A; Grünwald, V; Johannsen, M; Kloeters, C; Miller, K; Rief, M; Rogalla, P; Roigas, J | 1 |
| Judson, IR | 1 |
| Antonescu, CR; Baum, CM; Cohen, DP; Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; Griffith, D; Harlow, A; Heinrich, MC; Huang, X; Maki, RG; McKinley, A; Ou, WB; Town, A | 1 |
| Ambudkar, SV; Bates, SE; Robey, RW; Shukla, S | 1 |
| Gallo, JM; Zhou, Q | 2 |
| Fernández-Varo, G; Jiménez, W; Melgar-Lesmes, P; Morales-Ruiz, M; Rodés, J; Ros, J; Tugues, S | 1 |
| Chow, E; Ehrlich, L; Hird, AE; Ko, YJ; Probyn, L; Sinclair, E; Yip, D | 1 |
| Arrigoni, C; Denlinger, R; Evering, W; Heward, JK; Kim, TW; Patyna, S; Terron, A; Turnquist, SE; Vonderfecht, SL | 1 |
| Bengzon, J; Bexell, D; Darabi, A; Gisselsson, D; Gunnarsson, S; Roybon, L; Scheding, S; Tormin, A | 1 |
| Kroog, GS; Motzer, RJ | 1 |
| Boone, SL; Jameson, G; Lacouture, ME; Von Hoff, D | 1 |
| Messori, A; Trippoli, S | 1 |
| Asa, SL; Broom, R; Evans, A; Ezzat, S; Freeman, M; Joshua, AM; Knox, JJ | 1 |
| Kim, EA; Kwon, Y; Lee, KS; Park, IH; Ro, J | 1 |
| Alberti, L; Arifi, S; Blay, JY; Bringuier, PP; Cassier, PA; Dufresne, A; El Sayadi, H; Ray-Coquard, I; Scoazec, JY | 1 |
| Hartmann, JT; Kanz, L | 1 |
| Bluestone, JA; Bollag, G; Lang, J; Lee, MR; Louvet, C; Martinier, N; Szot, GL; Weiss, A; Zhu, S | 1 |
| Cabanillas, ME; Jimenez, C; Jonasch, E; Kyle, KL; Lano, EA; Matin, SF; Nunez, RF; Perrier, ND; Phan, A; Rich, TA; Santarpia, L; Shah, B; Waguespack, SG; Williams, MD | 1 |
| Greten, TF; Korangy, F; Malek, NP; Manns, MP | 1 |
| Azizi, M; Bobrie, G; Bouché, O; Deray, G; des Guetz, G; Halimi, JM; Lecomte, T; Levy, B; Mourad, JJ; Nochy, D; Oudard, S; Rieu, P; Sahali, D | 1 |
| Ashida, A; Kido, K; Murata, H; Saida, T; Takata, M | 1 |
| Ellis, S; Marsh, JE; Sampson, S; Savage, P; Winn, SK | 1 |
| Dham, A; Dudek, AZ; Lindgren, BR; Szczylik, C; Zolnierek, J | 1 |
| Bollée, G; Bruneval, P; Cazajous, G; Fakhouri, F; Goujon, JM; Knebelmann, B; Noël, LH; Patey, N; Robert, C | 1 |
| Loong, HH; Yeo, W | 1 |
| Bajetta, E; Guadalupi, V; Procopio, G | 1 |
| Baldridge, LA; Cheng, L; Cummings, OW; Hahn, NM; Reckova, M; Sweeney, CJ | 1 |
| Aydin, H; Bukowski, RM; Elson, P; Garcia, JA; George, S; Golshayan, AR; Heng, DY; Mekhail, TM; Rini, BI; Wood, LS; Zhou, M | 1 |
| Benhattar, J; Delaloye, AB; Elsig, V; Guillou, L; Leyvraz, S; Luthi, F; Michielin, O; Montemurro, M; Orcurto, MV; Prior, JO; Stupp, R | 1 |
| Brosa, M; Díaz, S; García del Muro, X; González, P; Grande, E; Paz-Ares, L | 1 |
| Haseke, N; Ihrler, S; Karl, A; Schöppler, G; Siebels, M; Stadler, T; Staehler, M; Stief, CG | 2 |
| Castaneda, S; Covello, KL; Fairchild, CR; Fargnoli, J; Hawken, DR; Kan, D; Kramer, R; Lee, FY; Lewin, A; Ryseck, RP; Wen, ML | 1 |
| Campbell, SC; Dreicer, R; Garcia, J; Klein, EA; Lane, BR; Novick, AC; Rini, BI; Thomas, AA | 1 |
| Czabanka, M; Heppner, F; Ullrich, A; Vajkoczy, P; Vinci, M | 1 |
| Raymond, E; Zhu, AX | 1 |
| Beuselinck, B; Pans, S; Schöffski, P; Wolter, P | 1 |
| Bukowski, RM; Chi, KN; Garcia, JA; Heng, DY; Jin, T; Kollmannsberger, C; Murray, N; Rini, BI | 1 |
| Beniak, J; Kakalejcik, M; Reckova, M | 1 |
| Daniels, GH | 1 |
| Bex, A; Blank, C; Boven, E; Haanen, J; Horenblas, S; van den Eertwegh, AJ; van der Veldt, AA | 1 |
| Biswas, S; Eisen, T; Kelly, J | 1 |
| Ballanger, P; Bernhard, JC; Bram, R; Cornelis, F; Deminière, C; Gabbay, G; Ravaud, A; Robert, G; Wallerand, H | 1 |
| Beijnen, JH; Burger, DM; Desar, IM; Van der Graaf, WT; Van Herpen, CM; Van Hoesel, QG | 1 |
| Andrieu, JM; Azizi, M; Banu, E; Chedid, A; Fournier, L; Helley, D; Medioni, J; Mejean, A; Oudard, S; Scotte, F | 1 |
| Christensen, J; Demetri, GD; Deshmukh, GD; Diehl, W; DiNitto, JP; Emmett, MR; English, JM; Gajiwala, KS; Greig, MJ; He, YA; Jacques, SL; Lunney, EA; Marshall, AG; McTigue, M; Molina, D; Quenzer, T; Wells, PA; Wu, JC; Yu, X; Zhang, HM; Zhang, Y; Zou, A | 1 |
| Froehner, M; Novotny, V; Platzek, I; Wirth, MP; Zastrow, S | 1 |
| Bang, SM; Kim, CJ; Kim, H; Kim, JH; Kim, JS; Kim, YJ; Lee, HE; Lee, JO; Lee, JS; Lee, KW | 1 |
| Antonian, L; Bello, CL; Haznedar, JO; Patyna, S; Peng, GW; Speed, W; Sukbuntherng, J; Sweeny, DJ; Wu, EY; Yu, X; Zhang, Q | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Berger, W; Lamm, W; Micksche, M; Pichelmeyer, O; Pirker, C; Schmidinger, M; Vogl, UM; Zielinski, CC | 1 |
| Mills, EJ; O'Regan, C; Perri, D; Rachlis, B; Thabane, L | 1 |
| Bergmann, L; Jäger, E; Jakse, G; Keilholz, U; Miller, K; Wirth, M | 1 |
| Alken, P; Bolenz, C; Häcker, A; Herrmann, E; Honeck, P; Michel, MS; Schöppler, G; Trojan, L | 1 |
| Bernstein, ML | 1 |
| Awada, AH; Hatoum, HA; Ishak, RS; Otrock, ZK; Shamseddine, AI | 1 |
| Ayllon, J; Cros, C; Launay-Vacher, V; Medioni, J; Oudard, S; Spano, JP | 1 |
| Brich, S; Casali, PG; Crippa, F; Gronchi, A; Marrari, A; Morosi, C; Orsenigo, M; Pierotti, MA; Pilotti, S; Rota, SA; Stacchiotti, S; Tamborini, E | 1 |
| Boven, E; Broxterman, HJ; Haanen, JG; van den Eertwegh, AJ; van der Veldt, AA; Vroling, L | 1 |
| Sevinc, A | 1 |
| Nurzyński, P; Opolski, G; Szaluś, N; Szczylik, C; Szmit, S | 1 |
| Hill, KL; Lipson, AC; Sheehan, JM | 1 |
| Mayor, S | 2 |
| Boven, E; Broxterman, HJ; de Haas, RR; Haanen, JB; Hoekman, K; Kuik, DJ; Schuurhuis, GJ; van Cruijsen, H; van den Eertwegh, AJ; van der Veldt, AA; van Hinsbergh, VW; Verheul, HM; Vroling, L | 1 |
| Bukowski, RM | 1 |
| Chu, D; Lacouture, ME; Weiner, E; Wu, S | 1 |
| Curiel, RE; Motzer, RJ; Patel, PH; Senico, PL | 1 |
| Fayyad, R; Figlin, RA; Hariharan, S; Hudes, G; Kempin, S; Motzer, RJ; Schwartz, LH; Wilding, G | 1 |
| Laber, DA; Mushtaq, M | 1 |
| Bas, CA; Gomez-Abuin, G; Karam, AA; Mezzadri, NA | 1 |
| Izzedine, H; Massard, C; Soria, JC | 1 |
| Baum, MS; Feldman, DR; Fischer, P; Flombaum, CD; Ginsberg, MS; Hassoun, H; Ishill, N; Motzer, RJ; Patil, S; Ronnen, E; Velasco, S | 1 |
| Schmidinger, M; Zielinski, CC | 1 |
| Chen, ZS; Dai, CL; Fu, LW; Liang, YJ; Tiwari, AK; Tong, XZ; Wang, F; Wang, YS; Yan, YY | 1 |
| Fortuna, G; Leuci, S; Mignogna, MD; Pollio, A; Ruoppo, E | 1 |
| Baillet, G; Barré, E; Bousquet, G; Desgrandchamps, F; Hindié, E; Just, PA; Mathieu, O; Misset, JL; Moretti, JL; Vercellino, L | 1 |
| Du, Y; Figlin, R; Herrmann, A; Xin, H; Yu, H; Zhang, C | 1 |
| Porta, C; Szczylik, C | 1 |
| Bjarnason, GA; Christensen, JG; Cruz-Munoz, W; Ebos, JM; Kerbel, RS; Lee, CR | 1 |
| Bargman, JM; Oreopoulos, DG; Simons, M; Tapiawala, SN | 1 |
| Amantea, M; Bello, CL; Houk, BE; Kang, D | 1 |
| Bellmunt, J; Calvo, E; Castellano, D; Climent, MA; Esteban, E; García del Muro, X; González-Larriba, JL; Maroto, P; Trigo, JM | 1 |
| Ahn, H; Ahn, JH; Choi, JS; Kim, TW; Kim, YR; Koh, JM; Lee, DH; Lee, JL; Lee, JS; Park, I; Park, KS; Park, TS | 1 |
| Choueiri, TK; Chowdhury, S | 1 |
| Bukowski, R; Cohen, P; Dreicer, R; Elson, P; Finke, JH; Garcia, J; Golshayan, A; Ireland, JL; Ko, JS; Rayman, PA; Rini, BI; Wood, L; Zea, AH | 1 |
| Chen, SH; Divino, CM; Kao, J; Ma, G; Meseck, M; Ozao-Choy, J; Pan, PY; Schwartz, M; Sung, M; Wang, GX | 1 |
| Alfaro, C; Dubrot, J; Erro, L; Gonzalez, A; Grande-Pulido, E; Gurpide, A; Hervas-Stubbs, S; Lopez-Picazo, JM; Melero, I; Palazon, A; Perez-Gracia, JL; Solano, S; Suarez, N | 1 |
| Blay, JY; Casali, PG; Cohen, DP; Demetri, GD; Deprimo, SE; George, S; Harmon, CS; Law, CN; Le Cesne, A; Morgan, JA; Ray-Coquard, I; Stephenson, P; Tassell, V | 1 |
| Blanke, CD; Fernandes, Gdos S; Freitas, D; Guedes, R; Hoff, PM | 1 |
| von Mehren, M; Watson, JC | 1 |
| Bertagnolli, MM; Raut, CP | 1 |
| Andreadis, C; Kontovinis, LF; Kortsaris, AH; Mouratidou, D; Papazisis, KT; Touplikioti, P | 1 |
| Chmielewski, G; Freshwater, K; Haznedar, J; Matsumoto, D; Morris, D; Patyna, S; Peng, G; Sukbuntherng, J | 1 |
| Mizutani, Y | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 2 |
| Farace, F; Geoerger, B; Lagodny, J; Rössler, J; Taylor, M; Vassal, G | 1 |
| Kamposioras, K; Mauri, D; Panou, C; Tsali, L; Valachis, A | 1 |
| Asemissen, AM; Keilholz, U; Knoedler, M; Miller, K; Schmittel, A; Steiner, U; Thiel, E; Zimmermann, K | 1 |
| Feyerabend, S; Schilling, D; Stenzl, A; Wicke, C | 1 |
| Jarkowski, A; Wong, MK | 1 |
| Albritton, KH; Butrynski, JE; D'Amato, GZ; Demetri, GD; Heinrich, MC; Janeway, KA; Pedrazzoli, P; Picus, J; Schlemmer, M; Siena, S; Van Den Abbeele, AD | 1 |
| Chen, SY; Chiang, WC; Fang, CC; Kao, PC; Lin, ZZ | 1 |
| Betjes, MG; Rolleman, EJ; Weening, J | 1 |
| Barnabei, A; Corsello, SM; Gasparini, G; Longo, R; Torino, F | 2 |
| Ahlman, H; Nilsson, B; Nilsson, O | 1 |
| Chan, JA; Kulke, MH | 1 |
| Liu, CY; Shields, AF; Weise, AM | 1 |
| Borgman, CL; Brandstetter, KA; Chirieac, LR; Gandhi, L; Li, D; McDermott, U; McNamara, KL; Padera, RF; Settleman, JE; Wong, KK | 1 |
| Bastien, L; Culine, S; de la Taille, A; Ledbai, S; Patard, JJ; Paule, B | 1 |
| Benichou, AS; Billemont, B; Blanchet, B; Dauphin, A; Goldwasser, F; Ropert, S; Saboureau, C; Taieb, F; Tod, M | 1 |
| Armand, JP; Domont, J; Lassau, N; Le Cesne, A; Massard, C; Soria, JC | 1 |
| Connault, J; Durant, C; Pistorius, MA; Planchon, B; Saint-Jean, M | 1 |
| Horn, L; Sandler, AB | 1 |
| Soulières, D; Taussky, D | 1 |
| Ames, RY; Brannigan, BW; Erlander, MG; Greninger, P; Haber, DA; Iafrate, AJ; Lee, DY; Lucien, L; Ma, XJ; Maheswaran, S; McCutcheon, K; McDermott, U; Milano, R; Settleman, J; Sharma, SV; Stubbs, H; Tam, A; Ulkus, LE | 1 |
| Hamada, Y; Shibata, A; Tahara, M; Yamaguchi, S | 1 |
| Cho, D; Choueiri, TK; Fournier, L; Medioni, J; Oudard, S; Zinzindohoué, F | 1 |
| Kurzyna, M; Opolski, G; Szczylik, C; Szmit, S; Zagrodzka, M | 1 |
| Maitland, ML; Snider, KL | 1 |
| Chen, MH | 1 |
| Ball, SA; Plowman, PN; Reznek, R; Richards, TM | 1 |
| Agarwal, N; Chen, A | 1 |
| Gall, P; Hengerer, A; Huppert, J; Kiessling, F; Kiselev, V; Lederle, W; Palmowski, M; Semmler, W; Strecker, R; Taupitz, M; Woenne, EC; Zwick, S | 1 |
| Bellmunt, J; Flodgren, P; Oudard, S; Roigas, J | 1 |
| Doi, T; Hirota, S; Komatsu, Y; Nakajima, K; Nishida, T; Nishitani, A; Shirao, K; Takahashi, T | 1 |
| Bagner, JW; Bergmann, L; Ecke, TH; Eimer, C; Gerullis, H; Maute, L; Otto, T | 1 |
| Dror Michaelson, M; Gurski, C; Kantoff, PW; Kaufman, DS; Michaelson, SZ; Oh, WK; Olivier, K; Regan, MM; Smith, MR; Spicer, B | 1 |
| Ravaud, A; Sire, M | 1 |
| Clohisy, DR; Frolich, JW; Manivel, JC; Skubitz, KM | 1 |
| Baruchel, S; Chong, AL; Irwin, MS; Kaplan, DR; Marrano, P; Smith, KM; Stempak, D; Thorner, PS; Yeger, H; Zhang, L | 1 |
| Dudek, AZ; Franklin, M; Murthaiah, PK; Truskinovsky, AM | 1 |
| Secasan, CC | 1 |
| Capellà, G; Casanovas, O; Castillo-Avila, W; Condom, E; Garcia Del Muro, X; Germà, JR; Mora, J; Piulats, JM; Vidal, A; Villanueva, A; Viñals, F | 1 |
| Billemont, B; Kelly, RJ; Rixe, O | 1 |
| Sternberg, CN | 1 |
| Bukowski, R; Flodgren, P; Ravaud, A; Schöffski, P | 1 |
| Burkitt, K; Chun, SY; Dang, DT; Dang, LH | 1 |
| Bojic, A; Lamm, W; Schmidinger, M; Vogl, UM; Zielinski, CC | 1 |
| Augereau, B; Gregory, T; Medioni, J; Mir, O; Oudard, S | 1 |
| Balleyguier, C; Celier, C; Escudier, B; Gautier, J; Medioni, J; Negrier, S; Oudard, S; Ravaud, A; Sablin, MP | 1 |
| Akhurst, T; Bhuchar, G; Butrynski, JE; D'Adamo, DR; Demetri, GD; George, S; Harmon, DC; Keohan, ML; Maki, RG; Merriam, P; Morgan, J; O'Mara, MM; Schwartz, GK; Van den Abbeele, AD; Wagner, AJ; Yap, JT | 1 |
| Desar, IM; Mulder, SF; Mulders, PF; Stillebroer, AB; van der Graaf, WT; van Herpen, CM; van Spronsen, DJ | 1 |
| Gan, HK; Knox, JJ; Seruga, B | 1 |
| Andresen, CJ; Bagi, CM; Christensen, J; Cohen, DP; Roberts, WG; Swanson, T; Tuthill, T; Wilkie, D | 1 |
| Gillessen, S; Omlin, A; Rothermundt, CA | 1 |
| Gelderblom, H; Grünwald, V; Hartmann, JT; Joensuu, H; Leyvraz, S; Montemurro, M; Reichardt, P; Roth, A; Schöffski, P; Schütte, J; Seddon, B; von Moos, R; Weber, E; Wendtner, CM | 1 |
| Abrams, TA; Ancukiewicz, M; Bhargava, P; Blaszkowsky, LS; Catalano, OA; Clark, JW; di Tomaso, E; Duda, DG; Enzinger, PC; Fuchs, CS; Hezel, AF; Jain, RK; Kwak, EL; Lahdenranta, J; Meyerhardt, J; Miksad, R; Ryan, DP; Sahani, DV; Sindhwani, V; Yoon, SS; Zhu, AX | 1 |
| Aieta, M; Autorino, R; Bruni, G; Cartenì, G; De Nunzio, C; De Placido, S; Di Lorenzo, G; Ewer, M; Ficorella, C; Giordano, A; Giuliano, M; Gonnella, A; Montesarchio, V; Ricevuto, E; Rizzo, M; Romano, C; Tudini, M | 1 |
| Bovée, JV; Gelderblom, H; Hogendoorn, PC; Kroep, JR; van der Molen, AJ | 1 |
| Goda, F; Himoto, T; Hosomi, N; Inukai, M; Kohno, M; Kohno, T; Masugata, H; Murao, K; Okuyama, H; Senda, S; Yamagami, A; Yukiiri, K | 1 |
| Shibuya, M | 1 |
| English, BC; Figg, WD; Price, DK | 1 |
| Behnam, SE; Fife, DJ; Linden, KG; Wu, JJ | 1 |
| Bjarnason, GA; Bukowski, RM; Chen, I; Figlin, RA; Garcia-del-Muro, X; Huang, X; Hutson, TE; Kim, ST; Michaelson, MD; Motzer, RJ; Negrier, S; Oudard, S; Pili, R; Solska, E; Sosman, JA; Szczylik, C; Thompson, JA; Tomczak, P; Wilding, G | 1 |
| DU, Q; Huang, M; Liu, X; Yao, X; Yin, KS | 1 |
| Blay, JY; Reichardt, P | 1 |
| Chung, BI; Harshman, LC; Kamaya, A; Srinivas, S | 1 |
| Aliberti, C; Ballardini, P; Manfredini, R; Margutti, G | 1 |
| Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
| Brower, V | 1 |
| Boterberg, T; Casneuf, VF; Delrue, L; Demetter, P; Peeters, M; Van Damme, N | 1 |
| Berchem, G; Dewilde, S; Mahassen, P | 1 |
| Battistella, M; Boukoucha, M; Chami, L; Cribier, B; Duvillard, P; Lassau, N; Mateus, C; Robert, C | 1 |
| Alasker, A; Guevremont, C; Karakiewicz, PI | 1 |
| Abel, EJ; Wood, CG | 1 |
| Cortés-Funes, H | 1 |
| Cesaretti, JA; Chen, SH; Huang, D; Kao, J; Lo, YC; Packer, S; Schwartz, ME; Stock, RG; Sung, MW; Vu, HL | 1 |
| Bex, A; Boven, E; van der Veldt, AA | 1 |
| Chuang, WP; Hsiao, CH; Li, AH; Wu, CF | 1 |
| Bozec, A; Etienne-Grimaldi, MC; Fischel, JL; Milano, G; Sudaka, A; Toussan, N | 1 |
| Benounna, M; Rivera, F; Sánchez de la Nieta, MD | 1 |
| Baek, KH; Dodd, RD; Dreyfuss, JM; Fisher, CJ; Jacks, T; Kirsch, DG; Lee, YJ; Mahmood, U; Nielsen, GP; Park, PJ; Rothrock, C; Ryeom, S; Stangenberg, L; Waterman, PR; Weissleder, R; Yoon, SS | 1 |
| Bosl, GJ; Carousso, M; Feldman, DR; Ginsberg, MS; Ishill, N; Motzer, RJ; Patil, S; Turkula, S | 1 |
| Escudier, B; Gross-Goupil, M; Lassau, N; Massard, C; Mejean, A; Michels, J | 1 |
| Abrio, MV; Castellano, D; Cerezo, SD; del Muro, XG; González-Larriba, JL; Grande, E; Guzmán, C; Pardo, A; Pérez-Gracia, JL; Ruiz, MA | 1 |
| McBride, D | 1 |
| Bayz, U; Can, IH; Doğan, S; Ozer, E; Samim, EE; Sayn, M; Yazici, G | 1 |
| Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC | 1 |
| Bamias, A; Dimopoulos, MA; Gyftaki, R; Koroboki, E; Lainakis, G; Manios, E; Zakopoulos, N | 1 |
| Green, C; Hoyle, M; Liu, Z; Moxham, T; Rogers, G; Stein, K; Thompson Coon, JS; Welch, K | 1 |
| Chen, HX; Cleck, JN | 1 |
| Boucher, E; Cheng, AL; Deprimo, S; Douillard, J; Faivre, S; Harmon, C; Kim, JS; Lanzalone, S; Lechuga, MJ; Lim, HY; Lin, X; Raymond, E; Ruiz-Garcia, A; Zappa, M | 1 |
| Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
| Melichar, B | 1 |
| Argyriou, AA; Dimitrakopoulos, F; Dimitropoulos, K; Giannopoulou, E; Kalofonos, HP; Koutras, AK | 1 |
| Bjarnason, GA; Bracarda, S; Bukowski, R; Castellano, D; Gore, ME; Haanen, J; Hariharan, S; Lee, SH; Mainwaring, P; Nieto, A; Oudard, S; Porta, C; Schöffski, P; Szczylik, C; Vrdoljak, E; Yuan, J | 1 |
| Bellmunt, J; Choueiri, TK | 1 |
| Campbell, SC; Fergany, A; Garcia, JA; Gill, IS; Klein, EA; Krishnamurthi, V; Novick, AC; Rini, BI; Stephenson, AJ; Thomas, AA; Zhou, M | 1 |
| Hirakawa, K; Kaizaki, R; Matsuoka, T; Matsuzaki, T; Miwa, A; Nakamura, K; Shinto, O; Tendo, M; Yashiro, M | 1 |
| Ang, BW; Cheng, CL; Chou, N; Lee, KM; Lee, SC; Wong, AL | 1 |
| Awasthi, S; Rao Lelsani, PC; Sahu, M; Sehrawat, A; Singhal, P; Singhal, SS; Vatsyayan, R; Yadav, S | 1 |
| Bil, J; Golab, J; Jakobisiak, M; Nowis, D; Zapala, L | 1 |
| Asmar, L; Bernold, D; Berry, WR; Boehm, KA; Fleming, MT; Galsky, MD; Hutson, TE; Periman, PO; Sonpavde, G; Weckstein, D; Zhan, F | 1 |
| Boix, E; Herrero, J; Meana, JA; Piñar, D | 1 |
| Bamias, A; Dimopoulos, MA; Fountzilas, G; Lainakis, G; Psimenou, E | 1 |
| Fokt, RM; Gillessen, S; Ohlschlegel, C; Schmid, HP; Templeton, A | 1 |
| Park, CY | 1 |
| Bruix, J; Forner, A; Llovet, JM | 1 |
| Balis, FM; Kim, A; Widemann, BC | 1 |
| Choong, NW; Cohen, EE; Dekker, A; Hu, HS; Ivy, P; Karrison, TG; Kozloff, M; Taber, D; Vokes, EE; Wade, J | 1 |
| Aieta, M; Autorino, R; Bruni, G; Cartenì, G; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Ficorella, C; Giannarini, G; Gonnella, A; Imbimbo, C; Longo, N; Mirone, V; Palmieri, G; Perdonà, S; Pignata, S; Rescigno, P; Rizzo, M; Tudini, M | 1 |
| Chen, I; Escudier, B; Flodgren, P; Fountzilas, G; Gillessen, S; Harmenberg, U; Maneval, EC; Mulder, SF; Peschel, C; Roigas, J; Srinivas, S; Vogelzang, NJ | 1 |
| Andreiuolo, F; Bobos, M; Calderaro, J; Fountzilas, G; Fragkoulidi, A; Kalogera-Fountzila, A; Marselos, M; Nikolaidou, M | 1 |
| Ikezoe, T; Nishioka, C; Yang, J; Yokoyama, A | 1 |
| Akyurek, N; Benekli, M; Buyukberber, S; Coskun, U; Demirci, U; Karakan, T; Tonyali, O; Yildiz, R | 1 |
| Samlowski, W; Vogelzang, NJ; Weissman, A | 1 |
| Baak-Pablo, RF; Boven, E; Eechoute, K; Gelderblom, H; Guchelaar, HJ; Haanen, JB; Mathijssen, RH; Reyners, AK; van der Straaten, T; van der Veldt, AA; van Erp, NP; Wessels, JA | 1 |
| Dreyer, C; Faivre, S; Raymond, E; Theou-Anton, N | 1 |
| Ansari, J; Deshmukh, N; Doherty, A; McCafferty, I; Porfiri, E; Wallace, M | 1 |
| Jafri, M; Porfiri, E | 1 |
| Benghiat, H; Collins, S; James, N; Karina, M; Oldroyd, A; Parry, H; Pascoe, J; Porfiri, E; Ray, D; Zachariah, A | 1 |
| Eisterer, W; Ploner, F | 1 |
| Cella, D | 2 |
| Schiff, D; van den Bent, MJ; Wen, PY | 1 |
| Kuszatal, E; Langiewicz, P; Nurzyński, P; Oborska, S; Obrocka, B; Szczylik, C; Waśko-Grabowska, A; Zołnierek, J | 1 |
| Amraoui, S; Boulon, C; Conri, C; Constans, J; Solanilla, A; Viguier, JB | 1 |
| Becker, CR; Berger, F; Nikolaou, K; Reiser, MF; Schinwald, N; Schlemmer, M; Sourbron, SP | 1 |
| Abrams, J; Al-Bashir, AK; Haacke, EM; Hillman, GG; Katkuri, Y; Li, M; Patel, AD; Singh-Gupta, V; Yunker, CK; Zhang, H | 1 |
| Chandramouli, GV; Hyodo, F; Krishna, MC; Matsumoto, K; Matsumoto, S; Mitchell, JB; Munasinghe, JP | 1 |
| Li, XG; Wang, GF; Wu, SG; Wu, SY; Xu, W; Zhang, JJ; Zhang, JY | 1 |
| Cersosimo, RJ | 1 |
| Doi, T; Komatsu, Y; Li, Y; Muro, K; Nishida, T; Ohtsu, A; Shirao, K; Ueda, E | 1 |
| Kosák, M; Koskuba, J; Kreze, A; Stáhalová, V; Zadrazilová, A | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Bharthuar, A; Iyer, R; Kuvshinoff, B; LeVea, C; Litwin, A; Pearce, L | 1 |
| Ivy, SP; Kaufman, BM; Wick, JY | 1 |
| Antonescu, CR; Baum, CM; Bello, CL; Chen, MH; Cohen, DP; Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; George, S; Heinrich, MC; Huang, X; Maki, RG; Morgan, JA; Van den Abbeele, AD | 1 |
| Blanke, CD | 1 |
| Baum, CM; Blackstein, ME; Demetri, GD; Deprimo, SE; Garrett, CR; Harmon, CS; Huang, X; Schöffski, P; Shah, MH; Verweij, J | 1 |
| Eisenhauer, EA; Ivy, P; Mackay, HJ; Oza, A; Sederias, J; Swenerton, K; Thomas, G; Tinker, A; Winquist, E | 1 |
| Cardoso, F; Senkus-Konefka, E | 1 |
| Bergh, J; Castany, R; Liljegren, A | 1 |
| Carbonell, CE; Coleman, TA; Davis, CH; Davis, WB; La Vine, DB | 1 |
| Chang, AP; Choo, SP; Chow, PK; Chung, AY; Huynh, H; Jin, Y; Koong, HN; Ngo, VC; Ong, HS; Ong, LC; Poon, D; Song, IC; Soo, KC; Thng, CH; Toh, HC; Zheng, L | 1 |
| Kalantari, HR | 1 |
| Chun, MG; Golub, TR; Hanahan, D; Libutti, SK; Lu, J; Nakakura, EK; Olson, P; Shai, A; Wang, Y; Zhang, H | 1 |
| Stang, JL; Tran, LM; Zhong, H | 1 |
| Choueiri, TK; Je, Y; Schutz, FA | 1 |
| Beynat, C; Coudert, B; Diaz, P; Favier, L; Ghiringhelli, F; Ladoire, S | 1 |
| Kang, DY; Kim, S; Lee, HJ; Lim, JS; Song, IC; Yun, HJ | 1 |
| Beatty, K; Bokar, J; Borden, E; Budd, GT; Bukowski, RM; Chen, HX; Cooney, MM; Dolwati, A; Dreicer, R; Elson, P; Garcia, JA; Ivy, P; Mekhail, T; Rini, BI; Triozzi, P; Tyler, A | 1 |
| Baker, SD; Chen, Z; Franke, R; Hu, S; Orwick, S; Rudek, MA; Sparreboom, A; Zhao, M | 1 |
| Bello, CL; Garrett, M; Khosravan, R; La Fargue, J; Lunde, NM; Marbury, TC; Ni, G; Swan, SK; Toh, M | 1 |
| Garnock-Jones, KP; Keating, GM | 1 |
| Etienne-Grimaldi, MC; Izzedine, H; Milano, G; Renée, N | 1 |
| Atrash, F; Bar-Sela, G; Hadad, S; Haim, N; Kedem, E; Pollack, S; Shahar, E | 1 |
| D'Adamo, D | 1 |
| Anderson, R; Bond, M; Hoyle, M; Moxham, T; Napier, M | 1 |
| Bosscher, JR; Brown, J; Debernardo, RL; Gehrig, PA; Hartenbach, EM; Hensley, ML; McCourt, CK; Scribner, DR; Sill, MW | 1 |
| Eigl, BJ; Hemmelgarn, B; Heng, DY; Vickers, MM | 1 |
| Choueiri, TK; Hirsch, MS; Mosquera, JM | 1 |
| Burrell, RA; Swanton, C | 1 |
| Dieckmann, K; Elandt, K; Hutterer, M; Koperek, O; Marosi, C; Prayer, D; Preusser, M; Sohm, M | 1 |
| Diaz, R; Hallahan, DE; Passarella, RJ; Phillips, JG; Wu, H; Zhou, L | 1 |
| Atkins, MB; Bukowski, RM; Cheng, T; Chi, KN; Choueiri, TK; Eigl, BJ; Golshayan, AR; Heng, DY; Knox, JJ; Kollmannsberger, C; McDermott, DF; North, S; Oh, WK; Regan, MM; Rini, BI; Ruether, JD; Sahi, C; Venner, P; Warren, MA; Xie, W | 1 |
| Atkins, J; Brahmer, J; Burgess, R; Chao, R; Govindan, R; Novello, S; Pallares, C; Rosell, R; Scagliotti, GV; Selaru, P; Socinski, MA; Tye, L; Wang, E | 1 |
| Kuczyk, MA; Merseburger, AS; Simon, A; Waalkes, S | 1 |
| Dikilitas, M; Er, O; Karaca, H; Lale, A; Ozkan, M | 1 |
| Abe, F; Dafferner, A; Hoke, TA; Samson, H; Scholar, E; Talmadge, JE; Westphal, S; Younos, I | 1 |
| Al Enazi, MM; Kadry, R; Mitwali, H | 1 |
| Crouthamel, MC; Gontarek, RR; King, AG; Kumar, R; Levin, RA; Rominger, DH; Tummino, PJ | 1 |
| Wilkes, GM | 1 |
| Agaram, NP; Antonescu, CR; Besmer, P; Clarkson, BD; Dematteo, RP; Guo, T; Hajdu, M; Maki, RG; Shinoda, H; Singer, S; Veach, D | 1 |
| Edeline, J; Laguerre, B; Patard, JJ; Rolland, Y | 1 |
| Borges, A; Bugalho, MJ; Domingues, R | 1 |
| Balvay, D; Chatellier, G; Cuenod, CA; Dromain, C; Escudier, B; Fournier, LS; Medioni, J; Oudard, S; Thiam, R; Trinquart, L | 1 |
| Goldschmeding, R; Overkleeft, EN; van Reekum, F; Verheul, HM; Voest, EE | 1 |
| Breau, RH; Leibovich, BC | 1 |
| Healy, ME; Krajewski, KM; Lai, KC; Miksad, RA; Rojas, R; Stein, MC; Zhu, AX | 1 |
| Papaetis, GS; Syrigos, KN | 1 |
| Agata, N; Akaza, H; Fujimoto, H; Hasegawa, Y; Houk, B; Miki, T; Mugiya, S; Naito, S; Niwakawa, M; Nonomura, N; Shinohara, N; Takahashi, M; Tomita, Y; Uemura, H; Yuasa, T | 2 |
| Bertagnolli, MM; Butrynski, JE; Demetri, GD; Fletcher, CD; George, S; Manola, J; Morgan, JA; Raut, CP; Wagner, AJ; Wang, Q | 1 |
| Schöffski, P; Wolter, P | 1 |
| Cappelleri, JC; Cella, D; Charbonneau, C; Chen, I; Kim, ST; Li, JZ; Luo, X; Motzer, RJ | 1 |
| Bouattour, M; Dreyer, C; Faivre, SJ; Raymond, E | 1 |
| Aragon-Ching, JB; Dahut, WL | 1 |
| Baum, C; Bello, CL; Dinolfo, M; Huang, X; Levine, S; Mulay, M; Patyna, S; Rosen, L; Toh, M; Van Vugt, A | 1 |
| Calvo, A; Gil-Bazo, I; Gonzalez, A; Grande-Pulido, E; Guillén-Grima, F; Gurpide, A; Melero, I; Panizo, A; Perez-Gracia, JL; Prior, C; Segura, V | 1 |
| Faivre, S; Hammel, P; Raymond, E; Ruszniewski, P | 1 |
| Biasco, G; Catena, F; Di Battista, M; Nannini, M; Pantaleo, MA | 1 |
| Bompas, E; Dillies, AF; Duprez, T; Faivre, S; Guigay, J; Henry, S; Kaminsky, MC; Machiels, JP; Michoux, N; Moxhon, A; Rommel, D; Schmitz, S; Zanetta, S | 1 |
| Escudier, B; Gore, M; Mickisch, G; Nuijten, M; Procopio, G; Walzer, S | 1 |
| Lipworth, AD; Robert, C; Zhu, AX | 1 |
| Cowey, CL; Fielding, JR; Rathmell, WK | 1 |
| de Bruijn, P; Lam, MH; Loos, WJ; Mathijssen, RH; Sleijfer, S; Wiemer, EA | 1 |
| Hohenberger, P | 1 |
| Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Staehler, M; Varga, Z | 1 |
| Sherman, SI | 1 |
| Atkins, MB; Choueiri, TK | 1 |
| Bzyl, J; Gaetjens, J; Günther, RW; Hauff, P; Kiessling, F; Lederle, W; Palmowski, M; Semmler, W; Socher, M | 1 |
| Digue, L; Ravaud, A; Smith, D; Trufflandier, N | 1 |
| Thompson, JA | 1 |
| Wood, LS | 1 |
| Agaimy, A; Schneider-Stock, R | 1 |
| Carli, P; Ceravolo, R; Donach, M; Faggioni, G; Farina, M; Furini, L; Lombardi, G; Nicoletto, O; Pastorelli, D; Zovato, S; Zustovich, F | 1 |
| Brade, AM; Chung, C; Dawson, LA; Joshua, AM | 1 |
| Gore, M; Larkin, J | 1 |
| Bello, CL; Demetri, GD; Houk, BE; Motzer, RJ; Poland, B; Rosen, LS | 1 |
| Li, X; Liu, J; Qiang, W; Yang, Y; Yao, J; Zeng, H; Zhu, Y | 1 |
| Baessler, T; Kampa, KM; Krusch, M; Mayer, F; Salih, HR; Salih, J; Schlicke, M | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Goh, V; Juttla, J; Nathan, PD; Stott, D; Vinayan, A | 1 |
| Briaire-de Bruijn, IH; Gelderblom, H; Hogendoorn, PC; Jordanova, ES; Ottenhoff, TH; Savage, ND; van der Burg, SH; van Dongen, M; van Hall, T; Walburg, KV | 1 |
| Gu, Y; Meng, F; Qu, B; Shu, Y; Sun, Y; Xu, Q; Zhao, W; Zhu, X | 1 |
| Costero, O; Martinez-Ara, J; Picazo, ML; Romero, S; Selgas, R; Zamora, P | 1 |
| Freĭdlin, IS; Kiseleva, EP; Kuznetsova, SA; Liamina, IV; Starikova, EA | 1 |
| Wang, ZY | 1 |
| Autorino, R; Di Lorenzo, G | 1 |
| Green, C; Hoyle, M; Liu, Z; Moxham, T; Stein, K; Thompson Coon, J; Welch, K | 1 |
| Lieber, ML; Shah, SN; Smith, AD | 1 |
| Cataruozolo, PE; Chuang, E; Collier, M; Gowland, PA; Huang, X; Kern, KA; Kozloff, M; Miller, K; Starr, A; Verkh, L | 1 |
| Kolb, MM; Kozloff, MF; Samant, M; Scappaticci, FA; Socinski, MA | 1 |
| Bayer, M; Berdel, WE; Kessler, T; Liersch, R; Mesters, RM; Schwöppe, C | 1 |
| Galle, PR; Gockel, I; Heidel, F; Lang, H; Lyros, O; Moehler, M; Mueller, A; Schimanski, CC | 1 |
| Chao, R; Harper, K; Huang, X; Ilagan, J; Liu, G; Robert, F; Sandler, A; Schiller, JH; Traynor, AM; Tye, L; Verkh, L | 1 |
| De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F | 1 |
| Miyazaki, Y; Nishida, T; Takahashi, T | 1 |
| Bello, CL; Garrett, M; Ryan, B; Sherman, L; Smeraglia, J; Toh, M | 1 |
| Boven, E; de Boer, MP; Eringa, EC; Serné, EH; Smulders, YM; van den Eertwegh, AJ; van der Veldt, AA; van Hinsbergh, VW | 1 |
| Mickisch, G; Nuijten, M | 1 |
| Hedvat, M; Jove, V; Van Meter, TE; Xin, H; Yang, F; Yu, H | 1 |
| Patel, SR; Pisters, PW | 1 |
| Gandhi, M; Guitart, JG; Kuzel, TM; Lacouture, M; Liu, SW | 1 |
| Heng, DY; Kollmannsberger, C | 1 |
| Bukowski, R; Elson, P; Garcia, J; Golshayan, A; Khan, G; Rini, B; Wood, L | 1 |
| Casali, PG; Gronchi, A; Grosso, F; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Stacchiotti, S | 1 |
| Peter, S; Rohde, D; Tong, TQ | 1 |
| Diehl, W; Emmett, MR; Gajiwala, KS; Greig, MJ; Lunney, EA; Marshall, AG; Wu, JC; Yu, X; Zhang, HM | 1 |
| Aubert, S; Copin, MC; Delehedde, M; Franquet, H; Kervoaze, G; Lassalle, P; Leroy, X; Villers, A; Zini, L | 1 |
| Ding, Y; Huang, D; Li, Y; Luo, WM; Qian, CN; Snider, J; Teh, BT; Vandenbeldt, K; Zhang, ZF | 1 |
| Ding, Y; Furge, KA; Futreal, PA; Huang, D; Kahnoski, R; Petillo, D; Qian, CN; Rini, BI; Teh, BT; Zhou, M | 1 |
| Bushmakin, AG; Cappelleri, JC; Cella, D; Charbonneau, C; Kim, ST; Li, JZ; Michaelson, MD; Motzer, RJ | 1 |
| Bex, A; Blank, C; Boven, E; Haanen, JB; Meijerink, MR; Van der Veldt, AA | 1 |
| Mena, AC | 1 |
| Antón-Aparicio, LM; Calvo, OF; Carral, A; Durana, J; García-Campelo, R; Grande, E; López, MR; Quindós, M; Soto, JM; Vázquez, DD | 1 |
| Aparicio, LM; Calvo, OF; López, MR; Vázquez, DD | 1 |
| Díaz-Rubio, E; López-Tarruella, S; Manzano, A; Martin, M; Puente, J | 1 |
| Blesa, JM; Pulido, EG | 1 |
| Guillén-Ponce, C; Mena, AC; Pulido, EG | 1 |
| Andrejak, M; Basille, D; Bentayeb, H; Boutemy, M; Dayen, C; Douadi, Y; Fournier, C; Garidi, R; Kanaan, M; Lecuyer, E | 1 |
| Chowdhry, BZ; Coles, SJ; Hamid, S; Hursthouse, MB; Male, L; Mendham, AP; Spencer, J | 1 |
| Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
| Chang, CC; Chi, KH; Ko, HL; Liao, CS; Mehta, MP; Tsang, YW; Yang, KC | 1 |
| Gasent, JM; Grande, E; Grávalos, C | 1 |
| Cai, T; Ding, W; He, Q; Lu, W; Tu, C; Wu, R; Yang, B; Yang, L; Zhu, H | 1 |
| Kurzrock, R; Lenihan, D; Tsimberidou, AM; Vaklavas, C | 1 |
| Oya, M | 1 |
| Bajorin, DF; Boyle, MG; Flaherty, AM; Gallagher, DJ; Gerst, SR; Ishill, N; Milowsky, MI; Regazzi, A; Riches, J; Trout, A | 1 |
| Baum, MS; Chen, I; Ginsberg, MS; Harmon, CS; Hudes, GR; Kim, ST; Motzer, RJ; Redman, BG | 1 |
| Decallonne, B; Op de Beeck, K; Rogiers, A; Schöffski, P; Thijs, M; Wolter, P | 1 |
| Albiges, L; Benatsou, B; Chami, L; Chebil, M; Escudier, BJ; Koscielny, S; Lassau, N; Roche, A | 1 |
| Boven, E; Haanen, JB; Meijerink, MR; van den Eertwegh, AJ; van der Veldt, AA | 1 |
| Dabora, SL; Nobil, A; Woodrum, C | 1 |
| Coli, R; Deshmukh, GD; Diehl, W; DiNitto, JP; English, JM; Jacques, SL; Worrall, JW; Wu, JC; Zhang, Y | 1 |
| Canipari, C; De Amici, M; Imarisio, I; Paglino, C; Porta, C; Quaglini, S; Sacchi, L | 1 |
| Minor, DR | 2 |
| Billemont, B; Boccon-Gibod, L; Bompas, E; Camparo, P; Couturier, J; Dutcher, J; Escudier, B; Guillot, A; Malouf, GG; Molinié, V; Oudard, S; Rixe, O; Rustine, A; Schleiermacher, G; Theodore, C | 1 |
| Ashman, LK; Griffith, R; Mashkani, B | 1 |
| Anastasiou, I; Andreadis, C; Bamias, A; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Karadimou, A; Kontovinis, L; Lainakis, G; Lampaki, S; Malettou, L; Papandreou, C; Papazisis, K; Razi, E; Skolarikos, A; Stravodimos, K; Syrigos, K; Timotheadou, E; Xanthakis, I | 1 |
| Bergmann, L; Miller, K | 2 |
| Bergmann, L | 1 |
| Miller, K | 1 |
| Gschwend, JE | 1 |
| Marschner, N | 1 |
| Jäger, E | 1 |
| Bose, D; Ellis, LM; Flaherty, KT; Hofstetter, W; Meric-Bernstam, F; Reardon, DA | 1 |
| Haseke, N; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K | 1 |
| Fournier, C; Tisman, G | 1 |
| Abdulkarim, B; Aghi, M; Chahal, M; Christensen, JG; Famulski, K; Graham, K; Jacques, A; Lesniak, D; Murray, D; Sabri, S; Xu, Y | 1 |
| Porta, C | 2 |
| Bierer, S; Herrmann, E; Wülfing, C | 1 |
| Hershman, JM; Liwanpo, L | 1 |
| Fujita, T; Iiri, T; Makita, N; Miyakawa, M | 1 |
| Cedres, S; Chao, R; Felip, E; Frickhofen, N; Fuhr, HG; Gatzemeier, U; Heigener, D; Lanzalone, S; Reck, M; Ruiz-Garcia, A; Stephenson, P; Thall, A | 1 |
| Asselineau, J; Catargi, B; de la Fouchardière, C; Delord, JP; Do Cao, C; Klein, M; Niccoli, P; Ravaud, A; Rodien, P | 1 |
| Bodoky, G; Borner, M; Hess, V; Inauen, R; Koeberle, D; Kovàcs, K; Lerch, S; Limacher, A; Majno, P; Montemurro, M; Roth, A; Saletti, P; Samaras, P; Simcock, M | 1 |
| Unno, M | 1 |
| Fesler, MJ; Katta, A; Richart, JM; Tan, A; Vuong, G | 1 |
| Dimou, AT; Saif, MW; Syrigos, KN | 1 |
| Cascone, T; Heymach, JV; Nilsson, MB; Saigal, B; Wu, HK; Xu, L; Zage, PE; Zeng, L; Zweidler-McKay, PA | 1 |
| Escudier, B | 2 |
| Amato, AM; Atkins, MB; Cho, DC; Choueiri, TK; Clement, J; McDermott, D; Oh, WK; Regan, MM; Rosenberg, JE; Signoretti, S | 1 |
| Dobre, S; Fewkes, NM; Guimond, M; Krauss, AC; Mackall, CL; Meadors, JL | 1 |
| Beattie, L; Brown, N; Coles, M; Dalton, JE; Johnson, K; Kaye, PM; Maroof, A; Narang, P; Owens, BM; Rosenquist, L | 1 |
| Gajda, M; Kroeger, N; Petersen, I; Settmacher, U; Steiner, T; Wunderlich, H; Zanow, J | 1 |
| Chen, SH; Eisenstein, S; Fu, S; Kao, J; Ko, EC; Sikora, AG | 1 |
| Kataja, V; Kellokumpu-Lehtinen, P; Nuttunen, P; Purmonen, T; Pyrhönen, S; Vuorinen, R | 1 |
| Aogi, K; Barrios, CH; Brickman, MJ; Ferrero, JM; Harbeck, N; Iwata, H; Kern, KA; Lee, SC; Liu, MC; Lugo-Quintana, R; Martin, M; Pivot, X; Tabei, T; Vanlemmens, L; Zhang, K | 1 |
| Katayama, K; Kawahara, H; Mitsuhashi, J; Noguchi, K; Sugimoto, Y | 1 |
| Barbastefano, J; Campbell, SC; Dreicer, R; Elson, P; Garcia, JA; Lane, BR; Rini, BI; Wood, LS | 1 |
| Kats-Ugurlu, G; Kiemeney, LA; Leenders, WP; Mulders, PF; Old, LJ; Oosterwijk, E; Oosterwijk-Wakka, JC | 1 |
| Fukudo, M; Inui, K; Kamba, T; Katsura, T; Mizuno, T; Nakamura, E; Ogawa, O; Terada, T | 2 |
| Bellmunt, J; Choueiri, TK; Je, Y; Rosenberg, JE; Schutz, FA | 1 |
| Garfield, DH; Hercbergs, A; Schöffski, P; Wolter, P | 1 |
| Bao-Hui, H; Hui-Min, W; Ping, G; Wei-Min, W | 1 |
| Blay, JY; Cassier, PA | 1 |
| Di Gion, P; Dodos, F; Fuhr, U; Jaehde, U; Kanefendt, F; Kinzig, M; Lindauer, A; Rodamer, M; Sörgel, F; Tomalik-Scharte, D | 1 |
| Beahm, C; Chen, MH; Chu, TF; Durand, JB; Force, T; Kerkela, R; Kramer, D; Vagnozzi, R; Woulfe, KC | 1 |
| Choueiri, TK | 1 |
| Bronstein, Y; Busaidy, NL; Cabanillas, ME; Feng, L; Hernandez, M; Lopez, A; Sherman, SI; Waguespack, SG; Williams, MD | 1 |
| Dalhaug, A; Nieder, C | 1 |
| Devarajan, P | 1 |
| Bazzi, W; Derweesh, IH; DiBlasio, CJ; Downs, TM; Kane, CJ; Kopp, R; Mehrazin, R; Millard, F; Patterson, AL; Silberstein, JL; Yunus, F | 1 |
| Hansen, T; Jäger, E; Koch, FP; Wagner, W; Walter, C | 1 |
| Cuesta Alcalá, JA; De Pablo Cárdenas, A; Millán Serrano, JA; Sánchez Zalabardo, D | 1 |
| Bunting, KD; Cohen, PA; Finke, JH; Ireland, J; Ko, JS; Li, G; Rayman, P; Rini, B; Swaidani, S | 1 |
| Albouy, B; Escudier, B; Gross Goupil, M; Massard, C | 1 |
| Ayllon, J; Barrascout, E; Cuenod, CA; Elaidi, R; Medioni, J; Mejean, A; Oudard, S; Scotte, F; Tartour, E | 1 |
| Escudier, B; Gross-Goupil, M | 1 |
| Boyle, H; Fléchon, A; Négrier, S | 1 |
| Agarwal, N; Batten, J; Callis-Duffin, K; Narayanan, S | 1 |
| Kondo, M; Nieder, C; Norum, J | 1 |
| Beatty, K; Bokar, J; Chen, HX; Cooney, MM; Dowlati, A; Dreicer, R; Elson, P; Garcia, JA; Ivy, P; Rini, BI; Tyler, A | 1 |
| Dalhaug, A; Haukland, E; Nieder, C | 1 |
| Corinaldesi, R; Morselli-Labate, AM; Pezzilli, R | 1 |
| Gong, K; He, ZS; Jin, J; Li, XS; Song, G; Song, Y; Wang, G; Yu, W; Zhang, Q; Zhang, Z; Zhao, Z; Zhou, LQ | 1 |
| Vaishampayan, U | 1 |
| Rini, BI; Shah, SN | 1 |
| Casali, PG; Conca, E; Gronchi, A; Messina, A; Morosi, C; Negri, T; Palassini, E; Pastorino, U; Pierotti, MA; Pilotti, S; Stacchiotti, S | 1 |
| Ahn, H; Ahn, JH; Hong, B; Hong, JH; Kim, CS; Kim, JE; Lee, DH; Lee, JL; Lee, JS; Na, S; Song, C; Yoo, C | 1 |
| Antonescu, CR; DeMatteo, RP; Demetri, GD; Ganjoo, KN; Maki, RG; Pisters, PW; Raut, CP; Riedel, RF; Schuetze, S; Sundar, HM; Trent, JC; von Mehren, M; Wayne, JD | 1 |
| Grünwald, V; Kalanovic, D; Merseburger, AS | 1 |
| Bang, YJ; Boku, N; Chen, JS; Chung, HC; Doi, T; Kang, WK; Kang, YK; Lechuga, MJ; Lu, DR; Ng, WT; Qin, S; Ruiz-Garcia, A; Shen, L; Sobrero, A; Sun, Y; Tursi, JM | 1 |
| Chan, AT; Cheng, SH; Cheung, CS; Ho, K; Hui, EP; Lau, CP; Lui, VW; Ma, BB; Ng, MH; Wong, CS | 1 |
| Cejka, D; Crevenna, R; Fuereder, T; Hoeflmayer, D; Jaeger-Lansky, A; Koehrer, S; Preusser, M; Strommer, S; Wacheck, V | 1 |
| Eriksson, B | 1 |
| Gnant, M | 1 |
| Deville, JL; Duffaud, F; Huynh, T; Salas, S | 1 |
| Bonvalot, S; Cioffi, A; Dômont, J; Le Cesne, A; Tardieu, M | 1 |
| Backer, JM; Backer, M; Blankenberg, FG; Hamby, CV; Levashova, Z; Pizzonia, J | 1 |
| den Hollander, M; Gelderblom, H; Hamberg, P; Loos, WJ; Sleijfer, S; Steeghs, N; Tascilar, M; van de Biessen, D; Verweij, J | 1 |
| Albers, P; Bergmann, L; Gschwend, J; Jäger, E; Keilholz, U; Miller, K | 1 |
| Lieber, ML; Remer, EM; Rini, BI; Shah, SN; Smith, AD | 2 |
| Calaoagan, JM; Ehrlich, PJ; Klon, AE; Laderoute, KR; Madrid, PB | 1 |
| Burstein, HJ; Dhakil, S; Fabian, C; Kozloff, M; Mayer, EL; Parmar, H; Patel, T; Qamar, R; Samant, M; Sundaram, S; Volterra, F | 1 |
| Dykema, K; Ellis, L; Furge, K; Hammers, HJ; Jaspers, J; Netto, G; Paesante, S; Pili, R; Rudek, M; Salumbides, B; Shah, P; Sharma, R; Shen, L; Teh, BT; Verheul, HM | 1 |
| Allory, Y; Bastien, L; Calvo, F; Cussenot, O; de La Taille, A; Deslandes, E; Menashi, S; Mourah, S; Naïmi, B; Paule, B; Podgorniak, MP; Porcher, R | 1 |
| Arnold, D; Ravaud, A; Schmidinger, M; Szczylik, C; Wagstaff, J | 1 |
| Arkadopoulos, N; Gennatas, C; Kondi-Pafiti, A; Michalaki, V | 1 |
| Baker, SD; Chen, Z; den Hartigh, J; den Hollander, M; Gelderblom, H; Guchelaar, HJ; König-Quartel, JM; Ploeger, BA; van Erp, NP; Zandvliet, AS | 1 |
| Ahlman, H; Andersson, A; Nilsson, B; Nilsson, E; Nilsson, O; Sjölund, K | 1 |
| Benesch, M; Hanzer, M; Nebl, A; Pilhatsch, A; Spendel, S; Urban, C | 1 |
| Duyster, J; Menzel, H; Peschel, C; Rummelt, C; Sigl, M; von Bubnoff, N | 1 |
| Bozas, G; Maraveyas, A; Ramasamy, V; Roy, A | 1 |
| Billemont, B; Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Massault, PP; Mir, O; Ropert, S; Vignaux, O | 1 |
| Abouantoun, TJ; Castellino, RC; MacDonald, TJ | 1 |
| Fagin, JA; Pfister, DG; Tuttle, RM | 1 |
| Bäuerle, T; Komljenovic, D; Merz, M; Semmler, W; Zwick, S | 1 |
| Bayraktar, S; Bayraktar, UD; Rocha-Lima, CM | 1 |
| Saijo, N | 1 |
| Sato, Y | 1 |
| Barnett, JW; Belunis, C; Chu, W; Deval, J; Hong, LN; Janson, C; Kuglstatter, A; Kutach, AK; Lam, D; Liu, CM; Lok, S; Novak, TJ; Shaw, D; Villaseñor, AG | 1 |
| Brandes, AA; Franceschi, E; Girardi, F | 1 |
| Choueiri, TK; Dal Cin, P; Kelly, PJ; Perez-Atayde, AR; Sher, DJ; Weiss, SE | 1 |
| Benekli, M; Bilge Yilmaz, I; Buyukberber, S; Coskun, U; Demirci, U; Erdem, O; Ozturk, B | 1 |
| Balvay, D; Banu, E; Chatellier, G; Cuenod, CA; Fournier, LS; Frija, G; Medioni, J; Oudard, S; Thiam, R; Trinquart, L | 1 |
| Gkountouvas, A; Kaldrimidis, P; Kostoglou-Athanassiou, I; Repousis, P; Veniou, E; Ziras, N | 1 |
| Cleary, JM; Lynch, TP; Nikiforov, YE; Palmer, EL; Randolph, GW; Sadow, PM; Wirth, LJ | 1 |
| Bargou, R; Dimitrakopoulou-Strauss, A; Hohenberger, P; Manegold, C; Marx, A; Mayer, F; Sauer, C; Spitzer, D; Strauss, L; Ströbel, P; Wolff, A | 1 |
| Chowdhury, S; Hutson, T; Jones, R; Lim, L; Mantle, M; Powles, T; Shamash, J | 1 |
| Billaud, M; Viollet, B | 1 |
| Alió, JL; Campos-Mollo, E; Javaloy, J; Lledó-Riquelme, M; Pérez-Santonja, JJ | 1 |
| Beck, J; Bellmunt, J; Escudier, B | 1 |
| Ansari, J; Collins, S; Fatima, A; Fernando, K; James, ND; Porfiri, E | 1 |
| Cho, CH; Kim, TY; Park, JW; Shin, HW | 1 |
| Ghenev, P; Izumi, K; Kitagawa, S; Mouri, H; Ohtsubo, K; Takeuchi, S; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K | 1 |
| Boven, E; de Boer, MP; Lankheet, NA; Serné, EH; van den Eertwegh, AJM; van der Veldt, AAM; Wijnstok, NJ | 1 |
| Bouvet, M; Fruehauf, J; Hoffman, RM; Imagawa, DK; Katz, MH; Kaushal, S; Keleman, A; Kim, G; Romney, E; Tran Cao, HS | 1 |
| Bjerregaard, JK; Jensen, BV; Jorgensen, TL; Nielsen, D; Pfeiffer, P; Qvortrup, C | 1 |
| Garralda Cabanas, E; Hitt, R; Homet Moreno, B | 1 |
| Chen, E; Coatney, RW; Davis, CB; Frazier, KS; French, KJ; Gales, TL; Hu, CX; McSurdy-Freed, J; Renninger, JP; Storck, LM; Zhao, S | 1 |
| Fenton, MS; Hershman, JM; Hogen, R; Marion, KM; Naeim, F; Salem, AK | 1 |
| Eames, T; Staehler, M; Wollenberg, A | 1 |
| Ghose, A; Tariq, Z; Veltri, S | 1 |
| Herrmann, TR; Kramer, M; Kuczyk, MA; Merseburger, AS; Schrader, AJ; Waalkes, S | 1 |
| Bouattour, M; Colichi, C; Delbaldo, C; Dreyer, C; Faivre, S; Raymond, E; Sablin, MP | 1 |
| Ding, X; He, Q; Lou, L; Lu, W; Xue, T; Yang, B; Yang, X; Zhao, Y; Zhu, H | 1 |
| Bories, E; Caillol, F; Giovannini, M; Gravis, G; Jeanniard-Malet, O; Pesenti, C | 1 |
| Hellenthal, NJ; Kim, HL; Litwin, A; Penetrante, R; Teh, BT; Underwood, W; Wilding, GE; Zhang, S | 1 |
| Canon, JL; De Greve, J; Focan, C; Fontaine, C; Martens, M; Paridaens, R; Squifflet, P; Vuylsteke, P; Wildiers, H; Wynendaele, W | 1 |
| Suddek, GM | 1 |
| Figlin, RA; Huang, X; Hutson, TE; Kim, ST; Michaelson, MD; Motzer, RJ; Négrier, S; Patil, S | 2 |
| Cai, SR; Chen, CQ; Chen, JH; He, YL; Ma, JP; Wu, KM; Zhan, WH; Zhang, XH | 1 |
| Alessi, DR; Deak, M; Dzamko, N; Hentati, F; Nichols, RJ; Prescott, AR; Reith, AD | 1 |
| Choueiri, TK; Corn, P; Dal Cin, P; Heng, DY; Hirsch, MS; Jonasch, E; Lim, ZD; McDermott, DF; Tamboli, P; Tannir, NM; Vaishampayan, U | 1 |
| Boender, PJ; de Wijn, R; Dueland, S; Flatmark, K; Folkvord, S; Giercksky, KE; Grøholt, KK; Hole, KH; Johansen, M; Nesland, JM; Ree, AH; Ruijtenbeek, R | 1 |
| Goldwasser, F; Mir, O; Ropert, S; Vignaux, O | 1 |
| Fisher, C; Fisher, R; Gore, M; Larkin, J; Livni, N; Pickering, L; Thway, K | 1 |
| Boven, E; Eechoute, K; Gelderblom, H; Guchelaar, HJ; Haanen, JB; Mathijssen, RH; Reyners, AK; van der Veldt, AA; van Erp, NP; Wessels, JA | 1 |
| Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J | 1 |
| Gu, JW; Huang, M; Miele, L; Tucker, KB; Wells, J; Young, E | 1 |
| Heppner, FL; Holtkamp, N; Reuss, D; von Deimling, A; Ziegenhagen, N; Zietsch, J | 1 |
| Fujisawa, M; Haraguchi, T; Miyake, H; Takenaka, A | 1 |
| Debiec-Rychter, M; Floris, G; Schöffski, P; Sciot, R; Wozniak, A | 1 |
| Eufinger, H; Hoefert, S | 1 |
| An, J; Bilenky, M; Birol, I; Butterfield, YS; Cezard, T; Chuah, E; Corbett, R; Fejes, AP; Griffith, M; Griffith, OL; Hirst, M; Holt, RA; Huntsman, DG; Jones, SJ; Laskin, J; Li, YY; Marra, MA; Martin, M; Mayo, M; Melnyk, N; Moore, RA; Morin, RD; Pugh, TJ; Severson, T; Shah, SP; Sutcliffe, M; Tam, A; Terry, J; Thiessen, N; Thomson, T; Varhol, R; Yee, J; Zeng, T; Zhao, Y | 1 |
| Hashimoto, Y; Iizuka, J; Kobayashi, H; Kondo, T; Nakano, M; Nishikawa, T; Tanabe, K | 1 |
| Ginsberg, MS; Molina, AM; Motzer, RJ | 1 |
| De Miguel Novoa, MP; Díaz Pérez, JÁ; Fuertes Zamorano, N; Molino González, A; Montañez Zorrilla, MC; Rojas-Marcos, PM | 1 |
| Rini, B; Rixe, O | 1 |
| Biagi, JJ; Chalchal, HI; Eisenhauer, EA; Ellard, SL; Grimshaw, R; Hirte, H; Ivy, SP; Lee, U; Oza, AM; Sederias, J | 1 |
| Canfield, SE; Dahm, P; Sultan, S | 1 |
| Berros, JP; Blay, P; Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fonseca, PJ; Fra, J; Izquierdo, M; Lacave, ÁJ; Luque, M; Muriel, C; Pardo, P; Sanmamed, M; Vieitez, JM; Villanueva, N | 1 |
| Apostolidou, E; Borthakur, G; Burger, I; Kantarjian, H; Thomas, D; Verstovsek, S | 1 |
| Baum, MS; Feldman, DR; Georges, M; Ginsberg, MS; Jia, X; Kroog, G; Molina, AM; Motzer, RJ; Patil, S; Reuter, VE; Tickoo, SK | 1 |
| Figlin, RA; Pal, SK; Yu, H | 1 |
| Armand, JP; Boven, E; Brega, NM; Countouriotis, AM; Hartog, V; Massard, C; Ruiz-Garcia, A; Soria, JC; Tillier, C | 1 |
| Ganser, A; Grünwald, V; Janssen, S; Karstens, JH; Morgan, M; Seidel, C; Welte, T | 1 |
| Altman, J; Kuzel, T; Parajuli, R; Perdekamp, M; Tallman, M | 1 |
| Cecere, FL; Di Costanzo, F; Doni, L; Moscetti, L; Padalino, D; Ruggeri, EM | 1 |
| Castelo, B; Espinosa, E; Pinto, A; Redondo, A; Zamora, P | 1 |
| Dhaun, N; Webb, DJ | 1 |
| Danser, AH; Kappers, MH; Sleijfer, S; Sluiter, W; van den Meiracker, AH; van Esch, JH | 1 |
| Hiromatsu, Y; Matsuoka, K; Miyajima, J; Muraishi, K; Sasaki, Y; Sato, S; Suekane, S; Tajiri, Y; Tani, J; Tokubuchi, I; Yamada, K | 1 |
| Berardi, R; Cascinu, S; Del Prete, M; Di Pietro Paolo, M; Faloppi, L; Maccaroni, E; Scartozzi, M | 1 |
| Bukowski, RM; Cowey, CL; Dreicer, R; Elson, P; Garcia, JA; Gilligan, T; Hutson, TE; Nemec, C; Rini, BI | 1 |
| Guo, K; He, Y; Huang, Y; Li, Y; Wang, Y | 1 |
| Arihara, Z; Fukazawa, H; Sakurai, K; Yoshida, K | 1 |
| Albers, P; Beuselinck, B; Decoene, J; Oudard, S | 1 |
| Cagli, B; Intagliata, S; Onetti Muda, A; Perrone, G; Persichetti, P; Santini, D; Segreto, F; Tonini, G | 1 |
| Breaker, K; Costa, LJ; Crighton, F; Drabkin, H; Flaig, TW; Gustafson, DL; Kim, FJ; Schultz, MK | 1 |
| Audrain, O; Boucher, E; Leroux, C; Picot, D; Raoul, JL; Zoheir, Y | 1 |
| del Muro, JG; Díaz, S; Grande, E; Paz-Ares, L | 1 |
| Bello, A; Burris, HA; Chao, R; Chiorean, EG; Jones, S; Lee, FC; Liau, KF; Royce, M; Sweeney, CJ; Tye, L; Verschraegen, CF | 1 |
| Andreadis, C; Antonakis, E; Christopoulou, M; Kontovinis, LF; Kortsaris, AH; Kouvatseas, G; Lafaras, C; Mouratidou, D; Papandreou, CN; Papazisis, KT | 1 |
| Ancukiewicz, M; Clark, JW; di Tomaso, E; Duda, DG; Fuchs, CS; Jain, RK; Miksad, R; Ryan, DP; Zhu, AX | 1 |
| Bojic, M; Clodi, M; Haitel, A; Heinzl, H; Kramer, G; Lamm, W; Schmidinger, M; Vogl, UM; Zielinski, CC | 1 |
| Bauman, JE; Capell, PT; Carr, LL; Eaton, KD; Goulart, BH; Kell, EM; Mankoff, DA; Martins, RG | 1 |
| Hara, K; Hijioka, S; Kawai, H; Kondo, S; Matsumoto, K; Mizuno, N; Niwa, Y; Sawaki, A; Tajika, M; Yamao, K | 1 |
| Bjarnason, GA; Bracarda, S; Carteni, G; Gore, ME; Hariharan, S; Hawkins, R; Lee, SH; Nieto, A; Oudard, S; Porta, C; Szczylik, C; Yuan, J | 1 |
| Chaskis, C; De Greve, J; Duerinck, J; Dujardin, M; Everaert, H; Lv, S; Michotte, A; Neyns, B; Nupponen, N; Sadones, J; Tynninen, O | 1 |
| Aglietta, M; Aieta, M; Buonerba, C; D'Aniello, C; De Placido, S; Di Lorenzo, G; Federico, P; Felici, A; Imbimbo, C; Longo, N; Milella, M; Mirone, V; Ortega, C; Palmieri, G; Rescigno, P; Ruggeri, EM | 1 |
| Ping, SY; Wu, CL; Yu, DS | 1 |
| Baldazzi, V; Carini, M; Lapini, A; Mazzanti, R; Santomaggio, C; Tassi, R | 1 |
| Larkin, J; Mukherji, D; Pickering, L | 1 |
| Bauer, S; Grabellus, F; Schmid, KW; Sheu, SY; Speich, N; Worm, K | 1 |
| Catlett, L; Eddy, S; Gordon, M; Healey, D; Huang, B; Rini, BI; Shannon, P; Stein, M; Stephenson, JJ; Tyler, A | 1 |
| Barbaud, A; Cuny, JF; Granel-Brocard, F; Guyot-Caquelin, P; Marchal, A; Schmutz, JL; Spaeth, D; Trechot, P | 1 |
| Ayllon, J; Barrascout, E; Beuselinck, B; Blesius, A; Elaidi, R; Escudier, B; Lang, H; Medioni, J; Morel, A; Oudard, S; Rixe, O; Schöffski, P; Wolter, P; Zucman-Rossi, J | 1 |
| Afonso-Afonso, FJ; Antón-Aparicio, LM; Aparicio-Gallego, G; Campos-Balea, B; Fernández-Calvo, O; Fírvida-Pérez, JL; Lázaro-Quintela, M; León-Mateos, L; Ramos-Vázquez, M; Vázquez-Estévez, S | 1 |
| Barni, S; Cabiddu, M; Carpo, M; Ghilardi, M; Petrelli, F | 1 |
| Charbonneau, C; Sandin, R | 1 |
| Delank, S; Eich, H; Wendtner, CM | 1 |
| Balemans, C; Mattijssen, V; Ruinemans, GM; Smit, HJ; Wiersma-van Tilburg, AJ | 1 |
| Hagymási, K; Tulassay, Z | 1 |
| Asakura, T; Fujinami, K; Goto, A; Komeya, M; Matsumoto, T; Senga, Y | 1 |
| Agrawal, S; Bazeos, A; Boleti, K; Chowdhury, S; Gillessen, S; Lim, L; Nathan, P; Peters, J; Powles, T; Sadev, A; Sarwar, N; Saunders, N; Shamash, J; Wilson, P | 1 |
| Bauerschlag, DO; Egberts, JH; Jonat, W; Kalthoff, H; Maass, N; Meinhold-Heerlein, I; Schem, C; Tiwari, S; Weigel, MT | 1 |
| Fratto, ME; Imperatori, M; Santini, D; Tomao, F; Tonini, G; Vincenzi, B | 2 |
| Akram, S; Chakravarthi, S; Judson, JP; Lim, AY; Segarra, I | 1 |
| Christensen, JG; Esparza, CO; Feng, J; Hu-Lowe, DD; Lee, JH; Plumlee, PA; Shojaei, F; Simmons, BH; Stewart, AE; Wong, A | 1 |
| Fujisawa, M; Miyake, H | 1 |
| Figlin, RA; Pal, SK | 1 |
| Beck, MY; Chang, HM; Choi, DR; Kang, YK; Kim, KP; Kim, TW; Lee, JL; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Fumita, S; Hashimoto, J; Ichikawa, Y; Kimura, N; Miyazaki, M; Nakagawa, K; Ohki, E; Okamoto, I; Shimizu, T; Takeda, M; Terashima, M; Tsurutani, J | 1 |
| Basappa, NS; Dreicer, R; Elson, P; Garcia, JA; Golshayan, AR; Rini, BI; Wood, L | 1 |
| Gkountouvas, A; Kaldrymides, P; Kostoglou-Athanassiou, I; Veniou, E; Ziras, N | 1 |
| Bellmunt, J; Choueiri, TK; Katz, L | 1 |
| Schmidt, C | 1 |
| Augwal, S; Boleti, K; Bower, M; Chowdhury, S; Green, J; Lim, L; Peters, J; Powles, T; Sadev, A; Sarwar, N; Saunders, N; Shamash, J | 1 |
| Chang, SG; Jeon, SH; Lee, CH; Lee, JH; Lim, TJ; Min, GE; Yoo, KH | 1 |
| Li, H; Shi, GH; Wang, CF; Yang, LF; Yang, ZY; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y | 1 |
| Frey, K; Giavazzi, R; Johannsen, M; Neri, D; Schliemann, C; Schwager, K | 1 |
| Hirashima, Y; Kawano, S; Morinaga, R; Otsu, S; Sakashita, H; Shirao, K; Watanabe, K | 1 |
| Flombaum, CD; Glezerman, IG; Jhaveri, KD; Kroog, G | 1 |
| Bowen, D; Byrd, J; Call, T; Erlichman, C; Ghosh, A; Hanson, C; Jelinek, D; Kay, N; Laplant, B; Laumann, K; Shanafelt, T; Villalona-Calero, M; Wu, W; Zent, C | 1 |
| Liang, ZY | 1 |
| Berney, DM; Gourlaouen, M; Kudahetti, SC; Powles, T; Reynolds, AR; Welti, JC; Wilson, P | 1 |
| Chong, G; Hamilton, K; Yoong, J | 1 |
| Bednaríková, D; Kocák, I | 1 |
| Blanke, CD; Huse, DM | 1 |
| Andersen, JL; Andersson, M; Kamby, C; Nielsen, DL | 1 |
| Düber, C; Galle, PR; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA | 1 |
| Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; Lampard, JG; McDermott, DF; North, S; Rini, BI; Xie, W | 1 |
| Brouwers, AH; de Jong, JR; de Vries, EG; den Dunnen, WF; Elsinga, PH; Gietema, JA; Hesselink, JW; Hollema, H; Hospers, GA; Lub-de Hooge, MN; Nagengast, WB; Oosting, SF; Price, PM; Warnders, FJ | 1 |
| Sulkes, A | 1 |
| Eechoute, K; Gelderblom, H; Gietema, J; Guchelaar, HJ; Haanen, JB; Mathijssen, RH; van den Eertwegh, AJ; van der Veldt, AA; van Erp, NP; Wessels, JA | 1 |
| Antón, I; Calvo, A; Catena, R; Larzábal, L; Lecanda, F; Luis-Ravelo, D; Salazar-Colocho, P; Zandueta, C | 1 |
| Cho, JH; Kang, WK; Lee, J; Lim, HY; Park, JO; Park, S; Park, SH; Park, YS | 1 |
| Chapelle, A; Guillot, B; Jacot, W; Kluger, N | 1 |
| Beck, M; Chang, HM; Cho, Y; Choi, DR; Kang, YK; Kim, TW; Lee, JL; Ryoo, BY; Ryu, MH; Yoon, DH | 1 |
| Choueiri, TK; Cleary, JM; Elson, P; Escudier, B; Garcia, JA; Heng, DY; Hutson, TE; Knox, JJ; Michaelson, MD; Ramaiya, N; Rini, BI; Zama, IN | 1 |
| Breza, J; Eret, V; Ferda, J; Hes, O; Holečková, P; Hora, M; Hyršl, L; Klečka, J; Kreuzberg, B; Mego, M; Michal, M; Petersson, F; Stránský, P; Urge, T | 1 |
| Brinkhaus, G; Gebauer, B; Wust, P | 1 |
| Rini, B | 1 |
| Aubin, F; Blanke, CD | 1 |
| Berkin, L; Brown, JE; Collinson, FJ; Khan, MM; Selby, PJ; Vasudev, NS | 1 |
| Deng, J; Figlin, R; Forman, S; Herrmann, A; Jensen, M; Kujawski, M; Reckamp, K; Scuto, A; Yu, H; Zhang, C | 1 |
| Board, R; Hawkins, R; O'Dwyer, J; Shablak, A | 1 |
| Bertolini, F; Braidotti, P; Calleri, A; Mancuso, P; Marighetti, P; Martin-Padura, I; Quarna, J; Rabascio, C | 1 |
| Bodei, L; Cinieri, S; de Braud, F; Delle Fave, G; Fazio, N; Lorizzo, K; Maiello, E; Orlando, L; Paganelli, G; Spada, F; Squadroni, M | 1 |
| Alacacioglu, A; Camci, C; Dikilitas, M; Er, O; Kalender, ME; Sagol, O; Sari, I; Sevinc, A; Soyuer, I; Yilmaz, U | 1 |
| Fjeld, JG; Fosså, SD; Hagen, G; Lilleby, W; Revheim, ME; Winge-Main, AK | 1 |
| Postema, PG; Regeer, MV; Richel, DJ; Stroes, ES; van der Valk, PR | 1 |
| Blumenschein, GR; Chao, RC; Cohen, RB; Heath, EI; Kim, ST; Loconte, NK; Lorusso, PM; Ruiz-Garcia, A; Wilding, G | 1 |
| Bieche, I; Bouattour, M; Dokmak, S; Faivre, S; Marijon, H; Paradis, V; Raymond, E; Zappa, M | 1 |
| Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A | 1 |
| Abou-Alfa, GK; Bekaii-Saab, T; Douglas, K; Goldberg, RM; Hall, M; Hollis, D; Kindler, HL; Niedzwiecki, D; O'Reilly, EM; Pluard, T; Schilsky, RL | 1 |
| Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B | 1 |
| Agresta, S; Antonia, S; Calitri, CE; Chiappori, A; D'Amato, G; Dean, M; Garrett, C; Han, G; Mahmood, ST; Schell, MJ; Vigil, CE; Zhao, X | 1 |
| Haseke, N; Karl, A; Muacevic, A; Nuhn, P; Siebels, M; Staehler, M; Stief, CG; Tüllmann, C; Wowra, B | 1 |
| Ikushima, H; Ishizu, A; Kamishima, T; Kanayama, H; Nonomura, K; Otsuka, N; Shimizu, C; Shinohara, N; Takahashi, M | 1 |
| Amundson, K; Baxi, SM; Bender, SL; Bergqvist, S; Buckman, D; Casperson, GF; Chen, E; Chen, JH; Hu-Lowe, DD; Jiang, X; Li, G; Wang, J; Wickman, G; Zhang, L; Zobel, J | 1 |
| Habuchi, T; Horikawa, Y; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H; Yuasa, T | 1 |
| Bach-Gansmo, T; Bruland, ØS; Revheim, ME; Røe, K; Seierstad, T; Skretting, A | 1 |
| Chu, DT | 1 |
| Biró, K; Küronya, Z | 1 |
| Abel, EJ; Culp, SH; Karam, JA; Margulis, V; Tamboli, P; Wang, H; Wood, CG; Zhang, XY | 1 |
| Alber, S; Bose, A; Cohen, PA; Finke, JH; Garcia, JA; Ko, JS; Rini, BI; Storkus, WJ; Taylor, JL; Watkins, SC | 1 |
| Arnott, J; Bruce, JY; Carducci, M; Eickhoff, J; Liu, G; Logan, T; Pili, R; Treston, A; Wilding, G | 1 |
| Aono, Y; Nishioka, Y; Sone, S | 1 |
| Desar, IM; Fiedler, W; Grünwald, V; Haanen, J; Mouritzen, U; Olsen, MW; van Herpen, CM | 1 |
| Fischer, R; Jaehde, U; Kanefendt, F; Kinzig, M; Lindauer, A; Moritz, B; Mross, K; Scheulen, ME; Sörgel, F; Strumberg, D | 1 |
| Arends, J; Büchert, M; Fasol, U; Fischer, R; Hense, J; Jaehde, U; Kanefendt, F; Moritz, B; Mross, K; Scheulen, ME; Strumberg, D | 1 |
| Conley, A; George, S; Lazar, AJ; Nolden, L; Reynoso, D; Trent, JC; Wang, WL | 1 |
| Argyriou, AA; Dimitropoulos, K; Giannopoulou, E; Kalofonos, HP; Petsas, T; Tsiata, E; Zolota, V | 1 |
| Brion, N; Paule, B | 2 |
| Muto, A; Neri, B; Politi, L; Rangan, S; Tassi, R; Vannini, A | 1 |
| Oudard, S | 1 |
| Jiao, XD; Li, R; Su, B; Takayama, K; Wang, JJ; Zhang, HP | 1 |
| Lolkema, MP; van Hillegersberg, R; Verheul, HM; Voest, EE; Walraven, M; Witteveen, PO | 1 |
| Eechoute, K; Mathijssen, RH; van Daele, PL; van Wijk, RG; van Zonneveld, M | 1 |
| Pazianas, M | 1 |
| Beutel, G; Ganser, A; Gruenwald, V; Haubitz, M; Ivanyi, P; Reuter, C; Schuch-Jantsch, S | 1 |
| Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R | 1 |
| Carroll, AR; Coleman, RL; Sood, AK | 1 |
| Bono, P; Joensuu, H; Rautiola, J; Utriainen, T | 1 |
| Gelderblom, H; Guchelaar, HJ; Hartigh, Jd; Ploeger, BA; Romijn, JA; van Erp, NP | 1 |
| Miller, MB; Nadauld, LD; Srinivas, S | 1 |
| Greten, TF; Korangy, F; Manns, MP | 1 |
| Beltran, L; Berney, D; Bex, A; Blank, C; Boletti, K; Chowdhury, S; Haanen, J; Horenblas, S; Kayani, I; O'Brien, T; Peters, J; Powles, T; Sadev, A; Sarwar, N; Shamash, J | 1 |
| Bozzi, F; Brich, S; Casali, PG; Cassinelli, G; Conca, E; Gronchi, A; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Stacchiotti, S; Zaffaroni, N | 1 |
| Choueiri, TK; Chowdhury, P; Chowdhury, S; Cowey, CL; Gore, ME; Harper, PG; Hutson, TE; Josephs, D; Karapetis, C; Larkin, JM; McDermott, DF; Pickering, LM; Powles, T; Van Hemelrijck, M | 1 |
| Christmas, T; Cordiner, RL; Fisher, RA; Ghosn, M; Gore, ME; Larkin, JM; Pickering, LM; Sohaib, SA | 1 |
| Amatulli, M; Claros, N; Corcoran, E; Duignan, IJ; Iacolina, M; Pennello, A; Plym, MJ; Samakoglu, S; Schwartz, J; Surguladze, D; Tonra, JR; Witte, L; Youssoufian, H | 1 |
| Rexer, H | 3 |
| Alberola, V; Casinello, J; Gasent, JM; Grande, E; Laforga, JB; Provencia, M | 1 |
| Dunn, RL; Filson, CP; Miller, DC; Redman, BG | 1 |
| Fenner, M; Ganser, A; Grünwald, V; Ivanyi, P; Länger, F; Merseburger, AS; Reuter, C; Seidel, C | 1 |
| Benedict, A; Charbonneau, C; Figlin, RA; Hariharan, S; Harmenberg, U; Négrier, S; Remák, E; Sandin, R; Sandström, P; Ullén, A | 1 |
| Akiyama, Y; Fujita, K; Murayama, N; Sasaki, Y; Sugiyama, M; Yamazaki, H | 1 |
| Bex, A; Chowdhury, S; Hutson, T; Jones, R; Lim, L; Mantle, M; Nathan, P; Powles, T | 1 |
| Chay, WY; Choong, CV; Goh, C; Tan, MH; Tan, PH; Tang, T; Tay, MH; Zam, NA | 1 |
| Andreadis, C; Bamias, A; Dimopoulos, M; Karadimou, A; Kontovinis, L; Laschos, K; Papazisis, K; Paraskevopoulos, P | 1 |
| Dudeck, O; Pink, D; Reichardt, P; Zeile, M | 1 |
| Campbell, SC; Fergany, AF; Garcia, JA; Ghoneim, IA; Gong, MC; Hansel, DE; Miocinovic, R; Stephenson, AJ | 1 |
| Blay, JY; Coscas, Y; Khayat, D; Pivot, X; Soria, JC; Spano, JP | 1 |
| Bang, YJ; Blanckmeister, C; Borbath, I; Chao, R; Chen, JS; Dahan, L; Hammel, P; Hörsch, D; Lombard-Bohas, C; Lu, DR; Metrakos, P; Patyna, S; Raoul, JL; Raymond, E; Ruszniewski, P; Smith, D; Valle, J; Van Cutsem, E; Vinik, A; Wiedenmann, B | 1 |
| Delle Fave, G; Jensen, RT | 1 |
| Atkins, MB; Choueiri, TK; Guo, M; Heng, DY; Jagannathan, J; Krajewski, KM; McDermott, DF; Pedrosa, I; Ramaiya, N; Schutz, FA; Van den Abbeele, AD; Yap, J | 1 |
| Poller, B; Schinkel, AH; Tang, SC; Wagenaar, E | 1 |
| Cohen, P; Finke, J; Ireland, J; Ko, J; Rayman, P; Rini, B | 1 |
| Fukui, I; Hatake, K; Inamura, K; Ishikwa, Y; Kodaira, M; Nakano, K; Takahashi, S; Urakami, S; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Batey, MA; de Brito, LR; Hall, AG; Irving, JA; Jackson, G; Leung, HY; Maitland, H; Newell, DR; Squires, MS; Zhao, Y | 1 |
| Ahuja, AT; Chan, ATC; Chan, SL; Hui, EP; Kam, MKM; King, AD; Loong, HH; Ma, BBY; Mo, F; Zee, BCY | 1 |
| Ganjoo, KN; Patel, S | 1 |
| Cho, DC; McDermott, DF; Mier, JW; Pandya, SS | 1 |
| Beer, AJ; Schwaiger, M | 1 |
| Allen, L; Barnett, J; Battle, MR; Goggi, JL; Morrison, MS | 1 |
| Angulo, JC | 1 |
| Ameur, N; Bidart, JM; Broutin, S; Caillou, B; Dupuy, C; Lacroix, L; Oumata, N; Petit, B; Robert, T; Schlumberger, M; Talbot, M | 1 |
| Bradshaw, MJ; Cheville, JC; Croghan, GA | 1 |
| Chen, Y; Cheng, K; Dong, H; Gao, F; Ge, J; He, JP; Hou, JM; Li, HZ; Li, LH; Lin, HJ; Liu, JY; Peng, XC; Qiu, M; Su, JM; Tan, BX; Wei, M; Wu, Y; Yang, L; Zhao, Y; Zhao, YL | 1 |
| Nishida, T; Tanji, N; Yanagihara, Y | 1 |
| Cano Megías, M; Carrasco De La Fuente, M; González Albarrán, O; Menacho Román, M; Pérez López, G | 1 |
| Diebold, J; Hirschmann, A; Rössle, M | 1 |
| Raut, CP; Winer, JH | 1 |
| Claes, A; Hamans, BC; Heerschap, A; Jeuken, JW; Leenders, WP; Navis, AC; Wesseling, P | 1 |
| Addeo, R; Caraglia, M | 1 |
| Anglesio, MS; Balkwill, F; Birrer, MJ; Bowtell, DD; Campbell, IG; Chakravarty, P; Coward, J; Cowin, PA; de Fazio, A; Friedlander, M; George, J; Gilks, CB; Gorringe, KL; House, CM; Huntsman, DG; Kalloger, SE; Kulbe, H; Lemech, C; Okamoto, A; Power, J; Rischin, D | 1 |
| Ravaud, A | 1 |
| Angeles Vaz, M; Carrato, A; García de Paredes, ML; Grande, E; Guillén, C; José Díez, J; Longo, F; Pachón, V | 1 |
| Beijnen, JH; Hillebrand, MJ; Lagas, JS; Lankheet, NA; Poller, B; Rosing, H; Schinkel, AH; Tang, SC | 1 |
| Branson, M; Hollaender, N; Neuenschwander, B; Rouyrre, N; Zuber, E | 1 |
| Demlová, R; Komínek, J; Ondrácková, B | 1 |
| Allen, GI; Chung, BI; Gill, HS; Harshman, LC; Srinivas, S; Yu, RJ | 1 |
| Abel, EJ; Brugarolas, J; Chapin, BF; Cost, NG; Culp, S; Delacroix, SE; Karam, JA; Margulis, V; Raj, GV; Sagalowsky, AI; Sleeper, JP; Smith, PJ; Wood, CG; Youssef, RF | 1 |
| Elsinghorst, PW; Gütschow, M; Kinzig, M; Rodamer, M; Sörgel, F | 1 |
| Ikeda, R; Iseki, K; Maeda, H; Nakano, K; Shibayama, Y; Sugawara, M; Taguchi, M; Takeda, Y; Yamada, K | 1 |
| Bosewa, T; Donnet, JP; Nallet, E; Vélayoudom-Céphise, FL; Vian, E; Wemeau, JL | 1 |
| Deutsch, E; Soria, JC | 1 |
| Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
| Amato, RJ; de Belin, J; Goonewardena, M; Harrop, R; Hawkins, RE; Kaufman, HL; Kelleher, M; McDonald, M; Naylor, S; Shingler, WH; Treasure, P | 1 |
| Fukui, I; Habuchi, T; Hatake, K; Horikawa, Y; Kimura, S; Maekawa, T; Maita, S; Mitobe, Y; Narita, S; Tsuchiya, N; Yuasa, T | 1 |
| Bello, CL; Ravaud, A | 1 |
| Kamiya, K; Kikuchi, H; Konno, H; Miyazaki, S; Ohta, M; Sakaguchi, T; Setoguchi, T; Yamamoto, M | 1 |
| Lian, E; Merchan, J; Silva, O; Stefanovic, A; Talebi, TN | 1 |
| Hanahan, D; Tuveson, D | 1 |
| Bokemeyer, C; Cheng, T; Chi, K; Czaykowski, P; Fenner, M; Glaesener, S; Hartmann, JT; Honecker, F; Kollmannsberger, C; Mayer, F; Oechsle, K; Winquist, E; Wood, L | 1 |
| O'Donnell, PH | 1 |
| Aguilar, G; Albanell, J; Bellmunt, J; Calvo, A; Carles, J; Castellano, D; Gallardo, E; González-Larriba, JL; Maroto, P; Mellado, B; Perez-Gracia, JL; Prior, C; Villanueva, X | 1 |
| Canipari, C; Chen, K; Duh, MS; Imarisio, I; Neary, M; Paglino, C; Porta, C | 1 |
| Bex, A; Clarke, N | 1 |
| Hanazaki, K; Ikezoe, T; Nishioka, C; Taguchi, T; Takezaki, Y; Yang, J; Yokoyama, A | 1 |
| Abal, L; Casanova, JM; Dolcet, X; Egido, R; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Moreno, S; Puig, S; Santacana, M; Sorolla, A; Valls, J; Velasco, A; Vilella, R; Yeramian, A | 1 |
| Aranda, E; Carrato, A; Chau, I; Countouriotis, AM; Cunningham, D; Guillen-Ponce, C; Iveson, TJ; Ramos, FJ; Ruiz-Garcia, A; Saunders, MP; Starling, N; Tabernero, J; Tursi, JM; Vázquez-Mazón, F; Wei, G | 1 |
| Cohen, EE; Fleming, GF; Gangadhar, TC; Geary, D; House, LK; Janisch, L; Kocherginsky, M; Maitland, ML; Ramirez, J; Ratain, MJ; Undevia, SD; Wu, K | 1 |
| Libutti, SK; Spiegel, AM | 1 |
| Fan, SY; Li, S; Liu, HY; Liu, ML; Lv, K; Wang, LL; Zheng, ZB; Zhou, XB | 1 |
| Jiang, Z; Wang, D; Zhang, L | 1 |
| Doi, T; Kakeji, Y; Kanda, T; Komatsu, Y; Nishida, T; Ohtsu, A; Onozawa, Y; Sawaki, A; Yamada, Y; Yamasaki, M | 1 |
| Blumenstengel, K; Grimm, MO; Groschek, M; Herrmann, E; Hutzschenreuter, U; Marschner, N; Ohlmann, CH; Overkamp, F; Pühse, G; Steiner, T | 1 |
| Al-Tourah, AJ; Buckstein, R; Chua, N; Crump, M; Eisenhauer, EA; Foo, AH; Ivy, SP; Kuruvilla, J; Lee, C; Macdonald, DA; Walsh, W | 1 |
| Maráz, A | 1 |
| Blanke, CD; Picus, J; Pisters, PWT; Sirulnik, A; Stealey, E; Trent, JC; von Mehren, M | 1 |
| Ayllon, J; Barrascout, E; Beuselinck, B; Medioni, J; Morel, A; Oudard, S; Scotte, F | 1 |
| Alves, MM; de Groot, JW; Hofstra, RM; Links, TP; Osinga, J; Plukker, JT; Verbeek, HH | 1 |
| Peres, J | 1 |
| Fujisawa, M; Kusuda, Y; Miyake, H; Terakawa, T | 1 |
| Duh, MS; Feinberg, BA; Fortner, B; Gilmore, J; Jolly, P; Neary, MP; Scott, J; Wang, ST | 1 |
| Tanji, N; Yokoyama, M | 1 |
| Goyal, A; Gupta, YK; Padhy, BM; Shanmugam, SP | 1 |
| Guillén, C; Martorell-Calatayud, A; Sanmartín, O; Traves-Zapata, V | 1 |
| Karakiewicz, PI; Maurin, C; Perrotte, P; Sun, M; Thuret, R | 1 |
| Ceresoli, GL; Colombo, P; De Sanctis, R; De Vincenzo, F; Gianoncelli, L; Graziotti, P; Lorenzi, E; Perrino, M; Santoro, A; Simonelli, M; Zucali, PA | 1 |
| Allen, P; Jonasch, E; Mahajan, A; Tannir, N; Verma, J | 1 |
| Bjarnason, G; Bukowski, R; Burnett, P; Creel, P; Davis, M; Dawson, N; Feldman, D; George, S; Hershman, J; Kollmannsberger, C; Lechner, T; Potter, A; Raymond, E; Treister, N; Wood, L; Wu, S | 1 |
| de Meijer, VE; Fallon, EM; Le, HD; Meisel, JA; Nehra, D; Puder, M; Rodig, SJ | 1 |
| Morimoto, J; Otsuki, Y; Shibata, MA; Tanaka, Y | 1 |
| Bromberg, JS; Ding, Y; Shi, Q; Xu, J; Yin, N; Zhang, N | 1 |
| Daignault, S; Dy, GK; Gadgeel, SM; Kalemkerian, GP; Ramnath, N; Schneider, BJ; Wozniak, AJ | 1 |
| Busch, J; Flörcken, A; Grünwald, V; Johannsen, M; Keilholz, U; Kempkensteffen, C; Miller, K; Weikert, S; Weinkauf, L; Westermann, J; Zimmermann, K | 1 |
| Bauer, S; Montemurro, M | 1 |
| Brower, SL; Ervin, PR; Hancher, LM; Suchy, SL; Wang, D | 1 |
| Baum, MS; Chen, I; Cohen, DP; Figlin, RA; Gore, ME; Hariharan, S; Lu, DR; Motzer, RJ; Rini, BI | 1 |
| Harbord, N | 1 |
| Bouattour, M; Boucher, E; Cheng, AL; Dokmak, S; Douillard, JY; Dreyer, C; Faivre, S; Im, SA; Kang, YK; Kim, JS; Lanzalone, S; Lechuga, MJ; Lim, HY; Lin, X; Raymond, E; Sablin, MP; Serrate, C; Vilgrain, V; Zappa, M | 1 |
| Abrahamova, J; Brabec, P; Buchler, T; Dusek, L; Klapka, R; Melichar, B; Vyzula, R | 1 |
| DiNitto, JP; Wu, JC | 1 |
| Aglietta, M; Bono, P; Boselli, S; Casali, PG; Coco, P; De Braud, F; De Pas, T; Grignagni, G; Jalava, T; Joensuu, H; Kappeler, C; Laurent, D; Spitalieri, G; Spreafico, C; Toffalorio, F | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Chen, MF; Chen, TW; Chen, YY; Cheng, CT; Jan, YY; Rau, KM; Yeh, CN | 1 |
| Bamias, A; Constantinidis, C; Deliveliotis, C; Dimopoulos, MA; Karadimou, A; Lainakis, G; Manios, E; Michas, F; Zakopoulos, N | 1 |
| Perazzo, F; Rodríguez-Reimúndes, E; Vilches, AR | 1 |
| Atri, M; Bjarnason, GA; Burns, PN; Hudson, JM; Lloyd, BA; Lueck, G; Milot, L; Sureshkumar, AR; Williams, R | 1 |
| Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Varga, Z | 1 |
| Bosquée, L; Corhay, JL; Thonnard, AS | 1 |
| Kleijn, SA; van der Veldt, AA | 1 |
| Barriuso, J; Castellano, D; Grande, E | 1 |
| Berruti, A; Pia, A; Terzolo, M | 1 |
| Coriat, R; Goldwasser, F; Mir, O | 1 |
| Al-Batran, SE; Biesterfeld, S; Ebert, MP; Galle, PR; Hartmann, JT; Kabisch, M; Lordick, F; Moehler, M; Mueller, A; Reimer, P; Trarbach, T; Wachtlin, D; Weihrauch, M | 1 |
| Choi, HJ; Jung, HS; Kim, MJ; Kim, SY; Kim, TM; Lee, Y; Park, KS | 1 |
| Nishida, T; Omori, T; Ueshima, S | 1 |
| Akimoto, H; Chinen, Y; Kawano, H; Kojo, M; Minami, K; Morita, K; Okamura, T; Saeki, H; Sakaguchi, Y; Sakamoto, Y; Soejima, Y; Sugiyama, M; Toh, Y | 1 |
| Carrato, A; Ferreiro, R; Grande, E; Pachón, V; Vaz, MA | 1 |
| Brufsky, AM; Copur, MS; Davis, J; Generali, D; Gernhardt, D; Giguere, JK; Gressot, L; Huang, X; Kern, KA; Liau, KF; Minton, SE; Paul, D; Richards, PD; Robert, NJ; Saleh, MN; Smith, JW | 1 |
| Huang, B; Lin, J; Wang, K; Xu, J; Yang, R; Zhang, Y; Zhu, L | 1 |
| Lewis, VO; Ravi, V; Wang, WL | 1 |
| Nozawa, M | 1 |
| Geoerger, B; Leblond, P | 1 |
| Demidov, LV; Petenko, NN; Timofeev, IV | 1 |
| Buonerba, C; Casciano, R; De Placido, S; Di Lorenzo, G; Liu, Z; Malangone, E; Sherman, S; Wang, X; Willet, J | 1 |
| Bajetta, E; Bearz, A; Calcagno, A; Cartenì, G; Chiappino, I; Guadalupi, V; Imarisio, I; Landi, L; Paglino, C; Porta, C; Procopio, G; Re, GL; Ricotta, R; Rizzo, M; Ruggeri, EM; Sabbatini, R; Verzoni, E; Zustovich, F | 1 |
| Antonarakis, ES; Carducci, MA; Eisenberger, MA; Hammers, H; Huang, P; Keizman, D; Kim, JJ; Pili, R | 1 |
| Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
| Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S | 1 |
| Abrey, L; Camps, C; Chao, RC; Grossi, F; Mazieres, J; Novello, S; Patyna, S; Scagliotti, G; Thall, A; Usari, T; Vernejoux, JM; Wang, Z | 1 |
| Fassnacht, M; Kreissl, MC; Schott, M; Spitzweg, C; Willhauck, MJ | 1 |
| Beltran, L; Berney, D; Bex, A; Blank, C; Boleti, E; Chowdhury, S; Haanen, J; Horenblas, S; Nathan, P; O'Brien, T; Peters, J; Powles, T; Sahdev, A; Sarwar, N; Shamash, J | 1 |
| Chen, FH; Chiang, CS; Fu, SY; Hong, JH; Jung, SM; Lee, CC; Tsai, CS; Wang, CC; Wen, CJ | 1 |
| Gong, P; Lv, Y; Wang, S; Zhang, G; Zhang, N; Zhao, Y | 1 |
| Campbell, TC; Hoang, T; Kim, K; Larson, MM; LoConte, NK; Marcotte, SM; O'Mahar, SE; Seo, S; Traynor, AM | 1 |
| Buonerba, C; Di Lorenzo, G | 1 |
| Busch, J; Fenner, M; Ganser, A; Grünwald, V; Johannsen, A; Johannsen, M; Reuter, C; Seidel, C; Weikert, S | 1 |
| Ortega, C; Porta, C; Ravasio, R; Sabbatini, R | 1 |
| Cunningham, D; Okines, AF; Reynolds, AR | 1 |
| Farsaci, B; Higgins, JP; Hodge, JW | 1 |
| Dickerman, B; Dong, B; Jha, BK; Kessler, P; Polyakova, I; Sen, GC; Silverman, RH | 1 |
| Al-Ahmadie, H; Bajorin, DF; Flaherty, AM; Gallagher, DJ; Garcia-Grossman, I; Gerst, SR; Gounder, SK; Milowsky, MI; Ostrovnaya, I; Regazzi, A; Riches, J; Trout, A | 1 |
| Andrews, DW; Axelrod, R; Camphausen, KA; Curran, WJ; Dicker, AP; Glass, J; Hyslop, T; Kamrava, M; Machtay, M; Werner-Wasik, M; Wuthrick, EJ | 1 |
| de Herder, WW; Feelders, RA; Kwekkeboom, D; van Schaik, E | 1 |
| Bladou, F; Boher, JM; Brunelle, S; Deville, JL; Eymard, JC; Gravis, G; Marcy, M; Narbonne, H; Sabatier, R; Salem, N; Viens, P; Walz, J | 1 |
| Decker, R; Escudier, B; Faelker, T; Hamid, O; Kania, M; Kelly, CS; Schmidinger, M; Sternberg, CN; Szczylik, C | 1 |
| Bay, JO; Blanc, E; Chevreau, C; Delva, R; Escudier, B; Ferlay, C; Geoffrois, L; Gravis, G; Laguerre, B; Legouffe, E; Négrier, S; Pérol, D; Rolland, F; Sevin, E | 1 |
| Blay, JY; Chaigneau, L; Curtit, E; Dobi, E; Kalbacher, E; Mansi, L; Nguyen, T; Pivot, X; Viel, E | 1 |
| Horn, T; Jan Danser, AH; Kappers, MH; Leijten, F; Sleijfer, S; Smedts, FM; Strevens, H; van den Meiracker, AH; van Esch, JH; Wesseling, S | 1 |
| Antón-Aparicio, LM; Cassinello, J; Castellano, D; Esteban, E; González-Larriba, JL; Grande, E; Sepúlveda, J | 1 |
| Ciancio, G; Ekwenna, O; Gorin, MA; Soloway, MS | 1 |
| Hatakeyama, K; Ishikawa, T; Kanda, T; Kosugi, S; Yajima, K | 1 |
| Albain, KS; Besse, B; Blais, N; Chao, RC; Gervais, R; Hainsworth, JD; Hamm, JT; Kim, ST; Laskin, J; Lipton, A; Masters, GA; Natale, RB; Page, RD; Selaru, P | 1 |
| Kim, SP; Thompson, RH | 1 |
| Chatellier, G; Cuenod, CA; Faraggi, M; Fournier, L; Hindié, E; Huchet, V; Hugonnet, F; Itti, E; Medioni, J; Oudard, S; Smadja, C | 1 |
| du Parcq, J; Fisher, C; Larkin, JM; Livni, N; Thway, K | 1 |
| Adamson, PC; Ahern, CH; Baruchel, S; Blaney, SM; Dubois, SG; Glade-Bender, J; Grier, HE; Ingle, AM; Ivy, P; Reid, JM; Shusterman, S; Wu, B | 1 |
| Beelen, RH; Schilte, MN; Stavenuiter, AW; Ter Wee, PM | 1 |
| Katanasaka, Y; Kitamura, Y; Kodera, Y; Koizumi, F; Nishio, K; Tamura, T; Tsuda, H | 1 |
| Duprez, O; Gao, F; Paes, MN; Visvardis, EE; Waxman, J | 1 |
| Hamada, JI; Hasegawa, T; Hayashi, Y; Ikeda, C; Kawahara, Y; Kita, D; Nakada, M; Nakanuma, Y; Obuchi, W; Ohtsuki, S; Sabit, H; Sato, Y; Terasaki, T; Watanabe, T; Yoshikawa, A | 1 |
| Chan, AL; Leung, HW | 1 |
| Bloor, A; Cross, NC; Erben, P; Gesk, S; Haferlach, C; Haferlach, T; Hochhaus, A; Hofmann, WK; Metzgeroth, G; Reiter, A; Ritter, M; Score, J; Telford, N; Walz, C | 1 |
| Dardano, A; Del Tacca, M; Ferdeghini, M; Monzani, F; Pasqualetti, G; Ricci, S | 1 |
| de Vries, IJ; Desar, IM; Galama, JM; Jacobs, JF; Mulder, SF; Mulders, PF; Olde Nordkamp, MA; Punt, CJ; Teerenstra, S; Torensma, R; van Herpen, CM; Vissers, KC | 1 |
| Ahn, HK; Kang, WK; Lee, J; Lee, S; Lim, HY; Park, JO; Park, SH; Park, YS; Sun, JM | 1 |
| Bergmann, L; Gschwend, J; Keilholz, U; Miller, K | 1 |
| Fujii, M; Fujisawa, M; Kitajima, K; Maeda, T; Miyake, H; Ohno, Y; Sugimura, K; Takahashi, S; Yoshikawa, T | 1 |
| Ahn, SH; An, SY; Choi, IJ; Jeon, EH; Jeong, WJ; Mo, JH; Park, MW | 1 |
| Bernhard, JC; De Clermont, H; Gross-Goupil, M; Quivy, A; Ravaud, A; Roca, S | 1 |
| Kunene, V; Porfiri, E | 1 |
| Agnelli, L; Baccarin, M; Baldan, F; Bertolini, F; Cadamuro, M; Cattaneo, A; Colombo, F; Foglieni, B; Guerneri, S; Maggioni, M; Marighetti, P; Martin-Padura, I; Mazzaferro, V; Mazzucchelli, S; Porretti, L; Prati, D; Rebulla, P; Rossi, G; Spreafico, M | 1 |
| Debiec-Rychter, M; Faa, G; Floris, G; Normant, E; Schöffski, P; Sciot, R; Van Looy, T; Wellens, J; Wozniak, A | 1 |
| Avril, N; Bomanji, J; Chowdhury, S; Dickson, J; Ell, P; Kayani, I; Lim, L; Nathan, P; Powles, T; Reynolds, A; Rockall, A; Sahdev, A; Shamash, J; Sharpe, K; Wilson, P | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Ahellal, Y; Errihani, H; Essadi, I; M'rabti, H; Tazi, EM; Tazi, MF | 1 |
| Birrer, MJ; Bowtell, D; Ellard, SL; Gilks, CB; Gout, PW; Huntsman, DG; Kagami, T; Lopez-Berestein, G; McAlpine, JN; Miller, DM; Mok, SC; Ozbun, L; Sood, AK; Stany, MP; Stone, RL; Vathipadiekal, V; Vivas-Mejia, P; Wang, Y; Wang, YZ; Xue, H | 1 |
| Busch, J; Grünwald, V; Hinz, S; Kempkensteffen, C; Magheli, A; Miller, K; Seidel, C; Weikert, S; Weinkauf, L; Wolff, I | 1 |
| Atkinson, B; Choueiri, TK; Chowdhury, S; Matrana, MR; Tannir, NM; Tsang, C | 1 |
| Chabner, BA; Fathi, AT | 1 |
| Andersson, S; Bokarewa, M; Brisslert, M; Dehlin, M; Erlandsson, M | 1 |
| Abel, EJ; Culp, SH; Matin, SF; Tamboli, P; Tannir, NM; Wood, CG | 1 |
| Boucher, E; Cheng, AL; DePrimo, SE; Douillard, JY; Faivre, S; Harmon, CS; Kim, JS; Lanzalone, S; Lechuga, MJ; Lim, HY; Lin, X; Raymond, E | 1 |
| Budak, K; Pestalozzi, B; Weisshaupt, Ch | 1 |
| Bajorin, DF; Bosl, GJ; Carousso, M; Feldman, DR; Ginsberg, MS; Motzer, RJ; Patil, S; Sheinfeld, J; Trinos, MJ | 1 |
| Bai, L; Evans, CP; Kung, HJ; Mack, PC; Ok, JH; Yang, JC | 1 |
| Pan, F; Pan, Y; Tian, J; Zhang, X; Zhang, Y | 1 |
| Bex, A; Blank, C; Haanen, J; Horenblas, S; Meinhardt, W; van Tinteren, H | 1 |
| Busch, J; Grünwald, V; Hinz, S; Johannsen, M; Kempkensteffen, C; Magheli, A; Miller, K; Seidel, C; Weikert, S; Wolff, I | 1 |
| Choueiri, TK; Dallabrida, SM; Heng, DY; Je, Y; Moslehi, JJ; Richards, CJ; Schutz, FA | 1 |
| Fukui, I; Hatake, K; Takahashi, S; Yonese, J; Yuasa, T | 1 |
| Danser, AH; de Krijger, RR; Eechoute, K; Kappers, MH; Leijten, F; Mathijssen, RH; Sleijfer, S; Smedts, FM; van den Meiracker, AH; van Esch, JH; Visser, TJ | 1 |
| Bang, YJ; Han, SW; Heo, DS; Im, SA; Kim, DW; Kim, JH; Kim, SH; Kim, TM; Kim, TY; Kim, WH; Koh, Y; Lee, HE; Lee, SH; Oh, DY | 1 |
| Chen, I; Chow Maneval, E; George, DJ; Harmon, CS; Hutson, TE; Kozloff, M; Liu, G; Logothetis, CJ; Mathew, P; Shore, ND; Wang, SL; Wilding, G; Zurita, AJ | 1 |
| Cunningham, D; Yim, KL | 1 |
| Debiec-Rychter, M; Faa, G; Floris, G; Machiels, K; Normant, E; Schöffski, P; Sciot, R; Stefan, C; Vanleeuw, U; Wozniak, A | 1 |
| Greineder, CF; Kohnstamm, S; Ky, B | 1 |
| Atkins, M; Bukowski, R; Choueiri, TK; Dutcher, J; Eisen, T; Elson, P; Escudier, B; Heng, DY; Manola, J; Mazumdar, M; McCormack, JB; Motzer, R; Négrier, S; Royston, P | 1 |
| Ahn, JB; Bang, YJ; Chung, HC; Hong, MH; Jeung, HC; Kim, HS; Kim, K; Koh, Y; Lee, SH; Rha, SY; Shin, SJ | 1 |
| Purmonen, TT | 1 |
| de Wijn, R; Flatmark, K; Fodstad, Ø; Folkvord, S; Rasmussen, H; Ree, AH; Saelen, MG | 1 |
| Choo, SP; Chow, PK; Chung, AY; Huynh, H; Ong, R; Soo, KC; Tai, WM; Toh, HC | 1 |
| Awasthi, N; Schwarz, MA; Schwarz, RE | 1 |
| Barré, L; Bernaudin, M; Delamare, J; Divoux, D; Marteau, L; Petit, E; Roussel, S; Sobrio, F; Toutain, J; Valable, S | 1 |
| Filipiak, KJ; Langiewicz, P; Nurzyński, P; Opolski, G; Szczylik, C; Szmit, S; Zaborowska, M; Złnierek, J | 1 |
| Calcinaro, F; D'Agostino, M; Durante, C; Filetti, S; Moretti, S; Puxeddu, E; Rhoden, K; Russo, D; Sponziello, M; Tallini, G; Tamburrano, G; Voce, P | 1 |
| Khoramnia, R; Wegner, A | 1 |
| Canter, D; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, P; Simhan, J; Uzzo, RG | 1 |
| Calvani, N; Cinefra, M; Cinieri, S; Gnoni, A; Leo, S; Lombardi, L; Lorusso, V; Maiello, E; Morelli, F; Orlando, L | 1 |
| Gao, H; Guo, W; Liu, X | 1 |
| Reichardt, A; Reichardt, P | 1 |
| Yim, KL | 1 |
| Cortes, J; Roché, H | 1 |
| Bazan, F; Bouchet, S; Curtit, E; Kalbacher, E; Maurina, T; Montange, D; Nguyen, T; Pivot, X; Royer, B; Thiery-Vuillemin, A | 1 |
| Batra, S; Choudhuri, R; Devasahayam, N; Gadisetti, C; Krishna, MC; Matsumoto, S; Mitchell, JB; Munasinghe, JP; Saito, K; Subramanian, S; Yasui, H | 1 |
| Aita, Y; Hara, H; Ikeda, T; Ishii, KA; Isobe, K; Kawakami, Y; Saito, Y; Shimano, H; Takekoshi, K; Tanaka, Y | 1 |
| Ballini, JP; Griffioen, AW; Lovisa, B; Nowak-Sliwinska, P; van Beijnum, JR; van den Bergh, H; Weiss, A; Wong, TJ | 1 |
| Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K | 1 |
| Deol, R; Lamba, G; Malhotra, BK; Sahni, R; Shah, D | 1 |
| Dreicer, R; Elson, P; Ganapathi, MK; Ganapathi, R; Garcia, JA; Kim, JJ; Rini, BI; Vaziri, SA; Wirka, R | 1 |
| Allolio, B; Fassnacht, M; Kroiss, M; Lutz, WK; Quinkler, M | 1 |
| Fukui, I; Habuchi, T; Hatake, K; Horikawa, Y; Inoue, T; Nakano, K; Narita, S; Saito, M; Takahashi, S; Tsuchiya, N; Urakami, S; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Blasi, E; Hemkens, M; Heyen, J; John-Baptiste, A; McHarg, A; Patyna, S; Ramirez, D; Steidl-Nichols, J | 1 |
| Ishihara, A; Kuroda, N; Takamori, H; Yamashita, Y | 1 |
| Backer, JM; Backer, MV; Blankenberg, FG; Goris, MG; Hamby, CV; Levashova, Z | 1 |
| Rini, BI; Suarez, C | 1 |
| Baum, MS; Brocks, DR; Feldman, DR; Fischer, PM; Ginsberg, MS; Molina, AM; Motzer, RJ; Patil, S; Trinos, MJ; Voss, MH | 1 |
| Barrios, CH; Bello, A; Brown, MP; Fein, L; Hariharan, S; Hernandez-Barajas, D; Lee, SH; Liu, JH; Martell, BA; Mundayat, R; Rha, SY; Wang, Z; Yuan, J | 1 |
| Avella, DM; Berg, A; Garcia, LS; Isom, HC; Kester, M; Kimchi, ET; Li, G; Liu, D; Lou, X; Rountree, CB; Schell, TD; Shereef, S; Staveley-O'Carroll, KF; Tagaram, HR; Yang, Q; Zhang, SS | 1 |
| Abrams, RM; Babiarz, JE; Chiao, E; Cohen, JD; Guo, L; Kameoka, S; Kolaja, KL; Taunton, J | 1 |
| Baltogiannis, G; Katsios, C; Roukos, DH | 1 |
| Joly, F | 1 |
| Corn, PG; Dayyani, F; Gallick, GE; Logothetis, CJ | 1 |
| Liakakos, T; Roukos, DH | 1 |
| Endo, T; Hasegawa, H; Hoshino, Y; Ishii, Y; Kaneko, G; Kitagawa, Y; Mikami, S; Mukai, M; Ochiai, H; Okabayashi, K; Oya, M | 1 |
| Gupta, R; Maitland, ML | 1 |
| Anderson, KC; Podar, K | 1 |
| Yamaki, K; Yoshino, S | 1 |
| Deeks, ED; Raymond, E | 1 |
| Grünberger, B | 1 |
| Boven, E; Broxterman, HJ; de Haas, RR; Haanen, JB; Koolwijk, P; van den Eertwegh, AJ; van der Veldt, AA; van Hinsbergh, VW; Vroling, L | 1 |
| Kwak, JY; Lee, NR; Song, EK; Yhim, HY; Yim, CY | 1 |
| Cao, K; Chen, J; Guo, S; Huang, B; Li, X; Mao, X; Mo, C; Pan, J; Qiu, S; Wang, Z; Zhuang, J | 1 |
| Baldazzi, V; Carini, M; Caruso, S; Garofoli, E; Lapini, A; Lunghi, A; Mazzanti, R; Tassi, R | 1 |
| Nagahama, K; Takahashi, D; Tamura, T; Tanaka, H; Tsuura, Y | 1 |
| Chang, PM; Chen, MH; Liu, CY; Liu, YC; Pan, CC; Yang, CY | 1 |
| Francescutti, V; Hare, R; Jarkowski, A; Khushalani, N; Wilkinson, N | 1 |
| Patil, DT; Rubin, BP | 1 |
| Elders, A; Fraser, C; Hislop, J; Jenkinson, D; Mowatt, G; Petty, R; Sharma, P; Vale, L | 1 |
| Assaraf, YG; Beerepoot, LV; Broxterman, HJ; de Haas, RR; Dekker, H; Gotink, KJ; Griffioen, AW; Honeywell, RJ; Jansen, G; Labots, M; Musters, RJ; Peters, GJ; Pili, R; Rudek, MA; Verheul, HM | 1 |
| Canter, DJ; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, P; Simhan, J; Sirohi, M; Street, R; Uzzo, RG | 1 |
| Henley, W; Hoyle, MW | 1 |
| Blais, N; Camidge, DR; Canil, C; Chao, RC; Chow, LQ; Diab, SG; Jonker, DJ; Laurie, SA; McWilliam, M; Ruiz-Garcia, A; Thall, A; Tye, L; Zhang, K | 1 |
| Cheng, H; Dicker, AP; Force, T; Kari, G; Koch, WJ; Rodeck, U | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V | 1 |
| Adriaansz, S; Beijnen, JH; Blank, CU; Huitema, AD; Lankheet, NA; Mallo, H; Rosing, H; Schellens, JH | 1 |
| Chu, Q; Feld, R; Foo, AH; Goffin, JR; Gupta, A; Laberge, F; Laskin, J; Laurie, SA; Lee, CW; Morzycki, W; Murray, N; Nicholas, G; Rao, S; Reiman, T; Sauciuc, D; Seely, J; Seymour, L | 1 |
| Agaoglu, F; Basaran, M; Bavbek, S; Darendeliler, E; Ekenel, M; Ozcan, F; Sen, F; Tunc, HM; Yildiz, I | 1 |
| Arranz, JA; Bellmunt, J; Castellano, DE; Climent, MA; Esteban, E; Font, A; Gallardo, E; Garcia-Donas, J; González del Alba, A; Leandro-García, LJ; Martínez, E; Mellado, B; Moreno, F; Puente, J; Robledo, M; Rodríguez-Antona, C | 1 |
| Kerbel, RS | 1 |
| Antonescu, C | 1 |
| Bearss, D; Carew, JS; Choy, G; Espitia, CM; Esquivel, JA; Giles, FJ; Kelly, KR; Mahalingam, D; Medina, EC; Nawrocki, ST; Taverna, P | 1 |
| Carducci, MA; Eisenberger, MA; Hammers, H; Huang, P; Ish-Shalom, M; Keizman, D; Pili, R | 1 |
| Akkus, M; Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Dane, F; Dursun, A; Gonul, II; Sevinc, A; Yildiz, R | 1 |
| Bender, C; Ullrich, A | 1 |
| Akanay-Diesel, S; Bölke, E; Budach, W; Erhardt, A; Gerber, PA; Haes, J; Häussinger, D; Hoff, NP; Homey, B; Kürle, S; Matuschek, C; Schulte, KW | 1 |
| Bali, S; Bhutta, MF; Brown, SD; Cheeseman, MT; Hilton, H; Hough, TA; Parker, A; Pathak, P; Potter, PK; Purnell, T; Romero, MR; Tyrer, HE; Vizor, L; Vowell, K; Wells, S; Williams, D | 1 |
| Cheng, S; Moslehi, J; Uraizee, I | 1 |
| Braun, D; Hershman, JM; Kim, TD; Köhrle, J; le Coutre, P; Schweizer, U | 1 |
| Patel, S | 1 |
| Carmichael, L; Chao, B; Eickhoff, J; Harrison, M; Ivy, P; Jeraj, R; Kolesar, J; Liu, G; Marnocha, R; Perlman, S; Simoncic, U; Vanderhoek, M; Wilding, G | 1 |
| Gong, K; He, ZS; Huang, LH; Jin, J; Li, XS; Shen, C; Song, G; Song, Y; Wang, G; Wu, X; Yu, W; Zhang, Q; Zhang, Z; Zhao, PJ; Zhao, Z; Zhou, LQ | 1 |
| Aparicio, LM; Gallego, GA; Pulido, EG | 1 |
| Amiri-Kordestani, L; Bates, SE; Fojo, T | 1 |
| Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Mackenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wang, Y; Wood, L | 1 |
| Adenis, A; Antonescu, CR; Blay, JY; Bompas, E; Bui, B; Casali, P; Cioffi, A; Coco, P; Coindre, JM; Debiec-Rychter, M; Duffaud, F; Isambert, N; Italiano, A; Keohan, ML; Le Cesne, A; Maki, RG; Rutkowski, P; Schöffski, P; Toulmonde, M | 1 |
| Caram, MV; Schuetze, SM | 1 |
| Kim, EJ; Zalupski, MM | 1 |
| Gállego Pérez-Larraya, J; Reyes-Botero, G; Sanson, M | 1 |
| Reed, MW; Young, RJ | 1 |
| Appleman, LJ; Carlson, DM; Chen, J; Cho, D; Choueiri, TK; Coates, A; Ernstoff, MS; Gupta, N; Kollmannsberger, CK; Michaelson, MD; Perry, DJ; Posadas, EM; Pradhan, R; Qian, J; Ricker, JL; Scappaticci, FA; Tannir, NM; Wong, YN | 1 |
| Chau, NG; Chen, EX; Chin, SF; Hotte, SJ; Siu, LL; Turner, S; Wang, L | 1 |
| Chu, GC; Hanahan, D; Nolan-Stevaux, O; Olson, P; Perry, SR | 1 |
| Di Fiore, F; Ménager, C; Michel, P; Pfister, C; Rigal, O | 1 |
| Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H; Sakai, I | 1 |
| Bennett, JJ; Rubino, MS | 1 |
| Brown, RL | 1 |
| Davis, DW; Fuller, GN; Gombos, DS; Jonasch, E; Matin, SF; McCutcheon, IE; Smith, LA; Tannir, NM; Waguespack, SG; Wen, S | 1 |
| Colon-Otero, G; Copland, JA; Kennedy, GT; Kennedy, WP; Marlow, LA; Santoso, JT; Vishnu, P; Wu, KJ | 1 |
| Hubner, RA; Valle, JW | 1 |
| Bove, B; Cauchi, C; Davey, M; Engstrom, PF; Lee, J; Litwin, S; Lopez, M; Somaiah, N; von Mehren, M | 1 |
| Danser, AH; de Beer, VJ; Duncker, DJ; Kappers, MH; Merkus, D; Sleijfer, S; van den Meiracker, AH; Zhou, Z | 1 |
| Calvo Aller, E; Castellano, D; Díaz Cerezo, S; González Larriba, JL; Kreif, N; López-Brea, M; Maroto, P; Martí, B | 1 |
| Ghinea, N; Pichon, C; Radu, A; Siraj, MA | 1 |
| Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J | 1 |
| Dörken, B; Flörcken, A; Hopfenmüller, W; Pezzutto, A; Singh, A; Takvorian, A; Van Lessen, A; Westermann, J | 1 |
| Ashley, SW; Grover, S; Raut, CP | 1 |
| Baaj, Y; Cook-Moreau, J; Faucher-Durand, K; Fourcade, L; Funalot, B; Mollard, S; Mousseau, Y; Nizou, A; Plainard, X; Qiu, H; Richard, L; Sturtz, FG | 1 |
| Antón-Aparicio, L; Aparicio-Gallego, G; Blanco, M; Figueroa, A; García-Campelo, R; Grande-Pulido, E; Valladares-Ayerbes, M | 1 |
| Ishida, H; Ito, H; Itoh, H; Tsuchiyama, K; Yokoyama, O | 1 |
| Chen, X; Guan, W; Hu, Z; Li, Y; Liu, F; Peng, E; Ye, Z; Zhuang, Q | 1 |
| Doval, DC; Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Thongprasert, S; Yi, JH | 1 |
| Adamson, PC; Ahern, CH; Baruchel, S; Blaney, SM; DuBois, SG; Glade-Bender, J; Ingle, AM; Ivy, P; Reid, JM; Shusterman, S | 1 |
| Bello, C; Bu, HZ; Kang, P; Patyna, S; Peng, GW; Pool, WF; Speed, B; Wu, EY | 1 |
| Celano, M; D'Agostino, M; Durante, C; Filetti, S; Maggisano, V; Moretti, S; Puxeddu, E; Russo, D; Sponziello, M; Verrienti, A; Voce, P | 1 |
| Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H | 1 |
| DE Grève, J; DE Witte, O; DU Four, S; Huylebrouck, M; LE Mercier, M; Lv, S; Michotte, A; Neyns, B; Quartier, E; Sadones, J; Salmon, I; Teugels, E | 1 |
| Chika, N; Kakimoto, M; Kikuchi, A; Koshiishi, H; Nishida, K; Okamura, T; Tokita, H; Yoshimura, T | 1 |
| Hazama, S; Inoue, Y; Oka, M; Suzuki, N; Yoshino, S | 1 |
| Hamilton, J; Hong, DS; Ketonen, LM; Kurzrock, R; McCutcheon, IE; Slopis, J; Subbiah, V | 1 |
| Amano, R; Doi, Y; Hirakawa, K; Noda, S; Yamada, N; Yashiro, M | 1 |
| Batteux, F; Chéreau, C; Kavian, N; Marut, W; Nicco, C; Servettaz, A; Weill, B | 1 |
| Lanocita, R; Procopio, G; Verzoni, E | 1 |
| Ahn, H; Ahn, JH; Cho, YM; Hong, JH; Kim, CS; Kim, TM; Lee, DH; Lee, JL; Lee, SH; Lim, HY; Park, SH; Song, C | 1 |
| Albiges, L; Caty, A; Dietrich, PY; Duclos, B; Escudier, B; Geoffrois, L; Gravis, G; Guillot, A; Joly, F; Kohser, F; Laguerre, B; Legouffe, E; Negrier, S; Oudard, S; Rolland, F; Theodore, CA | 1 |
| Brisse, H; Coulomb, A; Helfre, S; Hilbert, M; Larroquet, M; Mary, P; Orbach, D; Serinet, MO | 1 |
| Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
| Beijnen, JH; Lankheet, NA; Poller, B; Schinkel, AH; Tang, SC; Wagenaar, E | 1 |
| Bushmakin, AG; Cappelleri, JC; Cella, D; Charbonneau, C; Michaelson, MD; Motzer, RJ | 1 |
| Desar, IM; Hambrock, T; Heerschap, A; Mulders, PF; ter Voert, EG; van Asten, JJ; van der Graaf, WT; van Herpen, CM; van Laarhoven, HW; van Spronsen, DJ | 1 |
| Cortesi, E; Iacovelli, R; Mancini, ML; Palazzo, A; Risi, E | 1 |
| Edler, L; Kopp-Schneider, A; Wunder, C | 1 |
| Ohtsuka, T | 1 |
| Barnés, CM; Butterfield, C; Cassiola, F; Chaponis, D; Christison-Lagay, EA; Fallon, EM; Folkman, J; Kieran, M; Le, HD; Nehra, D; Panigrahy, D; Prox, D; Puder, M; Short, S | 1 |
| Deeken, JF; He, P; Rais, R; Rudek, MA; Xu, L; Zhao, M | 1 |
| Bastian, BC; Garrido, M; Hamid, O; Kashani-Sabet, M; Minor, DR; O'Day, SJ | 1 |
| Brentani, RR; Cooke, VG; Damascena, A; Duncan, MB; Kalluri, R; Keskin, D; Khan, Z; LeBleu, VS; Maeda, G; O'Connell, JT; Rocha, RM; Sugimoto, H; Teng, Y; Vong, S; Xie, L | 1 |
| Bang, YJ; Han, SW; Hur, HS; Im, SA; Kim, HP; Kim, TY; Kim, WH; Lee, KH; Min, A; Song, SH; Yoon, YK; Youn Oh, D | 1 |
| Christensen, JG; Lappin, PB; Lee, JH; Shojaei, F; Simmons, BH | 1 |
| Colecchia, M; Iacovelli, R; Mariani, L; Procopio, G; Torelli, T; Verzoni, E | 1 |
| Bruyere, F; Carmier, D; Combe, P; D'Arcier, BF; Linassier, C; Narciso, B | 1 |
| Curvale, G; Deville, JL; Ducournau, A; Gross, E; Lechevallier, E; Rochwerger, A; Salas, S; Venton, G; Zink, JV | 1 |
| Ankersmit, HJ; de Martino, M; Haitel, A; Hoetzenecker, K; Klatte, T; Roth, GA; Waldert, M | 1 |
| Clouthier, SG; Conley, SJ; Gheordunescu, E; Heath, AN; Kakarala, P; Korkaya, H; Newman, B; Wicha, MS | 1 |
| Choueiri, TK; Je, Y; Richards, CJ; Schutz, FA | 1 |
| Cho, G; Kang, JS; Kang, MR; Kim, JK; Kim, YR; Lee, CK; Park, SB; Song, Y; Suh, JY | 1 |
| Andresen, CJ; Bagi, CM; Gebhard, DF | 1 |
| Campos, TL; Choi, J; Han, G; Kvols, LK; Schell, MJ; Strosberg, JR; Valone, TL; Weber, JM | 1 |
| Boulanger, G; Edeline, J; Jouan, F; Martin, B; Oger, E; Patard, JJ; Rioux-Leclercq, N; Vigneau, C; Zerrouki, S | 1 |
| Byun, SS; Hong, SK; Joo, YM; Lee, BK; Lee, S; Lee, SE; Min, SH; Oh, JJ | 1 |
| Chiusa, M; Djafarzadeh, S; Hool, SL; Jakob, SM; Scherer, SJ; Seifriz, F; Suter, TM; Truetsch, P; Zbinden, S; Zuppinger, C | 1 |
| Aparicio, L; Fernández, O; Grande, E; Lázaro, M; León, L; Vázquez, S | 1 |
| Bergh, J; Bischoff, J; Bondarenko, IM; Chan, A; Cortes, J; Delaloge, S; Giorgetti, C; Greil, R; Huang, X; Kern, KA; Lichinitser, MR; Liljegren, A; Lortholary, A; Makhson, AN; Voytko, NL | 1 |
| Buonerba, C; De Placido, S; Di Lorenzo, G | 1 |
| Dolman, ME; Harmsen, S; Hennink, WE; Kéri, G; Kok, RJ; Lacombe, M; Orfi, L; Pieters, EH; Sparidans, RW; Storm, G; Szokol, B | 1 |
| Awada, A; Bergh, J; Cardoso, F; Gianni, L; Giorgetti, C; Huang, X; Kern, KA; Liljegren, A; Mariani, G; Verkh, L; Viganò, L | 1 |
| Dong, M; Phan, AT; Yao, JC | 1 |
| Bates, SE; Fojo, AT; Huang, X; Kim, ST; Motzer, RJ; Stein, WD; Wilkerson, J | 1 |
| Eto, M; Itsumi, M; Kuroiwa, K; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yokomizo, A | 1 |
| Buti, S; Buttitta, F; Calabrese, F; Cavazza, A; Di Chiara, F; Felicioni, L; Garagnani, L; Marchetti, A; Mengoli, MC; Migaldi, M; Nannini, N; Nicoli, D; Rea, F; Rossi, G; Sartori, G; Schirosi, L; Valli, R | 1 |
| Blay, JY; Bui-Nguyen, B; Demetri, GD; Galetic, I; Gelderblom, H; Hsu, Y; McArthur, GA; Reichardt, P; Rutkowski, P; Schlemmer, M; Yazji, S | 1 |
| Aste, MG; Buti, S; Conte, PF; Cosmai, L; Del Giovane, C; Di Lorenzo, G; Grosso, F; Iacovelli, R; Invernizzi, R; Lucia Manenti, A; Masini, C; Moscetti, L; Onofri, A; Ortega, C; Pagano, M; Porta, C; Procopio, G; Sabbatini, R | 1 |
| George, S; Hornick, JL; Jagannathan, JP; Ramaiya, NH; Shinagare, AB | 1 |
| Beenakker, JW; Cui, C; Danen, EH; Ghotra, VP; He, S; Lamers, GE; Meijer, AH; Snaar-Jagalska, BE; Spaink, HP | 1 |
| Bauerschlag, D; Baumann, KH; Canzler, U; Dewitz, T; du Bois, A; Hanker, LC; Hasenburg, A; Hillemanns, P; Hilpert, F; Kurzeder, C; Meier, W; Rau, J; Richter, B; Sehouli, J; Wagner, U; Wimberger, P; Wollschlaeger, K | 1 |
| Czeche, S; Feldt, S; Franzmann, A; Ludwig, WD; Quinzler, R; Schulz, M; Schüssel, K | 1 |
| Gao, F; Sita-Lumsden, A; Visvardis, EE; Waxman, J | 1 |
| Andrae, N; Haase, D; Hartig, R; Kalinski, T; Keilhoff, G; Kirches, E; Mawrin, C | 1 |
| Boku, N; Hamaguchi, T; Hashigaki, S; Hirohashi, T; Kato, K; Lechuga, MJ; Li, Y; Ohtsu, A; Shibata, A; Shimada, Y; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Döme, B; Török, S | 1 |
| Berger, R; Boursi, B; Carducci, MA; Eisenberger, MA; Gottfried, M; Hammers, H; Hayat, H; Ish-Shalom, M; Keizman, D; Kovel, S; Maimon, N; Peer, A; Pili, R; Sella, A; Sinibaldi, V | 1 |
| Haddad, H; Rini, BI | 1 |
| Agulnik, M; Huyck, TK; Svetlichnaya, J; Wayne, JD | 1 |
| Conley, SJ; Wicha, MS | 1 |
| Campbell, S; Dreicer, R; Elson, P; Fergany, A; Garcia, J; Gong, M; Kaouk, J; Klein, E; Krishnamurthi, V; Rabets, J; Rini, BI; Salem, M; Shah, S; Stephenson, A; Wood, L | 1 |
| Galsky, MD | 1 |
| Ansari, R; Fisher, W; Hanna, N; Koneru, K; Liu, Z; McClean, J; Robin, E; Schmitt, JM; Sommers, SR; Tong, Y | 1 |
| Barbault-Foucher, S; Le Beller, C; Martin, C; Mateus, C; Rieutord, A; Vignand-Courtin, C | 1 |
| Agarwal, N; Bello, A; Burke, JM; Cella, D; Edenfield, WJ; Figlin, RA; Hariharan, S; Hudes, GR; Hutson, TE; Korytowsky, B; Martell, B; Motzer, RJ; Olsen, MR; Thompson, JA; Valota, O; Wilding, G; Yuan, J | 1 |
| Buehler, D; Cleary, K; Hafez, GR; Hasenstein, JR; Kasmerchak, K; Kozak, KR; Moody, JS | 1 |
| Reidy-Lagunes, D; Thornton, R | 1 |
| Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N | 1 |
| Brzeskwiniewicz, M; Bylina, E; Falkowski, S; Grzesiakowska, U; Klimczak, A; Kroc, J; Limon, J; Lugowska, I; Melerowicz, W; Mierzejewska, E; Nowecki, ZI; Osuch, C; Rutkowski, P; Siedlecki, JA; Switaj, T; Wasielewski, K; Woźniak, A | 1 |
| Lim, ZD; Mahajan, A; Tannir, NM; Weinberg, J | 1 |
| Antonetti, R; Cignarelli, M; Costantino, E; Gerardi, AM; Landriscina, M; Maddalena, F; Natalicchio, MI; Piscazzi, A | 1 |
| Gano, L; Kniess, T; Kuchar, M; Oliveira, MC; Santos, I | 1 |
| Bruce, JN; Canoll, P; Christensen, JG; Crisman, C; D'Amico, R; Ebiana, V; Gil, O; Kennedy, BC; Lei, L; Rosenfeld, SS; Sisti, J | 1 |
| Ping, SY; Wu, CL; Yu, CP; Yu, DS | 1 |
| Lu, W; Lu, WQ | 1 |
| Telli, M; Witteles, RM | 1 |
| Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yi, JH; Yim, DS | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
| Autorino, R; Carteni, G; Castello, G; D' Alterio, C; Di Lorenzo, G; Facchini, G; Franco, R; La Mura, A; Nappi, O; Ottaiano, A; Perdona, S; Pignata, S; Portella, L; Rizzo, M; Scala, S | 1 |
| Kassem, MG; Korashy, HM; Motiur Rahman, AF | 1 |
| Bussolino, F; Capano, S; Casanovas, O; Giacca, M; Giraudo, E; Maione, F; Regano, D; Serini, G; Zentilin, L | 1 |
| Bowman, CJ; Cappon, GD; Coburn, AM; Patyna, S; Stedman, DB | 1 |
| Bauernhofer, T; Doleschal, B; Groschner, K; Hoefler, G; Hutterer, G; Kass, DA; Kirk, JA; Maechler, H; Pichler, M; Pieske, B; Rainer, PP; Saad, Z; Samonigg, H; Sivakumaran, V; von Lewinski, D | 1 |
| Bos, WE; de Jonge, MJ; Hamberg, AP; Nijsten, TE | 1 |
| Heymach, JV; Mateo, J; Zurita, AJ | 1 |
| Zhou, A | 1 |
| Bucci, F; Cassinelli, G; Cominetti, D; De Cesare, M; Di Francesco, AM; Lanzi, C; Meco, D; Orlandi, A; Passeri, D; Petrangolini, G; Pisano, C; Riccardi, R; Tortoreto, M; Zaffaroni, N; Zuco, V; Zunino, F | 1 |
| Ejima, K; Matsuoka, K; Momozono, K; Moriya, F; Nagayoshi, R; Noguchi, M; Suekane, S; Ueda, K | 1 |
| Canter, DJ; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, PB; Simhan, J; Teper, E; Uzzo, RG | 1 |
| Boni, G; Ferdeghini, M; Mariani, G; Monzani, F; Pasqualetti, G; Polini, A; Ricci, S; Tognini, S | 1 |
| Denda, T; Hashigaki, S; Kato, T; Komatsu, Y; Lechuga, MJ; Miyata, Y; Mizutani, N; Muro, K; Nagase, M; Nishina, T; Satoh, T; Tsuji, A; Tsuji, Y; Yoshida, M | 1 |
| Byun, SS; Hong, SK; Jeong, CW; Jeong, SJ; Kwak, C; Lee, SE; Yoon, CY | 1 |
| Arai, Y; Kawashima, A; Mukai, M; Nakai, Y; Nin, M; Nishimura, K; Nonomura, N; Takayama, H; Tanigawa, G; Tsujimura, A; Uemura, M; Yasunaga, Y | 1 |
| Hayashi, N; Ikeda, I; Inoue, T; Kishida, T; Kobayashi, K; Kubota, Y; Makiyama, K; Minamimoto, R; Miura, T; Murakami, T; Nakaigawa, N; Noguchi, S; Ohgo, Y; Sano, F; Tateishi, U; Ueno, D; Yao, M | 1 |
| Adamy, A; Ehdaie, B; Favaretto, RL; Garg, T; Ghoneim, TP; Maschino, AC; Motzer, RJ; Russo, P; Silberstein, JL | 1 |
| Burris, HA; Eakle, JF; Greco, FA; Hainsworth, JD; Lubiner, ET; Quinn, R; Rubin, MS; Shipley, D; Spigel, DR; Thompson, DS | 1 |
| Cheung, AK; Grainger, DW; Hogrebe, PC; Sanders, WG; Terry, CM | 1 |
| Albert, I; Chao, RC; Govindan, R; Karaseva, N; Krzakowski, M; Makhson, A; Miziara, JE; Papai, ZS; Portulas, ED; Reck, M; Scagliotti, GV; Selaru, P; Strausz, J; Szczesna, A; Thomas, M; Thongprasert, S; Tye, L; von Pawel, J; Wierzbicki, RF; Zhang, K | 1 |
| Koshenkov, VP; Rodgers, SE | 1 |
| Bex, A; de Graaf, AMA; de Hoog, CLMM; de Jong, TAM; Griffioen, AW; Jonasch, E; Mans, LA; Nowak-Sliwinska, P; van Beijnum, JR; Vyth-Dreese, FA | 1 |
| Ikeda, A; Iwasaki, H; Kawai, K; Kimura, T; Kojima, T; Miyazaki, J; Nishiyama, H; Oikawa, T; Shimano, H; Suetomi, T; Takaoka, E; Yoshino, T | 1 |
| Akarsu, E; Babacan, T; Balakan, O; Sevinc, A | 1 |
| Bouattour, M; Bruno, O; Couvelard, A; Dreyer, C; Faivre, S; Hentic, O; Raymond, E; Ronot, M; Serrate, C; Vilgrain, V | 1 |
| Benavent, M; de Miguel, MJ; Garcia-Carbonero, R | 1 |
| Capdevila, J; Tabernero, J | 1 |
| Coimbra, Rde C; Coppini, LP; de Barros, NM; de Moraes-Filho, MN; de Paula Fiod Costa, E; Dib, E; Farah, ME; Freymuller, E; Furlani, Bde A; Guerra, T; Lima, Ade S; Magalhães Júnior, O; Maia, M; Penha, FM; Rodrigues, EB | 1 |
| Fingerle, A; Gschwend, JE; Hauner, K; Horn, T; Kübler, HR; Maurer, T; Retz, M; Schulz, S; Thalgott, MK | 1 |
| Chan, AW; Odejide, OO; Schoenfeld, JD; Wirth, LJ | 1 |
| Wood, L | 1 |
| Chung, AS; Ferrara, N; Finkle, D; Komuves, L; Kowanetz, M; Ngu, H; Peale, F; Wu, X; Zhuang, G | 1 |
| Barck, KH; Cao, TC; Carano, RA; Cheng, JH; Couto, SS; Eastham-Anderson, J; Ferrara, N; Foreman, O; Forrest, WF; Hamilton, P; Ho, CC; Johnson, L; Jubb, AM; Kasman, I; Lima, A; Long, JE; McNutt, A; Molina, R; Nannini, MA; Reslan, HB; Singh, M | 1 |
| Beltran, L; Bycroft, J; Green, JS; Hussain, M; Nair, R; Peters, JL; Powles, T; Shaw, GL | 1 |
| Butrynski, JE; Choy, E; Corless, CL; Demetri, GD; Fletcher, JA; George, S; Heinrich, MC; Manola, JB; Morgan, JA; Solomon, SM; Tap, WD; Van den Abbeele, AD; von Mehren, M; Wagner, AJ; Wang, Q; Yap, JT; Zhu, M | 1 |
| Bellmunt, J; Gil-Martín, M; Gómez-Martín, C; Khosravan, R; Lechuga, MJ; Lin, X; Montagut, C; Núñez, JA; Puig, M; Salazar, R; Tursi, JM | 1 |
| Camidge, DR; Chan, E; Chow Maneval, E; Diab, S; Eckhardt, SG; Khosravan, R; Leong, S; Lin, X; Lockhart, AC; Messersmith, WA; Spratlin, J | 1 |
| Daimon, M; Kaino, W; Kameda, W; Karasawa, S; Kato, T; Oizumi, T; Susa, S; Takase, K; Tomita, Y; Wada, K | 1 |
| Lai, EC; Lau, SH; Lau, WY | 1 |
| Miura, T; Nemoto, K; Shioji, G; Tsuboi, N | 1 |
| Heidenreich, A; van Essen, J | 1 |
| Kuczyk, MA; Schnoeller, TJ; Schrader, AJ; Schrader, M; Steffens, S | 1 |
| Gao, J; Hong, J; Li, J; Shen, L | 1 |
| Castellano, D; De Velasco, G; Ravaud, A; Schmidinger, M; Vazquez, F | 1 |
| Bojic, M; Schmidinger, M | 1 |
| He, H; Shen, Z; Wang, H; Wang, X; Wu, Y; Zhang, C; Zhao, J; Zhou, W; Zhu, Y | 1 |
| Dreyer, C; Faivre, S; Hammel, P; Hentic, O; Maatescu, C; Raymond, E; Ruszniewski, P | 1 |
| Blay, JY; Casali, PG; Cohen, DP; Demetri, GD; Garrett, CR; Goldstein, D; Harmon, CS; Huang, X; Hurwitz, HI; Le Cesne, A; Leyvraz, S; McArthur, GA; Paz-Ares, L; Pousa, AL; Schöffski, P; Shah, MH; Tassell, V; Verweij, J; Xu, QC | 1 |
| Bamias, A; Dimitriadis, G; Dimopoulos, MA; Economopoulos, T; Migkou, M; Nicolatou-Galitis, O; Pectasides, D; Psyrri, A; Raber-Durlacher, JE | 1 |
| Raymond, E; Ruszniewski, P | 1 |
| Baba, S; Fujita, T; Ishii, D; Iwamura, M; Matsumoto, K; Tabata, K; Yoshida, K | 1 |
| Balmor, GR; Weitzen, R; Yarom, N | 1 |
| Fleissig, Y; Lehman, H; Regev, E | 1 |
| Chan, ES; Hansel, DE; Heston, WD; Larchian, WA; Patel, AR | 1 |
| Buchler, T; Cathomas, R; Chastonay, R; Haile, SR; Knuth, A; Liewen, H; Porta, C; Renner, C; Rothermundt, C; Samaras, P; Siciliano, RD; Stenner, F; Stoll, S | 1 |
| Agarwala, SS; Chen, CC; Garay, CC; Gesme, DH; Guo, A; Hess, GP; Hill, JW; Liu, Z | 1 |
| Bansal, S; Kawsar, HI; Myles, JL | 1 |
| Fallon, EM; Guo, L; Le, HD; Mitchell, PD; Nedder, AP; Nehra, D; Puder, M; Rueda, BR | 1 |
| Abrahamova, J; Bortlicek, Z; Buchler, T; Dusek, L; Melichar, B; Pavlik, T; Poprach, A; Puzanov, I; Vyzula, R | 1 |
| Bonenkamp, JJ; de Wilt, JH; Gelderblom, H; Hartgrink, HH; Sleijfer, S; Tielen, R; van Coevorden, F; van der Graaf, WT; Verhoef, C | 1 |
| Casali, PG; De Troia, B; Dei Tos, AP; Gronchi, A; Libertini, M; Marrari, A; Messina, A; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Stacchiotti, S | 1 |
| Lerut, E; Petrov, S; Tolkach, Y; Van Poppel, H | 1 |
| Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
| Awasthi, N; Ruan, W; Schwarz, MA; Schwarz, RE; Zhang, C | 1 |
| Boonjaraspinyo, S; Boonmars, T; Khuntikeo, N; Loilome, W; Nagano, I; Nielsen, PS; Pairojkul, C; Pinlaor, S; Sithithaworn, P; Wu, Z; Yongvanit, P | 1 |
| Drudi, F; Giuliani, J | 1 |
| Blumenschein, GR; Chao, RC; Ciuleanu, T; Groen, HJ; Juhasz, E; Robert, F; Ruiz-Garcia, A; Tye, L; Usari, T | 1 |
| Arias, SC; Camara, NO; Fanelli, C; Fujihara, CK; Kuriki, PS; Machado, FG; Malheiros, DM; Zatz, R | 1 |
| Geisberg, C; Pentassuglia, L; Sawyer, DB | 1 |
| Abrahamova, J; Bortlicek, Z; Buchler, T; Melichar, B; Pavlik, T; Poprach, A; Vyzula, R | 1 |
| Boninsegna, L; Crippa, S; Falconi, M; Partelli, S | 1 |
| Calvo, E; Esser, N; Fiedler, U; Graeser, R; Kim, D; Larkin, J; Tsuchihashi, Z | 1 |
| Hanovich, E; Hercbergs, AH; Kovel, S; Sella, A | 1 |
| Cesaretti, JA; Chen, SH; Forsythe, K; Galsky, M; Genden, EM; Kao, J; Ko, EC; Lau, KH; Ozao-Choy, J; Packer, SH; Schwartz, M; Stock, RG; Sung, MW; Tong, CC | 1 |
| Boleti, E; Chowdury, S; Crabb, SJ; Jones, R; Nathan, P; Powles, T; Protheroe, A; Rashid, S; Sarwar, N; Shamash, J; Stockdale, A; Wilson, P | 1 |
| Aparicio, A; Araujo, J; Bekele, NB; Jonasch, E; Lim, Z; Matin, S; Ng, C; Pagliaro, L; Plimack, E; Smith, L; Tamboli, P; Tannir, NM; Wood, CG; Xiao, L | 1 |
| Xu, JM | 1 |
| Halfdanarson, TR; Naraev, BG; Strosberg, JR | 1 |
| Cristofano, A; Malossi, A; Mozzicafreddo, A; Numico, G; Sicuro, M; Silvestris, N; Thiebat, B; Trogu, A | 1 |
| Athanasou, NA; Bradley, KM; Dijkstra, PD; Gelderblom, H; Gibbons, CL; Hassan, AB; Hogendoorn, PC; Kroep, JR; Nout, RA; van de Sande, MA; van der Heijden, L; van Rijswijk, CS | 1 |
| Lang, F; Lupescu, A; Shaik, N | 1 |
| Fuhr, U; Jaehde, U; Kanefendt, F; Lindauer, A; Mross, K | 1 |
| Bergadà, L; Dolcet, X; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Sorolla, A; Valls, J; Yeramian, A | 1 |
| Knight, JW | 1 |
| Donohue, JH; Nagorney, DM; Okuno, SH; Que, FG; Zaydfudim, V | 1 |
| Chamberlain, M; Chowdhary, S; Pan, E; Potthast, L; Smith, P; Yu, D; Yue, B | 1 |
| Blumenthal, GM; Cortazar, P; Justice, R; Murgo, A; Pazdur, R; Sridhara, R; Tang, S; Zhang, JJ | 1 |
| Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Kroiss, M; Lankheet, N; Laubner, K; Müller, HH; Pöllinger, A; Quinkler, M; Strasburger, CJ; van Erp, NP | 1 |
| Bird, D; Erler, JT; Foo, S; Foster, J; Frentzas, S; Gourlaouen, M; Mather, SJ; Pili, R; Powles, T; Preece, N; Reynolds, AR; Robertson, D; Sharpe, K; Soffe, J; Springer, CJ; van Weverwijk, A; Welti, JC | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Mardiak, J; Mego, M; Obertova, J; Reckova, M; Svetlovska, D; Sycova-Mila, Z | 1 |
| de Jesus-Gonzalez, N; Humphreys, BD; Moslehi, J; Robinson, E | 1 |
| Baumann, C; Dahal, BK; Davie, N; Evans, S; Fairman, D; Ghofrani, HA; Grimminger, F; Kilty, I; Kojonazarov, B; Kosanovic, D; Luitel, H; Majewski, M; Phillips, P; Pullamsetti, SS; Schermuly, RT; Seeger, W; Sydykov, A; Tian, X; Wayman, C; Weissmann, N | 1 |
| Cohen, DP; Demetri, GD; George, S; Lechner, T; Li, S; Reichardt, P | 1 |
| Arai, Y; Kawashima, A; Nakai, Y; Nin, M; Nishimura, K; Nonomura, N; Takayama, H; Tanigawa, G; Tsujimura, A; Uemura, M | 1 |
| Rajamanikandan, S; Srinivasan, P; Sudha, A; Vanajothi, R | 1 |
| Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Ivy, P; Krishnamurthi, SS; Meropol, NJ; Rath, L; Savvides, P | 1 |
| Jing, C; Ning, J; Yuanjie, N | 1 |
| Gallo, JM; Lv, H; Ma'ayan, A; Mazloom, AR; Xu, H; Zhou, Q | 1 |
| Casciano, R; Chulikavit, M; Garrison, LP; Liu, Z; Perrin, A; Wang, X | 1 |
| Dai, J; He, HC; Huang, X; Shen, ZJ; Su, TW; Sun, FK; Zhou, WL | 1 |
| Carlson, SJ; Fallon, EM; Mitchell, PD; Nedder, AP; Nehra, D; Potemkin, AK; Puder, M; Rueda, BR | 1 |
| Berlin, S; Campos, SM; Horowitz, NS; Matulonis, U; Penson, RT; Pereira, L; Roche, M; Szymonifka, J; Tyburski, K; Whalen, C | 1 |
| Fukui, I; Kitsukawa, S; Saito, K; Takahashi, S; Urakami, S; Yamamoto, S; Yasuda, Y; Yonese, J; Yuasa, T | 1 |
| Gallowitsch, HJ; Malle, P; Sorschag, M | 1 |
| Bai, W; He, AR; Hwang, J; Marshall, J; Mikhail, S; Navarro, R; Pishvaian, M; Shivapurkar, N; Wellstein, A | 1 |
| Byrne, MJ; Creaney, J; Dick, IM; Francis, RJ; Hasani, A; Millward, MJ; Musk, AW; Nowak, AK; Segal, A; van der Schaaf, A | 1 |
| Carley, W; DePrimo, SE; Harmon, CS; Huang, X; Kern, KA; Keyvanjah, K | 1 |
| Becker, JU; Grünwald, V; Kuczyk, MA; Merseburger, AS; Peters, I; von Klot, C | 1 |
| Aita, Y; Hara, H; Ikeda, T; Ishii, KA; Kawakami, Y; Saito, Y; Shimano, H; Takekoshi, K | 1 |
| Brown, MF; Chandler, J; Dudgeon, C; Shu, Y; Sun, J; Sun, Q; Xu, X; Yu, J; Zhang, L | 1 |
| Couvelard, A; de Gramont, A; Faivre, S; Hammel, P; Neuzillet, C; Raymond, E; Serova, M; Tijeras-Raballand, A | 1 |
| Saito, K | 1 |
| Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S | 1 |
| Burrell, K; Camphausen, K; Chung, C; Foltz, W; Graves, C; Jaffray, D; Jalali, S; Lindsay, P; Ménard, C; Milosevic, M; Wildgoose, P; Zadeh, G | 1 |
| Hong, JL; Li, J; Shen, L | 1 |
| Krzemieniecki, K; Sowa-Staszczak, A; Zygulska, AL | 1 |
| Gaustad, JV; Leinaas, MN; Rofstad, EK; Simonsen, TG | 1 |
| Boven, E; Eechoute, K; Gelderblom, H; Guchelaar, HJ; Haanen, JB; Kappers, MH; Mathijssen, RH; Oosting, S; Reyners, AK; van der Veldt, AA; van Herpen, CM; Wessels, JA | 1 |
| Agrillo, A; Facchini, A; Filiaci, F; Nastro Siniscalchi, E; Ungari, C | 1 |
| Aieta, M; Amadori, A; Barile, C; Basso, U; Borin, M; Celadin, R; Cristofanilli, M; Fassan, M; Grassi, A; Indraccolo, S; Jirillo, A; Lanza, C; Miatello, L; Rossi, E; Rugge, M; Sava, T; Troiani, L; Zamarchi, R; Zilio, F | 1 |
| Bagot, M; Basset-Seguin, N; Battistella, M; Bouaziz, JD; Comte, C; Farges, C; Kerob, D; le Maignan, C; Lebbé, C; Madjessli, N; Pagès, C; Penot, P; Vilmer, C | 1 |
| de Groot, JF; Henry, V; Heymach, JV; Holmes, L; Liang, J; Piao, Y; Zurita, AJ | 1 |
| Al Ghuzlan, A; Anderson, P; Ayala-Ramirez, M; Baudin, E; Cabanillas, ME; Caramella, C; Chougnet, CN; Deandreis, D; Habra, MA; Jimenez, C; Leboulleux, S; Palmer, JL; Waguespack, SG | 1 |
| Bridges, K; Brooks, C; Kuban, D; Mason, K; Mathew, P; Meyn, R; Sheu, T | 1 |
| Bottai, G; Santarpia, L | 1 |
| Igarashi, H; Ito, T; Jensen, RT; Takayanagi, R | 1 |
| Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ | 1 |
| Kunawudhi, A; Mahmood, U; Michaelson, MD; Palmer, EL; Saylor, PJ; Smith, MR | 1 |
| Kriegelstein, S; Messlinger, K; Steiner, T; Troeltzsch, M; Woodlock, T | 1 |
| Kondo, T | 1 |
| Hiramatsu, Y; Kamiya, K; Kikuchi, H; Konno, H; Miyazaki, S; Ohta, M; Sakaguchi, T; Setoguchi, T | 1 |
| Anderson, J; Bier, N; Cherian, A; Chowdhury, T; O'Meara, A; Prichard-Jones, K; Sebire, NJ; Sullivan, MO | 1 |
| Nishida, T; Ueshima, S; Wakasugi, M | 1 |
| Puche-Sanz, I; Vázquez-Alonso, F | 1 |
| Bradley, JM; Cohen, PA; Dominguez, AL; Finke, JH; Gendler, SJ; Gorman, JE; Ko, JS; McCurry, DB; Pathangey, LB; Rayman, PA; Rini, BI; Spencer, CD; Storkus, WJ; Zorro-Manrique, S | 1 |
| Breaker, K; Clemons, J; Flaig, TW; Gao, D; Garfield, D; Naam, M | 1 |
| Aldrighetti, D; Amadori, D; Bouko, Y; Canon, JL; Cardoso, F; Dirix, L; Giorgetti, C; Kern, KA; Machiels, JP; Usari, T; Verkh, L | 1 |
| Gong, K; Li, T; Ning, X; Wang, X; Wu, P; Zhang, C; Zhang, N | 1 |
| Benekli, M; Buyukberber, S; Cetin, B; Guz, G; Inal, S; Memis, L; Ozturk, SC; Turan, N | 1 |
| Atkinson, B; Chen, A; Sevin, A | 1 |
| Bodnar, L; Duchnowska, R; Miciuk, B; Szczylik, C; Waśniewski, L | 1 |
| Bruera, E; Busaidy, NL; Cabanillas, ME; Del Fabbro, E; Dev, R; Rodriguez, EC | 1 |
| Pfister, C; Pfrommer, H; Roser, F; Tatagiba, MS | 1 |
| Higashiyama, K; Iwase, Y; Maitani, Y; Saito, H; Seishi, Y; Sugino, T; Yamauchi, T | 1 |
| Barile, C; Basso, U; Brunello, A; Camerini, A; De Vivo, R; Falci, C; Maruzzo, M; Roma, A; Sacco, C; Sava, T; Zagonel, V | 1 |
| Abbas, M; Herrmann, TR; Jüttner, B; Kramer, M; Kuczyk, MA; Merseburger, AS; Peters, I; Reichelt, A; Teebken, OE; von Klot, C; Winkler, M | 1 |
| Gallia, GL; Joshi, AD; Loilome, W; Riggins, GJ; Siu, IM; Tyler, B | 1 |
| Ariad, S; Lazarev, I; Mermershtain, W; Shani-Shrem, N | 1 |
| Albersen, A; Hamberg, P; Njo, T; Porcelijn, L; Schilders, J; Zuetenhorst, H | 1 |
| Hirooka, N; Iwasaki, A; Matsuyama, S; Sekiguchi, Z; Takeshima, T; Takizawa, A; Tsuchiya, F | 1 |
| Arai, Y; Kakimoto, K; Matsuzaki, K; Nakata, W; Nakayama, M; Nishimura, K; Takeda, K; Ueda, N; Yamamoto, Y | 1 |
| Brickman, MJ; Citrin, DL; Dees, EC; Healey, P; Kern, KA; Li, S; Myers, SD; Paolini, J; Wang, Z; Yardley, DA | 1 |
| Chou, CY; Lin, YH; Lin, YT; Tsai, HH; Wang, KH | 1 |
| Kelly, WK; Lin, J | 1 |
| Manicke, NE; Ouyang, Z; Shen, L; Yang, Q; Zhang, J | 1 |
| Fine, HA; Iwamoto, FM; Kreisl, TN; Salgado, C; Shih, JH; Smith, P; Sul, J | 1 |
| Chiu, J; Cho, WY; Lang, B; Leung, R; Shek, T; Wong, H; Yat, WK; Yau, LC; Yau, T | 1 |
| Lin, CI; Moalem, J; Ruan, DT; Whang, EE | 1 |
| Albiges, L; Escudier, B; Iacovelli, R; Lanoy, E | 1 |
| Benhamouda, N; Carpentier, AF; Colussi, O; Dubreuil, O; Marcheteau, E; Pernot, S; Sandoval, F; Taieb, J; Tartour, E; Terme, M | 1 |
| Blais, N; Camidge, DR; Chao, RC; Chow, LQ; Doebele, RC; Jonker, DJ; Laurie, SA; Ruiz-Garcia, A; Soulières, D; Thall, A; Zhang, K | 1 |
| Bian, W; Ge, Z; Li, J; Qiu, F | 1 |
| Brugia, M; Cerullo, C; Muto, A; Neri, B; Rangan, S; Rediti, M; Tassi, R; Vannini, A | 1 |
| Chan, K; Laudadio, M; Mahipal, A; Mastrangelo, MJ; Sato, T; Tijani, L | 1 |
| Boyle, HJ; Chatté, G; Fléchon, A; Rivoire, M | 1 |
| Karakiewicz, PI; Sun, M; Trinh, QD | 1 |
| Chiba, H; Hirose, T; Kanagawa, K; Shimoda, N | 1 |
| Alzate-Morales, JH; Bergmann, R; Caballero, J; Cunha, S; Gano, L; Kniess, T; Muñoz, C; Steinbach, J | 1 |
| Berkers, J; Beuselinck, B; Body, JJ; Debruyne, P; Dumez, H; Elaidi, R; Karadimou, A; Lerut, E; Paridaens, R; Rogiers, A; Schöffski, P; Van Cann, T; Van Poppel, H; Willems, L; Wolter, P | 1 |
| Hensley, JR; Kulik, L; Lacouture, ME; Mulcahy, M; Nardone, B; Rademaker, A; West, DP | 1 |
| Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J | 1 |
| Bex, A; de Bruijn, R; Horenblas, S; Kroon, BK; Powles, T; Prevoo, W | 1 |
| De Amici, M; Ganini, C; Giunta, V; Imarisio, I; Paglino, C; Porta, C; Quaglini, S; Sacchi, L | 1 |
| Lin, CI; Lorch, JH; Ruan, DT; Whang, EE | 1 |
| Akyol, M; Alacacioglu, A; Benekli, M; Buyuberber, S; Ciltas, A; Coskun, U; Dane, F; Gumus, M; Isikdogan, A; Kaplan, MA; Karaca, H; Kefeli, U; Ozdemir, N; Ozkan, M; Seker, M; Sevinc, A; Suner, A; Tarhan, MO; Yildiz, R | 1 |
| Badalamenti, G; Bauer, S; Blackstein, M; Blay, JY; Casali, PG; Chung, J; Demetri, GD; Gelderblom, H; Hohenberger, P; Joensuu, H; Kang, YK; Kappeler, C; Kuss, I; Laurent, D; Le Cesne, A; Leahy, M; Maki, RG; Nguyen, BB; Nishida, T; Reichardt, P; Rutkowski, P; Schöffski, P; von Mehren, M; Xu, J | 1 |
| Cunningham, D; Waddell, T | 1 |
| Abouelkhair, KM; Bayer, AM; Elmasri, OA; Ibrahim, EM; Kazkaz, GA | 1 |
| Hsu, SL; Hwang, GY; Hwang, WL; Liu, HC; Teng, CL; Tsai, JR; Yu, CT | 1 |
| Han, JH; Han, JY; Kim, HJ; Kim, HT; Kim, HY; Kwak, MH; Lee, JS; Lee, YJ; Lim, KY; Yun, T | 1 |
| Hoekstra, R; Honeywell, RJ; Peters, GJ; van Erp, NP; Verheul, HM; Westgeest, HM | 1 |
| Chang, AY; Wang, M | 1 |
| Bruce, JN; Canoll, P; Cardoso, AL; Costa, PM; Nóbrega, C; Pedroso de Lima, MC; Pereira de Almeida, LF | 1 |
| Albersen, M; Berkers, J; Beuselinck, B; Govaere, O; Joniau, S; Lerut, E; Roskams, T; Schöffski, P; Swinnen, J; Van den Oord, J; van Kempen, LC; Van Poppel, H; Wolter, P | 1 |
| Baum, RP; Bert, T; Hommann, M; Hörsch, D; Kaemmerer, D; Petrovitch, A; Schrader, J; Zaknun, J | 1 |
| Adenis, A; Alt, M; Caty, A; Fumagalli, I; Penel, N; Vanhuyse, M; Zini, L | 1 |
| Blanc, E; Escudier, B; Ferlay, C; Genin, C; Gigante, M; Li, G; Negrier, S; Paul, S; Perol, D; Tostain, J; Zhao, A | 1 |
| Asmar, L; Galsky, MD; Gardner, TA; Hahn, NM; Hellerstedt, BA; Hutson, TE; Kocs, D; Lerner, SP; McKenney, SA; Melnyk, AM; O'Rourke, M; Powles, T; Rauch, M; Sonpavde, G; Vogelzang, NJ; Wang, Y; Yu, M | 1 |
| Bregant, C; Ganini, C; Imarisio, I; Morbini, P; Paglino, C; Porta, C; Vercelli, A | 1 |
| Bańkowski, K; Bodziachowska-Panfil, M; Giller, T; Kossykowska, M; Kubiszewski, M; Kutner, A; Malińska, M; Sidoryk, K; Woźniak, K; Łaszcz, M | 1 |
| Brown, J; Collinson, FJ; Gregory, WM; Hanlon, P; Hewison, J; Howard, H; Lowe, C; McCabe, C; McParland, L; Potrata, D; Selby, PJ; Tubeuf, S; Wah, T | 1 |
| Clutter, S; De Ruyter, ML; Lele, AV; Price, E | 1 |
| Hatch, DM; Roy, RC | 1 |
| Iljin, K; Kallioniemi, O; Ketola, K | 1 |
| Aieta, M; Bochicchio, AM; Capobianco, A; Coccaro, M; Gallucci, G; Improta, G; Maurea, N; Tartarone, A; Tocchetti, CG; Zupa, A | 1 |
| Arima, K; Kanda, H; Masui, S; Sugimura, Y; Yamada, Y | 1 |
| Ambring, A; Björholt, I; Lesén, E; Odén, A; Stierner, U | 1 |
| Kummer, G; Schultheis, B; Strumberg, D | 1 |
| Chen, CS; Chen, WM; Cheng, CL; Chiu, KY; Ho, HC; Li, JR; Ou, YC; Su, CK; Wang, SS; Yang, CK; Yang, CR | 1 |
| Agarwal, S; Chi, M; Dudek, AZ; Elmquist, WF; Mittapalli, RK; Oberoi, R; Raza, A; Singhal, M | 1 |
| Matsui, K; Moriyama, M; Nagata, T; Okumura, T; Omura, T; Sawada, S; Sekine, S; Shimada, Y; Tsukada, K; Yoshida, T; Yoshioka, I | 1 |
| Borker, R; Fonseca, E; Hess, G | 1 |
| Kawamoto, S; Kikutake, T; Yoshida, T | 1 |
| Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Minato, H; Morioka, E; Nakano, Y; Nakata, S; Noguchi, M; Ohnishi, T; Ohno, Y; Omote, K; Takamura, H; Tomita, Y; Ueda, N | 1 |
| Hara, H; Ikeda, T; Ishii, KA; Kawakami, Y; Miura, M; Otagiri, A; Saito, Y; Shimano, H; Takekoshi, K | 1 |
| Chao, RC; Hara, K; Hashigaki, S; Igarashi, H; Imamura, M; Ito, T; Kimura, N; Kondo, S; Mizuno, N; Morizane, C; Murakami, M; Nishida, T; Ohki, E; Okusaka, T; Sawaki, A; Yamao, K | 1 |
| Bello, E; Berndt, A; Camboni, G; Cavalletti, E; Colella, G; D'Incalci, M; Damia, G; Forestieri, D; Giavazzi, R; Licandro, SA; Richter, P; Taraboletti, G; Zucchetti, M | 1 |
| Frampas, E; Koscielny, S; Lassau, N; Vilgrain, V; Vullierme, MP; Zappa, M | 1 |
| Pal, SK; Vogelzang, NJ | 1 |
| Downey, FP; McDermott, RS; Teo, M | 1 |
| Funakoshi, T; Shimada, YJ | 1 |
| Harada, S; Kitsukawa, S; Kozuka, T; Kudo, K; Miyazawa, K; Sukegawa, G; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Huang, J; Huang, Y; Wang, T | 1 |
| El Gendy, MA; El-Kadi, AO; Korashy, HM; Maayah, ZH | 1 |
| Bui, B; Cioffi, A; Italiano, A; Kind, M; Maki, RG | 1 |
| Cai, Z; Chen, W; Jin, Q; Ye, X | 1 |
| Fujisawa, M; Miyake, H; Sakai, I | 1 |
| Barna, ME; Pastorello, M; Uomo, I | 1 |
| Corso, G; Di Mare, G; Lambert, Y; Marrelli, D; Mastrogiacomo, D; Neri, A; Roviello, F; Volterrani, L | 1 |
| Antón-Aparicio, LM; Bayona, C; Bolós, MV; Borrega, P; de Portugal, T; Espinosa Arranz, E; Fresno Vara, JA; Gallegos Sancho, MI; Gámez-Pozo, A; García-Domínguez, R; Madero, R; Pérez-Carrión, R; Ramos-Vázquez, M; Sánchez-Navarro, I | 1 |
| Czarnota, GJ; El Kaffas, A; Giles, A | 1 |
| Alasker, A; Bianchi, M; Hanna, N; Hansen, J; Ismail, S; Karakiewicz, PI; Meskawi, M; Perrotte, P; Sun, M; Tian, Z | 1 |
| Akintayo, A; Chen, Z; El-Rayes, B; Fanucchi, MP; Harvey, RD; Kauh, JS; Khuri, FR; Lewis, CM; Nadella, P; Owonikoko, TK; Ramalingam, SS; Rogatko, A; Shin, DM; Tighiouart, M | 1 |
| Alsop, DC; Atkins, MB; Bahamon, B; Bhatt, RS; Goldberg, SN; Mier, JW; O'Neill, A; Signoretti, S; Wang, X; Wood, CG; Zhang, L | 1 |
| Egawa, S; Fukushima, M; Ishii, S; Katsumata, H; Minami, S; Okamoto, Y; Yamanaka, D | 1 |
| Peng, L; Schwarz, RE | 1 |
| Davidoff, AM; Hartwich, J; Morton, C; Ng, CY; Orr, WS; Spence, Y | 1 |
| Beuselinck, B; Blesius, A; Chevreau, C; Escudier, B; Oudard, S; Ravaud, A; Rolland, F | 1 |
| Ahn, H; Ahn, JH; Ahn, Y; Choi, HJ; Hong, JH; Jeong, IG; Kim, CS; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
| Ashikari, A; Kobayashi, H; Kohno, Y; Namitome, R; Nishiyama, T; Saito, S; Yagi, Y | 1 |
| Bauerschlag, D; Bender, S; Glüer, CC; Hamann, S; Jonat, W; Kalthoff, H; Loermann, D; Lorenzen, AC; Rösel, F; Schem, C; Tiwari, S | 1 |
| Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA | 1 |
| Ahmadzadeh, A; Babaei, M; Elahi, F; Hassanpour, K; Yadollahzadeh, M | 1 |
| Godwin, AK; Ochs, MF; Rink, L; von Mehren, M; Zhou, Y | 1 |
| Buti, S; Donini, M; Passalacqua, R; Rossi, G; Rossi, V; Sergio, P | 1 |
| Baek, SG; Jean, WS; Kang, J; Kim, JM; Kim, YS; Ko, BY; Lee, GW; Lee, NS | 1 |
| Chao, TC; Chen, PC; Hsiao, FC; Lu, HJ; Ma, H; Shiau, CY; Tzeng, CH; Yen, CC | 1 |
| Cortesi, E; Iacovelli, R; Mezi, S; Naso, G; Palazzo, A; Pellegrino, D; Trenta, P | 1 |
| Öberg, K | 1 |
| Kulke, MH | 2 |
| Albers, C; Duyster, J; Illert, AL; Leischner, H; Peschel, C; Verbeek, M; von Bubnoff, N; Yu, C | 1 |
| Buti, S; Donini, M; Lazzarelli, S; Passalacqua, R | 1 |
| Bates, SE; Blagoev, KB; Fojo, AT; Motzer, RJ; Stein, WD; Wilkerson, J | 1 |
| Iiri, T; Makita, N | 1 |
| Rose, S | 1 |
| Grabowski, T; Grześkowiak, E; Karbownik, A; Matuszewski, M; Połom, W; Sobańska, K; Szałek, E; Urjasz, H; Wolc, A | 1 |
| Bourcier, ME; Vinik, AI | 1 |
| Barone, C; Basso, M; Biolato, M; Castaldi, P; De Gaetano, AM; Grieco, A; Iaculli, A; Leccisotti, L; Miele, L; Pompili, M; Riccardi, L; Rufini, V | 1 |
| Kim, H; Nagata, Y; Shoji, S; Terachi, T; Uchida, T; Usui, Y | 1 |
| Salup, RR | 1 |
| Cohen, SA; Derweesh, IH; Kane, CJ; Kopp, RP; Liss, MA; Mehrazin, R; Millard, F; Palazzi, KL; Park, SK; Patel, N; Patterson, AL; Raheem, OA; Stroup, SP | 1 |
| Berkers, J; Beuselinck, B; Claes, B; Couchy, G; Deplanque, G; Descazeaud, A; Elaidi, R; Gravis, G; Joly, F; Karadimou, A; Lambrechts, D; Lebret, T; Leclercq, NR; Lerut, E; Méjean, A; Molinié, V; Oudard, S; Paridaens, R; Patard, JJ; Schöffski, P; Teghom, C; van Poppel, H; Verkarre, V; Wolter, P; Zucman-Rossi, J | 1 |
| Morton, D; Nambiar, PR | 1 |
| Bravo, J; Cañueto, J; de Unamuno, P; Mir-Bonafé, JM | 1 |
| Gelmann, EP; Lim, E | 1 |
| Bex, A; Haanen, J | 1 |
| Abadie-Lacourtoisie, S; Azzouzi, AR; Bigot, P; Chautard, D; Delva, R; Hoarau, N; Latteux, G; Lebdai, S | 1 |
| Abodunde, OA; Berrou, M; Desai, R; LevakaVeera, RR; Nweke, N | 1 |
| Behrendt, FF; Bzyl, J; Mottaghy, FM; Palmowski, K; Palmowski, M; Rix, A; Verburg, FA; Winz, O | 1 |
| Chatterjee, S; Dufour, JF; Majumder, S; Piguet, AC | 1 |
| Funakoshi, T; Galsky, MD; Latif, A | 1 |
| Bruns, CJ; Camaj, P; Gamba, S; Haertl, C; Heinemann, V; Jung, A; Laubender, RP; Modest, DP; Primo, S; Schwarz, B; Stintzing, S | 1 |
| Gao, J; Li, J; Shen, L; Sun, N; Tian, Y; Yuan, J | 1 |
| Mankal, P; O'Reilly, E | 1 |
| Boudou-Rouquette, P; Delongchamps, NB; Giroux, J; Goldwasser, F; Huillard, O; Mir, O; Peyromaure, M; Ropert, S; Tlemsani, C; Zerbib, M | 1 |
| Al-Amin, A; Fred, RG; Idevall-Hagren, O; Li, J; Li, T; Mokhtari, D; Ravassard, P; Scharfmann, R; Tengholm, A; Turpaev, K; Welsh, N; Wuttke, A | 1 |
| Berger, J; Berkers, J; Beuselinck, B; Bigot, P; Claes, B; Couchy, G; de la Taille, A; Karadimou, A; Lambrechts, D; Lerut, E; Linassier, C; Méjean, A; Négrier, S; Oudard, S; Paridaens, R; Patard, JJ; Schöffski, P; Tourani, JM; Verkarre, V; Wolter, P; Zucman-Rossi, J | 1 |
| Breaker, K; Flaig, IP; Flaig, TW; La Rosa, FG; Naam, M | 1 |
| Jiang, XL; Luo, CL; Wu, XH; Zhang, Y | 1 |
| Cassinelli, G; Cominetti, D; Favini, E; Lanzi, C; Penco, S; Petrangolini, G; Pisano, C; Tortoreto, M; Vlodavsky, I; Zaffaroni, N; Zunino, F | 1 |
| Wang, Q; Zhang, Y | 1 |
| Libutti, SK; Saif, MW; Stevenson, R | 1 |
| Albert, FK; Baumgarten, P; Brokinkel, B; Ebel, H; Harter, PN; Hasselblatt, M; Mittelbronn, M; Plate, KH; Stummer, W; Zachskorn, C; Zinke, J | 1 |
| de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A | 1 |
| Ardizzoni, A; Bella, MA; Porzio, R; Rossi, G | 1 |
| Giaccone, G; Rajan, A; Thomas, A; Tiseo, M | 1 |
| Albiges, L; Di Palma, M; Escudier, B; Fizazi, K; Levy, A; Loriot, Y; Menard, J | 1 |
| Geissler, AK; Liu, Q; Mier, JW; Panka, DJ | 1 |
| Auf, G; Bayerl, SH; Broggini, T; Bruenner, J; Czabanka, M; Harms, C; Harms, U; Heppner, FL; Jabouille, A; Koch, A; Kremenetskaia, I; Mueller, S; Nieminen, M; Parmaksiz, G; Topalovic, M; Vajkoczy, P | 1 |
| Beijnen, JH; Huitema, AD; Lankheet, NA; Rosing, H; Schellens, JH; Steeghs, N | 1 |
| Ba-Ssalamah, A; Bareck, E; Brodowicz, T; Eisterer, W; Häfner, M; Högenauer, C; Kastner, U; Kühr, T; Längle, F; Liegl-Atzwanger, B; Ploner, F; Schoppmann, SF; Widmann, G; Wrba, F; Zacherl, J | 1 |
| Omrčen, T; Rini, B; Schmidinger, M; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E | 1 |
| Chen, I; McDermott, DF; Michaelson, MD; Patyna, S; Ruiz-Garcia, A; Ryan, DP; Schwarzberg, AB; Shapiro, GI; Stephenson, P; Tye, L; Zhu, AX | 1 |
| Bianconi, M; Bittoni, A; Burattini, L; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Loretelli, C; Maccaroni, E; Minardi, D; Montironi, R; Muzzonigro, G; Nicoletti, S; Scartozzi, M | 1 |
| Nishida, T; Tori, M; Yoshidome, K | 1 |
| Bydlowski, SP; Chierice, GO; Ferreira, AK; Filho, OM; Freitas, VM; Levy, D; Maria, DA; Rici, RE; Ruiz, JL | 1 |
| Becker, CR; Berger, F; Englhart, E; Hittinger, M; Reiser, MF; Schlemmer, M; Schramm, N; Übleis, C | 1 |
| Abe, R; Aoyagi, S; Fujita, Y; Hata, H; Hoshina, D; Saito, N; Shimizu, H; Yoshioka, N | 1 |
| Ji, T; Ong, HS; Wang, LZ; Yu, ZW; Zhang, CP | 1 |
| Chen, ZF; Chi, P; Guan, GX; Jiang, WZ; Liu, X; Lu, HS | 1 |
| Cao, H; Xu, J | 1 |
| Corn, PG; DePetrillo, TA; Heath, E; Kuban, D; Maier, J; Mathew, P; Meyn, R; Song, DY | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Lee, DH; Lee, JL; Park, I; Park, K; Park, SJ; Song, C | 1 |
| Inayama, Y; Kubota, Y; Makiyama, K; Nakaigawa, N; Nakayama, T; Sakata, R; Sano, F; Tatenuma, T; Yao, M | 1 |
| Chakravarthi, S; Haleagrahara, N; Judson, JP; Segarra, I; Tan, JR | 1 |
| Győrffy, B; Likó, I; Pénzváltó, Z; Schäfer, R; Szász, AM; Szendrői, A; Sztupinszki, Z; Tegze, B | 1 |
| Errihani, H; Kharmoum, S | 1 |
| Boussaha, T; Lepere, C; Rougier, P; Taieb, J | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Robert, C; Sibaud, V | 1 |
| Chen, J; Cong, L; Cui, Y; Han, J; Luan, Y; Sha, D; Shen, R; Wang, C; Wang, W; Zhang, Z | 1 |
| Christensen, JG; Ishiguro-Oonuma, T; McDonald, DM; Schriver, BJ; Sennino, B | 1 |
| An, H; Hu, X; Lin, Z; Liu, H; Liu, L; Liu, Y; Lv, T; Xu, J; Xu, L; Yin, H; Zhang, H; Zhang, J; Zhu, Y | 1 |
| Berney, D; Bex, A; Blank, C; Boleti, E; Chowdhury, S; Haanen, J; Jones, R; Kayani, I; Lim, L; Peters, J; Powles, T; Reynolds, AR; Sahdev, A; Shamash, J; Sharpe, K; Stewart, GD | 1 |
| Blacher, S; Cataldo, D; Detry, B; Erpicum, C; Foidart, JM; Lambert, V; Maertens, L; Maillard, C; Munaut, C; Noël, A; Paupert, J; Rakic, JM; Sounni, NE | 1 |
| Brugia, M; Cerullo, C; Neri, B; Rangan, S; Rediti, M; Tassi, R; Vannini, A | 1 |
| Chiu, WY; Hung, IF; Mok, MY; Shea, YF; Yau, CC | 1 |
| Bisht, S; Brossart, P; Feldmann, G | 1 |
| Kabashima, K; Matsuda, A; Matsui, M; Matubara, K; Sasahashi, M; Ueharaguchi, Y | 1 |
| Guerin, E; Kerbel, RS; Man, S; Xu, P | 1 |
| Calvani, N; Chiuri, V; Cinieri, S; Fedele, P; Gnoni, A; Lorusso, V; Maiello, E; Morelli, F; Orlando, L; Scavelli, C | 1 |
| Kulke, MH; Lagunes, DR; Yao, JC | 1 |
| Ammi, M; Azzouzi, AR; Baumert, H; Beauval, JB; Bensalah, K; Berger, J; Bernhard, JC; Bigot, P; Escudier, B; Fardoun, T; Grenier, N; Hétet, JF; Lagabrielle, S; Lebdai, S; Long, JA; Paparel, P; Patard, JJ; Rioux-Leclercq, N; Rouprêt, M; Soulié, M; Xylinas, E | 1 |
| Caulfield, TR; Cooper, SJ; Copland, JA; Marlow, LA; Tan, WW; Tun, HW; von Roemeling, CA; Wei, JJ; Wu, K | 1 |
| Devarakonda, S; Gopalan, PK; Govindan, R; Waqar, SN; Williams, K | 1 |
| Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T | 1 |
| Bergerot, P; Carmichael, C; Figlin, RA; Hsu, J; Hsu, S; Hu, J; Lau, C; Liu, X; Pal, SK; Saikia, J; Twardowski, P; Yuh, BF | 1 |
| Ding, LJ; Jiang, ZF; Meng, XY; Song, ST; Sun, B; Wu, SK; Zhao, X | 1 |
| Kato, T; Tomita, Y; Watanabe, T | 1 |
| Chen, CT; Chen, SH; Kao, J; Packer, SH; Schwartz, M; Sung, MW; Tong, CC | 1 |
| Arrowsmith, ER; Crane, EJ; Franco, LA; Hainsworth, JD; Khatcheressian, J; Rubin, MS | 1 |
| Boku, N; Hashigaki, S; Kimura, N; Lechuga, M; Machida, N; Miyata, Y; Muro, K; Suzuki, M | 1 |
| Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J | 1 |
| Albarrán-Planelles, C; Báez-Perea, JM; Jiménez-Gallo, D; Linares-Barrios, M; Martínez-Rodríguez, A | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, IV; Can, A; Demir, L; Dirican, A; Erten, C; Koeseoglu, M; Kucukzeybek, Y; Payzin, KB; Somali, I; Tarhan, MO; Yildiz, Y | 1 |
| Al-Harbi, H; Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; MacKenzie, M; North, S; Rini, BI; Vickers, MM | 1 |
| Barrios, CH; Bukowski, R; Escudier, B; Fly, K; Gore, ME; Hutson, TE; Lin, X; Matczak, E; Motzer, RJ; Rini, BI | 1 |
| Bracci, R; Cascinu, S; Maccaroni, E | 1 |
| Feldman, DR; Ginsberg, MS; Hsieh, JJ; Jia, X; Molina, AM; Motzer, RJ; Patil, S; Velasco, S | 1 |
| Bacus, S; Brown, AM; Doherty, KR; Kramer, JW; Moran, DM; Shell, SA; Talbert, DR; Trusk, PB; Wappel, RL | 1 |
| Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Chen, HR; Li, P; Lin, LZ; Pang, LJ | 1 |
| Choorapoikayil, S; de Bruin, A; den Hertog, J; Kers, R; Weijts, B | 1 |
| Cheng, S; Moslehi, J | 1 |
| Arap, W; Bankson, JA; Bryan, NS; Chintalgattu, V; Culver, JC; Dickinson, ME; Dunner, K; Entman, ML; Goel, A; Jiffar, T; Khakoo, AY; Kupferman, ME; Langley, RR; Pasqualini, R; Pati, S; Rees, ML; Taegtmeyer, H; Yao, H; Zhang, J | 1 |
| Bono, P; Joensuu, H; Peltola, K; Rautiola, J; Utriainen, T | 1 |
| Bennett, KL; Borgdorff, V; Breitwieser, FP; Colinge, J; Gridling, M; Müller, AC; Rix, U; Superti-Furga, G; Wagner, C; Wagner, SN; Winter, GE | 1 |
| Dong, B; Jha, BK; Nguyen, CT; Polyakova, I; Silverman, RH | 1 |
| Chung, B; Tsimafeyeu, I; Zart, JS | 1 |
| Banerjee, S; Baral, R; Barik, S; Bhuniya, A; Bose, A; Das, A; Ghosh, S; Ghosh, T; Pal, S; Paul, T; Roy, S; Sarkar, M | 1 |
| Abbas, MA; Disi, AM; Taha, MO | 1 |
| Fukudo, M; Katsura, T; Kunimatsu, S; Mizuno, T | 1 |
| Asmar, L; Boehm, KA; Bradie-Muller, SJ; Gluck, L; Mueller, SE; Reynolds, C; Spira, AI; Zhan, F | 1 |
| Boers-Sonderen, MJ; Desar, IM; Koopman, M; Punt, CJ; van Herpen, CM | 1 |
| Purohit, R | 1 |
| Baas, P; Blumenschein, GR; Butts, CA; Chao, RC; Chmielowska, E; Gao, F; Gridelli, C; Groen, HJ; Grossi, F; Harmon, C; Juhasz, E; Selaru, P; Socinski, MA; Tye, L; Usari, T; Williams, JA | 1 |
| Alemany, I; Arranz, JA; Bellmunt, J; Castellano, DE; Climent, MA; Esteban, E; Font, A; Gallardo, E; Garcia-Donas, J; González Del Alba, A; Hernando, S; Leandro-García, LJ; Mellado, B; Moreno, F; Morente, M; Puente, J; Robledo, M; Rodríguez-Antona, C | 1 |
| Brugarolas, J; Jacobs, C; Kim, DW; Pedrosa, I; Straka, C; Timmerman, RD | 1 |
| Bahleda, R; Escudier, B; Gueutin, V; Izzedine, H; Rouvier, P; Soria, JC; Varga, A | 1 |
| Prado, CM | 1 |
| Bitzer, M; Horger, M; Ioanoviciu, SD; Kopp, HG; Schulze, M; Spira, D; Wiesinger, B | 1 |
| Itoh, K; Komai, Y; Matsubara, N; Mukai, H; Naito, Y; Sakai, Y | 1 |
| Bamia, C; Bamias, A; Beuselinck, B; Chrisofos, M; de Guillebon, E; Dimopoulos, MA; Diosynopoulos, D; Elaidi, RT; Escudier, B; Fountzilas, G; Lang, H; Oudard, S; Papazisis, K; Stravodimos, K; Tzannis, K; Wolter, P | 1 |
| Dokduang, H; Juntana, S; Khuntikeo, N; Loilome, W; Namwat, N; Riggins, GJ; Techasen, A; Yongvanit, P | 1 |
| Chang, YC; Cheng, AL; Hsu, C; Lee, BS; Lin, LI; Liou, JY; Ou, DL | 1 |
| Ishida, R; Kobayashi, H; Nishikimi, T; Tsuzuki, T; Yamada, H; Yamauchi, Y; Yokoi, K; Yoshida, S | 1 |
| Arch, RH; Atkinson, MA; Bluestone, JA; Brekken, RA; Calderon, B; Kabre, B; Kubeck, S; Lang, J; Pullen, N; Szot, GL; Villalta, SA; Wasserfall, C | 1 |
| Bianco, R; Damiano, V; Formisano, L; Martignoni, G; Massari, F; Nappi, L; Rosa, R; Scarpa, A; Tortora, G | 1 |
| Francois, R; Hochwald, SN; Iyer, R; Seshadri, M; Zajac-Kaye, M; Zhang, J | 1 |
| Chen, LT; Chen, TS; Chiang, NJ; Hsueh, YS; Ko, CH; Li, CF; Lin, CL; Shan, YS; Shih, NY; Wang, LM; Yen, CC | 1 |
| Ancukiewicz, M; Catalano, OA; Duda, DG; Hayano, K; Jain, RK; Jiang, T; Sahani, DV; Zhu, AX | 1 |
| Beijnen, JH; de Vries, N; Schinkel, AH; Sparidans, RW; Tang, SC; Wagenaar, E | 1 |
| Khagi, S; Saif, MW | 1 |
| Saif, MW; Sarris, EG; Syrigos, KN | 1 |
| Banerjee, P; Begum, S; Castellanos, MR; Debata, PR; Genzer, O; Kleiner, MJ; Mata, A | 1 |
| Kim, GM; Kim, SY; Lee, JH | 1 |
| Abernethy, AP; Chen, C; George, DJ; Harrison, MR; Kirkendall, DT; Korytowsky, B; Stepanski, EJ; Walker, MS | 1 |
| Bachelot, T; Blasinska-Morawiec, M; Capitain, O; Cognetti, F; Crown, JP; Davidson, N; Diéras, V; Fasching, PA; Fountzilas, G; Greil, R; Huang, X; Kern, KA; Kreienberg, R; Liedtke, C; Miller, WH; Paolini, J; Ramos, M; Romieu, G; Staroslawska, E; Tassell, V; Wildiers, H; Yardley, DA | 1 |
| De Giorgi, U | 1 |
| Dai, B; Hong, YP; Lin, GW; Ma, CG; Qin, XJ; Shen, YJ; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
| Eilles, C; Grimm, D; Grosse, J; Infanger, M; Magnusson, NE; Pohl, F; Warnke, E; Wehland, M | 1 |
| Costello, B; Farrell, A; Foster, NR; Jatoi, A; Le-Lindqwister, NA; Mathew, J; Meyers, JP; Patel, K; Reynolds, J | 1 |
| Choi, YA; Ko, SY; Lee, KE; Park, JC; Park, SY; Seo, MJ; Sim, EH; Yang, YJ | 1 |
| Brugarolas, J; Grishin, N; Jiang, H; Kinch, L; Kockel, L; Peña-Llopis, S; Tran, TA | 1 |
| Grammas, P; Luo, J; Martinez, JM; Sanchez, A; Tripathy, D; Yin, X | 1 |
| Kaneda, Y; Katayama, I; Masuzawa, M; Nakamura, M; Nishizawa, A; Saeki, K; Satoh, T; Takehara, Y; Yokozeki, H | 1 |
| Amantini, C; Berardi, R; Bonfili, L; Burattini, L; Cascinu, S; Eleuteri, AM; Farfariello, V; Liberati, S; Morelli, MB; Mozzicafreddo, M; Nabissi, M; Santoni, G; Santoni, M | 1 |
| Bozzi, F; Casali, PG; Cominetti, D; Gronchi, A; Libertini, M; Messina, A; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Stacchiotti, S; Tamborini, E; Tortoreto, M; Zaffaroni, N | 1 |
| Carducci, MA; Fu, C; Gerber, S; Hammers, HJ; Kachhap, S; No, E; Sheibani, N; Van Den Berg, S; van der Zwan, A; Wang, WC | 1 |
| Abe, F; Arakawa-Todo, M; Hasegawa, T; Matsuura, K; Nomura, H; Tsukiyama, I; Ueyama, J | 1 |
| Aprile, G; Belli, C; Bergamo, F; Ceraulo, D; Cereda, S; Danova, M; Di Lucca, G; Franceschi, E; Fugazza, C; Mambrini, A; Milella, M; Novarino, A; Passardi, A; Reni, M; Villa, E | 1 |
| Aboagye, EO; Ashek, A; Barnes, G; Cotroneo, E; Cupitt, J; Dabral, S; Dubois, O; El-Bahrawy, MA; Fang, W; Gibbs, JS; Gsell, W; He, JG; Howard, LS; Jones, H; Nguyen, QD; Pullamsetti, SS; Tomasi, G; Wang, L; Wilkins, MR; Zhao, L | 1 |
| Ingels, A; Nolley, R; Peehl, DM; Santos, J; Thong, AE; Valta, MP; Young, SR; Zhao, H | 1 |
| Soulières, D | 1 |
| Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Rovida, A; Scanziani, E; Scarlato, V | 1 |
| Ellegaard, AM; Groth-Pedersen, L; Jäättelä, M; Kirkegaard, T; Klumperman, J; Nylandsted, J; Oorschot, V | 1 |
| Barney, BM; Bauer, HJ; Laack, NN; Macdonald, OK; Markovic, SN; Miller, RC; Olivier, KR; Sarkaria, JN | 1 |
| Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS | 1 |
| Gong, K; He, ZS; Huang, LH; Jin, J; Li, XS; Shen, C; Song, G; Song, Y; Yu, W; Zhang, CJ; Zhang, Q; Zhang, Z; Zhao, J; Zhao, PJ; Zhao, Z; Zhou, LQ | 1 |
| Akça, Z; Büyükçelik, A; Kaya, N; Mutlu, H | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Chovanec, M; Mardiak, J; Mego, M; Obertova, J; Palacka, P; Rajec, J | 1 |
| Bremer, C; Budny, T; Hahnenkamp, A; Heindel, W; Persigehl, T; Remmele, S; Ring, J; Schwartz, LH; Spiegel, HU; Stoeppeler, S | 1 |
| Blais, N; Camidge, DR; Chao, RC; Chow, LQ; Diab, SG; Jonker, DJ; Laurie, SA; Ruiz-Garcia, A; Soulières, D; Thall, A; Zhang, K | 1 |
| Boleti, E; Cella, D; Choueiri, TK; Crescenzo, R; De Giorgi, U; de Souza, P; Deen, K; Fife, K; Guo, J; Hackshaw, MD; Harmenberg, U; Hawkins, R; Hutson, TE; Jin, J; Jones, R; McCann, L; Merchan, JR; Motzer, RJ; Nathan, P; Pandite, LN; Reeves, J; Staehler, M; Sternberg, CN; Uemura, H; Wang, J | 1 |
| Basolo, F; Bocci, G; Borrelli, N; Canu, B; Danesi, R; Di Desidero, T; Fioravanti, A; Fontanini, G; Francia, G; Giannini, R; Kerbel, RS; Man, S; Orlandi, P; Xu, P | 1 |
| Baker, SD; Buaboonnam, J; Enemark, EJ; Inaba, H; Mullighan, CG; Neale, GA; Olsen, SR; Orwick, S; Rubnitz, JE; Shurtleff, S; Wang, YD; Zatechka, DS; Zimmerman, EI | 1 |
| Feng, Q; Hongqian, G; Ruipeng, J; Weidong, G; Xiang, Y; Xitai, S | 1 |
| Heng, DY; Molina, AM; Motzer, RJ | 1 |
| Garcia-Donas, J; Jonasch, E; Rodriguez-Antona, C | 1 |
| Deng, L; Gao, H | 1 |
| Lyseng-Williamson, KA | 1 |
| Bonezzi, K; Borsotti, P; Cvitkovic, E; D'Incalci, M; Frapolli, R; Giavazzi, R; Noel, K; Sala, F; Taraboletti, G; Ubezio, P; Zangarini, M; Zucchetti, M | 1 |
| Kubota, Y; Makiyama, K; Nakaigawa, N; Nakamura, M; Sakata, R; Sano, F; Tatenuma, T; Yao, M | 1 |
| Adriaansz, S; Beijnen, JH; Blank, CU; Haanen, JB; Huitema, AD; Lankheet, NA; Mallo, H; Schellens, JH | 1 |
| Ahn, JB; Kim, HR; Kim, HS; Kwon, WS; Lee, JH; Lim, SM; Park, HS; Rha, SY; Shin, SJ; Tanigawara, Y | 1 |
| Atkinson, BJ; Bathala, T; Corn, P; Jonasch, E; Kalra, S; Tannir, NM; Wang, X | 1 |
| Ding, J; Li, X; Meng, LH; Tong, LJ | 1 |
| Busch, C; de Wijn, R; Geisler, J; Kristensen, V; Lønning, PE; Ree, AH; Risberg, K; Røe, K; Tahiri, A | 1 |
| Boers-Sonderen, MJ; Hoentjen, F; Jacobs, JF; Mulder, SF; Nagtegaal, ID; van Herpen, CM; Wanten, GJ | 1 |
| Askeland, RW; Cyr, AR; Gillum, MP; Spanheimer, PM; Weigel, RJ; Woodfield, GW | 1 |
| Brunelle, S; Cappiello, M; Gilabert, M; Gravis, G; Provansal, M; Salem, N; Tarpin, C; Thomassin, J; Walz, Y | 1 |
| Imai, H; Kageyama, S; Katayama, N; Matsuoka, N; Mizuno, T; Oda, H; Saito, K; Sugawara, Y; Tamaru, S; Uchida, K; Yamashita, Y | 1 |
| Fujiwara, T; Fujiwara, Y; Uno, F | 1 |
| Sato, T; Valsecchi, ME | 1 |
| Korytowsky, B; Lechuga, MJ; Lin, X; Matczak, E; Molina, AM; Motzer, RJ; Wiltshire, R | 1 |
| Tóth, M | 1 |
| Bertheau, P; Bousquet, G; de Bazelaire, C; Faivre, S; Ferreira, I; Germain, S; Janin, A; Leboeuf, C; Mongiat-Artus, P; Raymond, E; Varna, M; Wang, L | 1 |
| Egawa, S; Endo, K; Hatano, T; Ishii, G; Kishimoto, K | 1 |
| Ferrero, S; Leone Roberti Maggiore, U; Valenzano Menada, M; Venturini, PL | 1 |
| Derbel Miled, O; Dionne, C; Droz, JP; Flechon, A; Negrier, S; Neidhart, EM; Segura-Ferlay, C; Terret, C | 1 |
| Alesini, D; Cascinu, S; Cortesi, E; De Marchis, L; Iacovelli, R; Naso, G; Palazzo, A; Santoni, M; Trenta, P | 1 |
| Fujita, K; Hatano, K; Kawashima, A; Nakai, Y; Nakata, W; Nonomura, N; Sato, M; Takayama, H; Uemura, M; Yoshida, T | 1 |
| Bartz-Schmidt, KU; Bayyoud, T; Hofmann, J; Spitzer, M; Yoeruek, E | 1 |
| Ebos, JM; Francia, G; Guerin, E; Kerbel, RS; Lee, CR; Man, S; Xu, P | 1 |
| Cho, IC; Chung, J; Joung, JY; Kwon, WA; Lee, KH; Nam, BH; Seo, HK; Yu, A | 1 |
| Cheng, AL; Chung, HC; Kang, YK; Kudo, M; Lanzalone, S; Lechuga, MJ; Lin, DY; Omata, M; Park, JW; Pitman Lowenthal, S; Poggi, G; Qin, S; Raymond, E; Song, X; Xu, J; Yang, L | 1 |
| Choi, YJ; Jo, J; Kang, YK; Lee, JJ; Park, I; Park, JH; Ryoo, BY; Ryu, JS; Ryu, MH; Tan, E; Yoo, C | 1 |
| Dornbusch, J; Erdmann, K; Froehner, M; Fuessel, S; Meinhardt, M; Wirth, MP; Wolff, I; Zacharis, A; Zastrow, S | 1 |
| Cerdán-Miguel, J; Cerdán-Santacruz, C; Esteban, F; García-Alonso, M; Jiménez, F; Ortega, M; Santos-Rancaño, R; Sanz, R; Sanz-Ortega, G; Zuloaga, J | 1 |
| Bang, YJ; Khosravan, R; Lechuga, MJ; Lee, KW; Lee, SY; Lin, X; Oh, DY; Park, SR; Park, YI; Roh, EJ; Valota, O | 1 |
| Cohen, PA; Finke, JH; Jaini, R; Rayman, P; Tuohy, VK | 1 |
| Carpenter, C; Choueiri, TK; Deen, KC; Johnson, T; Motzer, RJ; Pandite, LN; Xu, CF; Xue, Z | 1 |
| Li, J; Shi, Y; Xing, P | 1 |
| Elmquist, WF; Mittapalli, RK; Oberoi, RK | 1 |
| Inoue, T; Kawakita, S; Kinoshita, H; Masuda, T; Matsuda, T; Murota, T; Nishida, T | 1 |
| Han, BH; Huang, JQ; Jiang, LY; Li, SQ; Liu, YR; Yao, YH; Zhang, JL; Zhang, W; Zhao, YZ; Zhu, W | 1 |
| Asanuma, K; Cheng, E; Genta, RM; Hatanpaa, KJ; Huo, X; Melton, S; Peng, S; Pham, TH; Rezai, D; Sarode, V; Souza, RF; Spechler, SJ; Wang, DH; Wright, E; Xu, H; Yu, C; Zhang, Q; Zhang, X | 1 |
| Behrendt, FF; Gray, BD; Kiessling, F; Lederle, W; Mottaghy, FM; Pak, KY; Palmowski, K; Palmowski, M; Rix, A | 1 |
| Babaian, KN; Hu, X; Kenney, PA; Lin, X; Maity, T; Merrill, MM; Su, SC; Wood, CG; Yang, SF; Zhang, XY | 1 |
| Choi, MK; Hong, JY; Jung, HA; Kang, WK; Lee, J; Lim, HY; Maeng, CH; Park, JO; Park, SH; Park, YS; Yi, JH | 1 |
| Casado Herráez, A; Currás Freixes, M; Díaz Pérez, JÁ; Ochagavía Cámara, S | 1 |
| Campbell, S; Dreicer, R; Elson, P; Garcia, JA; Medsinge, A; Rini, BI; Salem, ME; Shah, SN; Wood, LS | 1 |
| Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M | 1 |
| Ding, JF; Zhong, DF | 1 |
| Demetri, GD; Jagannathan, J; Kang, YK; Kim, HJ; Lee, JJ; Nam, BH; Ramaiya, N; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Doi, T; Nishida, T | 1 |
| de Wit, D; den Hartigh, J; den Hollander, M; Gelderblom, H; Guchelaar, HJ; Hessing, T; König-Quartel, JM; Sparreboom, A; van Erp, NP | 1 |
| Alkiş, N; Bal, O; Demirci, A; Durnali, A; Ekinci, AŞ; Eşbah, O; Oksüzoğlu, B | 1 |
| Bonkovsky, HL; Hwang, SI; Lee, JG; McKinney, KQ; Mougeot, JL | 1 |
| Ishii, H; Kadota, J; Kushima, H | 1 |
| Bastide, C; Bay, JO; Bruyere, F; Guy, L; Karsenty, G; Mahammedi, H | 1 |
| Baek, JH; Cho, G; Cho, HJ; Kim, E; Kim, JK; Kim, MH; Kim, YR; Lee, CK; Lee, YS; Lim, D; Noh, GT; Song, Y; Suh, JY | 1 |
| Bellmunt, J; Pons, F | 1 |
| Brown, DW; Carlson, SJ; Fallon, EM; Nedder, AP; Nehra, D; Puder, M; Rueda, BR | 1 |
| Boggon, TJ; Calderwood, DA; Gao, J; Ha, BH; Lou, HJ; Morse, EM; Turk, BE; Zhang, R | 1 |
| Jin, L; Kong, X; Lou, L; Quan, H; Xu, Y; Zhao, J | 1 |
| Eilles, C; Grimm, D; Grosse, J; Magnusson, NE; Pietsch, J; Pohl, F; Warnke, E; Wehland, M; Wise, P | 1 |
| Beuselinck, B; De Smet, R; Debruyne, PR; Depoorter, L; Dumez, H; Joniau, S; Karadimou, A; Lerut, E; Oudard, S; Paridaens, R; Schöffski, P; Strijbos, M; Teghom, C; Van Calster, B; Van Poppel, H; Vano, YA; Wolter, P; Zucman-Rossi, J | 1 |
| Al-Mahrouki, A; Czarnota, GJ; El Kaffas, A; Giles, A; Tran, WT | 1 |
| Buchsbaum, DJ; Fauci, JM; Ferrone, S; Landen, CN; Londoño-Joshi, AI; Sabbatino, F; Straughn, JM; Wang, Y | 1 |
| Atri, M; Bjarnason, GA; Burns, PN; Hudson, JM; Karshafian, R; Milot, L; Williams, R | 1 |
| DePrimo, SE; Eisen, T; Figlin, RA; Harmon, CS; Huang, X; Hudes, GR; Hutson, TE; Kim, ST; Michaelson, MD; Motzer, RJ; Négrier, S; Williams, JA | 1 |
| Bamias, A; Bearz, A; Bellmunt, J; Imarisio, I; Melichar, B; Paglino, C; Porta, C; Procopio, G; Sabbatini, R; Schmidinger, M; Tinelli, C | 1 |
| Bianconi, M; Burattini, L; Cascinu, S; Di Primio, R; Lucarini, G; Mazzucchelli, R; Minardi, D; Montironi, R; Muzzonigro, G; Pistelli, M; Santoni, M; Scartozzi, M | 1 |
| Arakawa-Todo, M; Hasegawa, T; Kajikawa, K; Kato, Y; Kobayashi, I; Matsuura, K; Nakamura, K; Nishikawa, G; Saito, H; Sumitomo, M; Tsukiyama, I; Yamada, Y; Yoshizawa, T; Zennami, K | 1 |
| Fischer, JW; Freudenberger, T; Kretschmer, I; Nagy, N; Niedworok, C; Reis, H; Röck, K; Rübben, H; Szarvas, T; Vom Dorp, F | 1 |
| Novara, G; Zustovich, F | 1 |
| Duangsa-ard, S; Hongeng, S; Kasetsinsombat, K; Maneechotesuwan, K; Sa-ngiamsuntorn, K; Wamanuttajinda, V; Wongkajornsilp, A | 1 |
| Balakrishnar, B; Bennink, RJ; Daali, Y; Eechoute, K; Gurney, H; Huitema, AD; Kam, BL; Kloth, JS; Klümpen, HJ; Mathijssen, RH; Samer, CF; Schellens, JH; Wong, M; Yu, H; Zwinderman, AH | 1 |
| Mihajlović, J; Pechlivanoglou, P; Postma, MJ; Sabo, A; Tomić, Z | 1 |
| Gaustad, JV; Hompland, T; Pozdniakova, V; Rofstad, EK; Simonsen, TG | 1 |
| Al-Arifi, MN; Ansari, MA; El Gendy, MA; Korashy, HM; Maayah, ZH | 1 |
| Ahn, JH; Bellmunt, J; Castellano, D; Chang, YH; Chiang, PH; Chuang, CK; Diaz, JR; Donnellan, P; Duh, MS; Elaidi, R; Feinberg, BA; Hawkins, R; Huang, CY; Korves, C; Levy, A; McCaffrey, J; McDermott, D; McDermott, R; Mehmud, F; Nathan, P; Neary, MP; Oh, WK; Ou, YC; Porta, C; Rha, SY; Scott, J; Scotte, F; Sun, JM; Wagstaff, J | 1 |
| Al-Hawary, M; Bylow, KA; Daignault, S; Dreicer, R; Grivas, PD; Hussain, M; Keller, ET; Kohli, M; Nanus, DM; Petrylak, DP; Smith, DC; Sottnik, JL; Stadler, WM; Tagawa, ST; Vaughn, DJ; Wong, SG | 1 |
| Campos-Mollo, E; Cuenca-Navarro, N; Fernández-Sánchez, L; Lledó-Riquelme, M; Pérez-Santonja, JJ | 1 |
| Fujita, T; Iwamoto, Y; Koike, H; Takeuchi, H; Tsujino, H | 1 |
| Amela, E; Blanc, E; Chevreau, C; Delva, R; Escudier, B; Ferlay, C; Négrier, S; Oudard, S; Ravaud, A; Rolland, F; Tosi, D | 1 |
| Fukatsu, A; Gotoh, M; Hattori, R; Kuroda, M; Kuwahara, K; Morikawa, T; Sassa, N; Shimoyama, Y; Shiroki, R; Tsuzuki, T; Yoshino, Y | 1 |
| Borrello, MG; Cassinelli, G; Castiglioni, V; Cominetti, D; Dal Bo, L; Favini, E; Folini, M; Lanzi, C; Lopergolo, A; Nicolini, V; Perego, P; Scanziani, E; Tortoreto, M; Zaffaroni, N | 1 |
| Arav-Boger, R; Cai, H; Forman, M; He, R; Kapoor, A; Posner, GH; Venkatadri, R | 1 |
| Aghebati-Maleki, L; Baradaran, B; Shahneh, FZ; Zamani, F | 1 |
| Awad, GA; El-Safoury, DM; Motaleb, MA; Sakr, TM | 1 |
| Furuya, K; Joh, K; Kaku, Y; Kurosaka, D; Yoshida, K | 1 |
| Dell'Aquila, E; Frezza, AM; Grasso, RF; Guida, FM; Lanzetta, G; Santini, D; Silletta, M; Silvestris, N; Tonini, G; Venditti, O; Vincenzi, B | 1 |
| Bjarnason, GA; Escudier, B; Esteban, E; Hariharan, S; Hutson, TE; Lim, HY; Lu, DR; Motzer, RJ; Niethammer, A; Pittman, KB; Senico, P | 1 |
| Armstrong, AJ; Chen, I; Chow-Maneval, E; Galsky, MD; Lechuga, M; Leopold, L; Michaelson, MD; Mooney, DJ; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Wang, SL; Wood, BA | 1 |
| Arlot-Bonnemains, Y; Belaud-Rotureau, MA; Dolley-Hitze, T; Goujon, JM; Jouan, F; Laguerre, B; Lorcy, N; Rioux-Leclercq, N; Verhoest, G; Vigneau, C | 1 |
| Beijnen, JH; Huitema, AD; Knapen, LM; Lankheet, NA; Schellens, JH; Steeghs, N | 1 |
| Chan, A; Chau, NM; Chong, XJ; Chue, XP; Ho, HK; Kanesvaran, R; Tan, MH; Teo, YL; Wee, HL | 1 |
| Afsar, B; Benekli, M; Buyukberber, S; Cetin, B; Coskun, U; Deger, SM; Gonul, II; Gumusay, O; Ozet, A | 1 |
| Berger, R; Boursi, B; Carducci, MA; Eisenberger, MA; Gottfried, M; Hammers, H; Hayat, H; Ish-Shalom, M; Keizman, D; Kovel, S; Maimon, N; Mermershtain, W; Neumann, A; Peer, A; Pili, R; Rouvinov, K; Sella, A; Sinibaldi, V; Weitzen, R | 1 |
| Buchroithner, J; Capper, D; Embacher, S; Gotwald, T; Haybaeck, J; Herrlinger, U; Holzner, B; Hutterer, M; Marosi, C; Moik, M; Nowosielski, M; Oberndorfer, S; Preusser, M; Seiz, M; Stockhammer, F; Stockhammer, G; Tuettenberg, J; Vajkoczy, P; Wick, A | 1 |
| A, M; H J, H; L, M; M, K; N, M; P J, G; S, B | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Svoboda, M; Vyzula, R | 1 |
| Atri, M; Bjarnason, GA; Burns, PN; Hudson, JM; Khalil, B; Kiss, A; Milot, LM; Williams, R | 1 |
| Bahl, A; Castellano, D; Chen, I; Chow Maneval, E; Daugaard, G; Gschwend, J; Houede, N; Jones, R; Laestadius, F; Lechuga, MJ; Maurina, T; Michaelson, MD; Ostler, P; Ou, YC; Oudard, S; Paolini, J; Saad, F; Sengeløv, L; Stenzl, A; Ullèn, A; Wang, SL | 1 |
| Kato, Y; Yamamoto, T | 1 |
| Bae, WK; Kim, HR; Kim, HY; Kim, KH; Lee, HJ; Lee, S; Lim, HY; Rha, SY; Sun, JM | 1 |
| Akahoshi, S; Inoue, K; Kiyota, Y; Kiyozumi, Y; Motooka, Y; Yamaguchi, R; Yoshida, Y | 1 |
| Garcia-Roig, M; Lokeshwar, V; Ortiz, N | 1 |
| Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M | 1 |
| Agarwal, N; Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Lee, J; Mackenzie, M; North, S; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Tan, MH; Vaishampayan, UN; Wood, LA; Yuasa, T | 1 |
| Butrynski, JE; D'Adamo, D; Demetri, GD; Fisher, GA; Ganjoo, KN; George, S; Kamaya, A; McMillan, A; Morgan, JA; Villalobos, VM; Wagner, AJ | 1 |
| Appleman, LJ; Bass, MB; Friberg, G; Friedland, D; Gordon, MS; Hong, DS; Kurzrock, R; Mendelson, DS; Rasmussen, E; Samlowski, WE; Tannir, N; Vogelzang, NJ; Wu, BM; Zhong, ZD | 1 |
| Berney, DM; Bharwani, N; Chowdhury, S; Dilks, P; Miquel, ME; Powles, T; Rockall, AG; Sahdev, A; Shawyer, A; Wilson, PD | 1 |
| Arantes-Rodrigues, R; Colaço, A; Fidalgo-Gonçalves, L; Oliveira, P; Palmeira, C; Pinto-Leite, R; Santos, L | 1 |
| Aieta, M; Amadori, D; Baldazzi, V; Basso, U; Burattini, L; Camerini, A; Chiuri, VE; De Giorgi, U; De Vincenzo, F; Ferrari, V; Fornarini, G; Lo Re, G; Luzi Fedeli, S; Masini, C; Moscetti, L; Rosti, G; Sacco, C; Sava, T; Scarpi, E | 1 |
| Dai, B; Hong, YP; Lin, GW; Ma, CG; Qin, XJ; Shen, YJ; Shi, GH; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
| Chatterjee, P; Kumar, R; Sikka, K | 1 |
| Choy, E; Demetri, GD; George, S; Jagannathan, JP; Kurra, V; Manola, J; Ramaiya, NH; Shinagare, AB; Urban, T | 1 |
| Asa, SL; Cassol, CA; Ezzat, S; Guo, M; Liu, W; Winer, D | 1 |
| Dong, Z; Imai, A; Krishnamurthy, S; Nör, JE; Zeitlin, BD; Zhang, Z | 1 |
| Choi, CL; Cui, W; Han, YF; Hu, SQ; Lee, MY; Mak, SH; Rong, JH; Tsim, WK; Wang, YQ; Xu, DP; Zhang, ZJ | 1 |
| Grabowski, T; Grześkowiak, E; Karbownik, A; Sobańska, K; Szałek, E; Wolc, A | 1 |
| Basagoiti, AD; Baskaran, Z; Baza, B; Belaustegui, A; Bilbao-Meseguer, I; Bustinza, A; Castaño, M; Gil, MA; Jose, BS; Lopez-Gimenez, LR; Sautua, S; Serrano, L | 1 |
| Anders, RA; Deng, L; Fu, YX; Guo, X; Qiu, J; Tu, T; Yang, X; Zhou, L | 1 |
| Binger, KA; Bruce, JY; Carmichael, L; Eickhoff, J; Hammers, H; Heideman, JL; Jeraj, R; Johnston, SA; Kolesar, JM; Liu, G; Perlman, SB; Stein, MN | 1 |
| Arnaldi, G; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Massari, F; Procopio, G; Rizzo, M; Santoni, M; Tortora, G; Trementino, L | 1 |
| De Both, A; Kruse, V; Rottey, S; Somers, A; Van Belle, S; Van Bortel, L | 1 |
| Fujimoto, K; Momose, H; Morizawa, Y; Oyama, N; Takada, S; Toyoshima, Y | 1 |
| Gandhi, L; Heist, RS; Hodgson, L; Otterson, GA; Socinski, MA; Stinchcombe, TE; Villalona-Calero, MA; Vokes, EE; Wang, X; Watson, P | 1 |
| Huang, YL; Ping, SY; Shen, KH; Wu, CL; Yu, DS | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Balaña, C; Capellades, J; Gallego, O; Gil, MJ; Gonzalez, S; Perez, P; Reynes, G; Ribalta, T; Verger, E | 1 |
| Hong, YS; Jo, JC; Kim, KP; Kim, SY; Kim, TW; Lee, J; Lee, JL; Lee, JS; Park, YS; Ryu, JS | 1 |
| Yaqub, F | 1 |
| Barrios, CH; Bukowski, RM; Escudier, B; Figlin, RA; Fly, K; Gore, ME; Hutson, TE; Larkin, JM; Lin, X; Martell, B; Matczak, E; Motzer, RJ; Rini, BI | 1 |
| Dalton, B; Peters, T; Piszczek, J; Ruether, D; Urbanski, S | 1 |
| Castellano, D; Faivre, S; González, E; Salazar, R; Strosberg, J | 1 |
| Herman, RM; Krzemieniecki, K; Kucharz, J; Kuzniewski, M; Michałowska-Kaczmarczyk, A; Streb, J | 1 |
| Bampi, VF; Da Silva, JL; De Oliveira, LB; Gomes, CF | 1 |
| Bize, PE; Borchard, G; Denys, A; Doelker, E; Dormond, O; Fuchs, K; Jordan, O | 1 |
| Behera, R; Mensa-Wilmot, K; Thomas, SM | 1 |
| Aboulafia, D; Cianfrocca, ME; Deeken, JF; Dezube, BJ; Dowlati, A; Gerecitano, J; Haigentz, M; Henry, DH; Ivy, SP; Little, RF; Mitsuyasu, RT; Moore, PC; Ratner, L; Rudek, MA; Sullivan, R | 1 |
| Chen, H; Hou, W; Rojas, J; Sampath, P; Thorne, SH | 1 |
| Hashimoto, Y; Iizuka, J; Ikezawa, E; Kobayashi, H; Kondo, T; Nozaki, T; Omae, K; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Arranz, JA; Bellmunt, J; Calvo, A; Carles, J; Castellano, D; Climent, MA; del Alba, AG; Esteban, E; Font, A; Gallardo, E; Garcia-Donas, J; Gurpide, A; Guruceaga, E; Hernandez, AG; Lopez-Picazo, JM; Lozano, MD; Martínez, E; Mellado, B; Moreno, F; Perez-Gracia, JL; Prior, C; Puente, J; Rodriguez-Antona, C; Suarez, C | 1 |
| Aieta, M; Amadori, D; Baldazzi, V; Basso, U; Burattini, L; Camerini, A; Chiuri, VE; De Giorgi, U; De Vincenzo, F; Ferrari, V; Fornarini, G; Lo Re, G; Luzi Fedeli, S; Masini, C; Moscetti, L; Rihawi, K; Rosti, G; Sava, T; Scarpi, E | 1 |
| Agorreta, J; Ajona, D; Casanovas, O; Larrayoz, M; Montuenga, LM; Pajares, MJ; Pio, R; Zudaire, I | 1 |
| Desobry, K; Evola, M; Gay, D; Grammas, P; Luo, J; Martinez, J; Riley, J; Sanchez, A; Tripathy, D; Yin, X; Young, A | 1 |
| Akaihata, H; Haga, N; Hata, J; Ishibashi, K; Kataoka, M; Koguchi, T; Kojima, Y; Ogawa, S; Satoh, Y; Takahashi, N | 1 |
| De Lichtenberg, TH; Hermann, GG; Holm, ML; Højer Larsen, MJ; Mansourvar, Z; Rørth, M; Scheike, T | 1 |
| Haq, S; Hershman, JM; Liwanpo, L; Ro, C | 1 |
| Basaran, G; Cabuk, D; Dane, F; Korkmaz, T; Seber, S; Telli, F; Teomete, M; Turhal, S; Yumuk, PF | 1 |
| Barbounis, V; Efremidis, A; Kostakis, ID; Koumakis, G; Lypas, G; Panopoulos, C; Tolia, M; Tryfonopoulos, D; Tsoukalas, N | 1 |
| Bögemann, M; Herrmann, E; Hertle, L; Hoffmeister, I; Krabbe, LM; Moritz, R; Papavassilis, P; Thielen, B | 1 |
| Deng, GH; Jiang, Y; Liu, J; Peng, XC; Wang, Y; Wei, YQ; Zhang, J | 1 |
| Czabanka, M; Parmaksız, G; Vajkoczy, P; Vinci, M | 1 |
| Bergmann, L; Burkholder, I; Gauler, T; Grünwald, V; Kahl, C; Kube, U; Maute, L; Weikert, S | 1 |
| Dreicer, R; Elson, P; Garcia, JA; Mittal, K; Najjar, YG; Rini, BI; Wood, L | 1 |
| Afshar, M; Islam, MR; Kunene, V; Miscoria, M; Pirrie, S; Porfiri, E | 1 |
| Jia, B; Liu, H; Liu, Z; Ma, T; Shi, J; Sun, X; Wang, F; Wu, Y; Yu, X; Zhao, H | 1 |
| Hayano, K; Sahani, DV; Yoshida, H; Zhu, AX | 1 |
| Diekstra, MH; Gelderblom, H; Gurney, H; Huitema, AD; Kloth, JS; Klümpen, HJ; Lolkema, MP; Mathijssen, RH; Steeghs, N; Swen, JJ; van Schaik, RH; Yu, H | 1 |
| Giddabasappa, A; Goodman, J; Lappin, PB; Lee, J; Levkoff, T; Li, G; Nichols, T; Painter, CL; Pascual, B; Simmons, B; Xie, Z; Yan, Z; Zhang, CC; Zhang, Q | 1 |
| Choi, BS | 1 |
| Baek, SH; Han, JS; Joo, KW; Kim, DK; Kim, H; Kim, TM; Kim, YS; Lee, J; Lee, SH; Oh, KH | 1 |
| Bang, YJ; Chang, JW; Chung, HC; Kwong, P; Lee, SH; Li, RK; Mainwaring, P; Ng, C; Pitman Lowenthal, S; Sriuranpong, V; Toh, CK; Yuan, J | 1 |
| Faivre, S; Ishak, KJ; Korytowsky, B; Proskorovsky, I; Sandin, R; Valle, J | 1 |
| Devasahayam, N; Krishna, MC; Lizak, MJ; Matsumoto, S; Matsuo, M; Merkle, H; Mitchell, JB; Morris, HD; Munasinghe, JP; Saito, K; Suburamanian, S; Takakusagi, Y; Yasukawa, K | 1 |
| Bachelot, T; Blay, JY; Cesari, R; Garcia-Saenz, JA; Gutierrez, M; Huang, X; Kern, KA; Khosravan, R; Kozloff, MF; Lluch, A; Pivot, X; Prady, C; Tassell, V; Verma, S; Wang, Z | 1 |
| Battista, K; Buckstein, R; Howson-Jan, K; Ivy, SP; Kovacs, MJ; Oza, AM; Schuh, AC; Storring, JM; Wang, ES; Wang, L; Wells, RA; Xenocostas, A; Yee, KW | 1 |
| Habuchi, T; Inoue, T; Maita, S; Narita, S; Numakura, K; Saito, M; Satoh, S; Tsuchiya, N; Yonese, J; Yuasa, T | 1 |
| Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R | 1 |
| Akin, O; Berger, MF; Brannon, AR; Chen, YB; Cheng, EH; Cunha, LF; Hakimi, AA; Hsieh, JJ; Liu, H; Motzer, RJ; Pham, CG; Reuter, VE; Russo, P; Sander, C; Schultz, N; Scott, SN; Socci, ND; Takeda, S; Viale, A; Voss, MH | 1 |
| Bushmakin, AG; Cappelleri, JC; Cella, D; Charbonneau, C; Davis, MP; Figlin, RA; Korytowsky, B; Matczak, E; Michaelson, MD; Motzer, RJ; Négrier, S; Sandin, R | 1 |
| Baik, C; Balachandran, D; Blevins, DP; Cabanillas, ME; Dadu, R; Gunn, B; Hu, M; Ross, W | 1 |
| Arai, S; Hashita, T; Hatori, M; Ito, K; Katsuyama, Y; Koike, H; Matsui, H; Miyazawa, Y; Nomura, M; Ohki, R; Ohmori, S; Sekine, Y; Shibata, Y; Suzuki, K; Yamamoto, K | 1 |
| Ferrari, S; Paioli, A; Palmerini, E | 1 |
| Bertens, D; Desar, IM; Kessels, RP; Langenhuijsen, JF; Mulder, SF; Mulders, PF; Punt, CJ; van Herpen, CM; van Spronsen, DJ; Vissers, KC | 1 |
| Chambers, CR; Chu, MP; Ghosh, S; Ha, VH; Ngo, M; Sawyer, MB | 1 |
| Croft, SL; Sanderson, L; Yardley, V | 1 |
| Ambrosetti, D; Amiel, J; Gastaud, L; Grépin, R; Marsaud, A; Pagès, G; Pedeutour, F | 1 |
| Biczysko-Murawa, A; Grabowski, T; Grześkowiak, E; Karbownik, A; Matuszewski, M; Połom, W; Sobańska, K; Szałek, E; Wolc, A | 1 |
| Fujisawa, M; Furukawa, J; Harada, K; Miyake, H; Nishikawa, M; Tei, H | 1 |
| Bernhardt, A; Fallon, J; Greiner, JW; Guzman, W; Kradjian, G; Lan, Y; Neuteboom, B; Sabzevari, H; Schlom, J; Tighe, R | 1 |
| Cushen, SJ; MacEneaney, P; Maher, MM; McDermott, R; O'Sullivan, K; Power, DG; Ryan, AM; Teo, MY | 1 |
| Follana, P; François, E; Gugenheim, J; Saada, E; Saint Paul, MC | 1 |
| de Vos, R; Koldenhof, JJ; Teunissen, SC; Tillier, CN; Verheul, HM; Walraven, M; Witteveen, PO | 1 |
| Bono, P; Cella, D; De Giorgi, U; Diaz, J; Eisen, T; Escudier, B; Gschwend, JE; Hawkins, R; Khan, S; Mehmud, F; Négrier, S; Parikh, O; Porta, C; Powles, T; Redhu, S; Sevin, E; Sternberg, CN | 1 |
| Garnick, MB | 1 |
| Accordi, B; Barozzi, P; Basso, G; Bertacchini, J; Cocco, L; De Pol, A; Forghieri, F; Giordan, M; Guida, M; Liotta, L; Luppi, M; Marmiroli, S; Martelli, AM; Mediani, L; Milani, G; Petricoin, E | 1 |
| Jamison, J; Wang, JH; Wells, A | 1 |
| Ando, Y; Funahashi, Y; Gotoh, M; Inada-Inoue, M; Matsukawa, Y; Sassa, N | 1 |
| Astolfi, A; Casali, PG; Colombo, C; Conca, E; Crippa, F; Dagrada, GP; Dei Tos, AP; Gronchi, A; Indio, V; Maestro, R; Morosi, C; Negri, T; Pantaleo, MA; Pilotti, S; Stacchiotti, S; Tazzari, M; Toffolatti, L | 1 |
| Ahn, H; Hong, JH; Jeong, IG; Kim, CS; Kwon, T; Lee, JL; Song, C; You, D | 1 |
| Ahn, H; Cho, YM; Hong, JH; Jeong, IG; Kim, CS; Lee, JL; Song, C; Song, SH; You, D | 1 |
| Aik, OT; Htun, TH; Lim, NK; Meng, LL; Razack, AH | 1 |
| Davis, MP; Sharma, P; Shinde, SS | 1 |
| Cooper, ZA; Ferrone, CR; Ferrone, S; Flaherty, KT; Frederick, DT; Kirkwood, JM; Pepe, S; Pepin, D; Sabbatino, F; Scognamiglio, G; Wang, X; Wang, Y; Wargo, JA; Yu, L | 1 |
| Beijnen, JH; Cirkel, GA; de Jonge, MJ; Gadellaa-van Hooijdonk, CG; Haanen, JB; Huitema, AD; Kloth, JS; Lankheet, NA; Lolkema, MP; Mathijssen, RH; Schellens, JH; Sleijfer, S; Steeghs, N; Voest, EE | 1 |
| Adamson, D; Buckley, FD; Meiklejohn, DJ; Preston, G | 1 |
| Abdel-Aziz, AK; Abdel-Naim, AB; El-Demerdash, E; Elgendy, M; Shouman, S | 1 |
| Fujikawa, A; Hayashi, H; Moriyama, M; Namura, K; Ohta, J; Ohtake, S; Sawada, T | 1 |
| Hamada, A; Kato, K; Kawanishi, H; Okumura, K; Sawada, A; Sunada, T | 1 |
| Heng, DY; Imbulgoda, A; Kollmannsberger, C | 1 |
| Amiel, SA; Aylwin, SJ; Huda, MS; Ross, P | 1 |
| Brzezniak, C; Szabo, E | 1 |
| Nakamura, M; Sekiguchi, Z; Takeshima, T; Takizawa, A; Tsuchiya, F | 1 |
| Burrell, K; Chung, C; Foltz, W; Hill, R; Jalali, S; Singh, S; Zadeh, G | 1 |
| Blosser, W; Stancato, L; Stewart, J; Swearingen, ML; Tate, CM; Vakana, E; Wyss, LV | 1 |
| Calero, R; Johnsen, JI; Morchon, E; Serrano, R | 1 |
| Liang, H | 1 |
| Liang, X; Shi, Y | 1 |
| Fu, W; Guo, G; He, Z; Jin, J; Li, X; Zhang, C; Zhang, X; Zhou, L | 1 |
| Ara, M; Pastushenko, E | 1 |
| Bushmakin, AG; Cappelleri, JC; Charbonneau, C; Figlin, RA; Korytowsky, B; Michaelson, MD; Motzer, RJ; Négrier, S; Sandin, R | 1 |
| Hasegawa, T; Hisada, T; Matsuura, K; Nomura, H; Saito, H; Toyama, Y; Tsukiyama, I; Ueyama, J | 1 |
| Biondani, P; DE Braud, F; Grassi, P; Porcu, L; Procopio, G; Testa, I; Torri, V; Verzoni, E | 1 |
| Al Rawashdeh, W; Arns, S; Ehling, J; Gremse, F; Kiessling, F; Knüchel-Clarke, R; Kray, S; Lederle, W; Spöler, F | 1 |
| Choueiri, TK; Deen, K; Hutson, TE; McCann, L; Motzer, RJ | 1 |
| Aguilera, O; Borrero-Palacios, A; Caramés, C; Casado, V; Chamizo, C; Cristóbal, I; del Puerto-Nevado, L; García-Foncillas, J; Madoz-Gúrpide, J; Martínez-Useros, J; Rincón, R; Rodríguez-Remírez, M; Rojo, F; Rubio, G; Vega, R; Zazo, S | 1 |
| Fujisawa, M; Harada, K; Miyake, H; Miyazaki, A | 2 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Bellmunt, J; Bracarda, S; Cerbone, L; Choueiri, TK; Fay, AP; Foreshew, A; Hutson, TE; Lampron, ME; Pons, F; Porta, C; Powles, T; Sternberg, CN | 1 |
| Bates, S; Burotto, M; Fojo, T; Motzer, R; Stein, W; Wilkerson, J | 1 |
| Büchert, M; Burkholder, I; Jaehde, U; Kanefendt, F; Kuhlmann, J; Moritz, B; Mross, K; Scheulen, M; Sörgel, F; Strumberg, D | 1 |
| Grünwald, V; Paglino, C; Porta, C | 1 |
| Chang, WC; Chen, CW; Chen, TJ; Chen, TW; Chen, YY; Cheng, CT; Chiang, KC; Chung, WH; Chung-Yee Hui, R; Hung, SI; Jan, YY; Lin, YL; Su, SC; Yang, CH; Yeh, CN | 1 |
| Armstrong, AJ; Chen, I; Chow-Maneval, E; Clarke, SJ; Lechuga, M; Michaelson, MD; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Templeton, AJ; Vardy, JL; Wang, SL | 1 |
| Luyken, J; Neuhaus, T; Stier, S | 1 |
| Guillén, C; Llombart, B; Martorell-Calatayud, A; Nagore, E; Requena, C; Sanmartín, O; Sanz-Motilva, V; Serra-Guillén, C; Traves, V | 1 |
| Dominiak, PM; Goral, AM; Jarzembska, KN; Kutner, A; Malińska, M; Woźniak, K | 1 |
| Anastasiou, I; Bamia, C; Bamias, A; Beuselinck, B; Chrisofos, M; Constantinides, C; Deliveliotis, C; Dimopoulos, MA; Elaidi, TR; Escudier, B; Liontos, M; Mitropoulos, D; Oudard, S; Papatsoris, A; Stravodimos, K; Tzannis, K | 1 |
| Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Khambati, HK; Knox, JJ; Kollmannsberger, CK; MacKenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wood, L | 1 |
| Beaune, P; de Waziers, I; Favre, A; Figg, WD; Kiehl, P; McMullen, J; Montemurro, M; Narjoz, C; Rochat, B | 1 |
| Aitchison, M; Berney, D; Bex, A; Eory, L; Harrison, DJ; Laird, A; Lubbock, AL; Mackay, A; Martin, SA; McNeill, SA; Mullen, P; Nanda, J; O'Donnell, M; O'Mahony, FC; Overton, IM; Powles, T; Rashid, S; Riddick, AC; Stewart, GD | 1 |
| Cisar, L; Clark, JI; Escudier, B; Hariharan, S; Hutson, TE; Kannourakis, G; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Porfiri, E; Rini, BI; Rosbrook, B; Staehler, M; Tarazi, J; Zalewski, P | 1 |
| Dong, M; Fukuda, T; Fukudo, M; Inui, K; Kamba, T; Katsura, T; Matsubara, K; Mizuno, T; Ogawa, O; Terada, T; Vinks, AA; Yamasaki, T | 1 |
| Boralevi, F; Fricain, JC; Sibaud, V; Vigarios, E | 1 |
| Elledge, R; Elledge, RO; Raskauskiene, D | 1 |
| Borden, EC; Chen, H; Dowlati, A; Elson, P; Koon, H; Mittal, K; Rini, BI; Triozzi, P | 1 |
| Bao, X; Wang, MW; Zhang, YJ; Zhang, YP | 1 |
| Berkers, J; Beuselinck, B; De Wever, L; Dumez, H; Joniau, S; Lerut, E; Oyen, R; Paridaens, R; Schöffski, P; Strijbos, M; Van Poppel, H; Wolter, P | 1 |
| Fisher, R; Gutzeit, A; Koh, DM; Larkin, J; Lote, H; Sohaib, A; Thian, Y | 1 |
| Bozcuk, H; Coskun, HS; Gunduz, S; Mutlu, H; Uysal, M | 1 |
| Casserly, L; Gupta, R; Neenan, T; Quintyne, KI | 1 |
| Berger, J; Beuselinck, B; Cardinaels, N; Caty, A; Couchy, G; Joniau, S; Karadimou, A; Lambrechts, D; Lerut, E; Oudard, S; Paridaens, R; Patard, JJ; Ravaud, A; Schöffski, P; Sebe, P; Van Brussel, T; Verkarre, V; Wolter, P; Zerbib, M; Zucman-Rossi, J | 1 |
| Blattler, C; Castonguay, V; Fleming, G; Hirte, H; Ivy, PS; Lheureux, S; Mackay, HJ; Morgan, R; Oza, AM; Wang, L; Welch, S | 1 |
| Ashman, P; Cid Ruzafa, J; Desai, K; Khalid, JM; Maguire, A; Muston, D; Starczewska Amelio, JM; Tzivelekis, S | 1 |
| Elkord, E; Gilham, DE; Hawkins, RE; Shablak, A | 1 |
| Fujisawa, M; Furukawa, J; Kusuda, Y; Miyake, H | 1 |
| Go, S; Hanasaki, T; Hashimoto, T; Higuchi, Y; Ito, N; Kanamaru, S; Kanematsu, A; Kawakita, M; Kono, Y; Makino, Y; Matsumoto, K; Nagasawa, S; Nakanishi, Y; Nojima, M; Shimatani, K; Shimizu, Y; Shiraishi, Y; Suzuki, T; Taoka, R; Togo, Y; Tsuchihashi, K; Utsunomiya, N; Yamamoto, S; Yo, T | 1 |
| Fan, C; Gong, X; Yang, Y; Zhang, L; Zhao, S; Zheng, Q; Zhou, H | 1 |
| Blomqvist, LK; Farnebo, J; Grybäck, P; Harmenberg, U; Laurell, A; Sandström, P; Ullén, A; Wersäll, P | 1 |
| Beck, R; Burris, HA; Fandi, A; Garcia, JA; Infante, JR; Jungnelius, U; Li, S; Redman, B; Rini, B | 1 |
| Jiang, CY; Wang, HW; Wang, W | 1 |
| Bolanča, A; Jakšić, B; Jazvić, M; Krilić, D; Kusić, Z; Kust, D; Murgić, J; Prpić, M | 1 |
| Benjamin, RS; Bergman, MA; Boles, S; Bui, MM; Casper, ES; Conrad, EU; DeLaney, TF; Ganjoo, KN; George, S; Gonzalez, RJ; Heslin, MJ; Kane, JM; Mayerson, J; McGarry, SV; Meyer, C; O'Donnell, RJ; Pappo, AS; Paz, IB; Pfeifer, JD; Randall, RL; Riedel, RF; Schuetze, S; Schupak, KD; Schwartz, HS; Sundar, H; Van Tine, BA; von Mehren, M; Wayne, JD | 1 |
| Breazna, A; Demetri, GD; Ewer, MS; Lenihan, DJ; Motzer, RJ; Niculescu, L; Suter, TM | 1 |
| Fukasawa, S; Ichikawa, T; Kobayashi, M; Komaru, A; Namekawa, T; Ohzeki, T; Sato, Y; Takagi, K; Ueda, T; Uemura, H | 1 |
| Yokomizo, A | 1 |
| Agarwal, N; Bamias, A; Beuselinck, B; Bjarnason, GA; Choueiri, TK; Donskov, F; Ernst, DS; Heng, DY; Kim, JJ; Knox, JJ; Kollmannsberger, CK; Lee, JL; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Vaishampayan, UN; Wells, JC; Wood, LA; Yuasa, T | 1 |
| Czarnecka, AM; Oborska, S; Rzepecki, P; Szczylik, C | 1 |
| Chang, J; Connolly, MP; Currie, CJ; Poole, CD | 1 |
| Arlot-Bonnemains, Y; Belaud-Rotureau, MA; Bensalah, K; Collet, N; Dolley-Hitze, T; Jouan, F; Lavenu, A; Oger, E; Rioux-Leclercq, N; Verhoest, G; Vigneau, C | 1 |
| Blanchard, F; Di Fiore, F; Nouhaud, FX; Pfister, C; Rebibo, JD; Sabourin, JC | 1 |
| Yuasa, T | 1 |
| Elsner, A; Fitzner, B; Heuschkel, M; Jaster, R; Krause, BJ; Lange, F | 1 |
| Byun, SS; Cheon, J; Hong, SK; Jeong, SJ; Lee, SE; Moon, du G; Oh, MM; Park, HS; Yoon, CY | 1 |
| Fujita, T; Iwamura, M; Matsumoto, K; Tabata, K; Wakatabe, Y; Yoshida, K | 1 |
| Culver, K; Jonasch, E; Lin, PL; Liu, Z; Pal, SK; Scott, JA; Signorovitch, JE; Vogelzang, NJ | 1 |
| Ahmad, SF; Al-Suwayeh, HA; Ansari, MA; Bakheet, SA; Korashy, HM; Maayah, ZH | 1 |
| Doi, T; Naito, Y; Nishida, T | 1 |
| Bäuerle, T; Bendl, R; Bretschi, M; Fränzle, A; Hillengass, J; Merz, M; Semmler, W | 1 |
| Bladé, JS; Boudin, L; Bourgouin, S; de Jauréguiberry, JP; Romeo, É | 1 |
| Chou, A; Field, M; Gill, AJ; Hasovits, C; Hugh, TJ; Paik, J; Pavlakis, N; Toon, CW | 1 |
| Agrawal, V; Kim, J; Kim, K; Kim, YM; Kwon, YG; Lee, K; Lee, S; Park, H; Suh, YG | 1 |
| Bito, T; Hirai, M; Hirano, T; Kume, M; Makimoto, H; Mizumoto, A; Mukai, A; Nakagawa, T; Nishigori, C; Nishimura, K; Uda, A; Yamamoto, K; Yamashita, K | 1 |
| Anouar, Y; Baudin, E; Denorme, M; Dubessy, C; Gonzalez, BJ; Roux, C; Yon, L | 1 |
| Blacher, S; Calligaris, D; Cimino, J; De Pauw, E; De Tullio, P; Debois, D; Mari, B; Mazzucchelli, G; Noel, A; Paye, A; Primac, I; Sounni, NE; Truong, A | 1 |
| Bugalho, MJ; Marques, P; Vieira, Mda S | 1 |
| Agochukwu, N; Gautam, R; Linehan, WM; Merino, M; Ricketts, CJ; Shuch, B; Srinivasan, R; Vocke, CD | 1 |
| Abdel-Rahman, O; Fouad, M | 3 |
| Alonso, T; Díez, JJ; Grande, E; Iglesias, P | 1 |
| Musijowski, J; Piórkowska, E; Rudzki, PJ | 1 |
| Beaumont, JL; Bhattacharyya, H; Cella, D; Hahn, EA; Jensen, SE; Korytowsky, B; Motzer, R | 1 |
| Bellmunt, J; Castellano, D; Diaz, J; Donnellan, P; Duh, MS; Hawkins, R; Levy, A; McCaffrey, J; McDermott, R; Mehmud, F; Nathan, P; Neary, MP; Porta, C; Vekeman, F; Wagstaff, J | 1 |
| Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E | 1 |
| Lin, LZ; Yu, L | 1 |
| Anak, O; Barrios, CH; Bavbek, S; Beck, JT; Cheung, FY; Cosgriff, T; Falcon, S; Flaig, TW; Harker, WG; Kim, TM; Knox, JJ; Motzer, RJ; Niolat, J; Page, R; Patel, P; Pittman, K; Rha, SY; Sabbatini, R; Schiff, EM; Sellami, D; Srimuninnimit, V; Wang, X; Yadav, S | 1 |
| Boku, N; Endo, M; Fukutomi, A; Funakoshi, T; Kenmotsu, H; Machida, N; Onozawa, Y; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Berger, R; Boursi, B; Gottfried, M; Hayat, H; Keizman, D; Kovel, S; Livne-Segev, D; Maimon, N; Mermershtain, W; Neumann, A; Peer, A; Rouvinov, K; Sella, A; Weitzen, R | 1 |
| Gupta, S; Gupta, V; Rao, A | 1 |
| Faneca, H; Passadouro, M; Pedroso de Lima, MC | 1 |
| Czarnecka, AM; Rini, B; Szczylik, C | 1 |
| D'Asti, E; Dombrovsky, A; Garnier, D; Lau, K; Magnus, N; Meehan, B; Rak, J | 1 |
| Akman, T; Avci, N; Basaran, M; Bayoglu, IV; Dede, İ; Ekenel, M; Kanitez, M; Kaplan, MA; Kocar, M; Sürmeli, Z; Tural, D; Ulaş, A; Uysal, M; Varol, U; Yazici, O; Yildiz, I | 1 |
| Karampelas, IN; Saif, MW; Syrigos, KN | 1 |
| Bailey, AM; Meric-Bernstam, F; Mills, GB; Pagliaro, LC; Rao, P; Shaw, KR; Subbiah, V; Ward, JF | 1 |
| Chen, HY; Ding, KF; Hu, LF; Hu, YT; Li, Q; Liu, Y; Ruan, SQ; Wang, ZH; Xiao, Q; Zhang, SZ; Zheng, S | 1 |
| Coplin, MA; Donahue, RN; Farsaci, B; Grenga, I; Hodge, JW; Lepone, LM; Molinolo, AA | 1 |
| Bianco, C; Bianco, R; Ciardiello, F; Cipolletta, A; D'Amato, C; D'Amato, V; De Placido, S; Di Mauro, C; Formisano, L; Fulciniti, F; Marciano, R; Nappi, L; Raimondo, L; Rosa, R; Servetto, A; Veneziani, BM | 1 |
| Akman, L; Akman, T; Artunc Ulkumen, B; Erbas, O; Oltulu, F; Pala, EE; Pala, HG; Yavasoglu, A | 1 |
| English, PA; Figlin, RA; Huang, X; Hudes, GR; Hutson, TE; Martini, JF; Motzer, RJ; Valota, O; Williams, JA | 1 |
| Abrey, LE; Batchelor, T; DeAngelis, LM; Drappatz, J; Gavrilovic, I; Haidar, S; Kaley, TJ; Karimi, S; Lassman, AB; Lee, EQ; Ligon, K; Nolan, CP; Norden, A; Omuro, A; Plotkin, SR; Purow, B; Schiff, D; Wen, P | 1 |
| Casali, PG; Castelli, C; Colombo, C; Dagrada, P; Fiore, M; Gronchi, A; Huber, V; Negri, T; Pilotti, S; Rini, F; Rivoltini, L; Stacchiotti, S; Tazzari, M; Vergani, B; Villa, A | 1 |
| Allred, R; de Wit, D; Demetri, GD; Gelderblom, H; Guchelaar, HJ; Khosravan, R; van Erp, NP; Wiltshire, R | 1 |
| Andrews, DW; Axelrod, R; Camphausen, K; Curran, WJ; Dicker, AP; Evans, J; Glass, J; Haacke, EM; Hillman, GG; Lin, A; Shi, W; Werner-Wasik, M; Wuthrick, EJ | 1 |
| Wang, H; Wang, X; Zhang, K | 1 |
| Coquerel, B; Demange, E; Kassim, Y; Le Cerf, D; Perrot, V; Petit, A; Simon, T; Vannier, JP | 1 |
| Crews, LA; Gonzales, T; Kouznetsova, VL; Masliah, E; Overk, CR; Patrick, C; Paulino, A; Price, D; Rockenstein, E; Stocking, E; Tsigelny, IF; Wrasidlo, W | 1 |
| Booth, R; Kim, H | 1 |
| Acin, Y; Adenis, A; Bertucci, F; Blay, JY; Blésius, A; Bompas, E; Bouché, O; Bui-Nguyen, B; Bulusu, VR; Chaigneau, L; Domont, J; Dubreuil, P; Hermine, O; Isambert, N; Le Cesne, A; Mansfield, CD; Moussy, A; Ray-Coquard, I; Van Tine, BA | 1 |
| Kosaka, T; Mikami, S; Mizuno, R; Okada, Y; Oya, M; Saya, H | 1 |
| Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA | 1 |
| Hongo, F; Kamoi, K; Miki, T; Naitoh, Y; Nakamura, T; Naya, Y; Oishi, M; Okihara, K; Ueda, T | 1 |
| Ishii, Y; Johnson, KE; Ozono, S; Sakahara, H; Sugiyama, M; Sugiyama, T; Takayama, T; Takehara, Y; Wakayama, T; Wieben, O | 1 |
| Acharyya, S; Chopra, A; Fay, AP; Haaland, B; Lopes, Gde L | 1 |
| Chen, Y; Cheng, X; Cui, ZL; Lin, DH; Luo, LQ | 1 |
| Adam, M; Eichelberg, C; Fuehner, T; Ganser, A; Grünwald, V; Herrmann, E; Ivanyi, P; Merseburger, AS | 1 |
| Gurney, H; Zhang, A | 1 |
| Choe, MS; Ha, JY; Jung, HR; Kim, BH; Kim, CI; Park, CH; Sohn, JC | 1 |
| Albanell, J; Bellmunt, J; Beltran, M; Bonfill, T; Carles, J; Gallardo, E; Galtes, S; Moya, I; Pons, F; Rodon, J; Suarez, C | 1 |
| Chen, G; Fu, Y; Gu, H; Wang, M; Xie, X; Xu, X; Zhang, L | 1 |
| Grabowski, T; Grześkowiak, E; Karbownik, A; Lewandowska, M; Matuszewski, M; Połom, W; Sobańska, K; Szałek, E; Wolc, A | 1 |
| Burattini, L; Caricato, M; Cascinu, S; Conti, A; Guida, FM; Santini, D; Santoni, M; Savini, A; Tonini, G; Zeppola, T | 1 |
| Kılıç, L; Şen, F; Varol, U; Yıldız, I | 1 |
| Chung, H; Dhanda, R; Forsyth, M; Halm, M; Hutson, TE; Schnadig, ID; Vogelzang, NJ | 1 |
| Beuselinck, B; Claus, F; Cornelissen, L; De Keyzer, F; Dumez, H; Lerut, E; Van Poppel, H; Wolter, P | 1 |
| Baelde, HJ; Danser, AH; Kappers, MH; Lankhorst, S; Mathijssen, RH; Sleijfer, S; Smedts, FM; van den Meiracker, AH; van Esch, JH | 1 |
| Chi, J; Dong, X; Gu, Q; Ji, R; Jia, X; Leng, X; Li, J; Liu, F; Ma, Y; Sun, B; Sun, R; Zhang, C; Zhang, D; Zhao, X | 1 |
| Chen, JS; Chen, TW; Chen, YY; Cheng, CT; Chiang, KC; Hsu, CC; Jan, YY; Liu, YY; Tsai, CY; Tseng, JH; Wu, CE; Yeh, CN; Yeh, TS | 1 |
| Chen, J; Long, Y; Yin, X; Zhou, C | 1 |
| Grabowski, T; Grześkowiak, E; Karbownik, A; Matuszewski, M; Połom, W; Sobańska, K; Szałek, E; Wolc, A | 1 |
| Anjum, R; Bauer, S; Clackson, T; Eilers, G; Fletcher, JA; Garner, AP; Gozgit, JM; Heinrich, MC; Ketzer, J; Kohlmann, A; Ning, Y; Rivera, VM; Schrock, A; Serrano, C; Song, Y; Vodala, S; Wang, F; Wardwell, S; Zhou, T; Zhu, M | 1 |
| Bono, P; Donskov, F; Joensuu, H; Peltola, K; Rautiola, J | 1 |
| Banskota, S; Jeong, BS; Kim, DG; Kim, JA; Lee, H; Lee, YK; Nam, TG | 1 |
| Géczi, L; Kovács, E; Küronya, Z; Lahm, E | 1 |
| Cserháti, A; Kahán, Z; Maráz, A; Szilágyi, E; Uhercsák, G; Varga, Z | 1 |
| Gao, H; Han, Y; Jiang, Q; Peng, J; Wang, C | 1 |
| Bogdahn, U; Bosserhoff, AK; Brawanski, A; Hau, P; Heudorfer, F; Leukel, P; Meyer, K; Moeckel, S; Proescholdt, M; Riemenschneider, MJ; Seliger, C; Spang, R; Stangl, C; Vollmann-Zwerenz, A | 1 |
| Badalamenti, G; Baldi, GG; Casali, PG; Cominetti, D; Dagrada, GP; Dei Tos, AP; Festinese, F; Fumagalli, E; Grignani, G; Gronchi, A; Morosi, C; Negri, T; Pennacchioli, E; Pilotti, S; Provenzano, S; Spagnuolo, RD; Stacchiotti, S; Tortoreto, M; Toss, A; Zaffaroni, N | 1 |
| Braun, D; Donner, A; Evert, K; Evert, M; Glöckl, G; Grisk, O; Katsari, E; Koenen, A; Löhn, M; Meissner, T; Plettenburg, O; Rettig, R; Steinbach, A; Zimmermann, U | 1 |
| Faivre, S; Grande, E; Hubner, RA; Raymond, E; Valle, JW | 1 |
| Nishiyama, T; Niwa, N; Ozu, C; Saito, S; Yagi, Y | 1 |
| Chen, J; Chen, X; Du, H; Li, Q; Liao, M; Liu, M; Wang, X; Wang, Z; Yao, M | 1 |
| Barthelemy, P; Caty, A; Cheverau, C; Laplaige, P; Mouillet, G; Pouessel, D; Ravaud, A; Sebbagh, S; Thiery-Vuillemin, A; Vanno, YA | 1 |
| Capelli, AM; Costantino, G | 1 |
| Buonomano, P; Camera, L; Circelli, L; Colao, A; Del Prete, M; Di Somma, C; Faggiano, A; Marciello, F; Marotta, V; Modica, R; Ramundo, V; Rubino, M; Sciammarella, C | 1 |
| Brixi, H; Cadiot, G; de Mestier, L; Lombard-Bohas, C; Walter, T | 1 |
| Achen, MG; Chander, S; Choong, PF; Desai, J; Ferris, N; Fox, S; Herschtal, A; Hicks, RJ; Khamly, KK; Lewin, J; Mitchell, C; Ngan, SY; Powell, GJ; Slavin, J; Stacker, SA; Te Marvelde, L; Thomas, DM; Toner, GC; Young, RJ | 1 |
| Almeida, DR; Boldt, HC; Chin, EK; Sacher, BA | 1 |
| Ahmed, M; Coleman, CN; Curran, WJ; Dicker, AP; Finkelstein, SE; Houghton, P; Kirsch, DG; Machtay, M; Monjazeb, AM; Teicher, BA; Vikram, B; Wang, D; Wong, P; Xu-Welliver, M | 1 |
| Bagcchi, S | 1 |
| Rahman, A | 1 |
| Raj, N; Reidy-Lagunes, D | 1 |
| Arrowood, CA; Honeycutt, W; Howard, L; Hurwitz, HI; Latta, K; Meadows, KL; Niedzwiecki, D; Rushing, C | 1 |
| Alexandre, J; Behouche, A; Blanchet, B; Boudou-Rouquette, P; Cessot, A; Coriat, R; Dauphin, A; Durand, JP; Goldwasser, F; Golmard, JL; Huillard, O; Loriot, MA; Narjoz, C; Taieb, F; Thomas-Schoemann, A; Tod, M; Vidal, M | 1 |
| Barnhart, TE; Cai, W; Chen, F; Goel, S; Hernandez, R; Hong, H; Shi, S; Valdovinos, HF | 1 |
| Alago, W; Brown, KT; Cornelis, F; Covey, A; Erinjeri, JP; Getrajdman, GI; Litchman, T; Maybody, M; Sofocleous, CT; Solomon, SB; Takaki, H | 1 |
| Attwood, K; Burns, P; Cruz-Munoz, WR; Ebos, JM; Hudson, JM; Jedeszko, C; Kerbel, RS; Lee, CR; Mastri, M; Tracz, A | 1 |
| Dome, B; Fehniger, TE; Hegedus, B; Laszlo, V; Marko-Varga, G; Paku, S; Rezeli, M; Rozsas, A; Torok, S; Tovari, J; Vegvari, A | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Elledge, R; Foreman, C; Hilsenbeck, SG; Niravath, P; Rimawi, M; Rodriguez, A; Tham, YL; Wang, T | 1 |
| Liu, K; Wen, Y; Wu, L; Xiong, L; Yao, H; Zhang, Z | 1 |
| Adelaiye, R; Barrera, G; Ciamporcero, E; Ku, S; Miles, KM; Pili, R; Pizzimenti, S; Ramakrishnan, S; Sennino, B; Shen, L | 1 |
| Basso, U; Bezzon, E; Brunello, A; Maruzzo, M; Opocher, G; Pomerri, F; Roma, A; Zagonel, V; Zamarchi, R; Zovato, S | 1 |
| Adelaiye, R; Attwood, K; Ciamporcero, E; Conroy, D; Gillard, B; Kuhnert, F; Lalani, AS; Miles, KM; Pili, R; Seshadri, M; Shen, L; Sotomayor, P; Thurston, G | 1 |
| Beijnen, JH; de Wit, D; Huitema, AD; Kloth, JS; Mathijssen, RH; Schellens, JH; Steeghs, N; van Erp, NP; van Hasselt, JG; Yu, H | 1 |
| Adenis, A; Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Cassier, P; Chaigneau, L; Chevreau, C; Collard, O; Cropet, C; Cupissol, D; Duffaud, F; Eberst, L; Gentet, JC; Le Cesne, A; Marec-Berard, P; Pautier, P; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Thyss, A | 1 |
| de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Sebbagh, S; Serova, M; Slimane, K; Tijeras-Raballand, A | 1 |
| Casciano, R; Chua, A; Culver, K; Garrison, LP; Gorritz, M; Liu, Z; Pal, S; Perrin, A; Sherman, S; Wang, X | 1 |
| Connell, JJ; Döme, B; Fehniger, TE; Marko-Varga, G; Sugihara, Y; Török, S; Tóvári, J; Végvári, Á | 1 |
| Mullangi, R; Sharma, K; Srinivas, NR; Suresh, PS | 1 |
| Schmutz, JL | 1 |
| Deng, GH; Deng, YT; He, SS; Jiang, Y; Liu, J; Luo, XM; Mao, YY; Peng, XC; Wang, Y; Wei, YQ; Xia, XY; Zhang, J | 1 |
| Bartsch, G; Blaheta, RA; Haferkamp, A; Juengel, E; Kim, D; Makarević, J; Reiter, M; Tsaur, I | 1 |
| Aarts, MJ; Hamming, L; Joosten, SC; Soetekouw, PM; Tjan-Heijnen, VC; van Engeland, M; Veeck, J | 1 |
| Bize, PE; Borchard, G; Denys, A; Fuchs, K; Jordan, O | 1 |
| Baldazzi, V; Carini, M; Lapini, A; Mazzanti, R; Tassi, R | 1 |
| Arano, Y; Gushimiyagi, K; Kashiba, T; Nomura, Y; Sato, H; Sekine, Y; Siddig, S; Suzuki, S; Uehara, T; Ueno, K; Uzu, M; Yamaura, K | 1 |
| Chen, G; Fu, L; Li, X; Liang, G; Liu, Z; Wang, Z; Weng, Q; Yu, P; Zhang, H | 1 |
| Buchfelder, M; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Hatipoglu, G; Hock, SW; Savaskan, NE; Sehm, T; Weiss, R | 1 |
| Harvey, PA; Leinwand, LA | 2 |
| Aulitzky, WE; Bergmann, L; Burkholder, I; Edler, L; Fuxius, S; Hartung, G; Heil, G; Köberle, D; Maute, L; Moritz, B; Richly, H; Rüssel, J; Scheulen, ME; Weidmann, E; Weigang-Köhler, K; Wörmann, B | 1 |
| Bani, MR; Bassi, A; Bisighini, C; Damia, G; Fiordaliso, F; Ghilardi, C; Giavazzi, R; Moschetta, M; Piccirillo, R; Pretto, F; Rovida, A; Scarlato, V; Talamini, L | 1 |
| Lee, CH; Motzer, RJ | 1 |
| Altinmakas, E; Aparicio, A; Campbell, MT; Corn, PG; Millikan, RE; Siefker-Radtke, AO; Tannir, NM; Wen, SJ; Xiao, L | 1 |
| Barber, J; Casbard, A; Chester, J; Cowles, R; Crabb, S; Elliott, T; Evans, J; Geldart, T; Griffiths, G; Huddart, RA; Jones, RJ; Mead, G; Protheroe, A; Smith, J | 1 |
| Albiges, L; Escudier, B; Fizazi, K; Iacovelli, R; Loriot, Y; Massard, C; Massari, F | 1 |
| Cowen, EW; Massey, PR; Okman, JS; Wilkerson, J | 1 |
| Kume, H; Makino, K; Tomoishi, J; Yoda, K | 1 |
| Bongaerts, AH; Brouwers, AH; de Haas, S; de Jong, IJ; de Jong, JR; de Vries, EG; Dierckx, RA; Gietema, JA; Hollema, H; Lub-de Hooge, MN; Nagengast, WB; Oosting, SF; Oude Munnink, TH; Scherer, SJ; Sluiter, WJ; van Es, SC | 1 |
| Cetrangolo, P; Colombo, F; De Santis, F; Maggioni, M; Porretti, L; Prati, D; Razini, P; Torrente, Y; Torresani, E; Trombetta, E | 1 |
| Bernardini, M; Brossa, A; Bussolati, B; Fiorio Pla, A; Genova, T; Gkika, D; Grolez, G; Leroy, X; Prevarskaya, N; Villers, A | 1 |
| Avril, N; Hoimes, C; Hu, L; Lee, Z; Muzic, R; Sher, A; Valls, L | 1 |
| Bousquet, G; Duval, A; Ferreira, I; Feugeas, JP; Gapihan, G; Germain, S; Janin, A; Leboeuf, C; Mongiat-Artus, P; Ratajczak, P; Setterblad, N; Tan, S; Varna, M; Verine, J | 1 |
| Chan, A; Chau, NM; Chue, XP; Ho, HK; Kanesvaran, R; Tan, MH; Teo, YL; Wee, HL | 2 |
| Bareggi, C; Dell'orto, PG; Galassi, B; Gambini, D; Gianelli, U; Locatelli, E; Massironi, S; Tomirotti, M; Visintin, R | 1 |
| Götze, L; Hegele, A; Hofmann, R; Keil, C; Nockher, WA; Olbert, P | 1 |
| Ando, Y; Fukunaga, K; Imamura, CK; Katsuyama, Y; Miura, Y; Mushiroda, T; Okaneya, T; Suyama, K; Takano, T; Tanigawara, Y | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Sawyer, MB | 1 |
| Adelaiye, R; Bard, J; Bjarnason, GA; Buck, M; Chintala, S; Ciamporcero, E; Conroy, D; Fetterly, G; Ku, SY; Miles, KM; Orillion, A; Pili, R; Prey, J; Ramakrishnan, S; Shen, L; Sotomayor, P; Tsompana, M | 1 |
| Fujisawa, M; Furukawa, J; Kusuda, Y; Miyake, H; Muramaki, M; Terakawa, T | 1 |
| El Messaoudi, S; Noyez, L; Rongen, GA; Thijs, AM; van der Graaf, WT; van Herpen, CM; van Swieten, H; Verweij, V; Vos, JC; Wouterse, AC | 1 |
| Aydin, S; Gizzi, M; Machiels, JP | 1 |
| Campbell, SC; Derweesh, IH; Ercole, CE; Kim, HL; Klink, J; Lane, BR; O'Malley, R; Palazzi, KL; Rini, BI; Thomas, AA | 1 |
| Donskov, F; Fode, K; Geertsen, PF; Hermann, GG; Ibsen, R; Jensen, NV; Kjellberg, J; Soerensen, AV | 1 |
| Benson, P; Carpenter, C; Choueiri, TK; de Souza, P; Deen, K; Fay, AP; Figueroa, DJ; Gagnon, R; Ho, TH; Liu, Y; Motzer, RJ; Pandite, L; Powles, T; Signoretti, S | 1 |
| Pwint, T; Tyrrell, HE | 1 |
| Chan, A; Chau, NM; Hong, YW; Kanesvaran, R; Li, H; Lopes, G; Ng, QS; Tan, HS; Tan, MH; Tang, T; Tay, MH; Toh, CK; Wong, A; Yao, X | 1 |
| Assaraf, YG; Zhitomirsky, B | 1 |
| Chi, Z; Cui, C; Dai, J; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, H; Wang, X; Yan, X | 1 |
| Bolanča, A; Jakšić, B; Jazvić, M; Jukić, T; Kusić, Z; Kust, D; Murgić, J; Prgomet, A; Prpić, M | 1 |
| Bessho, H; Huang, D; Iwamura, M; Matsumoto, K; Ong, CK; Siew, EY; Tan, J; Tan, SY; Teh, BT; Wong, B | 1 |
| Boratyn-Nowicka, A; Ćwikła, JB; Jarząb, B; Kos-Kudła, B; Michalik, B; Nawrocki, S; Piątek, M; Rogowski, W; Szabłowska-Siwik, S; Wachuła, E; Zemczak, A | 1 |
| Ciuleanu, TE; Géczi, L; Leyman, S; Mardiak, J; Sajben, P; Torday, L; Vrdoljak, E; Zhang, K | 1 |
| Broom, RJ; Fong, PC; Mitchell, N | 1 |
| Arondekar, B; Deen, KC; Hackshaw, MD; Hansen, RN; Nagar, SP; Ramsey, SD; Sullivan, SD | 1 |
| Amdahl, J; Delea, TE; Diaz, J; Hackshaw, MD; Nakhaipour, HR | 1 |
| Huo, L; Jiang, B; Liu, H; Liu, J; Liu, Z; Lu, J | 1 |
| Artibani, W; Bimbatti, D; Brunelli, M; Ciccarese, C; Fantinel, E; Martignoni, G; Massari, F; Modena, A; Scarpa, A; Simbolo, M; Tortora, G | 1 |
| Chen, L; Dong, J; Li, X; Mai, H; Tang, Y; Zhang, B; Zhao, F | 1 |
| Bortlicek, Z; Buchler, T; Coufal, O; Dusek, L; Fiala, O; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Svoboda, M; Vyzula, R; Zemanova, M | 1 |
| Finke, JH; Grabowski, M; Hambardzumyan, D; Huang, P; Raychaudhuri, B; Rayman, P; Vogelbaum, MA | 1 |
| Becht, E; Beuselinck, B; Couchy, G; de Reyniès, A; Elaidi, R; Fridman, WH; Giraldo, N; Job, S; Karadimou, A; Méjean, A; Molinié, V; Oudard, S; Patard, JJ; Rioux-Leclercq, N; Sautès-Fridman, C; Sibony, M; Teghom, C; Verkarre, V; Zucman-Rossi, J | 1 |
| Bedogni, A; Bettini, G; Bonacina, R; Campisi, G; Di Fede, O; Fusco, V; Guglielmini, P; Lo Re, G; Merigo, E; Paglino, C; Porta, C; Saia, G; Scoletta, M; Vescovi, P | 1 |
| Basso, U; Bonetti, A; Bracarda, S; Calabrò, F; Capaccetti, B; Cartenì, G; Ciuffreda, L; Fea, E; Ferrari, V; Fly, K; Gasparini, G; Gasparro, D; Hariharan, S; Labianca, R; Lo Re, G; Masini, C; Porta, C; Ruggeri, EM; Sternberg, CN; Tassinari, D; Zhang, K | 1 |
| Berman, A; Brzezniak, C; Carter, CA; Giaccone, G; Guha, U; Lee, MJ; Lee, S; Ling, A; Loehrer, PJ; Meltzer, P; Rajan, A; Spittler, AJ; Steinberg, SM; Szabo, E; Thomas, A; Tomita, Y; Trepel, JB; Wang, Y | 1 |
| Marx, A; Weis, CA | 1 |
| Ito, T; Kutikov, A | 1 |
| Ahmed, Z; Bhushan, S; Chandan, BK; Guru, SK; Korkaya, H; Kumar, A; Kumar, S; Malik, F; Mondhe, DM; Pathania, AS; Seals, DF; Wani, ZA | 1 |
| Blay, JY; Cassier, P; Dufresne, A; Heudel, P; Pissaloux, D; Ray-Coquard, I; Wang, Q | 1 |
| Bergh, J; Borregaard, J; Dalhus, M; Damkier, P; Ersbøll, J; Hofland, K; Mickisch, G; Pieters, R; Pignatti, F; Salmonson, T; Skibeli, V; Slot, KB; Sylvester, R; Thoresen, H; Tzogani, K; Westgaard, I | 1 |
| He, CS; Huang, JK; Lin, QZ; Xie, M | 1 |
| Chan, JK; Chung, AY; Endaya, BB; Gnecchi, M; Ho, IA; Hui, KM; Huynh, H; Iyer, NG; Lam, PY; Leong, HS; Lim, KH; Newman, JP; Sia, KC; Toh, XY; Yulyana, Y | 1 |
| Boglione, A; Comandone, A | 1 |
| Bianconi, M; Cascinu, S; Minardi, D; Muzzonigro, G; Quaresima, L; Santoni, M; Scartozzi, M | 1 |
| Jonasch, E; Kalra, S; Rini, BI | 1 |
| Martinho, O; Reis, RM; Zucca, LE | 1 |
| Biasco, G; Chen, L; Demetri, GD; Fly, K; Fumagalli, E; Gelderblom, H; Hurwitz, HI; Kaiser, PE; Kang, YK; Lechuga, MJ; Matczak, E; Reichardt, P; Rosen, LS; Rutkowski, P; Schuette, J; Seddon, B; Williams, CC; Yalcin, S | 1 |
| Binkhorst, L; Burger, H; Chaves, I; de Bruijn, P; de Wit, AS; Hamberg, P; Kloth, JS; Lam, MH; Mathijssen, RH; van der Horst, GT; Wiemer, EA | 1 |
| Barouch-Bentov, R; Berkerman, E; Einav, S; Mulholland, J; Neveu, G; Ziv-Av, A | 1 |
| Demetri, GD; Doi, T; Kanda, T; Komatsu, Y; Kuss, I; Nishida, T; Sawaki, A; Yamada, Y | 1 |
| Chee, EL; Fernandez-Lastra, C; Lim, AY; Modamio, P; Segarra, I | 1 |
| Barber, N; Brown, A; Coward, J; Michael, A; Pandha, H | 1 |
| Azijli, K; Broxterman, HJ; de Haas, RR; Dekker, H; Gotink, KJ; Honeywell, RJ; Peters, GJ; Poel, D; Rovithi, M; Verheul, HM | 1 |
| Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L | 1 |
| An, H; Lin, Z; Liu, H; Liu, W; Liu, Y; Xu, J; Xu, L; Zhu, Y | 1 |
| Griffioen, AW; Kilarski, WW; Nowak-Sliwinska, P; Sarna, T; Szewczyk, G; van Beijnum, JR; van den Bergh, H; Verheul, HM; Weiss, A; Wong, TJ | 1 |
| Bing, N; Choueiri, TK; Davis, ID; Deen, KC; Esteban, E; Garcia-Donas, J; Johnson, T; McCann, L; Motzer, RJ; Pandite, LN; Rodríguez-Antona, C; Spraggs, CF; Sternberg, CN; Whittaker, JC; Xu, CF; Xue, Z | 1 |
| Chen, H; Chen, Y; Cui, G; Cui, W; Fang, J; Guo, X; Lee, SM; Liu, A | 1 |
| Baba, M; Hira, D; Kageyama, S; Kawauchi, A; Morita, SY; Noda, S; Okada, Y; Okamoto, K; Onishi, H; Otsuji, T; Terada, T; Yoshida, T | 1 |
| Azad, A; Davis, ID; Espinoza, D; Goldstein, D; Harrison, M; Harvie, R; Hudson, AL; Jovanovic, L; Kannourakis, G; Kichenadasse, G; Long, A; Lowenthal, RM; Martin, A; Nelson, CC; Pavlakis, N; Shapiro, J; Steer, C; Stockler, MR; Thompson, JF; Yip, S | 1 |
| Baylatry, MT; Bédouet, L; Beilvert, A; Labarre, D; Laurent, A; Louguet, S; Moine, L; Pascale, F; Servais, E; Verret, V | 1 |
| Hennink, WE; Hiemstra, C; Kazazi-Hyseni, F; Kiessling, F; Kok, RJ; Lammers, T; Ramazani, F; Steendam, R; Storm, G; Van Nostrum, CF | 1 |
| Akman, L; Akman, T; Aktug, H; Artunc Ulkumen, B; Erbas, O; Oltulu, F; Pala, EE; Pala, HG; Yavasoglu, A | 1 |
| Bhatt, RS; Choueiri, TK; Hamnvik, OP; Kaymakcalan, MD; Lin, X; McKay, RR; Rodriguez, GE; Sabbisetti, VS; Simantov, R | 1 |
| Egawa, C; Goto, T; Hashimoto, T; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kimura, K; Kuroda, Y; Kusama, H; Matsushita, K; Morimoto, Y; Nakahira, S; Nakatsuka, S; Nitta, K; Ohmura, Y; Ohzono, K; Okishiro, M; Sakisaka, H; Sato, Y; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H | 1 |
| Hosaka, S; Kawamoto, S; Kikutake, T; Nagao, S; Umemoto, S; Yonemitsu, K; Yoshida, T | 1 |
| Baggstrom, M; Bogart, J; Crawford, J; Graziano, SL; Gu, L; Masters, GA; Miller, AA; Otterson, GA; Pang, HH; Ready, NE; Thomas, SP; Vokes, EE | 1 |
| Frazier, OH; Hamilton, DJ; Li, Y; Rees, ML; Subramaniam, J; Taegtmeyer, H | 1 |
| Lin, XK; Liu, XS; Shou, CH; Sun, JY; Yang, WL; Yu, JR; Zhang, Q | 1 |
| Azimi, MS; Katakam, PV; Lacey, M; Mondal, D; Murfee, WL; Myers, L; Shi, Q; Stewart, SA | 1 |
| Dong, X; Gong, H; Jian, W; Liu, CF; Takyi-Williams, J; Tang, K; Wang, Y | 1 |
| Boerman, OC; de Weijert, MC; Franssen, GM; Leenders, WP; Mulders, PF; Oosterwijk, E; Oosterwijk-Wakka, JC; van der Laak, JA | 1 |
| Carley, W; DePrimo, SE; Harmon, CS; Heymach, JV; Huang, X; Khajavi, M; Kulke, MH; Lenz, HJ; Lin, E; Meropol, NJ; Tye, L; Wang, X; Wu, HK; Zurita, AJ | 1 |
| Fujii, Y; Ishiwata, Y; Kihara, K; Nagata, M; Saito, K; Takahashi, H; Takahashi, Y; Yasuhara, M | 1 |
| Berndsen, RH; Bonvin, D; Dyson, PJ; Griffioen, AW; Nowak-Sliwinska, P; Scherrer, E; Weiss, A; Wong, TJ | 1 |
| Berger, R; Carducci, MA; Eisenberger, MA; Gottfried, M; Keizman, D; Kim, JJ; Leibowitz-Amit, R; Maimon, N; Mermershtain, W; Peer, A; Rouvinov, K; Sella, A; Sinibaldi, V; Weitzen, R | 1 |
| Abdelmalek, RR; Edesa, WA | 1 |
| Bencsikova, B; Bortlicek, Z; Brabec, P; Jureckova, A; Kocak, I; Kocakova, I; Krejci, E; Spelda, S; Strenkova, J; Vyzula, R | 1 |
| Papadopoulos, EI; Scorilas, A; Yousef, GM | 1 |
| Adam, A; Barry, ER; Beran, G; Cairo, S; Clark, EA; D'Cruz, CM; Déas, O; Fawell, SE; Frigault, MM; Hattersley, M; Henry, RE; Jones, RD; Linsenmayer, D; Nicolle, D; Reimer, C; Schuller, AG; Smith, A; Wilson, J; Zinda, M | 1 |
| Akashi, K; Annan, DA; Dosaka-Akita, H; Horlad, H; Jinushi, M; Kinoshita, I; Kitada, S; Komohara, Y; Morita, T; Nakayama, T; Ohnishi, K; Suzu, S; Takeya, M; Yamada, S | 1 |
| Albiges, L; Derosa, L; Escudier, B; Izzedine, H; Le Teuff, G | 1 |
| Lee, LY; Maafi, M | 1 |
| Tanday, S | 1 |
| Chevreau, C; Culine, S; De Fromont, M; Escudier, B; Gravis, G; Jimenez, M; Laguerre, B; Ouali, M; Oudard, S; Ravaud, A; Rolland, F; Sevin, E; Theodore, C; Zanetta, S | 1 |
| Amir, E; Ethier, JL; Krzyzanowska, MK; Ocana, A; Seruga, B; Srikanthan, A | 1 |
| Döhner, H; Döhner, K; Fiedler, W; Ganser, A; Göhring, G; Götze, K; Heuser, M; Janning, M; Kayser, S; Kebenko, M; Krauter, J; Schittenhelm, M; Schlenk, RF; Teleanu, V; Thol, F; Weber, D | 1 |
| Ji, X; Li, J; Li, L; Lu, W; Ma, Y; Mou, Z; Wang, S; Wu, K; Zhou, T | 1 |
| Castricum, KC; Griffioen, AW; Honeywell, R; Kleibeuker, EA; Slotman, BJ; Ten Hooven, MA; Thijssen, VL; Verheul, HM | 1 |
| Antonescu, CR; Beckman, MJ; Besmer, P; Cohen, NA; Crawley, MH; DeMatteo, RP; Green, BL; Greer, JB; Kim, TS; Rossi, F; Santamaria-Barria, JA; Seifert, AM; Sorenson, EC; Zeng, S | 1 |
| Ji, ZG; Jin, J; Li, HZ; Wen, J | 1 |
| Altuntaş, O; Güllü, İ; Petekkaya, İ; Süslü, N | 1 |
| Takahashi, M | 1 |
| Cardoso, AL; Costa, PM; Cunha, P; Custódia, C; Pedroso de Lima, MC; Pereira de Almeida, L | 1 |
| Aderhold, C; Birk, R; Faber, A; Hörmann, K; Schultz, JD; Sommer, JU; Umbreit, C; Weiss, C | 1 |
| Chen, L; Cui, X; Gan, S; Hong, Y; Huang, H; Huang, Y; Li, L; Liu, B; Pan, X; Xu, D; Ye, J; Zhou, Q | 1 |
| Bozkurt, G; Çakmak, H; Ergin, K; Evliçoğlu, GE; Kocatürk, T | 1 |
| Castañeda, G; Muñoz, L; Rodríguez, J; Villa, JC | 1 |
| Casali, PG; Castelli, C; Colombo, C; Crippa, F; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Rini, F; Rivoltini, L; Stacchiotti, S; Tazzari, M; Vergani, B; Villa, A | 1 |
| Bekerman, E; Einav, S | 1 |
| Arriba, Ld; Casañas, E; Hernández, G; López-Pintor, RM; Ramírez, L | 1 |
| Bergh, J; Foukakis, T; Giorgetti, C; Hedayati, E; Jacobsson, H; Lindström, LS; Lövrot, J; Sandqvist, P; Xie, H | 1 |
| Calvo, A; Diaz, R; Manrique, I; Nguewa, PA; Redrado, M | 1 |
| Akin, MM; Demir, T; Eren, K; Turgut, B | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Prausova, J; Svoboda, M; Vyzula, R | 1 |
| Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D | 1 |
| Pilotte, AP | 1 |
| Bonnet, C; Sibon, I | 1 |
| Akaza, H; Aoki, K; Houzawa, H; Lee, SY; Naito, S; Pitman Lowenthal, S; Ueno, N | 1 |
| Fujisawa, M; Miyake, H; Nishikawa, M | 1 |
| Kalyan, A; Kulik, L; Nimeiri, H | 1 |
| Briley, LP; du Bois, A; Johnson, T; Parham, LR; Russo, M; Song, K; Spraggs, CF; Tada, H; Xu, CF | 1 |
| Chen, HM; Chen, SH; Coakley, BA; Divino, C; Eisenstein, S; Ferris, R; Gildener-Leapman, N; Kao, J; Ko, EC; Ma, G; Mandeli, J; Ozao, J; Pan, PY; Schwartz, M; Sung, M; Wang, LH | 1 |
| Boven, E; Castellano, D; Diekstra, MH; García-Donas, J; Gelderblom, H; Guchelaar, HJ; Mathijssen, RH; Rini, BI; Rodríguez-Antona, C; Swen, JJ | 1 |
| Czyrski, A; Grześkowiak, E; Karbownik, A; Kondys, K; Szałek, E | 1 |
| Choi, SH; Jang, J; Lee, HJ; Lee, YJ; Nam, JK | 1 |
| Kim, JH; Lee, JY; Lee, KJ; Lee, SM; Ryu, W; Seo, IH; Song, HB | 1 |
| Bobrzyk, M; Chronowska, J; Kukla, U; Madej, P; Okopień, B; Łabuzek, K | 1 |
| He, Y; Zhang, X | 1 |
| Berk, V; Bozkurt, O; Duran, AO; Duzkopru, Y; Hacıbekiroglu, I; Inanc, M; Kaplan, MA; Karaca, H; Ozaslan, E; Ozkan, M; Ucar, M; Uysal, M | 2 |
| Annaratone, L; Brossa, A; Bussolati, B; Camussi, G; Grange, C; Mancuso, L; Mazzone, M; Satolli, MA | 1 |
| Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U | 1 |
| Barnhart, TE; Cai, W; Chakravarty, R; Chen, F; Goel, S; Hernandez, R; Hong, H; Valdovinos, HF | 1 |
| Boccardi, V; Marano, L; Marrelli, D; Roviello, F | 1 |
| Akkar, OB; Cetin, A; Kacan, SB; Kacan, T; Karakus, S; Ozer, H; Yildiz, C | 1 |
| Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; Haas, NB; Jewett, M; Kane, CJ; Ky, B; Manola, J; Uzzo, RG; Wilding, G; Wood, CG; Wood, L | 1 |
| Carr, JC; De Andrade, JP; Kulak, MV; Lorenzen, AW; Spanheimer, PM; Sugg, SL; Weigel, RJ; Woodfield, GW | 1 |
| Baldini, C; Bridal, SL; Comperat, E; Dizeux, A; Lamuraglia, M; Le Guillou-Buffello, D; Lucidarme, O; Payen, T | 1 |
| Cottle-Delisle, C; Kebebew, E; Marx, S; Meltzer, P; Merkel, R; Neychev, V; Nilubol, N; Pacak, K; Steinberg, SM; Yao, J | 1 |
| Bensalah, K; Ouzaid, I | 1 |
| Baba, E; Iguchi, A; Kusaba, H; Sagara, K; Sakamoto, N; Takayoshi, K; Uchino, K | 1 |
| Kashiba, T; Sato, H; Shibata, Y; Ueno, K; Uzu, M; Yamada, R; Yamaura, K | 1 |
| Khoo, BL; Kumar, P; Lee, SC; Lim, CT; Nandi, S; Ow, SG; Tan, TZ; Thiery, JP; Warkiani, ME | 1 |
| Guo, H; Li, L; Liu, M; Liu, X; Wang, C; Wang, M; Wu, Z; Ye, C | 1 |
| Chan, ST; Khoo, HW; Lau, CL; Lim, AY; Mariño, EL; Modamio, P; Segarra, I; Selvaratanam, M | 1 |
| Burton, TM; Byfield, SA; Hackshaw, MD; McPheeters, JT; Nagar, SP | 1 |
| Bai, S; Bex, A; Ding, Z; Gao, J; German, P; Griffioen, AW; Hoang, A; Jonasch, E; Kalra, S; Karam, JA; Liu, XD; Matin, S; Rao, P; Sharma, P; Sircar, K; Sun, M; Tamboli, P; Tannir, N; Wood, C; Yetil, A; Zhang, X; Zhou, L; Zurita, A | 1 |
| Aitchison, M; Berney, D; Bex, A; Eory, L; Harrison, DJ; Laird, A; Lubbock, AL; Mackay, A; McNeill, SA; Mullen, P; Nanda, J; O'Donnell, M; O'Mahony, FC; Overton, IM; Powles, T; Riddick, AC; Stewart, GD | 1 |
| Füeßl, HS | 1 |
| Charbit, D; Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Sabourin, JC | 1 |
| Beuselinck, B; Jean-Baptiste, J; Schöffski, P; Van Keerberghen, CA; Wolter, P; Zucman-Rossi, J | 1 |
| Di Bella, S; Facchetti, R; Giannattasio, C; Giganti, MO; Maloberti, A; Mancia, G; Meani, P; Moreo, A; Musca, F; Pozzi, M; Ricotta, R; Sartore-Bianchi, A; Siena, S; Stucchi, M; Vallerio, P | 1 |
| Atkinson, BJ; Corn, PG; Jonasch, E; Kalra, S; Karam, JA; Matin, SF; Matrana, MR; Rao, P; Sircar, K; Tamboli, P; Tannir, NM; Wood, CG | 1 |
| Cherrington, JM; Laird, AD; Mendel, DB | 1 |
| Coker, SJ; Currie, S; Mooney, L; Skinner, M | 1 |
| He, S; Wang, Y; Yin, T | 1 |
| Albuquerque, M; Benhadji, KA; de Gramont, A; Dos Santos, C; Faivre, S; Neuzillet, C; Paradis, V; Raymond, E; Serova, M; Tijeras-Raballand, A | 1 |
| Atkins, MB; Choueiri, TK; McDermott, DF; McKay, RR; Michaelson, MD; Olivier, KM; Signoretti, S; Song, J; Van Allen, EM; Werner, L | 1 |
| Taieb, J; Tartour, É; Terme, M; Voron, T | 1 |
| Cui, CH; Duda, DG; Jain, RK; Jeong, HS; Jones, D; Liao, S; Padera, TP; Wattson, DA; Willett, CG | 1 |
| Demlova, R; Hezova, R; Kovarikova, A; Merhautova, J; Poprach, A; Radova, L; Slaby, O; Svoboda, M; Vyzula, R | 1 |
| Iguchi, T; Kato, M; Nakatani, T; Ninomiya, N; Tamada, S; Yamasaki, T | 1 |
| Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT | 1 |
| Bianconi, M; Bittoni, A; Cascinu, S; Cheng, L; Del Prete, M; Faloppi, L; Giampieri, R; Lopez-Beltran, A; Montironi, R; Scarpelli, M; Scartozzi, M | 1 |
| Afrin, LB; Cichocki, FM; Molderings, GJ; Patel, K | 1 |
| Hohenberger, P; Jakob, J; Kasper, B; Ronellenfitsch, U; Simeonova, A; Wenz, F | 1 |
| Bjarnason, GA; Bracarda, S; Bukowski, R; Carteni, G; Castellano, D; Crinò, L; Eberhardt, WE; Fly, K; Gore, ME; Haanen, J; Hariharan, S; Hawkins, RE; Kim, TM; Lechuga, MJ; Lee, SH; Mainwaring, P; Matczak, E; Oudard, S; Porta, C; Schöffski, P; Szczylik, C; Vrdoljak, E; Zhang, K | 1 |
| Komarov, YI; Latipova, DH; Novik, AV; Protsenko, SA; Semenova, AI; Teletaeva, GM | 1 |
| Kamata, S; Yoshinaga, A | 1 |
| Bordun, KA; Chaudhary, R; Cheung, D; Cheung, M; daSilva, M; Freed, DH; Glavinovic, T; Goyal, V; Herrmann, J; Jassal, DS; Kohli, M; Mandal, S; Mulvagh, S; Pitz, M; Premecz, S; Ravandi, A; Singal, PK; Thliveris, J; Villarraga, HR; White, CW | 1 |
| Bex, A; Blank, CU; Broeks, A; de Gruijl, TD; Gadiot, J; Guislain, A; Haanen, JB; Jordanova, ES; Kaiser, A; Sanders, J; van Boven, H | 1 |
| Arakaki, R; Inoue, T; Kamba, T; Kanno, T; Nakamura, E; Ogawa, O; Sakamoto, H; Shibasaki, N; Tsuruyama, T; Utsunomiya, N; Yamasaki, T | 1 |
| Gore, M; Kharkevich, G; Leyman, S; Mardiak, J; Sajben, P; Schöffski, P; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E; Zhang, K | 1 |
| Alcocer-Gómez, E; Apetoh, L; Battino, M; Bullón, P; Carrión, AM; Cordero, MD; Culic, O; Garrido-Maraver, J; Ghiringhelli, F; Marín-Aguilar, F; Román-Malo, L; Ruiz-Cabello, J; Ryffel, B; Sánchez-Alcazar, JA | 1 |
| Cella, CA; Elgendy, M; Fazio, N; Galdy, S; Minucci, S; Murgioni, S; Ravenda, PS; Spada, F; Zampino, MG | 1 |
| Schmidinger, M; Wittes, J | 1 |
| Bekaii-Saab, T; Blazer, M; Chen, JL; Clark, DJ; El-Dika, S; Knopp, MV; Liu, J; Mikhail, S; Neal, A; Rock, J; Tahiri, S; Timmers, C; Walker, J; Wei, L; Wu, C; Yang, X | 1 |
| Hainsworth, JD; Midha, R; Peacock, NW; Priego, VM; Shastry, M; Shipley, DL; Yardley, DA | 1 |
| He, S; Shen, G; Wang, Y; Yin, T | 1 |
| Cao, Y; Cao, Z; Chen, X; Hosaka, K; Jensen, L; Liu, Y; Sun, Y; Wang, J; Yang, H; Zhuang, R | 1 |
| Armstrong, AJ; George, DJ; Kanesvaran, R; Turnbull, JD; Watt, K; Wolkowiez, MC | 1 |
| Dezentjé, VO; Feberwee, T; van Erp, NP; van Kinschot, CM | 1 |
| Albiges, L; Escudier, B | 1 |
| Baelde, HJ; Clahsen-van Groningen, MC; Danser, AH; Hansen, A; Kappers, MH; Lankhorst, S; Mathijssen, RH; Sleijfer, S; Smedts, FM; van den Meiracker, AH | 1 |
| Bernards, N; Beynel, A; Boisgard, R; Bouet, S; Buvat, I; Kuhnast, B; Tavitian, B; Thézé, B | 1 |
| Baldetorp, B; Döme, B; Fehniger, TE; Gustavsson, L; Kim, Y; Kwon, HJ; Malm, J; Marko-Varga, G; Nishimura, T; Sugihara, Y; Török, S; Végvári, Á; Watanabe, K; Welinder, C | 1 |
| Cohen, EE; Fleming, GF; Harris, PJ; Janisch, L; Karovic, S; Karrison, TG; Levine, MR; Maitland, ML; O'Donnell, PH; Polite, BN; Ratain, MJ | 1 |
| Bjarnason, GA; Butz, H; Dharsee, M; Ding, Q; Evans, KR; Khella, HWZ; Kupchak, P; Latif, A; Lianidou, E; Pasic, MD; Rotondo, F; Yousef, GM | 1 |
| Kleibeuker, EA; Slotman, BJ; Ten Hooven, MA; Thijssen, VL; Verheul, HM | 1 |
| Pertijs, J; Rongen, GA; Thijs, AM; van den Broek, PH; van der Graaf, WT; van Herpen, CM; Verweij, V | 1 |
| Hayano, K; Lee, SH; Sahani, DV; Yoshida, H; Zhu, AX | 2 |
| Charles, LP; DeAnnuntis, L; Escudier, B; Gore, ME; Hariharan, S; Motzer, RJ; Porta, C; Rini, BI; Yang, L | 1 |
| Altavilla, A; Boni, L; Bracarda, S; Camerini, A; Derosa, L; Di Lorenzo, G; Escudier, B; Galli, L; Iacovelli, R; Longo, F; Morelli, F; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santoni, M; Sisani, M | 1 |
| Huang, J; Shan, L; Song, Y; Zhang, HT | 1 |
| Czarnota, GJ; El Kaffas, A; Falou, O; Fernandes, J; Giles, A; Hashim, A; Sadeghi-Naini, A; Tran, WT; Zhou, S | 1 |
| Fu, S; Hao, J; Liu, Y; Wang, B; Xu, Z; Yu, N; Zhang, A | 1 |
| Chau, NM; Choudhury, Y; Chowbay, B; Chu, YH; Kanesvaran, R; Koh, V; Lai, J; Li, H; Ng, QS; Phyo, WM; Tan, HS; Tan, MH; Tan, PH; Toh, CK | 1 |
| Ahluwalia, MS; Angelov, L; Barnett, GH; Brewer, CJ; Chao, ST; Elson, P; Mikkelsen, T; Parsons, MW; Peereboom, DM; Rump, M; Schilero, C; Smolenski, KN; Suh, JH; Vogelbaum, MA; Wang, D; Weil, RJ | 1 |
| Hasegawa, T; Hotta, K; Matsuura, K; Saito, H; Sugiura, Y; Tatsumi, Y; Tsukiyama, I; Ueyama, J | 1 |
| Koskinen, PK; Palin, N; Rintala, JM; Rintala, SE; Savikko, J; von Willebrand, E | 1 |
| Buchbinder, EI; Giobbie-Hurder, A; Hodi, FS; Lawrence, DP; Linette, GP; McDermott, DF; Ramaiya, NH; Sosman, JA; Van den Abbeele, AD | 1 |
| Gemma, A; Miyanaga, A | 1 |
| Kato, S | 1 |
| Shih, JY; Wu, H; Yang, JC | 1 |
| Blaes, J; Broggini, T; Czabanka, M; Harms, C; Harms, U; Mueller, S; Stange, L; Thomé, C; Vajkoczy, P; Weiler, M; Wick, W; Wüstner, M | 1 |
| Atkins, MB; Choueiri, TK; Demkow, T; Drosik, K; Gravis, G; Michaelson, MD; Navale, L; Ravaud, A; Tomczak, P; Warner, D; Wong, SS; Wu, B | 1 |
| Hirai, M; Hirano, T; Mizumoto, A; Nakagawa, T; Nakayama, Y; Takara, K; Yamamoto, K | 1 |
| Bilen, MA; Chen, HC; Hodges, S; Huang, S; Ilias-Khan, NA; Jonasch, E; Kearney, AY; Khakoo, AY; Tannir, NM; Wang, X; Zurita, AJ | 1 |
| Chen, Y; Qiu, S; Tu, X; Wang, D; Wu, R; Zhuang, J | 1 |
| Auberger, P; Belaid, A; Benhida, R; Colosetti, P; Cormerais, Y; Dufies, M; Giuliano, S; Grépin, R; Lacas-Gervais, S; Martin, A; Mazure, NM; Mograbi, B; Pagès, G; Parola, J | 1 |
| Aliper, A; Borisov, N; Buzdin, A; Kholodenko, R; Malakhova, G; Roumiantsev, S; Shepelin, D; Suntsova, M; Vasilov, R; Venkova, L; Zhavoronkov, A | 1 |
| Čaržavec, D; Gaćina, P; Kruljac, I; Kust, D; Ostojić, J; Peternac, AŠ; Prpić, M | 1 |
| Hara, T; Inoue, R; Kawai, Y; Kobayashi, K; Matsumoto, H; Matsuyama, H; Nagamori, S; Nagao, K; Osawa, T; Sakano, S; Yamamoto, Y | 1 |
| Abernethy, AP; George, DJ; Harrison, MR; Hirsch, BR; Mitchell, AP; Walker, MS | 1 |
| Agarwal, N; Beardmore, B; Boucher, K; Butterfield, RI; Hoffman, JM; Horn, KP; Kadrmas, DJ; Morton, KA; Yap, JT | 1 |
| Covell, LL; Ganti, AK | 1 |
| Fujisawa, M; Harada, K; Imai, S; Miyake, H; Miyazaki, A | 1 |
| Grandhi, MS; Lafaro, KJ; Pawlik, TM | 1 |
| Ahn, H; Ahn, JH; Hong, B; Hong, JH; Kim, MK; Lee, DH; Lee, JL; Park, I; Ryoo, HM; Song, C | 1 |
| Tomita, Y | 1 |
| Makis, W; McCann, K; McEwan, AJ; Sawyer, MB | 1 |
| Bai, S; Ding, Z; German, P; Giaccia, AJ; Hoang, AG; Jonasch, E; Karam, JA; Laird, DA; Liu, XD; Matin, SF; Rankin, EB; Rao, P; Sircar, K; Sun, M; Tamboli, P; Tannir, N; Walker, CL; Wood, CG; Zhang, X; Zhou, L | 1 |
| Racsa, PN; Whisman, TR; Worley, K | 1 |
| Blanc, E; Chevreau, C; Elena-Herrmann, B; Escudier, B; Gravis, G; Jobard, E; Négrier, S; Trédan, O | 1 |
| Houzawa, H; Komatsu, Y; Nishida, T; Ohki, E; Togo, K; Toyoshima, Y; Ueda, E; Ueno, N; Yoshida, A | 1 |
| Chen, S; Clapp, DW; Ferguson, MJ; Hutchins, G; Ingram, DA; Jiang, L; Li, X; Rhodes, SD; Territo, P; Vakili, ST; Yang, FC; Yang, X; Yuan, J; Zhang, S | 1 |
| Fujisawa, M; Harada, K; Imai, S; Miyake, H | 1 |
| Kim, DM; Kim, H; Lee, JH; Park, HO; Yeon, JH | 1 |
| Bédouet, L; Jubeli, E; Labarre, D; Laurent, A; Moine, L; Pascale, F; Saint-Maurice, JP; Slimani, K; Yagoubi, N | 1 |
| Antón Aparicio, L; León-Mateos, L; Mosquera, J | 1 |
| Boven, E; Castellano, D; Diekstra, MH; García-Donas, J; Gelderblom, H; Guchelaar, HJ; Liu, X; Mathijssen, RH; Rini, BI; Rodríguez-Antona, C; Swen, JJ | 1 |
| Fujikawa, A; Moriyama, M; Namura, K; Ota, J; Otake, S; Sawada, T | 1 |
| Du Four, S; Duerinck, J; Everaert, H; Hau, P; Michotte, A; Neyns, B; Sander, W; Van Binst, AM | 1 |
| Boers-Sonderen, MJ; De Geus-Oei, LF; Desar, IM; Fütterer, JJ; Mulder, SF; Mulders, PF; Oyen, WJ; Van Der Graaf, WT; Van Herpen, CM | 1 |
| Branžovský, J; Hes, O; Holubec, L; Hora, M; Kalusová, K; Pele, KB; Trávníček, I; Ürge, T | 1 |
| Atzori, F; Baghino, G; Boi, F; Ionta, MT; Mariotti, S; Pani, F; Tanca, L | 1 |
| Badalamenti, G; Bronte, G; Casali, P; De Lisi, D; Dei Tos, AP; Frezza, AM; Fumagalli, E; Nannini, M; Pantaleo, MA; Russo, A; Santini, D; Spalato Ceruso, M; Tonini, G; Vincenzi, B | 1 |
| Kunz, PL; Phan, AT; Reidy-Lagunes, DL | 1 |
| Atkins, MB; Barac, A; Freedman, AN; Fu, AZ; Jang, S; Minasian, L; Potosky, AL; Tsai, HT; Zheng, C | 1 |
| Rongen, GA; Tack, CJ; Thijs, AM; van der Graaf, WT; van Herpen, CM | 1 |
| Bondarenko, I; Dressler, H; Eisen, T; Jones, RJ; Loembé, AB; MacLeod, N; Mazurkiewicz, M; Shparyk, Y; Temple, G | 1 |
| Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Rebibo, JD | 1 |
| Beaumont, JL; Cella, D; Diaz, J; Khan, S; Lai, JS | 1 |
| Kayser, G; Klement, GL; Rössler, J; Saueressig, U; von Winterfeld, M | 1 |
| Demko, N; Federico, CA; Fergusson, D; Hakala, A; Henderson, VC; Kimmelman, J; MacKinnon, N | 1 |
| Chi, Z; Cui, C; Guo, J; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X | 1 |
| Li, CL; Shi, HZ; Tian, J | 1 |
| Ettinger, S; Fazli, L; Frees, S; Gleave, ME; Han, KS; Hong, SJ; Li, N; Park, KC; Raven, PA; So, AI | 1 |
| Debiec-Rychter, M; Lambrechts, D; Mazzone, M; Prenen, H; Sagaert, X; Sciot, R; Smeets, D | 1 |
| Benfini, K; degli Uberti, E; Di Pasquale, C; Falletta, S; Feo, C; Gagliano, T; Gentilin, E; Riva, E; Tagliati, F; Zatelli, MC | 1 |
| Ju, RJ; Li, XT; Li, XY; Lu, WL; Mu, LM; Shi, JF; Sun, MG; Yan, Y; Zeng, F; Zhao, Y | 1 |
| Bridgeman, VL; Foo, S; Frentzas, S; Gore, M; Larkin, J; Nathan, MR; Nathan, PD; Powles, T; Preece, N; Reynolds, AR; Springer, CJ; Vasudev, NS; Vermeulen, PB; Wan, E; Welti, JC | 1 |
| Bahl, A; Brown, J; Buchan, S; Hawkins, R; Jones, R; Pickering, L; Porfiri, E; Wagstaff, J | 1 |
| Bjarnason, GA; Cohen, DP; Davis, MP; Donskov, F; Goldstein, D; Lin, X; Michaelson, MD; Motzer, RJ; Puzanov, I; Rini, BI; Wiltshire, R | 1 |
| Chen, S; Chen, X; Dong, B; Huang, Q; Li, A; Li, Q; Liu, Y; Miao, J; Wang, Z; Yao, M; Zhang, N; Zhou, C | 1 |
| Bandaru, S; Dunna, NR; Girdhar, A; Hussain, T; Kandula, V; Nayarisseri, A; Pudutha, A | 1 |
| Crawford, K; Dusing, M; Frischer, JS; Knod, JL | 1 |
| Gomathi, T; Joseph, JJ; Sangeetha, D | 1 |
| Ahn, JH; Cho, YM; Lee, DH; Lee, JL; Park, I | 1 |
| Coakley, FV; Costantino, C; Ryan, C; Thomas, GV; Troxell, ML | 1 |
| Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W | 1 |
| Chen, XC; Ding, YQ; Gao, L; Luo, JD; Qin, Q; Sun, XC; Yang, X; Yang, Y; Yang, YH; Zhang, H; Zhou, XF; Zhu, HC | 1 |
| Carlisle, B; Demko, N; Freeman, G; Hakala, A; Hey, S; Kimmelman, J; London, AJ; MacKinnon, N; Ramsay, T | 1 |
| Soós, B; Szalma, J; Vajta, L | 1 |
| Jiang, M; Liu, TT; Shen, GF; Shi, JH; Wang, Q | 1 |
| Grünwald, V; Ivanyi, P | 1 |
| Chen, C; Li, G; Liu, FK; Liu, JY; Shen, L; Wu, GN; Wu, XY; Wu, ZF; Xu, H; Yao, XQ | 1 |
| Aramburu, O; Arévalo, M; Arias, JL; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Zambrano, S | 1 |
| Busch, JF; Ganser, A; Grünwald, V; Ivanyi, P; Koenig, J; Reuter, CW; Seidel, C; Trummer, A | 1 |
| Chai, CL; Ho, HK; Ngai, MH; So, CL; Sullivan, MB | 1 |
| Fujisawa, M; Miyake, H; Miyazaki, A | 1 |
| Engle, SK; Watson, DE | 1 |
| Cartenì, G; Vitale, MG | 1 |
| Albiges, L; Altinmakas, E; Choueiri, TK; Dubauskas Lim, Z; Jonasch, E; Karam, JA; Matin, SF; McDermott, DF; Ng, CS; Qiao, W; Rao, P; Sircar, K; Tamboli, P; Tannir, NM; Wang, X; Wood, CG | 1 |
| Bex, A; Ljungberg, B | 1 |
| Anckaert, E; Baurain, JF; De Brakeleer, S; De Grève, J; De Mey, J; Decoster, L; Majois, F; Neyns, B; Rorive, A; Rottey, S; Vande Broek, I | 1 |
| Berardi, R; Caramanti, M; Cascinu, S; Falconi, M; Morgese, F; Onofri, A; Pagliaretta, S; Partelli, S; Polenta, V; Rinaldi, S; Torniai, M | 1 |
| Argyros, O; Asvos, X; Davos, CH; Fokas, D; Karampelas, T; Papakyriakou, A; Sayyad, N; Tamvakopoulos, C; Tzakos, AG; Varela, A | 1 |
| Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ | 1 |
| Gardner, EE; Rudin, CM | 1 |
| Barett, C; Bikas, A; Burman, KD; Clark, BG; Desale, S; Gandhi, R; Jelinek, JS; Kundra, P; Mete, M; O'Keefe, K; Wartofsky, L; Wexler, JA; Wray, L | 1 |
| Abraham, RT; Bray, K; Cochran, N; De Jesus, R; Eng, CH; Fantin, VR; Fitzgerald, SL; Frias, E; George, E; Hoffman, GR; Lemon, L; Liu, S; Lucas, J; McAllister, G; Murphy, LO; Nyfeler, B; Tkach, D; Toral-Barza, L; Ugwonali, S; Wang, Z | 1 |
| Ettinger, S; Fazli, L; Frees, S; Gleave, ME; Gust, K; Han, KS; Hong, SJ; Kollmannsberger, C; Raven, PA; So, AI | 1 |
| Alekseev, B; Alyasova, A; Brechenmacher, T; Collins, L; Cosgriff, T; Karpenko, A; Karyakin, O; Kowalyszyn, R; Kurteva, G; Li, H; Lin, C; Morgan, L; Motzer, RJ; Neron, Y; Xie, L; Yang, L; Ye, D | 1 |
| Baelde, HJ; Clahsen-van Groningen, MC; Danser, AH; Lankhorst, S; Smedts, FM; van den Meiracker, AH | 1 |
| Kichenadasse, G; Mangoni, AA; Rowland, A; Sorich, MJ; Woodman, RJ | 2 |
| Ahn, H; Ahn, JH; Hong, B; Hong, JH; Jeong, IG; Koo, DH; Lee, DH; Lee, JL; Park, I; Song, C; You, D | 1 |
| Carpenter, C; Figlin, RA; Goldstein, D; McCann, L; Pandite, L; Rosenberg, JE; Townsend, RR | 1 |
| Koo, V; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ | 1 |
| Czarnecka, AM; Kornakiewicz, A; Solarek, W; Szczylik, C | 1 |
| Atri, M; Bjarnason, GA; Burns, PN; Hudson, JM; Milot, L; Moshonov, H; Sinaei, M; Williams, R | 1 |
| Chang, LL; Chen, Y; Chen, ZB; Wang, DD; Zhao, PG; Zhou, TY; Zhu, H | 1 |
| Abdelraouf, F; Baas, P; Hasan, B; Menis, J; O'Brien, M; Popat, S; Smit, E; Surmont, VF; van Meerbeeck, JP | 1 |
| Chang, CC; Chen, RJ; Chiou, HY; Hsieh, CC; Hsieh, CI; Lien, YC; Tai, CJ; Tzao, C; Wang, CK; Wu, CH; Wu, HC | 1 |
| Bogart, JA; Crawford, J; Gu, L; Pang, HH; Ready, NE; Salama, JK; Schild, SE; Vokes, EE; Wang, X | 1 |
| Brunelli, C; Carbone, F; Di Iorio, C; Gigli, L; Montecucco, F; Nencioni, A; Rosa, GM; Tagliasacchi, MI | 1 |
| Ding, J; Du, Y; Liu, JY; Tang, J; Zhou, Y | 1 |
| Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ; Yang, C | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M | 1 |
| Anand, M; Armstrong, AJ; Bratt, L; Carducci, MA; Creel, P; Davis, K; George, DJ; Halabi, S; Healy, P; Hobbs, C; Kim, S; Koontz, BF; Lee, WR; Moul, JW; Mundy, K; Nguyen, M; Reimer, B; Stein, M; Tran, PT; Wood, S | 1 |
| Bergh, J; Betsholtz, C; Foukakis, T; Genové, G; He, L; Landberg, G; Lindström, LS; Östman, A; Tobin, NP; Wennmalm, K | 1 |
| Blay, JY; Corsaro, M; Demetri, GD; Fly, K; Gelderblom, H; Goldstein, D; Gupta, S; Heinrich, MC; Huang, X; Im, SA; Kang, YK; Lechuga, MJ; Martini, JF; Reichardt, P; Rutkowski, P; Schöffski, P; Schuette, J; Soulières, D | 1 |
| Avoli, M; Benini, R; Khoja, Z; Roth, R; Wintermark, P | 1 |
| Bíró, K; Budai, B; Géczi, L; Gyergyay, F; Küronya, Z; Nagy, P; Nagyiványi, K; Németh, H; Noszek, L | 1 |
| Lin, Z; Shu, M; Wang, R; Zai, X; Zhang, B | 1 |
| Ha, AS; Imran, TF; Joseph, J; Shah, R; Thomas, R | 1 |
| Brossart, P; Diehl, L; Garbi, N; Gevensleben, H; Grünwald, B; Heine, A; Held, SA; Höchst, B; Knolle, P; Krüger, A; Kurts, C; Schilling, J | 1 |
| Blumenthal, DK; Cheung, AK; He, Y; Kim, SJ; Kwon, SH; Li, H; Li, L; Shiu, YT; Terry, CM; Tey, CS; Zhuplatov, I | 1 |
| Armstrong, AJ; Broderick, S; Eisen, T; Garcia, JA; George, DJ; Hainsworth, JD; Halabi, S; Hawkins, RE; Jones, RJ; Kollmannsberger, CK; Logan, TF; Lusk, CM; Oberg, S; Pickering, LM; Picus, J; Protheroe, A; Puzanov, I; Ryan, CW; Stadler, WM; Vaishampayan, UN | 1 |
| Alharbi, NO; Ansari, MA; Attafi, IM; Imam, F; Korashy, HM; Maayah, ZH; Moraished, BA; Raish, M | 1 |
| Belaustegui, A; Boven, E; Castellano, D; Diekstra, MH; García-Donas, J; Gelderblom, H; Guchelaar, HJ; Mathijssen, RH; Rini, BI; Rodríguez-Antona, C; Swen, JJ | 1 |
| Grabowski, T; Grześkowiak, E; Karbownik, A; Marcinkowska, D; Matuszewski, M; Połom, W; Płotek, W; Sobańska, K; Szałek, E; Szewczyk, A | 1 |
| Broxterman, HJ; De Haas, RR; Dekker, H; Halmos, B; Jiménez, CR; Knol, JC; Mier, JW; Pham, TV; Piersma, SR; Van Beusechem, VW; van der Mijn, JC; Verheul, HM | 1 |
| Choi, JY; Kim, H; Kim, MJ; Lee, M; Lim, JS; Park, MS | 1 |
| Algenstaedt, P; Fiedler, W; Hansen-Algenstaedt, N; Rüther, W; Schaefer, C; Schroeder, M; Viezens, L; Wellbrock, J | 1 |
| Bex, A; de Bruijn, RE; Haanen, JB; Horenblas, S; Nijkamp, J; Noe, A; Prevoo, W | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
| Diekstra, MH; Gelderblom, H; Guchelaar, HJ; Swen, JJ | 1 |
| Dulfer, RR; Eechoute, K; Hamberg, P; Kloth, JSL; Kruit, WHJ; Mathijssen, RHJ; Mendelaar, PAJ; Sleijfer, S; van der Holt, B; Wiemer, EAC | 1 |
| Amendola, V; Litti, L; Meneghetti, M; Toffoli, G | 1 |
| Granovetter, M | 1 |
| Furukawa, S; Handa, H; Hashimoto, A; Hashimoto, S; Mikami, S; Oikawa, T; Okada, Y; Onodera, Y; Oya, M; Sabe, H; Sugino, H; Yoshikawa, A | 1 |
| Anai, S; Fujimoto, K; Hayashi, Y; Hori, S; Hosokawa, Y; Kuwada, M; Miyake, M; Morizawa, Y; Nakagawa, Y; Nakai, Y; Otani, T; Otsuka, K; Samma, S; Tanaka, N; Tatsumi, Y; Tomioka, A | 1 |
| Choi, EK; Jeong, SY; Kim, J; Kim, N; Koo, HJ; Lee, JS; Lee, M; Woo, CW | 1 |
| Benedetto, P; Flores, A; Kovacs, K; Kwon, D; Merchan, JR; Montero, AJ; Rocha-Lima, C; Trent, JC | 1 |
| Banzato, A; Basso, U; Brunello, A; Diminutto, A; Fiduccia, P; Maruzzo, M; Roma, A; Zagonel, V; Zattoni, F; Zustovich, F | 1 |
| Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S | 1 |
| Chi, Z; Cui, C; Guo, J; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X | 1 |
| Delea, TE; Diaz, J; Latimer, N; Mehmud, F; Motzer, RJ; Pandite, L; Sternberg, CN | 1 |
| Blumenstengel, K; Busies, S; Hutzschenreuter, U; Marschner, N; Müller, L; Münch, A | 1 |
| Chen, D; Hakimi, AA; Hsieh, JJ; Knox, JJ; Lee, CH; Marker, M; Motzer, RJ; Voi, M; Voss, MH | 1 |
| Bezos, A; Kelso, MJ; Kirk, NS; Parish, CR; Ranson, M; Sudta, P; Suksamrarn, S; Willis, AC | 1 |
| Enokida, H; Fujisawa, M; Fukasawa, S; Fukunaga, K; Hara, I; Hashine, K; Hongo, F; Inoue, T; Kato, Y; Kitamura, H; Kubo, M; Low, SK; Matsuda, K; Matsuyama, H; Miki, T; Mushiroda, T; Nakanishi, H; Nishimura, K; Takahashi, A; Tanaka, T; Tatsugami, K; Tomita, Y; Uemura, H | 1 |
| Bize, P; Decosterd, LA; Denys, A; Doelker, E; Dormond, O; Duran, R; Fuchs, K; Jordan, O; Namur, J | 1 |
| Bo, B; Hu, J; Jiao, M; Li, J; Su, H; Zhang, J; Zhou, X; Zhu, T; Zong, Y | 1 |
| Brekken, RA; Goel, HL; Greiner, DL; Mercurio, AM; Pursell, B; Shultz, LD; Vander Kooi, CW | 1 |
| Eckstein, N; Frötschl, R; Haas, B; Weber-Lassalle, K | 1 |
| de Jongh, FE; Guillen, SS; Meijer, M | 1 |
| Dornbusch, J; Fuessel, S; Gottschalk, A; Grimm, MO; Junker, K; Klug, SJ; Meinhardt, M; Obaje, A; Ohlmann, CH; Schoffer, O; Walter, M; Wirth, MP; Zacharis, A; Zastrow, S | 1 |
| Brown-Glaberman, U; Chalasani, P; Iannone, M; Livingston, R; Marron, M; Specht, J; Stopeck, AT | 1 |
| Freyer, G; Le Saux, O; Négrier, S | 1 |
| Boers-Sonderen, MJ; Derikx, LA; Hoentjen, F; Mulder, SF; Mulders, PF; Nagtegaal, ID; van der Graaf, WT; van Herpen, CM; Wanten, GJ | 1 |
| Atkins, MB; Carducci, M; Cella, D; Choueiri, TK; Coomes, R; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Jewett, M; Kane, C; Kohli, M; Kuzel, TM; Manola, J; Matin, S; Pili, R; Pins, M; Puzanov, I; Sexton, WJ; Stadler, W; Uzzo, RG; Wagner, L; Wilding, G; Wong, YN; Wood, CG | 1 |
| Aranegui, B; Bueno, C; Espinosa Lara, P; Jiménez Reyes, J; Vargas-Machuca, I | 1 |
| Bogdahn, U; Bosserhoff, AK; Brawanski, A; Hau, P; Moeckel, S; Proescholdt, M; Riemenschneider, MJ; Spang, R; Vollmann-Zwerenz, A | 1 |
| Bodnar, L; Chrom, P; Semeniuk-Wojtas, A; Spencer, NJ; Stec, R; Szczylik, C | 1 |
| Akiyama, S; Fujishima, F; Imai, H; Ishioka, C; Kobayashi, A; Komine, K; Saijo, K; Sato, N; Shimodaira, H; Shirota, H; Shuin, T; Sugiyama, S; Takahashi, M; Takahashi, S | 1 |
| Barclay, JL; Gobe, GC; Johnson, DW; Li, L; Morais, C; Ng, KL; Oliver, K; Rajandram, R; Samaratunga, H; Small, DM; Vesey, DA; Wood, S | 1 |
| Galsky, MD; Mehrazin, R; Sfakianos, J; Tsao, CK | 1 |
| Beaumont, JL; Cella, D; Deen, KC; Diaz, J; Hackshaw, MD; McCann, L; Motzer, RJ; Powles, T; Salsman, JM | 1 |
| Alagh, A; Beksac, AT; Campbell, SC; Derweesh, IH; Gillis, K; Hamilton, Z; Jimenez, J; Kane, CJ; Lane, BR; Lee, HJ; Millard, F; Randall, JM; Tobert, C; Wang, S | 1 |
| Bao, YX; Deng, HB; Deng, LL; Guo, Y; Lu, CL; Lu, X; Zhao, XD | 1 |
| Azumi, M; Hashizume, K; Hori, J; Iwata, T; Kakizaki, H; Kita, M; Kobayashi, S; Matsumoto, S; Okazaki, S; Watanabe, M | 1 |
| Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K | 1 |
| Kononenko, OA; Stakhovskiy, EO; Stakhovskiy, OE; Vitruk, YV; Voylenko, OA; Vukalovych, PS | 1 |
| Chittoria, N; Dreicer, R; Elson, P; Garcia, JA; Haddad, H; Jonasch, E; Rini, BI; Tannir, NM; Wood, LS | 1 |
| De Meyer, T; Deforce, D; Harrison, DJ; Laird, A; Meynert, A; O'Mahony, F; Powles, T; Stewart, GD; Trooskens, G; Van Criekinge, W; Van Neste, C; Van Nieuwerburgh, F | 1 |
| Hwang, IG; Ji, JH; Lee, SJ; Lim, DH; Lim, HY; Lim, SH; Oh, SY; Park, SH; Yi, JH | 1 |
| Stone, L | 3 |
| Bergmann, L; Maute, L | 1 |
| Bernard, V; Binart, N; Bouilly, J; Carré, N; Kramer, P; Schlumberger, M; Visser, JA; Young, J | 1 |
| Chen, X; Cui, W; Han, Y; Hu, S; Hu, Z; Huang, L; Lin, J; Mak, S; Nirasha, S; Wang, C; Wang, Q; Wei, X; Xiang, S; Xu, D; Xu, S; Yu, J; Zhang, J; Zhang, Z; Zhao, K; Zheng, J; Zhou, D; Zhou, W | 1 |
| Ando, T; Hosokawa, A; Kajiura, S; Nakada, N; Nanjyo, S; Sugiyama, T | 1 |
| Chen, L; Ding, C; Mai, H; Zhang, B | 1 |
| Gu, W; Lu, X; Shi, G; Ye, D; Zhang, H; Zhu, Y | 1 |
| Annaert, P; Darville, N; De Jonghe, S; De Meulder, M; Mariën, D; Rossenu, S; Sterkens, P; Van den Mooter, G; van Heerden, M; Vermeulen, A; Vynckier, A | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Bompas, E; Bouché, O; Cassier, P; Cesne, AL; Chauzit, E; Cropet, C; Duffaud, F; Gautier, J; Isambert, N; Italiano, A; Mir, O; Molimard, M; Pérol, D; Ray-Coquard, I; Rios, M; Toulmonde, M | 1 |
| Boerma, M; Cao, M; Joseph, J; Melnyk, SB; Moros, EG; Pavliv, O; Sharma, S; Singh, SP; Sridharan, V; Thomas, CJ | 1 |
| Fukuda, H; Iida, S; Kondo, T; Takagi, T; Tanabe, K | 1 |
| Bono, P; Joensuu, H; Lampinen, A; Mirtti, T; Rautiola, J; Ristimäki, A; Saharinen, P | 1 |
| Führer, D; Kühl, H; Lahner, H; Lehmann, N; Poeppel, TD; Rinke, A; Unger, N | 1 |
| Asano, T; Hagiwara, M; Ito, K; Ito, Y; Kanao, K; Masuda, T; Masunaga, A; Mikami, S; Miyazaki, Y; Mizuno, R; Momma, T; Nakagawa, K; Oya, M; Oyama, M; Shirotake, S; Tanaka, N; Yasumizu, Y | 1 |
| Devine, L; Kelly, WK; Kluger, H; Lee, JJ; Li, J; Rink, L; Saif, MW | 1 |
| Billups, CA; Blaney, SM; Boyett, JM; Daryani, VM; Gajjar, A; Goldsmith, KC; Leary, S; Stewart, CF; Tanos, R; Wetmore, C | 1 |
| Blanchet, B; Da Silva, F; Goldwasser, F; Huillard, O; Thomas-Schoemann, A | 1 |
| Bao, Y; Chen, C; Chen, W; Ding, J; Fang, ZY; Gao, L; Gao, Y; Li, XF; Li, YM; Liu, B; Liu, F; Miao, X; Qu, L; Sun, HY; Sun, W; Sun, YH; Wang, HY; Wang, LH; Wang, X; Wang, Y; Wu, DS; Wu, ZJ; Xu, B; Xu, ZP; Xu, ZY; Yang, Q | 1 |
| Keck, B; Lieb, V; Lüdecke, G; Sikic, D | 1 |
| Barkhodari, A; Harshman, L; Minamimoto, R; Quon, A; Srinivas, S | 1 |
| Allen, E; Hanahan, D; Li, L; Miéville, P; Peng, MW; Saghafinia, S; Warren, CM | 1 |
| Bassani, N; Carles, J; Casanovas, O; García-Del-Muro, X; Graupera, M; Indraccolo, S; Jiménez-Valerio, G; Martínez-Lozano, M; Ochoa-de-Olza, M; Suárez, C; Vidal, A; Viñals, F | 1 |
| Clausse, M; Coulier, B; De Wulf, S; Frognier, R; Rezazadeh Azar, A; Van Cutsem, O | 1 |
| Brugarolas, J; Fedyshyn, S; Kucejova, B; Leong, HS; Pavia-Jimenez, A; Peña-Llopis, S; Power, N; Sivanand, S; Spence, P; Tran, TA; Xie, XJ; Yang, J | 1 |
| Chaudhary, CL; Choi, H; Gautam, J; Jang, H; Jeong, BS; Kim, GJ; Kim, JA; Lee, C; Lee, YJ; Nam, TG; Park, SW; Shah, S | 1 |
| Ding, Y; Gu, X; Wang, L; Wang, R; Wang, Z; Wei, L; Zhang, Y; Zhao, D | 1 |
| Fumagalli, E; Khosravan, R; Motzer, RJ; Rini, BI | 1 |
| Arrowsmith, ER; Crane, EJ; Flynt, A; Hainsworth, JD; Hamid, O; Mace, JR; Polzer, J; Reeves, JA; Roberson, S; Stille, JR | 1 |
| Andrikou, K; Bianconi, M; Bittoni, A; Burattini, L; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Loretelli, C; Montironi, R; Scartozzi, M; Zizzi, A | 1 |
| Bex, A; de Groot, S; Kiemeney, LA; Oosterwijk, E; Redekop, WK; Sleijfer, S; Uyl-de Groot, CA | 1 |
| Ji, SM; Li, JY; Li, L; Lu, W; Mou, ZZ; Ren, YP; Wang, LJ; Yuan, Y; Zhou, SP; Zhou, TY | 1 |
| Bernhard, JC; Daste, A; François, L; Gross-Goupil, M; Quivy, A; Ravaud, A | 1 |
| Abadie-Lacourtoisie, S; Amela, EY; Baciuchka, M; Boyle, H; Chevreau, C; Denechere, G; Deville, JL; Falkowski, S; Geoffrois, L; Gimel, P; Gross-Goupil, M; Guillot, A; Laguerre, B; Laramas, M; Legouffe, E; Oudard, S; Pfister, C; Rolland, F; Topart, D | 1 |
| Berger, R; Carducci, MA; Eisenberger, MA; Gottfried, M; Hammers, H; Ish-Shalom, M; Keizman, D; Maimon, N; Mermershtain, W; Neiman, V; Peer, A; Rosenbaum, E; Rouvinov, K; Sarid, D; Sella, A; Sinibaldi, V | 1 |
| Baracos, VE; Bathe, OF; Cervo, L; Giavazzi, R; Lecker, SH; Martinelli, GB; Olivari, D; Ottoboni, L; Piccirillo, R; Re Cecconi, AD; Resovi, A; Stretch, C; Talamini, L | 1 |
| Inoue, R; Kitamura, H; Masumori, N; Nishiyama, N; Shindo, T | 1 |
| Chen, W; Gratton, K; Kawakami, J; Lawson, KA; Morris, DG; Mostafa, AA; Shi, ZQ; Spurrell, J; Thakur, S | 1 |
| Eaddy, M; Hackshaw, MD; Holmes, M; Lankford, M; Ogbonnaya, A; Thomas, M | 1 |
| Besse, B; Dansin, E; Dubos, C; Girard, N; Greillier, L; Lindsay, CR; Mazieres, J; Pichon, E; Remon, J | 1 |
| Grünwald, V; Kalanovic, D; Lin, X; Simantov, R | 1 |
| Alimzhanov, M; Alsop, DC; Atkins, MB; Bhasin, MK; Bhatt, RS; Callea, M; Khanna, P; Kumar, R; Mier, JW; Pearsall, RS; Signoretti, S; Solban, N; Song, J; Wang, X | 1 |
| Hohenberger, P; Jakob, J; Kasper, B; Rauch, G; Ronellenfitsch, U; Simeonova, A; Wenz, F | 1 |
| Atzori, F; Baghino, G; Boi, F; Ionta, MT; Mariotti, S; Pani, F; Scartozzi, M; Tanca, L | 1 |
| Bedke, J; Gauler, T; Grünwald, V; Hegele, A; Herrmann, E; Hinz, S; Janssen, J; Miller, K; Schmitz, S; Schostak, M; Tesch, H; Zastrow, S | 1 |
| De Groot, S; Haanen, JB; Kiemeney, LA; Oosterwijk, E; Redekop, WK; Sleijfer, S; Uyl-de Groot, CA | 1 |
| Abdel-Aziz, AK; Helwa, R; Mantawy, EM; Said, RS | 1 |
| Bai, Q; Guo, J; Liu, L; Long, Q; Qu, Y; Wang, J; Xi, W; Xia, Y; Xiong, Y; Xu, J | 1 |
| Abe, H; Arai, K; Fukuda, T; Kamai, T; Masuda, A; Nukui, A; Yoshida, K | 1 |
| Boddy, AV; Galettis, P; Goulooze, SC; Martin, JH | 1 |
| Thoma, C | 1 |
| Andrews, DW; Brauer, PM; Hariharan, S; Leber, B; Oakes, CC; Oppermann, S; Shi, Y; Spaner, DE; Ylanko, J; Zúñiga-Pflücker, JC | 1 |
| Amantea, MA; Friberg, LE; Karlsson, MO; Schindler, E | 1 |
| Ait-Oudhia, S; Fetterly, G; Groman, A; Iyer, R; Mager, DE; Pokuri, V; Tomaszewski, G; Zagst, P | 1 |
| Bozzi, F; Brenca, M; Brich, S; Castelli, C; Conca, E; Gloghini, A; Gualeni, AV; Maestro, R; Negri, T; Pierotti, MA; Pilotti, S; Spagnuolo, RD; Stacchiotti, S; Tazzari, M | 1 |
| Fernández, C; Mariño, EL; Modamio, P; Segarra, I | 1 |
| Annala, M; Azad, AA; Chi, KN; Fazli, L; Mo, F; Nappi, L; Wyatt, AW | 1 |
| Kim, JH; Lee, JL; Park, I | 1 |
| Chen, X; Li, CL; Shi, HZ; Tian, J; Wang, D | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Chen, M; Qi, L; Yang, Z | 1 |
| Abdallah, AO; Arnaoutakis, K; Mahmoud, F; Makhoul, I | 1 |
| Papaxoinis, G; Saif, MW; Syrigos, K | 1 |
| Atallah, V; Bardet, S; Bonichon, F; De La Fouchardiere, C; Dierick-Galet, A; Do Cao, C; Godbert, Y; Hocquelet, A; Italiano, A; Leboulleux, S; Leduc, N; Zerdoud, S | 1 |
| Barysauskas, CM; Ben-Ami, E; Butrynski, JE; Choy, E; Corless, CL; Demetri, GD; Fletcher, JA; George, S; Heinrich, MC; Morgan, JA; Solomon, SM; Van den Abbeele, AD; von Mehren, M; Wagner, AJ; Yap, JT | 1 |
| Ma, W; Sun, R; Xu, W; Zeng, H; Zhang, L; Zhang, Y; Zheng, X | 1 |
| Anta, H; Fillat, C; Gibert, J; Guerrero, PE; Iglesias, M; José, A; Martínez-Bosch, N; Moreno, M; Munné-Collado, J; Navarro, P; Orozco, CA; Vinaixa, J; Viñals, F | 1 |
| Berger, R; Carducci, MA; Eisenberger, MA; Gottfried, M; Hammers, H; Keizman, D; Lee, JL; Mermershtain, W; Neiman, V; Neumann, A; Peer, A; Rosenbaum, E; Rouvinov, K; Sarid, D; Sella, A; Sinibaldi, V; Yildiz, I | 1 |
| Dimberg, A; Georganaki, M; Huang, H; Mangsbo, SM; van Hooren, L | 1 |
| Adamakis, I; Alamanis, C; Bamias, A; Christodoulou, C; Constantinidis, CA; Deliveliotis, C; Dimopoulos, MΑ; Karavasilis, V; Korkolopoulou, P; Kostouros, E; Koutsoukos, K; Lainakis, G; Liontos, M; Lykka, M; Mitropoulos, D; Papandreou, CN; Papatsoris, A; Patsouris, E; Saetta, A; Skolarikos, A; Stravodimos, K; Trigka, EA; Tzannis, K; Varkarakis, I | 1 |
| Aieta, M; Basso, U; Berardi, R; Conteduca, V; Crabb, SJ; De Giorgi, U; Derosa, L; Galli, L; La Russa, F; Lolli, C; Maruzzo, M; Massari, F; Santoni, M; Sava, T; Scarpi, E; Wheater, M | 1 |
| Allory, Y; Beuselinck, B; Couchy, G; Elaidi, R; Jean-Baptiste, J; Joniau, S; Lambrechts, D; Lerut, E; Meiller, C; Méjean, A; Oudard, S; Patard, JJ; Rolland, F; Roskams, T; Schöffski, P; Verkarre, V; Zucman-Rossi, J | 1 |
| Doehn, C; Rexer, H | 1 |
| Beuselinck, B; Punie, K; Schöffski, P; Van Cleemput, J; Van Keerberghen, CA; Van Limbergen, E; Van Wambeke, S; Wildiers, H; Wolter, P | 1 |
| Chagin, K; Djousse, L; Fraeman, KH; Gagnon, DR; Hall, SA; Nelson, J; Nordstrom, BL; Shantakumar, S; van Herk-Sukel, M | 1 |
| Gu, Y; Huang, X; Li, L; Luo, J; Sun, J; Wang, W; Wu, X; Yuan, H | 1 |
| Boháč, A; Moravčík, R; Stebelová, K; Zeman, M | 1 |
| Aziz, SA; Bhat, GM; Changal, KH; Lone, AR; Mir, MH | 1 |
| Aigner, F; Heidegger, I; Horninger, W; Pichler, R; Tulchiner, G | 1 |
| Im, SA; Kang, YK; Kim, TY; Lee, SJ; Park, JO; Park, SR; Ryoo, BY; Ryu, MH; Son, MK | 1 |
| Jalkanen, S; Joensuu, H; Laukkanen, MO; Laurila, JP; Salmi, M | 1 |
| Cisar, LA; Harnett, J; Hoang, CJ; MacLean, E; Mardekian, J | 1 |
| Choueiri, TK; Hamieh, L; Lin, X; McKay, RR; Moreira, RB; Simantov, R | 1 |
| Christophi, C; Fifis, T; Nguyen, L | 1 |
| Bruno, R; Chanu, P; Chen, Y; Claret, L; Mercier, F; Milligan, PA; Rosbrook, B; Yazdi, P; Zheng, J | 1 |
| Meng, CT; Ying, HY | 1 |
| Dekeister, K; Durbec, M; Graillot, E; Scoazec, JY; Walter, T | 1 |
| Brar, KK; Gaither, KA; Garcia, SR; Little, AA; McBride, AA; Meadows, GG; Platt, A; Zhang, F; Zhang, H; Zhu, Z | 1 |
| Chung, J; Joo, J; Joung, JY; Kim, S; Kim, SH; Lee, KH; Seo, HK | 1 |
| Back, HM; Chae, JW; Chan, A; Ho, HK; Karlsson, MO; Kwon, KI; Lee, J; Teo, YL; Yun, HY | 1 |
| Goto, Y; Ichikawa, T; Ishida, Y; Kojima, S; Kurozumi, A; Matsushita, R; Naya, Y; Nohata, N; Seki, N; Yamazaki, K; Yoshino, H | 1 |
| Beuselinck, B; Bjarnason, GA; Choueiri, TK; Donskov, F; Fraccon, AP; Heng, DY; Lee, JL; Pasini, F; Pezaro, C; Ptak-Chmielewska, A; Rini, BI; Ruiz-Morales, JM; Sim, HW; Sliwczynsk, A; Swierkowski, M; Szczylik, C; Teter, Z; Wells, JC; Wood, LA; Yuasa, T | 1 |
| Gao, Y; Guo, G; Li, H; Liu, K; Ma, X; Meng, Q; Song, Z; Wang, D; Wang, L; Zhang, X; Zhang, Y; Zhao, C | 1 |
| Choo, YW; Fernández, C; Lim, SH; Mariño, EL; Modamio, P; Ooi, IH; Segarra, I; Tan, SY; Tiew, AL; Wong, MM | 1 |
| Benedetti, F; Berti, F; Marangon, E; Pellizzoni, E; Resmini, M; Rizzolio, F; Saito, G; Toffoli, G; Tommasini, M | 1 |
| Chen, Y; Gao, D; Hu, G; Jiang, Y; Jin, F; Liu, H; Shao, X | 1 |
| Ding, L; Meng, X; Song, S; Sun, B; Wu, S; Zhao, X | 1 |
| Bieche, I; Bousquet, G; Bryan, BA; de Gramont, A; Dos Santos, C; Faivre, S; Gapihan, G; Janin, A; Lopez, A; Martinet, M; Mitchell, DC; Neuzillet, C; Raymond, E; Riveiro, ME; Serova, M; Tijeras-Raballand, A | 1 |
| M, Eel D | 1 |
| Golčić, M; Petković, M | 1 |
| Askin, G; Buchy, E; Cayre, F; Couvreur, P; Desmaele, D; Gouazou, S; Mougin, J; Mura, S; Sobot, D; Stella, B; Valetti, S | 1 |
| Avella, DM; Cole, DJ; Cooper, TK; Kaifi, JT; Kester, M; Kimchi, ET; Li, G; Li, N; Liu, D; Qi, X; Rockey, DC; Rountree, CB; Schell, TD; Staveley-O'Carroll, KF; Yang, QX | 1 |
| Aarts, MJ; Griffioen, AW; Heemskerk, JW; Kuijpers, MJ; Mattheij, N; Oude Egbrink, MG; Pineda, S; Sabrkhany, S; Sanders, L; van Geffen, JP | 1 |
| Droege, F; Geisthoff, U; Lang, S; Thangavelu, K | 1 |
| Bagan, P; Bilan, P; Couffinhal, JC; Dakhil, B; Fargeas, C; Mahé, E; Roger, A; Sigal, ML; Sin, C | 1 |
| Bu, P; Yang, Y | 1 |
| Dave, B; Phan, AT | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Hornova, J; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Studentova, H; Svoboda, M; Vyzula, R; Zemanova, M | 1 |
| Maki, RG; Martínez-Marín, V | 1 |
| Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yagisawa, T | 1 |
| Aitali, A; Albouzidi, A; Benani, F; Debbagh, A; Errihani, H; Ichou, M; Mahi, M; Sbitti, Y; Seddik, H; Slimani, K; Tarchouli, M | 1 |
| Gao, Y; Jia, J; Li, J; Li, W; Meng, Q; Qiao, N; Qu, C; Wang, D; Wang, X; Yang, S; Zhang, M | 1 |
| Fujita, K; Kawashima, A; Miyagawa, Y; Nagahara, A; Nonomura, N; Uemura, M; Ujike, T | 1 |
| Barnard, J; Diaz-Montero, CM; Finke, JH; Lindner, DJ; Mao, FJ; Parker, Y; Pink, JJ; Rini, BI; Zamanian-Daryoush, M | 1 |
| Habuchi, T; Huang, M; Inoue, T; Kagaya, H; Miura, M; Narita, S; Niioka, T; Numakura, K; Satoh, S; Takahashi, M; Tsuchiya, N; Tsuruta, H | 1 |
| Cheng, T; Chi, KN; Eigl, BJ; Eliasziw, M; North, S; Parimi, S; Ruether, D; Trudeau, M; Winquist, E | 1 |
| Bryniarski, P; Dumnicka, P; Giza, A; Herman, R; Krzemieniecki, K; Kucharz, J; Kusnierz-Cabala, B; Kuzniewski, M; Zygulska, AL | 1 |
| Buhari, SA; Chan, CW; Goh, BC; Hartman, M; Ho, J; Huang, Y; Iau, P; Jeyasekharan, AD; Lee, SC; Mogro, J; Ng, TC; Ow, SG; Pang, AS; Soh, TI; Sundar, R; Tan, CS; Tan, SH; Thng, CH; Wang, L; Wang, TT; Wong, AL; Zhang, B | 1 |
| Abe, M; Andersson, P; Cao, R; Cao, Y; Chen, F; Chen, X; Fischer, C; Hosaka, K; Iwamoto, H; Lim, S; Lu, Y; Nakamura, M; Nie, G; Seki, T; Skov, PV; Yang, Y; Zhang, Y | 1 |
| Al-Batran, SE; Galle, PR; Gepfner-Tuma, I; Hegewisch-Becker, S; Kanzler, S; Koenig, J; Kullmann, F; Maderer, A; Moehler, M; Otte, M; Rafiyan, MR; Ruessel, J; Schimanski, CC; Schmoll, HJ; Schollenberger, L; Siveke, JT; Thuss-Patience, PC; von Weikersthal, LF; Weißinger, F; Weusmann, J; Wilke, H | 1 |
| Alexandre, J; Bellesoeur, A; Blanchet, B; Goldwasser, F; Golmard, L; Huillard, O; Naji, F; Noé, G; Puszkiel, A; Rangarajan, S; Saidu, N; Thomas-Schoemann, A; Vidal, M | 1 |
| Brugarolas, J; Bruick, RK; Chang, J; Chen, W; Christie, A; Courtney, K; Frenkel, E; Gardner, KH; Geiger, H; Hao, G; Hill, H; Holloman, E; Homayoun, F; Hwang, TH; Josey, JA; Joyce, A; Kapur, P; Kim, MS; Ma, Y; McKay, RM; Patel, N; Pavia-Jimenez, A; Pedrosa, I; Reeves, C; Rizzi, JP; Sun, X; Wallace, EM; Wong, T; Xie, XJ; Xie, Y; Yell, P; Yousuf, Q; Zhang, H; Zojwalla, N | 1 |
| Bogusz, K; Brodziak, A; Czarnecka, AM; Korniluk, J; Labochka, D; Moszczuk, B; Owczarek, A; Sobczuk, P; Spychalska, M; Szczylik, C | 1 |
| Bryan, J; Griswold, M; Roda, M; Sirous, R; Smith, AD; Souza, F; Vasanji, A; Zhang, H; Zhang, X | 1 |
| de Haas, RR; Griffioen, AW; Honeywell, RJ; Peters, GJ; Poel, D; Rovithi, M; Verheul, HM | 1 |
| Li, T; Luo, Z; Wang, C; Wang, H; Wang, L; Zhang, S; Zhang, X | 1 |
| Bai, R; Li, J; Li, Y; Ma, Y; Shi, H; Wang, C; Xiao, J; Xu, W; Yang, C; Yu, H; Zhang, J | 1 |
| El Ashal, G; Elgebaly, A; Ghanem, E; Menshawy, A; Negida, A; Omar, A; Osama, O | 1 |
| Campanario, R; Juárez, A; Saiz, R; Soto, M | 1 |
| Munakata, S; Shiba, M; Takayama, H; Takeda, K; Wang, C | 1 |
| Allman, K; Beach, J; Elson, P; Garcia, JA; Gilligan, T; Martin, A; Ornstein, MC; Rini, BI; Wood, L | 1 |
| Hu, J; Li, C; Setrerrahmane, S; Xu, H; Yassin, S | 1 |
| Ito, T; Jensen, RT; Lee, L | 1 |
| Figlin, RA; Lin, X; Matczak, E; Michaelson, MD; Sella, A; Simantov, R | 1 |
| Braschi-Amirfarzan, M; Ramaiya, NH; Shinagare, AB; Steele, E; Tirumani, SH | 1 |
| Chi, Y; Cui, CX; Du, CX; Song, Y; Sun, Y; Sun, YK; Wang, JW; Yang, L; Zhang, W; Zhou, AP | 1 |
| Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M | 1 |
| Gómez-Sáez, JM | 1 |
| Casuscelli, J; Graser, A; Hellbach, K; Hummel, N; Ingrisch, M; Karpitschka, M; Schlemmer, M; Sommer, W; Staehler, M; Sterzik, A | 1 |
| Breza, J; Carteni, G; Casey, M; Chang, YH; Donskov, F; Escudier, B; George, DJ; Gerletti, P; Laguerre, B; Lechuga, M; Lin, X; Magheli, A; Martini, JF; Motzer, RJ; Pandha, HS; Pantuck, AJ; Patard, JJ; Patel, A; Ramaswamy, K; Ravaud, A; Staehler, M; Tomczak, P | 1 |
| Bedke, J; Bracarda, S; Crabb, SJ; Eisen, T; Fritsche, J; Kirner, A; Kogan, M; Ludwig, J; Mahr, A; Maurer, D; Mendrzyk, R; Oudard, S; Reinhardt, C; Rini, BI; Shkolnik, M; Singh-Jasuja, H; Stenzl, A; Wagner, C; Walter, S; Weikert, S; Weinschenk, T; Zdrojowy, R | 1 |
| Fujioka, Y; Fujita, H; Gomori, A; Harada, N; Haruma, T; Hashimoto, A; Inada, M; Ito, K; Kataoka, Y; Matsuo, K; Oda, N; Sakuragi, M; Suzuki, T; Tanaka, K; Yamamoto-Yokoi, H; Yonekura, K | 1 |
| Howe, JR; Maxwell, JE; Sherman, SK | 1 |
| Berger, MF; Bhanot, U; Bouvier, N; Chen, D; Chen, YB; Cheng, EH; Chevinsky, MS; Hakimi, AA; Hsieh, JJ; Huberman, KH; Knox, J; Lee, W; Marker, M; Motzer, RJ; Patel, P; Pinciroli, P; Redzematovic, A; Selcuklu, SD; Socci, ND; Viale, A; Voi, M; Voss, MH; Wang, PI; Weinhold, N; Won, HH; You, D | 1 |
| Angenendt, P; Diehl, F; Fredebohm, J; Holtrup, F; Löber, AK; Mehnert, DH; van Rahden, V | 1 |
| Aurilio, G; Cossu Rocca, M; Cullurà, D; de Cobelli, O; Iacovelli, R; Nolè, F; Verri, E | 1 |
| Bourlon, MT; Breaker, K; Clemons, JE; Flaig, TW; Gao, D; Lam, ET; Trigero, S | 1 |
| Ha, HK; Kim, AY; Kim, HJ; Kim, JS; Lee, JS; Park, SH | 1 |
| Baker, H | 1 |
| Broncel, M; Crosier, S; Daley, F; Finetti, MA; Holmes, K; Huang, PH; Jenks, A; Luczynski, MT; McCarthy, F; Natrajan, RC; Payne, LS; Ryall, KA; Tan, AC; Tanos, B; Todd, JR; Vyse, S; Wai, P; Williamson, D; Wong, JP | 1 |
| Andre, S; Braga, S; Brito, M; Cardoso, J; Dias, S; Orvalho, L; Passos-Coelho, JL; Pereira-Leal, JB; Salgado, L; Sanchez, P | 1 |
| Chen, XL; Chi, ZH; Cui, CL; Guo, J; Kong, Y; Lian, B; Mao, LL; Sheng, XN; Si, L; Tang, BX; Wang, X; Yan, XQ | 1 |
| Alharbi, NO; Ansar, MA; Belali, OM; Korashy, HM | 1 |
| Capozzi, M; DE Divitiis, C; Ottaiano, A; Romano, GM; Tafuto, S; Tatangelo, F; VON Arx, C | 1 |
| Escudier, B; Figlin, RA; Gannon, A; Motzer, RJ | 1 |
| Choi, HY; Chung, J; Jeon, SH; Kim, SH; Kim, WJ; Kim, YJ; Kwon, TG; Lee, HL; Lee, HM; Seo, SI | 1 |
| Payandeh, M; Sadeghi, E; Sadeghi, M | 1 |
| Brito, G; Dzik, C; Leite, KRM; Nahas, W; Paloppi, I; Reis, ST; Srougi, M; Viana, NI | 1 |
| Bang, YJ; Borbath, I; Castellano, D; Chen, JS; Faivre, S; Hammel, P; Ishak, KJ; Lee, SH; Lombard-Bohas, C; Lu, DR; Metrakos, P; Niccoli, P; Patyna, S; Raoul, JL; Raymond, E; Ruszniewski, P; Seitz, JF; Smith, D; Valle, JW; Van Cutsem, E; Vinik, A | 1 |
| Gilabert, M; Kavan, P; Rho, YS | 1 |
| Anai, S; Fujimoto, K; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y | 1 |
| Banerji, CR; Blanc, E; Harridge, SD; Jaka, O; Knight, RD; Moyle, LA; Prueller, J; Tedesco, FS; Zammit, PS | 1 |
| Benoit, G; Benoudiba, F; Brizard, M; Caillet, V; Corréas, JM; David, P; Deveaux, S; Elaidi, R; Gaudric, A; Hammel, P; Joly, D; Le Rest, C; Méjean, A; Oudard, S; Richard, S; Timsit, MO | 1 |
| Demartines, N; Dormond, O; Faes, S; Planche, A; Pythoud, C; Santoro, T; Uldry, E | 1 |
| Bilecz, A; Bridgeman, VL; Daley, F; Dome, B; Dvorak, HF; Foo, S; Frentzas, S; Gore, M; Hegedus, B; Hoetzenecker, K; Kerbel, RS; Kostaras, E; Kuczynski, EA; Larkin, J; Nathan, MR; Paku, S; Renyi-Vamos, F; Reynolds, AR; Schweiger, T; Vasudev, NS; Vermeulen, PB; Wan, E | 1 |
| Beutel, G; Drewes, N; Ganser, A; Grünwald, V; Ivanyi, P; Kielstein, JT; Morgan, M; Pirr, J | 1 |
| Huang, L; Huo, M; Satterlee, AB; Wang, Y; Xu, Y; Zhao, Y | 1 |
| Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH | 1 |
| Abdel-Aziz, AK; Bornaghi, V; Bossi, D; Colecchia, M; Elgendy, M; Fazio, N; Giandomenico, V; Kanesvaran, R; Lanfrancone, L; Lozano, MD; Mercurio, C; Minucci, S; Nole, F; Pallavicini, I; Perez-Gracia, JL; Procopio, G; Renne, G; Renne, SL; Teh, BT; Toh, CK | 1 |
| Angelini, S; Biasco, G; Gatto, L; Hrelia, P; Nannini, M; Pantaleo, MA; Ravegnini, G; Sammarini, G; Saponara, M; Simeon, V; Urbini, M; Venturoli, N; Zenesini, C | 1 |
| Boven, E; Castellano, D; García-Donas, J; Gelderblom, H; Guchelaar, HJ; Liu, X; Mathijssen, RH; Rini, BI; Rodríguez-Antona, C; Swen, JJ | 1 |
| Huang, C; Mei, H; Zheng, X; Zhou, M | 1 |
| Bedke, J; Stühler, V | 1 |
| Bang, YJ; Bottomley, A; Chao, RC; Hörsch, D; Korytowsky, B; Metrakos, P; Mundayat, R; Raoul, JL; Raymond, E; Reisman, A; Valle, JW; Vinik, A; Wang, Z | 1 |
| Fiocco, M; Guchelaar, HJ; Liu, X; Swen, JJ | 1 |
| Chu, Y; Guo, J; Hu, X; Wang, G; Zhao, Q | 1 |
| Chen, T; Chen, Z; Feng, X; Li, G; Li, Y; Qiu, H; Sun, X; Tao, K; Yu, J; Zhang, P; Zhou, Z | 1 |
| Chai, Y; Guo, H; Li, S; Li, X; Liu, M; Lv, K; Shen, W; Zhang, J | 1 |
| Bagheri-Yarmand, R; Gagel, RF; Grubbs, EG; Williams, MD | 1 |
| Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
| Kurzrock, R; Stewart, DJ | 1 |
| Chae, H; Chang, HM; Cho, H; Hong, SM; Hong, YS; Kang, YK; Kim, KP; Kim, SC; Kim, TW; Ryoo, BY; Ryu, MH; Song, MJ; Yoo, C | 1 |
| Atyabi, F; Bahrainian, S; Dinarvand, R; Saber, MM | 1 |
| Bao, N; Chen, L; Hu, J; Li, D; Shi, W; Sun, J | 1 |
| Azouz, MM; Bouassida, M; Chelbi, E; El Bouchtili, S; Ezzine, H; Hamzaoui, L; Mahmoudi, M; Medhioub, M; Touinsi, H | 1 |
| Adham, M; Forestier, J; Foulfoin, M; Graillot, E; Hervieu, V; Lombard-Bohas, C; Robinson, P; Rousset, P; Scoazec, JY; Walter, T | 1 |
| Fournier, L; Mauge, L; Mejean, A; Nassif, E; Oudard, S; Tartour, E; Thibault, C; Timsit, MO; Vano, Y; Verkarre, V | 1 |
| Guo, Q; Li, Y; Wang, G; Xu, J; Zhang, C; Zhang, J; Zhang, Y; Zheng, T | 1 |
| Hao, F; Li, J; Lu, W; Wang, L; Wang, S; Xue, J; Zhou, T; Zhu, X | 1 |
| Albiges, L; Bensalah, K; Bex, A; Dabestani, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Volpe, A | 1 |
| Ando, Y; Gyawali, B | 1 |
| Arosio, D; Battistini, L; Bianchini, F; Calorini, L; Portioli, E; Pupi, A; Sartori, A; Vacondio, F; Zanardi, F | 1 |
| Diao, Y; Gao, N; Jiang, W; Jin, G; Jin, Z; Li, W; Liu, Y; Wang, X; Wang, Z; Zhong, J | 1 |
| Afshar, M; Bardoli, AD; Miscoria, M; Pirrie, S; Porfiri, E; Stubbs, C; Wheeley, I | 1 |
| Bicknell, R; Heath, VL; Wragg, JW | 1 |
| Campitiello, M; Eid, N; Hennequin, L; Longo, R; Plastino, F; Quétin, P; Wendel, C | 1 |
| Bracarda, S; Casper, J; Escudier, B; Gross Goupil, M; Larkin, J; Negrier, S; Porta, C; Schmidinger, M | 1 |
| Deininger, E; Moch, H; Razafinjatovo, CF; Rechsteiner, M; Schraml, P; Stiehl, D | 1 |
| Chi, ZH; Guo, J; He, ZS; Li, XS; Sheng, XN; Wang, HK; Ye, DW; Zhang, HL | 1 |
| Burbidge, S; Colapietro, A; Delle Monache, S; Festuccia, C; Gravina, GL; Mancini, A; Marampon, F; Patient, L; Richardson, PJ; Sferra, R; Vitale, F | 1 |
| Chee, EL; Chee, YL; Chew, CC; Fernández, C; Koo, TW; Liew, MH; Mariño, EL; Modamio, P; Ng, S; Segarra, I | 2 |
| Al Mansour, M; Darwish, W; Imtiaz, S; Zekri, J | 1 |
| Li, H; Li, J; Wu, X; Zhang, X; Zhang, Y; Zheng, G | 1 |
| Joshi, A; Kannan, RA; Kothari, R; Menon, S; Noronha, V; Patil, VM; Popat, P; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Bedke, J; Burchardt, M; Kroeger, N; Stenzl, A | 1 |
| Bono, P; Peltola, K; Penttilä, P; Poussa, T; Rautiola, J | 1 |
| Black, PC; Struss, WJ | 1 |
| Huang, L; Luo, C; Wen, T; Xiao, H; Xiong, M | 1 |
| Bex, A | 1 |
| Adame, A; Fields, JA; Florio, J; He, JJ; Masliah, E; Metcalf, J; Overk, C; Rockenstein, E; Spencer, B; Wrasidlo, W | 1 |
| Chen, M; Lei, Y; Yildiz, S | 1 |
| Chen, TW; Chen, YY; Chiang, KC; Liu, CT; Liu, YY; Tsai, CY; Wang, SY; Yeh, CN; Yeh, TS | 1 |
| Chen, D; Hsieh, JJ; Marker, M | 1 |
| Allman, KD; Beach, J; Elson, P; Garcia, JA; Gilligan, T; Grivas, P; Martin, A; Ornstein, MC; Rini, BI; Wood, LS; Zanick, BR | 1 |
| Bjarnason, GA; Ganeshan, B; Haider, MA; Khalvati, F; Kiss, A; Vosough, A | 1 |
| Basterrechea, L; Boni, V; Carrato, A; Castellano, D; Cebrián, A; Cruz-Jurado, J; Esteban, E; García-Alonso, M; García-Carbonero, I; García-Foncillas, J; Gómez Del Pulgar, T; González Del Alba, A; González-Larriba, JL; Gonzálvez, ML; Lainez, N; Mahillo-Fernández, I; Martin, Y; Méndez-Vidal, MJ; Moreno, F; Munárriz-Ferrándiz, J; Perez-Valderrama, B; Reynés, G; Rodríguez-Remírez, M; Sáez, MI; Suárez, C; Villatoro, R; Viqueira, A | 1 |
| Chen, B; Chen, F; He, W; Hu, J; Liu, X; Wang, L; Xu, Z; Zhang, L | 1 |
| Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Xi, W; Xiong, Y; Xu, J; Yao, J | 1 |
| Angelousi, A; de Herder, W; Kaltsas, G; Kaltsatou, M; Kamp, K; O'Toole, D | 1 |
| Alamanou, M; Arany, Z; Byrne, AT; Cary, M; Conroy, E; Cutler, P; Ducret, A; Evans, R; Force, T; Gallagher, WM; Gascon, S; Hector, S; Jarzabek, MA; Jauhiainen, M; Knuuti, J; Ky, B; Lecomte, R; Liljenbäck, H; Maratha, A; McAuliffe, FM; Miller, IS; Murray, DW; O'Farrell, AC; Oikonen, V; Pallaud, C; Roivainen, A; Rousseau, JA; Saraste, A; Shiels, L; Silvola, JM; Udupi, GM | 1 |
| Kong, W; Liu, G; Liu, X; Qu, J; Suo, S; Wu, G; Xu, J; Zhang, J | 1 |
| Agarwal, N; Ghate, SR; Li, N; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML | 1 |
| Arai, Y; Ito, A; Kawasaki, Y; Kikuchi, M; Mano, N; Takasaki, S; Yamaguchi, H | 1 |
| Klatte, T | 1 |
| Afriansyah, A; Hamid, AR; Mochtar, CA; Umbas, R | 1 |
| Baggstrom, MQ; Baker, S; Crawford, JA; Edelman, MJ; Feliciano, J; Gu, L; Hahn, O; Novotny, P; Socinski, MA; Stinchcombe, TE; Vokes, EE; Wang, XF | 1 |
| Antón-Aparicio, LM; Leon, LA | 1 |
| Venkatesan, P | 1 |
| Aubert, RE; Clore, G; Epstein, RS; Herrera, V; Kourlas, H; La-Beck, NM; McLeod, HL; Walko, CM | 1 |
| Chen, S; Wang, W; Zhao, L; Zhou, J | 1 |
| Huang, S; Jonasch, E; Msaouel, P; Tannir, NM; Zurita, AJ | 1 |
| Iacopetta, D; Longo, P; Parisi, OI; Puoci, F; Saturnino, C; Scrivano, L; Sinicropi, MS | 1 |
| Jezova, M; Melicharkova, K; Michu, E; Mudry, P; Neradil, J; Rohleder, O; Seehofnerova, A; Slaby, O; Soukalova, J; Sterba, J; Veselska, R | 1 |
| Amaravadi, RK; Anglesio, MS; DeVorkin, L; Hattersley, M; Huntsman, DG; Kim, P; Levi, SM; Lum, JJ; Ries, J; Spowart, J; Tinker, AV; Winkler, JD | 1 |
| Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhou, L | 2 |
| Capri, S; Delea, TE; Porta, C | 1 |
| Abe, K; Iwata, T; Kakoki, K; Miyata, Y; Mochizuki, Y; Nagayasu, T; Obatake, M; Sakai, H | 1 |
| Choueiri, TK; Dakhil, S; Feldman, DR; George, DJ; Hahn, O; Halabi, S; Michaelson, MD; Morris, MJ; Olencki, T; Picus, J; Sanford, BL; Small, EJ; Walsh, MK | 1 |
| Gobe, GC; He, Y; Hooper, J; Jeffery, PL; Lourie, R; McGuckin, MA; Morais, C; Ng, CP; Oancea, I; Seim, I; Shah, ET; Sheng, Y; Wong, KY | 1 |
| Abbas, T; Gesy, K; Iqbal, N; Iqbal, U; Lee, C; Lim, J; Suo, A | 1 |
| Affolter, A; Brenner, W; Brieger, J; Heimes, AS; Jensen, A; Mann, WJ; Mayer, A; Samosny, G; Schneider, J; Sommer, K; Stenzinger, A; Weichert, W | 1 |
| Bauer, J; Grimm, D; Magnusson, NE; Randrup Hansen, C; Wehland, M | 1 |
| Chen, J; Chen, M; Feng, ST; Huang, K; Li, ZP; Lin, Y; Luo, Y; Xu, L | 1 |
| Bono, P; Hänninen, E; Joensuu, H; Peltola, KJ; Penttilä, P; Rautiola, J; Ristimäki, A | 1 |
| Adeduntan, R; Antoni, D; Noël, G; Paix, A; Waissi, W | 1 |
| Bakken, RR; Barouch-Bentov, R; Bekerman, E; Brannan, J; De Jonghe, S; Diamond, MS; Dye, JM; Einav, S; Govero, J; Herdewijn, P; Mateo, R; Nagamine, CM; Neveu, G; Pu, SY; Randall, G; Shulla, A; Wang, S; Xiao, F | 1 |
| Albiges, L; Champiat, S; Danlos, FX; Lambotte, O; Le Pavec, J; Marabelle, A; Michot, JM; Pradere, P | 1 |
| Dragomir, A; Edqvist, PH; Enblad, G; Niinivirta, M; Pontén, F; Ullenhag, GJ | 1 |
| Han, Q; Li, P; Tang, M; Zhang, K | 1 |
| Albiges, L; Ficarra, V; Heng, DY; Hsieh, JJ; Larkin, J; Purdue, MP; Schmidinger, M; Signoretti, S; Swanton, C | 1 |
| Cheng, S; Dong, X; Gu, Q; Li, L; Lin, X; Liu, F; Liu, J; Sun, H; Sun, S; Wang, Y; Yao, N; Yao, Z; Zhang, D | 1 |
| Atkins, MB; Choueiri, TK; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Manola, J; Uzzo, RG | 1 |
| Cho, A; Choi, YD; Hwang, SH; Kang, WJ; Rha, SY; Yun, M | 1 |
| Falkowski, S; Jagodzińska-Mucha, P; Klimczak, A; Koseła-Paterczyk, H; Kozak, K; Rogala, P; Rutkowski, P; Świtaj, T; Wągrodzki, M; Ługowska, I | 1 |
| Alivon, M; Boutouyrie, P; De Lepper, AG; Delhaas, T; Giroux, J; Goldwasser, F; Reesink, KD; Spronck, B | 1 |
| Asselineau, J; Bournaud-Salinas, C; Caron, P; Catargi, B; Daste, A; de la Fouchardière, C; Delord, JP; Digue, L; Do Cao, C; Doussau, A; Gimbert, A; Klein, M; Nicolli-Sire, P; Pedenon, D; Picat, MQ; Pouessel, D; Ravaud, A; Rodien, P; Wemeau, JL | 1 |
| Danser, AH; Lankhorst, S; Markó, L; Müller, DN; Rakova, N; Severs, D; Titze, J; van den Meiracker, AH | 1 |
| Kubo, N; Takeuchi, N | 1 |
| Dahlbäck, B; Fritz, HKM; Gustafsson, A | 1 |
| Barrios, CH; Beck, JT; Berkowitz, N; Chen, D; Cheung, F; Cosgriff, T; Flaig, TW; Geoffrois, L; Kim, TM; Knox, JJ; Marker, M; Motzer, RJ; Niolat, J; Page, RD; Patel, P; Pittman, K; Rha, SY; Sabbatini, R; Srimuninnimit, V; Yadav, S | 1 |
| Agarwal, N; Figlin, RA; Hariharan, S; Hutson, TE; Li, CX; Martini, JF; Motzer, RJ; Williams, JA | 1 |
| Kanehira, M; Kato, R; Kato, Y; Matsuura, T; Obara, W; Takata, R | 1 |
| Buda-Nowak, A; Dumnicka, P; Herman, RM; Kucharz, J; Kusnierz-Cabala, B; Kuzniewski, M; Zygulska, AL | 1 |
| Astsaturov, I; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, P; Naito, S; Tulin, A; Uzzo, RG | 1 |
| Cubedo, R; García Del Muro, X; López-Guerrero, JA; Martín-Broto, J; Martínez, V; Poveda, A; Romero, I; Serrano, C; Valverde, C | 1 |
| Alias, Z; Kabir, MZ; Mohamad, SB; Tayyab, S; Tee, WV | 1 |
| Fujisawa, M; Harada, K; Hirai, M; Hirata, S; Ioroi, T; Miyake, H; Nakagawa, T; Watanabe, A; Yamamoto, K; Yano, I | 1 |
| Kim, HS; Lahti, S; Ludwig, JM; Sun, L; Xing, M; Zeng, D | 1 |
| Ambert, V; Cambon-Thomsen, A; Castellano, D; Diekstra, MHM; Eisen, T; Fritsch, A; Garcia Donas, J; Guarch Troyas, R; Guchelaar, HJ; Hartmann, A; Hulsbergen-van de Kaa, C; Jaehde, U; Junker, K; Kiemeney, LALM; Martinez-Cardus, A; Masson, G; Maurits, JSF; Oosterwijk, E; Oosterwijk-Wakka, J; Oskarsdottir, A; Radu, MT; Rafnar, T; Rodriguez-Antona, C; Roessler, M; Ruijtenbeek, R; Stefansson, K; van der Zanden, LFM; Vermeulen, SH; Warren, A; Wessels, L | 1 |
| Ezz El Din, M | 1 |
| Dholakia, S; Fildes, JE; Friend, PJ | 1 |
| Abernethy, DR; Barnett-Griness, O; Gronich, N; Lavi, I; Rennert, G; Saliba, W | 1 |
| Cózar-Olmo, JM; Flores-Martín, JF; Moreno-Jiménez, J; Puche-Sanz, I; Vázquez-Alonso, F | 1 |
| Agalou, A; Argyros, O; Asvos, X; Beis, D; Davos, CH; Fokas, D; Karampelas, T; Papakyriakou, A; Tamvakopoulos, C; Varela, A | 1 |
| Antón, L; Basterretxea, L; Castellano, D; Del Muro, XG; Dueñas, M; Esteban, E; Gallardo, E; Juan-Fita, MJ; Laínez, N; Lambea, J; León, L; Maroto, JP; Martinez-Fernández, M; Méndez-Vidal, MJ; Paramio, JM; Pérez-Valderrama, B; Puente, J; Samaniego, ML; Sanz, J; Suarez, C; Suárez-Paniagua, B; Vázquez, S | 1 |
| Crumbaker, M; Guminski, A; Gurney, H; Pavlakis, N; Sabanathan, D; Wong, S | 1 |
| Apellániz-Ruiz, M; Böhringer, S; Boven, E; Castellano, D; Diekstra, MH; García-Donás, J; Gelderblom, H; Guchelaar, HJ; Mathijssen, RHJ; Rini, BI; Rodríguez-Antona, C; Roldán, JM; Swen, JJ | 1 |
| Dai, B; Liu, R; Ma, Y; Wang, W; Zhan, Y; Zhang, D; Zhang, Y | 1 |
| Gerst, F; Häring, HU; Lutz, SZ; Ullrich, A; Ullrich, S | 1 |
| Chen, XT; Guo, KY; He, YJ; Huang, YX; Li, YH; Song, CY; Wu, BY | 1 |
| Bebawi, E; Hatem, R; Schampaert, E | 1 |
| Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Bonneville-Levard, A; Chauffert, B; Chevreau, C; Cupissol, D; Duffaud, F; Fabbro, M; Feuvret, L; Le Cesne, A; Lebellec, L; Mir, O; Noel, G; Penel, N; Saada-Bouzid, E; Vauleon, E; Vinceneux, A | 1 |
| Chen, X; Cheng, Y; Cui, Z; Jia, S; Liang, S; Shen, T; Si, G; Song, S; Yu, H; Yu, X; Zhang, J; Zhang, X | 1 |
| Antonuzzo, L; Balestri, V; Brugia, M; Costanzo, FD; Giommoni, E; Laffi, A; Lunghi, A; Mazzoni, F; Mela, MM; Petreni, P | 1 |
| Burger, DM; Desar, IME; Kweekel, DM; Lankheet, NAG; Mulder, SF; van der Graaf, WTA; van Erp, NP; van Herpen, CML | 1 |
| Greco, F; Hadjinicolaou, AV; Moldenhauer, I; Nothacker, M; Peinemann, F; Roßmeißl, D; Seliger, B; Unverzagt, S | 1 |
| Cai, W; Chen, Y; Huang, J; Huang, Y; Kong, W; Zhang, J; Zhou, L | 1 |
| Blommestein, HM; De Groot, S; Kiemeney, LALM; Oosterwijk, E; Redekop, WK; Sleijfer, S; Uyl-de Groot, CA | 1 |
| Antón-Aparicio, L; Arranz, JA; Bayona, C; Bolós, MV; Castellano, D; Climent, MA; Espinosa, E; Esteban, E; Fernández Parra, E; Gallardo, E; Gallegos, I; García Donas, J; González Del Alba, A; Grande, E; Llinares, J; Maroto, JP; Méndez, MJ; Samaniego, L | 1 |
| Morimoto-Kamata, R; Yui, S | 1 |
| Belaud-Rotureau, MA; Bensalah, K; Bernhard, JC; Brunot, A; Dugay, F; Dupuis, F; Kammerer-Jacquet, SF; Laguerre, B; Lespagnol, A; Mathieu, R; Medane, S; Mosser, J; Peyronnet, B; Ravaud, A; Rioux-Leclercq, N; Verhoest, G; Yacoub, M | 1 |
| Iwamoto, H; Kugoh, H; Okada, F; Onuma, K; Osaki, M; Sejima, T; Takenaka, A; Yamaguchi, N; Yumioka, T | 1 |
| Bertolaso, P; Cochin, V; Daste, A; Gross-Goupil, M; Molimard, M; Ravaud, A | 1 |
| Agarwal, N; Gill, DM; Vaishampayan, U | 1 |
| Huang, WH; Lee, AR; Lee, CI; Yang, TH | 1 |
| Goto, H; Goto, S; Hamanoue, S; Iwasaki, F; Keino, D; Kitagawa, N; Miyagawa, N; Miyagi, Y; Sarashina, T; Sekiguchi, H; Shiomi, M; Sugiyama, M; Tanaka, Y; Yokosuka, T | 1 |
| Boult, JKR; Reynolds, AR; Robinson, SP; Vasudev, NS | 1 |
| Bergmann, L; Diekstra, MH; Fritsch, A; Gauler, T; Guchelaar, HJ; Hauser, S; Houtsma, D; Jaehde, U; Kanefendt, F; Kiemeney, LA; Kinzig, M; Moes, D; Moritz, B; Mross, K; Oosterwijk, E; Roessler, M; Schindele, D; Sörgel, F; Stelzer, C; Swen, JJ | 1 |
| Ardizzoni, A; Berardi, R; Bersanelli, M; Biasco, E; Buti, S; Cossu Rocca, M; De Giorgi, U; Fornarini, G; Galli, L; Guida, A; Iacovelli, R; Lolli, C; Masini, C; Massari, F; Mosca, A; Nolè, F; Pastorino, A; Pinto, C; Sabbatini, R; Santoni, M; Terrone, C; Tortora, G | 1 |
| Cha, TL; Chang, SY; Huang, SM; Lai, XM; Liu, SY; Sun, GH; Tsai, YT | 1 |
| Balestra, A; Bay, JO; Bernard, MA; Chevreau, C; Culine, S; Droz-Perroteau, C; Ferrière, JM; Fourrier-Réglat, A; Grelaud, A; Gross-Goupil, M; Lamarque, S; Lassalle, R; Moore, N; Moulin, F; Noize, P; Ravaud, A; Robinson, P; Rouyer, M | 1 |
| Cook, G; Goh, V; Kelly-Morland, C; Mallett, S; Montana, G; Nathan, P; Rudman, S | 1 |
| Hisaka, A; Sato, H; Shibata, Y; Shimizu, A; Ueno, K; Uzu, M | 1 |
| Bernhard, JC; Daste, A; François, L; Gross-Goupil, M; Laine, M; Ravaud, A | 1 |
| Andersen, LMK; Gaustad, JV; Rofstad, EK; Simonsen, TG | 1 |
| Bayat, S; Bensalah, K; Bernhard, JC; Brunot, A; Campillo-Gimenez, B; Dupuis, F; Edeline, J; Kammerer-Jacquet, SF; Laguerre, B; Lefort, M; Lespagnol, A; Mathieu, R; Mosser, J; Peyronnet, B; Ravaud, A; Rioux-Leclercq, N; Verhoest, G; Yacoub, M | 1 |
| Al-Shdefat, R; Alalaiwe, A; Alshahrani, SM; Alshetaili, AS; Alsulays, BB; Anwer, MK; Imam, F; Shakeel, F | 1 |
| Kimura, T; Miyamoto, N; Sawada, K; Takase, K; Uesugi, M | 1 |
| Alavi, A; Amiri, A; French, LE; Shear, NH; Wang, JY | 1 |
| Bertani, E; Bonomo, G; Cella, C; Fazio, N; Funicelli, L; Gibelli, B; Grana, C; Lambrescu, I; Martins, D; Pisa, E; Ravizza, D; Ribero, D; Rubino, M; Spada, F; Zerini, D | 1 |
| Amdahl, J; Chandiwana, D; Delea, TE; Diaz, J; Park, J; Sharma, A | 1 |
| Choueiri, TK; Kaymakcalan, MD; Lalani, AA; Lin, X; McKay, RR; Simantov, R | 1 |
| Chen, S; Gu, D; Wu, D; Xie, G; Zhang, L | 1 |
| Balakrishnar, B; Chan, M; Coulter, S; Fox, P; Gebski, V; Gurney, H; Liddle, C; Sabanathan, D; Zhang, A | 1 |
| Antić, M; Djuran, MI; Glišić, BĐ; Janjić, GV; Nikodinovic-Runic, J; Pavic, A; Radenković, S; Rychlewska, U; Savić, ND; Vojnovic, S; Warżajtis, B | 1 |
| Bao, L; Cao, Q; Chen, K; Chen, X; Gao, Y; Hu, W; Li, X; Liu, L; Qu, Y; Ru, Z; Ruan, H; Song, Z; Tong, J; Wang, K; Xiao, H; Xiao, W; Xiong, Z; Xu, G; Yang, H; Yuan, C; Zhang, X | 1 |
| Dong, Z; Gao, J; Gong, J; Li, J; Li, Y; Shen, L | 1 |
| Broder, MS; Chang, E; Neary, MP; Reddy, SR | 1 |
| Fukasawa, S; Hara, H; Horie, S; Kanao, K; Kimura, G; Kondo, T; Mizuno, R; Nakazawa, H; Oya, M; Shoji, S; Tanabe, K; Ueda, T | 1 |
| Chen, J; Chen, M; Feng, S; Jin, K; Li, J; Shao, C; Tan, H; Wang, W; Wang, Y; Xue, L; Yang, Q; Yu, X; Zhang, P | 1 |
| Bortlicek, Z; Buchler, T; Chloupková, R; Dusek, L; Fiala, O; Finek, J; Hornova, J; Kiss, I; Kopeckova, K; Kopecky, J; Lakomy, R; Melichar, B; Poprach, A; Slaby, O; Studentova, H; Svoboda, M; Vyzula, R; Zemanova, M | 1 |
| Bill, R; Blank, A; Krebs, P; Marinoni, I; Normand, L; Pantasis, S; Perren, A; Tschan, MP; Wiedmer, T | 1 |
| Fujii, Y; Ishioka, J; Kawamura, N; Kihara, K; Matsuoka, Y; Okuno, T; Saito, K; Uehara, S; Yamamoto, S; Yasuda, Y; Yokoyama, M; Yonese, J; Yuasa, T | 1 |
| Dalhaug, A; Nieder, C; Norum, J; Pawinski, A; Syed, MA | 1 |
| Durand-Zaleski, I; Fleury, L; Maroun, R; Maunoury, F; Nachbaur, G; Vanhille, JL | 1 |
| Inatsu, H; Kitamura, K; Nakashima, K | 1 |
| Che, Y; Gao, Q; Hou, B; Jiang, X; Liu, L; Ren, F; Wang, Y; Xu, S; Yan, S | 1 |
| Junkunlo, K; Noonin, C; Söderhäll, I; Söderhäll, K | 1 |
| Cooper, S; Hussain, A; Maddock, H; Mee, C; Sandhu, H | 1 |
| Balvay, D; Bennana, E; Dhaun, N; Lager, F; Moorhouse, R; Renault, G; Sourdon, J; Tavitian, B; Tharaux, PL; Viel, T | 1 |
| Goto, K; Hayashi, T; Inoue, S; Kitadai, Y; Kitano, H; Matsubara, A; Sentani, K; Shinmei, S; Teishima, J; Yasui, W; Yuge, R | 1 |
| Ambrosetti, D; Auberger, P; Bikfalvi, A; Borchiellini, D; Cassuto, O; Chamorey, E; Claren, A; Cooley, LS; Dufies, M; Escudier, B; Ferrero, JM; Frangeul, A; Gal, J; Giuliano, S; Grépin, R; Guyot, M; Jacquel, A; Milano, G; Ndiaye, PD; Negrier, S; Pagès, G; Parola, J; Porta, C; Rioux-Leclercq, N; Schiappa, R; Viotti, J | 1 |
| Ishikawa, S; Katagiri, A; Kazama, A; Mizusawa, T | 1 |
| Akslen, LA; Beisland, C; Bostad, L; Haug, Å; Heinrich, D; Hjelle, KM; Pilskog, M; Straume, O | 1 |
| Al Anazi, FE; Al-Atawi, FO; Alanazi, IO; Alsaad, AM; Alshamsan, A; Belali, OM; Korashy, HM; Maayah, ZH | 1 |
| Bozkurt, G; Cakmak, H; Ergin, K; Gokmen, E; Kocaturk, T | 1 |
| Akurati, S; Donelson, RB; Golzarian, J; Rostamzadeh, P; Weng, L | 1 |
| Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhong, H; Zhou, L | 1 |
| Bersanelli, M; Buti, S; Donini, M; Gattara, A; Leonardi, F; Passalacqua, R | 1 |
| Chu, C; Cui, X; Duan, X; Fu, Q; Gao, Y; Pan, X; Sun, Y; Wang, Y; Yang, Q | 1 |
| Azarpira, N; Heli, H; Karimian, K; Nazari-Vanani, R; Sattarahmady, N | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Chervoneva, I; Mastrangelo, MJ; Orloff, M; Sato, R; Sato, T; Shields, CL; Shields, JA; Valsecchi, ME | 1 |
| Bersanelli, M; Buti, S; DiPaola, RS; Haas, NB; Manola, J; Puligandla, M; Taguchi, S | 1 |
| Hirasaka, K; Nagano, H; Nikawa, T; Ohno, A; Teshima-Kondo, S; Tomida, C; Uchida, T; Yamagishi, N | 2 |
| Alì, G; Antonelli, A; Basolo, F; Bocci, G; Di Desidero, T; Ferrari, SM; Fioravanti, A; Fontanini, G; Francia, G; Orlandi, P | 1 |
| Bjarnason, GA; Raphael, J; Thawer, A | 1 |
| Breza, J; Carteni, G; Casey, M; Chang, YH; Donskov, F; Escudier, B; George, DJ; Gerletti, P; Laguerre, B; Lechuga, M; Lin, X; Magheli, A; Motzer, RJ; Pandha, HS; Pantuck, AJ; Patard, JJ; Patel, A; Ravaud, A; Serfass, L; Staehler, M; Tomczak, P | 1 |
| Adelaiye-Ogala, R; Arisa, S; Arrington, J; Buck, M; Budka, J; Chintala, S; Ciamporcero, E; Damayanti, NP; Draetta, GF; Elbanna, M; Ferris, M; Hancock, B; Hollenhorst, P; Hsu, CC; Irudayaraj, J; Keilhack, H; Kota, J; McCarthy, BP; Miles, KM; Orillion, A; Persohn, SA; Pettazzoni, P; Pili, R; Radovich, M; Seshadri, M; Shen, L; Tao, WA; Territo, PR; Zang, Y | 1 |
| Paeschke, N; Wittstock, M | 1 |
| Yousef, AJA | 1 |
| Cárcano, FM; da Silva Oliveira, RJ; de Lima, MA; Morini Matushita, MA; Reis, RM; Ribeiro, GG; Scapulatempo-Neto, C; Viana, CR; Zucca, LE | 1 |
| Acikgoz, E; Aktug, H; Demir, K; Duzagac, F; Guven, U; Oktem, G; Oltulu, F; Yavasoglu, A; Yigitturk, G | 1 |
| Casuscelli, J; Hsieh, JJ | 1 |
| Angus, SP; Beak, JY; Chen, X; Hicks, ST; Huang, W; Jensen, BC; Johnson, GL; Parry, TL; Sciaky, N; Stuhlmiller, TJ; Willis, MS; Zawistowski, JS | 1 |
| Ariad, S; Douvdevani, A; Dresler, H; Keizman, D; Mermershtain, W; Neulander, EZ; Riff, R; Rouvinov, K; Shani-Shrem, N | 1 |
| Bao, L; Chen, K; Gao, Y; Hu, W; Liu, L; Lou, N; Qu, Y; Ru, Z; Ruan, H; Tong, J; Xiao, H; Xiao, W; Xiong, Z; Xu, G; Yang, H; Yuan, C; Zhang, X; Zhou, Y | 1 |
| He, HL; Yao, WX | 1 |
| Agarwal, N; Ghate, SR; Li, N; Meiselbach, MK; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML | 2 |
| Arang, N; Bello, T; Dudgeon, DR; Glennon, EK; Gujral, TS; Kain, HS; Kaushansky, A; Walter, ENF | 1 |
| Albersen, M; Beuselinck, B; Couchy, G; de Reynies, A; Job, S; Laguerre, B; Lerut, E; Meiller, C; Méjean, A; Oudard, S; Patard, JJ; Rioux-Leclercq, N; Schöffski, P; Verbiest, A; Verkarre, V; Zucman-Rossi, J | 1 |
| de Rochefort, L; Dubuisson, RM; Ingels, A; Lassau, N; Leguerney, I; Opolon, P; Pitre-Champagnat, S; Poirier-Quinot, M; Robert, P; Robin, S; Violas, X | 1 |
| Higuchi, M; Hikasa, Y; Leong, ZP; Okida, A; Yamano, Y | 1 |
| Benson, C; Chou, AJ; Magnan, H; Rutkowski, P | 1 |
| Duplomb, S; Errihani, H; Layachi, M; Raiss, H; Tartas, S | 1 |
| Han, JJ; Kim, SY; Lee, YS; Maeng, CH | 1 |
| Fukuda, H; Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Airavaara, M; Alitalo, K; Antila, S; Aspelund, A; Chilov, D; Eichmann, A; Fang, S; Karaman, S; Koppinen, T; Li, Z; Mathivet, T; Nurmi, H; Park, JH; Saarma, M; Thomas, JL; Voutilainen, MH | 1 |
| Avniel-Polak, S; Gross, DJ; Grozinsky-Glasberg, S; Uri, I | 1 |
| Es'haghi, Z; Hooshmand, S | 1 |
| Kaur, B; Kaur, J; Singh, P | 1 |
| Abel Mahedi Mohamed, H; Nielsen, CEN; Schiodt, M | 1 |
| Cooper, SL; Hussain, A; Maddock, H; Mee, C; Sandhu, H | 1 |
| 'Aho, T; Armitage, JN; Eisen, T; Fife, K; Klatte, T; Matakidou, A; Riddick, AC; Sachdeva, M; Stewart, GD; Welsh, SJ | 1 |
| Cao, P; Jiang, XJ; Xi, ZJ | 1 |
| DU, YQ; Hu, FZ; Liu, CL; Qin, CP; Sheng, ZZ; Xu, T; Yin, HQ; Zhao, YH | 1 |
| Escobar, MA; McClellan, JM; Thomas, W | 1 |
| Buchler, T; Chloupkova, R; Dusek, L; Fiala, O; Finek, J; Kiss, I; Kopeckova, K; Kopecký, J; Lakomy, R; Melichar, B; Petrakova, K; Poprach, A; Slaby, O; Studentova, H; Zemanova, M | 1 |
| Ambrus, A; Horváth, P; Hubert, Á; Kiss, E; Mirzahosseini, A; Őrfi, L | 1 |
| Cheng, IG; Hespel, L; Kato, K; Kobayashi, M; Lee, E; Matsunaga, YT; Nakajima, H; Pauty, J; Soncin, F; Takahashi, H; Usuba, R; Yger, F | 1 |
| Laguna, MP | 1 |
| Jiang, T; Piao, D; Wang, W; Zhang, Z | 1 |
| Filip-Psurska, B; Kutner, A; Maj, E; Milczarek, M; Psurski, M; Wietrzyk, J | 1 |
| Antonuzzo, L; Badalamenti, G; Berardi, R; Bongiovanni, A; Brighi, N; Brizzi, MP; Campana, D; Carnaghi, C; Catena, L; Delle Fave, G; Faggiano, A; Falconi, M; Fazio, N; Femia, D; Gelsomino, F; Gritti, S; Ibrahim, T; Marconcini, R; Panzuto, F; Partelli, S; Pusceddu, S; Ricci, S; Rinzivillo, M; Schinzari, G; Spada, F; Spallanzani, A | 1 |
| Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Saito, Y; Takahashi, T; Takiguchi, S; Tanaka, K; Yamasaki, M | 1 |
| Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Wang, Z; Xiong, Y; Xu, J; Yang, Y | 1 |
| Chen, X; Jia, XK; Kuang, YH; Liao, LQ; Liu, YK; Lu, Y; Qin, QS; Wu, LS; Zhou, XC; Zhu, W | 1 |
| Atri, M; Bailey, C; Bjarnason, GA; Burns, PN; Hudson, JM; Kiss, A; Milot, L; Stanisz, G; Williams, R | 1 |
| Asai, A; Matsunaga, N; Matsuo, T; Mitsunari, K; Miyata, Y; Mochizuki, Y; Ohba, K; Sakai, H; Yasuda, T | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Kano, K; Maezawa, Y; Masuda, M; Ogata, T; Oshima, T; Rino, Y; Sato, T; Yamada, T; Yoshikawa, T; Yukawa, N | 1 |
| Pandey, M; Ramasamy, M; Shukla, M | 1 |
| Drakaki, A; Faiena, I; Pantuck, AJ; Salmasi, A | 1 |
| Abdel-Rahman, O | 1 |
| Abuohashish, H; Al-Jandan, B; Al-Mahalawy, H; Marei, HF; Zakaria, O | 1 |
| Golinelli, G; Pia, F; Rosa, MS; Toso, A; Valletti, PA | 1 |
| Abe, T; Hashimoto, R; Igarashi, H; Inoue, K; Ito, T; Karashima, T; Kawabe, K; Miki, M; Ogawa, Y; Ohishi, Y; Yamasaki, I | 1 |
| Al-Batran, SE; Galle, PR; Gehrke, N; Goepfert, K; Grimminger, P; Hegewisch-Becker, S; Maderer, A; Möhler, M; Nagel, M; Schattenberg, JM; Schulz, J; Thomaidis, T; Thuss-Patience, PC | 1 |
| Cserháti, A; Kahán, Z; Kószó, R; Maráz, A; Révész, J; Szilágyi, É; Uhercsák, G; Varga, L; Varga, Z | 1 |
| Debbagh, A; Errihani, H; Ichou, M; Mahi, M; Sbitti, Y; Slimani, K | 1 |
| Carlisle, B; Federico, CA; Kimmelman, J | 1 |
| Arén Frontera, O; Barrios, CH; Barthélémy, P; Bracarda, S; Castellano, D; Chen, AC; Choueiri, TK; Doan, J; Donskov, F; Escudier, B; George, S; Grimm, MO; Gurney, H; Hammers, HJ; Hawkins, R; Kollmannsberger, CK; McDermott, DF; McHenry, MB; Mekan, S; Melichar, B; Motzer, RJ; Neiman, V; Plimack, ER; Porta, C; Powles, T; Ravaud, A; Rini, BI; Salman, P; Sharma, P; Tannir, NM; Tomita, Y; Wind-Rotolo, M | 1 |
| Estilo, CL; Huryn, JM; Liang, STY; Owosho, AA; Sax, AZ; Wu, K; Yom, SK | 1 |
| Bakouny, Z; Eid, R; Haddad, FG; Kattan, J; Kourie, HR | 1 |
| Akahoshi, K; Akashi, T; Ban, D; Kudo, A; Mitsunori, Y; Mizuno, Y; Ogawa, K; Ogura, T; Ono, H; Tanabe, M; Tanaka, S; Tateishi, U | 1 |
| Fujiwara, T; Hatakeyama, H; Hisaka, A; Sato, H; Terui, A | 1 |
| Ishigame, T; Kase, K; Kenjo, A; Kimura, T; Kofunato, Y; Marubashi, S; Muto, M; Okada, R; Sato, N; Shimura, T; Watanabe, J | 1 |
| Cao, YW; Dong, Z; Guo, L; Kang, EH; Liu, Y; Niu, HT; Wang, YH; Zhang, W | 1 |
| Iizuka, J; Ishihara, H; Iwamoto, K; Kondo, T; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Horie, S; Kanayama, M; Nagata, M; Nagaya, N | 1 |
| Buchler, T; Fiala, O; Juracek, J; Kopecky, J; Kovacova, J; Poprach, A; Slaby, O; Svoboda, M | 1 |
| Berrino, L; De Angelis, A; Ferraro, E; Gorini, S; Malara, N; Rosano, G | 1 |
| Aki, R; Ito, T; Matsushita, Y; Miyake, H; Motoyama, D; Otsuka, A; Sugiyama, T; Tamura, K | 1 |
| Iizuka, J; Ishihara, H; Iwamoto, K; Kobayashi, H; Kondo, T; Omae, K; Tachibana, H; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Arai, Y; Ito, A; Kawasaki, Y; Kikuchi, M; Mano, N; Mitsuzuka, K; Noda, A; Saito, H; Sato, Y; Suzuka, M; Takasaki, S; Tanaka, M; Yamaguchi, H; Yamashita, S | 1 |
| Cai, W; Chen, YH; Dong, BJ; Huang, JW; Huang, YR; Kong, W; Li, MY; Xue, W; Yuan, YC; Zhang, J; Zhou, LX | 1 |
| Aitchison, M; Albiges, L; Beauval, JB; Beisland, C; Bensalah, K; Bernhard, JC; Chevreau, C; Colas, S; Cormier, L; Escudier, B; Geoffrois, L; Gravis, G; Gross-Goupil, M; Guy, L; Hubert, J; Laguerre, B; Lang, H; Lebret, T; Lechevallier, E; Linassier, C; Méjean, A; Oudard, S; Patard, JJ; Ravaud, A; Rolland, F; Theodore, C; Thezenas, S; Thiery-Vuillemin, A; Timsit, MO | 1 |
| Andersen, LMK; Gaustad, JV; Hauge, A; Rofstad, EK; Simonsen, TG; Wegner, CS | 1 |
| Brady, W; Brown, J; Chan, JK; Gershenson, DM; Kim, JH; Monk, BJ; Rose, PG; Secord, AA; Shahin, MS; Walker, JL | 1 |
| Chen, LJ; Li, BT; Mai, HX; Mei, GH; Tang, YY; Xu, XJ; Zhang, B; Zhao, FL | 1 |
| Danika, C; Efstathia, G; El Mubarak, MA; Kalofonos, HP; Konstantinos, SE; Leontari, I; Shaikh, AK; Sivolapenko, GB; Tzakos, AG; Vrettos, EI | 1 |
| Karimi, MH; Mahdavinia, GR; Massoumi, B | 1 |
| Aschelter, AM; Capriotti, G; Cerquetti, L; Lardo, P; Marchetti, P; Matarazzo, I; Nardone, MR; Petrangeli, E; Schiavi, F; Stigliano, A; Toscano, V | 1 |
| Chen, N; Liu, J; Shen, P; Yao, J; Zeng, H; Zhang, X | 1 |
| Gong, JF; Ji, JF; Li, J; Li, XT; Li, ZY; Shen, L; Sun, YS; Tang, L | 1 |
| Agostini, M; Buzzo, M; Crotti, S; D'Aronco, S; Giodini, L; Marangon, E; Posocco, B; Toffoli, G; Traldi, P | 1 |
| Banskota, S; Chaudhary, P; Dahal, S; Gautam, J; Jeong, BS; Kang, HE; Kim, DG; Kim, JA; Lee, IH; Nam, TG | 1 |
| Adashek, JJ; Bergerot, CD; Bergerot, PG; Dizman, N; Hsu, J; Pal, SK | 1 |
| Fuss, H; Jung, S; Lademann, J | 1 |
| Banerjee, D; Bhowmick, R; Manir, KS; Roy, C | 1 |
| Bajic, P; Clark, JI; Flanigan, RC; Joyce, CJ | 1 |
| Kitahara, T; Kodama, Y; Matsunaga, N; Sasaki, H; Sato, K; Yamada, M | 1 |
| Akiyama, N; Kogo, M; Kurihara, T; Murata, T; Nagatani, A; Naito, Y; Ogawa, Y; Sakamaki, H; Sasaki, H; Sasaki, T; Sunaga, T; Tomura, K; Usuda, M | 1 |
| Bargo, D; Bent-Ennakhil, N; Blackburn, S; Boegemann, M; Hubbe, M; Thomaidou, D; Wood, R | 1 |
| Escudier, B; Méjean, A; Thezenas, S | 1 |
| Kondoh, CN; Miura, Y; Yamanaka, T | 1 |
| Bex, A; Haanen, J; Powles, T | 1 |
| Flanigan, RC | 1 |
| Demkow, T; Demkow, U; Dumnicka, P; Giza, A; Kucharz, J; Kusnierz-Cabala, B; Wiechno, P | 1 |
| Brzozowska, M; Czech, M; Potemski, P; Połowinczak-Przybyłek, J; Śliwczyński, A; Szafraniec-Buryło, S; Wierzba, W | 1 |
| Bartnik, E; Brodziak, A; Czarnecka, AM; Dendek, C; Korniluk, J; Labochka, D; Sobczuk, P; Szczylik, C | 1 |
| Albiges, L; Bersanelli, M; Buti, S; Escudier, B; Fischer, R; Houede, N; Iacovelli, R; Laguerre, B; Lheureux, S; Negrier, S; Oudard, S; Porta, C; Procopio, G; Ravaud, A | 1 |
| Del Bene, G; Faggiano, A; Gianfrilli, D; Giannetta, E; Lauretta, R; Lenzi, A; Longo, F; Pozza, C; Rizza, L; Sbardella, E; Tenuta, M | 1 |
| Cao, DL; Huo, DZ; Qu, YY; Shi, GH; Wang, J; Xu, WH; Ye, DW; Yin, GC; Zhang, HL | 1 |
| Buzzo, M; Gagno, S; Giodini, L; Guardascione, M; Iacuzzi, V; Marangon, E; Poetto, AS; Posocco, B; Toffoli, G; Zanchetta, M | 1 |
| DuBois, SG; Khosravan, R; Wetmore, C; Yu, Y | 1 |
| Aljubran, A; Alzahrani, A; Badran, A; Bazarbashi, S; Eldali, A; Elshenawy, MA; Shahin, A | 1 |
| Desar, IME; Krens, SD; Mulder, SF; Smilde, T; van der Graaf, WTA; van Erp, NP; van Herpen, CML; Westerdijk, K | 1 |
| Gomes, A; Mankoski, R; Miller, A; Nellesen, D; Norregaard, C; Proudman, D; Sullivan, E | 1 |
| Hayashi, T; Ijiri, Y; Imano, H; Kato, R | 1 |
| Das, A; Ganjoo, A; Ganjoo, S | 1 |
| Hatakeyama, S; Ohyama, C | 1 |
| DuBois, SG; Khosravan, R; Verschuur, AC; Wang, E; Wetmore, C | 1 |
| Balasubramanian, A; Bolton, D; Perera, M; Qu, L; Weickhardt, A | 1 |
| Antonuzzo, A; Artale, S; Barzaghi, S; Bertù, L; Bolzacchini, E; Bregni, M; Danova, M; Dentali, F; Galli, L; Giordano, M; Nigro, O; Pinotti, G; Torchio, M | 1 |
| Bendová, B; Büchler, T; Fiala, O; Filipovský, J; Fínek, J; Hora, M; Ostašov, P; Rozsypalová, A; Šorejs, O; Šustr, J; Trávníček, I | 1 |
| Armitage, JN; Barrett, T; Connolly, S; Eisen, TGQ; Fife, KM; Gallagher, FA; Ingleson, V; Machin, AJ; Matakidou, A; Mullin, J; Priest, AN; Qian, W; Riddick, ACP; Stewart, GD; Thompson, N; Ursprung, S; Warren, A; Welsh, SJ; Zaccagna, F | 1 |
| Deniz, OC; Erdamar, S; Gündoğdu, Y; Köksal, İ; Saka, D; Şişman, G | 1 |
| Matsuda, T; Matsuo, T; Mitsunari, K; Miyata, Y; Mukae, Y; Nakamura, Y; Ohba, K; Sakai, H | 1 |
| Brahm, CG; de Goeij-de Haas, R; De Witt Hamer, PC; Dekker, H; Henneman, AA; Honeywell, RJ; Hovinga, KE; Jiménez, CR; Knol, JC; Labots, M; Peters, GJ; Pham, TV; Piersma, SR; van Linde, ME; Vandertop, WP; Verheul, HMW | 1 |
| Carbasse, C; Jacot, W; Leenhardt, F; Perrier, C; Pinguet, F; Viala, M | 1 |
| Danser, AHJ; Dechend, R; Dörr, A; Flörcken, A; Garrelds, IM; Kuehne, T; Linz, P; Markó, L; Müller, DN; van den Meiracker, AH | 1 |
| Gandhi, KA; Gota, V; Gurjar, M; Joshi, A; Mehta, P; Nookala, M; Noronha, V; Patil, A; Prabhash, K; Rane, P; Sharma, J | 1 |
| Fallah-Rad, N; Fleshner, L; Fleshner, N; Hersey, K; Nguyen, S; O'Halloran, S; Tiwari, R; Wise, J | 1 |
| Aarts, MJB; Brouns, SLN; de Bruijn, P; Heemskerk, JWM; Koolen, SLW; Kuijpers, MJE; Peters, NAJB; Sabrkhany, S; Swieringa, F; Tullemans, BME; van den Berkmortel, FWPJ | 1 |
| Bond, J; Ellison-Hughes, GM; Lewis-McDougall, FC; Ruchaya, P; Smith, AJ; Walmsley, R; Wright, KE | 1 |
| Kocak, I; Kocakova, I; Rihacek, M; Rihackova, E; Selingerova, I; Sterba, J; Valik, D | 1 |
| Fu, Q; Jiang, X; Jing, Y; Peng, H; Rexiti, K; Tao, S; Wei, X; Xiong, F | 1 |
| Ben Kridis, W; Charfeddine, S; Khanfir, A; Masmoudi, S | 1 |
| Antonarelli, G; Catania, C; Conforti, F; Corti, C; Curigliano, G; De Pas, T; Lo Russo, G; Manglaviti, S; Perrino, M; Salvini, P; Varano, GM; Zucali, PA | 1 |
| Amaro, F; Bastos, ML; Carvalho, M; Guedes de Pinho, P; Pinto, J; Pisoeiro, C; Valente, MJ | 1 |
| Afonso, J; Afonso, R; Alonso-Gordoa, T; Anguera, G; Asensio, Ú; Campayo, M; Casinello, J; Cassinello, NV; Climent, MA; de España, CG; de Velasco, G; Fernández-Calvo, O; Fernández-Parra, EM; Gallardo, E; García Del Muro, X; García Sánchez, L; García-Carbonero, I; González, IC; López-Martín, A; Méndez-Vidal, MJ; Núñez, NF; Ortega, EM; Pinto, Á; Polo, SH; Reig, O; Rodríguez-Vida, A; Rosero, A; Sánchez, ÁR; Santasusana, MD; Torregrosa, D; Valiente, PG | 1 |
| Hirota, S; Ishikawa, T; Kanda, T; Matsumoto, Y; Saijo, Y; Sasaki, K | 1 |
| Aljubran, A; Alzahrani, A; Alzannan, N; Badran, A; Bazarbashi, S; Elhassan, T; Elshenawy, M; Gad, AM; Maraiki, F | 1 |
| Ashby, CR; Chen, ZS; Dai, SJ; He, Q; He, WF; Jin, J; Li, SY; Wang, JQ; Xie, Y; Zhang, JS | 1 |
| Carducci, MA | 1 |
| Hu, K; Shu, M; Wang, X; Zhang, H | 1 |
| Ades, S; Ernstoff, MS; Gui, J; Highhouse, BJ; Labrie, BM; Lewis, LD; Ness, DB; Pooler, DB; Zhou, J | 1 |
534 review(s) available for pyrroles and su 11248
| Article | Year |
|---|---|
New therapeutic strategies for soft tissue sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Docetaxel; Epothilones; Guanidines; Humans; Indoles; Isoquinolines; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrroles; Sarcoma; Sirolimus; Sunitinib; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2003 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives.
Topics: Animals; Anti-HIV Agents; Drug Delivery Systems; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2004 |
Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Female; Humans; Indoles; Lung Neoplasms; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Phthalazines; Prognosis; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sunitinib; Treatment Outcome | 2004 |
Su-11248 Sugen.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drugs, Investigational; Humans; Indoles; Pyrroles; Sunitinib | 2004 |
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2005 |
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2005 |
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2005 |
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
Topics: Benzenesulfonates; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2005 |
Novel agents for the treatment of advanced kidney cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Epothilones; Gefitinib; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2004 |
SU11248 and AG013736: current data and future trials in renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2005 |
[Possibility of targeting FLT3 kinase for the treatment of leukemia].
Topics: Animals; Antibodies, Monoclonal; Benzoquinones; Carbazoles; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Lactams, Macrocyclic; Leukemia; Mutation; Piperazines; Pyrroles; Quinazolines; Quinones; Rifabutin; Staurosporine; Sunitinib | 2005 |
Targeted therapy for metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
[Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Cycle; Clinical Trials as Topic; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Protein Biosynthesis; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
[Progress in therapeutic strategy for renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Female; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Minimally Invasive Surgical Procedures; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2006 |
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2006 |
Sunitinib malate for the treatment of solid tumours: a review of current clinical data.
Topics: Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib | 2006 |
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
[Molecular-targeted agents in breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Indoles; Lapatinib; Middle Aged; Paclitaxel; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab | 2006 |
Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Humans; In Vitro Techniques; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; United States; United States Food and Drug Administration | 2006 |
Molecular targeting therapy for renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2006 |
Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2006 |
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2006 |
Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Niacinamide; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Education as Topic; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib | 2006 |
[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Female; Gastrointestinal Diseases; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Gastrointestinal stromal tumors: imatinib and beyond.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2006 |
Molecular biology of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Exons; Humans; Indoles; Kidney Neoplasms; Molecular Biology; Mutation; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2006 |
New weapons to snuff out kidney cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2006 |
The role of angiogenesis inhibition in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Multicenter Studies as Topic; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
Targeted therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Case Management; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Forecasting; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2006 |
Targeting von Hippel-Lindau pathway in renal cell carcinoma.
Topics: Benzenesulfonates; Biomedical Research; Carcinoma, Renal Cell; Enzyme Inhibitors; Everolimus; Humans; Indoles; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
KIT mutations in GIST.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Models, Biological; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Sunitinib | 2007 |
Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2006 |
Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cytokines; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Phenotype; Platelet-Derived Growth Factor; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2007 |
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sunitinib: from rational design to clinical efficacy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Design; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Leukemia, Myeloid, Acute; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2007 |
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Renal Cell; Drug Approval; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; United States; United States Food and Drug Administration | 2007 |
Emerging drugs for the treatment of soft tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Dacarbazine; Doxorubicin; Gastrointestinal Stromal Tumors; Humans; Ifosfamide; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sarcoma; Sunitinib | 2007 |
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles | 2006 |
PDGF receptors as targets in tumor treatment.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Extracellular Fluid; Fibroblasts; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Pressure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sunitinib; Translocation, Genetic | 2007 |
Recent advances in therapy for gastrointestinal stromal tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2007 |
[Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Drug Approval; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
The role of KIT in the management of patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2007 |
Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Leiomyomatosis; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; von Hippel-Lindau Disease | 2007 |
Combination of target agents: challenges and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Drug Resistance, Neoplasm; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2007 |
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab | 2007 |
Angiogenesis in cancer: molecular mechanisms, clinical impact.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Indoles; Microcirculation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Design of clinical trials of radiation combined with antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Combined Modality Therapy; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiation Dosage; raf Kinases; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Biology; Piperazines; Positron-Emission Tomography; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib | 2007 |
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Thrombosis; Vascular Endothelial Growth Factor A; Wound Healing | 2007 |
Second line therapies for the treatment of gastrointestinal stromal tumor.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2007 |
Pharmacologic application of sunitinib malate in the management of gastrointestinal stromal tumors.
Topics: Angiogenesis Inhibitors; Gastrointestinal Stromal Tumors; Humans; Indoles; Patient Education as Topic; Pyrroles; Sunitinib | 2007 |
Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Drug Administration Schedule; fms-Like Tyrosine Kinase 3; Gastrointestinal Stromal Tumors; Genotype; Humans; Indoles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2007 |
Sunitinib: bridging present and future cancer treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Forecasting; Humans; Indoles; Proto-Oncogene Mas; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2007 |
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
The effect of recent drug approvals on translational research and drug development.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomedical Research; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Approval; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; United States; United States Food and Drug Administration | 2007 |
C-kit, GIST, and imatinib.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2007 |
The role of targeted therapy in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2007 |
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
Topics: Advisory Committees; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Piperazines; Practice Guidelines as Topic; Prognosis; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed; United States | 2007 |
New challenges in kidney cancer therapy: sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Forecasting; Humans; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome | 2007 |
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2007 |
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Growth Factor; Sorafenib; Sunitinib | 2007 |
[Effect of angiogenesis inhibitors on renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Molecular basis for sunitinib efficacy and future clinical development.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; Humans; Indoles; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Angiogenesis as targeted breast cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
[Sunitinib and hypothyroidism].
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Humans; Hypothyroidism; Indoles; Pyrroles; Sunitinib | 2007 |
Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Endothelial Cells; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2007 |
Advances in the treatment of gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2007 |
Treatment options in renal cell carcinoma: past, present and future.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cytokines; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2007 |
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2007 |
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lactation; Lung Neoplasms; Neuroendocrine Tumors; Pregnancy; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
[Angiogenesis and renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2007 |
[Cutaneous side effects of antiangiogenic agents].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Pyridines; Pyrroles; Skin Diseases; Sorafenib; Sunitinib | 2007 |
Managing side effects of angiogenesis inhibitors in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2007 |
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2007 |
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2008 |
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2007 |
[Angiogenesis targeting in renal carcinomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2007 |
New developments in multitargeted therapy for patients with solid tumours.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2008 |
[Renal cell carcinoma and antiangiogenic therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Molecular pathobiology of gastrointestinal stromal sarcomas.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sarcoma; Sunitinib | 2008 |
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2008 |
Sunitinib in the management of gastrointestinal stromal tumours (GISTs).
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
Topics: Acneiform Eruptions; Antineoplastic Agents; Benzenesulfonates; Erythema; Esophagitis; Exanthema; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
Guillain-Barré syndrome after treatment with sunitinib malate?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Guillain-Barre Syndrome; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2008 |
[Molecular targeted therapy for renal cell carcinoma].
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indoles; Interferon-beta; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Liposomes; Mitochondrial Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
Topics: Angiogenesis Inhibitors; Drug Eruptions; Humans; Incidence; Indoles; Protein-Tyrosine Kinases; Pyrroles; Quality of Life; Sunitinib | 2008 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
Sunitinib therapy in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
[Cutaneous side effects of sorafenib and sunitinib].
Topics: Acrodermatitis; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Hair Diseases; Humans; Indoles; Nail Diseases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib; Sunitinib | 2008 |
[Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2008 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dioxoles; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Niacinamide; Oligonucleotides; Phthalazines; Piperazines; Proto-Oncogene Mas; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Tetrahydroisoquinolines; Trabectedin | 2006 |
Treatment options for metastatic renal cell carcinoma: a review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Graft vs Host Disease; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
New therapeutic options in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
[Lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2008 |
[GIST].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Targeted therapy in advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Management of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Esophageal Neoplasms; Esophagectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Pyrroles; Risk Assessment; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
The current status and evolving role of sunitinib in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Prognosis; Pyrroles; Risk Assessment; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
Developments in targeted therapy of advanced gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2008 |
Molecularly targeted therapy in breast cancer: the new generation.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Design; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Estrogen; Sunitinib | 2008 |
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials as Topic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
[Value of targeted therapies for renal cell cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2008 |
Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Diffusion of Innovation; Humans; Incidence; Indoles; Interferon-alpha; Interleukin-2; Molecular Biology; Neoplasm Staging; Nephrectomy; Niacinamide; Oncology Nursing; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Rare Diseases; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
An update on the medical therapy of advanced metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Severity of Illness Index; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Targeted therapy in renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
New therapies in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
[Molecular basis of targeted therapy in metastatic renal cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2008 |
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Hypertension; Indoles; Kidney Diseases; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2009 |
Novel approaches to imatinib- and sunitinib-resistant GIST.
Topics: Angiogenesis Inhibitors; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Benzenesulfonates; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2008 |
Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Congresses as Topic; Humans; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2008 |
[Molecular targeted therapy for renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Gene Targeting; Humans; Indoles; Kidney Neoplasms; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2008 |
Exploring the role of novel agents in the treatment of renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
Novel drugs for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2008 |
Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recombinant Proteins; Sirolimus; Sorafenib; Sunitinib | 2008 |
Vascular complications of selected cancer therapies.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cisplatin; Fluorouracil; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Thrombosis; Vascular Diseases | 2008 |
Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome | 2008 |
[Gastrointestinal stromal tumors. An update].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Systemic therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cytotoxins; Disease-Free Survival; Drug Therapy, Combination; Everolimus; Humans; Immunosuppressive Agents; Immunotherapy; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Stem Cell Transplantation; Sunitinib; TOR Serine-Threonine Kinases; Transplantation, Homologous | 2008 |
Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib | 2008 |
Pre-surgical targeted molecular therapy in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2009 |
Molecular therapy for the treatment of hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Early development of sunitinib in hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Indoles; Liver Neoplasms; Pyrroles; Sunitinib | 2009 |
Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2009 |
Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib | 2009 |
Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Hypoxia; Enzyme Inhibitors; Humans; Hypoxia-Inducible Factor 1; Indoles; Intercellular Signaling Peptides and Proteins; Mustard Compounds; Neoplasms; Neovascularization, Pathologic; Phenylpropionates; Pyrroles; Sunitinib | 2009 |
Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Foot Diseases; Hand Dermatoses; Humans; Incidence; Indoles; Kidney Neoplasms; Paresthesia; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sunitinib | 2009 |
Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Approval; Drug Design; Europe; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Interferons; Kidney Neoplasms; Palliative Care; Patient Selection; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; United States | 2009 |
Tolerability of first-line therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation Disorders; Carcinoma, Renal Cell; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Disease-Free Survival; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypothyroidism; Indoles; Interferons; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Proteins; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sunitinib; Wound Healing | 2009 |
A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Indoles; Male; Middle Aged; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2009 |
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Papillary; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2009 |
Perioperative treatment of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoadjuvant Therapy; Pharmacogenetics; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2009 |
Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
[Potential role of antiangiogenic treatment in neuroblastoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Child; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Neuroblastoma; Pyrroles; Sunitinib; United States; United States Food and Drug Administration | 2009 |
Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Case-Control Studies; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Therapy, Combination; Humans; Hypothyroidism; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Thyroid Function Tests; Treatment Outcome | 2009 |
Treatment of gastrointestinal stromal tumours: imatinib, sunitinib -- and then?
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Design; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib | 2009 |
Progress in the treatment of neuroendocrine tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pyrroles; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib | 2009 |
Targeted therapies in metastatic renal cancer in 2009.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factors | 2009 |
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2009 |
[Pharmacology profile of sunitinib malate (Sutent) Capsules) and clinical findings on this drug].
Topics: Animals; Antineoplastic Agents; Capsules; Carcinoma, Renal Cell; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Routes; Female; Hemorrhage; Humans; Hypertension; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Heart; Heart Diseases; Heart Failure; Humans; Indoles; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Trastuzumab | 2009 |
Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Indoles; Interferon-gamma; Kaplan-Meier Estimate; Kidney Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; Treatment Outcome | 2009 |
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Female; Fibromatosis, Aggressive; Follow-Up Studies; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2009 |
Prognostic markers and new, innovative treatments in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cancer Vaccines; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Renal toxicity of targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hypertension; Indoles; Kidney; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Sunitinib in solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Molecular Structure; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2009 |
Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Carcinoma; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Liver Neoplasms; Piperazines; Pyrimidines; Pyrroles; Soft Tissue Neoplasms; Subcutaneous Fat; Sunitinib | 2009 |
Angiogenesis regulated by VEGF and its receptors and its clinical application.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Design; Humans; Indoles; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; DNA Mutational Analysis; Europe; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Piperazines; Practice Guidelines as Topic; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2009 |
The role of antiangiogenesis therapy: bevacizumab and beyond.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Forecasting; Humans; Indoles; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2009 |
Adverse effects of anticancer agents that target the VEGF pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Brain Diseases; Capillary Leak Syndrome; Cardiovascular Diseases; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Forecasting; Gastrointestinal Diseases; Hemorrhage; Humans; Indoles; Kidney Diseases; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing | 2009 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
How can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib | 2009 |
Sunitinib in renal-cell carcinoma: expanded indications.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2009 |
Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Prostatic Neoplasms; Pyrroles; Sunitinib | 2009 |
Sunitinib and the benefits of a negative study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Indoles; Liver Neoplasms; Pyrroles; Sunitinib | 2009 |
Sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Interactions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Pyrroles; Risk Assessment; Sunitinib | 2009 |
Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Indoles; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
[Treatment of extensive disease].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Long-Term Care; Neoplasm Invasiveness; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Health Status; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Patient Satisfaction; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
[Internal medical therapy of gastrointestinal stroma tumors].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2009 |
Neurological adverse effects caused by cytotoxic and targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration | 2009 |
Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sirolimus; Stem Cell Transplantation; Sunitinib; Transplantation, Homologous | 2009 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
An overview of small-molecule inhibitors of VEGFR signaling.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cadherins; Clinical Trials, Phase III as Topic; Extracellular Matrix Proteins; Humans; Indoles; Integrins; Intercellular Signaling Peptides and Proteins; National Cancer Institute (U.S.); Neoplasms; Niacinamide; Peptide Hydrolases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Structure-Activity Relationship; Sunitinib; Transcription Factors; United States | 2009 |
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Hemorrhage; Humans; Incidence; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sorafenib; Sunitinib | 2009 |
Advances in the treatment of gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Delivery Systems; Drug Resistance, Neoplasm; Drugs, Investigational; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Drug Industry; Gastrointestinal Stromal Tumors; Humans; Indoles; Pyrroles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sunitinib | 2009 |
Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Humans; Hypercalcemia; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Paraneoplastic Syndromes; Pneumonectomy; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2010 |
Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
Topics: Animals; Drug Delivery Systems; Genetic Therapy; Humans; Indoles; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2009 |
Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Niacinamide; Paresthesia; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Syndrome | 2009 |
[Aspects of surgical treatment for gastro-intestinal stromal tumors].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Diagnostic Imaging; Disease Progression; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Laparoscopy; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Tyrosine kinase inhibitors and the thyroid.
Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms | 2009 |
Metastatic renal cell carcinoma: current standards of care.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Management of vascular endothelial growth factor and multikinase inhibitor side effects.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Drug Eruptions; Drug Monitoring; Fatigue; Humans; Indoles; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2009 |
[Gastrointestinal stromal tumors: evolution of a tumor concept from unclassifiable neoplasms to targeted molecular therapy].
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Indoles; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sequence Analysis, DNA; Sunitinib | 2010 |
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Blood Pressure; Carcinoma, Renal Cell; Endpoint Determination; Fatigue; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Leukocyte Count; Linear Models; Male; Middle Aged; Neoplasms; Neutrophils; Nonlinear Dynamics; Population; Pyrroles; Sunitinib | 2010 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Compounds in clinical Phase III and beyond.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostatins; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2010 |
Gastrointestinal stromal tumor: a bridge between bench and bedside.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2009 |
Gastrointestinal stromal tumors: current management.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Interactions; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Neoplasms; Pyrroles; Sunitinib | 2010 |
Progress in the management of advanced renal cell carcinoma (RCC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Everolimus; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2010 |
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Renal Cell; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2010 |
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Cardiovascular Diseases; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
[Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Drug Approval; Drug Delivery Systems; Drugs, Investigational; Evidence-Based Medicine; Germany; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate | 2010 |
[First-line therapy of metastatic renal cell carcinoma--update 2009].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Drugs, Investigational; Evidence-Based Medicine; Germany; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Prognosis; Pyrroles; Sirolimus; Sunitinib; Survival Rate | 2010 |
[Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Drugs, Investigational; Everolimus; Evidence-Based Medicine; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2010 |
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Chemotherapy, Adjuvant; Humans; Indoles; Neoadjuvant Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing | 2010 |
Update on systemic therapies of metastatic renal cell carcinoma.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biopsy, Needle; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Everolimus; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sirolimus; Sorafenib; Sunitinib; Survival Analysis | 2010 |
[Recent progress in the molecular-targeting treatment of neuroendocrine tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Drug Delivery Systems; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib | 2010 |
Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Clinical Trials as Topic; Combined Modality Therapy; Congresses as Topic; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Medical Oncology; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sirolimus; Sunitinib | 2010 |
Sunitinib for the management of advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Practice Guidelines as Topic; Pyrroles; Sunitinib | 2010 |
Targeting immune suppressing myeloid-derived suppressor cells in oncology.
Topics: Animals; Antineoplastic Agents; CD11b Antigen; Humans; Immune Tolerance; Immunotherapy; Indoles; Myeloid Cells; Neoplasms; Neovascularization, Pathologic; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2011 |
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Arterial Occlusive Diseases; Benzenesulfonates; Humans; Incidence; Indoles; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thromboembolism | 2010 |
Molecular response prediction in gastrointestinal stromal tumors.
Topics: Animals; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Optimal use of targeted agents for advanced gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome | 2010 |
[Treatment of locally advanced renal tumors].
Topics: Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2010 |
[Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Kidney Neoplasms; Markov Chains; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sirolimus; Sorafenib; Sunitinib | 2010 |
Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach.
Topics: Carcinoma, Renal Cell; Consensus; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Detection of Cancer; Evidence-Based Medicine; Fatigue; Female; Follow-Up Studies; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Mouth Diseases; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Skin Diseases; Sunitinib; Treatment Outcome | 2010 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome | 2010 |
[Neoadjuvant treatment and breast conserving surgery - a success of clinical research in breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Female; Humans; Indoles; Mastectomy, Segmental; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Protein-Tyrosine Kinases; Pyrroles; Radiotherapy; Randomized Controlled Trials as Topic; Sunitinib | 2010 |
[Antiangionic drugs in soft tissue sarcoma].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Doxorubicin; Humans; Indazoles; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
[Focus on GIST management].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2010 |
Molecular basis and management of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2010 |
[Treatment with antiangiogenic drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Bevacizumab; Humans; Imatinib Mesylate; Indoles; Neoplasms; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
[Anti-angiogenic drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Hypoxia-Inducible Factor 1; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cardiovascular Diseases; Female; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Indoles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sarcoma; Sunitinib | 2010 |
[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Drug Eruptions; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Structure-Activity Relationship; Sunitinib | 2010 |
Present state of target therapy for disseminated renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; DNA Mutational Analysis; Exons; Gastrointestinal Stromal Tumors; Genotype; Humans; Indoles; Prognosis; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Risk Assessment; Sunitinib; Transcriptional Activation | 2010 |
Angiogenesis as a therapeutic target in urothelial carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Matrix Metalloproteinases; Neoadjuvant Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2010 |
Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
Sunitinib for the treatment of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2011 |
Sunitinib for metastatic renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2010 |
Molecular basis of hypertension side effects induced by sunitinib.
Topics: Angiogenesis Inhibitors; Humans; Hypertension; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2011 |
[Multimodality therapy concepts for soft tissue sarcomas].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Cross-Sectional Studies; Gastrointestinal Stromal Tumors; Humans; Hyperthermia, Induced; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Palliative Care; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Sunitinib | 2010 |
[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Cell Cycle; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hepatectomy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Wnt Proteins | 2010 |
[A case of recurrent intracaval renal cell carcinoma effectively treated with sunitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pyrroles; Sunitinib; Vascular Neoplasms; Vena Cava, Inferior | 2010 |
New perspectives: role of sunitinib in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Indoles; Neoplasm Metastasis; Pyrroles; Sunitinib | 2010 |
[Molecular targeted therapy for renal cell carcinoma and other urological cancers].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Urologic Neoplasms | 2010 |
Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature.
Topics: Antineoplastic Agents; Carcinoma, Papillary; Combined Modality Therapy; Humans; Indoles; Male; Middle Aged; Pelvic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Remission Induction; Sunitinib; Thyroid Neoplasms | 2010 |
Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature.
Topics: Acute Kidney Injury; Aged; Female; Humans; Indoles; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib | 2011 |
[Hand-foot syndrome after administration of tyrosinkinase inhibitors].
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Syndrome | 2010 |
Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Models, Economic; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Antiangiogenic therapy for breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Metastatic gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Indoles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-kit; Pyrroles; Salvage Therapy; Sunitinib | 2011 |
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Neuroendocrine; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrroles; Receptors, Somatostatin; Sirolimus; Somatostatin; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab | 2011 |
[Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Doxorubicin; Drug Delivery Systems; ErbB Receptors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Mutation; Neoplasms; Piperazines; Prednisone; Pyrimidines; Pyrroles; Remission Induction; Rituximab; Sunitinib; Vincristine | 2010 |
[Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Europe; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
Role of tyrosine kinase inhibitors in tumor immunology.
Topics: Animals; Antigen-Presenting Cells; Antineoplastic Agents; Dendritic Cells; Humans; Indoles; Mice; Myeloid Cells; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; T-Lymphocytes, Regulatory; Treatment Outcome | 2011 |
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2011 |
Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Endoscopy; Female; Humans; Indoles; Intestinal Perforation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib | 2011 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2011 |
A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.
Topics: Adult; Angiogenesis Inhibitors; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Delivery Systems; Enzyme Inhibitors; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Neoplasm Staging; Pilot Projects; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis | 2011 |
In pursuit of new anti-angiogenic therapies for cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2011 |
Therapeutic advances in women's cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cetuximab; ErbB Receptors; Female; Genital Neoplasms, Female; Humans; Indoles; Intestinal Perforation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Myeloid derived suppressor cells in human diseases.
Topics: Animals; Biomarkers; Humans; Immunosuppression Therapy; Indoles; Inflammatory Bowel Diseases; Mice; Molecular Targeted Therapy; Myeloid Cells; Myelopoiesis; Neoplasms; Pyrroles; Sunitinib; Tretinoin | 2011 |
Sunitinib and other targeted therapies for renal cell carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Added value of molecular targeted agents in oncology.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Indoles; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, ErbB-2; Rituximab; Sunitinib; Trastuzumab | 2011 |
Current and emerging pharmacological treatments for gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Drugs, Investigational; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2011 |
Management of recurrent gastrointestinal stromal tumors.
Topics: Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Everolimus; Humans; Immunotherapy; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Everolimus; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Meta-Analysis as Topic; Neoplasm Metastasis; Pyrroles; Sunitinib | 2011 |
[Novelties in the treatment for advanced renal-cell cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Treatment of metastatic renal cell carcinoma and renal pelvic cancer.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Everolimus; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2011 |
Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Posterior Leukoencephalopathy Syndrome; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
[Treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.
Topics: Asthenia; Carcinoma, Renal Cell; Diarrhea; Dose-Response Relationship, Drug; Erythema; Exanthema; Fatigue; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrroles; Standard of Care; Sunitinib | 2011 |
Novel nephrotoxins.
Topics: Adenine; Alcohols; Angiogenesis Inhibitors; Anticonvulsants; Antipsychotic Agents; Dasatinib; Diphosphonates; Glutamates; Guanine; HIV Protease Inhibitors; Humans; Indoles; Kidney Diseases; Organophosphonates; Oxalates; Pamidronate; Pemetrexed; Phenindione; Plants, Toxic; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Selective Serotonin Reuptake Inhibitors; Sunitinib; Tenofovir; Thiazoles; Triazines | 2011 |
Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit.
Topics: Benzamides; Binding Sites; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Stability; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
Topics: Antineoplastic Agents; Benzamides; Giant Cell Tumors; Humans; Imatinib Mesylate; Indoles; Macrophage Colony-Stimulating Factor; Macrophages; Piperazines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Soft Tissue Neoplasms; Sunitinib; Synovial Membrane; Synovitis, Pigmented Villonodular; Tendons | 2011 |
[Current status in molecular-targeted therapy and IFNα for renal cell carcinoma in Japan].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Indoles; Interferon-alpha; Molecular Targeted Therapy; Pyrroles; Sirolimus; Sunitinib | 2011 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Patient Selection; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Risk Factors; Sunitinib; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Targeting angiogenesis in esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Disease Models, Animal; Disease-Free Survival; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
New therapeutic options for metastatic malignant insulinomas.
Topics: Antineoplastic Agents; Everolimus; Humans; Indoles; Insulinoma; Liver Neoplasms; Pancreatic Neoplasms; Pyrroles; Radiopharmaceuticals; Receptors, Somatostatin; Sirolimus; Somatostatin; Sunitinib | 2011 |
Angiogenesis in peritoneal dialysis.
Topics: Angiogenesis Inhibitors; Animals; Humans; Indoles; Neovascularization, Pathologic; Peritoneal Dialysis; Peritoneum; Pyrroles; Rats; Sunitinib | 2011 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Thyroid Neoplasms | 2011 |
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2011 |
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Follow-Up Studies; Heart Failure; Humans; Incidence; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Biotransformation; Carcinoma, Renal Cell; Cell Hypoxia; Clinical Trials as Topic; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Membrane Proteins; Multicenter Studies as Topic; Neoplasm Proteins; Neovascularization, Pathologic; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Receptors, Growth Factor; Retrospective Studies; Risk Factors; Severity of Illness Index; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Targeted drug therapies and cancer.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Drug Delivery Systems; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gefitinib; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Heart failure associated with sunitinib: lessons learned from animal models.
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiotoxins; Disease Models, Animal; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Indoles; Kidney Neoplasms; Mitochondria; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Signal Transduction; Sunitinib | 2011 |
Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib; Survival | 2011 |
[Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
Topics: Alleles; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; DNA Mutational Analysis; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Maintenance Chemotherapy; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2011 |
Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Endocrine Gland Neoplasms; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Molecular Targeted Therapy; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Docetaxel combined with targeted therapies in metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Indoles; Lapatinib; Pyrroles; Quinazolines; Sunitinib; Taxoids; Trastuzumab | 2012 |
Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.
Topics: Adrenocortical Carcinoma; Animals; Antineoplastic Agents; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Indoles; Mitotane; Pyrroles; Sunitinib | 2011 |
[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Fatigue; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Novel therapies for metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Angiogenesis Inhibitors; Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Atrasentan; Benzamides; Bevacizumab; Biomarkers, Tumor; Bone Remodeling; Cancer Vaccines; Clinical Trials as Topic; Clusterin; Dasatinib; Denosumab; Endothelin-1; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; RANK Ligand; Receptor Cross-Talk; Receptors, Androgen; Signal Transduction; Sunitinib; Taxoids; Thiazoles; Tissue Extracts; Treatment Failure; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2011 |
Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Heart Failure; Humans; Hypertension; Indoles; Myocytes, Cardiac; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Risk Factors; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A | 2011 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2011 |
[Systemic treatment of renal cell carcinoma - recent update].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Evidence-Based Medicine; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Palliative Care; Phenylurea Compounds; Practice Guidelines as Topic; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Gastrointestinal stromal tumor: advances in diagnosis and management.
Topics: Benzamides; Diagnosis, Differential; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Platelet-Derived Growth Factor; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
[Dermatologic side effects induced by new angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Reappraising antiangiogenic therapy for breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Molecular Targeted Therapy; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2012 |
Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
Topics: Benzamides; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Sunitinib-induced asthenia: from molecular basis to clinical relief.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Gene Expression Regulation; Humans; Incidence; Indoles; Neoplasms; Pyrroles; Severity of Illness Index; Signal Transduction; Sunitinib | 2011 |
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Confounding Factors, Epidemiologic; Cross-Over Studies; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Interferon-gamma; Neoplasms; Patient Selection; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Sunitinib; Treatment Outcome | 2011 |
Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Thiazoles | 2011 |
Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Anti-angiogenic therapy: concept to clinic.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.
Topics: Angiogenesis Inhibitors; Animals; Humans; Hypothyroidism; Incidence; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2011 |
Sunitinib for advanced pancreatic neuroendocrine tumors.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2011 |
Small intestine gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Neoadjuvant Therapy; Neoplasm Metastasis; Piperazines; Prognosis; Pyrimidines; Pyrroles; Sunitinib | 2012 |
New insights into molecular mechanisms of sunitinib-associated side effects.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Models, Biological; Pigmentation Disorders; Pyrroles; Signal Transduction; Sunitinib | 2011 |
VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular System; Drug Eruptions; Europe; Everolimus; Evidence-Based Medicine; Gastrointestinal Tract; Humans; Hypothyroidism; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Weight Loss; Wound Healing | 2012 |
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib | 2012 |
New strategies for advanced neuroendocrine tumors in the era of targeted therapy.
Topics: Antineoplastic Agents; Disease-Free Survival; Drug Therapy; Everolimus; Humans; Indoles; Models, Biological; Neuroendocrine Tumors; Octreotide; Pancreas; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2012 |
Advances in the treatment of pancreatic neuroendocrine tumours.
Topics: Antineoplastic Agents; Disease-Free Survival; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib | 2012 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Current treatment considerations in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Nephrectomy; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbazine; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Streptozocin; Sunitinib; Temozolomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors; Yttrium Radioisotopes | 2012 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles | 2012 |
[Resistance and treatment strategy of gastrointestinal stromal tumor target therapy].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Sunitinib malate.
Topics: Animals; Antineoplastic Agents; Chromatography; Cytochrome P-450 CYP3A; Humans; Indoles; Protein Kinase Inhibitors; Pyrroles; Solubility; Spectrum Analysis; Sunitinib | 2012 |
Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Interleukin-8; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2012 |
Adjuvant therapy of gastrointestinal stromal tumors.
Topics: Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2012 |
New targeted agents in gastroenteropancreatic neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Molecular Targeted Therapy; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2012 |
A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
Topics: Clinical Trials as Topic; Drug Discovery; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib | 2011 |
Sunitinib malate for the treatment of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Evidence-Based Medicine; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Current management of gastrointestinal stromal tumors--a comprehensive review.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vena Cava, Inferior | 2012 |
Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Prognosis; Pyrroles; Sunitinib | 2013 |
Sunitinib in pancreatic neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2012 |
Cardiac side effects of anticancer treatments: new mechanistic insights.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Daunorubicin; Doxorubicin; Heart Failure; Humans; Indoles; Myocardial Contraction; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Trastuzumab | 2012 |
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Differentiation; ErbB Receptors; Everolimus; Histone Deacetylases; Humans; Immunologic Factors; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Somatostatin; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal.
Topics: Adult; Antineoplastic Agents; Arthroplasty; Arthroscopy; Benzamides; Chemotherapy, Adjuvant; Female; Giant Cell Tumors; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Radioisotopes; Radiotherapy, Adjuvant; Sunitinib; Synovectomy; Synovial Membrane; Tendons; Tenosynovitis | 2013 |
Sunitinib and pancreatic neuroendocrine tumours. More assessment needed.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2012 |
FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Multimodal Imaging; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Pyrroles; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Medical Oncology; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles | 2012 |
Hypothyroidism during treatment with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyroid Neoplasms | 2012 |
Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib | 2013 |
[Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Topics: Antineoplastic Agents; Dacarbazine; Digestive System Surgical Procedures; Everolimus; Humans; Immunosuppressive Agents; Indoles; Japan; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Somatostatin; Streptozocin; Sunitinib; Temozolomide | 2012 |
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Density Conservation Agents; Denosumab; Humans; Indoles; Jaw Diseases; Osteonecrosis; Pyrroles; RANK Ligand; Sunitinib | 2012 |
[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2012 |
Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.
Topics: Animals; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immune Tolerance; Indoles; Mice; Myeloid Progenitor Cells; Neoplasms; Organ Specificity; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; STAT3 Transcription Factor; STAT5 Transcription Factor; Sunitinib; T-Lymphocytes; Tumor Escape | 2012 |
Targeting angiogenesis as a promising modality for the treatment of prostate cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antibodies, Monoclonal, Humanized; Bevacizumab; Disease Progression; Drug Therapy, Combination; Humans; Indoles; Male; Prostatic Neoplasms; Pyridines; Pyrroles; Signal Transduction; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2012 |
Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Radiopharmaceuticals; Signal Transduction; Sirolimus; Somatostatin; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Probability; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Tumor Burden | 2013 |
Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis.
Topics: Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2013 |
Pancreatic neuroendocrine neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromogranin A; Endosonography; Everolimus; Germany; Hepatectomy; Humans; Incidence; Indoles; Liver Transplantation; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Prevalence; Prognosis; Pyrroles; Sirolimus; Somatostatin; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Severe hypothyroidism presenting as myxedema coma in the postoperative period in a patient taking sunitinib: case report and review of literature.
Topics: Antineoplastic Agents; Arthroplasty, Replacement, Hip; Coma; Female; Femoral Fractures; Humans; Indoles; Middle Aged; Myxedema; Postoperative Complications; Pyrroles; Sunitinib | 2013 |
Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature.
Topics: Adult; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Fatal Outcome; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Middle Aged; Pre-Eclampsia; Pregnancy; Pyrroles; Sunitinib; Ventricular Dysfunction, Left | 2013 |
Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis.
Topics: Algorithms; Antineoplastic Agents; Humans; Hypothyroidism; Incidence; Indoles; Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sunitinib | 2013 |
Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
Topics: Antineoplastic Agents; Everolimus; Humans; Immunosuppressive Agents; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Systemic therapy for advanced pancreatic neuroendocrine tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Somatostatin; Sunitinib; Treatment Outcome | 2013 |
Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis.
Topics: Humans; Hypothyroidism; Indoles; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Sunitinib; Thyroid Diseases; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Do targeted agents offer clinical benefit as presurgical therapy?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Nephrectomy; Preoperative Care; Prognosis; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome | 2014 |
Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Hematologic Diseases; Humans; Incidence; Indoles; Neoplasms; Neutropenia; Publication Bias; Pyrroles; Risk; Sunitinib; Thrombocytopenia | 2013 |
Sunitinib malate for the treatment of pancreas malignancies--where does it fit?
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2013 |
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Sorafenib; Sunitinib | 2013 |
Novel agents in gastroenteropancreatic neuroendocrine tumors.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drugs, Investigational; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib | 2013 |
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Dermatofibrosarcoma protuberans on the right neck with superior vena cava syndrome: case report and literature review.
Topics: Adult; Antineoplastic Agents; Dermatofibrosarcoma; Head and Neck Neoplasms; Humans; Indoles; Male; Neck; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Superior Vena Cava Syndrome; Thorax; Vena Cava, Superior | 2013 |
[Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2013 |
Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bevacizumab; Clinical Trials as Topic; Digestive System Neoplasms; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Somatostatin; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2013 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indoles; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2013 |
Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib | 2013 |
Body composition in chemotherapy: the promising role of CT scans.
Topics: Anthracyclines; Body Composition; Body Weight; Chemotherapy, Adjuvant; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Muscle, Skeletal; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2013 |
Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Hypoxia; Co-Repressor Proteins; Cyclin-Dependent Kinase Inhibitor p18; Disease Progression; Disease-Free Survival; Everolimus; Gene Knock-In Techniques; Gene Knockout Techniques; Genetic Predisposition to Disease; Humans; Indoles; Islets of Langerhans; Molecular Chaperones; Molecular Targeted Therapy; Mutation; Neovascularization, Pathologic; Neuroendocrine Tumors; Nuclear Proteins; Octreotide; Pancreatic Neoplasms; Proto-Oncogene Proteins; Pyrroles; Receptor, Notch1; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Indoles; Male; Medication Adherence; Mouth Neoplasms; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Review Literature as Topic; Sunitinib | 2013 |
Side-effects associated with targeted therapies in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; Sunitinib | 2013 |
Systemic treatment options for untreated patients with metastatic clear cell renal cancer.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib | 2013 |
Molecular markers to predict response to therapy.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Bevacizumab; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Gene Dosage; Humans; Immunotherapy; Indazoles; Indoles; Kidney Neoplasms; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Genetic; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein | 2013 |
Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
Topics: Animals; Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2013 |
The potential role of sunitinib targeting melanomas.
Topics: Animals; Antineoplastic Agents; Humans; Indoles; Melanoma; Pyrroles; Skin Neoplasms; Sunitinib; Uveal Neoplasms | 2013 |
[Drug therapy for neuroendocrine tumours].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemoembolization, Therapeutic; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Liver Neoplasms; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Octreotide; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sirolimus; Somatostatin; Sunitinib | 2013 |
The potential of sunitinib as a therapy in ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Animals; Drug Approval; Drug Resistance, Neoplasm; Female; Humans; Indoles; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2013 |
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Induction Chemotherapy; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Clinical Trials, Phase III as Topic; Disease Models, Animal; Female; Heterografts; Humans; Indoles; Mice; Mice, Transgenic; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Neoplasm Transplantation; Pyrroles; Species Specificity; Sunitinib; Survival Analysis; Treatment Outcome | 2013 |
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting | 2014 |
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2013 |
[Medical treatment of renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Immunotherapy; Indoles; Interferon alpha-2; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Sirolimus; Societies, Medical; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2013 |
Sunitinib malate in the treatment of urothelial cancer.
Topics: Angiogenesis Inhibitors; Animals; Humans; Indoles; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Urogenital Neoplasms | 2014 |
Advanced kidney cancer: treating the elderly.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2013 |
Tumor angiogenesis and anti-angiogenic therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factors | 2013 |
Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antigens, Neoplasm; Cancer Vaccines; Carcinoma, Renal Cell; Combined Modality Therapy; Dendritic Cells; Electroporation; Everolimus; Humans; Immunotherapy, Active; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Proteins; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Pyrroles; Quinolines; RNA, Neoplasm; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2014 |
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome | 2013 |
Drug interactions with sunitinib.
Topics: Antineoplastic Agents; Diphosphonates; Drug Interactions; Drug Therapy, Combination; Humans; Indoles; Plants, Medicinal; Pyrroles; Sunitinib | 2015 |
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Incidence; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Risk; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Pancreatic NETs: where do we stand now?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Emerging therapeutic targets for synovial sarcoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sarcoma, Synovial; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
Sunitinib in the treatment of advanced solid tumors.
Topics: Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2014 |
Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.
Topics: Administration, Cutaneous; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2014 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Sunitinib re-challenge in advanced renal-cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Retreatment; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
[Oral toxicity of targeted anticancer therapies].
Topics: Angiogenesis Inhibitors; Benzamides; ErbB Receptors; Glossitis, Benign Migratory; Humans; Hyperpigmentation; Imatinib Mesylate; Indoles; Maxillary Diseases; Molecular Targeted Therapy; Mouth Mucosa; Osteonecrosis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Pyrroles; Radiation Injuries; Radiotherapy; Stomatitis; Stomatitis, Aphthous; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidence; Indoles; Models, Statistical; Piperazines; Prevalence; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rare Diseases; Registries; Sunitinib; Treatment Failure; United Kingdom | 2014 |
Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2014 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib | 2014 |
Targeted agents in treatment of neuroendocrine tumors of pancreas.
Topics: Antineoplastic Agents; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; Survival Analysis; Treatment Outcome | 2014 |
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib; Survival Analysis | 2014 |
Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
[Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2014 |
Combining targeted agents with modern radiotherapy in soft tissue sarcomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; Cyclin-Dependent Kinase 4; Humans; Indazoles; Indoles; Ipilimumab; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2014 |
Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Differentiation; Chemoradiotherapy; Clinical Trials as Topic; Drugs, Investigational; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neuroendocrine Tumors; Octreotide; Peptides, Cyclic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radioisotopes; Sirolimus; Somatostatin; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Treatment Outcome | 2014 |
Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.
Topics: Animals; Chromatography, Liquid; Humans; Indoles; Mass Spectrometry; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Prognosis; Pyrroles; Signal Transduction; Sunitinib; Tumor Microenvironment | 2015 |
Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
Topics: Antineoplastic Agents; Humans; Incidence; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Eruptions; Hand-Foot Syndrome; Humans; Indoles; Mucositis; Pyrroles; Sunitinib | 2015 |
Treatment of brain metastases from renal cell carcinoma with sunitinib and radiotherapy: our experience and review of the literature.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2011 |
Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Indoles; Italy; Jaw; Kidney Neoplasms; Male; Middle Aged; Osteonecrosis; Pyrroles; Retrospective Studies; Sunitinib; Zoledronic Acid | 2015 |
Kidney cancer in 2014: Key advances promise progress for kidney cancer patients.
Topics: Angiogenesis Inhibitors; Carcinogenesis; Carcinoma, Renal Cell; Disease Progression; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Nephrons; Organ Sparing Treatments; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
[Molecular biology of sarcoma and therapeutic choices].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzamides; Bone Neoplasms; Crizotinib; Denosumab; Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Gene Amplification; Gene Deletion; Giant Cell Tumor of Bone; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Phenylurea Compounds; Piperazines; Point Mutation; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sarcoma; Sarcoma, Ewing; Sunitinib; Synovitis, Pigmented Villonodular; Translocation, Genetic | 2015 |
The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for
Topics: Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Drug Approval; Europe; Humans; Imidazoles; Indazoles; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2015 |
Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Prognosis; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Analysis; Treatment Outcome | 2015 |
Renal cell carcinoma metastatic to the tongue: a case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Follow-Up Studies; Glossectomy; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Multimodal Imaging; Neoplasm Invasiveness; Palliative Care; Positron-Emission Tomography; Pyrroles; Recombinant Proteins; Sunitinib; Tomography, X-Ray Computed; Tongue Neoplasms | 2015 |
New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bone Density Conservation Agents; Denosumab; Humans; Indoles; Jaw Diseases; Osteonecrosis; Pyrroles; Sunitinib | 2015 |
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hemorrhage; Humans; Hypertension; Indoles; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Niacinamide; Pain; Pancytopenia; Phenylurea Compounds; Protease Inhibitors; Pyrroles; Salvage Therapy; Sepsis; Sorafenib; Sunitinib | 2015 |
Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Systemic therapy of hepatocellular carcinoma: current and promising.
Topics: Alanine; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Indoles; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Preoperative Care; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Triazines | 2015 |
Duodenal gastrointestinal stromal tumor: From clinicopathological features to surgical outcomes.
Topics: Age Distribution; Antineoplastic Agents; Benzamides; Biopsy, Fine-Needle; Endoscopy, Gastrointestinal; Endosonography; Europe; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Mutation; Pancreaticoduodenectomy; Phenylurea Compounds; Piperazines; Prevalence; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sex Distribution; Sunitinib; United States | 2015 |
Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: are we really making steps forward?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2015 |
Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinoma.
Topics: Animals; Cancer Vaccines; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Immunotherapy; Indoles; Precision Medicine; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside.
Topics: Angiogenesis Inducing Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Synergism; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Translational Research, Biomedical; Vascular Endothelial Growth Factor A | 2015 |
First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Signal Transduction; Sulfonamides; Sunitinib; Time Factors; Treatment Outcome | 2015 |
Drug compound characterization by mass spectrometry imaging in cancer tissue.
Topics: Animals; Antineoplastic Agents; Drug Compounding; Humans; Indoles; Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Pyrroles; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sunitinib; Xenograft Model Antitumor Assays | 2015 |
Combining radiotherapy with sunitinib: lessons (to be) learned.
Topics: Animals; Chemoradiotherapy; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2015 |
[Anti-angiogenesis and molecular targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors.
Topics: Antineoplastic Agents; Humans; Indoles; Intestinal Neoplasms; Liver Neoplasms; Liver Transplantation; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Pyrroles; Stomach Neoplasms; Sunitinib | 2015 |
Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Metastasectomy; Molecular Targeted Therapy; Neoadjuvant Therapy; Pyrroles; Sunitinib | 2016 |
Personalized Therapy for Generalized Lymphatic Anomaly/Gorham-Stout Disease With a Combination of Sunitinib and Taxol.
Topics: Administration, Metronomic; Adolescent; Child; Chronic Pain; Combined Modality Therapy; Dietary Fats; Drug Synergism; Drug Therapy, Combination; Fatal Outcome; Humans; Indoles; Lymphatic Abnormalities; Male; Osteolysis, Essential; Paclitaxel; Pelvic Bones; Pleural Effusion; Precision Medicine; Pyrroles; Radiography; Recurrence; Remission Induction; Respiration, Artificial; Respiratory Insufficiency; Sunitinib; Triglycerides | 2015 |
A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Indoles; Neoplasms; Pyrroles; Research Design; Sunitinib; Treatment Outcome | 2015 |
Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Humans; Indoles; Neoplasms; Pyrroles; Risk Assessment; Sunitinib; United States; United States Food and Drug Administration | 2016 |
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Immunotherapy; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2015 |
Clinical management of metastatic kidney cancer: the role of new molecular drugs.
Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2016 |
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review.
Topics: Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Liver Neoplasms; Neuroendocrine Tumors; Pyrroles; Somatostatin; Sunitinib | 2016 |
Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Update on cardiotoxicity of anti-cancer treatments.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bevacizumab; Cardiotoxicity; Echocardiography; Humans; Indoles; Lapatinib; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Pyrroles; Quinazolines; Radiation Injuries; Radiotherapy; Sunitinib; Taxoids; Trastuzumab; Troponin; Vinca Alkaloids | 2016 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Gene Expression; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug and Narcotic Control; Drugs, Generic; Humans; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Neoplasms; Organ Specificity; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Signal Transduction; Sunitinib; Toxicity Tests | 2016 |
First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Practice Patterns, Physicians'; Prognosis; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome | 2016 |
Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Forecasting; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2016 |
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Body Weight; Carcinoma, Renal Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Models, Biological; Pyrroles; Racial Groups; Sex Factors; Sunitinib | 2016 |
Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2016 |
Systemic therapy in metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Decision Trees; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Nivolumab; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Kidney cancer: Power couple: reovirus meets sunitinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Orthoreovirus, Mammalian; Pyrroles; Sunitinib | 2016 |
Sunitinib Possible Sex-Divergent Therapeutic Outcomes.
Topics: Animals; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Mice; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Treatment Outcome | 2016 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
Progress on the cardiotoxicity of sunitinib: Prognostic significance, mechanism and protective therapies.
Topics: Cardiotonic Agents; Cardiotoxicity; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Humans; Indoles; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2016 |
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2016 |
Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoadjuvant Therapy; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2016 |
Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Indoles; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2016 |
[Metastasis to the Tongue from Renal Cell Carcinoma 10 Years after Nephrectomy : A Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrectomy; Pyrroles; Recurrence; Remission Induction; Sunitinib; Tomography, X-Ray Computed; Tongue Neoplasms | 2016 |
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Pyrroles; Somatostatin; Sunitinib; Syndrome; Treatment Outcome | 2016 |
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2016 |
Sunitinib for the treatment of thyroid cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Thyroid Neoplasms | 2016 |
Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; CD47 Antigen; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases | 2016 |
Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Humans; Indoles; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2016 |
Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients.
Topics: Alleles; Antineoplastic Agents; Carcinoma, Renal Cell; Gene Frequency; Genetic Variation; Genotype; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2017 |
Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; White People | 2017 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Humans; Indoles; Neovascularization, Pathologic; Pyrroles; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Risk Assessment; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Sunitinib in kidney cancer: 10 years of experience and development.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Survival Rate | 2017 |
Benefit of Sunitinib in the treatment of pulmonary primitive neuroectodermal tumors: a case report and literature review.
Topics: Adult; Antineoplastic Agents; DNA Copy Number Variations; Female; Humans; Indoles; Lung Neoplasms; Neuroectodermal Tumors, Primitive; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Von Hippel-Lindau Tumor Suppressor Protein | 2016 |
Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Sunitinib | 2017 |
How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Research Design; Sunitinib | 2017 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Targeted Therapy for Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature.
Topics: Adult; Age of Onset; Antineoplastic Agents; Axitinib; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Catheter Ablation; Child; Combined Modality Therapy; Everolimus; Fatal Outcome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Oncogene Fusion; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Translocation, Genetic; Young Adult | 2017 |
Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Management; Drug Resistance, Neoplasm; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Visceral and bone metastases of a WHO grade 2 meningioma: A case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Female; Humans; Ilium; Indoles; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningioma; Neoplasm Grading; Pyrroles; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Ribs; Spinal Cord Compression; Spinal Neoplasms; Spine; Sunitinib | 2017 |
Renal cell carcinoma.
Topics: Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Diseases; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2017 |
GEIS guidelines for gastrointestinal sarcomas (GIST).
Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Sunitinib | 2017 |
The use of kinase inhibitors in solid organ transplantation.
Topics: Aminopyridines; Humans; Immunosuppressive Agents; Indoles; Morpholines; Organ Transplantation; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Syk Kinase | 2017 |
[New therapeutic schedules of Sunitinib: Current evidence regarding the 2:1 scheme.]
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Protocols; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Survival Rate | 2017 |
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
Topics: Angiogenesis Inhibitors; Bevacizumab; Humans; Indoles; Jaw Diseases; Niacinamide; Osteonecrosis; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib | 2017 |
Immunotherapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Bevacizumab; Cancer Vaccines; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Kidney Neoplasms; Longevity; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib | 2017 |
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Randomized Controlled Trials as Topic; Spain; Sunitinib; Survival Rate; Treatment Outcome | 2018 |
Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Comorbidity; Drug Interactions; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2017 |
Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolines; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2017 |
Drug-Induced Pyoderma Gangrenosum: A Review.
Topics: Cocaine; Drug Eruptions; Humans; Immunosuppressive Agents; Indoles; Isotretinoin; Propylthiouracil; Pyoderma Gangrenosum; Pyrroles; Sunitinib; Tumor Necrosis Factor-alpha; Withholding Treatment | 2018 |
Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
Topics: Antineoplastic Agents; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2017 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
[Current cases of falsified medicinal products within the competence of the Federal Institute for Drugs and Medical Devices (BfArM) : Case studies and extent].
Topics: Counterfeit Drugs; Drug and Narcotic Control; Drug Packaging; Filgrastim; Fraud; Germany; Humans; Indoles; National Health Programs; Polyethylene Glycols; Prescription Drugs; Pyrroles; Romania; Sunitinib | 2017 |
A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Network Meta-Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Pneumatosis cystoides intestinalis associated with sunitinib and a literature review.
Topics: Aged; Antineoplastic Agents; Female; Humans; Indoles; Pancreatic Neoplasms; Pneumatosis Cystoides Intestinalis; Pyrroles; Sunitinib | 2017 |
Update in the Therapy of Advanced Neuroendocrine Tumors.
Topics: Combined Modality Therapy; Cytoreduction Surgical Procedures; Everolimus; Humans; Indoles; Intestinal Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Somatostatin; Stomach Neoplasms; Sunitinib | 2017 |
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Pyridines; Pyrroles; Sunitinib | 2017 |
The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis.
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Indazoles; Indoles; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib | 2018 |
Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.
Topics: Doxorubicin; Humans; Indoles; Mitochondria, Heart; Pyrroles; Sunitinib; Trastuzumab | 2018 |
Sunitinib rechallenge with dose escalation in progressive metastatic renal cell carcinoma: A case report and literature review.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Pyrroles; Retrospective Studies; Sunitinib | 2018 |
Adjuvant treatment in renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2018 |
Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population.
Topics: Adult; Aged; Antineoplastic Agents; Arabs; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Saudi Arabia; Sunitinib | 2020 |
Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Infant; Male; Models, Biological; Neoplasms; Pyrroles; Sunitinib; Young Adult | 2021 |
Hematologic toxicities of sunitinib in patients with gastrointestinal stromal tumors: a systematic review and meta-analysis.
Topics: Anemia; Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia | 2022 |
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
Topics: Biomarkers; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2023 |
Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Network Meta-Analysis; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2023 |
415 trial(s) available for pyrroles and su 11248
| Article | Year |
|---|---|
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
Topics: Administration, Oral; Adult; Aged; Blast Crisis; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Genotype; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Metabolic Clearance Rate; Middle Aged; Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2003 |
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Topics: Aged; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Genotype; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Metabolic Clearance Rate; Middle Aged; Mutation; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2005 |
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Female; Humans; Hypertension; Indoles; Male; Middle Aged; Neoplasms; Pigmentation; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Skin; Sunitinib | 2006 |
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Quality of Life; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2006 |
Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects.
Topics: Adolescent; Adult; Biological Availability; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Indoles; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2006 |
Sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2006 |
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2006 |
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
Topics: Adult; Antineoplastic Agents; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Indoles; Prospective Studies; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Pyrroles; Sunitinib; Thyroiditis; Thyrotropin | 2006 |
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sunitinib | 2007 |
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers; Endothelial Cells; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Monocytes; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Blood Pressure; Dose-Response Relationship, Drug; Fatigue; Female; Follow-Up Studies; Heart Rate; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Pancreas; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Failure | 2008 |
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.
Topics: Adult; Aged; Biological Transport; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Indoles; Iodine; Iodine Radioisotopes; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Thyrotropin | 2007 |
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cluster Analysis; Humans; Indoles; Kidney Neoplasms; Membrane Proteins; Middle Aged; Neoplasm Proteins; Pyrroles; Solubility; Sunitinib; Time Factors; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Vascular Endothelial Growth Factors | 2007 |
Sunitinib efficacy against advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Retrospective Studies; Single-Blind Method; Sunitinib; Survival Rate; Treatment Outcome; United States | 2007 |
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2008 |
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cohort Studies; Colorectal Neoplasms; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Prognosis; Pyrroles; Salvage Therapy; Sunitinib; Survival Rate | 2007 |
[Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib | 2007 |
Targeted drugs for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma; Costs and Cost Analysis; Double-Blind Method; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Pyrroles; Recombinant Proteins; Sirolimus; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A | 2007 |
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cause of Death; Cisplatin; Disease Progression; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Pain; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Stomatitis; Sunitinib; Treatment Outcome | 2008 |
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Endpoint Determination; Humans; Indoles; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Research Design; Sunitinib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Survival Rate; Taxoids | 2008 |
The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Canada; Cost-Benefit Analysis; Cross-Over Studies; Disease-Free Survival; Drug Costs; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Markov Chains; Piperazines; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Sunitinib | 2008 |
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Risk Factors; Sunitinib | 2008 |
Activity of sunitinib in patients with advanced neuroendocrine tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoid Tumor; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Quality of Life; Risk Assessment; Single-Blind Method; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Placenta Growth Factor; Pregnancy Proteins; Prospective Studies; Pyrroles; Sunitinib; Time Factors; Treatment Failure; United States; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-3 | 2008 |
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
Topics: Administration, Oral; Antineoplastic Agents; Australia; Brazil; Canada; Carcinoma, Renal Cell; Drug Administration Schedule; Europe; Female; Health Status Indicators; Humans; Indoles; Injections, Subcutaneous; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Quality of Life; Russia; Sunitinib; Surveys and Questionnaires; Treatment Outcome; United States | 2008 |
Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents; Castration; Disease-Free Survival; Humans; Indoles; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Quality of Life; Sunitinib | 2008 |
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Topics: Adult; Aged; Benzamides; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2008 |
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Salvage Therapy; Sunitinib | 2009 |
Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Health Resources; Humans; Imatinib Mesylate; Indoles; Markov Chains; Models, Econometric; Neoplasm Metastasis; Piperazines; Placebos; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Failure | 2008 |
Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cellulitis; Diarrhea; Drug Eruptions; Female; Humans; Indoles; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sirolimus; Stomatitis; Sunitinib; Thrombocytopenia; Treatment Outcome | 2009 |
Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fatigue; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2009 |
Compassionate use of sorafenib in patients with advanced renal cell cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Pyrroles; Radiopharmaceuticals; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2009 |
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Platelet-Derived Growth Factor; Prognosis; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Phase II study of sunitinib in men with advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiogenic Proteins; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Radiography; Sunitinib; Taxoids; Time Factors; Treatment Outcome | 2009 |
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Positron-Emission Tomography; Pyrroles; Sarcoma; Soft Tissue Neoplasms; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2009 |
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Renal Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Injections, Subcutaneous; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Probability; Proportional Hazards Models; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2009 |
Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Patient Compliance; Pyrroles; Radiation Dosage; Sunitinib | 2009 |
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Pyrroles; Secondary Prevention; Sunitinib; Testicular Neoplasms | 2010 |
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Europe; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Quality of Life; Sunitinib; Surveys and Questionnaires | 2009 |
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2009 |
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Survival Analysis | 2009 |
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Castration; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrroles; Quality of Life; Sunitinib; Taxoids; Time Factors; Treatment Failure | 2010 |
Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Demography; Disease Progression; Female; Head and Neck Neoplasms; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Survival Analysis; Tomography, X-Ray Computed | 2010 |
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Europe; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Sunitinib; Time Factors; Treatment Outcome; United States | 2009 |
A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.
Topics: Aged; Angiogenesis Inhibitors; Anorexia; Area Under Curve; Carcinoma, Squamous Cell; Drug Administration Schedule; Fatigue; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzamides; Biomarkers, Tumor; Demography; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Japan; Male; Middle Aged; Neoplasm Proteins; Piperazines; Pyrimidines; Pyrroles; Solubility; Sunitinib; Treatment Failure; Young Adult | 2010 |
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
Topics: Adult; Aged; Benzamides; Cell Proliferation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2009 |
A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Uterine Cervical Neoplasms | 2010 |
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Tumor Burden | 2009 |
Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Indoles; Kidney Failure, Chronic; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Sunitinib | 2010 |
Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Indoles; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Uterine Neoplasms | 2009 |
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2009 |
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Japan; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Safety; Sunitinib; Survival Rate; Treatment Outcome | 2010 |
Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib.
Topics: Antineoplastic Agents; Arrhythmias, Cardiac; Aza Compounds; Dose-Response Relationship, Drug; Electrocardiography; Fluoroquinolones; Granisetron; Heart Ventricles; Humans; Indoles; Moxifloxacin; Neoplasms; Placebos; Protein-Tyrosine Kinases; Pyrroles; Quinolines; Risk; Sunitinib; Time Factors | 2009 |
Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Indoles; Magnetic Resonance Angiography; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2010 |
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Pyrroles; Safety; Sunitinib; Survival Rate | 2010 |
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Half-Life; Humans; Indoles; Male; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Taxoids | 2010 |
Pharmacokinetics of sunitinib malate in subjects with hepatic impairment.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Area Under Curve; Endpoint Determination; Female; Humans; Indoles; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pyrroles; Sample Size; Sunitinib | 2010 |
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Geography; Health Status; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Quality of Life; Research Design; Sunitinib; Surveys and Questionnaires | 2010 |
Phase II study of sunitinib in patients with metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Pyrroles; Sunitinib; Survival Analysis; Urinary Bladder Neoplasms; Urothelium | 2010 |
Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Analysis; Treatment Outcome | 2010 |
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib | 2010 |
Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU.
Topics: Antineoplastic Agents; Carcinoma, Medullary; Humans; Indoles; Pyrroles; Sunitinib; Thyroid Neoplasms | 2010 |
Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Indoles; Kaplan-Meier Estimate; Pyrroles; Sunitinib | 2010 |
Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2011 |
Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulins, Intravenous; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sunitinib; Tomography, X-Ray Computed; Tumor Cells, Cultured | 2010 |
The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Fatigue; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Republic of Korea; Sunitinib; Thrombocytopenia; Treatment Outcome | 2010 |
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Esophagogastric Junction; Female; Humans; Indoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2011 |
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Interactions; Female; Humans; Ifosfamide; Indoles; Male; Maximum Tolerated Dose; Neoplasms; Pyrroles; Sunitinib | 2010 |
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Marginal increase of sunitinib exposure by grapefruit juice.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Beverages; Biological Availability; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Labeling; Female; Food-Drug Interactions; Humans; Indoles; Male; Midazolam; Middle Aged; Neoplasms; Pyrroles; Sunitinib | 2011 |
Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome; United Kingdom | 2010 |
Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Preoperative Care; Prospective Studies; Pyrroles; Sunitinib | 2010 |
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Belgium; Breast Neoplasms; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Middle Aged; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Time Factors; Treatment Outcome | 2010 |
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CA-125 Antigen; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrroles; Recurrence; Sunitinib; Survival Analysis | 2011 |
Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Topics: Aged; Antineoplastic Agents; Female; Humans; Indoles; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Pyrroles; Sunitinib; Thrombocythemia, Essential | 2010 |
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Papillary; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; New York City; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2012 |
Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Japan; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.
Topics: Aged; Angiotensin II; Animals; Blood Pressure; Bradykinin; Carcinoma, Renal Cell; Cells, Cultured; Coronary Circulation; Endothelial Cells; Endothelin-1; Female; Gastrointestinal Stromal Tumors; Heart; Heart Rate; Humans; Hypertension; In Vitro Techniques; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Rats; Rats, Inbred WKY; Receptor Protein-Tyrosine Kinases; Renin; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2010 |
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Vomiting; Young Adult | 2010 |
Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Blood Platelets; Carcinoma, Hepatocellular; Cell Count; Cytokines; Female; Hematopoietic Stem Cells; Hemoglobins; Humans; Indoles; Leukocytes; Liver Neoplasms; Male; Middle Aged; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome | 2011 |
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Medullary; Cell Differentiation; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Pyrroles; Sunitinib; Thyroid Neoplasms; Tomography, Emission-Computed; Treatment Failure | 2010 |
Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Gastrointestinal Stromal Tumors; Humans; Hyperammonemia; Imatinib Mesylate; Indoles; Japan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Portography; Pyrimidines; Pyrroles; Remission Induction; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2011 |
Phase II study of sunitinib malate in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Cerebrovascular Circulation; Disease Progression; Female; Glioma; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrroles; Pyrrolidinones; Receptors, Platelet-Derived Growth Factor; Recurrence; Regional Blood Flow; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Thyroid Function Tests; Thyrotropin; Time Factors; Treatment Outcome | 2012 |
Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
Topics: Acute Kidney Injury; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colitis; Death, Sudden; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2011 |
Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Feasibility Studies; Female; Glutamates; Guanine; Humans; Indoles; Japan; Male; Middle Aged; Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The effect of sunitinib on immune subsets in metastatic clear cell renal cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Female; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrroles; Quinazolines; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Endpoint Determination; Female; Half-Life; Hematologic Diseases; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pyrroles; Salvage Therapy; Sunitinib; Survival Rate; Treatment Outcome | 2010 |
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.
Topics: Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histiocytoma, Malignant Fibrous; Humans; Indoles; Leiomyosarcoma; Liposarcoma; Male; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Recurrence; Retreatment; Sarcoma; Sunitinib; Survival Rate | 2011 |
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.
Topics: 2-Methoxyestradiol; Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colloids; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Estradiol; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nanoparticles; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Survival Analysis; Treatment Failure; United States | 2012 |
A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Indoles; Interleukins; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Recombinant Proteins; Sunitinib; Treatment Failure | 2011 |
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Indoles; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Pyrroles; Sunitinib | 2011 |
Mitotane has a strong and a durable inducing effect on CYP3A4 activity.
Topics: Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Enzyme Activation; Female; Humans; Indoles; Male; Middle Aged; Mitotane; Pyrroles; Sunitinib | 2011 |
The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome; Tumor Burden | 2011 |
[AUO (Working Group on Urological Oncology) study of metastasized renal cell carcinoma: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma with or without adjuvant sunitinib therapy ov
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Germany; Humans; Indoles; Kidney Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Prevalence; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
[Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Compassionate Use Trials; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Male; Prospective Studies; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Failure | 2011 |
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Double-Blind Method; Female; Humans; Indoles; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2011 |
Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Chemoradiotherapy; Epistaxis; Female; Hematemesis; Hemoptysis; Humans; Indoles; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome | 2011 |
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Cell Line, Tumor; Cluster Analysis; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Interleukin-6; Middle Aged; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Tissue Array Analysis; Treatment Outcome | 2011 |
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.
Topics: Aged; Antibodies, Neoplasm; Cancer Vaccines; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Vaccines, DNA | 2011 |
Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.
Topics: Adult; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease-Free Survival; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Indoles; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Pyrroles; Sunitinib; Testicular Neoplasms; Treatment Outcome; Young Adult | 2011 |
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cisplatin; Contrast Media; Disease-Free Survival; Female; Humans; Indoles; Interleukin-8; Kaplan-Meier Estimate; Male; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Urologic Neoplasms | 2011 |
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2012 |
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Drug Interactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2011 |
Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Salvage Therapy; Sunitinib; Time Factors; Treatment Outcome | 2011 |
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Humans; Indoles; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Sunitinib; Thrombocytopenia; Treatment Failure; Tumor Burden | 2011 |
A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices.
Topics: Academic Medical Centers; Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hospitals, Community; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Practice Patterns, Physicians'; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Registries; Sunitinib; United States; Young Adult | 2011 |
Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Early Termination of Clinical Trials; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Patient Dropouts; Platinum; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2011 |
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Perfusion Imaging; Pyrroles; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2011 |
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phthalazines; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2011 |
An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Mutation; Prospective Studies; Protein-Tyrosine Kinases; Pyrroles; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2011 |
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
[Use of sunitinib in metastatic renal cell carcinoma patients with poor prognosis].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2011 |
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival; Treatment Outcome | 2011 |
Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cranial Irradiation; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.
Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Female; Humans; Indoles; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Radiotherapy Dosage; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A | 2011 |
Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; International Agencies; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sunitinib; Tissue Distribution; Treatment Outcome | 2012 |
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Interferon-alpha; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sirolimus; Sunitinib | 2011 |
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Castration; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2011 |
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cell Hypoxia; Cohort Studies; Disease Progression; Humans; Indoles; Kidney Neoplasms; Middle Aged; Misonidazole; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Heart; Humans; Indoles; Male; Maximum Tolerated Dose; Neoplasms; Neutropenia; Pyrroles; Sunitinib | 2011 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Immunity, Cellular; Immunity, Humoral; Indoles; Influenza Vaccines; Influenza, Human; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Vaccination | 2011 |
Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Organ Size; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Gland; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Young Adult | 2011 |
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Neoplasm Proteins; Pyrroles; ROC Curve; Sunitinib; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor C | 2011 |
A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Probability; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids | 2012 |
Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neutropenia; Nomograms; Predictive Value of Tests; Pyrroles; Republic of Korea; Risk Factors; Sunitinib; Thrombocytopenia; Treatment Outcome | 2011 |
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sirolimus; Sunitinib | 2012 |
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Pyrroles; Sunitinib; Survival Analysis; Young Adult | 2012 |
Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Indoles; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2011 |
A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pemetrexed; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.
Topics: Aged; Antineoplastic Agents; Cohort Studies; Female; Humans; Indoles; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Pyrroles; Salvage Therapy; Sunitinib; Survival Rate | 2011 |
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Dideoxynucleosides; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Indoles; Kidney; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasms; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyrroles; Sunitinib; Treatment Failure | 2011 |
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Adenoid Cystic; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Proto-Oncogene Mas; Pyrroles; Salivary Gland Neoplasms; Sunitinib; Treatment Outcome | 2012 |
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Hemangioblastoma; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pilot Projects; Pyrroles; Radiography; Sunitinib; Treatment Outcome; von Hippel-Lindau Disease; Young Adult | 2011 |
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.
Topics: Aged; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; CD3 Complex; CD4 Antigens; Female; Forkhead Transcription Factors; Humans; Indoles; Interleukin-2 Receptor alpha Subunit; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Treatment Outcome | 2012 |
A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Disease-Free Survival; Female; Humans; India; Indoles; Male; Middle Aged; Prospective Studies; Pyrroles; Republic of Korea; Sunitinib; Survival Analysis; Thailand | 2012 |
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Humans; Indoles; Neoplasms; Powders; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Young Adult | 2012 |
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Child; Child, Preschool; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Valproic Acid; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Young Adult | 2012 |
A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.
Topics: Acrylic Resins; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Embolization, Therapeutic; Female; Gelatin; Hepatic Artery; Humans; Indoles; Intestinal Neoplasms; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neuroendocrine Tumors; Proportional Hazards Models; Pyrroles; Statistics, Nonparametric; Sunitinib; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2012 |
[Urgent patient admission to Working Group for Urological Oncology (AUO) studies on metastasized renal cell carcinoma needed: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma ± adjuv
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Germany; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Patient Selection; Pyrroles; Sunitinib | 2012 |
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Humans; Indoles; International Agencies; Middle Aged; Prospective Studies; Pyrroles; Receptor, ErbB-2; Sunitinib; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Administration Schedule; Drug Interactions; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Treatment Outcome | 2012 |
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Remission Induction; Sunitinib; Survival Rate; Treatment Outcome | 2012 |
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2012 |
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monother
Topics: Angiogenesis Inhibitors; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Platinum Compounds; Proportional Hazards Models; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2012 |
Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; Indoles; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrroles; Sunitinib | 2012 |
The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2012 |
Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Indoles; Male; Middle Aged; Paclitaxel; Pyrroles; Sunitinib | 2012 |
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Proportional Hazards Models; Pyrroles; Risk Assessment; Sunitinib; Survival Analysis; Treatment Outcome | 2012 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Platinum; Pyrroles; Salvage Therapy; Stomach Neoplasms; Sunitinib; Survival Rate; Taxoids; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Indoles; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2012 |
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Quinazolines; Smoking; Sunitinib; Treatment Outcome | 2012 |
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib | 2012 |
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Indoles; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Pyrroles; Stomach Neoplasms; Sunitinib; Survival Rate; Tissue Distribution | 2013 |
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2012 |
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
Topics: Adult; Aged; Benzamides; Biomarkers, Tumor; Cross-Over Studies; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neovascularization, Pathologic; Piperazines; Placebos; Pyrimidines; Pyrroles; Retreatment; Sunitinib; Survival Analysis; Young Adult | 2012 |
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Tissue Distribution | 2012 |
Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Prognosis; Pyrroles; Radiotherapy, Image-Guided; Sunitinib; Survival Rate | 2012 |
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2012 |
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sunitinib; Young Adult | 2012 |
Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Calibration; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; Germany; Humans; Indoles; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Protein Stability; Pyrroles; Reference Standards; Reproducibility of Results; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-3 | 2012 |
A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Female; Glioma; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2012 |
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Approval; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; United States; United States Food and Drug Administration | 2012 |
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Disease Progression; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Indoles; Male; Middle Aged; Mitotane; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2012 |
Sunitinib in patients with cisplatin-refractory germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; Female; Humans; Indoles; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Pyrroles; Slovakia; Sunitinib; Treatment Outcome | 2012 |
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blood Pressure; Carcinoma, Renal Cell; Child; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Indoles; Kidney Neoplasms; Male; Middle Aged; Piperazines; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib | 2012 |
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2013 |
A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Prospective Studies; Pyrroles; Sunitinib; Survival Rate | 2012 |
Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.
Topics: Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Humans; Indoles; Male; Molecular Targeted Therapy; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Radionuclide Imaging; Sunitinib; Technetium Tc 99m Medronate; Tomography, X-Ray Computed; Treatment Failure | 2012 |
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Indoles; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Safety and activity of sunitinib in elderly patients (≥ 70 years) with metastatic renal cell carcinoma: a multicenter study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Phase II open-label study of sunitinib in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Middle Aged; Nausea; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2012 |
Continuous daily sunitinib for recurrent glioblastoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Quality of Life; Sunitinib; Survival Rate | 2013 |
Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden | 2012 |
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Pemetrexed; Pyrroles; Sunitinib | 2013 |
Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
A pilot study of sunitinib malate in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pilot Projects; Prognosis; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Treatment Outcome; Uveal Neoplasms | 2012 |
The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Severity of Illness Index; Sorafenib; Sunitinib | 2012 |
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Benzamides; Double-Blind Method; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Survival Rate; Treatment Failure | 2013 |
A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asthenia; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Enzyme-Linked Immunosorbent Assay; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome | 2012 |
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pyrroles; Sunitinib; Survival Rate; Urinary Bladder Neoplasms; Urothelium | 2013 |
Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2012 |
The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal canc
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Quality-Adjusted Life Years; Sunitinib; Survival Analysis; United Kingdom; Withholding Treatment; Young Adult | 2012 |
Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Axitinib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hand-Foot Syndrome; Heparin; Humans; Imidazoles; Indazoles; Indoles; Male; Middle Aged; Niacinamide; Ointments; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrroles; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
Topics: Adult; Aged; Angiogenesis Inhibitors; Asian People; Biomarkers, Tumor; Chromogranin A; Female; Gastrins; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Early Detection of Cancer; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Pilot Projects; Prognosis; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2013 |
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Pyrroles; Sunitinib; Thyroid Neoplasms | 2013 |
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolones; Salvage Therapy; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib; Survival Analysis | 2013 |
A phase II study of sunitinib in advanced hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pyrroles; Risk Assessment; Risk Factors; Sunitinib; Survival Analysis; Treatment Outcome | 2013 |
Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring.
Topics: Chromatography, Liquid; Drug Monitoring; Edetic Acid; Humans; Indoles; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Sunitinib; Tandem Mass Spectrometry | 2013 |
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib | 2013 |
Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria.
Topics: Adolescent; Adult; Algorithms; Antineoplastic Agents; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imaging, Three-Dimensional; Indoles; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Pyrroles; Radiographic Image Interpretation, Computer-Assisted; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Young Adult | 2013 |
Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Drug Interactions; Feasibility Studies; Goserelin; Humans; Indoles; Leuprolide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Radiotherapy, Intensity-Modulated; Seminal Vesicles; Sunitinib; Tosyl Compounds | 2013 |
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Withholding Treatment | 2013 |
A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Diarrhea; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome | 2013 |
Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Combined Modality Therapy; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Radiosurgery; Sunitinib | 2014 |
Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; Sunitinib; Treatment Outcome | 2013 |
Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Drug Combinations; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Pyrroles; Stomach Neoplasms; Sunitinib; Tegafur; Treatment Outcome | 2014 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid | 2013 |
Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sulfonamides; Sunitinib; Survival Rate; Treatment Failure | 2014 |
Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Catheter Ablation; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunologic Factors; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Indoles; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Sunitinib; Treatment Outcome | 2013 |
Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Indoles; Irinotecan; Maximum Tolerated Dose; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Survival; Treatment Outcome | 2013 |
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2013 |
"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.
Topics: Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Young Adult | 2013 |
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Female; Humans; Indoles; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrroles; Sunitinib; Survival Analysis | 2013 |
Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.
Topics: Adult; Aged; Animals; Benzamides; Cell Division; Dichloroacetic Acid; Disease Models, Animal; Drug Monitoring; Familial Primary Pulmonary Hypertension; Female; Fibroblasts; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gene Expression Profiling; Glycolysis; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Indoles; Lung; Male; Middle Aged; Monocrotaline; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Sunitinib; Young Adult | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Indoles; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Pemetrexed; Pyrroles; Sunitinib; Young Adult | 2013 |
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib | 2013 |
The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome.
Topics: Aged; Antineoplastic Agents; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Pyrroles; Seasons; Sunitinib; Sweat | 2013 |
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Renal Cell; Female; Genotype; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Pyrroles; Republic of Korea; Sunitinib | 2013 |
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib; Young Adult | 2013 |
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Benzimidazoles; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolones; Sunitinib | 2013 |
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrroles; Stomach Neoplasms; Sunitinib | 2013 |
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Republic of Korea; Sunitinib; Time Factors; Treatment Outcome | 2013 |
Quantifying vascular heterogeneity using microbubble disruption-replenishment kinetics in patients with renal cell cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Female; Fluorocarbons; Humans; Image Interpretation, Computer-Assisted; Indoles; Kidney Neoplasms; Kinetics; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Ultrasonography | 2014 |
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferon-alpha; Interleukin-8; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-3 | 2014 |
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Transitional Cell; Confounding Factors, Epidemiologic; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Pyrroles; Sample Size; Sunitinib; Treatment Outcome; Urologic Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Survival; Treatment Outcome | 2014 |
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Time Factors; TOR Serine-Threonine Kinases; Treatment Failure; Young Adult | 2014 |
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Discovery; Gossypol; Humans; Indoles; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Radiography; Retrospective Studies; Sunitinib; Survival Rate; Taxoids; Time Factors | 2014 |
A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Pyrroles; Sunitinib; Survival Rate | 2014 |
A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cross-Sectional Studies; Everolimus; Fatigue; Female; Humans; Incidence; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Physicians; Pyrroles; Quality of Life; Self Report; Sirolimus; Sorafenib; Sunitinib; Surveys and Questionnaires | 2014 |
Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.
Topics: Angiogenesis Inhibitors; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Retrospective Studies; Review Literature as Topic; Sunitinib; Survival Rate | 2014 |
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Humans; Indoles; Kaplan-Meier Estimate; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Outcome | 2014 |
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Failure; Tumor Burden; Young Adult | 2014 |
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma.
Topics: Adult; Aged; Biomarkers; Carcinoma, Renal Cell; Diffusion Magnetic Resonance Imaging; Female; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Pyrroles; Radiography; Sunitinib; Treatment Outcome | 2014 |
Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Outcome Assessment, Health Care; Phenylurea Compounds; Piperazines; Prospective Studies; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Failure; World Health Organization | 2014 |
A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2014 |
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Pyrroles; Remission Induction; Salvage Therapy; Sunitinib; Survival Rate | 2014 |
Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study.
Topics: Aged; Antineoplastic Agents; Biopsy; Brain Neoplasms; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Radiotherapy; Sunitinib; Time Factors; Treatment Outcome | 2014 |
A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Fibromatosis, Aggressive; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Tumor Burden; Young Adult | 2014 |
A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infections; Humans; Indoles; Male; Middle Aged; Neoplasms; Pyrroles; Ritonavir; Sunitinib | 2014 |
Fractal analysis of contrast-enhanced CT images to predict survival of patients with hepatocellular carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boston; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Fractals; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pyrroles; Radiography; Sunitinib | 2014 |
Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2014 |
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Sunitinib; Trastuzumab; Treatment Outcome | 2014 |
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Kaplan-Meier Estimate; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pyrroles; Remission Induction; Sunitinib; Thrombocytopenia; Treatment Outcome | 2014 |
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Models, Statistical; Neoplasm Metastasis; Pyrroles; Quality of Life; Retrospective Studies; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2014 |
Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cognition; Cognition Disorders; Cross-Sectional Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Memory; Middle Aged; Neoplasm Metastasis; Neuropsychological Tests; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib | 2014 |
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Over Studies; Double-Blind Method; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Patient Preference; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib; Surveys and Questionnaires | 2014 |
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Male; Middle Aged; Neoplasms; Nervous System Diseases; Pilot Projects; Protein Kinase Inhibitors; Pyrroles; Salvage Therapy; Sunitinib | 2014 |
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Follow-Up Studies; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2014 |
Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Japan; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Pyrroles; Quality of Life; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Indoles; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2014 |
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Hemoglobins; Humans; Indoles; Inflammation; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Placebos; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Retrospective Studies; Sunitinib; Taxoids | 2014 |
Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Cell Line, Tumor; Comparative Genomic Hybridization; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Proteomics; Pyrroles; Reproducibility of Results; RNA Interference; Sunitinib; Time Factors; Tissue Array Analysis; Transfection; Treatment Outcome; Up-Regulation; Vascular Endothelial Growth Factor A | 2014 |
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden | 2014 |
Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Female; Gastrointestinal Hormones; Humans; Indoles; Male; Middle Aged; Neoplasms; Neuropeptides; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; California; Carcinosarcoma; Chicago; Endometrial Neoplasms; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ontario; Pyrroles; Sunitinib | 2014 |
A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib; Thalidomide; Treatment Outcome | 2014 |
Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Placebo Effect; Pyridines; Pyrroles; Quality of Life; Sunitinib; Treatment Failure | 2015 |
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cross-Over Studies; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome; Young Adult | 2014 |
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
Topics: Adolescent; Adult; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Indoles; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Platinum Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrroles; Retroperitoneal Neoplasms; Sunitinib; Testicular Neoplasms; Young Adult | 2014 |
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
Topics: Adult; Angiogenesis Inhibitors; Angiopoietin-2; Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Drug Monitoring; Drug Screening Assays, Antitumor; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kidney Neoplasms; Male; Matrix Metalloproteinase 2; Polymorphism, Single Nucleotide; Prognosis; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-3; Von Hippel-Lindau Tumor Suppressor Protein | 2014 |
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Thiazoles; Treatment Failure | 2014 |
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; Male; MAP Kinase Signaling System; Mice, SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prospective Studies; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Sunitinib | 2014 |
Sunitinib still fi rst-line therapy for metastatic renal cancer.
Topics: Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Prognosis; Pyrroles; Risk Assessment; Sirolimus; Sunitinib; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Sunitinib for atypical and anaplastic meningioma.
Topics: Angiogenesis Inhibitors; Confidence Intervals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local; Pyrroles; Single-Blind Method; Sunitinib; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Pilot Projects; Piperazines; Placebos; Protein Kinase Inhibitors; Purines; Pyrroles; Sildenafil Citrate; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
Topics: Aged; Angiogenesis Inhibitors; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Body Weight; Constitutive Androstane Receptor; Cytochrome P-450 CYP3A; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyrroles; Receptors, Steroid; Sunitinib; Treatment Outcome | 2015 |
A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Pyrroles; Sunitinib | 2015 |
The off-label use of targeted therapies in sarcomas: the OUTC'S program.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Off-Label Use; Phenylurea Compounds; Pyrroles; Registries; Sarcoma; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2014 |
A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome; Young Adult | 2015 |
SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Urologic Neoplasms | 2015 |
Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2014 |
[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2015 |
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Female; Gene Expression; Humans; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Lymphocyte Count; Macrophages; Male; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Singapore; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Compassionate Use Trials; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Dysgeusia; Female; Follow-Up Studies; Humans; Hypertension; Incidence; Indoles; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Neutropenia; Pyrroles; Stomatitis; Sunitinib; Thrombocytopenia; Treatment Outcome | 2015 |
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Prognosis; Pyrroles; Sunitinib; Survival Rate; Thymoma; Thymus Neoplasms | 2015 |
Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Calcium-Binding Proteins; Carcinoma, Renal Cell; China; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Sunitinib; Time Factors; Treatment Failure; Vascular Endothelial Growth Factor A | 2015 |
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Child; Diarrhea; Disease-Free Survival; Fatigue; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Sarcoma; Sunitinib; Treatment Outcome; Young Adult | 2015 |
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
Topics: Administration, Oral; Aged; Animals; Antineoplastic Agents; Chronotherapy; Circadian Rhythm; Cross-Over Studies; Drug Evaluation, Preclinical; Female; Humans; Indoles; Male; Mice; Middle Aged; Neoplasms; Prospective Studies; Pyrroles; Sunitinib | 2015 |
Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Double-Blind Method; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Sunitinib; Survival Analysis; Young Adult | 2015 |
The tolerability of sunitinib in elderly patients with metastatic renal cancer.
Topics: Aged; Antineoplastic Agents; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Maximum Tolerated Dose; Prognosis; Pyrroles; Retrospective Studies; Sunitinib | 2015 |
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult | 2015 |
Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Quality of Life; Retrospective Studies; Sunitinib; Treatment Outcome | 2015 |
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Australia; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sunitinib; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2015 |
Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoid Tumor; Cytokines; Disease-Free Survival; Female; Humans; Indoles; Leukocyte Count; Monocytes; Neuroendocrine Tumors; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; France; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2015 |
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pyrroles; Remission Induction; Sunitinib; Treatment Outcome | 2015 |
Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cell Hypoxia; Cell Proliferation; Docetaxel; Female; Gene Expression Profiling; Humans; Indoles; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Prospective Studies; Pyrroles; Sunitinib; Taxoids; Tomography, X-Ray Computed | 2015 |
Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
Topics: Antineoplastic Agents; CD11b Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cell Survival; Disease Progression; Flow Cytometry; Humans; Immune System; Immunosuppressive Agents; Indoles; Leukocytes, Mononuclear; Monocytes; Myeloid Cells; Neoplasm Metastasis; Neoplasms; Phosphorylation; Pyrroles; Radiosurgery; Sialic Acid Binding Ig-like Lectin 3; STAT3 Transcription Factor; Sunitinib; Treatment Outcome | 2015 |
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib | 2015 |
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Chemotherapy, Adjuvant; Double-Blind Method; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Ventricular Function, Left | 2015 |
Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical tria
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cytoreduction Surgical Procedures; Digestive System Neoplasms; Disease-Free Survival; Everolimus; Gastrointestinal Neoplasms; Gastrointestinal Tract; Genotype; Humans; Indoles; Mutation; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Prospective Studies; Pyrroles; Research Design; Sunitinib | 2015 |
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2015 |
Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Chemoradiotherapy; Extremities; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Prognosis; Prospective Studies; Pyrroles; Radiotherapy, Adjuvant; Retroperitoneal Neoplasms; Sarcoma; Sunitinib | 2015 |
Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Young Adult | 2015 |
A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers.
Topics: Adult; Aged; Angiogenesis Inhibitors; Complement Factor B; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Recurrence; Sunitinib; Transcriptome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C | 2015 |
Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Collagen Type I; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Peptides; Pyrroles; Snake Venoms; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Dynamic Contrast-Enhanced MRI Kinetic Parameters as Prognostic Biomarkers for Prediction of Survival of Patient with Advanced Hepatocellular Carcinoma: A Pilot Comparative Study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Pilot Projects; Proportional Hazards Models; Pyrroles; Sunitinib | 2015 |
Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Cognition Disorders; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neuropsychological Tests; Pyrroles; Radiosurgery; Salvage Therapy; Sunitinib; Treatment Outcome | 2015 |
Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.
Topics: Antineoplastic Agents; Female; Humans; Indoles; Male; Melanoma; Mucous Membrane; Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Skin Neoplasms; Sunitinib | 2015 |
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cohort Studies; Drug Administration Schedule; Female; Humans; Indoles; Injections, Intravenous; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Recombinant Fusion Proteins; Sunitinib | 2015 |
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Ventricular Dysfunction, Left | 2015 |
FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Indoles; Kidney Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Pyrroles; Radiopharmaceuticals; Sunitinib; Treatment Outcome | 2015 |
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib | 2015 |
[Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal c
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2015 |
Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hand-Foot Syndrome; Humans; Incidence; Indoles; Japan; Male; Middle Aged; Neutropenia; Prognosis; Proportional Hazards Models; Pyrroles; Severity of Illness Index; Sunitinib; Thrombocytopenia; Treatment Outcome | 2015 |
[In Process Citation].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Germany; Humans; Indoles; Ipilimumab; Kidney Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Nivolumab; Prognosis; Pyrroles; Societies, Medical; Sunitinib; Urology | 2015 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioma; Humans; Indoles; Lomustine; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Temozolomide | 2015 |
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Withholding Treatment | 2015 |
The early effect of sunitinib on insulin clearance in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Blood Glucose; Carcinoma, Renal Cell; Female; Glucose Clamp Technique; Humans; Hypoglycemia; Indoles; Insulin; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Time Factors | 2016 |
A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2015 |
Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indazoles; Indoles; Kidney Neoplasms; Lymph Nodes; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Quality of Life; Risk Assessment; Sulfonamides; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2016 |
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Early Termination of Clinical Trials; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Survival Rate; Young Adult | 2016 |
Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Endothelial Cells; Endpoint Determination; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Mutation; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Proto-Oncogene Proteins c-kit; Pyrroles; Skin Neoplasms; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Iodine Radioisotopes; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Pyrroles; Radiotherapy; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
Topics: Adolescent; Adult; Aged; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2016 |
Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Pressure; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2016 |
Impact of Acquisition Method and Region of Interest Placement on Inter-observer Agreement and Measurement of Tumor Response to Targeted Therapy Using Dynamic Contrast-Enhanced Ultrasound.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Disease-Free Survival; Drug Monitoring; Female; Humans; Image Interpretation, Computer-Assisted; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Observer Variation; Patient Positioning; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Ultrasonography | 2016 |
Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Patient Selection; Positron-Emission Tomography; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Sample Size; Small Cell Lung Carcinoma; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Salvage Therapy; Sunitinib; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cranial Irradiation; Disease-Free Survival; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Placebos; Pyrroles; Retrospective Studies; Small Cell Lung Carcinoma; Sunitinib | 2016 |
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
Topics: Adult; Aged; Disease-Free Survival; Docetaxel; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Pyrroles; Quality of Life; Salvage Therapy; Sunitinib; Taxoids | 2016 |
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Indoles; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2016 |
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Topics: Adult; Aged; Carcinoma, Renal Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Proportional Hazards Models; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Benefits of pazopanib over sunitinib for renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Patient Safety; Prognosis; Pyrimidines; Pyrroles; Quality of Life; Sensitivity and Specificity; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Administration Schedule; Epothilones; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Tubulin Modulators | 2016 |
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cytokines; Everolimus; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib | 2016 |
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib; Young Adult | 2016 |
Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cluster Analysis; DNA Methylation; DNA Mutational Analysis; Epigenesis, Genetic; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pilot Projects; Promoter Regions, Genetic; Pyrroles; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2016 |
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2016 |
Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2016 |
Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Child; Child, Preschool; Combined Modality Therapy; Drug Monitoring; Drug Resistance, Neoplasm; Ependymoma; Female; Glioma; Humans; Indoles; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Pyrroles; Retreatment; Sunitinib; Treatment Outcome; Young Adult | 2016 |
A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Male; Neoplasm Metastasis; Peptides, Cyclic; Pyrroles; Receptors, CXCR4; Sunitinib | 2016 |
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.
Topics: Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proteinuria; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A | 2016 |
Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03).
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cohort Studies; Female; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Prognosis; Pyrroles; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Sarcoma; Sunitinib | 2016 |
PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor.
Topics: Adult; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Models, Biological; Models, Statistical; Nonlinear Dynamics; Positron-Emission Tomography; Pyrroles; Radiopharmaceuticals; Sunitinib; Survival Analysis; Survival Rate; Treatment Outcome; Tumor Burden | 2016 |
Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Humans; Indoles; Liver Neoplasms; Models, Theoretical; Neovascularization, Pathologic; Pilot Projects; Pyrroles; Sunitinib; Survival Rate; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Sunitinib | 2016 |
[First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion")
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Patient Selection; Pyrroles; Research Design; Sunitinib; Treatment Outcome; Young Adult | 2016 |
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retreatment; Sunitinib; Treatment Failure; Treatment Outcome | 2017 |
BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.
Topics: Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Body Surface Area; Carcinoma, Renal Cell; Female; Genotype; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Models, Biological; Monte Carlo Method; Neoplasm Metastasis; Nonlinear Dynamics; Polymorphism, Genetic; Pyrroles; Sunitinib | 2016 |
Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Management; Docetaxel; Follow-Up Studies; Humans; Indoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Sunitinib; Survival Rate; Taxoids | 2016 |
Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Contrast Media; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Indoles; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Preoperative Period; Pyrroles; Sunitinib; Treatment Outcome | 2016 |
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Female; Fluorouracil; Humans; Indoles; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pyrroles; Stomach Neoplasms; Sunitinib | 2016 |
Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
Topics: Aged; Aged, 80 and over; Algorithms; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Middle Aged; Prospective Studies; Pyrroles; Quality of Life; Response Evaluation Criteria in Solid Tumors; Software; Sunitinib; Surveys and Questionnaires; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Vascular Neoplasms | 2016 |
Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary: identification of the best benefited patients.
Topics: Adult; Antineoplastic Agents; Biomarkers; China; Female; Fluorodeoxyglucose F18; Humans; Indoles; Male; Middle Aged; Neoplasms, Unknown Primary; Outcome Assessment, Health Care; Patient Selection; Positron Emission Tomography Computed Tomography; Prevalence; Prognosis; Pyrroles; Radiopharmaceuticals; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden | 2017 |
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Survival Analysis; Young Adult | 2016 |
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Topics: Aged; Cancer Vaccines; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2016 |
Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Pyrroles; Sunitinib; Treatment Outcome; Tumor Hypoxia | 2017 |
A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Prospective Studies; Pyrroles; Quality of Life; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2016 |
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.
Topics: Antineoplastic Agents; Cross-Sectional Studies; Disease-Free Survival; Double-Blind Method; Humans; Indoles; Kaplan-Meier Estimate; Neuroendocrine Tumors; Pancreatic Neoplasms; Proportional Hazards Models; Pyrroles; Sunitinib; Survival Rate | 2017 |
Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Prospective Studies; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome; von Hippel-Lindau Disease | 2016 |
Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.
Topics: Antineoplastic Agents; Female; Humans; Indoles; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Reported Outcome Measures; Pyrroles; Quality of Life; Retrospective Studies; Sunitinib | 2016 |
Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Tertiary Care Centers; Treatment Outcome; Young Adult | 2017 |
A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2017 |
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Fatigue; Female; Humans; Hypertension; Indoles; Intention to Treat Analysis; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mucositis; Neoplasm Staging; Neutropenia; Platinum Compounds; Pyrroles; Quality of Life; Sunitinib; Survival Rate; Thrombocytopenia | 2017 |
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Pyridines; Pyrroles; Risk Factors; Sunitinib | 2017 |
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate | 2017 |
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck; Pyrroles; Sunitinib; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome | 2017 |
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cross-Over Studies; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Young Adult | 2017 |
Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Genetic Markers; Genotype; Germ-Line Mutation; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Neoplasm Metastasis; Pharmacogenomic Variants; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2017 |
Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypoalbuminemia; Indoles; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Renal Cell; Colorectal Neoplasms; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Indoles; Interleukin-8; Kidney Neoplasms; Male; Middle Aged; Models, Biological; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2017 |
Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated
Topics: Adult; Aged; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Proliferation; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Indazoles; Indoles; London; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasms, Second Primary; Positron-Emission Tomography; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2017 |
Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta-Thromboglobulin; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Killer Cells, Natural; Lymphocytes, Tumor-Infiltrating; Macrophages; Male; Mice; Middle Aged; Neoplasm Grading; Neoplasm Transplantation; Nephrectomy; Neutrophils; Prospective Studies; Pyrroles; Retrospective Studies; Sirolimus; Sunitinib; Survival Rate | 2017 |
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Health Status Indicators; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate | 2017 |
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Proportional Hazards Models; Pyrroles; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2018 |
The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Volume; Carcinoma, Renal Cell; Contrast Media; Disease-Free Survival; Drug Monitoring; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Predictive Value of Tests; Prognosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Ultrasonography | 2018 |
Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib | 2018 |
Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Keratin-18; Leucovorin; Male; Middle Aged; Peptide Fragments; Placebos; Pyrroles; Stomach Neoplasms; Sunitinib | 2018 |
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Pyrroles; Quality of Life; Risk; Sunitinib; Survival Analysis; Survival Rate | 2018 |
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Nephrectomy; Patient Selection; Postoperative Complications; Prognosis; Pyrroles; Risk Assessment; Sunitinib; Survival Analysis | 2018 |
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Ovarian Epithelial; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pyrroles; Sunitinib; Young Adult | 2018 |
Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Necrosis; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor C | 2022 |
Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Pyrroles; Sunitinib | 2023 |
A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Pyrroles; Sirolimus; Sunitinib | 2023 |
2135 other study(ies) available for pyrroles and su 11248
| Article | Year |
|---|---|
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
Topics: Acute Disease; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Transplantation; Endothelial Growth Factors; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid; Lymphokines; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Phosphorylation; Point Mutation; Protein Processing, Post-Translational; Protein Structure, Tertiary; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Signal Transduction; Sunitinib; Tandem Repeat Sequences; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2003 |
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Topics: Animals; Antineoplastic Agents; Cell Division; Enzyme Inhibitors; Female; Humans; Indoles; Inhibitory Concentration 50; Kinetics; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Phosphorylation; Protein-Tyrosine Kinases; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Time Factors; Tumor Cells, Cultured | 2003 |
Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosi
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Biological Availability; Enzyme Inhibitors; Indoles; Mice; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solubility; Structure-Activity Relationship; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Small Cell; Cell Division; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Mice; Mice, Nude; Phosphorylation; Phosphotyrosine; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Stem Cell Factor; Sunitinib; Tumor Cells, Cultured | 2003 |
SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Lewis Lung; Combined Modality Therapy; Endothelium, Vascular; Glioblastoma; Humans; Indoles; Mice; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2003 |
Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.
Topics: Animals; Enzyme Inhibitors; Female; Hair Color; Humans; Indoles; Mice; Mice, Inbred C57BL; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2003 |
A widely applicable, high-throughput TR-FRET assay for the measurement of kinase autophosphorylation: VEGFR-2 as a prototype.
Topics: Antibodies; Biotinylation; Enzyme Inhibitors; Fluorescence Resonance Energy Transfer; Fluoroimmunoassay; Indoles; Kinetics; Peptides; Phosphorylation; Phosphotransferases; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Enzyme Inhibitors; Female; Fluorouracil; Humans; Indoles; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Transplantation; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; Sunitinib; Time Factors | 2003 |
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Indoles; Mice; Mice, Nude; Neoplasm Transplantation; Osteoclasts; Osteolysis; Phosphorylation; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Macrophage Colony-Stimulating Factor; Sunitinib; Tumor Cells, Cultured | 2003 |
Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction.
Topics: Animals; Antineoplastic Agents; Chromatography, Liquid; Enzyme Inhibitors; Haplorhini; Indoles; Mass Spectrometry; Protein-Tyrosine Kinases; Pyrroles; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Tissue Distribution | 2004 |
Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor.
Topics: Animals; Biomarkers; Cadherins; Cell Line, Tumor; Colonic Neoplasms; Enzyme Inhibitors; Feasibility Studies; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neoplasm Transplantation; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Transplantation, Heterologous | 2004 |
Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials.
Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Drug Stability; Drug Storage; Humans; Hydrogen-Ion Concentration; Indoles; Particle Size; Powders; Pyrroles; Solubility; Sunitinib; Temperature | 2004 |
New cancer therapeutics: target-specific in, cytotoxics out?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Delivery Systems; Enzyme Inhibitors; Gefitinib; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Proteomics; Pyrroles; Quinazolines; Sunitinib | 2004 |
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
Topics: Antineoplastic Agents; Cell Division; Cell Line; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Synergism; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Leukemia; Pyrroles; Sunitinib; Zinc Fingers | 2004 |
Three molecularly targeted drugs tested in kidney cancer clinical trials.
Topics: Adenocarcinoma, Clear Cell; Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease-Free Survival; Enzyme Inhibitors; Humans; Indoles; Kidney Neoplasms; Phosphotransferases; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome | 2004 |
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Topics: Adenoma, Islet Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Clinical Protocols; Cyclophosphamide; Disease Models, Animal; Endothelial Cells; Imatinib Mesylate; Indoles; Mice; Mice, Transgenic; Neovascularization, Pathologic; Pancreatic Neoplasms; Pericytes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sunitinib | 2005 |
The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Carcinoma, Lewis Lung; Cell Movement; Cells, Cultured; Endothelium, Vascular; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Secondary Prevention; Sunitinib; Umbilical Cord | 2004 |
Sonographic depiction of changes of tumor vascularity in response to various therapies.
Topics: Angiogenesis Inhibitors; Animals; Combined Modality Therapy; In Situ Nick-End Labeling; Indoles; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pyrroles; Sunitinib; Ultrasonography, Doppler, Color; Vascular Endothelial Growth Factor A | 2005 |
Multi-kinase inhibitors create buzz at ASCO.
Topics: Antineoplastic Agents; Benzenesulfonates; Biotechnology; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Phosphotransferases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2005 |
Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase.
Topics: Fluorine Radioisotopes; Indoles; Neoplasm Proteins; Positron-Emission Tomography; Protein-Tyrosine Kinases; Pyrroles; Radiopharmaceuticals; Structure-Activity Relationship; Sunitinib | 2005 |
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
Topics: Aminoquinolines; Aniline Compounds; Cell Line; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Kinetics; Morpholines; Mutation; Naphthalenes; Neoplasms; Oncogene Proteins v-abl; Organic Chemicals; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Sunitinib | 2005 |
Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Nail Diseases; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2005 |
Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Colonic Neoplasms; Contrast Media; Gadolinium DTPA; HT29 Cells; Humans; Image Enhancement; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
New targets, therapies, and toxicities: lessons to be learned.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Neoplasms; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2006 |
Treatment options in metastatic renal carcinoma: an embarrassment of riches.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2006 |
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.
Topics: Angiogenesis Inhibitors; Animals; Class I Phosphatidylinositol 3-Kinases; Combined Modality Therapy; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Neoplasms; Neovascularization, Pathologic; Oxindoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Propionates; Pyrroles; Quinazolines; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A | 2006 |
Assessment of anti-metastatic drug efficacy via localization and quantification of ex vivo murine bone tumor load using high-throughput MRI T1 parametric analysis.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Prognosis; Pyrroles; Sunitinib; Treatment Outcome | 2006 |
New drug increases survival in stomach cancer.
Topics: Gastrointestinal Stromal Tumors; Humans; Indoles; Prognosis; Pyrroles; Stomach Neoplasms; Sunitinib; Survival Analysis; Treatment Outcome | 2006 |
Sunitinib maleate.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Design; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib; Tumor Cells, Cultured | 2006 |
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Doxorubicin; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2006 |
Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine.
Topics: Aged; Benzamides; Drug Interactions; Female; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Thyroid Function Tests; Thyrotropin; Thyroxine | 2006 |
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Topics: Angiogenesis Inducing Agents; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; HT29 Cells; Humans; Imatinib Mesylate; Indoles; Mice; Mice, Inbred Strains; Piperazines; Propionates; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2006 |
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Mutation; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2006 |
Trials probe new agents for kidney cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Lapatinib; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2006 |
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Proliferation; Humans; Indoles; Mice; NIH 3T3 Cells; Oxindoles; Phosphorylation; Propionates; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrroles; STAT3 Transcription Factor; Sunitinib | 2006 |
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2006 |
A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Capillary Permeability; Choroidal Neovascularization; Disease Models, Animal; Disease Progression; Female; Fluorescein; Fluorescein Angiography; Indoles; Mice; Mice, Inbred C57BL; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gastrointestinal Stromal Tumors; Humans; Indoles; Morpholines; Phosphotransferases; Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2006 |
Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Delivery Systems; Humans; Indoles; Interleukin-2; Karnofsky Performance Status; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Niacinamide; Nurse's Role; Oncology Nursing; Patient Education as Topic; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Risk Assessment; Safety Management; Sorafenib; Sunitinib; Survival Analysis | 2006 |
Three new drugs available to fight kidney cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Lapatinib; Multicenter Studies as Topic; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Long-term response with sunitinib for metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Remission Induction; Sunitinib; Time Factors | 2006 |
New therapeutic options for renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
Topics: Acute Disease; Amino Acid Sequence; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Base Sequence; Cell Division; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; Mice, Nude; Mutagenesis, Site-Directed; Neoplasm Transplantation; Point Mutation; Pyrroles; Sunitinib | 2006 |
We have a new treatment, but you can't afford it.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Costs and Cost Analysis; Drug Costs; Humans; Indoles; Kidney Neoplasms; Male; Medicare; Physician's Role; Pyrroles; Sunitinib | 2006 |
ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Proliferation; Drug Therapy, Combination; Gastrointestinal Stromal Tumors; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphoproteins; Phosphorylation; Piperidines; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 70-kDa; STAT3 Transcription Factor; Sunitinib; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2006 |
New hope for RCC patients.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lapatinib; Pyrroles; Quinazolines; Sirolimus; Sunitinib | 2006 |
The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Everolimus; Hematologic Neoplasms; Humans; Indoles; Leukemia; Mutation; Phosphoproteins; Protein Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2006 |
Sunitinib for imatinib-resistant GIST.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Multicenter Studies as Topic; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2006 |
[Sunitinib for gastrointestinal stromal cell tumors and advanced renal cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2006 |
The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Division; Enzyme Inhibitors; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Middle Aged; Neoplasm, Residual; Phosphotransferases; Pyrroles; Sunitinib; Treatment Outcome | 2006 |
Treatment outcome for metastatic papillary renal cell carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Papillary; Carcinoma, Renal Cell; Clinical Trials as Topic; Cytokines; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2006 |
Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.
Topics: Adult; Antineoplastic Agents; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Indoles; Prospective Studies; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Thyroiditis; Thyrotropin | 2006 |
Current and future management of GIST.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Sunitinib relieves renal cell carcinoma spinal cord compression.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Pyrroles; Spinal Cord Compression; Spinal Neoplasms; Sunitinib | 2007 |
Sunitinib malate.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cell Division; Cell Line, Tumor; Disease Progression; Endothelium, Vascular; Enzyme Inhibitors; Gastrointestinal Stromal Tumors; Humans; Indoles; Leukemia, Myeloid; Lung Neoplasms; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2007 |
Good news for metastatic renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2006 |
Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dermatitis, Seborrheic; Erythema; Foot; Hand; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Syndrome | 2006 |
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Thyroid Function Tests; Thyroid Hormones | 2007 |
Salvation by registration.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Clinical Trials as Topic; Editorial Policies; Humans; Indoles; Kidney Neoplasms; Periodicals as Topic; Pyrroles; Registries; Sunitinib | 2007 |
Renal-cell carcinoma--molecular pathways and therapies.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Gene Silencing; Humans; Hypoxia-Inducible Factor 1; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein | 2007 |
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Approval; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Safety; Sunitinib; United States; United States Food and Drug Administration | 2007 |
Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Pyrroles; Sunitinib | 2006 |
New drugs 07, part I.
Topics: Abatacept; Acetanilides; Alprostadil; Anidulafungin; Antidiuretic Hormone Receptor Antagonists; Antifungal Agents; Antineoplastic Agents; Arabinonucleosides; Benzazepines; Benzenesulfonates; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Echinocandins; Fatty Acids; Humans; Hypoglycemic Agents; Immunoconjugates; Immunosuppressive Agents; Indoles; Insulin; Insulin Detemir; Insulin, Long-Acting; Intercellular Signaling Peptides and Proteins; Lenalidomide; Lubiprostone; Niacinamide; Patient Education as Topic; Peptides, Cyclic; Phenylurea Compounds; Piperazines; Pyridines; Pyrroles; Ranolazine; Sorafenib; Sunitinib; Thalidomide; United States | 2007 |
Fatigue with sunitinib-induced hypothyroidism.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2007 |
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis.
Topics: Angiogenesis Inhibitors; Chronic Disease; Humans; Indoles; Male; Middle Aged; Psoriasis; Pyrroles; Remission Induction; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Two new drugs for renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Drug Interactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Newly approved therapies for RCC and their effect on the standard of care.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Interferons; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2007 |
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Biological Availability; Humans; Indoles; Mice; Protein Kinase Inhibitors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2007 |
ASCO 2006 highlights: targeted therapy for renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urinary Bladder Neoplasms | 2007 |
Sunitinib and hypothyroidism.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Hypothyroidism; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib | 2007 |
Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cytokines; Drug Costs; Humans; Indoles; Kidney Neoplasms; Long-Term Care; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2007 |
Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib.
Topics: Acute Disease; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antineoplastic Agents; Cholecystostomy; Emphysematous Cholecystitis; Gastrointestinal Stromal Tumors; Humans; Hyperbilirubinemia; Indoles; Leukocytosis; Male; Middle Aged; Neoplasm Metastasis; Probability; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2007 |
Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.
Topics: Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Indoles; Iodide Peroxidase; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib; Thyroid Function Tests | 2007 |
[Anti-angiogenetic agents for solid tumors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Transformation, Neoplastic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed | 2007 |
Macrocytosis and cobalamin deficiency in patients treated with sunitinib.
Topics: Antineoplastic Agents; Erythrocyte Indices; Humans; Indoles; Pyrroles; Sunitinib; Transcobalamins; Vitamin B 12 Deficiency | 2007 |
Effect of sunitinib on metastatic gastrointestinal stromal tumor in patients with neurofibromatosis type 1: a case report.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neurofibromatosis 1; Omentum; Pyrroles; Sunitinib | 2007 |
[Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatal Outcome; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Pyrroles; Safety; Sunitinib; Treatment Outcome | 2007 |
Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Tumor Lysis Syndrome | 2007 |
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Hormone Replacement Therapy; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Thyroid Hormones | 2007 |
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Thyroid Function Tests; Thyroid Hormones | 2007 |
Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunologic Factors; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Survival Rate | 2007 |
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2007 |
Hypertension as a predictive factor of Sunitinib activity.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2007 |
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Docetaxel; Gene Expression Profiling; Humans; Indoles; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sunitinib; Survival Rate; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2007 |
Sunitinib malate and multiple receptor tyrosine kinases inhibitors: are they also novel drugs for chronic and neurophatic pain?
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neoplasms; Pain; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Signal Transduction; Sunitinib | 2007 |
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Brain; Brain Neoplasms; Cell Line, Tumor; Flow Cytometry; Focal Adhesion Protein-Tyrosine Kinases; Glioblastoma; Humans; Immunohistochemistry; Immunoprecipitation; Indoles; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Organ Culture Techniques; Phosphorylation; Pyrroles; src-Family Kinases; Sunitinib; Xenograft Model Antitumor Assays | 2007 |
Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neovascularization, Pathologic; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
[Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Controlled Clinical Trials as Topic; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Kidney; Kidney Neoplasms; Meta-Analysis as Topic; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors | 2007 |
Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Male; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Technology Transfer; Treatment Outcome | 2007 |
Complete cerebral response with sunitinib for metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2007 |
Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
Topics: Administration, Oral; Antineoplastic Agents; Fatal Outcome; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tumor Lysis Syndrome | 2007 |
Reversible posterior leukoencephalopathy syndrome induced by sunitinib.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Brain; Brain Diseases; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Pyrroles; Seizures; Sunitinib; Syndrome; Treatment Outcome | 2007 |
[Imatinib . Sunitinib].
Topics: Angiogenesis Inhibitors; Benzamides; Carcinoma, Renal Cell; Dermatofibrosarcoma; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms; Sunitinib; Survival Rate | 2007 |
Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiomyopathies; Contraindications; Echocardiography; Female; Humans; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Severity of Illness Index; Sunitinib; Ventricular Dysfunction, Left | 2007 |
Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report.
Topics: Humans; Indoles; Male; Middle Aged; Prostatic Neoplasms; Pyrroles; Sunitinib; Thyroiditis; Thyrotoxicosis | 2007 |
Eccrine squamous syringometaplasia associated with sunitinib therapy.
Topics: Aged; Antineoplastic Agents; Eccrine Glands; Humans; Indoles; Male; Pyrroles; Sunitinib; Sweat Gland Neoplasms; Syringoma | 2007 |
Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2008 |
Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'.
Topics: Antineoplastic Agents; Humans; Indoles; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Receptors, Cell Surface; Sunitinib | 2007 |
Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Treatment Outcome | 2007 |
Temsirolimus for advanced renal-cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sirolimus; Sunitinib | 2007 |
High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
Topics: Adult; Aged; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2008 |
[Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; ErbB Receptors; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2007 |
Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.
Topics: Antineoplastic Agents; Female; Humans; Hypertension; Indoles; Middle Aged; Neurotoxicity Syndromes; Purpura, Thrombotic Thrombocytopenic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cognition Disorders; Dementia, Vascular; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2007 |
Macrocytosis due to treatment with sunitinib.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Vitamin B 12 Deficiency | 2007 |
Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2007 |
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats.
Topics: Angiogenesis Inhibitors; Animals; Cells, Cultured; Disease Models, Animal; Hypertension, Portal; Indoles; Inflammation; Liver Cirrhosis; Male; Portal Pressure; Pyrroles; Rats; Rats, Wistar; Sunitinib | 2007 |
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.
Topics: Angiogenesis Inducing Agents; Animals; Antineoplastic Agents; Blood Proteins; Cell Hypoxia; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Mice; Mice, SCID; Neoplasms; Organ Specificity; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Potential biomarkers in metastatic gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Platelets; Bone Marrow; Flow Cytometry; Gastrointestinal Stromal Tumors; Humans; Indoles; Interleukin-6; Neoplasm Metastasis; Phenotype; Pyrroles; Sunitinib; Thrombopoietin | 2007 |
Unanswered questions regarding the management of sunitinib-induced hypothyroidism.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Humans; Hypothyroidism; Indoles; Neoplasms; Pyrroles; Sunitinib; Thyroid Hormones | 2007 |
Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; MAP Kinase Kinase 1; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Pyrroles; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sunitinib; Tumor Cells, Cultured | 2008 |
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
Topics: Aged; Atrial Fibrillation; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Chest Pain; Drug Interactions; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sampling Studies; Severity of Illness Index; Sorafenib; Sunitinib | 2007 |
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2008 |
Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib.
Topics: Aged; Carcinoma, Renal Cell; Humans; Indoles; Male; Necrosis; Pyrroles; Sunitinib | 2007 |
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Coronary Thrombosis; Diagnosis, Differential; Female; Heart Atria; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Neoadjuvant Therapy; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Ultrasonography | 2008 |
Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit.
Topics: Aged; Aged, 80 and over; Benzamides; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Male; Middle Aged; Mutation; Neoplasms, Unknown Primary; Piperazines; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib | 2008 |
Cardiac toxicity of sunitinib.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Humans; Indoles; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2007 |
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
Topics: Animals; Antineoplastic Agents; Blood Pressure; Female; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Indoles; Male; Mice; Middle Aged; Multicenter Studies as Topic; Protein-Tyrosine Kinases; Pyrroles; Rats; Retrospective Studies; Stroke Volume; Sunitinib | 2007 |
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2008 |
Brain metastases in patients with renal cell cancer receiving new targeted treatment.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report.
Topics: Adult; Antineoplastic Agents, Hormonal; Biopsy, Needle; Carcinoid Tumor; Follow-Up Studies; Humans; Indoles; Ki-67 Antigen; Lymphatic Diseases; Male; Necrosis; Neoplasm Staging; Octreotide; Pneumonectomy; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrroles; Radiography, Thoracic; Sunitinib; Synaptophysin; Thymus Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Home blood-pressure monitoring in patients receiving sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carcinoma, Renal Cell; Heart Rate; Home Nursing; Humans; Hypertension; Indoles; Kidney Neoplasms; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Telemedicine | 2008 |
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Endothelial Cells; Female; Fluorescent Antibody Technique; Humans; Indoles; Lenalidomide; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrroles; Rats; Sunitinib; Thalidomide; Xenograft Model Antitumor Assays | 2008 |
Allergic interstitial nephritis possibly related to sunitinib use.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Eosinophilia; Female; Humans; Indoles; Kidney; Kidney Neoplasms; Nephrectomy; Nephritis, Interstitial; Proteinuria; Pyrroles; Sunitinib | 2007 |
Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2008 |
Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Nephrectomy; Protein Kinases; Pyrazoles; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2008 |
Disillusionment bias in clinical trials testing new drugs.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Europe; Humans; Indoles; Informed Consent; Interferons; Pyrroles; Selection Bias; Spain; Sunitinib; Treatment Refusal | 2008 |
Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis.
Topics: Antineoplastic Agents; Carcinoid Tumor; Drug Eruptions; Erythema; Follow-Up Studies; Foot Dermatoses; Hand Dermatoses; Humans; Immunosuppressive Agents; Indoles; Male; Middle Aged; Mouth Mucosa; Mucositis; Pyrroles; Risk Assessment; Skin Diseases, Vesiculobullous; Sunitinib; Treatment Outcome | 2008 |
[New drugs; sunitinib and sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib | 2008 |
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Time Factors | 2007 |
Acute cardiac failure after sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Fatal Outcome; Heart Failure; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2008 |
Rare case of hemangiopericytoma responds to sunitinib.
Topics: Angiogenesis Inhibitors; Bone Neoplasms; Hemangiopericytoma; Humans; Indoles; Lung Neoplasms; Male; Maxillary Sinus Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pelvic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Radiography; Rare Diseases; Sunitinib | 2008 |
F-18 FDG PET/CT assessment of gastrointestinal stromal tumor response to sunitinib malate therapy.
Topics: Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Indoles; Liver Neoplasms; Middle Aged; Pyrroles; Radiography; Radionuclide Imaging; Radiopharmaceuticals; Sunitinib | 2008 |
Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Child; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Indoles; Mice; Neoplasms, Experimental; Pyrroles; Sunitinib; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2008 |
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; CD8-Positive T-Lymphocytes; Cell Division; Cell Movement; Cells, Cultured; Cytokines; Dendritic Cells; Dextrans; Endocytosis; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indoles; Interleukin-4; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Toll-Like Receptor 4 | 2008 |
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Collagen; Collagen Type IV; Dacarbazine; Drug Combinations; Glioma; Immunoenzyme Techniques; Indoles; Laminin; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Proteoglycans; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sunitinib; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Remission of diabetes while on sunitinib treatment for renal cell carcinoma.
Topics: Antineoplastic Agents; Blood Glucose; Carcinoma, Renal Cell; Dendritic Cells; Diabetes Complications; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Indoles; Insulin; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cost-Benefit Analysis; Cytokines; Decision Support Techniques; Disease-Free Survival; Drug Costs; Female; Finland; Health Care Costs; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Markov Chains; Models, Economic; Palliative Care; Protein Kinase Inhibitors; Pyrroles; Quality-Adjusted Life Years; Sunitinib; Time Factors; Treatment Failure | 2008 |
Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Coma; Fatal Outcome; Female; Fibroma; Fibrosarcoma; Humans; Indoles; Liver Neoplasms; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Treatment Failure | 2008 |
Severe epistaxis with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Epistaxis; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2008 |
Skin ulcers in Klippel-Trenaunay syndrome respond to sunitinib.
Topics: Adult; Angiogenesis Inhibitors; Female; Humans; Indoles; Klippel-Trenaunay-Weber Syndrome; Pyrroles; Skin Ulcer; Sunitinib; Treatment Outcome | 2008 |
[New drugs; sunitinib and sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Heart; Humans; Indoles; Myocardium; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib.
Topics: Abdominal Cavity; Administration, Oral; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Indoles; Mice; Mice, Inbred C57BL; Pyrroles; Sunitinib; Tissue Adhesions; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Response to sunitinib in medullary thyroid cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Medullary; Female; Humans; Indoles; Proto-Oncogene Proteins c-ret; Pyrroles; Sunitinib; Thyroid Neoplasms | 2008 |
Metastatic renal cell carcinoma with partial response to sunitinib complicated by ureteral obstruction from necrotic tumor.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Middle Aged; Necrosis; Pyrroles; Sunitinib; Ureteral Obstruction | 2009 |
Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Agents; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib | 2008 |
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Thyrotoxicosis; Thyrotropin; Thyroxine | 2008 |
Editorial comment on: Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Movement; Humans; Indoles; Kisspeptins; Matrix Metalloproteinase Inhibitors; Molecular Biology; Neoplasm Invasiveness; Pyrroles; Receptors, G-Protein-Coupled; Receptors, Kisspeptin-1; Sunitinib; Treatment Outcome; Tumor Suppressor Proteins | 2009 |
[Consensus on the medical treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2007 |
Cardiotoxicity associated with sunitinib.
Topics: Angiogenesis Inhibitors; Cardiomyopathies; Humans; Indoles; Pyrroles; Sunitinib; Troponin I | 2008 |
Cardiotoxicity associated with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2008 |
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2008 |
Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.
Topics: Adenocarcinoma, Follicular; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Papillary; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Thyroid Neoplasms | 2008 |
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Probability; Protein-Tyrosine Kinases; Pyrroles; Registries; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Stroke Volume; Sunitinib; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Re: Pierre I. Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al. Neoadjuvant Sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008;53:845-8.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Heart Diseases; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Pyrroles; Sunitinib; Thrombosis | 2008 |
Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Pyoderma Gangrenosum; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
[Neoadjuvant therapy for renal cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Indoles; Kidney Neoplasms; Lymph Node Excision; Male; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Acute severe hypothyroidism induced by sunitinib.
Topics: Acute Disease; Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Indoles; Pyrroles; Sunitinib | 2008 |
A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Female; Gastrointestinal Stromal Tumors; Health Care Costs; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.
Topics: Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Combined Modality Therapy; Diagnosis, Differential; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Nephrectomy; Prognosis; Pyrroles; Sunitinib | 2008 |
SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Indoles; Pancreatic Neoplasms; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents; Sunitinib | 2008 |
Severe gastrointestinal hemorrhage due to metastatic renal cell carcinoma to the pancreas successfully controlled by transarterial embolization and adjuvant administration of Sunitinib Malate.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Embolization, Therapeutic; Gastrointestinal Hemorrhage; Humans; Indoles; Kidney Neoplasms; Male; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2008 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nicotinic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urea | 2008 |
Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Pneumatosis Cystoides Intestinalis; Pyrroles; Radiography; Sunitinib | 2009 |
Stability of sunitinib in oral suspension.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Drug Compounding; Drug Stability; Drug Storage; Indoles; Pyrroles; Refrigeration; Sunitinib; Suspensions | 2008 |
Effect of sunitinib on growth and function of FRTL-5 thyroid cells.
Topics: Angiogenesis Inhibitors; Animals; Biological Transport; Cell Line; Dose-Response Relationship, Drug; Indoles; Iodine Radioisotopes; Pyrroles; Rats; Receptors, Thyrotropin; RNA, Messenger; Sunitinib; Symporters; Thyroid Gland; Time Factors | 2008 |
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Infusions, Intravenous; Male; Mice; Mice, Nude; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Xenograft Model Antitumor Assays | 2008 |
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Health Surveys; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Quality of Life; Salvage Therapy; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
Sunitinib in the treatment of tubulocystic carcinoma of the kidney. A case report.
Topics: Adult; Biopsy, Needle; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Diagnosis, Differential; Drug Administration Schedule; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Neoplasm Staging; Nephrectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Multicenter Studies as Topic; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythrocyte Indices; Female; Hematologic Tests; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib | 2008 |
Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Sunitinib malate as the salvage therapy in advanced rectal carcinoid tumor.
Topics: Antineoplastic Agents; Carcinoid Tumor; Humans; Indoles; Male; Middle Aged; Pyrroles; Rectal Neoplasms; Salvage Therapy; Sunitinib | 2008 |
Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies.
Topics: Antibodies, Anti-Idiotypic; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Thyroid Gland; Thyroiditis, Autoimmune; Thyrotropin; Thyroxine; Triiodothyronine | 2008 |
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chi-Square Distribution; DNA Primers; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2008 |
Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Green Fluorescent Proteins; Humans; Hypoxia; Indoles; Microscopy, Confocal; Neovascularization, Pathologic; Pyrroles; Receptors, Notch; Retinal Diseases; Retinal Neovascularization; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Zebrafish | 2008 |
Sunitinib-related fulminant hepatic failure: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Failure, Acute; Pyrroles; Sunitinib | 2008 |
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
Topics: Adenosine Triphosphate; Animals; Benzamides; Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Electron Transport; Galactose; Glucose; Imatinib Mesylate; Indoles; Male; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocytes, Cardiac; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Thiazoles | 2008 |
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Thyroid Function Tests | 2008 |
[Targeted therapy - point blank or single shot].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Time Factors; Treatment Outcome; Young Adult | 2008 |
Watchdog set to reject four drugs for kidney cancer on the NHS.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Approval; Drug Costs; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; State Medicine; Sunitinib; United Kingdom | 2008 |
[New therapeutic regimes in metastasic renal-cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
[Antiangiogenics: new therapeutic standards in metastatic kidney cancer].
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
The case / progressive hypertension and proteinuria on anti-angiogenic therapy.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Hypertension; Indoles; Kidney; Models, Biological; Proteinuria; Pyrroles; Sunitinib; Syndrome; Vascular Endothelial Growth Factor A | 2008 |
Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Diabetic Angiopathies; Drug Eruptions; Foot; Foot Diseases; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Necrosis; Paresthesia; Pyrroles; Skin; Sunitinib | 2008 |
Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Managed Care Programs; Markov Chains; Models, Economic; Neoplasm Metastasis; Pyrroles; Quality-Adjusted Life Years; Sunitinib; Survival Rate | 2008 |
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polycythemia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Sample Size; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2008 |
Acute hepatic failure following monotherapy with sunitinib for ovarian cancer.
Topics: Antineoplastic Agents; Fatal Outcome; Female; Humans; Indoles; Liver Failure, Acute; Lymphatic Metastasis; Middle Aged; Ovarian Neoplasms; Pyrroles; Sunitinib | 2009 |
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Nomograms; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2008 |
Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspases; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Indoles; Mice; Mice, SCID; Microcirculation; Pain; Pyrroles; Radiation-Sensitizing Agents; Sunitinib; Tumor Burden | 2008 |
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proctocolitis; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Major treatment improvements encourage kidney cancer researchers to seek further gains.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Scrotal cutaneous side effects of sunitinib.
Topics: Antineoplastic Agents; Drug Eruptions; Genital Diseases, Male; Humans; Indoles; Male; Pyrroles; Scrotum; Sunitinib | 2008 |
Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; In Vitro Techniques; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase.
Topics: Antineoplastic Agents; Apoptosis; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Cell Cycle; Cell Line; Cell Proliferation; Cyclooxygenase Inhibitors; Dinoprostone; Gene Expression; Humans; Indoles; Indomethacin; Phosphorylation; Pyrroles; Retinoblastoma Protein; S Phase; Sunitinib; Thyroid Neoplasms | 2008 |
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD1; Carcinoma, Renal Cell; Cell Lineage; Dendritic Cells; Disease-Free Survival; Female; Glycoproteins; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Myeloid Cells; Pyrroles; Sunitinib | 2008 |
[Renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
Pharmacokinetics of sunitinib in hemodialysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Humans; Indoles; Kidney Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Renal Dialysis; Renal Insufficiency; Sunitinib; Young Adult | 2009 |
Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lymph Node Excision; Lymphatic Diseases; Male; Middle Aged; Pyrroles; Sunitinib | 2009 |
Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib.
Topics: Acetyl-CoA Carboxylase; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Animals, Newborn; Antineoplastic Agents; Apoptosis; Cells, Cultured; Hypoglycemic Agents; Indoles; L-Lactate Dehydrogenase; Metformin; Muscle Cells; Oxidative Stress; Phenformin; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Ribosomal Protein S6 Kinases, 90-kDa; Sunitinib | 2008 |
Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Humans; Indoles; Molecular Structure; Pyrroles; Reproducibility of Results; Sunitinib; Tandem Mass Spectrometry | 2008 |
Sunitinib-induced acute hemolysis without hypertension: a case report.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Hemolysis; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2008 |
Documentation of thyroid function in clinical studies with sunitinib: why does it matter?
Topics: Angiogenesis Inhibitors; Female; Humans; Hypothyroidism; Indoles; Male; Neoplasms; Pyrroles; Sunitinib; Thyroid Function Tests; Treatment Outcome | 2008 |
[Systemic therapy of metastasizing renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2008 |
Cardiovascular toxicity of new agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cardiovascular Diseases; Cardiovascular System; Humans; Indoles; Protein Kinase Inhibitors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
[Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2008 |
Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
Topics: Antineoplastic Agents; Benzenesulfonates; Cardiovascular Diseases; Humans; Indoles; Neoplasms; Niacinamide; Patient Care Team; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2008 |
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Cardiovascular Diseases; Echocardiography; Electrocardiography; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2008 |
Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Blood Glucose; Carcinoma, Renal Cell; Female; Humans; Indoles; Insulin-Like Growth Factor I; Kidney Neoplasms; Male; Middle Aged; NF-kappa B; Pyrroles; Retrospective Studies; Sunitinib | 2008 |
Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Dental Fistula; Humans; Indoles; Jaw Diseases; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Osteonecrosis; Pyrroles; Sunitinib | 2009 |
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Case-Control Studies; CD3 Complex; CD4-Positive T-Lymphocytes; Female; Humans; Immunosuppression Therapy; Indoles; Interferon-gamma; Interleukin-4; Kidney; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Recombinant Proteins; Sunitinib; T-Lymphocytes, Regulatory; Th1 Cells; Th2 Cells | 2008 |
Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Perforation; Male; Neoplasm Recurrence, Local; Peritonitis; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Withholding Treatment | 2009 |
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Withholding Treatment | 2009 |
Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.
Topics: Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2008 |
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Biological Transport; Cell Line, Transformed; Cell Line, Tumor; Humans; Hydrolysis; Imatinib Mesylate; Indoles; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Photoaffinity Labels; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Interactions; Glioma; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Male; Mice; Mice, Nude; Pyrroles; Sunitinib; Temozolomide; Tissue Distribution; Xenograft Model Antitumor Assays | 2009 |
Vascular endothelial growth factor and angiopoietin-2 play a major role in the pathogenesis of vascular leakage in cirrhotic rats.
Topics: Angiopoietin-1; Angiopoietin-2; Animals; Capillary Permeability; Carbon; Drug Combinations; Endothelium, Vascular; Indoles; Liver; Liver Cirrhosis; Male; Mesentery; Microvessels; Pancreas; Povidone; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Staining and Labeling; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pain Management; Palliative Care; Pyrroles; Quality of Life; Sunitinib; Zoledronic Acid | 2008 |
Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors.
Topics: Adrenal Glands; Animals; Antineoplastic Agents; Bone Marrow; Female; Gastrointestinal Tract; Growth Plate; Incisor; Indoles; Lymphoid Tissue; Macaca fascicularis; Male; Microscopy, Electron; Neovascularization, Pathologic; Ovary; Pancreas; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Recovery of Function; Signal Transduction; Sunitinib; Toxicity Tests, Chronic | 2008 |
Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas.
Topics: Animals; Antigens; Bone Marrow Cells; Cell Line, Tumor; Cell Movement; Dermoscopy; Female; Flow Cytometry; Genetic Therapy; Glioma; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indoles; Male; Mesenchymal Stem Cells; Proteoglycans; Pyrroles; Rats; Receptors, Platelet-Derived Growth Factor; Stromal Cells; Sunitinib | 2009 |
Blackberry-induced hand-foot skin reaction to sunitinib.
Topics: Antineoplastic Agents; Cell Phone; Colorectal Neoplasms; Drug Eruptions; Female; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Middle Aged; Pyrroles; Sunitinib | 2009 |
Cost effectiveness of sunitinib.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Data Interpretation, Statistical; Drug Costs; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Agents; Humans; Indoles; Male; Middle Aged; Mutation; Paraganglioma; Pheochromocytoma; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2009 |
Major response to sunitinib (Sutene) in metastatic malignant phyllodes tumor of breast.
Topics: Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phyllodes Tumor; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition.
Topics: Chemotherapy, Adjuvant; Follow-Up Studies; Hair Color; Humans; Hypopigmentation; Ileum; Indoles; Intestinal Neoplasms; Leiomyoma; Male; Middle Aged; Neoplasm Recurrence, Local; Periodicity; Proto-Oncogene Proteins c-kit; Pyrroles; Risk Assessment; Sunitinib; Twins, Monozygotic | 2008 |
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood Glucose; Diabetes Mellitus, Type 1; Female; Humans; Imatinib Mesylate; Indoles; Leukocytes; Mice; Mice, Inbred NOD; Mice, SCID; Pancreas; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Sunitinib | 2008 |
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
Topics: Adrenal Gland Neoplasms; Adult; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Drug Delivery Systems; Female; Humans; Indoles; Neoplasms, Multiple Primary; Pheochromocytoma; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Treatment Outcome; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein | 2009 |
[Vascular and renal effects of anti-angiogenic therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Glomerular Filtration Rate; Glomerulonephritis; Humans; Indoles; Kidney; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Mucous Membrane; Mutation; Neoplasm Metastasis; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyrroles; Skin Neoplasms; Stem Cell Factor; Sunitinib | 2009 |
Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?
Topics: Acute Disease; Acute Kidney Injury; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephritis, Interstitial; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2009 |
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Analysis | 2009 |
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
Topics: Adenoma, Sweat Gland; Adult; Antineoplastic Agents; Female; Humans; Indoles; Kidney; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Sunitinib; Thrombosis; Vascular Endothelial Growth Factor A | 2009 |
Imatinib-induced interstitial lung disease and sunitinib-associated intra-tumour haemorrhage.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Hemorrhage; Humans; Imatinib Mesylate; Indoles; Lung Diseases, Interstitial; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Activity of sunitinib in patients with advanced neuroendocrine tumors.
Topics: Antineoplastic Agents; Humans; Indoles; Neuroendocrine Tumors; Pyrroles; Sunitinib | 2009 |
Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate.
Topics: Adult; Antineoplastic Agents; Female; Humans; Indoles; Paraganglioma; Pyrroles; Sunitinib | 2009 |
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Delivery Systems; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2008 |
Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bevacizumab; Drug Synergism; Endothelial Cells; Epothilones; Female; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2008 |
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Carcinoma, Renal Cell; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Preoperative Care; Pyrroles; Risk Assessment; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Cell Line, Tumor; Desmin; Doxorubicin; Glioblastoma; Hemodynamics; Indoles; Mice; Mice, Nude; Microcirculation; Pyrroles; Sunitinib | 2009 |
Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nephrectomy; Pain; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2009 |
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Survival Rate; Treatment Outcome | 2009 |
Treatment of hemodialyzed patient with sunitinib.
Topics: Anemia; Antineoplastic Agents; Carcinoma, Renal Cell; Coronary Artery Bypass; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypertension; Indoles; Male; Middle Aged; Nausea; Nephrectomy; Pyrroles; Remission Induction; Renal Dialysis; Sunitinib; Thrombocytopenia; Treatment Outcome; Vomiting | 2009 |
Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Thyrotoxicosis | 2009 |
Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2009 |
Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma.
Topics: Aged; Biopsy, Needle; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Pharmacokinetics of sunitinib in an obese patient with a GIST.
Topics: Adult; Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Obesity; Pyrroles; Sunitinib | 2009 |
Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.
Topics: Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Pancreatic Neoplasms; Pyrroles; Salvage Therapy; Sunitinib | 2009 |
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Phosphorylation; Piperazines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Spectrometry, Fluorescence; Sunitinib | 2009 |
Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Pyrroles; Renal Dialysis; Skin Neoplasms; Sunitinib | 2009 |
Metastatic adrenocortical carcinoma treated with sunitinib: a case report.
Topics: Adrenal Cortex Neoplasms; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Resistance, Neoplasm; Humans; Indoles; Male; Mitotane; Pyrroles; Radiotherapy, Adjuvant; Sunitinib; Treatment Failure; Treatment Outcome; Young Adult | 2009 |
Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Female; Indoles; Macaca fascicularis; Male; Mice; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Sunitinib; Tandem Mass Spectrometry | 2009 |
Statin therapy as the fundamental therapy for cardiovascular prevention: be careful.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Humans; Indoles; Male; Neoplasms; Prospective Studies; Pyrroles; Sunitinib | 2009 |
Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase C; Protein Kinase C beta; Pyridines; Pyrroles; Ribosomal Protein S6 Kinases; Signal Transduction; Sorafenib; Sunitinib | 2009 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney; Kidney Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Time Factors | 2009 |
[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Cohort Studies; Data Interpretation, Statistical; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Surveys and Questionnaires; Time Factors; Urology | 2009 |
Hits and misses in targeting pediatric cancers.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Infant; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?
Topics: Angiogenesis Inhibitors; Diphosphonates; Humans; Imidazoles; Indoles; Jaw Diseases; Osteonecrosis; Pyrroles; Sunitinib; Zoledronic Acid | 2009 |
Response to sunitinib malate in advanced alveolar soft part sarcoma.
Topics: Adult; Drug Evaluation; ErbB Receptors; Female; Humans; Indoles; Male; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sarcoma, Alveolar Soft Part; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases | 2009 |
Sunitinib-induced hemoglobin changes are related to the dosing schedule.
Topics: Animals; Antineoplastic Agents; Drug Administration Schedule; Hemoglobins; Humans; Indoles; Polycythemia; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2009 |
Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Blood Pressure; Carcinoma, Renal Cell; Diuretics; Drug Therapy, Combination; Electrocardiography; Female; Furosemide; Gated Blood-Pool Imaging; Heart Failure; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Metoprolol; Pyrroles; Sunitinib; Treatment Outcome; Troponin | 2009 |
Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain; Brain Edema; Brain Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Seizures; Sorafenib; Sunitinib | 2009 |
NICE recommends kidney cancer drug it previously rejected on cost grounds.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Drug Approval; Drug Costs; Humans; Indoles; Kidney Neoplasms; Pyrroles; Quality-Adjusted Life Years; Sunitinib; United Kingdom | 2009 |
Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Biomarkers, Tumor; Blood Cell Count; Carcinoma, Renal Cell; Endothelial Cells; Erythropoietin; Female; Flow Cytometry; Hematopoietic Stem Cells; Humans; Indoles; Kidney Neoplasms; Kinetics; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Foot Diseases; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Niacinamide; Paresthesia; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib.
Topics: Acalculous Cholecystitis; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
From theoretical synergy to clinical supra-additive toxicity.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Drug Synergism; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Inhibitory Concentration 50; Methotrexate; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; RNA, Messenger; Sunitinib; Time Factors; Topotecan; Transfection; Up-Regulation; Vincristine | 2009 |
Sunitinib adverse event: oral bullous and lichenoid mucositis.
Topics: Antineoplastic Agents; Blister; Female; Humans; Indoles; Lichenoid Eruptions; Middle Aged; Pyrroles; Stomatitis; Sunitinib | 2009 |
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Renal Cell; Cell Growth Processes; Cell Line, Tumor; Female; Humans; Indoles; Kidney Neoplasms; Mice; Neovascularization, Pathologic; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2009 |
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Humans; Indoles; Mice; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Prolonged use of the tyrosine kinase inhibitor in a peritoneal dialysis patient with metastatic renal cell carcinoma: possible beneficial effects on peritoneal membrane and peritonitis rates.
Topics: Abdominal Neoplasms; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Peritoneal Dialysis; Peritonitis; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2009 |
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Linear Models; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors | 2009 |
Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Humans; Indoles; Liver Neoplasms; Male; Mediastinal Neoplasms; Pheochromocytoma; Pyrroles; Sunitinib | 2009 |
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferon-gamma; Kidney Neoplasms; Male; Middle Aged; Myeloid Cells; Pyrroles; Sunitinib; Suppressor Factors, Immunologic; T-Lymphocytes, Regulatory | 2009 |
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.
Topics: Amino Acid Sequence; Animals; Carcinoma, Lewis Lung; Colonic Neoplasms; Indoles; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Molecular Sequence Data; Myeloid Cells; Protein Kinase Inhibitors; Pyrroles; Sunitinib; T-Lymphocytes, Regulatory | 2009 |
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Cell Line, Tumor; Dendritic Cells; Humans; Indoles; Interleukin-12; Kidney Neoplasms; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Monocytes; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes; Vascular Endothelial Growth Factor A | 2009 |
Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Controversies in the surgical management of GIST in the era of imatinib.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.
Topics: Administration, Oral; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Embryonic Development; Enzyme Inhibitors; Female; Fetal Development; Fetal Viability; Indoles; Maternal-Fetal Exchange; Mothers; Pregnancy; Pyrroles; Rabbits; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Sunitinib | 2009 |
Tyrosine kinase inhibitors in treatment of fibrous histiocytoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Histiocytoma, Malignant Fibrous; Humans; Indoles; Kidney Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2009 |
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Salvage Therapy; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2009 |
Toxic dermatolysis, tissue necrosis and impaired wound healing due to sunitinib treatment leading to forefoot amputation.
Topics: Aged; Amputation, Surgical; Angiogenesis Inhibitors; Anti-Bacterial Agents; Carcinoma, Renal Cell; Cutis Laxa; Debridement; Foot Dermatoses; Forefoot, Human; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pyrroles; Stevens-Johnson Syndrome; Sunitinib; Treatment Outcome; Wound Healing | 2009 |
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Piperazines; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib; Survival Rate; Treatment Failure; Treatment Outcome | 2009 |
Sunitinib-induced myxedema coma.
Topics: Aged; Angiogenesis Inhibitors; Coma; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Pyrroles; Sunitinib | 2009 |
Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Nephrotic Syndrome; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine.
Topics: Acetaminophen; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Indoles; Liver Failure; Middle Aged; Pyrroles; Sunitinib; Thyroxine | 2009 |
Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis.
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Genetic Engineering; Immunohistochemistry; Indoles; Lung Neoplasms; Mice; Mutation; Neoplasm Metastasis; Neovascularization, Pathologic; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrroles; Sunitinib | 2009 |
NICE celebrates 10th anniversary amid renal cancer drug controversy.
Topics: Antineoplastic Agents; Humans; Indoles; Kidney Neoplasms; Practice Guidelines as Topic; Pyrroles; Sunitinib; United Kingdom; Urology | 2009 |
Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Indoles; Linear Models; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sunitinib | 2009 |
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Fatal Outcome; Female; Hemangiopericytoma; Humans; Indoles; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recurrence; Solitary Fibrous Tumors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Ultrasonography | 2010 |
[Necrotizing hand-foot skin reaction induced by antiangiogenic in a patient with Thevenard neuroacropathy].
Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Antineoplastic Agents; Female; Foot; Hand; Hereditary Sensory and Autonomic Neuropathies; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Necrosis; Pyrroles; Skin Ulcer; Sunitinib | 2009 |
Hypofractionated radiotherapy with concomitant sunitinib - is there a radiosensitizing effect?
Topics: Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Disease Progression; Dose Fractionation, Radiation; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pleural Neoplasms; Pyrroles; Radiation-Sensitizing Agents; Sunitinib | 2009 |
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
Topics: Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Gene Amplification; Gene Expression Profiling; Humans; Indoles; Ligands; Lung Neoplasms; Lymphokines; Platelet-Derived Growth Factor; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Rhabdomyosarcoma; RNA, Small Interfering; Sunitinib | 2009 |
Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sunitinib | 2009 |
Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Echocardiography; Heart Failure; Heart Neoplasms; Humans; Indoles; Male; Middle Aged; Poland; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Reversible posterior leucoencephalopathy syndrome associated with sunitinib.
Topics: Female; Humans; Hypertension; Indoles; Middle Aged; Posterior Leukoencephalopathy Syndrome; Pyrroles; Sunitinib | 2009 |
Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Blood Vessels; Carcinoma, Squamous Cell; Contrast Media; Female; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2009 |
Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Compassionate Use Trials; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sirolimus; Sunitinib | 2010 |
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Pressure; Carcinoma, Renal Cell; Humans; Hypertension; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Cell Line, Tumor; Disease Models, Animal; Gene Expression; Humans; Immunohistochemistry; Indoles; Mice; Neovascularization, Pathologic; Neuroblastoma; Oligonucleotide Array Sequence Analysis; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor.
Topics: Accidents, Traffic; Adamantinoma; Antineoplastic Agents; Appendicitis; Enzyme Inhibitors; Foot; Fractures, Bone; Humans; Immunohistochemistry; Indoles; Lung Neoplasms; Male; Middle Aged; Psoriasis; Pyrroles; Receptor Protein-Tyrosine Kinases; Smoking; Sunitinib; Tomography, X-Ray Computed; Vitamin B 12 Deficiency | 2010 |
Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypothyroidism; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib | 2009 |
Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Male; Mice; Mice, Nude; Neoplasms, Germ Cell and Embryonal; Neovascularization, Pathologic; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Survival Analysis; Testicular Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Expanding the boundaries of clinical practice: building on experience with targeted therapies.
Topics: Antineoplastic Agents, Alkylating; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib; Survival Analysis | 2009 |
New paradigms in gastrointestinal stromal tumour management.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Intestinal Neoplasms; Intestine, Small; Kidney Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2009 |
Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Colonic Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Management of cardiac adverse events occurring with sunitinib treatment.
Topics: Antihypertensive Agents; Antineoplastic Agents; Diuretics; Drug Therapy, Combination; Heart; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib | 2009 |
Olecranon bursitis in patients treated with sunitinib for renal cell carcinoma.
Topics: Aged; Bursitis; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Olecranon Process; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Sequential sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2009 |
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Models, Animal; Dose-Response Relationship, Drug; Focal Adhesion Kinase 2; Humans; Indoles; Liver Neoplasms; Male; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Nude; Sulfonamides; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
'Sunitinib withdrawal phenomenon' or spontaneous regression in renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Remission Induction; Remission, Spontaneous; Sunitinib | 2009 |
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Patient Selection; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2009 |
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Chemokine CXCL12; Female; Humans; Indoles; Interleukin-6; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Stem Cells; Sunitinib | 2009 |
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Coronary Disease; Female; Heart; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Stroke Volume; Sunitinib; Ventricular Function, Left | 2009 |
Early detection of hypertension in a patient treated with sunitinib by measuring cardio-ankle vascular index.
Topics: Aged, 80 and over; Ankle Brachial Index; Blood Flow Velocity; Blood Pressure; Diastole; Female; Humans; Hypertension; Indoles; Pyrroles; Stroke Volume; Sunitinib; Ultrasonography | 2009 |
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Disease Models, Animal; Humans; Indoles; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Sunitinib-induced hand-foot syndrome: a new, distinct form.
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Male; Pyrroles; Sunitinib; Syndrome | 2010 |
Effective therapy for metastatic renal cancer, whither to now.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Probability; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib; Survival Analysis; Treatment Outcome | 2009 |
Inhibitory effects of sunitinib on ovalbumin-induced chronic experimental asthma in mice.
Topics: Angiogenesis Inhibitors; Animals; Asthma; Blotting, Western; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Female; Immunoglobulin E; Immunohistochemistry; Immunoprecipitation; In Vitro Techniques; Indoles; Inflammation; Interleukin-13; Interleukin-4; Lung; Mice; Mice, Inbred BALB C; Ovalbumin; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib | 2009 |
Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib.
Topics: Female; Humans; Indoles; Kidney Neoplasms; Laparoscopy; Middle Aged; Nephrectomy; Pyrroles; Radiography; Sunitinib; Thrombosis; Vascular Neoplasms | 2009 |
Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Gynecomastia; Humans; Indoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2009 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Cytokines; Disease-Free Survival; Endothelial Cells; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A | 2009 |
Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Epidermal Growth Factor; fas Receptor; Gemcitabine; Indoles; Male; Mice; Microvessels; Neovascularization, Pathologic; Pancreatic Neoplasms; Placenta Growth Factor; Pregnancy Proteins; Protein Kinase Inhibitors; Pyrroles; Radiotherapy, Adjuvant; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hemoglobins; Hemolysis; Humans; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma.
Topics: Acrospiroma; Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Skin Neoplasms; Sunitinib; Treatment Outcome | 2010 |
Re: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. A. A. Thomas, B. I. Rini, B. R. Lane, J. Garcia, R. Dreicer, E. A. Klein, A. C. Novick And S. C. Campbell. J Urol 2009; 181: 518-523.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Pyrroles; Sunitinib | 2009 |
Cardiac magnetic resonance imaging in sunitinib malate-related cardiomyopathy: no late gadolinium enhancement.
Topics: Aged; Antineoplastic Agents; Electrocardiography; Female; Gadolinium; Heart Failure; Humans; Image Enhancement; Indoles; Magnetic Resonance Imaging; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2009 |
Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Head and Neck Neoplasms; Humans; Indoles; Mice; Mice, Nude; Neoplasm Transplantation; Pyrroles; Radiotherapy; Sunitinib; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2009 |
Sunitinib-aggravated hypertension.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2009 |
Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Combined Modality Therapy; Drug Screening Assays, Antitumor; Indoles; Mice; Mice, Transgenic; Pyrroles; Random Allocation; Receptor, Platelet-Derived Growth Factor beta; Sarcoma; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.
Topics: Angiogenesis Inhibitors; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Tumor Lysis Syndrome; Ultrasonography | 2010 |
New study sheds light on angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Humans; Indoles; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pyrroles; Sunitinib | 2009 |
The nasal septum: an unusual presentation of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Nasal Septum; Nose Neoplasms; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2009 |
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Gastrointestinal Stromal Tumors; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Skin Diseases; Sorafenib; Stomatitis; Sunitinib; Young Adult | 2009 |
Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib.
Topics: Aged; Algorithms; Angiogenesis Inhibitors; Antineoplastic Agents; Blood Pressure Monitoring, Ambulatory; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Prospective Studies; Pyrroles; Sunitinib | 2009 |
An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glioma; Humans; Indoles; Lapatinib; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrroles; Quinazolines; Sunitinib | 2010 |
Surgical resection of renal cell carcinoma after targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2009 |
Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma.
Topics: Adenocarcinoma, Scirrhous; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Flow Cytometry; Fluorouracil; Indoles; Mice; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Sunitinib | 2010 |
Subdural collections arising from calvarial metastases following discontinuation of anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Goserelin; Hematoma, Subdural, Intracranial; Humans; Indoles; Letrozole; Leukopenia; Nitriles; Pyrroles; Skull; Sunitinib; Triazoles | 2009 |
Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; DNA, Antisense; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; GTPase-Activating Proteins; Humans; Indoles; Kidney Neoplasms; Kinetics; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pyridines; Pyrroles; RNA, Small Interfering; Sorafenib; Sunitinib; Transfection; Tumor Burden | 2010 |
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Mice; Myocytes, Cardiac; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Prenylation; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib | 2010 |
Sunitinib-induced thyrotoxicosis.
Topics: Aged; Antineoplastic Agents; Carbimazole; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Prednisone; Propranolol; Pyrroles; Sunitinib; Thyroid Hormones; Thyrotoxicosis | 2009 |
Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Nephrectomy; Pyrroles; Sunitinib | 2009 |
Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Failure, Chronic; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Renal Dialysis; Sunitinib; Treatment Outcome | 2009 |
Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3).
Topics: Animals; Antineoplastic Agents; Calcitriol; Cell Differentiation; Drug Synergism; Indoles; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Monocytes; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Vitamins | 2009 |
Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.
Topics: Acute Disease; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Liver; Liver Failure; Middle Aged; Peritoneal Neoplasms; Piperazines; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Long-term response in primary renal cancer to sequential antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors | 2009 |
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Constitutive Androstane Receptor; Cytochrome P-450 CYP1A1; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Predisposition to Disease; Haplotypes; Humans; Indoles; Leukopenia; Male; Middle Aged; Mucositis; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrroles; Risk Factors; Sunitinib; Young Adult | 2009 |
Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Pyrroles; Renal Dialysis; Sunitinib | 2009 |
A differential response to sunitinib: sustained systemic response paralleled by intra-dural progression in the spine. Should standard response criteria be reviewed?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indoles; Male; Middle Aged; Pyrroles; Spinal Neoplasms; Sunitinib; Tomography, X-Ray Computed | 2009 |
Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Medical Audit; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; United Kingdom | 2009 |
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Disease Progression; Drug Delivery Systems; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
[An image of vena cava thrombosis].
Topics: Adenocarcinoma, Clear Cell; Aged, 80 and over; Angiogenesis Inhibitors; Fibrinolytic Agents; Heart Atria; Heparin, Low-Molecular-Weight; Humans; Image Processing, Computer-Assisted; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Nephrectomy; Postoperative Complications; Pyrroles; Recurrence; Sunitinib; Thrombectomy; Tinzaparin; Tomography, X-Ray Computed; Vena Cava, Inferior; Venous Thrombosis | 2009 |
Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Perfusion Imaging; Pilot Projects; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.
Topics: Animals; Antineoplastic Agents; Capillary Permeability; Carcinoma, Renal Cell; Contrast Media; Female; Gadolinium DTPA; Humans; Hypoxia; Immunoprecipitation; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2009 |
Estimation of tumor microvessel density by MRI using a blood pool contrast agent.
Topics: Angiogenesis Inhibitors; Animals; Artifacts; Blood Volume; Carcinoma, Squamous Cell; Cerebrovascular Circulation; Contrast Media; Dextrans; Female; Ferrosoferric Oxide; Indoles; Injections, Intravenous; Magnetic Resonance Angiography; Magnetite Nanoparticles; Mice; Mice, Inbred C3H; Microvessels; Neovascularization, Pathologic; Phantoms, Imaging; Predictive Value of Tests; Pyrroles; Soft Tissue Neoplasms; Sunitinib | 2009 |
[Establishment of homogeneous time-resolved fluorescence immunoassay for high throughput screening of protein tyrosine kinase inhibitors].
Topics: Fluoroimmunoassay; High-Throughput Screening Assays; Indoles; Peptides; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
[Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2009 |
Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Biomarkers in GIST: partly ready for prime-time use.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Indoles; Predictive Value of Tests; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Time Factors | 2009 |
Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Solubility; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Sunitinib in breast cancer: friend or foe.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Indoles; Pyrroles; Sunitinib; Taxoids | 2009 |
Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Indoles; Liver Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Pyrroles; Sunitinib; Taxoids; Tomography, X-Ray Computed | 2009 |
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2010 |
Bevacizumab + sunitinib: microangiopathic haemolytic anaemia. A serious drug interaction between 2 cancer drugs.
Topics: Anemia, Hemolytic; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Interactions; Humans; Indoles; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, SCID; Neovascularization, Pathologic; Phosphorylation; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Sunitinib | 2009 |
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.
Topics: Angiogenesis Inhibitors; Animals; Cell Differentiation; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indoles; Mice; Mice, Inbred C57BL; MicroRNAs; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Tumor Cells, Cultured | 2009 |
Induced-fit docking studies of the active and inactive states of protein tyrosine kinases.
Topics: Binding Sites; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Hydrogen Bonding; Indoles; Ligands; Models, Molecular; Oxindoles; Propionates; Protein Structure, Secondary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrroles; Quinazolines; Reproducibility of Results; Sunitinib | 2009 |
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcitonin; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Susceptibility; Everolimus; Fatal Outcome; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonia, Bacterial; Pneumothorax; Protein Precursors; Pyridines; Pyrroles; Rupture, Spontaneous; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2010 |
Biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma on sunitinib treatment.
Topics: Benzamides; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Male; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
Topics: Adenosine Triphosphatases; Animals; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blood-Brain Barrier; Carrier Proteins; Cells, Cultured; Drug Evaluation, Preclinical; Humans; Hydrolysis; Indoles; Mice; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Swine; Xenopus laevis | 2009 |
Everolimus: in advanced renal cell carcinoma.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
Topics: Angiogenesis Inhibitors; Chromatography, High Pressure Liquid; Humans; Indoles; Protein Kinase Inhibitors; Pyrroles; Reproducibility of Results; Sunitinib | 2009 |
Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor.
Topics: Administration, Oral; Anti-Allergic Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Desensitization, Immunologic; Drug Hypersensitivity; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Prednisone; Promethazine; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Peritoneal Dialysis; Pyrroles; Renal Dialysis; Sunitinib | 2009 |
A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chromosomes, Human, Pair 11; Chromosomes, Human, X; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Indoles; Karyotyping; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Translocation, Genetic | 2009 |
Advances in personalized therapeutics in non-small cell lung cancer: 4q12 amplification, PDGFRA oncogene addiction and sunitinib sensitivity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Indoles; Lung Neoplasms; Precision Medicine; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2009 |
Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate.
Topics: Aged; Antineoplastic Agents; Esthesioneuroblastoma, Olfactory; Humans; Immunohistochemistry; Indoles; Male; Nasal Cavity; Neoplasm Recurrence, Local; Nose Neoplasms; Pyrroles; Salvage Therapy; Sunitinib | 2010 |
Recombinant peptides as biomarkers for tumor response to molecular targeted therapy.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Peptide Library; Peptides; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2009 |
Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Disease Progression; Female; Immune Evasion; Indoles; Mammary Neoplasms, Animal; Mice; Mice, Inbred Strains; Mice, Transgenic; Myeloid Cells; Pyrroles; Receptor, ErbB-2; Sunitinib; T-Lymphocytes, Regulatory | 2010 |
Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hypopigmentation; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2009 |
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Hematologic Diseases; Hematopoietic Stem Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Myelopoiesis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Substrate Specificity; Sulfonamides; Sunitinib | 2009 |
Drug essentials. Small molecule multitargeted TKI therapy.
Topics: Benzenesulfonates; Drug Interactions; Humans; Indoles; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2008 |
Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Proliferation; Drug Resistance, Neoplasm; Exons; Gastrointestinal Stromal Tumors; Genotype; Humans; Indoles; Mice; Mutagenesis; Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib | 2009 |
Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.
Topics: Antihypertensive Agents; Antineoplastic Agents; Aortic Aneurysm; Aortic Dissection; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nephrectomy; Pyrroles; Sirolimus; Sunitinib | 2010 |
A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Medullary; Humans; Indoles; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-ret; Pyrroles; Sunitinib; Thyroid Neoplasms; Treatment Outcome | 2009 |
Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cohort Studies; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Therapy for metastatic RCC--questions remain.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Gait Disorders, Neurologic; Hepatitis, Autoimmune; Humans; Indoles; Liver Neoplasms; Male; Postural Balance; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sensation Disorders; Sunitinib | 2009 |
Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application.
Topics: Angiogenesis Inhibitors; Animals; Brain; Brain Neoplasms; Chromatography, Liquid; Drug Stability; Glioma; Humans; Indoles; Infusions, Intravenous; Male; Mice; Mice, Nude; Pyrroles; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Sunitinib; Tandem Mass Spectrometry; Tissue Distribution | 2010 |
Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.
Topics: Adult; Aged; Antineoplastic Agents; Feasibility Studies; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Data Interpretation, Statistical; Female; Health Status Indicators; Humans; Immunologic Factors; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Models, Economic; Models, Statistical; Pyrroles; Sunitinib; Surveys and Questionnaires | 2009 |
Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Endpoint Determination; Humans; Indoles; Liver Neoplasms; Pyrroles; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Humans; Indoles; Male; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain-Derived Neurotrophic Factor; Carcinoma, Renal Cell; Cytokines; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Humans; Indoles; Kidney Neoplasms; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Sunitinib; Survival Rate; Tumor Necrosis Factor-alpha | 2009 |
Sunitinib paves the way for targeted therapies in neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoid Tumor; Cell Line, Tumor; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Melphalan; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Procarbazine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Vinblastine; Xenograft Model Antitumor Assays | 2009 |
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; France; Gastrointestinal Diseases; Germany; Health Care Costs; Hematologic Diseases; Hospital Costs; Hospitalization; Humans; Hypertension; Indoles; Interferon alpha-2; Interferon-alpha; Italy; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Recombinant Proteins; Sunitinib; United Kingdom; Venous Thrombosis | 2010 |
The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiographic Image Enhancement; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.
Topics: Administration, Oral; Adult; Angiogenesis Inhibitors; Biotransformation; Calibration; Chromatography, Liquid; Dealkylation; Female; Humans; Indoles; Pyrroles; Reference Standards; Reproducibility of Results; Sunitinib; Tandem Mass Spectrometry | 2010 |
[Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Benzenesulfonates; Carcinoma, Renal Cell; Cooperative Behavior; Data Collection; Drug Delivery Systems; Drug Utilization; Germany; Humans; Immunotherapy; Indoles; Interdisciplinary Communication; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Medical Oncology; Niacinamide; Patient Care Team; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Urology | 2010 |
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Prognosis; Pyrroles; Sunitinib | 2009 |
Comparison of conventional time-intensity curves vs. maximum intensity over time for post-processing of dynamic contrast-enhanced ultrasound.
Topics: Algorithms; Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Contrast Media; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Indoles; Mice; Mice, Nude; Microbubbles; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Ultrasonography | 2010 |
VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Time Factors | 2010 |
Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Prognosis; Pyrroles; Salvage Therapy; Sunitinib; Treatment Outcome | 2010 |
Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiodermatitis; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Health policy: The UK 'postcode lottery' in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Health Care Rationing; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Regional Health Planning; Sorafenib; Sunitinib; Survival Rate; United Kingdom | 2009 |
Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Remission Induction; Sunitinib | 2009 |
The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Indoles; K562 Cells; Killer Cells, Natural; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib | 2009 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.
Topics: Antineoplastic Agents; Arteries; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Kidney; Kidney Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Benzamides; Female; Forkhead Transcription Factors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Indoles; Interleukin-10; Intestinal Neoplasms; Macrophages; Male; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Cell Surface; Sunitinib; T-Lymphocytes, Regulatory | 2010 |
Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cytokines; Dermatitis, Contact; Female; Flow Cytometry; Histocytochemistry; Humans; Indoles; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Neoplasms; Picryl Chloride; Pyrroles; Specific Pathogen-Free Organisms; Sunitinib; T-Lymphocytes | 2010 |
Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Enalapril; Glomerulosclerosis, Focal Segmental; Humans; Indoles; Kidney; Kidney Neoplasms; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Thrombotic Microangiopathies | 2010 |
[Effect of sutent and celecoxib on the properties of endothelial cells in vitro].
Topics: 5'-Nucleotidase; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Celecoxib; Cell Movement; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Indoles; Pyrazoles; Pyrroles; Sulfonamides; Sunitinib | 2009 |
Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Topics: Adult; Aged; Analysis of Variance; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pilot Projects; Pyrroles; Sunitinib; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Cells, Cultured; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; ErbB Receptors; Esophageal Neoplasms; Flow Cytometry; Humans; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Sunitinib; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2010 |
Tyrosine kinase inhibitor-induced macrocytosis.
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2009 |
Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Capillaries; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Skin; Sunitinib | 2010 |
SUN vs BEVthornIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Computer Simulation; Confidence Intervals; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Models, Theoretical; Probability; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2010 |
Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Fatty Acids, Monounsaturated; Gene Expression Regulation, Neoplastic; Humans; Indoles; Medulloblastoma; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Transfection | 2010 |
Effect of sunitinib on renal cell carcinoma cutaneous metastasis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Skin Neoplasms; Sunitinib | 2009 |
Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Renal Insufficiency; Sorafenib; Sunitinib | 2010 |
Tumor response to sunitinib malate observed in clear-cell sarcoma.
Topics: Antineoplastic Agents; Female; Humans; Indoles; Middle Aged; Pyrroles; Sarcoma, Clear Cell; Soft Tissue Neoplasms; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry.
Topics: Amino Acid Substitution; Benzamides; Binding Sites; Deuterium Exchange Measurement; Drug Resistance; Imatinib Mesylate; Indoles; Mass Spectrometry; Molecular Sequence Data; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cells, Cultured; Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Neoplasm Proteins; Proteoglycans; Pyrroles; Sunitinib; Umbilical Cord; Vascular Endothelial Growth Factor A | 2010 |
Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Female; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; RNA Interference; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Neutralizing; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Interleukin-8; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2010 |
Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.
Topics: Adult; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Disease Progression; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Time Factors; Tomography, X-Ray Computed; Vena Cava, Inferior; Venous Thrombosis | 2010 |
Anti-cancer drugs. Editorial.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indoles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2010 |
Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma.
Topics: Adrenalectomy; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrroles; Radiography; Sunitinib; Treatment Outcome | 2010 |
Renal cell carcinoma: complete response.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Radiography; Smoking; Sunitinib; Thrombocytopenia; Treatment Outcome | 2010 |
Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Diarrhea; Female; Heart Function Tests; Humans; Hypothyroidism; Indoles; Lymphatic Metastasis; Middle Aged; Paclitaxel; Pyrroles; Remission Induction; Sunitinib; Trastuzumab | 2010 |
Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient.
Topics: Activities of Daily Living; Adenocarcinoma; Antineoplastic Agents; Carcinoembryonic Antigen; Colorectal Neoplasms; Compassionate Use Trials; Humans; Indoles; Male; Middle Aged; Pain; Pyrroles; Sunitinib | 2010 |
Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy.
Topics: Adult; Antineoplastic Agents; Bronchial Fistula; Bronchial Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Mediastinal Neoplasms; Pyrroles; Sunitinib | 2010 |
Seven 3-methylidene-1H-indol-2(3H)-ones related to the multiple-receptor tyrosine kinase inhibitor sunitinib.
Topics: Crystallography, X-Ray; Indoles; Models, Molecular; Molecular Structure; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2010 |
Angiogenic blockade and radiotherapy in hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Analysis of Variance; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Gastrointestinal Hemorrhage; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Pyrroles; Radiotherapy, Intensity-Modulated; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2010 |
The potential role of sunitinib in gastrointestinal cancers other than GIST.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Pyrroles; Sunitinib | 2010 |
Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, Nude; Pyrroles; Sunitinib; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2010 |
[Renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatal Outcome; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Organ Size; Pyrroles; Sunitinib; Thyroid Gland | 2010 |
Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Contrast Media; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Prognosis; Pyrroles; Sunitinib; Ultrasonography | 2010 |
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2010 |
Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Asparaginase; Bevacizumab; Cystadenoma; Disease Models, Animal; Drug Administration Schedule; Female; Indoles; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Pyrroles; Sirolimus; Sunitinib; Survival Rate; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Vincristine | 2010 |
Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.
Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Catalytic Domain; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Humans; Imatinib Mesylate; Indoles; Kinetics; Microchemistry; Models, Biological; Mutant Proteins; Peptide Mapping; Phosphorylation; Phosphotyrosine; Piperazines; Protein Binding; Protein Interaction Domains and Motifs; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Recombinant Fusion Proteins; Sunitinib | 2010 |
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib.
Topics: Biomarkers; Carcinoma, Renal Cell; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Gelatinases; Humans; Indoles; Kidney; Kidney Neoplasms; Lipocalins; Neoplasms; Neutrophils; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2010 |
Risk of bleeding not increased by sorafenib or sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2010 |
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Topics: Adolescent; Adult; Antineoplastic Agents; Antiviral Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates; Carcinoma, Renal Cell; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, X; Everolimus; Female; Gene Fusion; Humans; Immunosuppressive Agents; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Research Report; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Translocation, Genetic; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2010 |
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
Topics: Benzamides; Binding Sites; Carbazoles; Computer Simulation; Dasatinib; Drug Design; Furans; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Staurosporine; Sunitinib; Thiazoles | 2010 |
Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2010 |
[The introduction of targeted drugs].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Delivery Systems; Evidence-Based Medicine; Germany; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2010 |
[Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Disease Progression; Drug Approval; Drug Delivery Systems; Drugs, Investigational; Germany; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Survival Rate | 2010 |
[Monitoring of metastatic renal cell carcinoma--standards and challenges].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Drug Monitoring; Drugs, Investigational; Follow-Up Studies; Germany; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Pyrroles; Sunitinib; Survival Rate; Tomography, X-Ray Computed | 2010 |
[Outlook: Future therapy of renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Delivery Systems; Everolimus; Evidence-Based Medicine; Forecasting; Germany; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Prognosis; Pyrroles; Sirolimus; Sunitinib | 2010 |
Plasma N-terminal pro-brain natriuretic peptide as prognostic marker in fatal cardial decompensation with sunitinib malate therapy.
Topics: Aged; Carcinoma, Renal Cell; Echocardiography; Heart Failure; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Natriuretic Peptide, Brain; Neoplasm Metastasis; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Thrombosis | 2010 |
Sorafenib-associated remission of psoriasis in hypernephroma: case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psoriasis; Pyridines; Pyrroles; Retreatment; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Separation; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression; Gene Expression Profiling; Glioblastoma; Humans; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Radiotherapy; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2010 |
Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Recombinant Proteins; Sunitinib | 2010 |
How does sunitinib cause hypothyroidism?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2010 |
Sunitinib induces hypothyroidism with a markedly reduced vascularity.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Middle Aged; Organ Size; Pyrroles; Sunitinib; Thyroid Gland | 2010 |
Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Male; Necrosis; Neoplasm Metastasis; Pneumothorax; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Tomography, X-Ray Computed | 2010 |
Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Cell Movement; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Indoles; Mice; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Neuroblastoma; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-ret; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Interleukin-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sunitinib; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2010 |
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Epidemiologic Methods; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Bone Marrow; Flow Cytometry; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Homeodomain Proteins; Immunoprecipitation; Indoles; Mice; Mice, Inbred C57BL; Mice, Knockout; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Thymus Gland | 2010 |
Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice.
Topics: Actins; Animals; CD4-Positive T-Lymphocytes; Immunocompetence; Indoles; Interferon-gamma; Leishmania donovani; Leishmaniasis, Visceral; Mice; Mice, Inbred C57BL; Nitric Oxide; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Splenomegaly; Sunitinib | 2010 |
Downsizing a tumor thrombus of advanced renal cell carcinoma with neoadjuvant systemic therapy and resulting histopathological effects.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Nephrectomy; Pyrroles; Sunitinib; Thrombectomy; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2010 |
Current and predicted cost of metastatic renal cell carcinoma in Finland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Confidence Intervals; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Female; Finland; Health Care Costs; Humans; Indoles; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Odds Ratio; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Azides; Drug Resistance, Neoplasm; Estrone; Germ-Line Mutation; Humans; Indoles; K562 Cells; Mice; Neoplasm Proteins; Prazosin; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vincristine | 2010 |
Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2010 |
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrases; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2011 |
ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Renal Cell; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib | 2010 |
Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pyrroles; Research Design; Sunitinib; Treatment Outcome | 2010 |
Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.
Topics: Adult; Biomarkers; Blood Pressure; Female; Humans; Indoles; Male; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Time Factors | 2010 |
Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Animals; Biopsy; Capillaries; Cell Survival; Echocardiography; Humans; Indoles; Inhibitory Concentration 50; Mechanistic Target of Rapamycin Complex 1; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mitochondria; Multiprotein Complexes; Myocardium; Myocytes, Cardiac; Protein Kinase Inhibitors; Proteins; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Transcription Factors; Ventricular Remodeling | 2009 |
Prognostic factors in patients treated with VEGF-targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factors | 2010 |
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Off-Label Use; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Thyroglobulin; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Databases, Factual; Erlotinib Hydrochloride; Humans; Indoles; Middle Aged; Neoplasms; Prognosis; Pyrroles; Quinazolines; Severity of Illness Index; Sunitinib; Trastuzumab | 2010 |
The promise of biomarkers for personalized renal cancer care.
Topics: Biomarkers; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney; Kidney Neoplasms; Neoplasms; Nervous System Neoplasms; Patients; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Epidemiologic Methods; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Nephrons; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Osteonecrosis of the jaw related to sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Male; Mandibular Diseases; Middle Aged; Molar; Neoplasm Recurrence, Local; Nephrectomy; Osteonecrosis; Postoperative Complications; Pyrroles; Sunitinib; Tooth Extraction | 2011 |
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.
Topics: Animals; Carcinoma, Renal Cell; CD11b Antigen; CD8-Positive T-Lymphocytes; Female; Humans; Immunologic Factors; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Myeloid Cells; Pyrroles; Sunitinib; Suppressor Factors, Immunologic; T-Lymphocyte Subsets | 2010 |
[Renal cell carcinoma management and therapies in 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Everolimus; Humans; Indoles; Interferons; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Metabolic Networks and Pathways; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
[Targeted therapies: sequential and combined treatments].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Combined Modality Therapy; Cytokines; ErbB Receptors; Humans; Indoles; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
[Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Digestive System; Heart; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Lung Injury; Mucous Membrane; Muscle Fatigue; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
[Advanced renal carcinomas with special situations. How to treat them?].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Psoriasis; Pyrroles; Sunitinib | 2010 |
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2010 |
Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib (case report).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Pyrroles; Radiotherapy Dosage; Sunitinib; Tomography, X-Ray Computed | 2010 |
Tyrosine kinase inhibitors and acute pancreatitis.
Topics: Acute Disease; Antineoplastic Agents; Humans; Indoles; Neoplasms; Pancreatitis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2010 |
[Clinical study of Sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2010 |
Editorial comment.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Editorial comment.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Diagnostic Imaging; DNA Mutational Analysis; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Indoles; Piperazines; Prognosis; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Indoles; Mice; Mice, Nude; Nasopharyngeal Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Taxoids; Xenograft Model Antitumor Assays | 2011 |
mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Everolimus; Female; Humans; Immunohistochemistry; Immunosuppressive Agents; Indoles; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Protein Serine-Threonine Kinases; Pyrroles; Sirolimus; Stomach Neoplasms; Sunitinib; TOR Serine-Threonine Kinases; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2010 |
Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors.
Topics: Animals; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Drug Administration Schedule; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indoles; Male; Mice; Molecular Imaging; Platelet Endothelial Cell Adhesion Molecule-1; Protein Engineering; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Technetium; Time Factors; Tomography, Emission-Computed, Single-Photon; Vascular Endothelial Growth Factor A | 2010 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Drug Delivery Systems; Everolimus; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK).
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Cells, Cultured; Embryo, Mammalian; Fibroblasts; Fluorescence Resonance Energy Transfer; Humans; Immunoblotting; Indoles; Mice; Mice, Knockout; Models, Molecular; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Epithelium; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Mesoderm; Mice; Mice, Nude; Microvessels; Pericytes; Phenotype; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2010 |
Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Neoplasm Metastasis; Protein Isoforms; Pyrroles; RNA, Messenger; Solubility; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Tolerance; Fatigue; Humans; Indoles; Kidney Neoplasms; Medical History Taking; Neoplasm Metastasis; Proportional Hazards Models; Pyrroles; Sunitinib | 2010 |
Abscess formation mimicking disease progression, in a patient with metastatic renal cell carcinoma during sunitinib treatment.
Topics: Abdominal Abscess; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Pyrroles; Sunitinib | 2010 |
Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.
Topics: Aged; Benzamides; Chemotherapy, Adjuvant; Disease Progression; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sequence Deletion; Sunitinib; Survival Analysis; Tomography, X-Ray Computed | 2010 |
Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Compassionate Use Trials; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Necrosis; Postoperative Complications; Pyrroles; Radiotherapy, Adjuvant; Reoperation; Sarcoma, Alveolar Soft Part; Skin Transplantation; Soft Tissue Neoplasms; Sunitinib; Surgical Flaps; Thigh | 2010 |
Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myelomonocytic, Chronic; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Diphosphonates; Drug Synergism; Humans; Imidazoles; Indoles; Infusions, Intravenous; Kidney Neoplasms; Male; Mandibular Diseases; Middle Aged; Neoplasm Staging; Osteonecrosis; Pyrroles; Sacrum; Spinal Neoplasms; Sunitinib; Zoledronic Acid | 2010 |
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Topics: Adult; Benzenesulfonates; Disease Progression; Fatal Outcome; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells.
Topics: Angiogenesis Inducing Agents; Animals; Antineoplastic Agents; Becaplermin; Cell Count; Cell Line, Tumor; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Humans; Indoles; Medulloblastoma; Mice; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; PTEN Phosphohydrolase; Pyrroles; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sunitinib; Time Factors | 2011 |
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms | 2010 |
Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Bone Neoplasms; Breast Neoplasms; Contrast Media; Diphosphonates; Humans; Imidazoles; Indoles; Longitudinal Studies; Magnetic Resonance Imaging; Pyrroles; Random Allocation; Rats; Rats, Nude; Sunitinib; Xenograft Model Antitumor Assays; Zoledronic Acid | 2010 |
Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation.
Topics: Binding Sites; Crystallography, X-Ray; Drug Design; Indoles; Protein Engineering; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrroles; src-Family Kinases; Structure-Activity Relationship; Sunitinib | 2010 |
Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Brain Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Neoplasm Metastasis; Pyrroles; Sunitinib | 2010 |
Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Biopsy; Gastrointestinal Stromal Tumors; Histamine Antagonists; Humans; Hyperpigmentation; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Keratoderma, Palmoplantar; Liver Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Rosacea; Skin; Skin Pigmentation; Sunitinib; Treatment Outcome | 2011 |
Current management of GISTs.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer.
Topics: Adult; Aged; Carcinoma, Medullary; Cell Differentiation; Combined Modality Therapy; Enzyme Inhibitors; Female; Hematopoietic System; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Thyroid Neoplasms | 2010 |
Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Medullary; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Pyrroles; Sunitinib; Thyroid Neoplasms | 2010 |
Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.
Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Indoles; Male; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Thymoma; Thymus Neoplasms | 2010 |
The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Approval; Everolimus; Humans; Indoles; Kidney Neoplasms; Practice Guidelines as Topic; Pyrroles; Sirolimus; Sunitinib; United Kingdom | 2010 |
Close encounters of a novel kind: a multi-targeted cancer drug meets a metabolic sensor.
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib | 2010 |
Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.
Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Corneal Neovascularization; Disease Models, Animal; Fluorescein Angiography; Indoles; Male; Ophthalmic Solutions; Platelet-Derived Growth Factor; Pyrroles; Rabbits; Random Allocation; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib | 2011 |
Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells.
Topics: Antineoplastic Agents; Cell Hypoxia; HT29 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Neoplasms; Protein Biosynthesis; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sunitinib | 2010 |
Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib.
Topics: Aged; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Carcinoma, Renal Cell; Hemorrhage; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pulmonary Alveoli; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2010 |
Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon.
Topics: Angiogenesis Inhibitors; Capillaries; Carcinoma, Renal Cell; Humans; Hypertension; Indoles; Kidney Neoplasms; Palliative Care; Pyrroles; Skin; Sunitinib | 2010 |
Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Indoles; Inhibitory Concentration 50; Kaplan-Meier Estimate; Luminescent Proteins; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrroles; Red Fluorescent Protein; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Compassionate Use Trials; Denmark; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrroles; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Sunitinib; Treatment Outcome | 2010 |
Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Echocardiography; Heart; Immunohistochemistry; In Situ Nick-End Labeling; Indazoles; Indoles; Male; Microscopy, Electron, Transmission; Mitochondria; Myocardium; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Rats; Sorafenib; Sulfonamides; Sunitinib; Troponin I | 2010 |
Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Papillary; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; MAP Kinase Kinase 4; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sunitinib; Symporters; Thyroid Neoplasms | 2010 |
Treatment of multidrug resistant advanced alveolar soft part sarcoma with sunitinib.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Lung Neoplasms; Male; Pyrroles; Quality of Life; Sarcoma, Alveolar Soft Part; Sunitinib; Treatment Outcome | 2012 |
Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line; Cell Proliferation; Indoles; Microtubule-Associated Proteins; Myocytes, Cardiac; Pyrroles; Rats; RNA Interference; Sunitinib | 2010 |
Three cases of severe ulcerative esophagitis induced by SUTENT®.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Esophagitis; Gastrointestinal Hemorrhage; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prostatic Neoplasms; Pyrroles; Sunitinib; Ulcer | 2012 |
Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antioxidants; Body Weight; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cisplatin; Drug Synergism; Female; Indoles; Kidney; Male; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Organ Size; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor A | 2011 |
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Pyrroles; Sunitinib; Survival Analysis | 2011 |
[Efficacy of tyrosine kinase inhibitor therapy combined with surgical resection in patients with metastatic gastrointestinal stromal tumor].
Topics: Adult; Aged; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intraoperative Period; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2010 |
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 14-3-3 Proteins; Amino Acid Sequence; Animals; Blotting, Western; Cell Line; Cells, Cultured; Cytoplasm; Dose-Response Relationship, Drug; Green Fluorescent Proteins; Humans; Inclusion Bodies; Indoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Microscopy, Fluorescence; Middle Aged; Mutation; Parkinson Disease; Phosphorylation; Protein Binding; Protein Serine-Threonine Kinases; Pyrroles; Serine; Sunitinib; Swiss 3T3 Cells | 2010 |
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Pyrroles; Sunitinib; Translocation, Genetic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Indoles; Least-Squares Analysis; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Phosphotransferases; Pyrroles; Radiation Tolerance; Rectal Neoplasms; Rectum; Remission Induction; Signal Transduction; Substrate Specificity; Sunitinib; Treatment Outcome | 2010 |
VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indoles; Infarction; Intestines; Male; Plaque, Atherosclerotic; Pyrroles; Risk Factors; Sunitinib; Thromboembolism; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A | 2011 |
Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Agents; Carcinoma; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neoplasm Staging; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2010 |
Myelosuppression by sunitinib is flt-3 genotype dependent.
Topics: Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukopenia; Polymorphism, Genetic; Pyrroles; Sunitinib; Thrombocytopenia | 2010 |
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome | 2011 |
SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Humans; Immunohistochemistry; In Vitro Techniques; Indoles; Nerve Sheath Neoplasms; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Metastatic collecting duct carcinoma of the kidney responded to sunitinib.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Ribs; Sunitinib | 2011 |
Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Carcinoma, Renal Cell; Diphosphonates; Humans; Indoles; Injections, Intravenous; Kidney Neoplasms; Mandibular Diseases; Middle Aged; Mucositis; Osteonecrosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Risk Factors; Stomatitis; Sunitinib; Tooth Extraction | 2010 |
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.
Topics: Adenocarcinoma; Benzenesulfonates; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Indoles; Lung Neoplasms; Mitogen-Activated Protein Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Selection, Genetic; Sorafenib; Sunitinib; Tongue Neoplasms | 2010 |
Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.
Topics: Aged; Antineoplastic Agents; Arthritis, Rheumatoid; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Everolimus; Humans; Hypercholesterolemia; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pyrroles; Randomized Controlled Trials as Topic; Salvage Therapy; Sirolimus; Sunitinib | 2011 |
[Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Middle Aged; Prevalence; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sunitinib; Thyroid Hormones; Thyrotropin | 2010 |
Renal cell carcinoma: ten years of significant advances.
Topics: Angiogenesis Inhibitors; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Drug Discovery; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Medical Oncology; Neoplasm Metastasis; Pyrroles; Sunitinib | 2010 |
Evidence-based urology in practice: randomized controlled trials stopped early for benefit.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Evidence-Based Medicine; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrectomy; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2010 |
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Deciphering the anticancer mechanisms of sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Profiling; Indoles; Mammary Neoplasms, Experimental; Mice; Models, Biological; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Recall pneumonitis during systemic treatment with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphocytes; Mediastinal Neoplasms; Middle Aged; Neoplasms, Radiation-Induced; Pneumonia; Prognosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2010 |
Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neoplasms; Colonic Polyps; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Indoles; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Pyrroles; Remission Induction; Sunitinib; Time Factors; Tretinoin | 2010 |
Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Pyrroles; Renal Dialysis; Rhabdomyolysis; Sunitinib; Treatment Outcome | 2010 |
Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun?
Topics: Blood Pressure; Carcinoma, Renal Cell; Endothelin-1; Gastrointestinal Stromal Tumors; Heart Rate; Humans; Hypertension; Indoles; Kidney Neoplasms; Models, Biological; Proteinuria; Pyrroles; Receptor Protein-Tyrosine Kinases; Renin; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Risk of arterial thrombosis not increased by sorafenib or sunitinib.
Topics: Angiogenesis Inhibitors; Arterial Occlusive Diseases; Benzenesulfonates; Evidence-Based Medicine; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Reproducibility of Results; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thromboembolism | 2010 |
Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Atrophy; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Hyperthyroidism; Hypothyroidism; Indoles; Japan; Male; Middle Aged; Organ Size; Protein Kinase Inhibitors; Pyrroles; Regional Blood Flow; Sunitinib; Thyroid Gland; Thyroiditis; Thyrotoxicosis | 2010 |
Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; GPI-Linked Proteins; Humans; Immunomagnetic Separation; Immunotherapy, Adoptive; Indoles; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Linear Models; Nasopharyngeal Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib | 2011 |
Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume.
Topics: Female; Humans; Hypothyroidism; Indoles; Middle Aged; Organ Size; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Thyroid Function Tests; Thyroid Gland; Thyrotoxicosis; Ultrasonography | 2010 |
Recurrent scrotal hemangiomas during treatment with sunitinib.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Genital Neoplasms, Male; Hemangioma; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Recurrence; Scrotum; Skin Neoplasms; Sunitinib; Zoledronic Acid | 2010 |
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chromatography, Liquid; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Tandem Mass Spectrometry | 2010 |
Changes in resting energy expenditure (REE) as a function of tumor response to sunitinib in a cachexic patient with a metastatic endocrine tumor of the pancreas.
Topics: Antineoplastic Agents; Cachexia; Calorimetry, Indirect; Eating; Energy Metabolism; Hepatectomy; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pyrroles; Rest; Splenectomy; Sunitinib; Treatment Outcome; Weight Loss | 2010 |
A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cost-Benefit Analysis; Cytokines; Disease Progression; Disease-Free Survival; Drug Costs; Drug Resistance, Neoplasm; Female; Health Care Costs; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Markov Chains; Middle Aged; Models, Economic; Palliative Care; Protein Kinase Inhibitors; Pyrroles; Quality-Adjusted Life Years; Spain; Sunitinib | 2010 |
Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Pyrroles; Sunitinib | 2010 |
Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyrotropin; Treatment Outcome | 2011 |
Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2011 |
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Feasibility Studies; Female; Humans; Indoles; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; BCG Vaccine; Bcl-2-Like Protein 11; bcl-X Protein; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Membrane Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
A novel primary KIT exon 9 single nucleotide substitution c.1427G>T (p.Ser476Ile) in a gastrointestinal stromal tumor.
Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Disease Progression; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Molecular Sequence Data; Peritoneal Neoplasms; Piperazines; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2010 |
[Leg ulcerations and sunitinib].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Eruptions; Female; Humans; Indoles; Kidney Neoplasms; Leg Ulcer; Liver Neoplasms; Lung Neoplasms; Pyrroles; Risk Factors; Sarcoma; Sunitinib; Venous Thrombosis | 2010 |
Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Progression of intramedullary metastasis during perioperative cessation of sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Spinal Neoplasms; Sunitinib | 2010 |
Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Pyrroles; Recombinant Proteins; Sunitinib; United Kingdom | 2010 |
Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Quinazolines; Sunitinib | 2010 |
Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Proliferation; Disease-Free Survival; Female; Hematopoietic Stem Cells; Humans; Indoles; Insulin-Like Growth Factor I; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice.
Topics: Animals; Antineoplastic Agents; Disease Progression; Female; Humans; Immunohistochemistry; Indoles; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2010 |
Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Antineoplastic Agents; Antipyretics; Biomarkers; Brain; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug Interactions; Hyperemia; Indoles; Kidney; Liver; Male; Mice; Mice, Inbred ICR; Necrosis; Protein Kinase Inhibitors; Pyrroles; Random Allocation; Sunitinib | 2010 |
HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.
Topics: Angiogenesis Inhibitors; Animals; Drug Resistance, Neoplasm; Hepatocyte Growth Factor; Humans; Indoles; Mice; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; NIH 3T3 Cells; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sunitinib; Transfection | 2010 |
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2010 |
Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biological Availability; Compassionate Use Trials; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Half-Life; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Staging; Piperazines; Protease Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis | 2011 |
The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Tumor Burden; Young Adult | 2011 |
¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Neoplasms; Carbon Radioisotopes; Carcinoma, Transitional Cell; Humans; Indoles; Methionine; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
The cancer-HIV/AIDS treatment conundrum.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Cytochrome P-450 CYP3A; Drug Administration Schedule; Drug Antagonism; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Neoplasms; Pyrroles; Risk Factors; Ritonavir; Sunitinib | 2010 |
Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate.
Topics: Acute Kidney Injury; Angioplasty, Balloon, Coronary; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Agents; Coronary Stenosis; Fatal Outcome; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multiple Organ Failure; Protein Kinase Inhibitors; Pyrroles; Renal Dialysis; Sunitinib; Treatment Outcome | 2010 |
Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Penile Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Pyrroles; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Indoles; Interleukin-2; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrroles; Recombinant Fusion Proteins; Sunitinib | 2010 |
Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report.
Topics: Antineoplastic Agents; Cutaneous Fistula; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Indoles; Infusions, Intra-Arterial; Middle Aged; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Urinary Fistula | 2010 |
[The role of pathologists in the target therapy of gastrointestinal tumors].
Topics: Anoctamin-1; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chloride Channels; Drug Delivery Systems; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Membrane Proteins; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib.
Topics: Aged; Angiogenesis Inhibitors; Drug Resistance, Neoplasm; Endothelial Cells; Female; Fibroblast Growth Factor 2; Humans; Immunoblotting; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Signal Transduction; Sunitinib; Tissue Array Analysis | 2011 |
Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Papilledema; Pyrroles; Sunitinib | 2011 |
Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Retrospective Studies; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Failure; Treatment Outcome | 2010 |
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factors | 2011 |
VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; Indoles; Male; Mice; Mice, Nude; Positron-Emission Tomography; Pyrroles; Sunitinib; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2011 |
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Constitutive Androstane Receptor; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib | 2011 |
PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Neoplasms; Cell Adhesion; Cell Line; Cell Proliferation; Gene Expression Profiling; Humans; Indoles; Lung Neoplasms; Mice; Neoplasm Invasiveness; Pyrroles; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Stromal Cells; Sunitinib | 2011 |
Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Renal Dialysis; Retrospective Studies; Sunitinib | 2010 |
Lower limbs erosions induced by sunitinib.
Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Anti-Infective Agents, Local; Carcinoma, Renal Cell; Foot Ulcer; Hand; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrroles; Skin Ulcer; Sunitinib; Treatment Outcome | 2011 |
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Chi-Square Distribution; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Exons; Female; Gastrointestinal Stromal Tumors; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Phenotype; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Time Factors; Treatment Failure | 2012 |
Sunitinib rechallenge in metastatic renal cell carcinoma patients.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Retreatment; Retrospective Studies; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Tubulocystic renal carcinoma: a clinical perspective.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
[Multimodal interventional therapy of a large renal cell carcinoma in a patient with high anesthesia risk - a case report].
Topics: Anesthesia, General; Antineoplastic Agents; Biopsy, Needle; Brachytherapy; Carcinoma, Renal Cell; Catheter Ablation; Chemotherapy, Adjuvant; Combined Modality Therapy; Conscious Sedation; Contraindications; Embolization, Therapeutic; Follow-Up Studies; Health Status Indicators; Humans; Image Processing, Computer-Assisted; Indoles; Kidney; Kidney Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Neoplasm Staging; Pulmonary Emphysema; Pyrroles; Radiology, Interventional; Radiotherapy, Adjuvant; Respiratory Insufficiency; Sunitinib; Tomography, X-Ray Computed | 2011 |
Kidney cancer: Does hypothyroidism predict clinical outcome?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
Sunitinib-induced severe hypothyroidism with cardiac compromise.
Topics: Heart Diseases; Humans; Hypothyroidism; Indoles; Male; Middle Aged; Pyrroles; Severity of Illness Index; Sunitinib | 2011 |
Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.
Topics: Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dendritic Cells; Female; Immunotherapy, Adoptive; Indoles; Lymphocytes, Tumor-Infiltrating; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Pyrroles; STAT3 Transcription Factor; Sunitinib; T-Lymphocytes, Regulatory; Tumor Burden | 2010 |
Management of a new isolated metastasis during sunitinib treatment in renal cell carcinoma patients: a lesson from two cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Medical Oncology; Neoplasm Metastasis; Palliative Care; Pyrroles; Radiation-Sensitizing Agents; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Circulating perivascular progenitors: a target of PDGFR inhibition.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Cells; Cell Count; Cell Differentiation; Cell Survival; Humans; Indoles; Mice; Neoplasms; Pericytes; Platelet Endothelial Cell Adhesion Molecule-1; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Stem Cells; Sunitinib | 2011 |
Cyclooxygenase-2 expression in gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Male; Middle Aged; Mitosis; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Tumor Burden | 2010 |
Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fluorodeoxyglucose F18; Humans; Indoles; Kidney Neoplasms; Middle Aged; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2011 |
Blue toe syndrome and sunitinib.
Topics: Antineoplastic Agents; Blue Toe Syndrome; Carcinoma, Renal Cell; Heparin, Low-Molecular-Weight; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2011 |
Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Indoles; Liver Neoplasms; Male; Pyrroles; Radiography; Sunitinib | 2011 |
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine | 2011 |
Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Brain Neoplasms; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Radiosurgery; Spinal Neoplasms; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Pyrroles; Sunitinib; Thyroid Function Tests; Thyroid Gland; Tomography, X-Ray Computed | 2011 |
Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Bevacizumab; Endothelial Cells; Haplorhini; HEK293 Cells; Humans; Immunoglobulin Fc Fragments; Immunoglobulin G; Indoles; Integrin alpha5beta1; Killer Cells, Natural; Lung Neoplasms; Macrophages; Mice; Mice, Inbred BALB C; Mice, SCID; Mice, Transgenic; NIH 3T3 Cells; Phagocytosis; Pyrroles; Receptors, IgG; Sunitinib | 2010 |
A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib.
Topics: Adult; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Pyrroles; Sunitinib; Translocation, Genetic | 2011 |
Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT.
Topics: Animals; Cell Proliferation; Drug Monitoring; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Mice; Mice, Nude; Molecular Targeted Therapy; Multimodal Imaging; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Models, Animal; DNA Fingerprinting; Everolimus; Female; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Polymorphism, Single Nucleotide; Pyrroles; Sirolimus; Sunitinib; Transfection; Tumor Cells, Cultured; von Hippel-Lindau Disease; Xenograft Model Antitumor Assays | 2011 |
Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.
Topics: Animals; Antibodies, Blocking; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Epitopes, T-Lymphocyte; Female; Immunotherapy, Adoptive; Indoles; Lymph Nodes; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Pyrroles; Receptors, CXCR3; Sunitinib; T-Lymphocytes; Tumor Microenvironment; Vascular Cell Adhesion Molecule-1 | 2011 |
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients.
Topics: Adult; Aged; Biomarkers, Tumor; Colorectal Neoplasms; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2011 |
The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins.
Topics: Cell Line, Tumor; Cell Movement; ErbB Receptors; Focal Adhesion Kinase 1; Glioblastoma; Humans; Indoles; Integrin beta1; Integrin beta3; Integrins; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2010 |
Efficacy of sunitinib in patients with renal cell carcinoma with bone metastases.
Topics: Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Sunitinib | 2010 |
Response and safety of sunitinib in a heavily pre-treated metastatic non-small cell lung carcinoma patient.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Male; Pyrroles; Sunitinib | 2010 |
More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Everolimus; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Effect of sunitinib combined with ionizing radiation on endothelial cells.
Topics: Animals; Cell Line, Tumor; Cell Survival; Cells, Cultured; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Endothelial Cells; Humans; Indoles; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents; Radiation, Ionizing; Sunitinib; Treatment Outcome | 2011 |
Suppressing effects of sunitinib on allergic rhinitis: previously undefined side effects with therapeutic potential.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Immunoglobulin E; Indoles; Kidney Neoplasms; Mast Cells; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Rhinitis, Allergic, Seasonal; Sunitinib | 2011 |
Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Germany; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Monocytes; Neoplastic Cells, Circulating; Pilot Projects; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Survival Rate; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Risk Factors; Sunitinib | 2011 |
Pyoderma gangrenosum with the use of sunitinib.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Prednisone; Protein Kinase Inhibitors; Pyoderma Gangrenosum; Pyrroles; Skin; Sunitinib; Treatment Outcome | 2011 |
Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.
Topics: Adult; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Female; Flow Cytometry; Fluorescent Antibody Technique; Follow-Up Studies; Humans; Immunoenzyme Techniques; Immunoprecipitation; In Situ Hybridization, Fluorescence; Indoles; Male; Middle Aged; Proto-Oncogene Proteins c-ret; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Retrospective Studies; Sarcoma, Alveolar Soft Part; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2011 |
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Renal Dialysis; Retrospective Studies; Sunitinib; Treatment Outcome | 2011 |
Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome | 2011 |
Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Models, Animal; Drug Interactions; Female; Humans; Hypoxia-Inducible Factor 1; Indoles; Kidney Neoplasms; Lymphatic Vessels; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Neovascularization, Pathologic; Pericytes; Pyrroles; Stromal Cells; Sunitinib; Tumor Burden; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Von Hippel-Lindau Tumor Suppressor Protein | 2011 |
Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Young Adult | 2011 |
Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Palliative Care; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2011 |
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Markov Chains; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib; Sweden; United States | 2011 |
Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
Topics: Antineoplastic Agents; Benzenesulfonates; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Hydroxylation; Indoles; Liver; Microsomes, Liver; Midazolam; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Center poor-prognosis classification.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Nose Neoplasms; Pyrroles; Skull Neoplasms; Sunitinib; Tomography, X-Ray Computed | 2011 |
Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors | 2012 |
Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Tomography, Emission-Computed | 2011 |
Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cystectomy; Female; Humans; Indoles; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Promising advances in the treatment of malignant pancreatic endocrine tumors.
Topics: Antineoplastic Agents; Disease Progression; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quality of Life; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell ca
Topics: Academic Medical Centers; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Boston; Carcinoma, Renal Cell; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Observer Variation; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Pyrroles; Reproducibility of Results; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2011 |
Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blood-Brain Barrier; Cells, Cultured; Dogs; Humans; Indoles; Mice; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Topoisomerase I Inhibitors; Topotecan | 2011 |
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antigens, Ly; Carcinoma, Renal Cell; CD11b Antigen; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Immunosuppression Therapy; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Myeloid Cells; Neoadjuvant Therapy; Neoplasm Metastasis; Pyrroles; Sunitinib; Tumor Burden; Tumor Escape | 2011 |
Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2011 |
PET of αvbeta3-integrin and αvbeta5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time?
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Glioblastoma; Humans; Indoles; Integrin alphaVbeta3; Male; Mice; Mice, Nude; Peptides; Polyethylene Glycols; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Vitronectin; Reproducibility of Results; Sensitivity and Specificity; Sunitinib | 2011 |
Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Glioblastoma; Humans; Indoles; Integrin alphaVbeta3; Male; Mice; Mice, Nude; Peptides; Polyethylene Glycols; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Vitronectin; Reproducibility of Results; Sensitivity and Specificity; Sunitinib | 2011 |
[Comment to: "Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel"].
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Male; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Failure | 2011 |
Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Medullary; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Indoles; Interleukin-8; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; RNA Interference; Sunitinib; Tenascin; Thyroid Neoplasms; Transforming Growth Factor beta2; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
A 51-year-old man with rapidly progressive metastatic sarcomatoid renal cell carcinoma: an apparent complete clinical response to second-line therapy with sunitinib and low-dose interferon-alpha.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Ventricular Function, Left | 2011 |
Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability.
Topics: Animals; Biological Availability; Catechin; Chemical Precipitation; Herb-Drug Interactions; Humans; Indoles; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Mice; Mice, Inbred C57BL; Plant Extracts; Pyrroles; Rats; Rats, Sprague-Dawley; Sunitinib; Tea | 2011 |
Spontaneous regression of metastatic renal cancer after short-term treatment with sunitinib.
Topics: Antineoplastic Agents; Bone Neoplasms; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neoplasm Regression, Spontaneous; Pyrroles; Remission Induction; Sunitinib | 2011 |
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
Topics: Adult; Benzamides; Benzenesulfonates; Carcinoma, Renal Cell; Choristoma; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Pleural Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thymus Gland; Thyroxine | 2011 |
Mutational spectrum and therapy response of metastasized GIST in Central Switzerland - a population-based study.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Benzamides; Disease Progression; DNA Mutational Analysis; DNA Primers; Exons; Female; Gastrointestinal Stromal Tumors; Genetics, Population; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Switzerland | 2011 |
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Glioma; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pyrroles; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indoles; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2011 |
Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Topics: Acridines; Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Brain; Dogs; Drug Resistance, Multiple; Humans; Indoles; Male; Mice; Mice, Knockout; Pyrroles; Sunitinib; Tetrahydroisoquinolines; Tissue Distribution | 2012 |
A proof of concept phase II non-inferiority criterion.
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Confidence Intervals; Everolimus; Humans; Indoles; Kidney Neoplasms; Pyrroles; Research Design; Sirolimus; Sunitinib | 2011 |
[Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cost-Benefit Analysis; Drug Costs; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
Topics: Aged; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Urinary Bladder | 2013 |
The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Nephrectomy; Patient Selection; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Radiography; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Texas; Thrombectomy; Time Factors; Treatment Outcome; Tumor Burden; Vena Cava, Inferior; Venous Thrombosis | 2011 |
Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of sunitinib (SU11248) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: application to an explorative study.
Topics: Chromatography, Liquid; Female; Humans; Indoles; Infant, Newborn; Linear Models; Male; Pyrroles; Reproducibility of Results; Research Design; Sensitivity and Specificity; Sunitinib; Tandem Mass Spectrometry | 2011 |
Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Substrate Specificity; Sunitinib; Swine; Transfection | 2011 |
A CT scan aspect of "hypodense thyroid gland" after sunitinib treatment for metastatic carcinoma of the kidney.
Topics: Adult; Antineoplastic Agents; Female; Goiter; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Thyroid Function Tests; Thyroid Gland; Thyrotoxicosis; Tomography, X-Ray Computed | 2011 |
Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?
Topics: Antineoplastic Agents; Carcinoma; Female; Hematemesis; Hemoptysis; Humans; Indoles; Male; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Pyrroles; Sunitinib | 2011 |
Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome | 2011 |
Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cell Proliferation; Collagen Type I; Disease Models, Animal; Female; Humans; Indoles; Kidney Neoplasms; Macrophage Colony-Stimulating Factor; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Osteoclasts; Peptides; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Radiography; Sunitinib | 2011 |
Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Pyrroles; Renal Dialysis; Sunitinib | 2012 |
Translational medicine: Cancer lessons from mice to humans.
Topics: Animals; Clinical Trials, Phase III as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Everolimus; Humans; Indoles; Mice; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sirolimus; Sunitinib; Survival Rate; Translational Research, Biomedical | 2011 |
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2011 |
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Fatigue; Female; Humans; Indoles; Italy; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Oncology Service, Hospital; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Targeted caval cytoreduction: solid foundations or shifting sands?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Evidence-Based Medicine; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Nephrectomy; Patient Selection; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Risk Factors; Sunitinib; Thrombectomy; Time Factors; Treatment Outcome; Tumor Burden; Vena Cava, Inferior; Venous Thrombosis | 2011 |
Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Indoles; Melanoma; Morpholines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2011 |
Synthesis and antitumor activity of 5-[1-(3-(dimethylamino)propyl)-5-halogenated-2-oxoindolin-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamides.
Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Design; Halogens; Humans; Indoles; Inhibitory Concentration 50; Molecular Structure; Pyrroles; Sunitinib | 2011 |
Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Cells, Cultured; Docetaxel; Human Umbilical Vein Endothelial Cells; Humans; Immunoblotting; Indoles; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pyrroles; Sunitinib; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Nephrectomy; Osteotomy; Pneumonectomy; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome | 2011 |
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
Topics: Anilides; Axitinib; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Thyroid Gland; Tumor Cells, Cultured | 2011 |
Recent studies show promise for treating rare pancreatic tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Data Interpretation, Statistical; Disease-Free Survival; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Off-Label Use; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Rare Diseases; Signal Transduction; Sirolimus; Sunitinib; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; United States | 2011 |
Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Prognosis; Pyrroles; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Cancer Care Facilities; Carcinoma, Renal Cell; Community Health Services; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Practice Patterns, Physicians'; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; United States | 2012 |
[Gottron-like papules induced by sunitinib].
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Humans; Indoles; Male; Pyrroles; Skin Diseases, Papulosquamous; Sunitinib | 2011 |
Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Dedifferentiation; Combined Modality Therapy; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Nephrectomy; Peripheral Nervous System Diseases; Protein Kinase Inhibitors; Pyrroles; Remission Induction; Rhabdoid Tumor; Sunitinib | 2011 |
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
Sunitinib inhibits postoperative adhesions in a rabbit model.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Female; Indoles; Microvessels; Protein Kinase Inhibitors; Pyrroles; Rabbits; Receptor Protein-Tyrosine Kinases; Sunitinib; Tensile Strength; Tissue Adhesions; Uterus; Wounds and Injuries | 2011 |
Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Body Weight; Female; Humans; Immunoenzyme Techniques; Indoles; Lymphatic Metastasis; Lymphatic Vessels; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Pyrroles; Sunitinib; Tumor Cells, Cultured; Tyrosine; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival.
Topics: Animals; Antibodies, Monoclonal; Diabetes Mellitus, Experimental; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppressive Agents; Indoles; Islets of Langerhans Transplantation; Lymphangiogenesis; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Pyrroles; Sphingosine; Sunitinib; T-Lymphocytes; Transplantation Tolerance; Transplantation, Homologous; Vascular Endothelial Growth Factor Receptor-3 | 2011 |
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
Topics: Adult; Aged; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2011 |
Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Indoles; Pyrroles; Quality Control; Reference Standards; Sunitinib | 2011 |
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Blood Pressure; Carcinoma, Renal Cell; Confounding Factors, Epidemiologic; Disease-Free Survival; Humans; Hypertension; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Treatment Outcome | 2011 |
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Sunitinib; Taiwan; Treatment Failure; Treatment Outcome; Young Adult | 2011 |
The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Benzopyrans; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Carcinoma, Renal Cell; Ethanolamines; Female; Humans; Hydrochlorothiazide; Hypertension; Indoles; Irbesartan; Male; Middle Aged; Nebivolol; Prevalence; Pyrroles; Reproducibility of Results; Sunitinib; Tetrazoles; Time Factors; Treatment Outcome | 2011 |
[Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Tumor Lysis Syndrome | 2011 |
Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Area Under Curve; Carcinoma, Renal Cell; Contrast Media; Evidence-Based Medicine; Female; Fluorocarbons; Humans; Indoles; Kidney Neoplasms; Male; Microbubbles; Middle Aged; Neoplasm Metastasis; Pyrroles; Reproducibility of Results; Statistics, Nonparametric; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Ultrasonography | 2011 |
[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Data Collection; Disease Progression; Drug Delivery Systems; Everolimus; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
[Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
Advances in pancreatic neuroendocrine tumor treatment.
Topics: Antineoplastic Agents; Blood Glucose; Diabetes Complications; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib | 2011 |
Advances in pancreatic neuroendocrine tumor treatment.
Topics: Antineoplastic Agents; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2011 |
Advances in pancreatic neuroendocrine tumor treatment.
Topics: Animals; Antineoplastic Agents; Diabetes Mellitus, Type 1; Glucagonoma; Humans; Indoles; Insulinoma; Mice; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib | 2011 |
Advances in pancreatic neuroendocrine tumor treatment.
Topics: Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2011 |
Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: a case report.
Topics: Adult; Antineoplastic Agents; Critical Care; Critical Illness; Humans; Hypoglycemia; Indoles; Male; Neuroendocrine Tumors; Prednisolone; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2011 |
[Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Recurrence; Sunitinib | 2011 |
[A case of imatinib-resistant GIST treated by sunitinib].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Quality of Life; Sunitinib; Tomography, X-Ray Computed | 2011 |
Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Remission Induction; Sunitinib; Treatment Outcome | 2011 |
Development of an AlphaScreen-based high-throughput screening assay for inhibitors of human vascular endothelial growth factor receptor-3.
Topics: Dose-Response Relationship, Drug; Escherichia coli; High-Throughput Screening Assays; Humans; Indoles; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Structure-Activity Relationship; Sunitinib; Vascular Endothelial Growth Factor Receptor-3 | 2011 |
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indoles; Italy; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2011 |
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination.
Topics: Aged; Angiogenesis Inhibitors; Angiotensins; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrroles; Renin-Angiotensin System; Retrospective Studies; Sunitinib; Treatment Outcome | 2011 |
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Thrombocytopenia | 2011 |
[New therapeutic options for advanced thyroid cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2011 |
Vasculatures in tumors growing from preirradiated tissues: formed by vasculogenesis and resistant to radiation and antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Transplantation; Cell Aggregation; Cell Hypoxia; Cell Line, Tumor; Coloring Agents; Drug Resistance, Neoplasm; Endothelial Cells; Green Fluorescent Proteins; Indoles; Macrophages; Male; Mice; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neovascularization, Pathologic; Nitroimidazoles; Prostatic Neoplasms; Pyrroles; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents; Salvage Therapy; Sunitinib; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2011 |
Design, synthesis and biological evaluation of novel 4-thiazolidinones containing indolin-2-one moiety as potential antitumor agent.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Female; Fibroblasts; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Lung Neoplasms; Pyrroles; Sunitinib; Thiazolidines | 2011 |
Efficacy of sunitinib rechallenge in kidney cancer: are mTOR inhibitors involved or is it only a matter of time?
Topics: Antineoplastic Agents; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2011 |
Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2011 |
Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Health Care Costs; Humans; Indoles; Interferon-alpha; Italy; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2011 |
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoembryonic Antigen; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flow Cytometry; Humans; Immune System; Indoles; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms, Experimental; Pyrroles; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sunitinib; T-Lymphocytes, Regulatory; Treatment Outcome | 2012 |
Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity.
Topics: Animals; Antineoplastic Agents; Cardiovirus Infections; eIF-2 Kinase; Encephalomyocarditis virus; Endoribonucleases; Humans; Immunity, Innate; Indoles; Membrane Proteins; Mice; Mice, Knockout; Protein Serine-Threonine Kinases; Pyrroles; Sunitinib | 2011 |
Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Pressure; Carcinoma, Transitional Cell; Cell Cycle Proteins; Drug Administration Schedule; Humans; Hypertension; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Logistic Models; New York City; Phosphoproteins; Phosphorylation; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Tissue Array Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Urologic Neoplasms; Urothelium; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Incidence; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
[KIT and KIT: from biology to clinical use].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2012 |
The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system.
Topics: Angiogenesis Inhibitors; Animals; Blood Pressure; Dose-Response Relationship, Drug; Endothelin-1; Hypertension; Indoles; Kidney; Male; Nitric Oxide; Oxidative Stress; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Nephrectomy; Organ Sparing Treatments; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Tumor Burden | 2012 |
[Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Salvage Therapy; Sunitinib | 2011 |
Sunitinib prior to planned cytoreductive nephrectomy: is this the new litmus test for metastatic renal cell carcinoma?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2011 |
Bevacizumab, sunitinib: osteonecrosis of the jaw.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Humans; Indoles; Jaw Diseases; Osteonecrosis; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Metastatic renal mucinous tubular and spindle cell carcinoma. Atypical behavior of a rare, morphologically bland tumor.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Nephrectomy; Pyrroles; Rare Diseases; Sunitinib | 2012 |
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Endothelial Cells; Female; Humans; Indoles; Lymphangiogenesis; Lymphatic Metastasis; Lymphatic Vessels; Mammary Neoplasms, Experimental; Mice; Neovascularization, Pathologic; Phosphorylation; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor D; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2011 |
Lung Aspergillosis in renal cell carcinoma patient treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Lung Neoplasms; Male; Opportunistic Infections; Pulmonary Aspergillosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2012 |
Recurrent anaplastic meningioma treated by sunitinib based on results from quantitative proteomics.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Female; Humans; Immunohistochemistry; Indoles; Meningeal Neoplasms; Meningioma; Middle Aged; Molecular Targeted Therapy; Proteomics; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Spectrometry, Mass, Electrospray Ionization; Sunitinib | 2012 |
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzenesulfonates; DNA, Neoplasm; Drug Resistance, Neoplasm; Eosinophilia; ETS Translocation Variant 6 Protein; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Indoles; Male; Middle Aged; Molecular Sequence Data; Niacinamide; Oncogene Fusion; Oncogene Proteins, Fusion; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ets; Pyridines; Pyrroles; Repressor Proteins; Sorafenib; Sunitinib | 2011 |
New perspectives: role of Sunitinib in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Indoles; Pyrroles; Sunitinib | 2011 |
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2012 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cooperative Behavior; Cytokines; Disease Progression; Everolimus; Evidence-Based Medicine; Humans; Indazoles; Indoles; Interdisciplinary Communication; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Care Team; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.
Topics: Animals; Carcinoma; Carcinoma, Papillary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; MAP Kinase Kinase Kinases; Mice; Mutation; Nuclear Proteins; Proto-Oncogene Proteins B-raf; Pyrroles; raf Kinases; Signal Transduction; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Quinolones; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Sunitinib-induced acute psychosis: case report.
Topics: Aged; Bipolar Disorder; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Psychotic Disorders; Pyrroles; Sunitinib | 2011 |
Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Proliferation; Cell Shape; Clone Cells; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Genome, Human; Humans; Indoles; Liver Neoplasms; Mice; Microscopy, Fluorescence; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Pyrroles; Sunitinib; Time Factors; Tumor Cells, Cultured | 2011 |
The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Stem Cell Factor; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Metastatic collecting duct carcinoma of the kidney treated with sunitinib.
Topics: Antineoplastic Agents; Biopsy; Bone Neoplasms; Carcinoma, Renal Cell; Diagnosis, Differential; Fatal Outcome; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Ribs; Sunitinib | 2011 |
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers.
Topics: Animals; Cell Death; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Disease Progression; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Glucose; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Mice, Nude; Microdissection; Microvessels; Molecular Targeted Therapy; Necrosis; Ovarian Neoplasms; Pyrroles; RNA, Small Interfering; Signal Transduction; Sunitinib; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2011 |
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2011 |
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Topics: Antineoplastic Agents; Benzothiazoles; Carbazoles; Clinical Trials as Topic; Cytokines; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib; Tandem Repeat Sequences | 2011 |
Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation.
Topics: Animals; Antigen Presentation; Antineoplastic Agents; Arthritis, Experimental; Autoantibodies; Bone and Bones; Cartilage; Dendritic Cells; fms-Like Tyrosine Kinase 3; Humans; Indoles; Joints; Mice; Mice, Inbred BALB C; Pyrroles; Sunitinib; Synovitis | 2011 |
Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Odds Ratio; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Survival Rate; Texas; Time Factors; Treatment Outcome; Tumor Burden; Young Adult | 2011 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
Topics: Adolescent; Adult; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Endpoint Determination; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Pyrroles; Retroperitoneal Neoplasms; Retrospective Studies; Sunitinib; Suramin; Testicular Neoplasms; Topotecan; Treatment Outcome; Young Adult | 2012 |
Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Topics: Benzodioxoles; Carcinoma, Renal Cell; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; src-Family Kinases; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Taxoids; Time Factors | 2011 |
Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chi-Square Distribution; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Everolimus; Female; Germany; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Time Factors; Treatment Failure | 2011 |
Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
Topics: Aged; Animals; Antineoplastic Agents; Body Weight; Capillaries; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Indoles; Iodide Peroxidase; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Protein-Tyrosine Kinases; Pyrroles; Rats; Rats, Inbred WKY; Regional Blood Flow; Regression Analysis; Retrospective Studies; Stomach Neoplasms; Sunitinib; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine | 2011 |
VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Genotype; Humans; Indoles; Male; Middle Aged; Prognosis; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Growth Processes; Cell Line, Tumor; Female; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
Topics: Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; International Cooperation; Kidney Neoplasms; Logistic Models; Male; Models, Biological; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Survival Analysis; Time Factors | 2011 |
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination.
Topics: Adult; Aged; Analysis of Variance; Bone Marrow Cells; Cell Hypoxia; Female; Humans; Immunomagnetic Separation; Indoles; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Phosphopeptides; Phosphorylation; Protein-Tyrosine Kinases; Pyrroles; Rectal Neoplasms; Signal Transduction; Sunitinib | 2011 |
Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Random Allocation; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.
Topics: Angiogenesis Inhibitors; Animals; Biological Transport; Brain; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cerebrovascular Circulation; Disease Models, Animal; Glioma; Indoles; Kinetics; Magnetic Resonance Imaging; Misonidazole; Neovascularization, Pathologic; Permeability; Positron-Emission Tomography; Pyrroles; Rats; Sunitinib; Treatment Outcome | 2011 |
Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Cytokines; Disease Progression; Disease-Free Survival; Humans; Hypertension; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2012 |
Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Cell Growth Processes; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; HEK293 Cells; Humans; Indoles; Mice; Mice, Inbred NOD; Mice, SCID; Microvessels; Neoplasms, Experimental; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Random Allocation; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Neurosensory retinal detachment due to sunitinib treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indoles; Male; Middle Aged; Papilledema; Pyrroles; Retinal Detachment; Sunitinib | 2011 |
Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Indazoles; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2011 |
Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2012 |
Flare up of symptoms after discontinuation of sunitinib in patient with lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Administration, Oral; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome; Withholding Treatment | 2011 |
Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Humans; Indoles; Kidney Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Pancreatic Neoplasms; Pyrroles; Renal Dialysis; Sunitinib | 2011 |
Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Electron Spin Resonance Spectroscopy; Female; Indoles; Magnetic Resonance Imaging; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neovascularization, Pathologic; Oxygen; Pyrroles; Sunitinib | 2011 |
Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-Associated Death Protein; Blotting, Western; Bromodeoxyuridine; Cell Line, Tumor; Cell Proliferation; Coloring Agents; In Situ Nick-End Labeling; Indicators and Reagents; Indoles; Microarray Analysis; Oncogene Protein v-akt; PC12 Cells; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Rats; Ribosomal Protein S6 Kinases; RNA, Small Interfering; Signal Transduction; Sunitinib; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cell Line; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Erlotinib Hydrochloride; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Photochemotherapy; Porphyrins; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Verteporfin; Wet Macular Degeneration | 2012 |
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection | 2012 |
Sunitinib and Thrombosis.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Prognosis; Pyrroles; Sunitinib; Thrombosis | 2012 |
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function.
Topics: Angiogenesis Inhibitors; Animals; Blood Cell Count; Blood Chemical Analysis; Blood Pressure; Echocardiography; Enzyme Inhibitors; Guinea Pigs; Heart; Heart Rate; In Vitro Techniques; Indoles; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Sunitinib; Telemetry | 2012 |
Renal carcinoma with (6;11)(p21;q12) translocation: report of an adult case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biomarkers, Tumor; Carcinoma, Renal Cell; Cathepsin K; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 6; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indoles; Interferons; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Oncogene Proteins, Fusion; Pyrroles; Sirolimus; Sunitinib; Translocation, Genetic | 2011 |
Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Endothelial Cells; Female; Humans; Indoles; Lutetium; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, SCID; Neovascularization, Pathologic; Pyrroles; Radioisotopes; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Determining the optimal dose and schedule of sunitinib: some answers, more questions.
Topics: Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2012 |
Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sirolimus; Sunitinib | 2012 |
Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.
Topics: Adenocarcinoma; Adoptive Transfer; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Disease Models, Animal; Hep G2 Cells; Hepatocytes; Humans; Immune Tolerance; Immunocompetence; Indoles; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrroles; STAT3 Transcription Factor; Sunitinib | 2012 |
Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations.
Topics: AMP-Activated Protein Kinase Kinases; Blotting, Western; Cell Survival; Electrophysiological Phenomena; Enzyme Activation; Humans; Indoles; Induced Pluripotent Stem Cells; Myocardial Contraction; Myocytes, Cardiac; Protein Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Ribosomal Protein S6 Kinases, 90-kDa; Sunitinib | 2011 |
New target therapies for patients with neuroendocrine tumors of the pancreas.
Topics: Antineoplastic Agents; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome; United States; United States Food and Drug Administration | 2011 |
Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Models, Animal; Everolimus; Humans; Indoles; Mice; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Female; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Male; Middle Aged; Peritonitis; Pyrroles; Sunitinib | 2012 |
Tyrosine kinase inhibitor sunitinib relieves systemic and oral antigen-induced anaphylaxes in mice.
Topics: Anaphylaxis; Animals; Antigens; Enzyme-Linked Immunosorbent Assay; Immunosuppressive Agents; Indoles; Male; Mast Cells; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Rats; Sunitinib | 2012 |
Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2012 |
Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Agents; Brain Diseases, Metabolic; Confusion; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hyperammonemia; Indoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Treatment Outcome | 2011 |
The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Protein Kinase C-epsilon; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sunitinib; Wound Healing | 2011 |
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A | 2013 |
Sunitinib-induced hyperparathyroidism: a possible mechanism to altered bone homeostasis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Calcium; Carcinoma, Renal Cell; Female; Humans; Hyperparathyroidism; Hypophosphatemia; Indoles; Kidney Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2012 |
Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction.
Topics: Aged; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney; Male; Nephrotic Syndrome; Proteinuria; Pyrroles; Sunitinib | 2012 |
Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Combined Modality Therapy; Female; Gene Fusion; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Nephrectomy; Nephrotic Syndrome; Pyrroles; Sunitinib; Translocation, Genetic; Treatment Outcome | 2011 |
Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor.
Topics: Aged; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Pneumatosis Cystoides Intestinalis; Pyrroles; Radiography, Abdominal; Sunitinib; Tomography, X-Ray Computed | 2011 |
Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Radiography; Sirolimus; Sunitinib | 2011 |
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; HCT116 Cells; HT29 Cells; Humans; Indoles; Kidney Neoplasms; Lysosomes; Mice; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2011 |
Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Interleukin-6; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasm Transplantation; Prostatic Neoplasms; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; RNA, Messenger; Sulfonamides; Sunitinib | 2011 |
Improved curve fits to summary survival data: application to economic evaluation of health technologies.
Topics: Algorithms; Antineoplastic Agents; Biomedical Technology; Carcinoma, Renal Cell; Computer Simulation; Cost-Benefit Analysis; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Models, Statistical; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Sunitinib; Survival Analysis; Treatment Outcome | 2011 |
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Benzenesulfonates; Cardiotoxins; Cell Survival; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Indoles; Male; Models, Animal; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; Sunitinib; Zebrafish | 2011 |
Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Biotransformation; Calibration; Carcinoma, Renal Cell; Chromatography, High Pressure Liquid; Dealkylation; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Limit of Detection; Protein Kinase Inhibitors; Pyrroles; Reproducibility of Results; Sunitinib; Sweat; Tandem Mass Spectrometry | 2011 |
Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Survival Analysis; Turkey | 2011 |
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Disease-Free Survival; Female; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Patient Selection; Phenotype; Polymorphism, Single Nucleotide; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Risk Factors; Spain; Sunitinib; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-3 | 2011 |
Targeted therapy for patients with renal-cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2011 |
Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Humans; Imidazoles; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-pim-1; Pyridazines; Pyrroles; Real-Time Polymerase Chain Reaction; Sunitinib | 2011 |
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Count; Disease Progression; Disease-Free Survival; Epidemiologic Methods; Female; Humans; Indoles; Kidney Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Pyrroles; Sunitinib; Young Adult | 2012 |
Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Mitosis; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survivin; Treatment Outcome | 2011 |
PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Indoles; Kidney Neoplasms; Melanoma; Protein Serine-Threonine Kinases; Pyrroles; Ribosomal Protein S6 Kinases, 90-kDa; RNA Interference; RNA, Small Interfering; Sunitinib | 2012 |
Sunitinib induced pyoderma gangrenosum-like ulcerations.
Topics: Aged; Antineoplastic Agents; Erythema; Humans; Hyperpigmentation; Hypopigmentation; Indoles; Male; Negative-Pressure Wound Therapy; Pyoderma Gangrenosum; Pyrroles; Sunitinib; Ulcer | 2011 |
HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants.
Topics: Animals; Blister; Body Fluids; Cell Hypoxia; Disease Models, Animal; Ear, Middle; Gene Expression Regulation; Hearing Loss; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Mutant Strains; Nitroimidazoles; Otitis Media with Effusion; Phthalazines; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Reversible cardiomyopathy associated with sunitinib and sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cardiomyopathies; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.
Topics: Animals; Benzamides; Binding, Competitive; Biological Transport; Cells, Cultured; Clinical Trials as Topic; Dogs; Down-Regulation; Drug Evaluation, Preclinical; Humans; Imatinib Mesylate; Indoles; Iodine Radioisotopes; Monocarboxylic Acid Transporters; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Symporters; Thyroxine; Transfection; Triiodothyronine | 2012 |
Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2011 |
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Risk Factors; Serum Albumin; Sorafenib; Sunitinib; Survival Rate; Young Adult | 2012 |
Sporadic CNS hemangioblastomatosis, response to sunitinib and secondary polycythemia.
Topics: Adult; Antineoplastic Agents; Brain; Central Nervous System Neoplasms; Hemangioblastoma; Humans; Indoles; Magnetic Resonance Imaging; Male; Polycythemia; Pyrroles; Spinal Cord; Sunitinib | 2012 |
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antigens, CD34; Blood Flow Velocity; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Contrast Media; Drug Evaluation, Preclinical; Humans; Immunohistochemistry; Indoles; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microbubbles; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Treatment Outcome; Tumor Burden; Ultrasonography | 2011 |
Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate | 2011 |
Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Gastrointestinal stromal tumors of the stomach.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Gastroscopy; Humans; Imatinib Mesylate; Indoles; Laparoscopy; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Stomach Neoplasms; Sunitinib | 2012 |
RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Growth Processes; Cell Line, Tumor; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Synergism; Epothilones; Female; Humans; Indoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pyrroles; rhoB GTP-Binding Protein; Sunitinib; Up-Regulation | 2012 |
Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress.
Topics: Angiogenesis Inhibitors; Animals; Blood Pressure; Coronary Circulation; Endothelin-1; Female; Hemodynamics; Indoles; Male; Motor Activity; Nitric Oxide; Oxidative Stress; Pulmonary Circulation; Pyrroles; Reactive Oxygen Species; Rest; Sunitinib; Sus scrofa; Vasoconstriction | 2012 |
Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
Topics: Angiogenesis Inhibitors; Antiviral Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib | 2011 |
Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Receptors, FSH; Retrospective Studies; Sensitivity and Specificity; Sunitinib | 2012 |
[Renal tolerance of targeted therapies].
Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2012 |
Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Carcinoma 256, Walker; Cell Movement; Cells, Cultured; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fingolimod Hydrochloride; Indoles; Male; Mammary Neoplasms, Experimental; Myocytes, Smooth Muscle; Neoplasm Transplantation; Propylene Glycols; Proto-Oncogene Proteins c-sis; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, Platelet-Derived Growth Factor beta; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Statistics, Nonparametric; Sunitinib; Tumor Burden; Tyrphostins | 2012 |
[Advanced sarcomatoid renal cell carcinoma effectively treated with sunitinib: report of a case].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sarcoma; Sunitinib | 2011 |
Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
Topics: Absorption; Administration, Oral; Adult; Animals; Biological Availability; Carbon Isotopes; Carbon Radioisotopes; Feces; Female; Half-Life; Humans; Indoles; Injections, Intravenous; Macaca fascicularis; Male; Middle Aged; Pyrroles; Rats; Rats, Sprague-Dawley; Sunitinib; Tissue Distribution; Young Adult | 2012 |
Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Humans; Indoles; Iodide Peroxidase; MAP Kinase Signaling System; Oncogene Protein v-akt; Phosphorylation; Pyrroles; Receptors, Thyrotropin; Sunitinib; Symporters; Thyroglobulin; Thyroid Neoplasms | 2012 |
Health-related quality of life in Japanese patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Aged; Carcinoma, Renal Cell; Female; Health Status; Humans; Indoles; Japan; Kidney Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrroles; Quality of Life; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2013 |
Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Cetuximab; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Humans; Indoles; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recurrence; Sunitinib | 2011 |
[Twenty-one-year survival case of rectal GIST treated with combined therapies].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Pyrroles; Rectal Neoplasms; Recurrence; Sunitinib; Time Factors | 2011 |
[A case of gastrointestinal stromal tumor (GIST) successfully treated with resection after a long-term control medication by molecular targeted drugs].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2011 |
VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Blotting, Western; Cell Movement; Cells, Cultured; Culture Media, Conditioned; Enzyme-Linked Immunosorbent Assay; Human Umbilical Vein Endothelial Cells; Humans; Indoles; MAP Kinase Kinase 1; MAP Kinase Signaling System; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Wound Healing | 2012 |
Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Disease Progression; Fibroblasts; Indoles; Mice; Phosphorylation; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Scleroderma, Systemic; Skin; Sunitinib | 2012 |
Sorafenib: muscle wasting.
Topics: Benzamides; Benzenesulfonates; Humans; Imatinib Mesylate; Indoles; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Rhabdomyolysis; Sorafenib; Sunitinib | 2011 |
Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden | 2012 |
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Remission Induction; Retrospective Studies; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2012 |
Alveolar soft part sarcoma in childhood: is Sunitinib-Sutent® treatment an effective approach?
Topics: Adolescent; Angiogenesis Inhibitors; Child; Combined Modality Therapy; Female; Humans; Indoles; Lung Neoplasms; Pyrroles; Receptor Protein-Tyrosine Kinases; Sarcoma, Alveolar Soft Part; Sunitinib | 2012 |
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult | 2012 |
P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Brain; Cell Line; Dogs; Humans; Indoles; Male; Mice; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Neoplasm Proteins; Pyrroles; Sunitinib; Tetrahydroisoquinolines | 2012 |
Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Sunitinib | 2012 |
Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Pilot Projects; Pyrroles; Sunitinib; Time Factors | 2012 |
Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Genital Diseases, Male; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Scrotum; Skin Diseases; Sunitinib; Vulvar Diseases | 2012 |
An adaptive group sequential phase II design to compare treatments for survival endpoints in rare patient entities.
Topics: Algorithms; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Computer Simulation; Data Interpretation, Statistical; Humans; Indoles; Kidney Neoplasms; Proportional Hazards Models; Pyrroles; Rare Diseases; Research Design; Sample Size; Sirolimus; Sunitinib; Survival | 2012 |
Sunitinib-induced hand-foot syndrome in a renal cell carcinoma: a sclerodermatous and rheumatoid arthritis-like case.
Topics: Aged; Antineoplastic Agents; Arthritis, Rheumatoid; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Pyrroles; Scleroderma, Diffuse; Sunitinib | 2012 |
Inhibition of neuroblastoma cell proliferation with omega-3 fatty acids and treatment of a murine model of human neuroblastoma using a diet enriched with omega-3 fatty acids in combination with sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Arachidonic Acid; Cell Line, Tumor; Cell Proliferation; Diet; Dose-Response Relationship, Drug; Fatty Acids, Omega-3; Fish Oils; Humans; Indoles; Lipid Metabolism; Male; Mice; Mice, SCID; Microvessels; Mitochondria; Neuroblastoma; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Topics: Antineoplastic Agents; Chromatography, Liquid; Clinical Trials, Phase I as Topic; Drug Stability; Humans; Indoles; Neoplasms; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Tandem Mass Spectrometry | 2012 |
Sunitinib therapy for melanoma patients with KIT mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gene Amplification; Gene Expression; Humans; Indoles; Male; Melanoma; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2012 |
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Crizotinib; Epithelial-Mesenchymal Transition; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Niacinamide; Pericytes; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Tumor Cells, Cultured | 2012 |
Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Mutational Analysis; DNA-Binding Proteins; Down-Regulation; Drug Synergism; Endonucleases; Enzyme-Linked Immunosorbent Assay; Gene Expression; Humans; Immunohistochemistry; Indoles; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Stomach Neoplasms; Sunitinib | 2012 |
HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sunitinib | 2012 |
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib | 2012 |
Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2012 |
Complete pathological response after sequential therapy with sunitinib and radiotherapy for metastatic clear cell renal carcinoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Chemoradiotherapy; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Palliative Care; Pyrroles; Sunitinib | 2012 |
Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Prognosis; Proteasome Endopeptidase Complex; Pyrroles; Sunitinib; Survival Analysis | 2012 |
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.
Topics: Angiogenesis Inhibitors; Animals; beta Catenin; Breast Neoplasms; Cell Count; Cell Hypoxia; Cell Line, Tumor; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Neoplastic Stem Cells; Pyrroles; Signal Transduction; Sunitinib | 2012 |
Is apparent diffusion coefficient reliable and accurate for monitoring effects of antiangiogenic treatment in a longitudinal study?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Diffusion Magnetic Resonance Imaging; Female; Glioblastoma; Image Enhancement; Image Interpretation, Computer-Assisted; Indoles; Longitudinal Studies; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome | 2012 |
Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Pyrroles; Sunitinib; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2012 |
Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Blood Glucose; Carcinoma, Renal Cell; Diabetes Mellitus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2012 |
Cancer therapy modulates VEGF signaling and viability in adult rat cardiac microvascular endothelial cells and cardiomyocytes.
Topics: Angiogenesis Inhibitors; Animals; Cell Survival; Cells, Cultured; Coronary Vessels; Doxorubicin; Endothelial Cells; Heart Ventricles; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; L-Lactate Dehydrogenase; Male; Microvessels; Myocytes, Cardiac; Protein Stability; Pyrroles; Rats; Rats, Wistar; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Second-line treatment for renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Retreatment; Sulfonamides; Sunitinib | 2012 |
Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells.
Topics: Animals; Area Under Curve; Cell Line; Cell Survival; Drug Carriers; Drug Delivery Systems; Fibrosis; Humans; Immunohistochemistry; Indoles; Kidney; Kidney Diseases; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Muramidase; Organoplatinum Compounds; Protein-Tyrosine Kinases; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sunitinib | 2012 |
Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Indoles; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred C3H; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sunitinib; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Time Factors; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2012 |
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Benzenesulfonates; Carcinoid Tumor; Carcinoma, Squamous Cell; CD5 Antigens; DNA Mutational Analysis; Enzyme Activation; Female; Genetic Association Studies; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thymoma; Thymus Neoplasms; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins | 2012 |
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Contraindications; Female; Humans; Indoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Renal Dialysis; Retrospective Studies; Sorafenib; Sunitinib | 2012 |
Intracranial metastasis from pediatric GI stromal tumor.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2012 |
Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model.
Topics: Animals; Beclomethasone; Breast Neoplasms; Cell Movement; Cell Transformation, Neoplastic; Disease Models, Animal; Endothelial Cells; Humans; Indoles; Mice; Myeloid Cells; Neoplasm Metastasis; Neutrophils; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Xenograft Model Antitumor Assays; Zebrafish | 2012 |
Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Databases as Topic; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Hormones | 2012 |
Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells.
Topics: Angiogenesis Inhibitors; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; DNA; Dose-Response Relationship, Drug; fms-Like Tyrosine Kinase 3; Humans; Indoles; Meningeal Neoplasms; Meningioma; Protein Kinase Inhibitors; Pyrroles; Radiation Tolerance; Receptors, Platelet-Derived Growth Factor; Sunitinib | 2012 |
Steve Jobs's cancer. Pancreatic neuroendocrine tumors are becoming more common (the bad news) and also more treatable (the good news).
Topics: Antineoplastic Agents; Everolimus; Famous Persons; Humans; Indoles; Liver Neoplasms; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Pyrroles; Risk Factors; Sirolimus; Sunitinib | 2012 |
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2012 |
Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2012 |
Antiangiogenic agents: fueling cancer's hypoxic roots.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Hypoxia; Humans; Indoles; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2012 |
Editorial comment.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoadjuvant Therapy; Pyrroles; Sunitinib | 2012 |
Cutaneous side effects associated with sunitinib: an analysis of 8 cases.
Topics: Adult; Antineoplastic Agents; Female; France; Humans; Indoles; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Skin; Skin Diseases; Sunitinib | 2012 |
Efficacy of Tie2 receptor antagonism in angiosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Hemangiosarcoma; Humans; Imidazoles; Indoles; Mice; Mice, Nude; Pyridines; Pyrroles; Receptor, TIE-2; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Xenograft Model Antitumor Assays | 2012 |
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Multivariate Analysis; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2012 |
Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2013 |
Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma, Papillary; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; MAP Kinase Signaling System; Oncogene Proteins, Fusion; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Pyrroles; ras Proteins; Sunitinib; Thyroid Neoplasms | 2012 |
Radioiodinated sunitinib as a potential radiotracer for imaging angiogenesis-radiosynthesis and first radiopharmacological evaluation of 5-[125I]Iodo-sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Cell Proliferation; Female; Humans; Indoles; Inhibitory Concentration 50; Iodine Radioisotopes; Magnetic Resonance Spectroscopy; Mice; Molecular Structure; Oxindoles; Pyrroles; Radiopharmaceuticals; Sunitinib | 2012 |
The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Disease Models, Animal; Disease Progression; Glioblastoma; Indoles; Mice; Mice, Transgenic; Pyrroles; Radiation Dosage; Sunitinib | 2012 |
Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Epirubicin; Female; Humans; Indoles; Mice; Neoplasm Metastasis; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
Underestimating cardiac toxicity in cancer trials: lessons learned?
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Drug Labeling; Drug Monitoring; Heart Diseases; Humans; Indoles; Neoplasms; Pyrroles; Stroke Volume; Sunitinib; Ventricular Dysfunction, Left | 2012 |
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VE
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Enzyme Inhibitors; ErbB Receptors; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrroles; Salvage Therapy; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Line, Tumor; Chi-Square Distribution; Disease-Free Survival; Female; Humans; Immunohistochemistry; Indoles; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Receptors, CXCR4; Risk Assessment; Risk Factors; RNA, Messenger; Sunitinib; Time Factors; Treatment Outcome | 2012 |
Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.
Topics: Angiogenesis Inhibitors; Animals; Cell Hypoxia; Combined Modality Therapy; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Genetic Therapy; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Liver Neoplasms; Lymphatic Metastasis; Mice; Mice, Transgenic; Neoplasm Invasiveness; Neovascularization, Physiologic; Neuroendocrine Tumors; NF-kappa B; Pancreatic Neoplasms; Pericytes; Proto-Oncogene Proteins c-met; Pyrroles; Recombinant Proteins; Semaphorin-3A; Sunitinib; Tumor Burden; Uterine Cervical Neoplasms | 2012 |
Reproductive toxicity assessment of sunitinib, a multitargeted receptor tyrosine kinase inhibitor, in male and female rats.
Topics: Animals; Body Weight; Embryonic Development; Epididymis; Estrous Cycle; Female; Fertility; Indoles; Male; Organ Size; Pregnancy; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Reproduction; Spermatozoa; Sunitinib; Testis; Toxicity Tests | 2012 |
Sunitinib causes dose-dependent negative functional effects on myocardium and cardiomyocytes.
Topics: Aged; Animals; Antineoplastic Agents; Calcium; Dose-Response Relationship, Drug; Electron Spin Resonance Spectroscopy; Female; Heart; Humans; In Vitro Techniques; Indoles; Male; Mice; Mice, Inbred C57BL; Myocardial Contraction; Myocytes, Cardiac; Protein Kinase Inhibitors; Pyrroles; Reactive Oxygen Species; Sarcomeres; Sunitinib | 2012 |
Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome.
Topics: Benzamides; Female; Hand-Foot Syndrome; Humans; Imatinib Mesylate; Indoles; Male; Piperazines; Protein Kinase Inhibitors; PUVA Therapy; Pyrimidines; Pyrroles; Sunitinib | 2012 |
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chemokine CCL2; Chemokine CXCL16; Chemokines, CXC; DNA Topoisomerases, Type I; Female; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Mice, Nude; Pyrroles; Receptors, Scavenger; Rhabdomyosarcoma; Sarcoma; Sunitinib; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a case.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cytokines; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, SCID; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis.
Topics: Adenocarcinoma, Follicular; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Off-Label Use; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2012 |
The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Insulin-Like Growth Factor I; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-met; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Sunitinib; Taxoids; Zinc Sulfate | 2013 |
Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib | 2012 |
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Indoles; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC).
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Postoperative Complications; Pyrroles; Risk Assessment; Risk Factors; Sunitinib | 2012 |
A biodegradable perivascular wrap for controlled, local and directed drug delivery.
Topics: Animals; Blood Vessel Prosthesis; Delayed-Action Preparations; Drug Delivery Systems; Elastic Modulus; Equipment Design; Hyaluronic Acid; Indoles; Jugular Veins; Lactic Acid; Polyesters; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Porosity; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Swine | 2012 |
Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Female; Humans; Indoles; Male; Microvessels; Middle Aged; Neovascularization, Pathologic; Pyrroles; Retrospective Studies; Sunitinib | 2012 |
A case of acute adrenal insufficiency unmasked during sunitinib treatment for metastatic renal cell carcinoma.
Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pyrroles; Sunitinib; Thyroid Function Tests; Thyrotoxicosis | 2012 |
Sunitinib-induced autoimmune thyroiditis in a patient with metastatic renal cell carcinoma: a case report.
Topics: Aged; Antibodies; Carcinoma, Renal Cell; Female; Humans; Indoles; Iodide Peroxidase; Kidney Neoplasms; Pyrroles; Sunitinib; Thyroglobulin; Thyroiditis, Autoimmune; Tomography, X-Ray Computed | 2012 |
Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2012 |
In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Count; Cell Line; Dose-Response Relationship, Drug; Electroretinography; Endothelium, Vascular; Fluorescein Angiography; Humans; Indoles; Intravitreal Injections; Photoreceptor Cells, Vertebrate; Protein-Tyrosine Kinases; Pyrroles; Rabbits; Retinal Ganglion Cells; Retinal Pigment Epithelium; Sunitinib; Umbilical Veins | 2012 |
Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoplastic Cells, Circulating; Pyrroles; Sunitinib; Vena Cava, Inferior; Venous Thrombosis | 2012 |
Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Chemoradiotherapy; Female; Humans; Indoles; Middle Aged; Pyrroles; Radiotherapy, Intensity-Modulated; Sunitinib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2012 |
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Imatinib Mesylate; In Vitro Techniques; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Anti-Idiotypic; Disease Models, Animal; Drug Therapy, Combination; Genetic Engineering; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Blood Loss, Surgical; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Length of Stay; London; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Postoperative Complications; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Gland; Thyrotoxicosis | 2012 |
Sunitinib treatment for refractory malignant pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Indoles; Pheochromocytoma; Pyrroles; Radiography; Radionuclide Imaging; Sunitinib; Treatment Outcome | 2012 |
[Metastatic apocrine adenocarcinoma of the penis: cytostatic therapy].
Topics: Adult; Antineoplastic Agents; Apocrine Glands; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Humans; Indoles; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Penile Neoplasms; Positron-Emission Tomography; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Sweat Gland Neoplasms; Tomography, X-Ray Computed; Tumor Burden | 2012 |
Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Asian People; Benzamides; China; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2012 |
Dose matters: the importance of appropriate dosing: a case report on sunitinib treatment in a patient with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2012 |
Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Gingival Hemorrhage; Humans; Indoles; Kidney Neoplasms; Mandibular Diseases; Middle Aged; Neoplasm Metastasis; Osteonecrosis; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2012 |
New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib | 2012 |
C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Leukopenia; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Taste Disorders | 2012 |
Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Topics: Adult; Aged; Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Genotype; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Knockout; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Pyrroles; Retrospective Studies; Sunitinib; Young Adult | 2012 |
Drug-induced palate osteonecrosis following nasal surgery.
Topics: Angiogenesis Inhibitors; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Drug Therapy, Combination; Humans; Indoles; Male; Middle Aged; Nasal Surgical Procedures; Oral Fistula; Palate, Hard; Pamidronate; Pyrroles; Sunitinib | 2012 |
Sunitinib related osteonecrosis of jaw: a case report.
Topics: Actinomyces; Actinomycosis; Amoxicillin; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Clavulanic Acid; Female; Humans; Indoles; Kidney Neoplasms; Mandible; Mandibular Diseases; Middle Aged; Molar, Third; Osteonecrosis; Pyrroles; Sunitinib; Tooth Extraction; Tooth Socket | 2012 |
Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Humans; Indoles; Mice; Mice, Inbred C3H; Neoplasm Invasiveness; Pyrroles; Sunitinib; Urinary Bladder Neoplasms | 2012 |
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Acute renal failure: a rare side effect of sunitinib therapy.
Topics: Acute Kidney Injury; Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents; Female; Humans; Indoles; Ovarian Neoplasms; Pyrroles; Sunitinib | 2012 |
Effect of sunitinib on functional reproductive outcome in a rabbit model.
Topics: Animals; Female; Indoles; Models, Animal; Pregnancy; Pregnancy Outcome; Pyrroles; Rabbits; Random Allocation; Reproduction; Sunitinib; Tissue Adhesions; Treatment Outcome; Uterus | 2012 |
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Exanthema; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Registries; Retrospective Studies; Skin; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2012 |
Sunitinib malate in solitary fibrous tumor (SFT).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antigens, CD34; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Retrospective Studies; Solitary Fibrous Tumors; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Epithelioid hemangioendothelioma of the kidney treated with sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Hemangioendothelioma, Epithelioid; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bevacizumab; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Pyrroles; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma.
Topics: Aged; Base Sequence; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Female; Humans; Indoles; Male; Middle Aged; Mutation; Neoplasm Staging; Opisthorchiasis; Platelet-Derived Growth Factor; Prognosis; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2012 |
Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Cytokines; Female; Humans; Immunotherapy; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib | 2012 |
Chronic VEGF blockade worsens glomerular injury in the remnant kidney model.
Topics: Animals; Catheter Ablation; Glomerulosclerosis, Focal Segmental; Indoles; Kidney Diseases; Kidney Glomerulus; Male; Pyrroles; Rats; Rats, Wistar; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2012 |
Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; World Health Organization | 2012 |
Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Drug Administration Schedule; Everolimus; Female; Indoles; Kidney Neoplasms; Luciferases; Luminescent Measurements; Mice; Mice, Inbred BALB C; Pyrroles; Random Allocation; Sirolimus; Sunitinib | 2012 |
Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Hypothyroidism; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Nephrectomy; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine | 2012 |
[More attention should be paid to the understanding of gastroenteropancreatic neuroendocrine tumors].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Gastrointestinal Neoplasms; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Peptides, Cyclic; Pyrroles; Sirolimus; Somatostatin; Sunitinib | 2012 |
Takotsubo syndrome in a patient treated with sunitinib for renal cancer.
Topics: Adenocarcinoma, Clear Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Sunitinib; Takotsubo Cardiomyopathy | 2012 |
Sunitinib-sensitive suicidal erythrocyte death.
Topics: Aniline Compounds; Annexin A5; Antineoplastic Agents; Apoptosis; Calcium; Caspases; Cell Size; Ceramides; Cyclic AMP; Erythrocytes; Hemolysis; Humans; Imidazoles; Indoles; Oligopeptides; p38 Mitogen-Activated Protein Kinases; Phosphatidylserines; Protein Binding; Pyridines; Pyrroles; Sunitinib; Xanthenes | 2012 |
Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Endometrium; Female; Humans; Indoles; NF-kappa B; Pyrazines; Pyrroles; Sunitinib | 2012 |
Ethics, politics and protests: using contentious issues in reproductive sciences as educational opportunities.
Topics: Bioethical Issues; Bioethics; Curriculum; Humans; Indoles; Politics; Problem Solving; Pyrroles; Sunitinib; Thinking; Universities | 2012 |
Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Minnesota; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib | 2012 |
Contrasting effects of sunitinib within in vivo models of metastasis.
Topics: Animals; Antineoplastic Agents; Indoles; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Management of antiangiogenic therapy-induced hypertension.
Topics: Angiogenesis Inhibitors; Antihypertensive Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Hypertension; Indoles; Kidney Neoplasms; Lisinopril; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome; Withholding Treatment | 2012 |
Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling.
Topics: Animals; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Ventricular Function, Right; Ventricular Remodeling | 2013 |
How to identify active novel agents in rare cancers and then make them available: a need for a paradigm shift.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2012 |
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; C-Reactive Protein; Carcinoma, Renal Cell; Confidence Intervals; Female; Humans; Hyponatremia; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Leukocytosis; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Severity of Illness Index; Sodium; Sorafenib; Sunitinib | 2012 |
Structural and functional analysis of KIT gene encoding receptor tyrosine kinase and its interaction with sunitinib and HDAC inhibitors: an in silico approach.
Topics: Antineoplastic Agents; Cell Movement; Computer Simulation; Gene Expression Regulation, Neoplastic; Genotype; Histone Deacetylase Inhibitors; Humans; Indoles; Models, Molecular; Mutation; Phenotype; Polymorphism, Single Nucleotide; Protein Binding; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor Protein-Tyrosine Kinases; RNA Splicing; Sunitinib; Untranslated Regions | 2012 |
The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.
Topics: Androgens; Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Orchiectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Vascular Endothelial Growth Factor Receptor-2; von Willebrand Factor; Xenograft Model Antitumor Assays | 2012 |
Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Blotting, Western; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Glioma; Graft Survival; Humans; Indoles; Male; Mice; Mice, Nude; Microdialysis; Neoplasm Transplantation; Neovascularization, Pathologic; Phenotype; Phospholipase C gamma; Polymerase Chain Reaction; Pyrroles; Sunitinib | 2012 |
Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Everolimus; Humans; Indoles; Markov Chains; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Quality-Adjusted Life Years; Sirolimus; Sunitinib; Survival Analysis; United States | 2012 |
Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Female; Humans; Indoles; Male; Middle Aged; Pheochromocytoma; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2012 |
Sunitinib reduces recurrent pelvic adhesions in a rabbit model.
Topics: Animals; Disease Models, Animal; Female; Indoles; Postoperative Complications; Protein Kinase Inhibitors; Pyrroles; Rabbits; Recurrence; Sunitinib; Tissue Adhesions; Uterus | 2012 |
Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; C-Reactive Protein; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib | 2013 |
Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer.
Topics: Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Fluorouracil; Humans; Indoles; MicroRNAs; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
[Partial nephrectomy after neoadjuvant administration of sunitinib facilitates preservation of a solitary kidney].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Image Interpretation, Computer-Assisted; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Organ Sparing Treatments; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2012 |
Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Catecholamines; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Inositol 1,4,5-Trisphosphate; PC12 Cells; Pheochromocytoma; Phospholipase C gamma; Protein Kinase C; Pyrroles; Rats; Receptors, Vascular Endothelial Growth Factor; RNA, Small Interfering; Signal Transduction; Sunitinib; Tyrosine 3-Monooxygenase | 2012 |
The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; Colonic Neoplasms; DNA Primers; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Histological Techniques; Humans; In Situ Nick-End Labeling; Indoles; Luciferases; Oncogene Protein v-akt; Proto-Oncogene Proteins; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib | 2012 |
Targeting neuroendocrine tumor: mixing standard options with novel therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Humans; Indoles; Medical Oncology; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Temozolomide; Treatment Outcome | 2012 |
Editorial comment from Dr Saito to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2012 |
Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Diffusion Magnetic Resonance Imaging; Glioma; Indoles; Mice; Mice, Inbred NOD; Mice, SCID; Pyrroles; Radiotherapy, Conformal; Sunitinib; Tumor Burden | 2013 |
[Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2012 |
Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Basement Membrane; Blood Vessels; Cell Hypoxia; Female; Humans; Indoles; Melanoma; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Spheroids, Cellular; Sunitinib; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2012 |
Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
Topics: Aged; Angiogenesis Inhibitors; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease Progression; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pyrroles; Risk Factors; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Apoptosis; Biomarkers, Tumor; Disease Progression; Endothelial Cells; Female; Humans; Indoles; Keratin-18; Kidney Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Prospective Studies; Pyrroles; Sunitinib; Treatment Failure | 2012 |
Stabilization of multiple metastatic epithelioid sarcoma under treatment with sunitinib malate.
Topics: Adult; Amputation Stumps; Amputation, Surgical; Antineoplastic Agents; Axilla; Drug Administration Schedule; Forearm; Hand; Humans; Indoles; Male; Muscle Neoplasms; Neoplasm Recurrence, Local; Pyrroles; Sarcoma; Skin Neoplasms; Sunitinib; Treatment Outcome; Umbilicus | 2013 |
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Humans; Immunohistochemistry; Indoles; Mesoderm; Mice; Mice, Nude; Myeloid Cells; Neovascularization, Pathologic; Phenotype; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Vascular Endothelial Growth Factor; Stem Cells; Sunitinib; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Paraganglioma; Pheochromocytoma; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2012 |
Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Fluorescent Antibody Technique; fms-Like Tyrosine Kinase 3; Humans; Indoles; Male; Mice; Mice, Nude; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Radiation-Sensitizing Agents; Receptor, Platelet-Derived Growth Factor beta; Sunitinib; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
Rapid relapse after resection of a sunitinib-resistant gastrointestinal stromal tumor harboring a secondary mutation in exon 13 of the c-KIT gene.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Recurrence; Sunitinib | 2012 |
Persistent complete response after single-agent sunitinib treatment in a case of TFE translocation positive relapsed metastatic pediatric renal cell carcinoma.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Child; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Remission Induction; Sunitinib; Tomography, X-Ray Computed; Translocation, Genetic | 2013 |
[Responses to treatment and switching tyrosine kinase inhibitors in gastrointestinal stromal tumor(GIST)].
Topics: Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Editorial comment from Dr Vázquez-Alonso and Dr Puche-Sanz to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2012 |
Thyroid dysfunction in patients treated with sunitinib or sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Gland; Thyroid Hormones | 2012 |
The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells.
Topics: Animals; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Erythropoietin; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Indoles; Kidney Neoplasms; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Protein Kinase Inhibitors; Pyrroles; Receptors, Erythropoietin; Recombinant Proteins; Signal Transduction; Sunitinib | 2012 |
Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2012 |
Tyrosine kinase inhibitor induced pancreatitis.
Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Pancreatitis; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib | 2013 |
Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Neurotoxicity Syndromes; Posterior Leukoencephalopathy Syndrome; Pyrroles; Severity of Illness Index; Sunitinib | 2013 |
Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.
Topics: Adult; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Drug Resistance; Fatal Outcome; Female; Hormone Replacement Therapy; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Liver Neoplasms; Pyrroles; Severity of Illness Index; Sunitinib; Thyroid Gland; Thyroxine | 2012 |
Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro.
Topics: Angiogenic Proteins; Cell Proliferation; Humans; Indoles; Meningeal Neoplasms; Meningioma; Neovascularization, Pathologic; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-sis; Pyrroles; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Tumor Cells, Cultured; Tyrosine; Vascular Endothelial Growth Factor A; Xanthones | 2012 |
A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
Topics: Animals; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Immunohistochemistry; Indoles; Irinotecan; Liposomes; Mice; Mice, Nude; PC12 Cells; Pyrroles; Rats; Sunitinib; Tissue Distribution | 2012 |
Neoadjuvant targeted therapy in a primary metastasized renal cell cancer patient leads to down-staging of inferior vena cava thrombus (IVC) enabling a cardiopulmonary bypass-free tumor nephrectomy: a case report.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cardiopulmonary Bypass; Contraindications; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Thrombectomy; Thrombosis; Treatment Outcome; Vena Cava, Inferior | 2014 |
Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Female; Gefitinib; Glioblastoma; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Mice; Mice, Nude; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Rats, Inbred F344; Spheroids, Cellular; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Liver Failure; Male; Middle Aged; Pyrroles; Sunitinib | 2013 |
Sunitinib-associated pseudothrombocytopenia induced by IgM antibody.
Topics: Humans; Immunoglobulin M; Indoles; Male; Middle Aged; Platelet Aggregation; Pyrroles; Sunitinib; Thrombocytopenia | 2013 |
[A case of interstitial lung disease due to sunitinib].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Diseases, Interstitial; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib | 2012 |
[Cardiac tamponade due to pericardial metastasis from renal cell carcinoma : a case report].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cardiac Tamponade; Echocardiography; Heart Neoplasms; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pericardiocentesis; Pericardium; Pyrroles; Sunitinib | 2012 |
Sunitinib-induced scrotal cutaneous side-effect.
Topics: Aged; Antineoplastic Agents; Humans; Indoles; Male; Pyrroles; Scrotum; Skin Diseases; Sunitinib | 2013 |
High throughput paper spray mass spectrometry analysis.
Topics: Animals; Cattle; Chemistry Techniques, Analytical; Indoles; Mass Spectrometry; Nicotine; Paper; Pyrroles; Sunitinib; Time Factors | 2013 |
Strategic combination therapy overcomes tyrosine kinase coactivation in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Flavonoids; Humans; Indoles; Phosphorylation; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2012 |
VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Count; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Indoles; Mice; Mice, Inbred BALB C; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; T-Lymphocytes, Regulatory; Tumor Escape; Vascular Endothelial Growth Factor A | 2013 |
Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; China; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Humans; Indoles; Kidney Neoplasms; Limit of Detection; Linear Models; Pyrroles; Reproducibility of Results; Sunitinib; Tandem Mass Spectrometry | 2013 |
Lung toxicity in a patient treated with sunitinib.
Topics: Antineoplastic Agents; Humans; Indoles; Lung Diseases; Male; Middle Aged; Pyrroles; Sunitinib | 2012 |
Conditional survival of patients with metastatic renal-cell carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Analysis | 2012 |
[A case of advanced renal cell carcinoma with inferior vena cava thrombus treated with sunitinib as neoadjuvant therapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Thrombectomy; Thrombosis; Vena Cava, Inferior | 2012 |
Synthesis, in silico, in vitro, and in vivo investigation of 5-[¹¹C]methoxy-substituted sunitinib, a tyrosine kinase inhibitor of VEGFR-2.
Topics: Carbon Isotopes; Cell Line; Dose-Response Relationship, Drug; Humans; Indoles; Molecular Structure; Protein Kinase Inhibitors; Pyrroles; Structure-Activity Relationship; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Osteonecrosis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Hepatocyte Growth Factor; Humans; Indoles; Interleukin-6; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2013 |
Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Benzimidazoles; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Humans; Immunosuppressive Agents; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms | 2012 |
Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Turkey | 2013 |
Evaluation of regorafenib in colorectal cancer and GIST.
Topics: Antineoplastic Agents; Benzamides; Colorectal Neoplasms; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2013 |
Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Differentiation; G1 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Indoles; Leukemia, Myeloid, Acute; Pyrroles; Sunitinib; Treatment Outcome; Tumor Cells, Cultured | 2013 |
Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Humans; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Indoles; Mice; MicroRNAs; PTEN Phosphohydrolase; Pyrroles; RNA-Binding Proteins; Signal Transduction; Sunitinib; Up-Regulation | 2013 |
A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Hypoxia; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Indoles; Kidney Neoplasms; MicroRNAs; Pyrroles; Sunitinib; Tumor Cells, Cultured | 2013 |
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Cancer Care Facilities; Carcinoma, Renal Cell; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Drugmakers struggle with Indian patents.
Topics: Antineoplastic Agents; Benzamides; Drug Design; Drug Industry; Humans; Imatinib Mesylate; India; Indoles; Niacinamide; Patents as Topic; Phenylurea Compounds; Piperazines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2012 |
Physicochemical characteristics of sunitinib malate and its process-related impurities.
Topics: Chemical Phenomena; Crystallography, X-Ray; Drug Contamination; Indoles; Pyrroles; Sunitinib | 2013 |
Cancer and deliberate hypothyroidism, anesthesia, and myxedema coma: the curse of oncologic outcomes based on hypothyroidism.
Topics: Antineoplastic Agents; Coma; Female; Humans; Indoles; Myxedema; Postoperative Complications; Pyrroles; Sunitinib | 2013 |
Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells.
Topics: Apoptosis; Cadherins; Cell Line, Tumor; Cell Movement; Cell Survival; Disulfiram; Drug Screening Assays, Antitumor; Drug Synergism; High-Throughput Screening Assays; Humans; Indoles; Male; Neoplasm Invasiveness; Oncogene Proteins, Fusion; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Receptors, Androgen; Signal Transduction; Sunitinib | 2012 |
[Management of sunitinib-associated adverse events].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Pyrroles; Sunitinib | 2012 |
Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Sweden; Young Adult | 2013 |
Sarcomatoid non-small cell lung cancer responding to sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Pyrroles; Sarcoma; Sunitinib; Treatment Outcome | 2013 |
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Knockout; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Establishment and characterization of a novel xenograft model of human gastrointestinal stromal tumor in mice.
Topics: Aged; Animals; Benzamides; Disease Models, Animal; Esophageal Neoplasms; Exons; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Indoles; Male; Mice; Molecular Targeted Therapy; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Transplantation, Heterologous | 2013 |
Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; United States | 2013 |
[A case of hepatectomy for gastrointestinal stromal tumor with multiple liver metastasis after size reduction in a Jehovah's Witness patient].
Topics: Adult; Antineoplastic Agents; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Indoles; Jehovah's Witnesses; Liver Neoplasms; Male; Pyrroles; Sunitinib | 2012 |
[A case of drug resistant recurrent gastrointestinal stromal tumor treated surgically by resection, partial hepatectomy and diaphragmectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Diaphragm; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Jejunal Neoplasms; Liver Neoplasms; Male; Peritoneal Neoplasms; Piperazines; Pyrimidines; Pyrroles; Recurrence; Sunitinib | 2012 |
Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells.
Topics: Adaptor Proteins, Signal Transducing; Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Proteins; Indoles; Mechanistic Target of Rapamycin Complex 1; Microtubule-Associated Proteins; Molecular Targeted Therapy; Multiprotein Complexes; PC12 Cells; Pheochromocytoma; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteins; Pyrroles; Rats; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
Topics: Alanine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Female; Humans; Indoles; Mice; Mice, Nude; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Rabeprazole; Random Allocation; Sunitinib; Triazines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Beyond the maths of biology: long-term spontaneous tumoral regression after sunitinib withdrawal.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Pyrroles; Remission, Spontaneous; Sunitinib | 2013 |
Early onset recall pneumonitis during targeted therapy with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Glucocorticoids; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Prednisolone; Protein Kinase Inhibitors; Pulse Therapy, Drug; Pyrroles; Radiation Dosage; Radiation Pneumonitis; Spinal Neoplasms; Sunitinib; Thoracic Vertebrae; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.
Topics: Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Aspirin; Carcinoma, Renal Cell; Cyclooxygenase 2 Inhibitors; Esophagitis; Humans; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Tetrazoles; Valine; Valsartan | 2013 |
Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation.
Topics: Antineoplastic Agents; Breast Neoplasms; Cytochrome P-450 CYP1A1; Dactinomycin; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Inhibitors; Female; Gene Expression Regulation, Enzymologic; Humans; Indoles; Ligands; MCF-7 Cells; Protein-Tyrosine Kinases; Pyrroles; Receptors, Aryl Hydrocarbon; Resveratrol; RNA, Messenger; Stilbenes; Sunitinib; Transcriptional Activation | 2013 |
Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series.
Topics: Adolescent; Adult; Antineoplastic Agents; Desmoplastic Small Round Cell Tumor; Drug Administration Schedule; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2013 |
[The effect and mechanism of SU11248 on proliferation of nasopharyngeal carcinoma cell line CNE-2].
Topics: Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cyclin G1; Cyclin-Dependent Kinase Inhibitor p27; Gene Expression Regulation, Neoplastic; Humans; Indoles; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Pyrroles; RNA, Messenger; Sunitinib | 2013 |
Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Pyrroles; Signal Transduction; Sunitinib; Tumor Cells, Cultured | 2013 |
Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Cost-Benefit Analysis; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Outcome Assessment, Health Care; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib | 2013 |
Gastro-pleuro-pericardial fistula following combined radiation and chemotherapy for lung metastases from renal cell carcinoma: report of a case.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemoradiotherapy; Enzyme Inhibitors; Fistula; Gastric Fistula; Heart Diseases; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pericardium; Pleural Diseases; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Renal Cell; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Logistic Models; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests; Prospective Studies; Pyrroles; ROC Curve; Statistics, Nonparametric; Sunitinib; Survival Analysis; Treatment Outcome | 2012 |
Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound.
Topics: Angiogenesis Inhibitors; Animals; Dose-Response Relationship, Drug; Immunohistochemistry; Indoles; Mice; Neoplasms, Experimental; Pyrroles; Sunitinib; Ultrasonography, Doppler | 2013 |
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2013 |
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; Indoles; Kidney Neoplasms; Mice; Pyrazoles; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Sunitinib, a small-molecule receptor tyrosine kinase inhibitor, suppresses neointimal hyperplasia in balloon-injured rat carotid artery.
Topics: Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Becaplermin; Carotid Artery Injuries; Cell Movement; Cell Proliferation; Cells, Cultured; DNA Replication; Extracellular Signal-Regulated MAP Kinases; Heparin-binding EGF-like Growth Factor; Humans; Hyperplasia; In Vitro Techniques; Indoles; Intercellular Signaling Peptides and Proteins; Male; Muscle, Smooth, Vascular; Neointima; Phosphorylation; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Pyrroles; Rats; Rats, Wistar; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib | 2013 |
ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2012 |
HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Injections, Intraperitoneal; Mice; Mice, SCID; Neuroblastoma; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Tumor Burden | 2013 |
Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nephrectomy; Pyrroles; Retrospective Studies; Sunitinib; Survival; Treatment Outcome | 2013 |
Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.
Topics: Acute Disease; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Male; Neoplasm Metastasis; Neutropenia; Pancreatitis; Pyrroles; Sunitinib; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2013 |
[Two cases of bowel perforation in patients with metastatic renal cancer treated with a molecularly targeted drug].
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2012 |
Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases.
Topics: Acid Phosphatase; Angiogenesis Inhibitors; Animals; Antigens, CD34; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Indoles; Isoenzymes; Mice; Mice, Nude; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tartrate-Resistant Acid Phosphatase; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Neuroendocrine tumor of the gallbladder.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Catheter Ablation; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Indoles; Middle Aged; Pyrroles; Sunitinib; Taxoids; Ultrasonography | 2013 |
ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzamides; Cell Adhesion Molecules; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Library; Genetic Loci; Humans; Imatinib Mesylate; Indoles; Phosphoproteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RNA, Small Interfering; Sunitinib; Transforming Growth Factor beta3; Zinc Fingers | 2013 |
When a thymic carcinoma "becomes" a GIST.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Thymoma; Thymus Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model.
Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Conjunctiva; Corneal Neovascularization; Disease Models, Animal; Female; Immunoenzyme Techniques; Indoles; Platelet Endothelial Cell Adhesion Molecule-1; Pyrroles; Rabbits; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Refractory cutaneous angiosarcoma successfully treated with sunitinib.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Female; Hemangiosarcoma; Humans; Indoles; Pyrroles; Skin Neoplasms; Sunitinib; Treatment Outcome | 2013 |
The genetics of neuroendocrine tumors.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Co-Repressor Proteins; DNA Helicases; Everolimus; Humans; Indoles; Molecular Chaperones; Mutation; Neuroendocrine Tumors; Nuclear Proteins; Pancreatic Neoplasms; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyrroles; Sirolimus; Sunitinib; X-linked Nuclear Protein | 2013 |
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
Topics: Antineoplastic Agents; Benzothiazoles; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib | 2013 |
A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2012 |
Taking cancer-drug toxicity to heart.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Doxorubicin; Heart Failure; Heart Function Tests; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Trastuzumab | 2013 |
Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not?
Topics: Administration, Oral; Animals; Area Under Curve; Azithromycin; Chromatography, High Pressure Liquid; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Half-Life; Indoles; Isoenzymes; Male; Metabolic Clearance Rate; Protein Kinase Inhibitors; Pyrroles; Rabbits; Risk Assessment; Spectrophotometry, Ultraviolet; Sunitinib | 2012 |
Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma).
Topics: Abdominal Neoplasms; Aged; Antineoplastic Agents; Biomarkers, Tumor; Child; Drug Administration Schedule; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Pancreatic Neoplasms; Paraganglioma; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome; Vipoma | 2013 |
[A case of complete response of multiple lung metastases of renal cell carcinoma with the flexible administration of sunitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pyrroles; Sunitinib | 2013 |
Editorial comment.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2013 |
Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2013 |
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2014 |
The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals.
Topics: Animals; Body Weight; Carcinogenicity Tests; Cell Proliferation; Female; Genes, ras; Indoles; Male; Mice; Mice, Transgenic; Models, Animal; Neoplasms, Experimental; Pyrroles; Rats; Rats, Sprague-Dawley; Sunitinib | 2013 |
Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Keratosis, Actinic; Kidney Neoplasms; Lung Neoplasms; Male; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2013 |
Renal cell cancer treated with a single-edged sword.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2013 |
[Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2013 |
Colchicine toxicity precipitated by interaction with sunitinib.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Colchicine; Drug Interactions; Humans; Indoles; Male; Pyrroles; Sunitinib | 2013 |
Accuracy of a clinical PET/CT vs. a preclinical μPET system for monitoring treatment effects in tumour xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Monitoring; Equipment Design; Equipment Failure Analysis; Female; Fluorodeoxyglucose F18; Indoles; Mice; Mice, Nude; Multimodal Imaging; Neoplasms, Experimental; Positron-Emission Tomography; Pyrroles; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Apoptosis; Cell Differentiation; Cell Line; Cell Movement; Cell Survival; Cells, Cultured; Chick Embryo; Collagen; Hepatic Stellate Cells; Humans; Indoles; Neovascularization, Physiologic; Pyrroles; Rats; Rats, Wistar; Sunitinib; Wound Healing | 2013 |
KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epidermal Growth Factor; ets-Domain Protein Elk-1; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Indoles; Inhibitory Concentration 50; Mutation; Phosphorylation; Proto-Oncogene Proteins p21(ras); Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib | 2013 |
Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Asian People; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Sequence Data; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Body Mass Index; Carcinoma, Renal Cell; Female; Forecasting; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sarcopenia; Sunitinib | 2013 |
Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl.
Topics: Benzamides; Cell Membrane; Cell Survival; Cells, Cultured; Green Fluorescent Proteins; HEK293 Cells; Humans; Imatinib Mesylate; Indoles; Insulin; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Phosphates; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoric Monoester Hydrolases; Phosphorylation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Time Factors | 2013 |
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2013 |
Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; G1 Phase; Indoles; Kidney Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pyrroles; Signal Transduction; Sunitinib; Up-Regulation; Xanthones; Xenograft Model Antitumor Assays | 2012 |
Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Child; Drug Synergism; Female; Glucuronidase; Heparin; Humans; Indoles; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Osteosarcoma; Pyrroles; Rhabdomyosarcoma; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Sunitinib reverse multidrug resistance in gastric cancer cells by modulating Stat3 and inhibiting P-gp function.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Humans; Indoles; Pyrroles; Rhodamine 123; RNA, Messenger; STAT3 Transcription Factor; Stomach Neoplasms; Sunitinib; Vincristine | 2013 |
Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Immunohistochemistry; In Situ Hybridization; Indoles; Male; Meningioma; Middle Aged; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Long-lasting clinical benefit of sunitinib malate in the treatment of a case of heavily pre-treated metastatic liposarcoma.
Topics: Aged; Antineoplastic Agents; Humans; Indoles; Liposarcoma; Lung Neoplasms; Male; Mutation; Neck; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib | 2013 |
"Pseudocavitation" in thymic carcinoma during treatment with sunitinib.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Heart Failure; Humans; Indoles; Male; Middle Aged; Prognosis; Pyrroles; Sunitinib; Thymus Neoplasms | 2013 |
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Renal Cell; CD11b Antigen; Cell Line; Cell Proliferation; Chemokine CXCL12; Drug Resistance, Neoplasm; Endostatins; Female; Gene Knockdown Techniques; Humans; Indoles; Mice; Myeloid Cells; Procollagen-Proline Dioxygenase; Proto-Oncogene Proteins c-mdm2; Pyrroles; Spiro Compounds; Sunitinib; Transplantation, Heterologous; Tumor Burden; Tumor Suppressor Protein p53 | 2013 |
Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Dacarbazine; DNA Methylation; DNA, Neoplasm; Glioma; Heterografts; Humans; Indoles; Male; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Pyrroles; Sunitinib; Temozolomide; Tumor Cells, Cultured; Vascular Resistance | 2013 |
Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria.
Topics: Adult; Aftercare; Austria; Benzamides; Biopsy; Child; Combined Modality Therapy; Cooperative Behavior; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Endoscopy, Gastrointestinal; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Mitotic Index; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Nomograms; Palliative Care; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib | 2013 |
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
[Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Anti-angiogenic and anti-metastatic activity of synthetic phosphoethanolamine.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Cytoskeleton; Ethanolamines; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Tubules, Proximal; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mitochondria; Neoplasm Metastasis; Neovascularization, Pathologic; Oxidation-Reduction; Pyrroles; Rats; Sunitinib; Transcription, Genetic; Vascular Endothelial Growth Factor Receptor-1; Wound Healing | 2013 |
Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Hemangiosarcoma; Heterografts; Humans; In Vitro Techniques; Indoles; Male; Mice; Mice, Inbred NOD; Mice, SCID; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Skin Neoplasms; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
[Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2013 |
Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2012 |
[A case of myocardiac metastasis of clear cell renal carcinoma successfully treated with sunitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Heart Neoplasms; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2013 |
Potential protective effect of sunitinib after administration of diclofenac: biochemical and histopathological drug-drug interaction assessment in a mouse model.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspartate Aminotransferases; Blood Urea Nitrogen; Brain; Chemical and Drug Induced Liver Injury; Creatinine; Diclofenac; Drug Interactions; Indoles; Kidney; Liver; Male; Mice; Mice, Inbred ICR; Myocardium; Protective Agents; Protein Kinase Inhibitors; Pyrroles; Spleen; Sunitinib | 2013 |
Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; ras Proteins; Signal Transduction; Sunitinib; Transcriptome | 2013 |
Erosive nappy erythema following sunitinib intake.
Topics: Antineoplastic Agents; Buttocks; Drug Eruptions; Erythema; Humans; Indoles; Male; Middle Aged; Pyrroles; Scrotum; Sunitinib | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma.
Topics: Aged; Antineoplastic Agents; Blood Glucose; Fluorodeoxyglucose F18; Humans; Indoles; Insulinoma; Liver Neoplasms; Male; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, Emission-Computed | 2013 |
Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice.
Topics: Animals; Antibodies; Antineoplastic Agents; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Indoles; Lymphatic Metastasis; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Confocal; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Triazoles; Vascular Endothelial Growth Factor C | 2013 |
Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells.
Topics: Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Disease Progression; DNA Damage; G1 Phase; Humans; Indoles; Interleukins; Kidney Neoplasms; NF-kappa B; Proto-Oncogene Proteins c-raf; Pyrroles; S Phase; Sunitinib; Tumor Necrosis Factor Decoy Receptors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2013 |
Sunitinib inhibits inflammatory corneal lymphangiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Cell Proliferation; Corneal Neovascularization; Disease Models, Animal; Enzyme Inhibitors; Fluorescent Antibody Technique, Indirect; Glycoproteins; Indoles; Lymphangiogenesis; Lymphatic Vessels; Macrophages, Peritoneal; Male; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Placenta Growth Factor; Platelet Endothelial Cell Adhesion Molecule-1; Pregnancy Proteins; Protein-Tyrosine Kinases; Pyrroles; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
No rebound tumour growth after sunitinib treatment.
Topics: Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib; Survival Analysis | 2013 |
The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2012 |
Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour.
Topics: Humans; Hyperammonemia; Indoles; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2013 |
A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prednisone; Pyoderma Gangrenosum; Pyrroles; Sunitinib | 2013 |
A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Indoles; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Sunitinib; Time Factors; Treatment Outcome | 2013 |
Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib | 2013 |
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Comorbidity; Dose-Response Relationship, Drug; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thrombectomy; Thrombosis; Treatment Outcome; Vena Cava, Inferior | 2014 |
Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Synergism; Female; Gene Expression; Humans; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Pyrimidines; Pyrroles; Sirolimus; Stearoyl-CoA Desaturase; Sulfonamides; Sunitinib; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid | 2013 |
Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Pyrroles; Risk Assessment; Sunitinib | 2013 |
[Clinical observation of sunitinib treatment for refractory advanced breast cancer ulcer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Indoles; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Ulcer | 2013 |
Acute renal failure during the "off" period after sunitinib administration: possible mechanism of vascular endothelial growth factor cascade hyperactivation.
Topics: Acute Kidney Injury; Antineoplastic Agents; Fatal Outcome; Female; Humans; Indoles; Middle Aged; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2013 |
Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nevus, Pigmented; Pyrroles; Sunitinib | 2013 |
Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antiviral Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Hematologic Tests; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutrophils; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2013 |
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Databases, Factual; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival; Treatment Outcome | 2013 |
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Survival Rate; Young Adult | 2013 |
Transient sunitinib resistance in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib | 2013 |
Long-term response to sunitinib therapy for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
Topics: Caspase 3; Caspase 7; Cell Survival; Cells, Cultured; Cholesterol; Crizotinib; Enzyme Activation; ERG1 Potassium Channel; Erlotinib Hydrochloride; Ether-A-Go-Go Potassium Channels; Humans; Indoles; Ion Channels; Lipids; Myocytes, Cardiac; Patch-Clamp Techniques; Pluripotent Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; RNA; Sunitinib | 2013 |
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid | 2013 |
Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor.
Topics: Disease-Free Survival; Female; Humans; Indoles; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Pyrroles; Sunitinib | 2013 |
Loss of Pten promotes angiogenesis and enhanced vegfaa expression in zebrafish.
Topics: Animals; Chromones; Drug Therapy, Combination; Endothelial Cells; Haploinsufficiency; Hemangiosarcoma; Humans; Indoles; Morpholines; Mutation; Neovascularization, Pathologic; Phosphoprotein Phosphatases; Proto-Oncogene Proteins c-akt; Pseudopodia; Pyrroles; RNA, Messenger; Sunitinib; Up-Regulation; Vascular Endothelial Growth Factor A; Zebrafish; Zebrafish Proteins | 2013 |
Cardio-oncology: it takes two to translate.
Topics: Angiogenesis Inhibitors; Animals; Coronary Vessels; Heart; Indoles; Microvessels; Pericytes; Pyrroles; Sunitinib | 2013 |
Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity.
Topics: Angiogenesis Inhibitors; Animals; Coronary Vessels; Heart; Indoles; Mice; Mice, Inbred C57BL; Microvessels; Pericytes; Pyrroles; Sunitinib | 2013 |
A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF.
Topics: AMP-Activated Protein Kinases; Blotting, Western; Cell Line; Cell Survival; Chromatography, Liquid; Enzyme Inhibitors; Fluorescent Antibody Technique; Humans; Indoles; Mass Spectrometry; Melanocytes; Melanoma; Microphthalmia-Associated Transcription Factor; Oncogenes; Pyrroles; RNA Interference; RNA, Small Interfering; Staurosporine; Sunitinib; Transfection | 2014 |
Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Combined Modality Therapy; eIF-2 Kinase; Endoribonucleases; Female; Immunity, Innate; Indoles; Kidney Neoplasms; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Prostatic Neoplasms; Pyrroles; Sunitinib; Vesiculovirus | 2013 |
Neem leaf glycoprotein is superior than cisplatin and sunitinib malate in restricting melanoma growth by normalization of tumor microenvironment.
Topics: Animals; Antineoplastic Agents; Azadirachta; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cisplatin; Cytokines; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Indoles; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Plant Leaves; Pyrroles; Sunitinib | 2013 |
Sunitinib as an anti-endometriotic agent.
Topics: Animals; Apoptosis; Endometriosis; Endometrium; Epithelial Cells; Female; In Situ Nick-End Labeling; Indoles; Protein Kinase Inhibitors; Pyrroles; Rats; Sunitinib | 2013 |
Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphate; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Brain; Indoles; Male; Pantoprazole; Pyrroles; Rats; Rats, Wistar; Sunitinib; Tissue Distribution | 2013 |
Role of ELA region in auto-activation of mutant KIT receptor: a molecular dynamics simulation insight.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Hydrogen Bonding; Indoles; Molecular Dynamics Simulation; Mutation; Protein Structure, Secondary; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib | 2014 |
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Hypoxia; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; RNA, Messenger; Sunitinib; Survival; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months.
Topics: Ablation Techniques; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Radiosurgery; Sunitinib | 2013 |
Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
Topics: Acute Kidney Injury; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Carcinoma, Renal Cell; Cisplatin; Cyclophosphamide; Diphosphonates; Doxorubicin; Female; Glutamates; Guanine; Humans; Imidazoles; Indoles; Interferons; Kidney Tubules; Lung Neoplasms; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Middle Aged; Necrosis; Nephrectomy; Pemetrexed; Prednisone; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Vincristine; Zoledronic Acid | 2013 |
[Advantages of volume perfusion CT for evaluating the response of solid tumors to treatment with sunitinib].
Topics: Aged; Female; Humans; Imaging, Three-Dimensional; Indoles; Male; Middle Aged; Neoplasms; Perfusion Imaging; Prognosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Asymptomatic Diseases; Blood Cell Count; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Function Tests; Kidney Neoplasms; Liver Function Tests; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Patient Preference; Phenylurea Compounds; Population Surveillance; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors | 2013 |
Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; European Union; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Metastasis; Predictive Value of Tests; Prognosis; Pyrroles; Sunitinib; Survival Analysis | 2013 |
Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
Topics: Angiogenesis Inhibitors; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Communication; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Enzyme Activation; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sorafenib; Sunitinib | 2013 |
Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cells, Cultured; Checkpoint Kinase 2; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
[Case of multiple lung metastases of renal cell carcinoma failing to respond to Interferon-alpha (IFN-alpha) and sunitinib but markedly responding to everolimus].
Topics: Carcinoma, Renal Cell; Endoscopy; Everolimus; Humans; Immunosuppressive Agents; Indoles; Interferon-alpha; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Pneumonectomy; Pyrroles; Sirolimus; Sunitinib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2013 |
Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function.
Topics: Animals; Diabetes Mellitus, Type 1; Female; Humans; Hyperglycemia; Indoles; Inflammation; Islets of Langerhans; Mice; Mice, Inbred NOD; Pancreas; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Growth Processes; Everolimus; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Random Allocation; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Benzamides; Chlorocebus aethiops; COS Cells; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Molecular Docking Simulation; Mutation, Missense; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Thiazoles | 2013 |
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
Topics: Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain; Dasatinib; DNA, Complementary; Female; Gene Dosage; Half-Life; Indoles; Male; Maternal-Fetal Exchange; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Pregnancy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; RNA; Sex Characteristics; Sorafenib; Sunitinib; Thiazoles | 2013 |
Neuroendocrine tumors: treatment updates.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Everolimus; Humans; Indoles; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pyrroles; Sirolimus; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2013 |
Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Indoles; Niacinamide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Curcumin potentiates the ability of sunitinib to eliminate the VHL-lacking renal cancer cells 786-O: rapid inhibition of Rb phosphorylation as a preamble to cyclin D1 inhibition.
Topics: Antineoplastic Agents; CDC2 Protein Kinase; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Curcumin; Cyclin D1; Cyclin-Dependent Kinase 4; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Retinoblastoma Protein; Signal Transduction; Sorafenib; Sunitinib | 2013 |
Case of sunitinib-induced Stevens-Johnson syndrome.
Topics: Antineoplastic Agents; Humans; Indoles; Male; Middle Aged; Pyrroles; Stevens-Johnson Syndrome; Sunitinib | 2013 |
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2013 |
[Hematologic adverse effects in patients with renal cell carcinoma treated with sunitinib].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Retrospective Studies; Sunitinib; Young Adult | 2013 |
Impact of sunitinib on human thyroid cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytokines; Humans; Indoles; Interleukin-6; Interleukin-8; Protein Kinase Inhibitors; Pyrroles; Radiation, Ionizing; RNA, Messenger; Sunitinib; Thyroid Neoplasms; Tumor Necrosis Factor-alpha; Up-Regulation; Vascular Endothelial Growth Factor D; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
[A case of pneumatosis intestinalis associated with sunitinib treatment for renal cell carcinoma].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Lung; Male; Pneumatosis Cystoides Intestinalis; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2013 |
Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Blotting, Western; Cell Cycle Proteins; Cell Line; Cell Proliferation; Cells, Cultured; Drosophila Proteins; Endothelial Cells; Hemocytes; Humans; Indoles; Mechanistic Target of Rapamycin Complex 1; Models, Molecular; Molecular Sequence Data; Multiprotein Complexes; Mutation; Protein Structure, Tertiary; Pyrroles; Receptor Protein-Tyrosine Kinases; RNA Interference; Sequence Homology, Amino Acid; Sunitinib; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2013 |
Sunitinib enhances neuronal survival in vitro via NF-κB-mediated signaling and expression of cyclooxygenase-2 and inducible nitric oxide synthase.
Topics: Animals; Blotting, Western; Cell Death; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Gene Expression Regulation, Enzymologic; Indoles; L-Lactate Dehydrogenase; Mice; Nerve Tissue Proteins; Neurons; NF-kappa B; Nitric Oxide Synthase Type II; Pyrroles; Signal Transduction; Sunitinib | 2013 |
Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Dendritic Cells; Female; Hemangiosarcoma; Indoles; Interferon-gamma; Interleukin-2; Lymphocytes; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Protein Kinase Inhibitors; Pyrroles; Sendai virus; Skin Neoplasms; Sunitinib; Tumor Burden; Virion | 2013 |
Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Membrane Potential, Mitochondrial; Necrosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reactive Oxygen Species; Sulfonamides; Sunitinib; Urinary Bladder Neoplasms | 2013 |
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Solitary Fibrous Tumors; Sulfonamides; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Screening assay for blood vessel maturation inhibitors.
Topics: Actins; Angiogenesis Inhibitors; Animals; Benzamides; Blood Vessels; Cell Line; Coculture Techniques; Drug Evaluation, Preclinical; Endothelial Cells; Fibroblasts; Green Fluorescent Proteins; HEK293 Cells; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; Indoles; Lentivirus; Mice; Muscle, Smooth; Neovascularization, Physiologic; Pericytes; Piperazines; Promoter Regions, Genetic; Pyrimidines; Pyrroles; Stem Cells; Sunitinib | 2013 |
Drug interaction between sunitinib and cimetidine and contribution of the efflux transporter ATP-binding cassette C2 to biliary excretion of sunitinib in rats.
Topics: Animals; ATP-Binding Cassette Transporters; Bile; Cimetidine; Drug Interactions; Hyperbilirubinemia; Indoles; Injections, Intravenous; Male; Mass Spectrometry; Pyrroles; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Sunitinib | 2013 |
Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Gene Expression Profiling; Graft Survival; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Knockout; Middle Aged; Molecular Sequence Data; Neoplasm Metastasis; Pyrroles; Sequence Homology, Amino Acid; Sunitinib; Transplantation, Heterologous; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2014 |
Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Movement; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Indoles; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Topotecan | 2013 |
Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance.
Topics: Apoptosis; Cell Survival; Drug Resistance, Neoplasm; HeLa Cells; Humans; Indoles; Lysosomes; MCF-7 Cells; Neoplasms; Pyrroles; Sphingomyelin Phosphodiesterase; Sunitinib | 2013 |
Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT).
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Bevacizumab; Duodenal Diseases; Humans; Indazoles; Indoles; Intestinal Diseases; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography; Radiosurgery; Radiotherapy Dosage; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Stomach Ulcer; Sulfonamides; Sunitinib; Ulcer | 2013 |
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib | 2013 |
Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Young Adult | 2013 |
Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor.
Topics: Aged; Antineoplastic Agents; Exanthema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2014 |
[Is the same tyrosine kinase inhibitor still effective after development of brain metastases? A Case report].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Humans; Indoles; Kidney Neoplasms; Male; Protein-Tyrosine Kinases; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Vessel size imaging (VSI) by robust magnetic resonance (MR) relaxometry: MR-VSI of solid tumors in correlation with immunohistology and intravital microscopy.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Dextrans; Female; Humans; Immunohistochemistry; Indoles; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, Nude; Microscopy; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrroles; Random Allocation; Sunitinib | 2013 |
Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Down-Regulation; Endothelial Cells; ErbB Receptors; Humans; Indoles; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Skin; Sunitinib; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
Topics: Adolescent; Alleles; Animals; Antineoplastic Agents; Cell Line, Tumor; Child; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Mice; Models, Molecular; Molecular Conformation; Mutation; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors.
Topics: Angiogenesis Inhibitors; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Pyrroles; Radiography; Rectal Neoplasms; Sunitinib; Treatment Outcome | 2013 |
Sphingosine kinase-1 activation causes acquired resistance against Sunitinib in renal cell carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Indoles; Kidney Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sunitinib | 2014 |
Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Calixarenes; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endothelial Cells; Female; Galectin 1; Glioblastoma; Half-Life; Humans; Indoles; Inhibitory Concentration 50; Mice; Mice, Nude; Molecular Targeted Therapy; Ovarian Neoplasms; Pyrroles; Sunitinib; Tissue Distribution; Xenograft Model Antitumor Assays | 2013 |
[A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents].
Topics: Animals; Antineoplastic Agents; Birt-Hogg-Dube Syndrome; Carcinoma, Renal Cell; Everolimus; Humans; In Vitro Techniques; Indoles; Kidney Neoplasms; Male; Mice, Knockout; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2013 |
Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2014 |
Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Inhibitory Concentration 50; Lung Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; Sirolimus; Sunitinib; Tissue Culture Techniques; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Topics: Aged; Cell Line, Tumor; Cluster Analysis; ErbB Receptors; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Mutant Proteins; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Skin; Skin Neoplasms; Substrate Specificity; Sulfonamides; Sunitinib; Vemurafenib | 2013 |
Severe exacerbation of Crohn's disease during sunitinib treatment.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Crohn Disease; Disease Progression; Fatal Outcome; Glucocorticoids; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prednisone; Pyrroles; Recurrence; Risk Factors; Severity of Illness Index; Sunitinib; Treatment Outcome | 2014 |
Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Estrogen Receptor alpha; Female; Flow Cytometry; Humans; Indoles; Mammary Neoplasms, Experimental; MAP Kinase Signaling System; MCF-7 Cells; Mice; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Random Allocation; Signal Transduction; Sunitinib; Tamoxifen; Transcription Factor AP-2 | 2014 |
Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Oral Hygiene; Pain; Periodontal Index; Pyrroles; Sunitinib; Surveys and Questionnaires; Tooth Migration; Treatment Outcome | 2013 |
[A case report of a well-differentiated neuroendocrine tumor in which sunitinib treatment resulted in stable disease].
Topics: Antineoplastic Agents; Cell Differentiation; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pyrroles; Sunitinib | 2013 |
[A long-term control of gastrointestinal stromal tumor with sunitinib].
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Indoles; Jejunal Neoplasms; Jejunostomy; Liver Neoplasms; Pyrroles; Sunitinib; Time Factors | 2013 |
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Young Adult | 2014 |
Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Renal Cell; Cell Line, Tumor; Endothelial Cells; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Shrinkage of prostate volume in sunitinib-treated patients with renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Dysuria; Endosonography; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Organ Size; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Pyrroles; Quality of Life; Sunitinib; Tomography, X-Ray Computed; Urination | 2013 |
Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Disease-Free Survival; Drug Eruptions; Female; Humans; Indoles; Kidney Neoplasms; Male; Neutropenia; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Basigin; Blotting, Western; Carcinoma, Renal Cell; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Indoles; Kidney; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sunitinib; Tumor Cells, Cultured | 2013 |
Cytotoxic properties of sunitinib and sorafenib on human corneal epithelial cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers; Cell Line; Cell Survival; Enzyme-Linked Immunosorbent Assay; Epithelium, Corneal; Humans; Immunohistochemistry; Indoles; Membrane Proteins; Microscopy, Fluorescence; Microscopy, Phase-Contrast; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Sunitinib; Tetrazolium Salts; Thiazoles | 2014 |
Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Nomograms; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Survival Rate | 2013 |
Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; DNA Mutational Analysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Ki-67 Antigen; Kidney Neoplasms; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Proportional Hazards Models; Pyrroles; Sunitinib; Time Factors; Tissue Array Analysis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Von Hippel-Lindau Tumor Suppressor Protein | 2013 |
Rectal perforation associated with sunitinib therapy.
Topics: Aged; Angiogenesis Inhibitors; Humans; Indoles; Intestinal Perforation; Male; Pyrroles; Rectal Diseases; Sunitinib | 2013 |
Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy.
Topics: Adjuvants, Immunologic; Animals; Antigen-Presenting Cells; Cancer Vaccines; Cell Proliferation; Disease Progression; Female; Immunotherapy; Indoles; Lactalbumin; Lymph Nodes; Mice; Mice, Inbred BALB C; Pyrroles; Spleen; Sunitinib; T-Lymphocytes; Vaccination | 2014 |
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.
Topics: Bilirubin; Biomarkers, Pharmacological; Genetic Association Studies; Genotype; Gilbert Disease; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Indoles; Liver; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib | 2013 |
[Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small cell lung cancer].
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2013 |
Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.
Topics: Animals; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Half-Life; Indoles; Mice; Mice, Knockout; Pyrroles; Sunitinib; Tandem Mass Spectrometry | 2013 |
[Pre- surgical therapy with sunitinib for adrenal metastasis from renal cell carcinoma : a case report].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Preoperative Care; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein-Tyrosine Kinases; Pyrroles; Receptor, ErbB-2; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2014 |
Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Autocrine Communication; Barrett Esophagus; Biomarkers; Biomarkers, Tumor; Cell Line; Cell Proliferation; Esophageal Neoplasms; Female; Humans; Immunohistochemistry; Indoles; MAP Kinase Signaling System; Mice; Phospholipase C gamma; Phosphorylation; Precancerous Conditions; Protein Kinase C; Pyrroles; Real-Time Polymerase Chain Reaction; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
A low molecular weight zinc2+-dipicolylamine-based probe detects apoptosis during tumour treatment better than an annexin V-based probe.
Topics: Amines; Angiogenesis Inhibitors; Animals; Annexin A5; Apoptosis; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Molecular Probes; Molecular Weight; Neoplasms, Experimental; Organometallic Compounds; Picolinic Acids; Pyrroles; Skin Neoplasms; Sunitinib; Tumor Cells, Cultured; Zinc | 2014 |
Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinogenesis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Lysophospholipids; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Neoplasm Invasiveness; Phosphoric Diester Hydrolases; Pyrroles; Signal Transduction; Sunitinib; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Disease-Free Survival; Female; Genetic Association Studies; Homozygote; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Single Nucleotide; Proportional Hazards Models; Pyrroles; Stomach Neoplasms; Sunitinib; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Three cases of sporadic medullary thyroid carcinoma in progression treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Medullary; Combined Modality Therapy; Hand-Foot Syndrome; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neck Dissection; Neoplasms, Second Primary; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Thrombocytopenia; Thyroid Neoplasms; Thyroidectomy | 2014 |
Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2014 |
Rechallenge of drugs in the era of targeted therapy.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2013 |
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP3A; Female; Humans; Indoles; Male; Midazolam; Middle Aged; Neoplasms; Phenotype; Prospective Studies; Pyrroles; Sunitinib | 2014 |
Sunitinib-induced severe hypoglycemia in a diabetic patient.
Topics: Antineoplastic Agents; Blood Glucose; Carcinoma, Renal Cell; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Severity of Illness Index; Sunitinib | 2014 |
Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Heme Oxygenase-1; Humans; Imatinib Mesylate; Indoles; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Proteome; Pyrimidines; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Sunitinib-related interstitial pneumonia after treatment with temsirolimus: a case of possible recall phenomenon.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Diseases, Interstitial; Male; Middle Aged; Pyrroles; Radiography; Sirolimus; Sunitinib | 2014 |
Sunitinib--CLIO conjugate: a VEGFR/PDGFR-targeting active MR probe.
Topics: Cell Line, Tumor; Ferric Compounds; Humans; Indoles; Magnetic Resonance Imaging; Microscopy, Electron, Transmission; Molecular Probes; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2014 |
Evaluation of anastomotic strength and drug safety after short-term sunitinib administration in rabbits.
Topics: Administration, Oral; Anastomosis, Surgical; Angiogenesis Inhibitors; Animals; Colon; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Heart; Indoles; Liver; Placebos; Postoperative Complications; Pyrroles; Rabbits; Random Allocation; Stress, Mechanical; Sunitinib; Wound Healing | 2014 |
Substrate and inhibitor specificity of the type II p21-activated kinase, PAK6.
Topics: Amino Acid Sequence; Catalytic Domain; Crystallization; Crystallography, X-Ray; HEK293 Cells; Humans; Indoles; Models, Molecular; Molecular Sequence Data; p21-Activated Kinases; Peptide Fragments; Phosphorylation; Protein Conformation; Pyrazoles; Pyrroles; Sequence Homology, Amino Acid; Signal Transduction; Substrate Specificity; Sunitinib | 2013 |
Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Indoles; Interleukin-3; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Random Allocation; Sunitinib | 2014 |
Mechanisms of apoptosis in irradiated and sunitinib-treated follicular thyroid cancer cells.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Inhibitor of Apoptosis Proteins; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Survivin; Thyroid Neoplasms | 2014 |
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Belgium; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
Sunitinib effects on the radiation response of endothelial and breast tumor cells.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Endothelial Cells; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Mice; Mice, SCID; Pyrroles; Radiation Tolerance; Sunitinib; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2014 |
Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.
Topics: Antibodies, Monoclonal; B7 Antigens; Cell Proliferation; Drug Resistance, Neoplasm; Epitopes; Female; Humans; Indoles; Neoplastic Stem Cells; Ovarian Neoplasms; Pyrroles; Sunitinib | 2014 |
A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases | 2013 |
VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2013 |
Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes.
Topics: Aged; Blood Pressure Determination; Carcinoma, Renal Cell; Disease Management; Female; Follow-Up Studies; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Compliance; Prognosis; Pyrroles; Sunitinib | 2013 |
Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer.
Topics: Animals; Biglycan; Gene Expression Regulation, Neoplastic; Humans; Indoles; Leucine; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyrroles; RNA, Messenger; Sorafenib; Sunitinib; Urinary Bladder Neoplasms | 2013 |
Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3⁺CD56⁺ subset through the co-culturing dendritic cells.
Topics: Antineoplastic Agents; CD3 Complex; CD56 Antigen; Cell Line, Tumor; Coculture Techniques; Cytokine-Induced Killer Cells; Dendritic Cells; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Indoles; Interferon-gamma; Macrophages; Pyrroles; Sunitinib; T-Lymphocytes, Regulatory | 2013 |
Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biotransformation; Cytochrome P-450 CYP3A; Female; Humans; Hypnotics and Sedatives; Indoles; Male; Midazolam; Middle Aged; Phenotype; Prospective Studies; Pyrroles; Radiopharmaceuticals; Sunitinib; Technetium Tc 99m Sestamibi | 2014 |
Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Everolimus; Health Care Costs; Humans; Indoles; Kidney Neoplasms; Markov Chains; Models, Economic; Pyrroles; Quality-Adjusted Life Years; Serbia; Sirolimus; Sunitinib; Survival Rate | 2013 |
Magnetic resonance imaging identifies early effects of sunitinib treatment in human melanoma xenografts.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Female; Humans; Indoles; Magnetic Resonance Imaging; Melanoma, Amelanotic; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrroles; Skin Neoplasms; Sunitinib; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Development of cardiac hypertrophy by sunitinib in vivo and in vitro rat cardiomyocytes is influenced by the aryl hydrocarbon receptor signaling pathway.
Topics: Animals; Cardiomegaly; Cell Survival; Cells, Cultured; Cytochrome P-450 CYP1A1; Dose-Response Relationship, Drug; Enzymes; Gene Expression Regulation; Imidazoles; Indoles; Male; Myocytes, Cardiac; Pyridines; Pyrroles; Rats; Rats, Wistar; Receptors, Aryl Hydrocarbon; Resveratrol; Signal Transduction; Stilbenes; Sunitinib | 2014 |
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Asia; Bevacizumab; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; United States | 2014 |
[Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model].
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Arteries; Bevacizumab; Cornea; Corneal Neovascularization; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Indoles; Male; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyrroles; Rabbits; Sunitinib; Sutures; Vascular Endothelial Growth Factor A; Veins | 2013 |
Sunitinib treatment for multiple brain metastases from jejunal gastrointestinal stromal tumor: case report.
Topics: Aged; Angiogenesis Inhibitors; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Indoles; Jejunal Neoplasms; Magnetic Resonance Imaging; Male; Pyrroles; Radiosurgery; Sunitinib; Tomography, X-Ray Computed | 2014 |
Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sunitinib | 2014 |
Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Medullary; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Humans; Indoles; Mice; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Thyroid Neoplasms | 2014 |
In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action.
Topics: Antiviral Agents; Artemisinins; Butadienes; Cell Line; Cytomegalovirus; Digitoxin; Digoxin; Drug Combinations; Drug Interactions; Fibroblasts; Foscarnet; Ganciclovir; Humans; Indoles; Nitriles; Ouabain; Pyrroles; Sunitinib; Virus Replication | 2014 |
Biodistribution of 99mTc-sunitinib as a potential radiotracer for tumor hypoxia imaging.
Topics: Animals; Cell Hypoxia; Indoles; Isotope Labeling; Mice; Neoplasms, Experimental; Organotechnetium Compounds; Pyrroles; Radiopharmaceuticals; Sunitinib; Tomography, Emission-Computed, Single-Photon | 2013 |
Therapeutic effects of sunitinib, one of the anti-angiogenetic drugs, in a murine arthritis.
Topics: Animals; Ankle Joint; Antirheumatic Agents; Arthritis, Experimental; Bone Density; Indoles; Mice; Pyrroles; Sunitinib; Treatment Outcome; Wrist Joint | 2014 |
Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?
Topics: Aged; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Skin Neoplasms; Sunitinib | 2013 |
All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Hypertension; Immunohistochemistry; Indoles; Kidney Failure, Chronic; Kidney Glomerulus; Kidney Neoplasms; Male; Middle Aged; Proteinuria; Pyrroles; Registries; Retrospective Studies; Sunitinib; Syndrome; Vascular Endothelial Growth Factor A | 2014 |
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Topics: Aged; Antineoplastic Agents; Benzamides; Body Weight; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Female; Gastric Acid; Half-Life; Histamine H2 Antagonists; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasms; Outpatients; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Tandem Mass Spectrometry | 2014 |
Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cohort Studies; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Quality of Life; Skin; Sunitinib | 2014 |
Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hemoglobin A; Humans; Indazoles; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2014 |
Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Smoking; Sunitinib; Treatment Outcome; Young Adult | 2014 |
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cytokines; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2014 |
Dramatic effect of sunitinib with rapid but transient improvement for psoriasis in a patient with metastatic renal carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Psoriasis; Pyrroles; Remission Induction; Sunitinib | 2013 |
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Registries; Renal Insufficiency; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2014 |
[A case of imatinib-resistant gastrointestinal stromal tumor treated with low-dose sunitinib].
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Male; Peritoneal Neoplasms; Piperazines; Pyrimidines; Pyrroles; Recurrence; Salvage Therapy; Sunitinib | 2013 |
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Eligibility Determination; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Humans; Indoles; Pyrroles; Sunitinib; Urinary Bladder Neoplasms | 2013 |
Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
[Exploratory analysis of the effect of toxicity of sunitinib on the clinical outcome of patients with advanced renal cell carcinoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Nephrogenic epistaxis.
Topics: Adult; Carcinoma, Renal Cell; Chemoradiotherapy; Diagnosis, Differential; Epistaxis; Humans; Indoles; Kidney Diseases; Male; Neoplasm Metastasis; Nose; Nose Neoplasms; Positron-Emission Tomography; Pyrroles; Recurrence; Sunitinib; Tomography, X-Ray Computed | 2014 |
Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Topics: Adrenal Gland Neoplasms; Adult; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Design; Female; Humans; Immunohistochemistry; Indoles; Male; Mice; Middle Aged; Molecular Targeted Therapy; Mutation; Paraganglioma; Pheochromocytoma; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 4; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Succinate Dehydrogenase; Sunitinib; Tissue Array Analysis | 2014 |
Xenograft tumors vascularized with murine blood vessels may overestimate the effect of anti-tumor drugs: a pilot study.
Topics: Animals; Blood Vessels; Cell Proliferation; Cisplatin; Endothelial Cells; Heterografts; Humans; Indoles; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Pilot Projects; Pyrroles; Signal Transduction; Species Specificity; Sunitinib; Tissue Engineering; Tumor Microenvironment | 2013 |
Sunitinib produces neuroprotective effect via inhibiting nitric oxide overproduction.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Apoptosis; Cells, Cultured; Cerebellum; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation; Humans; Indazoles; Indoles; Neurons; Neuroprotective Agents; Neurotoxins; Nitric Oxide; omega-N-Methylarginine; Pyrroles; Rats; Rats, Sprague-Dawley; Sunitinib | 2014 |
Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Antineoplastic Agents; Aza Compounds; Biotransformation; Chromatography, High Pressure Liquid; Ciprofloxacin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Fluoroquinolones; Indoles; Injections, Intravenous; Levofloxacin; Male; Models, Animal; Moxifloxacin; Polypharmacy; Protein Kinase Inhibitors; Pyrroles; Quinolines; Rabbits; Spectrophotometry, Ultraviolet; Sunitinib | 2013 |
Pazopanib outscores sunitinib on tolerability.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib | 2014 |
Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection.
Topics: Animals; Cells, Cultured; Citrobacter rodentium; Diarrhea; Enterobacteriaceae Infections; Humans; Immunity, Innate; Indoles; Interleukin-17; Interleukin-22; Interleukins; Intestines; Lymphocytes; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Mucous Membrane; Nuclear Receptor Subfamily 1, Group F, Member 3; Pyrroles; STAT3 Transcription Factor; Sunitinib; T-Lymphocytes, Helper-Inducer | 2014 |
Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib | 2014 |
[Brain metastasis which appeared during complete response of lung metastatic lesion by sunitinib treatment in a patient with renal cell carcinoma].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Remission Induction; Sunitinib | 2013 |
NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
Topics: Acute-Phase Proteins; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cells, Cultured; Drug Resistance, Neoplasm; Indoles; Kidney Neoplasms; Lipocalin-2; Lipocalins; Male; Mice; Mice, Nude; Proto-Oncogene Proteins; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2014 |
Extensive necrotizing fasciitis associated with sunitinib therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fasciitis, Necrotizing; Gram-Positive Bacterial Infections; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Subcutaneous Fat; Sunitinib | 2014 |
[The changes in complete blood count in patients treated with sunitinib malate for metastatic clear cell renal cell carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Cell Count; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pilot Projects; Pyrroles; Sunitinib | 2013 |
The effect of the anti-angiogenic drug sunitinib malate on the vascular architecture of oral squamous cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Carcinoma, Squamous Cell; Cricetinae; Humans; Indoles; Male; Mesocricetus; Microscopy, Electron, Scanning; Mouth Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2014 |
Drug-eluting beads loaded with antiangiogenic agents for chemoembolization: in vitro sunitinib loading and release and in vivo pharmacokinetics in an animal model.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Survival; Chemoembolization, Therapeutic; Delayed-Action Preparations; Drug-Eluting Stents; Indoles; Metabolic Clearance Rate; Microspheres; Neoplasms, Experimental; Organ Specificity; Pyrroles; Rabbits; Sunitinib; Tissue Distribution | 2014 |
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African | 2014 |
Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Genetic Therapy; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oncolytic Virotherapy; Oncolytic Viruses; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Vaccinia virus; Vascular Endothelial Growth Factor A | 2014 |
Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Indoles; Kidney Neoplasms; Male; Matrix Metalloproteinase 9; MicroRNAs; Middle Aged; Models, Biological; Neoplasm Metastasis; Paracrine Communication; Prognosis; Pyrroles; Reproducibility of Results; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphopenia; Male; Neoplasm Staging; Neutropenia; Prognosis; Pyrroles; Risk Factors; Sunitinib; Treatment Outcome | 2014 |
Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Mice; Mice, Inbred BALB C; Pyrroles; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
A new paradigm for the treatment of Alzheimer's disease: targeting vascular activation.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Angiogenesis Inhibitors; Animals; Antifibrinolytic Agents; Avoidance Learning; Blood Vessels; Brain; Endothelial Cells; Humans; Indoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Presenilin-1; Pyrroles; Reaction Time; Sunitinib; Time Factors; Vitamin K 3 | 2014 |
Sunitinib for refractory malignant pheochromocytoma: two case reports.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Humans; Immunohistochemistry; Indoles; Liver Neoplasms; Male; Middle Aged; Pheochromocytoma; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
Maturing of renal cancer therapeutics.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2014 |
Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
Topics: Aged; Algorithms; Carcinoma, Renal Cell; Combined Modality Therapy; Denmark; Enzyme Inhibitors; Female; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Survival Rate; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Sunitinib does not block thyroid peroxidase in patients.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Iodide Peroxidase; Kidney Neoplasms; Perchlorates; Pyrroles; Sunitinib; Thyroid Function Tests; Thyrotropin | 2014 |
Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Postmenopause; Premenopause; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Sunitinib; Survival Rate; Trastuzumab; Turkey; Young Adult | 2014 |
A collecting duct carcinoma producing carcinoembryonic antigen and Ca-125 in a 29-year-old woman.
Topics: Adult; Antineoplastic Agents; CA-125 Antigen; Carcinoembryonic Antigen; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Neoplasm Invasiveness; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2014 |
[Systemic treatment of metastatic renal cell carcinoma: change of paradigms after introduction of targeted therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2014 |
Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model.
Topics: Adrenergic alpha-Agonists; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Indoles; Inhibitory Concentration 50; Interleukin-6; Interleukin-8; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Norepinephrine; Propranolol; Pyrroles; Receptors, Adrenergic, beta; Signal Transduction; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor A | 2014 |
Antiangiogenic therapy inhibits the recruitment of vascular accessory cells to the perivascular niche in glioma angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Bone Marrow Cells; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Glioma; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Rats; Sunitinib; Tumor Microenvironment | 2014 |
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
Topics: Adult; Aged; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2014 |
Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin αvβ3 and vascular endothelial growth factor.
Topics: Animals; Colonic Neoplasms; Fluorescent Dyes; Glioblastoma; HT29 Cells; Humans; Indoles; Infrared Rays; Integrin alphaVbeta3; Longitudinal Studies; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Optical Imaging; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Indoles; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2014 |
Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.
Topics: Amyloid Precursor Protein Secretases; Angiogenesis Inhibitors; Cell Line, Tumor; Contrast Media; Humans; Indoles; Magnetic Resonance Imaging; Molecular Imaging; Neovascularization, Pathologic; Pyrroles; Radiography; Sunitinib; Tetrahydronaphthalenes; Ultrasonography; Valine; Xenograft Model Antitumor Assays | 2014 |
Risks associated with sunitinib use and monitoring to improve patient outcomes.
Topics: Antineoplastic Agents; Female; Humans; Indoles; Male; Proteinuria; Pyrroles; Renal Insufficiency; Sunitinib | 2014 |
Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Proteinuria; Pyrroles; Renal Insufficiency; Republic of Korea; Retrospective Studies; Risk Factors; Sunitinib; Treatment Outcome | 2014 |
Methods for adjusting for bias due to crossover in oncology trials.
Topics: Antineoplastic Agents; Bias; Cost-Benefit Analysis; Cross-Over Studies; Humans; Indoles; Kaplan-Meier Estimate; Models, Statistical; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2014 |
In vivo imaging of tumor physiological, metabolic, and redox changes in response to the anti-angiogenic agent sunitinib: longitudinal assessment to identify transient vascular renormalization.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Contrast Media; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; Female; Humans; Indoles; Magnetic Resonance Imaging; Mice, Inbred C3H; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oxidation-Reduction; Oxygen; Pyrroles; Pyruvic Acid; Sunitinib; Xenograft Model Antitumor Assays | 2014 |
Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Organ Specificity; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Tumor Burden | 2014 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2014 |
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.
Topics: Aged; Carcinoma, Renal Cell; Exome; Genome, Human; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 1 Protein; Tumor Suppressor Proteins | 2014 |
Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer.
Topics: Academic Medical Centers; Angiogenesis Inhibitors; Anilides; Combined Modality Therapy; Drugs, Investigational; Esophageal Fistula; Fatal Outcome; Humans; Indoles; Male; Middle Aged; Neck Dissection; Phenylurea Compounds; Postoperative Complications; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinolines; Receptor Protein-Tyrosine Kinases; Respiratory Tract Fistula; Risk Factors; Sunitinib; Texas; Thyroid Neoplasms; Thyroidectomy; Tracheoesophageal Fistula | 2014 |
Suicide attempt with an overdose of sunitinib.
Topics: Drug Overdose; Humans; Indoles; Male; Middle Aged; Pyrroles; Suicide, Attempted; Sunitinib | 2014 |
Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?
Topics: Adult; Aged; Aged, 80 and over; Antacids; Carcinoma, Renal Cell; Disease-Free Survival; Drug Interactions; Female; Gastric Acid; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2015 |
Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Disease Models, Animal; Drug Repositioning; Indoles; Inhibitory Concentration 50; Lapatinib; Leishmania; Leishmaniasis; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Indoles; Kidney Neoplasms; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Pyrroles; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide.
Topics: Acetaminophen; Animals; Area Under Curve; Drug Interactions; Indoles; Male; Pyrroles; Rabbits; Sunitinib | 2015 |
Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Humans; Indoles; Kidney Neoplasms; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Tissue Inhibitor of Metalloproteinase-2; Treatment Outcome | 2014 |
The immunocytokine NHS-IL12 as a potential cancer therapeutic.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Docetaxel; Female; Humans; Immunoglobulin G; Immunomodulation; Indoles; Interferon-gamma; Interleukin-12; Lymphocyte Activation; Macaca fascicularis; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms, Experimental; Protein Engineering; Pyrroles; Recombinant Fusion Proteins; Sunitinib; Survival Rate; Taxoids; Tumor Burden | 2014 |
Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Body Composition; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed | 2017 |
Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Female; Hemangioendothelioma, Epithelioid; Humans; Indoles; Liver Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Neovascularization, Pathologic; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cohort Studies; Decision Making; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Netherlands; Niacinamide; Phenylurea Compounds; Pyrroles; Quality of Life; Self Report; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
How to interpret patient preferences in selecting the best drug: are the current measurements up to the job?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Patient Preference; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2014 |
Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Benzothiazoles; Drug Synergism; Feedback, Physiological; Humans; Indoles; Leukemia, Myeloid, Acute; Middle Aged; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteome; Proto-Oncogene Proteins c-akt; Pyrroles; Retrospective Studies; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Young Adult | 2014 |
PKCδ regulates force signaling during VEGF/CXCL4 induced dissociation of endothelial tubes.
Topics: Cell Movement; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Humans; Indoles; Neovascularization, Physiologic; Platelet Factor 4; Protein Kinase C-delta; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing | 2014 |
Acute aortic dissection in a patient receiving multiple tyrosine kinase inhibitors for 5 years.
Topics: Acute Disease; Angiogenesis Inhibitors; Aortic Aneurysm; Aortic Dissection; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Long-Term Care; Lymphatic Metastasis; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2014 |
Activity of sunitinib in extraskeletal myxoid chondrosarcoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Neoplasms; Calmodulin-Binding Proteins; Chondrosarcoma; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Gene Rearrangement; Genotype; Humans; Indoles; Male; Middle Aged; Neoplasms, Connective and Soft Tissue; Phenotype; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-ret; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Receptors, Steroid; Receptors, Thyroid Hormone; RNA-Binding Protein EWS; RNA-Binding Proteins; Sunitinib; TATA-Binding Protein Associated Factors; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombectomy; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2014 |
Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Predictive Value of Tests; Proto-Oncogene Proteins c-sis; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Superior vena caval syndrome secondary to metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nephrectomy; Pulmonary Embolism; Pyrroles; Radiotherapy; Sunitinib; Superior Vena Cava Syndrome | 2014 |
Acute hyperammonemic encephalopathy in a non-cirrhotic patient with hepatocellular carcinoma reversed by arginine therapy.
Topics: Antineoplastic Agents; Arginine; Brain Diseases, Metabolic; Carcinoma, Hepatocellular; Humans; Hyperammonemia; Indoles; Liver Neoplasms; Male; Pyrroles; Sunitinib; Young Adult | 2014 |
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Silencing; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; MAP Kinase Signaling System; Melanoma; Mice; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Sulfonamides; Sunitinib; Up-Regulation; Vemurafenib | 2014 |
Sunitinib-associated thrombotic microangiopathy: a significant risk.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Humans; Indoles; Pyrroles; Sunitinib; Thrombotic Microangiopathies | 2014 |
Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Caco-2 Cells; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cell Survival; Chloroquine; Drug Synergism; Female; HCT116 Cells; HeLa Cells; Hep G2 Cells; Humans; Immunohistochemistry; Indoles; MCF-7 Cells; Mice; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2014 |
[A case of pneumatosis cystoides intestinalis secondary to sunitinib treatment for renal cell carcinoma].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Pneumatosis Cystoides Intestinalis; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2014 |
[A case of adrenal metastasectomy in renal cell carcinoma after neoadjuvant therapy with sunitinib].
Topics: Adrenal Gland Neoplasms; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pyrroles; Sunitinib | 2014 |
Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes.
Topics: Antineoplastic Agents; Diabetes Mellitus, Type 1; Fatal Outcome; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Indoles; Insulin Aspart; Insulin Glargine; Insulin, Long-Acting; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2014 |
Images in clinical medicine. Sunitinib-associated hair depigmentation.
Topics: Adult; Antineoplastic Agents; Female; Hair; Humans; Indoles; Pigmentation Disorders; Pyrroles; Sunitinib; Thymoma; Thymus Neoplasms | 2014 |
[Metastatic collecting duct carcinoma with relatively long-term survival treated with sunitinib: a case report].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Lymphatic Metastasis; Male; Middle Aged; Pyrroles; Sunitinib | 2014 |
MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Glioblastoma; Humans; Image Processing, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Mice; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sunitinib | 2014 |
A method to assess target gene involvement in angiogenesis in vitro and in vivo using lentiviral vectors expressing shRNA.
Topics: Adipocytes; Animals; Cell Line, Tumor; Coculture Techniques; Endothelial Cells; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genetic Vectors; Humans; Indoles; Lentivirus; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pyrroles; RNA, Small Interfering; Sp1 Transcription Factor; Stem Cells; Sunitinib | 2014 |
Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Indoles; Mice; Mice, Nude; N-Myc Proto-Oncogene Protein; Neovascularization, Pathologic; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Proto-Oncogene Mas; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib | 2014 |
[Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors].
Topics: Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indazoles; Indoles; Liver Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sulfonamides; Sunitinib | 2014 |
[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Quality of Life; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2014 |
Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Young Adult | 2014 |
Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Endpoint Determination; Humans; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2014 |
Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Blood Proteins; Enzyme-Linked Immunosorbent Assay; Humans; Indoles; Male; Orosomucoid; Pyrroles; Rats; Rats, Sprague-Dawley; Serum Albumin; Sunitinib | 2014 |
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Optical tomography of MMP activity allows a sensitive noninvasive characterization of the invasiveness and angiogenesis of SCC xenografts.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Female; Humans; Indoles; Matrix Metalloproteinases; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Skin Neoplasms; Stromal Cells; Sunitinib; Tomography, Optical Coherence; Uterine Cervical Neoplasms; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2014 |
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Microvessels; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Phosphoproteins; Proportional Hazards Models; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction.
Topics: Administration, Oral; Animals; Apoptosis; Biomarkers; Biopsy; Cell Death; Cell Line, Tumor; Disease Models, Animal; Erythema; Fas Ligand Protein; fas Receptor; Female; Foot; Gene Expression Regulation; Hand; Humans; Indoles; Keratinocytes; Mice; Mice, Inbred C3H; Pyrroles; Sunitinib; Time Factors | 2014 |
Discontinuation of the tyrosine kinase inhibitor sunitinib in patients with metastatic renal cell carcinoma: a case series.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Remission Induction; Sunitinib | 2014 |
Sunitinib-induced pseudoporphyria.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Diagnosis, Differential; Drug Eruptions; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Porphyrias; Pyrroles; Sunitinib | 2015 |
Sunitinib: from charge-density studies to interaction with proteins.
Topics: Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Hydrogen Bonding; Indoles; Models, Molecular; Molecular Conformation; Protein Kinase Inhibitors; Proteins; Pyrroles; Static Electricity; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Cytoreduction Surgical Procedures; Disease-Free Survival; Europe; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dasatinib; Hep G2 Cells; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib; Thiazoles | 2014 |
The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Renal Cell; Female; Genotype; Humans; Indoles; Japan; Kidney Neoplasms; Male; Metabolic Clearance Rate; Models, Biological; Neoplasm Proteins; Pyrroles; Sunitinib | 2014 |
Metastatic involvement of the maxillary antrum from an uncommon source.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemoradiotherapy, Adjuvant; Embolization, Therapeutic; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Maxillary Sinus Neoplasms; Nephrectomy; Niacinamide; Palatal Neoplasms; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2014 |
Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dideoxynucleosides; Drug Monitoring; Early Detection of Cancer; Female; Glioblastoma; Indoles; Mice; Mice, Inbred C57BL; Mice, Nude; Multimodal Imaging; Positron-Emission Tomography; Pyrroles; Radiopharmaceuticals; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Eosinophils; Female; Hemoglobins; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2014 |
Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrotic Syndrome; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2014 |
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies; Sunitinib; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2014 |
In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Lymphocytes; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2014 |
Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Hyponatremia; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Risk Factors; Serum Albumin; Sodium; Sorafenib; Sunitinib; Survival Rate | 2015 |
[The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of metastatic renal cell carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib | 2014 |
Synthesis and in vivo SAR study of indolin-2-one-based multi-targeted inhibitors as potential anticancer agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Indoles; Mice; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyrroles; Structure-Activity Relationship; Sunitinib | 2014 |
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Cone-Beam Computed Tomography; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome.
Topics: Adult; Antineoplastic Agents; Female; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; von Hippel-Lindau Disease | 2015 |
Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome | 2014 |
Gastrointestinal stromal tumors, version 2.2014.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2014 |
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Humans; Hypertension; Incidence; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Middle Aged; Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Sunitinib | 2014 |
Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2014 |
Editorial comment from Dr Yokomizo to efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2014 |
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Confidence Intervals; Cytoreduction Surgical Procedures; Databases, Factual; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms, Multiple Primary; Nephrectomy; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Assessment; Sunitinib; Survival Analysis; Treatment Outcome | 2014 |
Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.
Topics: Adult; Aged; Bone Marrow Cells; Carcinoma, Renal Cell; Humans; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Benzoates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pyrroles; Sunitinib; Telmisartan; Xenograft Model Antitumor Assays | 2014 |
[Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2014 |
Editorial comment from Dr Yuasa to efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2014 |
Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.
Topics: Actins; Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Indoles; Male; Matrix Metalloproteinase 2; Niacinamide; Pancreas; Pancreatic Stellate Cells; Phenotype; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Rats, Inbred Lew; RNA, Messenger; Signal Transduction; Sorafenib; Sunitinib; Time Factors; Transforming Growth Factor beta1 | 2014 |
Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Indoles; Male; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; Sunitinib; Taxoids; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Leukopenia as a biomarker of sunitinib outcome in advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib | 2014 |
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Topics: Adult; Animals; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Neoplasm Staging; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Mitogen-activated protein kinases pathways mediate the sunitinib-induced hypertrophy in rat cardiomyocyte H9c2 cells.
Topics: Animals; Antineoplastic Agents; Biomarkers; Blotting, Western; Cardiac Myosins; Cell Line; Cell Survival; Enzyme Inhibitors; Flow Cytometry; Gene Expression Regulation; Indoles; Mitogen-Activated Protein Kinases; Myocytes, Cardiac; Myosin Heavy Chains; Natriuretic Peptide, Brain; Pyrroles; Rats; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sunitinib | 2015 |
Assessing treatment response of osteolytic lesions by manual volumetry, automatic segmentation, and RECIST in experimental bone metastases.
Topics: Algorithms; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cone-Beam Computed Tomography; Diphosphonates; Disease Models, Animal; Follow-Up Studies; Imidazoles; Indoles; Pyrroles; Radiographic Image Interpretation, Computer-Assisted; Rats; Rats, Nude; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Zoledronic Acid | 2014 |
Rectal perforation after two years of treatment with sunitinib for metastatic kidney cancer.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Colon, Sigmoid; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Radiography; Rectum; Retropneumoperitoneum; Sunitinib | 2014 |
Skin rash, a kidney mass and a family mystery dating back to World War II.
Topics: Adult; Alleles; Carcinoma, Renal Cell; Chromosome Deletion; Combined Modality Therapy; Drug Delivery Systems; Exanthema; Fumarate Hydratase; Genetic Counseling; Humans; Indoles; Kidney Medulla; Kidney Neoplasms; Leiomyomatosis; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Microfluidic Analytical Techniques; Multiplex Polymerase Chain Reaction; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Multiple Primary; Nephrectomy; New South Wales; Oligonucleotide Array Sequence Analysis; Precision Medicine; Pyrroles; Rod Opsins; Skin; Skin Neoplasms; Sunitinib; World War II | 2014 |
Combined effect of vascular-leakage-blocker Sac-1004 and antiangiogenic drug sunitinib on tumor angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Therapy, Combination; Indoles; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pyrroles; Saponins; Sunitinib | 2014 |
Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3).
Topics: Antineoplastic Agents; Cell Line, Transformed; Cell Proliferation; Cyclic S-Oxides; Gene Expression Regulation; Humans; Indoles; Inhibitor of Apoptosis Proteins; Keratinocytes; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Sunitinib; Survivin; Tetrazolium Salts | 2014 |
Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Survival; Dose-Response Relationship, Drug; Heterografts; Indoles; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; PC12 Cells; Phenylurea Compounds; Pheochromocytoma; Protein Kinase Inhibitors; Pyrroles; Rats; Sorafenib; Sunitinib; Time Factors; Tumor Burden | 2014 |
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Progression; Fatty Acid Synthases; Homeodomain Proteins; Humans; Indoles; Lipids; Metabolomics; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteomics; Pyrroles; RNA Interference; Sorafenib; Sunitinib; Transplantation, Heterologous | 2014 |
Ectopic cushing in a patient with medullary thyroid carcinoma: hypercortisolism control and tumor reduction with Sunitinib.
Topics: ACTH Syndrome, Ectopic; Adrenocortical Hyperfunction; Antineoplastic Agents; Carcinoma, Neuroendocrine; Humans; Indoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Thyroid Neoplasms | 2015 |
Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Germ-Line Mutation; Humans; Indoles; Kidney Neoplasms; Membrane Proteins; Middle Aged; Molecular Targeted Therapy; Pedigree; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Thyroglobulin; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2015 |
Determination of sunitinib in human plasma using liquid chromatography coupled with mass spectrometry.
Topics: Chromatography, Liquid; Humans; Indoles; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Sunitinib | 2014 |
Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Fatigue; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Pyrroles; Randomized Controlled Trials as Topic; Self Report; Sunitinib; Treatment Outcome | 2014 |
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cohort Studies; Europe; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis | 2014 |
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2015 |
[Treatment of late stage liver cancer by Chinese herbs combined sunitinib in one case].
Topics: Drugs, Chinese Herbal; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2014 |
Clinicopathological features and outcomes of gastric cancer patients with pulmonary lymphangitis carcinomatosa.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Diseases; Lymphangitis; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyrroles; Retrospective Studies; Stomach Neoplasms; Sunitinib; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indoles; Israel; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2014 |
Scrotal cutaneous toxicity: an uncommon but important side-effect of sunitinib.
Topics: Antineoplastic Agents; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Scrotum; Skin Diseases; Sunitinib | 2016 |
MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; Indoles; MicroRNAs; Oligonucleotides, Antisense; Pancreatic Neoplasms; Phosphatidylcholines; Pyrroles; Sunitinib; Transfection | 2014 |
The use of sunitinib in renal cell carcinoma: where are we now?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib | 2014 |
Ageing-related responses to antiangiogenic effects of sunitinib in atherosclerosis-prone mice.
Topics: Aging; Angiogenesis Inhibitors; Animals; Apolipoproteins E; Atherosclerosis; Carcinoma, Lewis Lung; Female; Indoles; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Transplantation; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2014 |
Sunitinib mesylate inhibits proliferation of human colonic stromal fibroblasts in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Becaplermin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colon; Colonic Neoplasms; Fibroblasts; Fluorouracil; Humans; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Stromal Cells; Sunitinib; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
Topics: Angiogenesis Inhibitors; Animals; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Female; Flow Cytometry; Humans; Indoles; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib; Vaccines, Synthetic | 2014 |
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
Topics: Actin Cytoskeleton; Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Everolimus; Hedgehog Proteins; Humans; Indoles; Inhibitory Concentration 50; Kidney Neoplasms; Kruppel-Like Transcription Factors; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Micrometastasis; Nuclear Proteins; Paxillin; Proto-Oncogene Proteins c-akt; Pyridines; Pyrroles; Receptors, G-Protein-Coupled; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Smoothened Receptor; Sunitinib; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2014 |
The effects of sunitinib on endometriosis.
Topics: Angiogenesis Inhibitors; Animals; Danazol; Disease Models, Animal; Endometriosis; Estrogen Antagonists; Female; Indoles; Peritoneal Diseases; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sunitinib; Tissue Adhesions | 2015 |
Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy.
Topics: Adaptive Immunity; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Immunosuppression Therapy; Indoles; Lymphocytes; Male; Middle Aged; Myeloid Progenitor Cells; Pyrroles; Solitary Fibrous Tumors; Sunitinib; Treatment Outcome; Tumor Microenvironment | 2014 |
Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Female; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Young Adult | 2014 |
A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioma; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Pyrroles; Radiosurgery; Remission Induction; Retreatment; Sunitinib | 2014 |
Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; G1 Phase Cell Cycle Checkpoints; Humans; Indoles; Multidrug Resistance-Associated Proteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; src-Family Kinases; Sunitinib | 2014 |
Direct effect of bevacizumab on glioblastoma cell lines in vitro.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autocrine Communication; Bevacizumab; Brain Neoplasms; Calcium Signaling; Cell Culture Techniques; Cell Division; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Hyaluronic Acid; Hydrogels; Indoles; MAP Kinase Signaling System; Neoplasm Invasiveness; Neoplasm Proteins; Placenta Growth Factor; Pregnancy Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
Topics: AIDS Dementia Complex; Animals; Antineoplastic Agents; Cyclin-Dependent Kinase 5; Dasatinib; Erlotinib Hydrochloride; Flavonoids; HIV Envelope Protein gp120; In Vitro Techniques; Indoles; Lapatinib; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Rats; Roscovitine; Sunitinib; Thiazoles | 2014 |
Permeability analysis of neuroactive drugs through a dynamic microfluidic in vitro blood-brain barrier model.
Topics: Amines; Animals; Benzazepines; Biological Transport; Blood-Brain Barrier; Cell Survival; Cells, Cultured; Coculture Techniques; Cyclohexanecarboxylic Acids; Endothelial Cells; Ethosuximide; Gabapentin; gamma-Aminobutyric Acid; Indoles; L-Lactate Dehydrogenase; Mice; Microfluidic Analytical Techniques; Neuroglia; Permeability; Piperidines; Pyrroles; Quinoxalines; Rats; Rats, Sprague-Dawley; Sertraline; Sunitinib; Tetrahydronaphthalenes; Valine; Varenicline | 2014 |
Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas.
Topics: Antineoplastic Agents; Cadherins; Carcinoma, Renal Cell; Cell Hypoxia; Cell Movement; Drug Resistance, Neoplasm; Gene Expression; Humans; Hyaluronan Receptors; Immunohistochemistry; Indoles; Kidney Neoplasms; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Tumor Necrosis Factor-alpha | 2015 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Child; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Irinotecan; Male; Membrane Potential, Mitochondrial; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Complete response of sunitinib therapy for renal cell cancer recurrence in the native kidney after renal transplantation: a case report.
Topics: Adult; Carcinoma, Renal Cell; Humans; Indoles; Kidney; Kidney Neoplasms; Kidney Transplantation; Male; Neoplasm Recurrence, Local; Postoperative Care; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Use of three-dimensional time-resolved phase-contrast magnetic resonance imaging with vastly undersampled isotropic projection reconstruction to assess renal blood flow in a renal cell carcinoma patient treated with sunitinib: a case report.
Topics: Adult; Carcinoma, Renal Cell; Contrast Media; Female; Humans; Imaging, Three-Dimensional; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Nephrectomy; Pyrroles; Renal Circulation; Sunitinib; Time Factors | 2014 |
[Effect of SU11248 on leukemia cell line K562 and its molecular mechanisms].
Topics: Apoptosis; Cell Proliferation; Fusion Proteins, bcr-abl; Humans; Indoles; K562 Cells; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pyrroles; RNA, Messenger; Sunitinib; Telomerase | 2014 |
Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Lung Diseases, Interstitial; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sunitinib | 2014 |
Racial disparity in metastatic renal cell cancer: the pharmaco-anthropology of sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2014 |
Relationships between the effect of sunitinib and immature blood vessels in metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Vessels; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Nephrectomy; Pericytes; Platelet Endothelial Cell Adhesion Molecule-1; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome | 2015 |
Blocking autocrine VEGF signaling by sunitinib, an anti-cancer drug, promotes embryonic stem cell self-renewal and somatic cell reprogramming.
Topics: Animals; Antineoplastic Agents; Autocrine Communication; Cell Differentiation; Cell Lineage; Cell Proliferation; Cells, Cultured; Cellular Reprogramming; Embryonic Stem Cells; Endoderm; Endoplasmic Reticulum Stress; Female; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Leukemia Inhibitory Factor; Mice; Models, Biological; Pluripotent Stem Cells; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
The pharmacokinetics and hypoglycaemic effect of sunitinib in the diabetic rabbits.
Topics: Administration, Oral; Animals; Area Under Curve; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Hyperglycemia; Hypoglycemic Agents; Indoles; Male; Protein Kinase Inhibitors; Pyrroles; Rabbits; Sunitinib | 2014 |
Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cardiac Tamponade; Diagnosis, Differential; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2014 |
Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Belgium; Carcinoma, Renal Cell; Diarrhea; Edema; Female; Follow-Up Studies; Humans; Incidence; Indoles; Intestines; Kidney Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Pyrroles; Retrospective Studies; Sunitinib | 2015 |
Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study.
Topics: Acute Kidney Injury; Amlodipine; Angiogenesis Inhibitors; Animals; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Follow-Up Studies; Glomerular Filtration Rate; Hypertension; Indoles; Pyrimidines; Pyrroles; Rats; Rats, Inbred WKY; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.
Topics: AC133 Antigen; Adult; Aged; Angiogenesis Inhibitors; Animals; Antigens, CD; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hypoxia; Indoles; MCF-7 Cells; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Neoplastic Cells, Circulating; Nuclear Proteins; Peptides; Pyrroles; Sunitinib; Triple Negative Breast Neoplasms; Twist-Related Protein 1 | 2014 |
Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Drug Substitution; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retreatment; Sunitinib; Treatment Outcome; Young Adult | 2014 |
Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Combined Modality Therapy; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Propensity Score; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2015 |
The influence of the time-of-day administration of the drug on the pharmacokinetics of sunitinib in rabbits.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Blood Glucose; Drug Administration Schedule; Indoles; Male; Protein Kinase Inhibitors; Pyrroles; Rabbits; Sunitinib | 2014 |
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Imidazoles; Indoles; Inhibitory Concentration 50; Models, Molecular; Molecular Conformation; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridazines; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Thrombocytopenia; Treatment Outcome | 2016 |
Pyridoxine-derived bicyclic amido-, ureido-, and carbamato-pyridinols: synthesis and antiangiogenic activities.
Topics: Angiogenesis Inhibitors; Animals; Bridged Bicyclo Compounds; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Indoles; Lactams; Neovascularization, Physiologic; Pyridines; Pyrroles; Structure-Activity Relationship; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
[Successful sunitinib treatment of a patient with Stauffer's syndrome].
Topics: Alkaline Phosphatase; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; gamma-Glutamyltransferase; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Paraneoplastic Syndromes; Peritoneal Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
[Therapeutic significance of sunitinib-induced "off-target" side effects].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Retrospective Studies; Stomatitis; Sunitinib; Treatment Outcome | 2014 |
Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; Flavones; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Male; Mice; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Xenograft Model Antitumor Assays | 2015 |
Response-predictive gene expression profiling of glioma progenitor cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Pharmacological; Brain Neoplasms; Cell Differentiation; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Humans; Indoles; Microarray Analysis; Neoplasm Proteins; Neoplastic Stem Cells; Pyrroles; Signal Transduction; Sunitinib; Tumor Cells, Cultured | 2014 |
Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption.
Topics: Aged; Animals; Antineoplastic Agents; Arterial Pressure; Blood Pressure; Female; Humans; Hypertension; Indoles; Kidney Tubules; Male; Middle Aged; Pyrroles; Rats; Receptors, Vascular Endothelial Growth Factor; rho-Associated Kinases; Sodium; Sodium, Dietary; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Resistance; Vasodilation | 2014 |
Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Drug Administration Schedule; Fatigue; Hand-Foot Syndrome; Humans; Indoles; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Pyrroles; Stomatitis; Sunitinib; Thyroid Diseases | 2014 |
Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib.
Topics: Antineoplastic Agents; Aortic Aneurysm, Thoracic; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Determination of sunitinib and its active metabolite, N-desethyl sunitinib in mouse plasma and tissues by UPLC-MS/MS: assay development and application to pharmacokinetic and tissue distribution studies.
Topics: Animals; Chromatography, High Pressure Liquid; Indoles; Kidney; Liver; Lung; Mice; Pyrroles; Sunitinib; Tandem Mass Spectrometry; Tissue Distribution | 2015 |
Unbinding pathways of VEGFR2 inhibitors revealed by steered molecular dynamics.
Topics: Catalytic Domain; Humans; Indoles; Molecular Dynamics Simulation; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib.
Topics: Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Indoles; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Failure | 2015 |
Sunitinib achieved fast and sustained control of VIPoma symptoms.
Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Humans; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Pyrroles; Sunitinib; Time Factors; Vipoma | 2015 |
Rapid involution of choroidal metastasis secondary to renal cell carcinoma with oral sunitinib.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Choroid Neoplasms; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Ultrasonography; Visual Acuity | 2015 |
VEGF₁₂₁-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system.
Topics: Animals; Drug Delivery Systems; Glioblastoma; Glioma; Humans; Indoles; Mice; Nanoparticles; Pyrroles; Silicon Dioxide; Sunitinib; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2014 |
Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy.
Topics: Adult; Aged; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Embolization, Therapeutic; Female; Gastrointestinal Stromal Tumors; Hepatic Artery; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2014 |
Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.
Topics: Angiogenesis Inhibitors; Animals; Humans; Indoles; Mice; Mice, SCID; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Female; Indoles; Kidney; Liver; Mice, Inbred BALB C; Pyrroles; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Mice; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Radiography; Retrospective Studies; Sunitinib; von Hippel-Lindau Disease | 2015 |
Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Calcium-Binding Proteins; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Membrane Proteins; Mice; Mice, SCID; Neovascularization, Pathologic; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.
Topics: Antineoplastic Agents; Body Weight; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Indoles; Metabolic Clearance Rate; Models, Biological; Pyrroles; Sunitinib | 2015 |
Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Differentiation; Drug Administration Schedule; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Sirolimus; Sunitinib; Xenograft Model Antitumor Assays | 2015 |
Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Health Expenditures; Health Services; Humans; Imidazoles; Indazoles; Indoles; Markov Chains; Models, Econometric; Pyrroles; Quality-Adjusted Life Years; Sunitinib; United States | 2015 |
Localization of sunitinib in in vivo animal and in vitro experimental models by MALDI mass spectrometry imaging.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colonic Neoplasms; Female; Humans; Indoles; Mice; Mice, Inbred BALB C; Molecular Imaging; Pyrroles; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sunitinib | 2015 |
[Adverse effects of Sutent(®): pseudoporphyria and scrotal necrosis].
Topics: Antineoplastic Agents; Blister; Genital Diseases, Male; Humans; Imatinib Mesylate; Indoles; Male; Necrosis; Neoplasm Proteins; Photosensitivity Disorders; Protein Kinase Inhibitors; Pyrroles; Scrotum; Sunitinib | 2014 |
The effect of chronic stress on anti-angiogenesis of sunitinib in colorectal cancer models.
Topics: Adrenergic alpha-Agonists; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Chronic Disease; Colorectal Neoplasms; Disease Models, Animal; Female; Humans; Indoles; Interleukin-8; Mice; Mice, Inbred BALB C; Norepinephrine; Pyrroles; Receptors, Adrenergic, beta; Signal Transduction; Stress, Psychological; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2015 |
Sunitinib-eluting beads for chemoembolization: methods for in vitro evaluation of drug release.
Topics: Drug Liberation; Embolization, Therapeutic; In Vitro Techniques; Indoles; Microspheres; Pyrroles; Sunitinib; Time Factors | 2015 |
Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cholesterol; Female; Humans; Hyperlipidemias; Hypothyroidism; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Triglycerides | 2015 |
Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Topics: Acridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Kinetics; Membrane Transport Modulators; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrroles; RNA, Messenger; Sunitinib; Tetrahydroisoquinolines | 2015 |
Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Design; G1 Phase Cell Cycle Checkpoints; Humans; Indoles; Molecular Docking Simulation; Oxindoles; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2014 |
Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Progression; Endothelial Cells; Glioma; Humans; Indoles; Mice; Neovascularization, Pathologic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Pyrroles; Rats; Rodentia; Sunitinib; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Dietary phytoestrogens present in soy dramatically increase cardiotoxicity in male mice receiving a chemotherapeutic tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cardiotoxins; Glycine max; Indoles; Male; Mice; Myocytes, Cardiac; Phytoestrogens; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.
Topics: Angiogenesis Inhibitors; Animals; Cachexia; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Humans; Indoles; Kidney Neoplasms; Male; Mice, Inbred C57BL; Mice, Nude; Muscle Proteins; Muscle, Skeletal; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Time Factors; Tripartite Motif Proteins; Tumor Burden; Ubiquitin-Protein Ligases; Weight Loss; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2015 |
Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Withholding Treatment | 2015 |
89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biological Transport; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Radioactive Tracers; Radioisotopes; Radionuclide Imaging; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Zirconium | 2015 |
Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma Cells.
Topics: ATP-Binding Cassette Transporters; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Humans; Indoles; Liver Neoplasms; Lysosomes; Pyrroles; Sunitinib | 2014 |
Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Indoles; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Contrast Media; Diffusion Magnetic Resonance Imaging; Gadolinium DTPA; Humans; Image Enhancement; Indoles; Kidney Neoplasms; Magnetic Resonance Spectroscopy; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrroles; Radiopharmaceuticals; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tyrosine | 2014 |
Stem cells increase in numbers in perinecrotic areas in human renal cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Necrosis; Neoplastic Stem Cells; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2015 |
Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Prospective Studies; Pyrroles; Singapore; Sunitinib | 2015 |
Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: a new predictive factor?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Pyrroles; Sunitinib | 2014 |
Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.
Topics: Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Renal Cell; Female; Gene Frequency; Genotype; Humans; Indoles; Japan; Kidney Neoplasms; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib | 2014 |
Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?
Topics: Axitinib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Nucleoside Transport Proteins; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice, SCID; Microvessels; Polycomb Repressive Complex 2; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle.
Topics: Adult; Aged; Coronary Artery Bypass; Electric Stimulation; Female; Heart Atria; Heart Failure; Humans; Indoles; Ischemia; Male; Middle Aged; Myocardial Contraction; Myocardium; Pyrroles; Reperfusion Injury; Solvents; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Tubulocystic carcinoma of the kidney with fatal outcome in an adolescent male.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pleural Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome | 2015 |
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Costs and Cost Analysis; Denmark; Drug Costs; Efficiency; Employment; Everolimus; Female; Fluorouracil; Health Care Costs; Hospitalization; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Radiography; Radiotherapy; Registries; Sirolimus; Sorafenib; Sunitinib | 2015 |
Sunitinib and improved diabetes control.
Topics: Antineoplastic Agents; Blood Glucose; Carcinoma, Renal Cell; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Indoles; Insulin; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2014 |
Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biological Transport; Cell Line, Tumor; Cell Nucleus; Doxorubicin; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Lysosomes; MCF-7 Cells; Microscopy, Fluorescence; Mitoxantrone; Models, Biological; Pyrroles; Sunitinib | 2015 |
[Genetic polymorphisms of PDGFR associated with thrombocytopenia in Chinese patients with clear-cell metastatic renal cell carcinoma treated with sunitinib].
Topics: Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Genotype; Humans; Indoles; Polymorphism, Genetic; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Thrombocytopenia; Treatment Outcome | 2014 |
Sunitinib-induced thyrotoxicosis - a not so rare entity.
Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Thyrotoxicosis | 2015 |
Inhibition of placental growth factor in renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Mice, Nude; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Sunitinib; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report.
Topics: Antineoplastic Agents; Disease Progression; Disease-Free Survival; Humans; Indoles; Leukopenia; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2014 |
Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Europe; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2015 |
Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib | 2015 |
Health care costs among renal cancer patients using pazopanib and sunitinib.
Topics: Carcinoma, Renal Cell; Female; Health Care Costs; Health Services; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; United States | 2015 |
Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Models, Economic; Pyrimidines; Pyrroles; Quality of Life; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Analysis; United States | 2015 |
Synthetic miR-145 Mimic Enhances the Cytotoxic Effect of the Antiangiogenic Drug Sunitinib in Glioblastoma.
Topics: Angiogenesis Inhibitors; Apoptosis; Cell Line; Glioblastoma; Humans; Indoles; MicroRNAs; Pyrroles; Sunitinib | 2015 |
Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Mutation; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Risk; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2015 |
[Inhibition of sunitinib on the expressions of PD-L1 and PD-L2 of mouse bone marrow-derived dendritic cells].
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Bone Marrow; Cells, Cultured; Dendritic Cells; Female; Gene Expression; Indoles; Mice; Mice, Inbred C57BL; Programmed Cell Death 1 Ligand 2 Protein; Pyrroles; Sunitinib | 2015 |
Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sunitinib | 2015 |
Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Brain; Brain Neoplasms; Cell Line; Chickens; Glioma; Humans; Indoles; Lymphocytes, Tumor-Infiltrating; Mice, Transgenic; Myeloid Cells; Neoplasm Transplantation; Protein-Tyrosine Kinases; Pyrroles; Spleen; Sunitinib; Survival Analysis; T-Lymphocytes; Treatment Outcome | 2015 |
Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Indoles; Kidney Neoplasms; Male; Mutation; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Sunitinib in thymic carcinoma: enigmas still unresolved.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Indoles; Male; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Pyrroles; Sunitinib; Thymoma; Thymus Neoplasms | 2015 |
The anti-angiogenic and cytotoxic effects of the boswellic acid analog BA145 are potentiated by autophagy inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Autophagy; Cell Line; Cell Proliferation; Cell Survival; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Pyrroles; Sunitinib; Triterpenes | 2015 |
Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling.
Topics: Carcinoma, Hepatocellular; Cell Proliferation; Culture Media, Conditioned; Fetus; Gene Knockdown Techniques; Humans; Indoles; Liver Neoplasms; Mesenchymal Stem Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib; Sunitinib | 2015 |
[The importance of mutational status in prognosis and therapy of GIST].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Phenylurea Compounds; Piperazines; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sensitivity and Specificity; Sunitinib | 2015 |
AXL as a modulator of sunitinib response in glioblastoma cell lines.
Topics: Angiogenesis Inhibitors; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; ErbB Receptors; Gene Knockdown Techniques; Glioblastoma; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sunitinib | 2015 |
AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets.
Topics: Blotting, Western; Cell Line; Erlotinib Hydrochloride; Hepacivirus; Hepatitis C; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Luciferases; Microscopy, Fluorescence; Plasmids; Protein Serine-Threonine Kinases; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Sunitinib; Virus Internalization | 2015 |
Sunitinib tissue distribution changes after coadministration with ketoconazole in mice.
Topics: Animals; Antifungal Agents; Area Under Curve; Drug Interactions; Female; Half-Life; Indoles; Ketoconazole; Mice; Mice, Inbred ICR; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tissue Distribution | 2016 |
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
Topics: Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Tandem Mass Spectrometry | 2015 |
p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Indoles; Interleukin-6; Mice; Mice, Nude; NF-kappa B; p21-Activated Kinases; Phosphorylation; Pyrroles; RNA Interference; Sunitinib | 2015 |
Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition.
Topics: Animals; Cell Line, Tumor; Chickens; Colorectal Neoplasms; Female; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Indoles; Lysosomes; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Phototherapy; Pyrroles; Sunitinib | 2015 |
Sunitinib effective for rare thymus cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Indoles; Pyrroles; Sunitinib; Thymus Neoplasms; Treatment Outcome | 2015 |
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Indoles; Interleukin-8; Kidney Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib; Survival Analysis; Young Adult | 2015 |
FGF2 Prevents Sunitinib-Induced Cardiotoxicity in Zebrafish and Cardiomyoblast H9c2 Cells.
Topics: Angiogenesis Inhibitors; Animals; Cardiotoxicity; Cell Line; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Fibroblast Growth Factor 2; Heart Diseases; Heart Rate; Humans; Indoles; Molecular Docking Simulation; Myoblasts; Phospholipase C gamma; Pyrroles; raf Kinases; Receptor, Fibroblast Growth Factor, Type 1; Sunitinib; Zebrafish | 2016 |
Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Gene Frequency; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2015 |
Anti-angiogenic drug delivery from hydrophilic resorbable embolization microspheres: an in vitro study with sunitinib and bevacizumab.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Cell Line; Drug Delivery Systems; Embolization, Therapeutic; Human Umbilical Vein Endothelial Cells; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Liver Neoplasms; Mice; Microspheres; Pyrroles; Sunitinib; Tumor Cells, Cultured | 2015 |
Sunitinib microspheres based on [PDLLA-PEG-PDLLA]-b-PLLA multi-block copolymers for ocular drug delivery.
Topics: Administration, Ophthalmic; Angiogenesis Inhibitors; Animals; Chick Embryo; Chorioallantoic Membrane; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Drug Liberation; Indoles; Intravitreal Injections; Lactic Acid; Microscopy, Electron, Scanning; Microspheres; Neovascularization, Pathologic; Polyesters; Polyethylene Glycols; Polymers; Pyrroles; Solvents; Sunitinib; Time Factors | 2015 |
Therapeutic effect of sunitinib on diabetes mellitus related ovarian injury: an experimental rat model study.
Topics: Angiogenesis Inhibitors; Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Fibrosis; Immunohistochemistry; Indoles; NF-kappa B; Ovary; Primary Ovarian Insufficiency; Pyrroles; Rats; Sunitinib | 2015 |
Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiotensins; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrroles; Renin-Angiotensin System; Sirolimus; Sunitinib; Treatment Outcome | 2015 |
[A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Duodenal Neoplasms; Fatal Outcome; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Middle Aged; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sunitinib; Treatment Outcome | 2014 |
[A case of small intestinal gastrointestinal stromal tumor (GIST) with peritoneal dissemination, treated effectively with molecular target drug after operation].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Molecular Targeted Therapy; Peritoneal Neoplasms; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2014 |
A PKM2 signature in the failing heart.
Topics: Angiogenesis Inhibitors; Animals; Carrier Proteins; Fetal Heart; Gene Expression; Glucose; Glycolysis; Heart; Heart Failure; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Insulin Resistance; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Pyrroles; Pyruvate Kinase; Sunitinib; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2015 |
Primary gastrointestinal stromal tumor of the liver treated with sequential therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; DNA Mutational Analysis; Drug Substitution; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Liver Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
An ex vivo model for anti-angiogenic drug testing on intact microvascular networks.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Endothelial Cells; In Vitro Techniques; Indoles; Male; Mesenteric Arteries; Microscopy; Microvessels; Models, Biological; Pyrroles; Rats; Rats, Wistar; Sunitinib; Time-Lapse Imaging; Tissue Culture Techniques | 2015 |
Application of paper spray-MS in PK studies using sunitinib and benzethonium as model compounds.
Topics: Animals; Benzethonium; Blood Chemical Analysis; Drug Stability; Humans; Indoles; Limit of Detection; Linear Models; Male; Mass Spectrometry; Mice; Mice, Inbred ICR; Paper; Pyrroles; Sunitinib | 2015 |
Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Female; Heterografts; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrroles; Real-Time Polymerase Chain Reaction; Sunitinib | 2015 |
Pharmacokinetic-pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Asian People; Blood Platelets; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Indoles; Intestinal Absorption; Japan; Male; Middle Aged; Models, Biological; Platelet Count; Pyrroles; Sunitinib; Thrombocytopenia | 2015 |
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Cell Line, Tumor; Chick Embryo; Combined Modality Therapy; Cymenes; Disease Models, Animal; Doxorubicin; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Oxygen Consumption; Photochemotherapy; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tumor Burden | 2015 |
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Artifacts; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Reproducibility of Results; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2016 |
Efficacy and toxicity of sunitinib in metastatic renal cell carcinoma patients in Egypt.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Egypt; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Young Adult | 2015 |
Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Czech Republic; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Time Factors | 2015 |
Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; MicroRNAs; Multigene Family; Muscle Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sunitinib | 2015 |
Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.
Topics: Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2016 |
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Papillary; Carcinoma, Renal Cell; Cell Line, Tumor; Crizotinib; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Indoles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyrroles; Sunitinib; Triazines; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Coculture Techniques; Drug Resistance, Neoplasm; Female; Hepatitis A Virus Cellular Receptor 2; Heterografts; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Macrophages; Male; Membrane Proteins; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Proteins; Neoplasm Transplantation; Prognosis; Pyrroles; Sirolimus; Sunitinib; Tumor Cells, Cultured | 2015 |
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; France; Humans; Hypertension; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Renin-Angiotensin System; Retrospective Studies; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2015 |
Actinometric and Φ-order photodegradation properties of anti-cancer Sunitinib.
Topics: Antineoplastic Agents; Drug Stability; Ethanol; Indoles; Isomerism; Kinetics; Light; Models, Chemical; Photolysis; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Sunitinib benefits patients with small-cell lung cancer.
Topics: Humans; Indoles; Pyrroles; Small Cell Lung Carcinoma; Sunitinib | 2015 |
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
Topics: Adult; Aged, 80 and over; Canada; Cardiovascular Diseases; Female; Humans; Indoles; Male; Middle Aged; Myocardial Ischemia; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2015 |
Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dopamine; Drug Resistance, Neoplasm; Drug Synergism; Female; Flow Cytometry; Humans; Indoles; Microscopy, Fluorescence; Neoplastic Stem Cells; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Humans; Indoles; Neovascularization, Pathologic; Pyrroles; Radiation Dosage; Radiation, Ionizing; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Topics: Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Piperazines; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Effects of sunitinib malate on growth of human bladder transitional cell line T24 in vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Fas Ligand Protein; fas Receptor; Humans; In Vitro Techniques; Indoles; Poly(ADP-ribose) Polymerases; Pyrroles; Sunitinib; Urinary Bladder Neoplasms; Wound Healing | 2015 |
[Erlotinib, sunitinib, and everolimus].
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Everolimus; Humans; Indoles; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sirolimus; Sunitinib | 2015 |
MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Chemotherapy, Adjuvant; Drug Carriers; Gene Expression Regulation, Neoplastic; Glioblastoma; Indoles; Male; Mice, Inbred C57BL; MicroRNAs; Nanomedicine; Nanoparticles; Oligonucleotides, Antisense; Protein Kinase Inhibitors; Pyrroles; rhoB GTP-Binding Protein; RNAi Therapeutics; Scorpion Venoms; Sunitinib; Technology, Pharmaceutical; Time Factors; Tumor Burden | 2015 |
Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Topics: Amphiregulin; Carcinoma, Squamous Cell; EGF Family of Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Indoles; Molecular Targeted Therapy; Niacinamide; Papillomaviridae; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Sunitinib; TOR Serine-Threonine Kinases | 2015 |
Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Quality of Life; Sunitinib; Treatment Outcome | 2015 |
The effects of topical everolimus and sunitinib on corneal neovascularization.
Topics: Actins; Administration, Topical; Angiogenesis Inhibitors; Animals; Cornea; Corneal Neovascularization; Drug Therapy, Combination; Everolimus; Indoles; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pyrroles; Rats; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Diarrhea; Drug Administration Schedule; Everolimus; Humans; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Mitotic Index; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Somatostatin; Sunitinib; Tomography, X-Ray Computed | 2015 |
Quantitation of sunitinib, an oral multitarget tyrosine kinase inhibitor, and its metabolite in urine samples by nonaqueous capillary electrophoresis time of flight mass spectrometry.
Topics: Electrophoresis, Capillary; Humans; Indoles; Limit of Detection; Protein Kinase Inhibitors; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Sunitinib | 2015 |
Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Agents; Female; Humans; Immunophenotyping; Indoles; Lymphocytes, Tumor-Infiltrating; MART-1 Antigen; Neoplasm Staging; Oncogene Proteins, Fusion; Positron-Emission Tomography; Pyrroles; Sarcoma, Clear Cell; Sunitinib; Tomography, X-Ray Computed; Transcription Factors; Treatment Outcome | 2015 |
Infectious disease. Combating emerging viral threats.
Topics: Adenine; Adenosine; Antiviral Agents; Benzamides; Chloroquine; Communicable Diseases, Emerging; Cyclosporins; Cytosine; Dengue; Drug Approval; Drug Design; Erlotinib Hydrochloride; Hemorrhagic Fever, Ebola; Humans; Imatinib Mesylate; Indoles; Organophosphonates; Piperazines; Purine Nucleosides; Pyrimidines; Pyrroles; Pyrrolidines; Quinazolines; Sunitinib; Viruses | 2015 |
Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Male; Mice; Neoplastic Stem Cells; Neovascularization, Pathologic; Prostate; Prostatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
The Suppression of Wound Healing Response with Sirolimus and Sunitinib Following Experimental Trabeculectomy in a Rabbit Model.
Topics: Alkylating Agents; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Fibroblast Growth Factor 2; Fibroblast Growth Factors; Immunosuppressive Agents; Indoles; Male; Mitomycin; Platelet-Derived Growth Factor; Pyrroles; Rabbits; Sirolimus; Sunitinib; Trabecular Meshwork; Trabeculectomy; Transforming Growth Factor beta; Wound Healing | 2016 |
Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Metastasis; Prognosis; Pyrroles; Registries; Retrospective Studies; Sunitinib; Treatment Outcome | 2015 |
Potential role of anti-VEGF targeted therapies in cervical artery dissection: A case report.
Topics: Angiogenesis Inhibitors; Aphasia; Bone Neoplasms; Carcinoma, Renal Cell; Carotid Artery, Internal, Dissection; Combined Modality Therapy; Endovascular Procedures; Hematoma; Humans; Hyperhomocysteinemia; Indoles; Infarction, Middle Cerebral Artery; Inflammation; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nephrectomy; Paresis; Protein Kinase Inhibitors; Pyrroles; Radiography; Radiotherapy, Adjuvant; Stents; Sunitinib; Vasa Vasorum; Vascular Endothelial Growth Factor A; Vitamin B 12 Deficiency | 2015 |
Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Japan; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Product Surveillance, Postmarketing; Proportional Hazards Models; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration-resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo.
Topics: Animals; Antineoplastic Agents; Humans; Indoles; Male; Mice; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrroles; Sunitinib; Tumor Cells, Cultured | 2015 |
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
Topics: Angiogenesis Inhibitors; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Gene Deletion; Humans; Indazoles; Indoles; Lapatinib; Membrane Proteins; Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Sulfonamides; Sunitinib | 2015 |
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Disease Progression; Disease-Free Survival; Female; Haplotypes; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Netherlands; Ohio; Pharmacogenetics; Polymorphism, Single Nucleotide; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Spain; Sunitinib; Time Factors; Treatment Outcome | 2015 |
The pharmacokinetic interaction between levofloxacin and sunitinib.
Topics: Animals; Area Under Curve; Drug Interactions; Indoles; Infusions, Intravenous; Levofloxacin; Male; Pyrroles; Rabbits; Sunitinib | 2015 |
Pirfenidone enhances the efficacy of combined radiation and sunitinib therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Line, Tumor; Collagen; Combined Modality Therapy; Indoles; Mice; Microvessels; Pyridones; Pyrroles; Radiation Tolerance; Sunitinib; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2015 |
Impact insertion of transfer-molded microneedle for localized and minimally invasive ocular drug delivery.
Topics: Administration, Ophthalmic; Animals; Corneal Neovascularization; Drug Delivery Systems; Human Umbilical Vein Endothelial Cells; Indoles; Mice, Inbred C57BL; Microinjections; Needles; Neovascularization, Physiologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
[Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
Topics: Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Benzamides; Humans; Imatinib Mesylate; Indoles; Neovascularization, Pathologic; Paraganglioma; Pheochromocytoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Thalidomide | 2015 |
[Clinical management of advanced gastrointestinal stromal tumors after failure of at least both imatinib and sunitinib targeted therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Pyrroles; Sunitinib | 2015 |
Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2016 |
Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Topics: Angiogenesis Inhibitors; Animals; Basic Helix-Loop-Helix Transcription Factors; Bevacizumab; Cell Differentiation; Cell Hypoxia; Cell Proliferation; Cell Survival; Cells, Cultured; Endothelial Progenitor Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice, SCID; Neoplastic Stem Cells; Neovascularization, Pathologic; Neovascularization, Physiologic; Protein Kinase Inhibitors; Pyrroles; RNA Interference; Signal Transduction; Sunitinib; Time Factors; Transfection; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Indoles; Mice, Nude; Nanoparticles; Neoplasms; Peptides, Cyclic; Porosity; Positron-Emission Tomography; Pyrroles; Silicon Dioxide; Sunitinib | 2015 |
Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Proliferation; Disease Models, Animal; Endometriosis; Endometrium; Female; Indazoles; Indoles; Niacinamide; Ovarian Reserve; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Indoles; Middle Aged; Neoplasm Staging; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sunitinib; Tumor Cells, Cultured | 2015 |
VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Survival; Contrast Media; Drug Monitoring; Female; Imatinib Mesylate; Indoles; Mice; Mice, Inbred BALB C; Molecular Imaging; Neoplasms, Experimental; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Results of the first trial assessing adjuvant tyrosine kinase inhibitors in renal cell carcinoma do not reASSURE.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Early Termination of Clinical Trials; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Treatment Outcome | 2015 |
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Renal Cell; Cholangiopancreatography, Magnetic Resonance; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Effect of enhanced expression of connexin 43 on sunitinib-induced cytotoxicity in mesothelioma cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Transformation, Neoplastic; Connexin 43; Drug Resistance, Neoplasm; Gap Junctions; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Indoles; Mesothelioma; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sunitinib | 2015 |
Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Dosage; Humans; Indoles; Keratins; MCF-7 Cells; Neoplastic Cells, Circulating; Pyrroles; Spheroids, Cellular; Sunitinib; Treatment Outcome; Tumor Cells, Cultured | 2015 |
Synthesis and antitumor activity of 5-(5-halogenated-2-oxo-1H-pyrrolo[2,3-b]pyridin-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamides.
Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Indoles; MCF-7 Cells; Pyrimidines; Pyrroles; Structure-Activity Relationship; Sunitinib | 2015 |
Oestrogen enhances cardiotoxicity induced by Sunitinib by regulation of drug transport and metabolism.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cardiotoxicity; Cytochrome P-450 CYP1A1; Dose-Response Relationship, Drug; Estrogens; Female; Indoles; Male; Mice; Myocytes, Cardiac; Phenylephrine; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; Sex Characteristics; Sunitinib; Type C Phospholipases | 2015 |
Sunitinib-ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Brain; Drug Interactions; Female; Ibuprofen; Indoles; Kidney; Liver; Male; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Pyrroles; Sex Characteristics; Sunitinib; Tissue Distribution | 2015 |
Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Databases, Factual; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Medication Adherence; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; United States | 2015 |
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; B7-H1 Antigen; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Resistance, Neoplasm; Heterografts; Humans; Immune Tolerance; Indoles; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice, Nude; Neoplasm Transplantation; Pyrroles; Sunitinib; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tumor Cells, Cultured; Tumor Microenvironment; Up-Regulation | 2015 |
Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Cluster Analysis; Comparative Genomic Hybridization; DNA-Binding Proteins; Drug Design; Female; Gene Expression Profiling; Genotype; Humans; Hypoxia; Indoles; Kidney Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Nephrectomy; Nuclear Proteins; Pilot Projects; Protein Array Analysis; Protein Kinase Inhibitors; Pyrroles; RNA, Messenger; Sunitinib; Transcription Factors; Von Hippel-Lindau Tumor Suppressor Protein | 2015 |
[Memory resides in the hair].
Topics: Adult; Drug Administration Schedule; Female; Hair Color; Hair Diseases; Humans; Indoles; Pyrroles; Sunitinib; Thymus Neoplasms | 2015 |
Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chronic Disease; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Diseases; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2015 |
Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Endoscopy, Gastrointestinal; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2015 |
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System.
Topics: Aged; Antineoplastic Agents; Arteries; Blood Pressure; Carcinoma, Renal Cell; Female; Heart; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pulse Wave Analysis; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; Vascular Stiffness | 2016 |
Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome | 2016 |
CCR 20th Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back.
Topics: Anniversaries and Special Events; History, 21st Century; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib | 2015 |
Effects of acute and chronic sunitinib treatment on cardiac function and calcium/calmodulin-dependent protein kinase II.
Topics: Animals; Blood Pressure; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Drug Administration Schedule; Guinea Pigs; Heart Diseases; Heart Rate; Indoles; Male; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression; HMGB1 Protein; Imidazoles; Indoles; Mammary Neoplasms, Experimental; Membrane Glycoproteins; Mice, Inbred BALB C; Neoplasm Transplantation; Pyrroles; Sunitinib; Toll-Like Receptor 7; Toll-Like Receptor 8; Up-Regulation | 2015 |
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hep G2 Cells; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyrroles; Quinolines; Signal Transduction; Sorafenib; Sunitinib; Transforming Growth Factor beta1 | 2015 |
[Impact of VEGF-A in exhaustion of intratumoral T cells].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lymphocytes, Tumor-Infiltrating; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms, Experimental; Programmed Cell Death 1 Receptor; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; T-Lymphocytes, Cytotoxic; Vascular Endothelial Growth Factor A | 2015 |
Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Colonic Neoplasms; Head and Neck Neoplasms; Humans; Indoles; Lymph Nodes; Lymphatic Metastasis; Mice; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2015 |
miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2015 |
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Life Style; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2015 |
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays | 2015 |
Successful treatment of mast cell activation syndrome with sunitinib.
Topics: Adult; Biopsy; Duodenum; Female; Humans; Indoles; Mast Cells; Mastocytosis; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Young Adult | 2015 |
[Systemic therapy of soft tissue sarcomas].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ifosfamide; Indazoles; Indoles; Male; Molecular Targeted Therapy; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Polyethylene Glycols; Pyrimidines; Pyrroles; Radiography; Sarcoma; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2015 |
[Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrectomy; Pyrroles; Recurrence; Sunitinib; Tomography, X-Ray Computed | 2015 |
The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers; Blood Pressure; Cardiotoxicity; Echocardiography; Heart; Indoles; Male; Mice; Mice, Inbred C57BL; Myocardium; Pyrroles; Sunitinib; Troponin I; Ventricular Function, Left | 2015 |
Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Everolimus; Female; Humans; Immunotherapy; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Cells; Neoplasm Metastasis; Programmed Cell Death 1 Receptor; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; T-Lymphocytes; Treatment Outcome | 2015 |
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Indoles; Interleukin-13 Receptor alpha2 Subunit; Kidney Neoplasms; Mice, Inbred BALB C; Mice, SCID; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2015 |
AMPK Phosphorylation Modulates Pain by Activation of NLRP3 Inflammasome.
Topics: Adult; AMP-Activated Protein Kinases; Animals; Carrier Proteins; Female; Fibromyalgia; Humans; Indoles; Inflammasomes; Interleukin-18; Interleukin-1beta; Male; Metformin; Mice; Middle Aged; NLR Family, Pyrin Domain-Containing 3 Protein; Pain; Pain Perception; Phosphorylation; Pyrroles; Sunitinib | 2016 |
HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model.
Topics: Acriflavine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Female; Hypoxia-Inducible Factor 1; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Myeloid Cells; Necrosis; Neovascularization, Pathologic; Protein Multimerization; Pyrroles; Spleen; Sunitinib; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2014 |
Invasiveness and metastasis of retinoblastoma in an orthotopic zebrafish tumor model.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Heterografts; Humans; Indoles; Mice; Morpholinos; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Retinoblastoma; Sunitinib; Vascular Endothelial Growth Factor A; Zebrafish | 2015 |
Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery.
Topics: Bariatric Surgery; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Indoles; Kidney Neoplasms; Male; Obesity; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2015 |
Sorafenib-Sunitinib Sequence: The Jury Is Out.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2015 |
Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With Sunitinib.
Topics: Animals; Antineoplastic Agents; Blood Pressure; Dose-Response Relationship, Drug; Indoles; Kidney; Kidney Diseases; Male; Podocytes; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Inbred WKY; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Misonidazole; Positron-Emission Tomography; Pyrroles; Sunitinib | 2015 |
miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; MicroRNAs; Middle Aged; Models, Statistical; Neovascularization, Pathologic; Prognosis; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Transforming Growth Factor beta; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension.
Topics: Acetylcholine; Adult; Aged; Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Endothelium, Vascular; Forearm; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Mesenteric Arteries; Middle Aged; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroprusside; Pyrroles; Rats; Regional Blood Flow; Sunitinib; Vascular Endothelial Growth Factor A; Vasodilation; Vasodilator Agents | 2015 |
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
Topics: Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; Dysgeusia; Dyspepsia; Fatigue; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Mucositis; Nausea; Pyrroles; Stomatitis; Sunitinib; Time Factors | 2016 |
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2015 |
Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein; Young Adult | 2015 |
Assessment of tumor response to radiation and vascular targeting therapy in mice using quantitative ultrasound spectroscopy.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Death; Cell Line, Tumor; Chemoradiotherapy; Fibroblast Growth Factors; Humans; Immunohistochemistry; Indoles; Mice, SCID; Neoplasm Transplantation; Oxygen; Pyrroles; Spectrum Analysis; Sunitinib; Treatment Outcome; Ultrasonography | 2015 |
Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Synergism; Female; Glucocorticoid-Induced TNFR-Related Protein; Immunotherapy; Indoles; Kidney Neoplasms; Killer Cells, Natural; Lymphocyte Activation; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrroles; Sunitinib | 2016 |
Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Pyrroles; Singapore; Sunitinib; Treatment Outcome; Young Adult | 2015 |
Lack of Contribution of Multidrug Resistance-associated Protein and Organic Anion-transporting Polypeptide to Pharmacokinetics of Regorafenib, a Novel Multi-Kinase Inhibitor, in Rats.
Topics: Animals; ATP-Binding Cassette Transporters; Bile; Immunoblotting; Indoles; Injections, Intravenous; Liver; Male; Mass Spectrometry; Multidrug Resistance-Associated Protein 2; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; Pyrroles; Rats, Sprague-Dawley; Sunitinib | 2015 |
Oral Platelet-Derived Growth Factor and Vascular Endothelial Growth Factor Inhibitor Sunitinib Prevents Chronic Allograft Injury in Experimental Kidney Transplantation Model.
Topics: Administration, Oral; Allografts; Animals; Cell Movement; Cell Proliferation; Cells, Cultured; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Graft Rejection; Indoles; Kidney; Kidney Transplantation; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neointima; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrroles; Rats, Wistar; Signal Transduction; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factors | 2016 |
Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Oncogene Proteins, Fusion; Pyrroles; Sunitinib | 2015 |
NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Culture Media, Conditioned; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Mice; Mutation; Neovascularization, Pathologic; Neovascularization, Physiologic; NF-kappa B; Promoter Regions, Genetic; Pyrroles; RNA Interference; Signal Transduction; Sunitinib; Time Factors; Transcription Factor AP-1; Transfection; Tumor Burden; Tumor Necrosis Factor Ligand Superfamily Member 15; Up-Regulation | 2016 |
Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Humans; Indoles; Kidney Neoplasms; Pyrroles; Signal Transduction; Sunitinib | 2015 |
Sunitinib monotherapy instead of mitotane combination therapy for the treatment of refractory adrenocortical carcinoma.
Topics: Adrenocortical Carcinoma; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Humans; Indoles; Lung Neoplasms; Mitotane; Multiple Pulmonary Nodules; Nephrectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2015 |
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.
Topics: Angiogenesis Inhibitors; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indoles; Lysosomes; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; HeLa Cells; Hep G2 Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Jurkat Cells; MCF-7 Cells; Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcriptome | 2015 |
Pleural and pericardial effusions combined with ascites in a patient with severe sunitinib-induced hypothyroidism.
Topics: Antineoplastic Agents; Ascites; Carcinoma, Renal Cell; Fatal Outcome; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Pyrroles; Sunitinib | 2016 |
Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Survival Analysis; Treatment Outcome | 2015 |
Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome; Turkey | 2015 |
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Patients; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Bone Neoplasms; Chemoradiotherapy; Female; Humans; Indoles; Mutation; Pheochromocytoma; Pyrroles; Remission Induction; Succinate Dehydrogenase; Sunitinib | 2016 |
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Axl Receptor Tyrosine Kinase; Carcinoma, Renal Cell; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Indoles; Kinetics; Liver Circulation; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Pyrroles; Sunitinib | 2015 |
Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cohort Studies; Drug Costs; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Medicare; Middle Aged; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United States; Young Adult | 2015 |
A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Metabolome; Middle Aged; Pyrroles; Serum; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2015 |
Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Disease Models, Animal; Female; Fibroblasts; Indoles; Male; Mast Cells; Mice; Mice, Transgenic; Neurofibroma, Plexiform; Positron-Emission Tomography; Pyrroles; Sunitinib; Tumor Microenvironment | 2016 |
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2016 |
Identification of a Mitochondrial DNA Polymerase Affecting Cardiotoxicity of Sunitinib Using a Genome-Wide Screening on S. pombe Deletion Library.
Topics: Antineoplastic Agents; Cardiotoxicity; DNA Polymerase gamma; DNA-Directed DNA Polymerase; Genome-Wide Association Study; Genomic Library; HeLa Cells; High-Throughput Screening Assays; Humans; Indoles; Mitochondria; Pyrroles; Schizosaccharomyces; Schizosaccharomyces pombe Proteins; Sequence Deletion; Sunitinib | 2016 |
Embolization biomaterial reinforced with nanotechnology for an in-situ release of anti-angiogenic agent in the treatment of hyper-vascularized tumors and arteriovenous malformations.
Topics: Acrylates; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Biocompatible Materials; Cell Proliferation; Cells, Cultured; Cornea; Delayed-Action Preparations; Drug Compounding; Drug Delivery Systems; Embolization, Therapeutic; Endothelium, Vascular; Gels; Human Umbilical Vein Endothelial Cells; Indoles; Intercostal Muscles; Nanospheres; Neovascularization, Pathologic; Pyrroles; Rabbits; Random Allocation; Sheep, Domestic; Sunitinib | 2015 |
Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.
Topics: Animals; Antihypertensive Agents; Antineoplastic Agents; Humans; Hypertension; Indoles; Nitric Oxide Donors; Pyrroles; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.
Topics: Aged; Alleles; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Interleukin-13; Interleukin-8; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Survival Rate | 2015 |
[PATHOLOGICAL COMPLETE RESPONSE WITH EVEROLIMUS FOR MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA RESISTANT TO SUNITINIB].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Everolimus; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Remission Induction; Sunitinib; Tomography, X-Ray Computed | 2015 |
Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Case-Control Studies; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Indoles; Kidney; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Tissue Array Analysis | 2015 |
Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
Topics: Adult; Aged; Antineoplastic Agents; Autoantibodies; Autoimmunity; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Thyroglobulin; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine | 2015 |
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Sunitinib; Time Factors | 2016 |
New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Agents; Everolimus; Hormones; Humans; Indoles; Intestinal Neoplasms; Intestines; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Pancreas; Pancreatic Neoplasms; Pyrroles; Somatostatin; Stomach; Stomach Neoplasms; Sunitinib | 2015 |
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cardiovascular Diseases; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Risk Factors; SEER Program; Sorafenib; Sunitinib; Survival Analysis; United States | 2016 |
[Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
[A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Pilot Projects; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nevus, Spindle Cell; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2015 |
Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2α pathway.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Renal Cell; Cell Hypoxia; Cell Line, Tumor; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Fluorescent Antibody Technique; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Microscopy, Confocal; Pyrroles; RNA, Small Interfering; Signal Transduction; Stress, Physiological; Sunitinib; Transfection; Xenograft Model Antitumor Assays | 2015 |
Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.
Topics: Antineoplastic Agents; Cytogenetics; Female; Hemangiosarcoma; Humans; Indoles; Liver Neoplasms; Middle Aged; Mutation; Phospholipase C gamma; Pyrroles; Signal Transduction; Sunitinib | 2015 |
Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors.
Topics: Adrenal Cortex Neoplasms; Antineoplastic Agents; Cell Survival; ErbB Receptors; Growth Inhibitors; Humans; Indoles; Pyrroles; Sunitinib | 2015 |
A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diffusion; Female; Indoles; Liposomes; Materials Testing; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanocapsules; Nanocomposites; Neoplasm Invasiveness; Particle Size; Pyrroles; Sunitinib; Surface Properties; Treatment Outcome; Tumor Burden; Vinblastine; Vinorelbine | 2015 |
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Endothelial Cells; Female; Humans; Indoles; Kidney Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Pyrroles; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2016 |
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indazoles; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom | 2016 |
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neutropenia; Pyrroles; Sunitinib; Survival Rate; Young Adult | 2015 |
Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzoates; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Drug Tolerance; Esterases; Female; Humans; Hydrolysis; Indoles; Mice; Neoplasms; Phosphorylation; Prodrugs; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; STAT3 Transcription Factor; Sunitinib; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Topics: Angiogenesis Inhibitors; Anilides; Carcinoma, Neuroendocrine; Databases, Chemical; Drug Discovery; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Molecular Structure; Niacinamide; Oligonucleotides; Piperidines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Murine colitis treated with multitargeted tyrosine kinase inhibitors.
Topics: Animals; Axitinib; Colitis; Imidazoles; Indazoles; Indoles; Male; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Sunitinib loaded chitosan nanoparticles formulation and its evaluation.
Topics: Angiogenesis Inhibitors; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Delivery Systems; Drug Liberation; Indoles; Kinetics; Nanoparticles; Particle Size; Pyrroles; Spectroscopy, Fourier Transform Infrared; Sunitinib; X-Ray Diffraction | 2016 |
Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Metastatic renal cell carcinoma without evidence of a renal primary.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Diagnosis, Differential; Diagnostic Imaging; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Liver Neoplasms; Lymph Node Excision; Male; Pyrroles; Sunitinib | 2016 |
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Sunitinib modulates the radiosensitivity of esophageal squamous cell carcinoma cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; DNA Breaks, Double-Stranded; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Flow Cytometry; Humans; Indoles; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents; Sunitinib | 2016 |
[Sunitinib and zoledronic acid induced osteonecrosis of the jaw].
Topics: Adult; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Indoles; Mandible; Oral Surgical Procedures; Osteonecrosis; Pyrroles; Sunitinib; Treatment Outcome; Zoledronic Acid | 2015 |
Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA).
Topics: Animals; Binding Sites; Cattle; Circular Dichroism; Fluorescence Resonance Energy Transfer; Gefitinib; Indoles; Lapatinib; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrroles; Quinazolines; Serum Albumin, Bovine; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Sunitinib; Thermodynamics | 2015 |
Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Aorta; Breast Neoplasms; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Isoflavones; Male; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Neovascularization, Physiologic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Rats, Sprague-Dawley; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Time Factors; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2015 |
Inflammatory and fibrotic processes are involved in the cardiotoxic effect of sunitinib: Protective role of L-carnitine.
Topics: Animals; Antineoplastic Agents; Blood Pressure; Cardiotonic Agents; Cardiotoxicity; Carnitine; Cytokines; Endomyocardial Fibrosis; Gene Expression; Heart Diseases; Indoles; Male; Myocarditis; Myocytes, Cardiac; NF-kappa B; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Sunitinib | 2016 |
Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2016 |
Photoinduced Isomerization and Hepatoxicities of Semaxanib, Sunitinib and Related 3-Substituted Indolin-2-ones.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Molecular Structure; Photochemical Processes; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Stereoisomerism; Structure-Activity Relationship; Sunitinib | 2016 |
Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Topics: Animals; Antineoplastic Agents; Axitinib; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2016 |
Natriuretic Peptides as Cardiovascular Safety Biomarkers in Rats: Comparison With Blood Pressure, Heart Rate, and Heart Weight.
Topics: Animals; Atrial Natriuretic Factor; Biomarkers; Blood Pressure; Cardiomegaly; Heart Rate; Indoles; Male; Minoxidil; Natriuretic Peptide, Brain; NG-Nitroarginine Methyl Ester; Nifedipine; Organ Size; Peptide Fragments; Prostaglandins F, Synthetic; Pyrroles; Rats; Rats, Sprague-Dawley; Sunitinib; Thyroxine | 2016 |
Comparing Everolimus to Sunitinib in Non-clear-cell Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2016 |
Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Proliferation; Drug Design; Gonadotropin-Releasing Hormone; Humans; Indoles; Male; Mice; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Receptors, LHRH; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comorbidity; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Fees, Pharmaceutical; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Drug therapy: Preclinical oncology - reporting transparency needed.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Clinical Trials as Topic; Evidence-Based Medicine; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Medical Oncology; Meta-Analysis as Topic; Neoplasms; Pancreatic Neoplasms; Practice Guidelines as Topic; Pyrroles; Research Design; Research Report; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2016 |
Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy.
Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Chloroquine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Knockout Techniques; Humans; Indoles; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrroles; Radiation Tolerance; Sunitinib; Ubiquitin-Activating Enzymes | 2016 |
Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Resistance, Neoplasm; Endothelial Cells; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Blood Pressure; Indoles; Kidney Diseases; Male; Pyrroles; Rats; Rats, Inbred WKY; Sodium Chloride, Dietary; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Time Factors; Withholding Treatment | 2016 |
Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer.
Topics: Axitinib; Carcinoma, Renal Cell; Cell Communication; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Neoplastic Stem Cells; Niacinamide; Oxygen; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Tumor Microenvironment | 2016 |
[Sunitinib suppresses migration of ovarian cancer cells through negative modulation of TGF-β-mediated epithelial-mesenchymal transition].
Topics: Antigens, CD; Cadherins; Cell Line, Tumor; Cell Movement; Down-Regulation; Epithelial-Mesenchymal Transition; Female; Humans; Indoles; Ovarian Neoplasms; Pyrroles; Smad Proteins; Snail Family Transcription Factors; Sunitinib; Transcription Factors; Transforming Growth Factor beta; Up-Regulation | 2015 |
The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells.
Topics: Animals; Anticarcinogenic Agents; Biomarkers, Tumor; Breast Neoplasms; Catechin; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Immunoenzyme Techniques; Indoles; Insulin Receptor Substrate Proteins; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Prognosis; Pyrroles; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sunitinib; Tea; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2016 |
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Topics: Aged; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; United States | 2016 |
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC).
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Singapore; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Gene Expression; Genomics; Hemangioendothelioma; Hormones; Humans; Indoles; Microvessels; Middle Aged; Prognosis; Pyrroles; Sunitinib; Taxoids; Transcription, Genetic | 2016 |
Does angiogenesis play a role in the establishment of mesial temporal lobe epilepsy?
Topics: Angiogenesis Inhibitors; Animals; Cell Count; Disease Models, Animal; Epilepsy, Temporal Lobe; Hippocampus; Indoles; Lectins; Male; Neovascularization, Pathologic; Pilocarpine; Pyrroles; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Sunitinib; Time Factors | 2016 |
Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
Topics: Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Models, Molecular; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma; Retinoid X Receptor alpha; Sorafenib; Sunitinib | 2016 |
Heart failure associated with small molecule tyrosine kinase inhibitors.
Topics: Aged; Aged, 80 and over; Dasatinib; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2016 |
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
Topics: Celecoxib; Cell Differentiation; Cells, Cultured; Dasatinib; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Humans; Immune Tolerance; Indoles; Monocytes; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2016 |
Prevention of Venous Neointimal Hyperplasia by a Multitarget Receptor Tyrosine Kinase Inhibitor.
Topics: Animals; Arteriovenous Shunt, Surgical; Becaplermin; Blood Vessel Prosthesis Implantation; Carotid Artery, Common; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Female; Graft Occlusion, Vascular; Humans; Hyperplasia; Indoles; Jugular Veins; Myocytes, Smooth Muscle; Neointima; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Sus scrofa; Time Factors; Tissue Culture Techniques; Vascular Endothelial Growth Factor A | 2015 |
Differential Effects of Sunitinib on the Expression Profiles of Xenobiotic-Metabolizing Enzymes and Transporters in Rat Liver and Kidneys.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Cytochrome P450 Family 4; Glucuronosyltransferase; Glutathione Transferase; Indoles; Isoenzymes; Kidney; Lipid Peroxidation; Liver; Male; NAD(P)H Dehydrogenase (Quinone); Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Steroid 16-alpha-Hydroxylase; Sunitinib; Transcriptome; Xenobiotics | 2016 |
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chi-Square Distribution; Cytochrome P-450 CYP3A; Disease-Free Survival; Europe; Female; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hypertension; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Ohio; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2017 |
The influence of the time-of-day administration of sunitinib on the penetration through the blood-brain and blood-aqueous humour barriers in rabbits.
Topics: Animals; Aqueous Humor; Blood-Aqueous Barrier; Blood-Brain Barrier; Cerebrospinal Fluid; Circadian Clocks; Indoles; Male; Protein Kinase Inhibitors; Pyrroles; Rabbits; Sunitinib; Time Factors | 2016 |
Sunitinib activates Axl signaling in renal cell cancer.
Topics: Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Gene Ontology; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Inhibitory Concentration 50; Kidney Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sunitinib | 2016 |
Lack of anti-tumor activity by anti-VEGF treatments in hepatic hemangiomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Female; Hemangioma; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2016 |
Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone.
Topics: Angiogenesis Inhibitors; Animals; Bone Neoplasms; Breast Neoplasms; Female; Indoles; Mice; Mice, SCID; Microcirculation; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Tumor Burden | 2016 |
Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Erythrocyte Indices; Erythrocytes; Female; Hemoglobins; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2016 |
Detection of low-quantity anticancer drugs by surface-enhanced Raman scattering.
Topics: Antineoplastic Agents; Camptothecin; Doxorubicin; Humans; Indoles; Irinotecan; Limit of Detection; Paclitaxel; Pyrroles; Spectrum Analysis, Raman; Sunitinib; Surface Properties | 2016 |
Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.
Topics: ADP-Ribosylation Factor 6; ADP-Ribosylation Factors; Adult; Aged; Aged, 80 and over; Amides; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Female; GTP-Binding Protein alpha Subunits, G12-G13; Guanine Nucleotide Exchange Factors; HEK293 Cells; Humans; Immunohistochemistry; Indoles; Isoxazoles; Kidney Neoplasms; Lysophospholipids; Male; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Nerve Tissue Proteins; Propionates; Pyridines; Pyrroles; Receptors, Lysophosphatidic Acid; Signal Transduction; Sirolimus; Sunitinib; Triazoles | 2016 |
The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study.
Topics: Aged; Carcinoma, Renal Cell; Demography; Disease-Free Survival; Female; Humans; Hypertension; Incidence; Indoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2016 |
Synergistic Effect of Anti-Angiogenic and Radiation Therapy: Quantitative Evaluation with Dynamic Contrast Enhanced MR Imaging.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Combined Modality Therapy; Contrast Media; Gadolinium DTPA; Humans; Indoles; Lung Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Muscle, Skeletal; Neoplasms, Experimental; Pyrroles; Random Allocation; Sunitinib; Thigh; Transplantation, Heterotopic; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease Progression; Female; Humans; Indoles; Inflammation; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2016 |
Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Cross-Over Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Analysis | 2016 |
Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Documentation; Fatigue; Female; Germany; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Registries; Sirolimus; Sorafenib; Stomatitis; Sunitinib | 2017 |
Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Aorta; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Methylation; Models, Molecular; Neovascularization, Physiologic; Pyrroles; Rats; Sunitinib | 2016 |
Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Renal Cell; Case-Control Studies; Female; Genetic Association Studies; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Thrombocytopenia | 2016 |
Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Indoles; Liver Neoplasms, Experimental; Pyrroles; Rabbits; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor A | 2016 |
In Vitro and In Vivo Evaluation of Targeted Sunitinib-Loaded Polymer Microbubbles Against Proliferation of Renal Cell Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Delayed-Action Preparations; Drug Synergism; Female; High-Energy Shock Waves; High-Intensity Focused Ultrasound Ablation; Indoles; Kidney Neoplasms; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Microbubbles; Pyrroles; Sunitinib | 2016 |
P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Bevacizumab; Carcinogenesis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Indoles; Inhibitory Concentration 50; Male; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Prostatic Neoplasms; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2016 |
Lethal acute liver failure in a patient treated with sunitinib.
Topics: Acute Kidney Injury; Aged; Carcinoma, Renal Cell; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Liver Failure, Acute; Male; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2016 |
Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Prognosis; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbonic Anhydrase IX; Carbonic Anhydrases; Cyclophosphamide; Doxorubicin; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib | 2016 |
Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?
Topics: Aged; Antineoplastic Agents; Capsule Endoscopy; Carcinoma, Renal Cell; Diarrhea; Endoscopy, Gastrointestinal; Female; Humans; Indoles; Intestinal Mucosa; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2016 |
Yellowish nail pigmentation caused by sunitinib.
Topics: Aged; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Nail Diseases; Pigmentation Disorders; Pyrroles; Risk Assessment; Sunitinib | 2016 |
Validation Study: Response-Predictive Gene Expression Profiling of Glioma Progenitor Cells In Vitro.
Topics: Brain Neoplasms; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Humans; Indoles; Microarray Analysis; Neoplastic Stem Cells; Pyrroles; Sunitinib | 2016 |
Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease.
Topics: Adenoma, Islet Cell; Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Fatal Outcome; Genes, Tumor Suppressor; Germ-Line Mutation; Humans; Indoles; Kidney Neoplasms; Male; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2016 |
Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Cytoskeletal Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Microscopy, Confocal; Middle Aged; Neovascularization, Pathologic; Nerve Tissue Proteins; Pyrroles; RNA, Messenger; RNA, Small Interfering; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Platelet Count; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2016 |
Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Genes, erbB-1; Humans; Indoles; Lung Neoplasms; Mutation; Proto-Oncogene Proteins p21(ras); Pyrroles; Sunitinib; TNF-Related Apoptosis-Inducing Ligand | 2016 |
[Successful Management by Immunoglobulin for Sunitinib-Induced Thrombocytopenia in a Patient with Advanced Metastatic Renal Cell Carcinoma].
Topics: Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Humans; Immunoglobulins; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib; Thrombocytopenia | 2016 |
Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Male; Neoplasm Metastasis; Prognosis; Pyrroles; Retrospective Studies; Sarcopenia; Sunitinib | 2016 |
[NEOADJUVANT TARGET THERAPY IN A RENAL-CELL CANCER].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2016 |
Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Prognosis; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
Kidney cancer: No advantage of adjuvant sunitinib or sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2016 |
[Systemic therapy of metastatic renal cell carcinoma].
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2016 |
The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study.
Topics: Animals; Antineoplastic Agents; Female; Indoles; Mice; Ovarian Reserve; Ovulation; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2016 |
Sunitinib, a Clinically Used Anticancer Drug, Is a Potent AChE Inhibitor and Attenuates Cognitive Impairments in Mice.
Topics: Acetylcholinesterase; Animals; Antineoplastic Agents; Cholinergic Antagonists; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Exploratory Behavior; Indans; Indoles; Male; Maze Learning; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Piperidines; Pyrroles; Scopolamine; Sunitinib | 2016 |
[A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Rectal Neoplasms; Sunitinib | 2016 |
[Sunitinib inhibits the expressions of co-stimulatory molecule ligands on dendritic cells].
Topics: B7-1 Antigen; B7-2 Antigen; B7-H1 Antigen; Carcinoma, Renal Cell; Cells, Cultured; Dendritic Cells; Down-Regulation; Female; Humans; Indoles; Ligands; Male; Monocytes; Programmed Cell Death 1 Ligand 2 Protein; Pyrroles; Sunitinib | 2016 |
Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2016 |
The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension.
Topics: Angiogenesis Inhibitors; Animals; Antipsychotic Agents; Clodronic Acid; Delayed-Action Preparations; Drug Liberation; Indoles; Injections, Intramuscular; Liposomes; Macrophages; Male; Neovascularization, Pathologic; Paliperidone Palmitate; Prodrugs; Pyrroles; Rats, Wistar; Sunitinib; Suspensions | 2016 |
Effects of local irradiation combined with sunitinib on early remodeling, mitochondria, and oxidative stress in the rat heart.
Topics: Animals; Cell Death; Heart; Indoles; Male; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Sunitinib; Ventricular Remodeling | 2016 |
Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Signal Transduction; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Immunoenzyme Techniques; Indoles; Ki-67 Antigen; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrroles; Sunitinib; Survival Rate; Vesicular Transport Proteins | 2016 |
Sunitinib Efficacy in Patients with Advanced pNET in Clinical Practice.
Topics: Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Indoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Practice Patterns, Physicians'; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2016 |
Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Databases, Factual; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker.
Topics: Aged; Calcium Channel Blockers; Carcinoma, Renal Cell; Drug Interactions; Drug Monitoring; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2016 |
Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA.
Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Blotting, Northern; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Exosomes; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrroles; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Long Noncoding; RNA, Neoplasm; Signal Transduction; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Glycolysis; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Pyrroles; Radiopharmaceuticals; Sunitinib; Tomography, X-Ray Computed; Tumor Burden | 2016 |
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucose; Glutamine; Glycolysis; Humans; Imidazoles; Indazoles; Indoles; Intestinal Neoplasms; Lactic Acid; Membrane Transport Proteins; Mice; Models, Biological; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sirolimus; Stomach Neoplasms; Sunitinib; TOR Serine-Threonine Kinases; Up-Regulation | 2016 |
Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Everolimus; Humans; Indoles; Kidney Neoplasms; Male; Mice, Nude; Phenotype; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
CT halo sign and crazy paving pattern due to lung metastases hemorrhage after sunitinib therapy.
Topics: Angiogenesis Inhibitors; Hemorrhage; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2017 |
Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.
Topics: Animals; Carcinoma, Renal Cell; Coculture Techniques; Drug Resistance, Neoplasm; Endothelial Cells; Fibroblasts; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; MAP Kinase Signaling System; Mice; Paracrine Communication; Pyrroles; Receptors, Fibroblast Growth Factor; Sunitinib; Tumor Cells, Cultured | 2016 |
5-Hydroxy-7-azaindolin-2-one, a novel hybrid of pyridinol and sunitinib: design, synthesis and cytotoxicity against cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Down-Regulation; Drug Design; Humans; Indoles; Protein Transport; Pyridines; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Tumor Suppressor Protein p53 | 2016 |
Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report.
Topics: Adult; Antineoplastic Agents; Cetuximab; ErbB Receptors; Esthesioneuroblastoma, Olfactory; Genotyping Techniques; Humans; Indoles; Magnetic Resonance Imaging; Male; Mutation; Nasal Cavity; Neoplasm Recurrence, Local; Nose Neoplasms; Precision Medicine; Proto-Oncogene Proteins c-ret; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Kidney cancer: Exosome transmission of sunitinib resistance.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Exosomes; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2016 |
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Genotype; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Registries; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2016 |
Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Drug Dosage Calculations; Drug Synergism; Erlotinib Hydrochloride; Female; Indoles; Lung Neoplasms; Mice; Mice, Nude; Models, Biological; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retreatment; Retrospective Studies; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Comorbidity; Diabetes Mellitus; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Metformin; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2016 |
Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia.
Topics: Animals; Benzylamines; Biomarkers; Cachexia; Chemokine CXCL12; Cyclams; Cytokines; Disease Models, Animal; Female; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Indoles; Male; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; Muscular Atrophy; Neoplasms; Pyrroles; Rats; Receptors, CXCR4; Signal Transduction; Sunitinib | 2016 |
[Dosing Schedules and Outcomes in Patients Treated with First-Line Sunitinib for Advanced Renal Cell Carcinoma].
Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2016 |
Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
Topics: Adaptive Immunity; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Oncolytic Virotherapy; Oncolytic Viruses; Pyrroles; Reoviridae; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States.
Topics: Aged; Carcinoma, Renal Cell; Drug Prescriptions; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; United States | 2016 |
Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Sunitinib; Thymoma; Thymus Neoplasms; Treatment Outcome; Young Adult | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden | 2016 |
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Immunoglobulin Fc Fragments; Indazoles; Indoles; Kidney Neoplasms; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Hypothyroidism and Thyroid Autoimmunity as a Prognostic Biomarker of Better Response in Metastatic Cancer Long-Term Survivors Treated with Sunitinib.
Topics: Aged; Antineoplastic Agents; Biomarkers; Female; Humans; Hypothyroidism; Immunoenzyme Techniques; Indoles; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrroles; Sunitinib; Survivors; Thyroid Neoplasms; Thyroiditis, Autoimmune; Treatment Outcome | 2016 |
Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Prescriptions; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Molecular Targeted Therapy; Netherlands; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Avoidance Learning; Body Temperature; Body Weight; Cognition Disorders; Disease Models, Animal; Female; Indoles; Locomotion; Maze Learning; Mice; Nerve Degeneration; Prepulse Inhibition; Pyrroles; RNA, Messenger; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Young Adult | 2016 |
Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Renal Cell; CD28 Antigens; Chemotherapy, Adjuvant; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Proteins; Nephrectomy; Preoperative Period; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; V-Set Domain-Containing T-Cell Activation Inhibitor 1; Vascular Endothelial Growth Factor A; Young Adult | 2016 |
Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Computer Simulation; Disease Progression; Dose-Response Relationship, Drug; Drug Monitoring; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Models, Biological; Monte Carlo Method; Pyrroles; Sunitinib; Time Factors; Treatment Outcome | 2016 |
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
Topics: Adenine; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cellular Microenvironment; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Imaging, Three-Dimensional; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Quinazolinones; Reproducibility of Results; Signal Transduction; Stromal Cells; Sulfonamides; Sunitinib; Up-Regulation | 2016 |
Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Autophagy; Drug Resistance, Neoplasm; Female; Humans; Indoles; Male; Pyrroles; Solitary Fibrous Tumors; Sunitinib; Transcriptome | 2016 |
Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Exome Sequencing; Female; Fumarate Hydratase; GRB2 Adaptor Protein; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
Re: Nizar M. Tannir, Eric Jonasch, Laurence Albiges, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN):A Randomized Multicenter Phase 2 Trial. Eur Urol 2016;69:866-74.
Topics: Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Prospective Studies; Pyrroles; Sunitinib | 2017 |
Metastatic Renal Cell Carcinoma Presenting as Painful Chewing Successfully Treated with Combined Nivolumab and Sunitinib.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Mastication; Neoplasm Metastasis; Nivolumab; Pain; Pyrroles; Sunitinib; Treatment Outcome; United States | 2016 |
Novel therapeutic approaches and mechanisms in neuroendocrine tumors: the role of targeted agents.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Grading; Neovascularization, Pathologic; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Signal Transduction; Somatostatin; Sunitinib; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2016 |
Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Thyroid Neoplasms; Treatment Outcome | 2016 |
Synergistic inhibition of sunitinib and ethaselen against human colorectal cancer cells proliferation.
Topics: Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Humans; Indoles; Inhibitory Concentration 50; Mitochondria; Organoselenium Compounds; Phosphorylation; Pyrroles; Sunitinib; Thioredoxin-Disulfide Reductase; Thioredoxins; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Indoles; Mice; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2016 |
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2016 |
Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; CD11b Antigen; CD40 Antigens; Cell Line, Tumor; Dendritic Cells; Drug Synergism; Endothelial Cells; Fibrosarcoma; Indoles; Intercellular Adhesion Molecule-1; Kaplan-Meier Estimate; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Pyrroles; Sunitinib; T-Lymphocytes, Cytotoxic; Up-Regulation; Vascular Cell Adhesion Molecule-1 | 2016 |
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Cycle Proteins; Class Ia Phosphatidylinositol 3-Kinase; Class Ib Phosphatidylinositol 3-Kinase; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoproteins; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Retrospective Studies; Ribosomal Protein S6 Kinases, 70-kDa; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2017 |
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib | 2016 |
Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
A Case of Severe Acute Cardiac Failure on Sunitinib After Left-Sided Thoracal Radiation Therapy.
Topics: Female; Heart Failure; Humans; Hypokinesia; Indoles; Middle Aged; Pyrroles; Sunitinib; Triple Negative Breast Neoplasms | 2017 |
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Cohort Studies; Computer Communication Networks; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.
Topics: Animals; Bleomycin; Bronchi; Cell Proliferation; Disease Models, Animal; Epithelial Cells; Extracellular Matrix; Female; Fibroblasts; Humans; Indoles; Mesoderm; Mice; Mice, Inbred C57BL; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrroles; Signal Transduction; Smad Proteins; Small Molecule Libraries; Sunitinib; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2016 |
Inhibition of VEGF mediated post receptor signalling pathways by recently developed tyrosine kinase inhibitor in comparison with sunitinib.
Topics: Angiogenesis Inhibitors; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Indoles; MAP Kinase Signaling System; Neovascularization, Physiologic; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2016 |
Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Developing Countries; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Prospective Studies; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; White People; Young Adult | 2016 |
Paratesticular Metastasis of a Clear-Cell Renal-Cell Carcinoma With Renal Vein Thrombus Mimicking Primary Testicular Cancer.
Topics: Carcinoma, Renal Cell; Diagnosis, Differential; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Orchiectomy; Pyrroles; Sunitinib; Testicular Neoplasms; Thrombectomy; Treatment Outcome; Venous Thrombosis | 2017 |
Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.
Topics: Animals; Cell Movement; Female; Indoles; Leukocytes; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Transendothelial and Transepithelial Migration | 2016 |
Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cohort Studies; Female; Health Care Costs; Humans; Indazoles; Indoles; Male; Middle Aged; Prescription Fees; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult | 2016 |
Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Indoles; Kidney Neoplasms; Male; Metformin; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadherins; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Diphosphates; Epithelial-Mesenchymal Transition; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, Inbred CBA; Protein Kinase Inhibitors; Pyrroles; Stilbenes; Sunitinib; Vimentin; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Logistic Models; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Time Factors | 2016 |
Efficiency of Sunitinib in Chinese Patients with Advanced Progressive Pancreatic Neuroendocrine Tumor.
Topics: Antineoplastic Agents; Disease-Free Survival; Humans; Indoles; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2016 |
Sunitinib-induced sudden hearing loss.
Topics: Clinical Trials, Phase II as Topic; Female; Hearing Loss, Sudden; Humans; Indoles; Middle Aged; Neuroendocrine Tumors; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Tinnitus; Vertigo | 2016 |
The immunomodulatory, antitumor and antimetastatic responses of melanoma-bearing normal and alcoholic mice to sunitinib and ALT-803: a combinatorial treatment approach.
Topics: Alcoholism; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Female; Indoles; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Proteins; Pyrroles; Recombinant Fusion Proteins; Sunitinib; T-Lymphocytes, Regulatory | 2016 |
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Renal Cell; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indoles; MicroRNAs; Pyrroles; RNA, Small Interfering; Sunitinib; Transcriptome; Treatment Failure; Ubiquitin-Protein Ligases | 2016 |
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib | 2016 |
Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Prospective Studies; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Sunitinib; Tissue Array Analysis; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Sunitinib DDI with paracetamol, diclofenac, mefenamic acid and ibuprofen shows sex-divergent effects on the tissue uptake and distribution pattern of sunitinib in mice.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrier Proteins; Diclofenac; Drug Interactions; Female; Ibuprofen; Indoles; Male; Mefenamic Acid; Mice; Mice, Inbred ICR; Pyrroles; Sex Characteristics; Sunitinib; Tissue Distribution | 2016 |
Fluorescent molecularly imprinted nanogels for the detection of anticancer drugs in human plasma.
Topics: Antineoplastic Agents; Blood Chemical Analysis; Drug Monitoring; Indoles; Molecular Imprinting; Nanogels; Polyethylene Glycols; Polyethyleneimine; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Sunitinib | 2016 |
Development of a blood-brain barrier model in a membrane-based microchip for characterization of drug permeability and cytotoxicity for drug screening.
Topics: Blood-Brain Barrier; Brain; Cell Survival; Cells, Cultured; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Indoles; Microchip Analytical Procedures; Microfluidic Analytical Techniques; Models, Biological; Permeability; Pyrroles; Sunitinib | 2016 |
Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Indoles; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Salvage Therapy; Sunitinib; Treatment Outcome; Ulcer | 2016 |
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Renal Cell; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Random Allocation; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Utilization of Sunitinib for Renal Cell Cancer: an Egyptian University hospital experience.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Papillary; Carcinoma, Renal Cell; Egypt; Female; Follow-Up Studies; Hospitals, University; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Young Adult | 2016 |
Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer - A new potential biomarker?
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cholesterol; Ferritins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Indazoles; Indoles; Iron; Kidney Neoplasms; Lipids; Metabolome; Models, Theoretical; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Triglycerides | 2016 |
In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Indoles; Microscopy, Electron, Transmission; Nanoparticles; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2016 |
Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Topics: Adoptive Transfer; Animals; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cytotoxicity, Immunologic; Disease Models, Animal; Enzyme Inhibitors; Histocompatibility Antigens Class II; Immune Tolerance; Immunotherapy; Indoles; Liver Neoplasms; Mice; Neoplasm Staging; Programmed Cell Death 1 Receptor; Pyrroles; Sunitinib; T-Lymphocytes, Regulatory | 2017 |
Sunitinib uptake inhibits platelet function in cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Blood Coagulation; Blood Platelets; Carcinoma, Renal Cell; Case-Control Studies; Female; Healthy Volunteers; Hemorrhage; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Pyrroles; Signal Transduction; Sunitinib | 2016 |
Improvement in hereditary hemorrhagic telangiectasia after treatment with the multi-kinase inhibitor Sunitinib.
Topics: Aged; Follow-Up Studies; Humans; Indoles; Male; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Telangiectasia, Hereditary Hemorrhagic; Treatment Outcome | 2016 |
[Leg ulcers occurring under tyrosine kinase inhibitor therapy (sunitinib, nilotinib)].
Topics: Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Cholangiocarcinoma; Female; Humans; Indoles; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Pyrroles; Sunitinib; Withholding Treatment; Wound Healing | 2017 |
Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Czech Republic; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Registries; Retrospective Studies; Sunitinib; Time-to-Treatment | 2016 |
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Time Factors | 2017 |
Metachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent?
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Neoplasms, Second Primary; Pancreatic Neoplasms; Prognosis; Pyrroles; Sunitinib | 2016 |
Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Topics: Adrenomedullin; Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Kidney Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Prognosis; Pyrroles; Sunitinib; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Clinical and histopathological effects of presurgical treatment with sunitinib for renal cell carcinoma with inferior vena cava tumor thrombus at a single institution.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Preoperative Care; Pyrroles; Retrospective Studies; Sunitinib; Thrombosis; Vascular Neoplasms; Vena Cava, Inferior | 2016 |
MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
Topics: Adult; Animals; Benzamides; Carcinoma, Renal Cell; Cell Line, Tumor; Diphenylamine; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Myeloid-Derived Suppressor Cells; Neoplasm Proteins; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrroles; Receptors, Interleukin-2; Sunitinib; Tumor Burden; Tumor Escape; Xenograft Model Antitumor Assays | 2016 |
Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib | 2017 |
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Erythrocyte Indices; Erythrocytes; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2016 |
Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.
Topics: Angiogenesis Inhibitors; Animals; Female; Humans; Indoles; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Leukocytes, Mononuclear; Lymphocyte Count; Male; Middle Aged; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib | 2016 |
Targeting renal cell carcinoma with a HIF-2 antagonist.
Topics: Animals; Aryl Hydrocarbon Receptor Nuclear Translocator; Basic Helix-Loop-Helix Transcription Factors; Binding Sites; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Erythropoietin; Female; Gene Expression Regulation, Neoplastic; Humans; Indans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Mutation; Pyrroles; Reproducibility of Results; Sulfones; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Retreatment; Risk Factors; Sunitinib; Treatment Outcome | 2017 |
Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth.
Topics: Animals; Antineoplastic Agents; Autophagy; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chick Embryo; Chorioallantoic Membrane; Colonic Neoplasms; HT29 Cells; Humans; Indoles; Pulse Therapy, Drug; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; China; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Prognosis; Pyrroles; Retrospective Studies; Sarcoma, Alveolar Soft Part; Sunitinib; Survival Rate; Young Adult | 2016 |
[Complete response to tyrosine kinase inhibitors in metastatic renal cancer. Report of four cases].
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Sunitinib | 2016 |
Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Tumor Burden | 2017 |
In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT‑116 xenograft model in nude mice.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; HCT116 Cells; Humans; Indoles; Mice; Neovascularization, Pathologic; Peptides; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Regression Analysis; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
Sunitinib-associated Pancreatic Atrophy in Patients with Gastrointestinal Stromal Tumor: A Toxicity with Prognostic Implications Detected at Imaging.
Topics: Adult; Aged; Antineoplastic Agents; Atrophy; Case-Control Studies; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Pancreas; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed | 2016 |
[Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma].
Topics: Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Female; Humans; Indoles; Iodine; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
Topics: A549 Cells; Animals; Bone Neoplasms; Cell Differentiation; Cell Proliferation; Crizotinib; Disease Models, Animal; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoclasts; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrroles; Quinolines; RANK Ligand; Receptor, Macrophage Colony-Stimulating Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Thiourea; Tibia; Transplantation, Heterologous; X-Ray Microtomography | 2016 |
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; DNA-Binding Proteins; Everolimus; Female; Histone Demethylases; Histone-Lysine N-Methyltransferase; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Mutation; Nuclear Proteins; Prognosis; Proportional Hazards Models; PTEN Phosphohydrolase; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Von Hippel-Lindau Tumor Suppressor Protein; Young Adult | 2017 |
Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS.
Topics: Antineoplastic Agents; DNA Mutational Analysis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Outcome Assessment, Health Care; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Reproducibility of Results; Sunitinib | 2016 |
Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Rate | 2017 |
Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Erythrocyte Indices; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Computed tomography features and predictive findings of ruptured gastrointestinal stromal tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hematoma; Hemoperitoneum; Humans; Imatinib Mesylate; Indoles; Intestine, Small; Male; Middle Aged; Necrosis; Peritonitis; Pyrroles; Rupture, Spontaneous; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Young Adult | 2017 |
Sunitinib as adjuvant therapy for renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Sunitinib; Treatment Outcome | 2016 |
Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors.
Topics: Apoptosis; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Indazoles; Indoles; Oncogenes; Pyrimidines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Rhabdoid Tumor; Sulfonamides; Sunitinib | 2016 |
[Efficacy and the multivariate analysis of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2016 |
FoxO3a is Essential for the Antiproliferative and Apoptogenic Effects of Sunitinib in MDA-MB231 Cell Line.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Forkhead Box Protein O3; Gene Silencing; Humans; Indoles; Oxidative Stress; Pyrroles; Sunitinib | 2016 |
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2017 |
The Complete Response to Targeted Drugs Without Surgery or Radiotherapy: A Case of Pituitary Metastasis From Renal Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Diabetes Insipidus; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Pyrroles; Sunitinib | 2016 |
Gene expression profile of renal cell carcinomas after neoadjuvant treatment with sunitinib: new pathways revealed.
Topics: Adult; Aged; Carcinoma, Renal Cell; Chemokine CCL20; Chemokine CXCL6; DNA Methylation; Female; Fibrinogen; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indoles; Insulin-Like Growth Factor Binding Protein 1; Male; Middle Aged; Neoadjuvant Therapy; Pyrroles; Signal Transduction; Sunitinib; Transcriptome | 2017 |
Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Differentiation; Everolimus; Female; Humans; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases | 2017 |
Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Cycle Proteins; Cell Line, Tumor; Disease-Free Survival; Everolimus; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphoproteins; Protein Kinase Inhibitors; Pyrroles; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy.
Topics: Animals; Cell Differentiation; Cell Proliferation; Cells, Cultured; Enzyme Inhibitors; Gene Expression; Homeodomain Proteins; Humans; Indoles; Mice; Muscles; Muscular Dystrophy, Facioscapulohumeral; Myoblasts; Proto-Oncogene Proteins c-ret; Pyrroles; Satellite Cells, Skeletal Muscle; Sunitinib | 2016 |
Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Cell Proliferation; Cells, Cultured; Down-Regulation; Endothelial Cells; Female; Humans; Hydrogen-Ion Concentration; Indoles; Mice; Mice, Inbred C57BL; Pyrroles; Sodium Bicarbonate; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Topics: Angiogenesis Inhibitors; Capillaries; Humans; Immunotherapy; Indoles; Lung Neoplasms; Models, Biological; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2017 |
Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium Channel Blockers; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2017 |
Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment.
Topics: Animals; Antineoplastic Agents; Calcium Phosphates; Cancer Vaccines; Cell Line, Tumor; Cell Survival; Cytokines; Female; Immunotherapy, Active; Indoles; Melanoma; Membrane Proteins; Mice, Inbred C57BL; Micelles; Oligodeoxyribonucleotides; Peptide Fragments; Polymers; Proto-Oncogene Proteins c-akt; Pyrroles; STAT3 Transcription Factor; Sunitinib; Tumor Burden; Tumor Microenvironment | 2017 |
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib | 2017 |
Dual modulation of MCL-1 and mTOR determines the response to sunitinib.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Stability; Glycogen Synthase Kinase 3 beta; Humans; Indoles; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred NOD; Mice, Nude; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Demography; Disease Progression; Female; Gastrointestinal Stromal Tumors; Genetic Association Studies; Genetic Predisposition to Disease; Haplotypes; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Time Factors; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2017 |
A novel PDGF receptor inhibitor-eluting stent attenuates in-stent neointima formation in a rabbit carotid model.
Topics: Angiogenesis Inhibitors; Animals; Carotid Arteries; Cell Movement; Cell Proliferation; Cells, Cultured; Drug-Eluting Stents; Endothelial Cells; Indoles; Male; Myocytes, Smooth Muscle; Neointima; Phosphorylation; Pyrroles; Rabbits; Receptors, Platelet-Derived Growth Factor; Stents; Sunitinib; Tunica Intima | 2017 |
Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneity.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Genetic Heterogeneity; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pharmacogenomic Testing; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Sunitinib | 2016 |
Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indoles; Kidney Neoplasms; Lymphocyte Count; Mice; Mice, Inbred BALB C; Myeloid-Derived Suppressor Cells; Neoplasm Transplantation; Pyrroles; STAT3 Transcription Factor; Sunitinib; T-Lymphocytes, Regulatory | 2017 |
[Changes of diagnosis and treatment for gastrointestinal stromal tumors during a 18-year period in four medical centers of China].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Combined Modality Therapy; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2016 |
Synthesis and Antitumor Activity of 5-Bromo-7-azaindolin-2-one Derivatives Containing a 2,4-Dimethyl-1H-pyrrole-3-carboxamide Moiety.
Topics: A549 Cells; Antineoplastic Agents; Aza Compounds; Cell Survival; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Indoles; Pyrroles; Sunitinib | 2016 |
ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
Topics: Activating Transcription Factor 4; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Animals; Apoptosis; Blotting, Western; Carcinoma, Neuroendocrine; Cell Proliferation; Cell Survival; Female; Genes, Tumor Suppressor; HEK293 Cells; Humans; Immunohistochemistry; Indoles; Kaplan-Meier Estimate; Male; Mice; Mice, Knockout; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Real-Time Polymerase Chain Reaction; Sunitinib; Thyroid Gland; Thyroid Neoplasms; Ubiquitination; Young Adult | 2017 |
Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Stomach Neoplasms; Sunitinib | 2017 |
Targeted drug delivery of Sunitinib Malate to tumor blood vessels by cRGD-chiotosan-gold nanoparticles.
Topics: Cell Survival; Cells, Cultured; Chitosan; Drug Carriers; Drug Liberation; Gold; Humans; Indoles; Nanoparticles; Neoplasms; Particle Size; Peptides, Cyclic; Pyrroles; Sunitinib; Surface Properties | 2017 |
Design, synthesis and cytotoxic activities of scopoletin-isoxazole and scopoletin-pyrazole hybrids.
Topics: Antineoplastic Agents; Cell Line, Tumor; Humans; Indoles; Isoxazoles; Pyrazoles; Pyrroles; Scopoletin; Sunitinib | 2017 |
Gastrointestinal stromal tumours (GISTs): A descriptive study on 29 cases.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Stomach Neoplasms; Sunitinib; Survival Rate; Tumor Burden; Weight Loss | 2016 |
Treatment of metastatic pancreatic neuroendocrine tumors: relevance of ENETS 2016 guidelines.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Everolimus; Female; Guidelines as Topic; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Pyrroles; Retrospective Studies; Societies, Medical; Sunitinib; Young Adult | 2017 |
Pharmacokinetic-Pharmacodynamic Modeling of the Anti-Tumor Effect of Sunitinib Combined with Dopamine in the Human Non-Small Cell Lung Cancer Xenograft.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dopamine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Indoles; Lung Neoplasms; Mice; Mice, Nude; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2017 |
Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Europe; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Practice Guidelines as Topic; Pyrroles; Societies, Medical; Sunitinib; Urology | 2017 |
Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting the α
Topics: Angiogenesis Inhibitors; Animals; Cell Line; Humans; Indoles; Integrin alphaVbeta3; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Oligopeptides; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib.
Topics: Adenine; Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Line; Dendritic Cells; Female; Immunotherapy; Indoles; Lapatinib; Lymphocytes; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Spleen; Succinates; Sunitinib; Toll-Like Receptor 7 | 2016 |
A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antigens, Neoplasm; Becaplermin; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Cyclin D1; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Proto-Oncogene Proteins c-sis; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors.
Topics: Angiogenesis Inhibitors; Animals; Aquaporin 1; Breast Neoplasms; Carrier Proteins; Cell Movement; Cytokines; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Indoles; Luminescent Measurements; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Pyrroles; Real-Time Polymerase Chain Reaction; Sunitinib | 2017 |
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neurosurgical Procedures; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Elongin; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kidney Neoplasms; Mutation, Missense; Protein Binding; Protein Interaction Domains and Motifs; Proteolysis; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Signal Transduction; Sunitinib; Transfection; Tumor Suppressor Protein p53; Von Hippel-Lindau Tumor Suppressor Protein | 2017 |
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Interactions; Drug Synergism; Glioblastoma; Heterografts; Humans; Indoles; Mice; Pyrroles; Receptors, CXCR4; Sunitinib | 2017 |
Mixed Results for Sunitinib in Renal Cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
Sunitinib-paracetamol sex-divergent pharmacokinetics and tissue distribution drug-drug interaction in mice.
Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Angiogenesis Inhibitors; Animals; Area Under Curve; Brain; Drug Interactions; Female; Indoles; Kidney; Liver; Male; Mice, Inbred ICR; Protein Kinase Inhibitors; Pyrroles; Sex Characteristics; Sunitinib | 2017 |
Sunitinib tolerance and efficacy in patients with metastatic renal cell carcinoma according to ethnic and geographic factors.
Topics: Carcinoma, Renal Cell; Developing Countries; Geography; Humans; Kidney Neoplasms; Pyrroles; Sunitinib | 2017 |
Metastatic renal clear cell carcinoma to the rectum, lungs, ilium, and lymph nodes: A case report.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Humans; Ilium; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Nephrectomy; Pyrroles; Rectal Neoplasms; Sunitinib | 2017 |
Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk; Risk Assessment; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2017 |
Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Commentary on: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2017 |
Adjuvant sunitinib in renal cell carcinoma: from evidence to recommendation.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2017 |
The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration.
Topics: Acyltransferases; Animals; Antineoplastic Agents; Autophagy; Cognitive Dysfunction; Cyclin-Dependent Kinase 5; Disease Models, Animal; Disease Progression; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Indoles; Mice; Mice, Transgenic; Microtubule-Associated Proteins; Neurons; Pyrroles; Sequestosome-1 Protein; Signal Transduction; Sunitinib; tat Gene Products, Human Immunodeficiency Virus; Transgenes | 2017 |
Re: James J. Hsieh, David Chen, Patricia I. Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14.
Topics: Biomarkers; Carcinoma, Renal Cell; Everolimus; Genomics; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2017 |
Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Mutation; Neoplasm Metastasis; Postoperative Complications; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Car
Topics: Biomarkers; Carcinoma, Renal Cell; Everolimus; Genomics; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2017 |
CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Pyrroles; Radiographic Image Enhancement; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Renal Cell; Cyclooxygenase 2; Disease-Free Survival; Female; Gene Frequency; Genetic Association Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Genetic; Multivariate Analysis; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Treatment Outcome | 2017 |
The Role of Vascular Endothelial Growth Factor in Small-airway Remodelling in a Rat Model of Chronic Obstructive Pulmonary Disease.
Topics: Airway Remodeling; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Indoles; Lipopolysaccharides; Male; Neovascularization, Pathologic; Nicotiana; Pulmonary Disease, Chronic Obstructive; Pyrroles; Rats, Sprague-Dawley; Smoke; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; N-Acetylgalactosaminyltransferases; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polypeptide N-acetylgalactosaminyltransferase; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2017 |
Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments.
Topics: Antineoplastic Agents; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Severity of Illness Index; Sunitinib; Treatment Outcome | 2017 |
A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.
Topics: Animals; Fluorodeoxyglucose F18; Heart; Humans; Indoles; Male; Metabolic Networks and Pathways; Myocardium; Positron-Emission Tomography; Proteomics; Pyrroles; Rats; Rats, Sprague-Dawley; Sunitinib; Ventricular Function, Left | 2017 |
Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Observer Variation; Phenylurea Compounds; Pyrroles; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; SEER Program; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2017 |
Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma after Nephrectomy.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib | 2017 |
Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors.
Topics: Female; Humans; Hypertension; Indoles; Male; Neoplasms; Neovascularization, Pathologic; Nitric Oxide Donors; Pyrroles; Sunitinib | 2015 |
Intermittent sunitinib for metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Prognosis; Pyrroles; Sunitinib | 2017 |
Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.
Topics: Cohort Studies; Female; Humans; Hypertension; Hypothyroidism; Indoles; Male; Middle Aged; Niacinamide; Pharmacoepidemiology; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2017 |
Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Topics: Aminoacetonitrile; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Humans; Indoles; Mice, Nude; Pyrroles; Sunitinib; Taxoids; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2017 |
Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Cluster Analysis; Cytokines; Disease Progression; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Prognosis; Pyrroles; Sunitinib; Treatment Outcome | 2017 |
Synthesis of sericin-based conjugates by click chemistry: enhancement of sunitinib bioavailability and cell membrane permeation.
Topics: Antineoplastic Agents; Biological Availability; Cell Membrane Permeability; Cell Survival; Click Chemistry; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Female; HeLa Cells; Humans; Indoles; Inhibitory Concentration 50; Protein Kinase Inhibitors; Pyrroles; Sericins; Solubility; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Sunitinib; Technology, Pharmaceutical; Uterine Cervical Neoplasms | 2017 |
Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Family Health; Female; Germ-Line Mutation; Heterozygote; Humans; Indoles; Infant, Newborn; Male; Molecular Targeted Therapy; Myofibromatosis; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sunitinib; Treatment Outcome; Vinblastine | 2017 |
Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma.
Topics: Adenocarcinoma, Clear Cell; Aminoquinolines; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; Indoles; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyamines; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2017 |
Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prealbumin; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Serum Albumin, Human; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease-Free Survival; Humans; Indazoles; Indoles; Italy; Kidney Neoplasms; National Health Programs; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Analysis | 2017 |
MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Renal Cell; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Immunoenzyme Techniques; Indoles; Kidney Neoplasms; Mucins; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Tumor Cells, Cultured | 2017 |
Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Costs; Drug Dosage Calculations; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2017 |
Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Disease-Free Survival; Head and Neck Neoplasms; Humans; Immunohistochemistry; Indoles; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Radiation-Sensitizing Agents; Risk Assessment; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Sunitinib | 2017 |
Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
Topics: Adult; Antineoplastic Agents; Female; Humans; Indoles; Intestinal Neoplasms; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Stomach Neoplasms; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome; Up-Regulation | 2017 |
Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects.
Topics: Adaptor Protein Complex 1; Adaptor Protein Complex 2; Animals; Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Dengue; Dengue Virus; Drug Evaluation, Preclinical; Drug Synergism; Ebolavirus; Erlotinib Hydrochloride; Female; Hemorrhagic Fever, Ebola; Hepacivirus; Hepatitis C; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Male; Mice, 129 Strain; Mice, Inbred C57BL; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Pyrroles; Sunitinib; Virus Internalization | 2017 |
Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy.
Topics: Antibodies, Monoclonal, Humanized; Aspergillosis, Allergic Bronchopulmonary; Carcinoma, Renal Cell; Humans; Immunocompromised Host; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Programmed Cell Death 1 Receptor; Pyrroles; Sunitinib | 2017 |
Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Receptors, Cell Surface; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
[Knockdown of ATG5 enhances the sensitivity of human renal carcinoma cells to sunitinib].
Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Carcinoma, Renal Cell; Cell Line, Tumor; Gene Knockout Techniques; Humans; Indoles; Pyrroles; Sunitinib | 2017 |
Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Antigens, CD; Breast; Cadherins; Cell Line, Tumor; Female; Fluorescent Antibody Technique; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Nuclear Proteins; Pyrroles; Sunitinib; Tissue Array Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Twist-Related Protein 1; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Brain; Diclofenac; Drug Interactions; Female; Indoles; Kidney; Liver; Male; Mice, Inbred ICR; Protein Kinase Inhibitors; Pyrroles; Sex Characteristics; Sunitinib; Tissue Distribution | 2017 |
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma.
Topics: Adult; Aged; Bone Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sarcoma, Alveolar Soft Part; Sunitinib | 2017 |
Patient-specific blood pressure correction technique for arterial stiffness: evaluation in a cohort on anti-angiogenic medication.
Topics: Adult; Aged; Algorithms; Angiogenesis Inhibitors; Blood Pressure; Carotid Arteries; Cohort Studies; Cross-Sectional Studies; Female; Humans; Indoles; Male; Manometry; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pulse Wave Analysis; Pyrroles; Sorafenib; Sunitinib; Vascular Stiffness | 2017 |
Salt Sensitivity of Angiogenesis Inhibition-Induced Blood Pressure Rise: Role of Interstitial Sodium Accumulation?
Topics: Animals; Blood Pressure; Hypertension; Indoles; Lymphangiogenesis; Male; Pyrroles; Rats; Rats, Inbred WKY; Skin; Sodium, Dietary; Sunitinib | 2017 |
Gastrointestinal stromal tumor of the stomach with axillary lymph node metastasis: A case report.
Topics: Aged; Axilla; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Metastasis; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Pyrroles; Stomach Neoplasms; Sunitinib; Tomography, X-Ray Computed | 2017 |
Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages.
Topics: Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Renal Cell; Cell Movement; Cell Survival; HEK293 Cells; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Structure-Activity Relationship; Sunitinib; Tumor Cells, Cultured | 2017 |
Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2017 |
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sunitinib | 2017 |
LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cholesterol; Cholesterol, LDL; Drug Interactions; Elafin; Endothelial Cells; Female; Humans; Indoles; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sunitinib; Xenograft Model Antitumor Assays | 2017 |
Comprehensive insight into the binding of sunitinib, a multi-targeted anticancer drug to human serum albumin.
Topics: Antineoplastic Agents; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Indoles; Molecular Docking Simulation; Protein Binding; Pyrroles; Serum Albumin, Human; Spectrometry, Fluorescence; Sunitinib; Thermodynamics | 2017 |
Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2 with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Analysis in Japanese Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Renal Cell; Female; Follow-Up Studies; Genetic Association Studies; Humans; Indoles; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies; STAT3 Transcription Factor; Stomatitis; Sunitinib | 2017 |
In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma-A pilot study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug-Eluting Stents; Humans; In Vitro Techniques; Indoles; Liver Neoplasms; Pyrroles; Sunitinib | 2017 |
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Young Adult | 2017 |
Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Tertiary Care Centers; Treatment Outcome; Young Adult | 2017 |
Tyrosine kinase-targeting drugs-associated heart failure.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Case-Control Studies; Cetuximab; Cohort Studies; Heart Failure; Humans; Incidence; Indoles; Israel; Middle Aged; Neoplasms; Odds Ratio; Panitumumab; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sunitinib; Trastuzumab | 2017 |
Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasms, Experimental; Oxindoles; Pyrroles; Sunitinib; Tumor Burden; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2017 |
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Indoles; Kaplan-Meier Estimate; Male; MicroRNAs; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Pyrroles; Retrospective Studies; ROC Curve; Signal Transduction; Sunitinib | 2017 |
Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2018 |
Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Treatment Outcome; Tumor Burden | 2017 |
Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI-H460 cells by repressing MAP kinase pathways and inflammatory mediators.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Berberine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Indoles; Inflammation Mediators; Lung Neoplasms; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Pyrroles; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Sunitinib specifically augments glucose-induced insulin secretion.
Topics: Aniline Compounds; Animals; Cell Line; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Extracellular Signal-Regulated MAP Kinases; Glucose; Indoles; Insulin; Insulin Secretion; Insulin-Like Growth Factor I; Isoquinolines; Phenylpropionates; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Rats; Signal Transduction; Sulfonamides; Sunitinib | 2017 |
Sunitinib Induces NK-κB-dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Carcinoma, Hepatocellular; Coculture Techniques; Combined Modality Therapy; Cytotoxicity, Immunologic; Gene Expression; Hep G2 Cells; Humans; Immunologic Surveillance; Immunotherapy, Adoptive; Indoles; Killer Cells, Natural; Ligands; Liver Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; NF-kappa B; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Pyrroles; RNA, Small Interfering; Signal Transduction; Sunitinib | 2017 |
Potential Sunitinib-Induced Coronary Artery and Aortic Dissections.
Topics: Antineoplastic Agents; Aortic Aneurysm, Thoracic; Aortic Dissection; Computed Tomography Angiography; Coronary Aneurysm; Coronary Angiography; Female; Humans; Indoles; Intestinal Neoplasms; Middle Aged; Pyrroles; Sunitinib | 2017 |
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chordoma; Erlotinib Hydrochloride; Female; France; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Skull Base Neoplasms; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2017 |
PDGF-BB/KLF4/VEGF Signaling Axis in Pulmonary Artery Endothelial Cell Angiogenesis.
Topics: Animals; Becaplermin; Cell Hypoxia; Cell Movement; Cell Proliferation; Endothelial Cells; G1 Phase Cell Cycle Checkpoints; Imatinib Mesylate; Indoles; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lung; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; RNA Interference; Signal Transduction; Sunitinib; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Remodeling | 2017 |
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chromatography, High Pressure Liquid; Drug Monitoring; Feasibility Studies; Female; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Tandem Mass Spectrometry; Treatment Outcome; Young Adult | 2017 |
Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cost of Illness; Cost-Benefit Analysis; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Netherlands; Pyrroles; Quality-Adjusted Life Years; Registries; Regression Analysis; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Insulin-like growth factor-1 signaling is responsible for cathepsin G-induced aggregation of breast cancer MCF-7 cells.
Topics: Autocrine Communication; Axitinib; Breast Neoplasms; Cathepsin G; Cell Aggregation; Female; Humans; Imidazoles; Indazoles; Indoles; Insulin-Like Growth Factor I; MCF-7 Cells; Phosphorylation; Pyrazines; Pyrroles; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Small Molecule Libraries; Sunitinib | 2017 |
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Renal Cell; Female; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indoles; Male; Middle Aged; Prognosis; Proto-Oncogene Proteins c-met; Pyrroles; Sunitinib | 2017 |
Identification of MicroRNAs Involved in Resistance to Sunitinib in Renal Cell Carcinoma Cells.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; MicroRNAs; Pyrroles; Sunitinib | 2017 |
Synthesis and Evaluation of Novel 2-Pyrrolidone-Fused (2-Oxoindolin-3-ylidene)methylpyrrole Derivatives as Potential Multi-Target Tyrosine Kinase Receptor Inhibitors.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gene Expression; HCT116 Cells; Humans; Indoles; Molecular Docking Simulation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Structure, Secondary; Pyrroles; Pyrrolidinones; Receptor, Platelet-Derived Growth Factor beta; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Collagen; Drug Screening Assays, Antitumor; Drug Synergism; Female; Hepatoblastoma; Humans; Indoles; Infant; Inhibitory Concentration 50; Irinotecan; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Recurrence; Sorafenib; Sunitinib | 2017 |
Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Contrast Media; Dextrans; Drug Resistance, Neoplasm; Female; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, SCID; Microscopy, Fluorescence; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2017 |
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
Topics: Aged; Antineoplastic Agents; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2017 |
HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Renal Cell; Carrier Proteins; Cell Line, Tumor; Cytokines; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Models, Biological; Protein Binding; Protein Kinase Inhibitors; Proteolysis; Pyrroles; Ribonucleoproteins, Small Nuclear; Sunitinib; Ubiquitination | 2017 |
Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Drug Administration Schedule; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Young Adult | 2017 |
Connexin 43 enhances Bax activation via JNK activation in sunitinib-induced apoptosis in mesothelioma cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Connexin 43; Connexins; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; Mesothelioma; Mitochondria; Phosphorylation; Pyrroles; Signal Transduction; Sunitinib | 2017 |
Pulmonary arterial hypertension due to an intratumoral shunt: an unexpected side effect of sunitinib.
Topics: Aged; Carcinoma, Renal Cell; Heart Failure; Humans; Hypertension, Pulmonary; Indoles; Liver Neoplasms; Male; Pyrroles; Sunitinib | 2017 |
Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Female; Humans; Indoles; Melanoma; Mice; Neovascularization, Pathologic; Peptide Fragments; Properdin; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Tumor Hypoxia; Xenograft Model Antitumor Assays | 2017 |
Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment.
Topics: Adipocytes; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis | 2017 |
Anticancer Efficacy of Self-Nanoemulsifying Drug Delivery System of Sunitinib Malate.
Topics: Antineoplastic Agents; Drug Delivery Systems; Drug Liberation; Emulsions; Excipients; HT29 Cells; Humans; Indoles; Nanoparticles; Pyrroles; Renal Dialysis; Solubility; Sunitinib; Surface-Active Agents; Suspensions | 2018 |
Hsp90 inhibitor geldanamycin attenuates the cytotoxicity of sunitinib in cardiomyocytes via inhibition of the autophagy pathway.
Topics: Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Autophagy-Related Protein-1 Homolog; Beclin-1; Benzoquinones; Cardiotoxicity; Cell Differentiation; Cell Line; Cell Lineage; Cytoprotection; Dose-Response Relationship, Drug; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Indoles; Induced Pluripotent Stem Cells; Lactams, Macrocyclic; Myocytes, Cardiac; Protein Kinase Inhibitors; Pyrroles; Rats; RNA Interference; Signal Transduction; Sunitinib; Transfection | 2017 |
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Markov Chains; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Rate; United Kingdom | 2017 |
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
Topics: Aged; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Female; Gastrointestinal Diseases; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Carcinoma, Renal Cell; Chemoradiotherapy, Adjuvant; Circulating Tumor DNA; Combined Modality Therapy; Humans; Indoles; Kidney; Kidney Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Nephrectomy; Programmed Cell Death 1 Receptor; Pyrroles; Radiosurgery; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Survival Rate; Time Factors | 2017 |
Mononuclear gold(III) complexes with phenanthroline ligands as efficient inhibitors of angiogenesis: A comparative study with auranofin and sunitinib.
Topics: A549 Cells; Angiogenesis Inhibitors; Animals; Auranofin; HeLa Cells; Humans; Indoles; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Molecular Docking Simulation; Phenanthrolines; Pyrroles; Sunitinib; Thioredoxin Reductase 1; Vascular Endothelial Growth Factor Receptor-2; Zebrafish | 2017 |
Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Caveolin 1; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Prognosis; Pyrroles; Sunitinib; Young Adult | 2017 |
Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Drug Substitution; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Sunitinib; Treatment Failure; Treatment Outcome | 2017 |
Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cost of Illness; Everolimus; Humans; Indoles; Middle Aged; Molecular Targeted Therapy; Nausea; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sunitinib; Thrombocytopenia; Vomiting; Young Adult | 2017 |
Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Angiogenic Proteins; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Inflammation Mediators; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; ROC Curve; Sunitinib; Treatment Outcome | 2017 |
Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China.
Topics: Adult; Aged; China; Female; Humans; Indoles; Male; Middle Aged; Neuroendocrine Tumors; Pyrroles; Retrospective Studies; Sunitinib; Young Adult | 2017 |
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Gene Knockdown Techniques; Humans; Indoles; Lysosomal-Associated Membrane Protein 2; Lysosomes; Mice; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2017 |
Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region.
Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Rural Population; Sulfonamides; Sunitinib | 2017 |
Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Databases, Factual; Disease-Free Survival; Everolimus; Female; France; Humans; Imidazoles; Indazoles; Indoles; Insurance, Health; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Indoles; Leiomyosarcoma; Life Support Care; Male; Mesna; Pyrroles; Sunitinib; Taxoids | 2017 |
Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Sunitinib induces genomic instability of renal carcinoma cells through affecting the interaction of LC3-II and PARP-1.
Topics: DNA Breaks, Double-Stranded; Genomic Instability; HEK293 Cells; HeLa Cells; Humans; Immunoprecipitation; Indoles; Microscopy, Fluorescence; Microtubule-Associated Proteins; Poly (ADP-Ribose) Polymerase-1; Protein Binding; Pyrroles; Sequestosome-1 Protein; Sunitinib | 2017 |
PDGF/VEGF-Related Receptor Affects Transglutaminase Activity to Control Cell Migration During Crustacean Hematopoiesis.
Topics: Animals; Astacoidea; Cell Movement; Cell Shape; Cells, Cultured; Evolution, Molecular; Hematopoiesis; Indoles; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sunitinib; Transglutaminases; Vascular Endothelial Growth Factor, Endocrine-Gland-Derived | 2017 |
Attenuation of Sunitinib-induced cardiotoxicity through the A3 adenosine receptor activation.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Cell Survival; Heart; Heart Rate; Hemodynamics; HL-60 Cells; Humans; Indoles; MicroRNAs; Protein Kinase C-alpha; Pyrroles; Receptor, Adenosine A3; Signal Transduction; Sunitinib; Ventricular Function, Left | 2017 |
Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism.
Topics: Anaerobiosis; Animals; Antineoplastic Agents; Endothelin Receptor Antagonists; Glycolysis; Indoles; Mice, Inbred C57BL; Myocardium; Proteome; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2017 |
Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Therapy, Combination; Everolimus; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Luminescent Measurements; Mice; Molecular Imaging; Molecular Targeted Therapy; Neovascularization, Pathologic; Platelet-Derived Growth Factor; Pyrroles; Signal Transduction; Stromal Cells; Sunitinib; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
Continuous remission of renal cell carcinoma with tumour thrombus after severe adverse events following short-term treatment with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pyrroles; Remission Induction; Sunitinib; Thrombosis; Vena Cava, Inferior | 2017 |
Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles; Sunitinib | 2017 |
Sunitinib Inhibits Breast Cancer Cell Proliferation by Inducing Apoptosis, Cell-cycle Arrest and DNA Repair While Inhibiting NF-κB Signaling Pathways.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; DNA Repair; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Indoles; NF-kappa B; Pyrroles; Sunitinib; Tumor Cells, Cultured | 2017 |
Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Cornea; Corneal Neovascularization; Indoles; Male; MicroRNAs; Pyrroles; Rats; Silver Nitrate; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
In vitro evaluation of sunitinib loaded bioresorbable microspheres for potential application in arterial chemoembolization.
Topics: Chemoembolization, Therapeutic; Drug Delivery Systems; Drug Liberation; Indoles; Microspheres; Pyrroles; Sunitinib | 2017 |
Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphocyte Count; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Neutrophils; Niacinamide; Nutritional Status; Phenylurea Compounds; Preoperative Period; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Young Adult | 2017 |
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Quality of Life; Retrospective Studies; Sunitinib | 2017 |
Cuprous oxide nanoparticles trigger ER stress-induced apoptosis by regulating copper trafficking and overcoming resistance to sunitinib therapy in renal cancer.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Copper; Endoplasmic Reticulum Stress; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Nanoparticles; Pyrroles; Sunitinib | 2017 |
A novel self-nanoemulsifying formulation for sunitinib: Evaluation of anticancer efficacy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Emulsions; Humans; Indoles; Male; MCF-7 Cells; Mice; Nanoparticles; Particle Size; Pyrroles; Rats, Sprague-Dawley; Sunitinib; Tissue Distribution | 2017 |
Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Incidence; Indoles; Male; Melanoma; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Assessment; Sunitinib; Survival Rate; Treatment Outcome; United States; Uveal Neoplasms; Young Adult | 2018 |
Antiangiogenic agent sunitinib induces epithelial to mesenchymal transition and accelerates motility of colorectal cancer cells.
Topics: Angiogenesis Inhibitors; Cell Movement; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; HCT116 Cells; Humans; Indoles; Neuropilin-1; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Transcriptome | 2017 |
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.
Topics: Aged; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Synergism; Female; Humans; Indoles; Irinotecan; Male; Mice; Mice, Nude; Pyrroles; Sunitinib; Thyroid Carcinoma, Anaplastic | 2017 |
Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2018 |
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
Topics: Animals; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred ICR; Mice, SCID; Neovascularization, Pathologic; Phosphorylation; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |
Jejunal Gastrointestinal Stromal Tumor.
Topics: Aged; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Jejunal Neoplasms; Jejunum; Male; Pyrroles; Sunitinib | 2017 |
Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Treatment Outcome | 2018 |
Repression of the Notch pathway prevents liver damage in streptozotocin-induced diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Down-Regulation; Immunohistochemistry; Indoles; Jagged-1 Protein; Liver; Liver Diseases; Male; Mice; Pyrroles; Receptor, Notch1; Signal Transduction; Sunitinib | 2017 |
Are We Ready for Adjuvant Sunitinib in High-risk Renal Cell Carcinoma?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2018 |
Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Recepto
Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Cells, Cultured; Dose-Response Relationship, Drug; Echocardiography; ErbB Receptors; Erlotinib Hydrochloride; Fatty Acids; Female; Gene Expression Profiling; Heart; Heart Diseases; Indoles; Mice; Molecular Targeted Therapy; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Protein Interaction Maps; Protein Kinase Inhibitors; Proteomics; Pyrroles; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Sunitinib; Time Factors | 2017 |
Circulating Cell-Free DNA Levels in Patients with Metastatic Renal Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Axitinib; Carcinoma, Renal Cell; Cell-Free Nucleic Acids; Combined Modality Therapy; Disease-Free Survival; Everolimus; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Predictive Value of Tests; Prospective Studies; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2017 |
Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
Topics: 3' Untranslated Regions; Animals; Antagomirs; Base Sequence; Carcinogenesis; Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Nude; MicroRNAs; Mutagenesis; Nuclear Proteins; Pyrroles; RNA Interference; RNA, Small Interfering; Sequence Alignment; Sunitinib; Transcription Factors; Transplantation, Heterologous; Up-Regulation | 2017 |
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Databases, Factual; Female; Health Expenditures; Humans; Indazoles; Indoles; Insurance Claim Review; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Medicare; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; United States | 2017 |
Identifying host regulators and inhibitors of liver stage malaria infection using kinase activity profiles.
Topics: Animals; Cell Line, Tumor; HEK293 Cells; Hepatocytes; Host-Parasite Interactions; Humans; Indoles; Liver; Malaria; Mice; Piperazines; Plasmodium yoelii; Protein Kinase Inhibitors; Protein Kinases; Purines; Pyrroles; RNA Interference; Roscovitine; Sporozoites; Sunitinib | 2017 |
Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pyrroles; Sunitinib; Transcriptome; Treatment Outcome | 2018 |
Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma.
Topics: Animals; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cell Line, Tumor; Everolimus; Heterografts; Humans; Indoles; Magnetic Resonance Imaging; Male; Mice; Molecular Imaging; Molecular Targeted Therapy; Pyrroles; Sunitinib; Treatment Outcome | 2017 |
Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Imatinib Mesylate; Indoles; Male; Monocrotaline; Nestin; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pulmonary Artery; Pyrroles; Rats, Wistar; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling | 2018 |
Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
Topics: Adolescent; Antineoplastic Agents; Child; Europe; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome; United States; Young Adult | 2017 |
Lingual metastasis as an initial presentation of renal cell carcinoma: a case report.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Tongue Neoplasms | 2017 |
Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib | 2017 |
Development and plasticity of meningeal lymphatic vessels.
Topics: Animals; Animals, Newborn; Biological Transport; Cerebrospinal Fluid; Dependovirus; Gene Deletion; Humans; Indoles; Injections, Intraventricular; Lymph Nodes; Lymphangiogenesis; Lymphatic Vessels; Male; Meninges; Mice, Inbred C57BL; Microspheres; Myocytes, Smooth Muscle; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Spinal Cord; Sunitinib; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor D; Vascular Endothelial Growth Factor Receptor-3 | 2017 |
Hydrophilic modified magnetic multi-walled carbon nanotube for dispersive solid/liquid phase microextraction of sunitinib in human samples.
Topics: Antineoplastic Agents; Hair; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Liquid Phase Microextraction; Magnetic Phenomena; Molecular Structure; Nails; Nanotubes, Carbon; Pyrroles; Solid Phase Microextraction; Sunitinib | 2018 |
Rational modification of semaxanib and sunitinib for developing a tumor growth inhibitor targeting ATP binding site of tyrosine kinase.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Indoles; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Structure-Activity Relationship; Sunitinib | 2018 |
Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Dasatinib; Denmark; Everolimus; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Pyrroles; Retrospective Studies; Sunitinib | 2018 |
Involvement of mitogen activated kinase kinase 7 intracellular signalling pathway in Sunitinib-induced cardiotoxicity.
Topics: Animals; Aporphines; Cardiotoxicity; Heart; HL-60 Cells; Humans; Indoles; Male; MAP Kinase Kinase 7; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Myocardial Infarction; Pyrroles; Quinolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sunitinib | 2018 |
Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Nivolumab; Probability; Prognosis; Proportional Hazards Models; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sex Factors; Sulfonamides; Sunitinib; Survival Rate; Thrombocytosis | 2018 |
[Sunitinib induces autophagy via suppressing Akt/mTOR pathway in renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Humans; Indoles; Kidney Neoplasms; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Proto-Oncogene Proteins c-akt; Pyrroles; RNA Interference; Sunitinib; TOR Serine-Threonine Kinases | 2016 |
[Expression of MEK/ERK signal pathways in renal cell carcinoma with bone metastasis].
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Indoles; Kidney Neoplasms; MAP Kinase Signaling System; Mutation; Pyrroles; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Solid pseudopapillary tumour (Frantz's tumour) of the pancreas in childhood: successful management of late liver metastases with sunitinib and chemoembolisation.
Topics: Adolescent; Antineoplastic Agents; Carcinoma, Papillary; Combined Modality Therapy; Embolization, Therapeutic; Female; Humans; Indoles; Liver Neoplasms; Magnetic Resonance Imaging; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Czech Republic; Databases, Factual; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2018 |
DNA binding of sunitinib: Spectroscopic evidence via circular dichroism and nuclear magnetic resonance.
Topics: Antineoplastic Agents; Binding Sites; Circular Dichroism; DNA; Indoles; Ligands; Nucleic Acid Conformation; Plasmids; Proton Magnetic Resonance Spectroscopy; Pyrroles; Structure-Activity Relationship; Sunitinib | 2018 |
A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs.
Topics: Angiogenesis Inhibitors; Biological Assay; Blood Vessels; Gene Knockdown Techniques; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Microvessels; Models, Biological; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A | 2018 |
Re: A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Pyrroles; Sunitinib | 2018 |
Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Calcitriol; Carcinoma, Non-Small-Cell Lung; Cholecalciferol; Cisplatin; Cytostatic Agents; Dihydroxycholecalciferols; Docetaxel; Female; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins c-sis; Pyrroles; Sunitinib; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2018 |
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.
Topics: Adult; Aged; Antineoplastic Agents; Humans; Indoles; Italy; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2018 |
[Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib].
Topics: Adult; Aged; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Sunitinib | 2018 |
CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Receptors, Interleukin-8A; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2018 |
Topical Sunitinib ointment alleviates Psoriasis-like inflammation by inhibiting the proliferation and apoptosis of keratinocytes.
Topics: Administration, Topical; Animals; Apoptosis; Cell Line; Cell Proliferation; Down-Regulation; Gene Expression Regulation; Indoles; Inflammation; Keratinocytes; Male; Mice; Organ Size; Phosphoproteins; Psoriasis; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2018 |
Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2018 |
[A Long-Term Survivor Who Are Responding to Sunitinib Treatment for Recurrent Imatinib-Resistant Gastrointestinal Stromal Tumor(GIST)of the Stomach].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Pyrroles; Recurrence; Stomach Neoplasms; Sunitinib; Time Factors | 2017 |
Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female.
Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Krukenberg Tumor; Peritoneal Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2018 |
Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy.
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
Effects of sunitinib targeted chemotherapy on the osseointegration of titanium implants.
Topics: Animals; Antineoplastic Agents; Dental Implants; Drug Delivery Systems; Femur; Indoles; Male; Osseointegration; Pyrroles; Rabbits; Random Allocation; Sunitinib; Titanium; X-Ray Microtomography | 2018 |
Skull Base Metastasis From Occult Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Neoplasms, Unknown Primary; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Skull Base Neoplasms; Sorafenib; Sunitinib | 2018 |
An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Neuroendocrine; Everolimus; Female; Humans; Indoles; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; von Hippel-Lindau Disease | 2018 |
VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells.
Topics: Bevacizumab; Cell Movement; Colonic Neoplasms; Drug Resistance, Neoplasm; HCT116 Cells; Humans; Indoles; Neoplasm Invasiveness; Neuropilin-1; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A | 2018 |
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Neoplasms, Second Primary; Pancreas; Pancreatic Neoplasms; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Trials that say "maybe": the disconnect between exploratory and confirmatory testing after drug approval.
Topics: Antineoplastic Agents; Calcium Channel Blockers; Clinical Trials as Topic; Drug Approval; Drug Industry; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pregabalin; Pyrroles; Sorafenib; Sunitinib | 2018 |
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Incidence; Indoles; Ipilimumab; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Pyrroles; Retrospective Studies; Sunitinib; Zoledronic Acid | 2018 |
Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Proportional Hazards Models; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Young Adult | 2018 |
Investigation of Metabolomic Changes in Sunitinib-Resistant Human Renal Carcinoma 786-O Cells by Capillary Electrophoresis-Time of Flight Mass Spectrometry.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Electrophoresis, Capillary; Humans; Indoles; Kidney Neoplasms; Mass Spectrometry; Metabolomics; Pyrroles; Sunitinib | 2018 |
[A Case of Long-Term Survival of Metastatic and Recurrent Duodenal Gastrointestinal Stromal Tumor Treated with Multimodality Managements].
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Resistance, Neoplasm; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Pyrroles; Sunitinib | 2018 |
Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Monocarboxylic Acid Transporters; Muscle Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Symporters; Vascular Endothelial Growth Factor A | 2018 |
AR involved in sunitinib resistance.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Phosphorylation; Pyrroles; Sunitinib | 2018 |
Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib | 2018 |
The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Count; Female; Fluorescent Antibody Technique; Humans; Indoles; Kidney Neoplasms; Neoplastic Cells, Circulating; Pyrroles; Sunitinib | 2018 |
Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; MicroRNAs; Middle Aged; Prognosis; Pyrroles; ROC Curve; Sensitivity and Specificity; Sunitinib; Treatment Outcome | 2018 |
Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Health Care Costs; Health Resources; Humans; Indazoles; Indoles; Insurance Claim Review; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Medicare; Patient Acceptance of Health Care; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Time Factors; Treatment Outcome; United States | 2018 |
Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Thrombocytopenia; Treatment Outcome | 2018 |
Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Survival Rate; Treatment Failure | 2018 |
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Multivariate Analysis; Neutropenia; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Thrombocytopenia; Treatment Outcome | 2018 |
DCE-MRI of Sunitinib-Induced Changes in Tumor Microvasculature and Hypoxia: A Study of Pancreatic Ductal Adenocarcinoma Xenografts.
Topics: Animals; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Female; Humans; Hypoxia; Image Enhancement; Immunohistochemistry; Indoles; Magnetic Resonance Imaging; Male; Mice; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Sunitinib; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Renal Cell; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Female; Humans; Immunotherapy, Adoptive; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Postoperative Care; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2018 |
Development of a novel conjugatable sunitinib analogue validated through in vitro and in vivo preclinical settings.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Stability; Humans; Indoles; Linear Models; Mice; Mice, Inbred BALB C; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib | 2018 |
pH-controlled sunitinib anticancer release from magnetic chitosan nanoparticles crosslinked with κ-carrageenan.
Topics: Antineoplastic Agents; Carrageenan; Chitosan; Cross-Linking Reagents; Drug Carriers; Drug Liberation; Hydrogel, Polyethylene Glycol Dimethacrylate; Hydrogen-Ion Concentration; Indoles; Magnetite Nanoparticles; Pyrroles; Spectroscopy, Fourier Transform Infrared; Sunitinib; Surface Properties; X-Ray Diffraction | 2018 |
Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation: A case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indoles; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Paraganglioma; Pyrroles; Succinate Dehydrogenase; Sunitinib; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2018 |
MRI in predicting the response of gastrointestinal stromal tumor to targeted therapy: a patient-based multi-parameter study.
Topics: Adult; Aged; Diffusion Magnetic Resonance Imaging; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine.
Topics: Chromatography, Liquid; Humans; Hydrogen-Ion Concentration; Indoles; Isomerism; Light; Pyrroles; Sunitinib; Tandem Mass Spectrometry; Temperature; Time Factors | 2018 |
Antitumor activity of BJ-1207, a 6-amino-2,4,5-trimethylpyridin-3-ol derivative, in human lung cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chickens; Chorioallantoic Membrane; Humans; Indoles; Lung Neoplasms; NADPH Oxidases; Pyridines; Pyrroles; Reactive Oxygen Species; Signal Transduction; Structure-Activity Relationship; Sunitinib; Transplantation, Heterologous | 2018 |
Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antioxidants; Capecitabine; Carotenoids; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Skin; Sorafenib; Sunitinib | 2018 |
Sunitinib-induced acute severe hypothyroidism in a case of metastatic gastrointestinal stromal tumor: A case report.
Topics: Aged; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Indoles; Male; Pyrroles; Sunitinib; Thyrotropin | 2018 |
Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Cytoreduction Surgical Procedures; Humans; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib | 2019 |
The influence of light sources on sunitinib measurements with photoisomerization.
Topics: Chromatography, Liquid; Drug Monitoring; Drug Stability; Humans; Indoles; Photochemical Processes; Pyrroles; Sunitinib; Tandem Mass Spectrometry | 2019 |
[A Cost-effectiveness Analysis of Sunitinib vs. Interferon-alpha in Patient with Advanced Renal Cell Carcinoma in Japan].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Interferon-alpha; Japan; Kidney Neoplasms; Markov Chains; Molecular Targeted Therapy; Monte Carlo Method; Pyrroles; Quality-Adjusted Life Years; Sunitinib | 2018 |
Sunitinib Treatment Modification in First-Line Metastatic Renal Cell Carcinoma: Analysis of the STAR-TOR Registry.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Registries; Sunitinib; Survival Analysis; Treatment Outcome | 2018 |
Sunitinib Alone or after Nephrectomy in Renal Cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
Sunitinib Alone or after Nephrectomy in Renal Cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
Sunitinib Alone or after Nephrectomy in Renal Cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Pyrroles; Sunitinib | 2019 |
Re: Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib | 2019 |
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib | 2019 |
Radiological Response and Neutrophil-to-Lymphocyte Ratio as Predictive Factors for Progression-Free and Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Lymphocytes; Neutrophils; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2019 |
Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Poland; Protein Kinase Inhibitors; Public Health Practice; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2019 |
Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Bayes Theorem; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2019 |
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?
Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2021 |
Thyroid profile during the alternative Sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib; Thyroid Gland | 2020 |
C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
Topics: Adult; Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; China; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Progression-Free Survival; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2019 |
A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Indoles; Isomerism; Male; Pyrroles; Reproducibility of Results; Sunitinib; Tandem Mass Spectrometry | 2020 |
Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics.
Topics: Administration, Oral; Adolescent; Age Factors; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Computer Simulation; Cytochrome P-450 CYP3A; Drug Administration Schedule; Drug Dosage Calculations; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Models, Biological; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Young Adult | 2020 |
The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2021 |
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Topics: Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Formularies as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Managed Care Programs; Medicaid; Medicare; Molecular Diagnostic Techniques; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sulfonamides; Sunitinib; Treatment Failure; Triazines; United States | 2020 |
Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events.
Topics: Antineoplastic Agents; Axitinib; Caspases; HMGB1 Protein; Humans; Indazoles; Indoles; Inflammasomes; Interleukin-1beta; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; THP-1 Cells | 2021 |
"Hand foot genital syndrome": Proposition of a new term, induced by Sunitinib in a patient of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2021 |
Editorial Comment from Dr Hatakeyama and Dr Ohyama to Clinical utility of head computed tomography scan during systemic therapy for metastatic renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Pyrroles; Sunitinib; Tomography | 2021 |
Changes in prescribing habits for the treatment of metastatic renal clear cell carcinoma (mRCC) in Australia.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Habits; Humans; Kidney Neoplasms; Northern Territory; Pyrroles; Sunitinib | 2021 |
Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Prognosis; Pyrroles; Retrospective Studies; Sunitinib | 2022 |
Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line.
Topics: Aged; Carcinoma, Renal Cell; Cardiovascular Agents; Disease-Free Survival; Humans; Indazoles; Indoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2021 |
Sunitinib induced colitis manifesting as invasive diarrhea in a patient with renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Colitis; Diarrhea; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2022 |
Alternative Treatment with Every-Other-Day Dosing of Sunitinib for Metastatic Renal Cell Carcinoma: Extended Follow-Up.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Follow-Up Studies; Humans; Kidney Neoplasms; Nivolumab; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2022 |
Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Indoles; Proteomics; Pyrroles; Sunitinib | 2022 |
Oral targeted therapy dose adaptation in older patients with cancer: A real-life French cohort.
Topics: Administration, Oral; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2022 |
Effect of Sunitinib Treatment on Skin Sodium Accumulation in Patients With Renal Cancer: a Pilot Study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Pilot Projects; Pyrroles; Sodium; Sunitinib | 2022 |
Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility Studies; Humans; Kidney Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2022 |
Time trends for drug specific adverse events in patients on sunitinib; implications for remote monitoring.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; COVID-19; COVID-19 Drug Treatment; Humans; Indoles; Kidney Neoplasms; Pandemics; Pyrroles; Retrospective Studies; Sunitinib | 2022 |
Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study.
Topics: Antineoplastic Agents; Blood Platelets; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2022 |
Receptor tyrosine kinase inhibitors negatively impact on pro-reparative characteristics of human cardiac progenitor cells.
Topics: Animals; Humans; Imatinib Mesylate; Indoles; Protein Kinase Inhibitors; Pyrroles; Rats; Sorafenib; Stem Cells; Sunitinib | 2022 |
Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Child; Erythrocyte Indices; Humans; Indoles; Kidney Neoplasms; Pyrroles; Retrospective Studies; Sunitinib | 2022 |
Sunitinib-Induced Congestive Heart Failure in a Patient with Gastrointestinal Stromal Tumor.
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Indoles; Pyrroles; Sunitinib | 2022 |
Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.
Topics: Humans; Indoles; Neoplasms, Glandular and Epithelial; Platinum; Pyrroles; Retrospective Studies; Sunitinib; Thymoma; Thymus Neoplasms; Treatment Outcome | 2022 |
Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety.
Topics: Amino Acids; Antineoplastic Agents; Carcinoma, Renal Cell; Glycerophospholipids; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2022 |
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2023 |
Sunitinib therapy for imatinib-resistant and/or intolerant gastrointestinal stromal tumors: comparison of safety and efficacy between standard and reduced dosage regimens.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2023 |
GIST: Molecular Profiling Suggests 2nd Therapy.
Topics: Antineoplastic Agents; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Indoles; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib | 2023 |
Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib | 2023 |